DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

42 CFR Parts 405, 410, 411, 414, 415, and 424

[CMS-1321-P]

RIN 0938-AO24

Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2007 and Other Changes to Payment Under Part B

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Proposed rule.

SUMMARY: This proposed rule would address certain provisions of the Deficit Reduction Act of 2005, as well as make other proposed changes to Medicare

Part B payment policy.

We are proposing these changes to ensure that our payment systems are updated to reflect changes in medical practice and the relative value of services. This proposed rule also discusses geographic practice cost indices (GPCI) changes; requests for additions to the list of telehealth services; payment for covered outpatient drugs and biologicals; payment for renal dialysis services; policies related to private contracts and opt-out; policies related to bone mass measurement services, independent diagnostic testing facilities, the physician self-referral prohibition; laboratory billing for the technical component (TC) of physician pathology services; the clinical laboratory fee schedule; certification of advanced practice nurses; health information technology, and the health care information transparency initiative.

DATES: Comment Date: Comments will be considered if we receive them at one of the addresses provided below, no later than 5 p.m. on October 10, 2006.

ADDRESSES: In commenting, please refer to file code CMS-1321-P. Because of staff and resource limitations, we cannot accept comments by facsimile (fax) transmission.

You may submit comments in one of three ways (no duplicates, please):

1. Electronically. You may submit electronic comments on specific issues in this regulation to http://www.cms.hhs.gov/eRulemaking. Click on the link "Submit electronic comments on CMS regulations with an open comment period." (Attachments should be in Microsoft Word,

WordPerfect, or Excel; however, we prefer Microsoft Word.)

2. By mail. You may mail written comments (one original and two copies) to the following address only: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS-1321-P, P.O. Box 8015, Baltimore, MD 21244-8015.

Please allow sufficient time for mailed comments to be received before the close of the comment period.

- 3. By express or overnight mail. You may send written comments (one original and two copies) to the following address only: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS-1321-P, Mail Stop C4-26-05, 7500 Security Boulevard, Baltimore, MD 21244-1850.
- 4. By hand or courier. If you prefer, you may deliver (by hand or courier) your written comments (one original and two copies) before the close of the comment period to one of the following addresses. If you intend to deliver your comments to the Baltimore address, please call telephone number (410) 786–7197 in advance to schedule your arrival with one of our staff members.

Room 445–G, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201; or 7500 Security Boulevard, Baltimore, MD 21244–1850.

(Because access to the interior of the HHH Building is not readily available to persons without Federal Government identification, commenters are encouraged to leave their comments in the CMS drop slots located in the main lobby of the building. A stamp-in clock is available for persons wishing to retain a proof of filing by stamping in and retaining an extra copy of the comments being filed.)

Comments mailed to the addresses indicated as appropriate for hand or courier delivery may be delayed and received after the comment period.

Submission of comments on paperwork requirements. You may submit comments on this document's paperwork requirements by mailing your comments to the addresses provided at the end of the "Collection of Information Requirements" section in this document.

For information on viewing public comments, see the beginning of the **SUPPLEMENTARY INFORMATION** section.

FOR FURTHER INFORMATION CONTACT: Pam West, (410) 786–2302 (for issues related to practice expense).

Stephanie Monroe, (410) 786–6864 (for issues related to the geographic practice cost index).

Craig Dobyski, (410) 786–4584 (for issues related to list of telehealth services).

Roberta Epps, (410) 786–4503 (for issues related to diagnostic imaging services).

Bill Larson, (410) 786–4639 (for issues related to coverage of bone mass measurement and addition of ultrasound screening for abdominal aortic aneurysm to the "Welcome to Medicare" benefit).

Dorothy Shannon, (410) 786–3396 (for issues related to the outpatient therapy cap).

Catherine Jansto, (410) 786–7762 (for issues related to payment for covered outpatient drugs and biologicals).

Henry Richter, (410) 786–4562 (for issues related to payments for end-stage renal disease facilities).

Fred Grabau, (410) 786–0206 (for issues related to private contracts and opt-out provision).

Lisa Öhrin, (410) 786–4565 (for issues related to physician self-referral prohibitions).

David Walczak (410) 786–4475 (for issues related to reassignment provisions).

August Nemec (410) 786–0612 (for issues related to independent diagnostic testing facilities).

Anita Greenberg, (410) 786–4601 (for issues related to the clinical laboratory fee schedule).

James Menas (410) 786–4507 (for issues related to payment for physician pathology services).

Diane Milstead, (410) 786–3355 or Gaysha Brooks (410) 786–9649 (for all other issues).

SUPPLEMENTARY INFORMATION:

Submitting Comments: We welcome comments from the public on all issues set forth in this rule to assist us in fully considering issues and developing policies. You can assist us by referencing the file code CMS-1321-P and the specific "issue identifier" that precedes the section on which you choose to comment.

Inspection of Public Comments: All comments received before the close of the comment period are available for viewing by the public, including any personally identifiable or confidential business information that is included in a comment. We post all comments received before the close of the comment period on the following Web site as soon as possible after they have been received: http://www.cms.hhs.gov/eRulemaking. Click on the link "Electronic Comments on CMS Regulations" on that Web site to view public comments.

Comments received timely will also be available for public inspection as they are received, generally beginning approximately 3 weeks after publication of a document, at the headquarters of the Centers for Medicare & Medicaid Services, 7500 Security Boulevard, Baltimore, Maryland 21244, Monday through Friday of each week from 8:30 a.m. to 4 p.m. To schedule an appointment to view public comments, phone 1–800–743–3951.

Information on the physician fee schedule can be found on the CMS homepage. You can access this data by using the following directions:

- 1. Go to the following Web site: http://www.cms.hhs.gov/PhysicianFeeSched/.
- 2. Select "PFS Federal Regulation Notices."

To assist readers in referencing sections contained in this preamble, we are providing the following table of contents. Some of the issues discussed in this preamble affect the payment policies, but do not require changes to the regulations in the *Code of Federal Regulations*. Information on the regulation's impact appears throughout the preamble and is not exclusively in section VI.

Table of Contents

- I. Background
 - A. Development of the Relative Value System
 - 1. Work RVUs
 - 2. Practice Expense Relative Value Units (PE RVUs)
 - 3. Resource-Based Malpractice RVUs
 - 4. Refinements to the RVUs
 - 5. Adjustments to RVUs Are Budget Neutral
 - B. Components of the Fee Schedule Payment Amounts
- C. Most Recent Changes to the Fee Schedule
- II. Provisions of the Proposed Rule
- A. Resource-Based PÉ RVUs and Practice Expense Proposals for Calendar Year 2007
- B. Geographic Practice Cost Indices
- C. Medicare Telehealth Services
- D. Miscellaneous Coding Issues
- 1. Global Period for Remote Afterloading High Intensity Brachytherapy Procedures
- 2. Assignment of RVUS to CPT Codes for Proton Beam Treatment Delivery Services
- E. Deficit Reduction Act (DRA) Related Proposals
- Section 5102 of the DRA—Proposed Adjustments for Payments to Imaging Services
- 2. Section 5107 of the DRA—Revisions to Payments for Therapy Services
- Section 5112 of the DRA—Proposed Addition of Ultrasound Screening for Abdominal Aortic Aneurysm (AAA)
- 4. Section 5113 of the DRA—Proposed Non-Application of the Part B Deductible for Colorectal Cancer Screening Tests
- Section 5114—Proposed Addition of Diabetes Outpatient Self-Management Training Services (DSMT) and Medical

- Nutrition Therapy (MNT) for the FQHC Program
- F. Proposed Payment for Covered Outpatient Drugs and Biologicals (ASP Issues)
- G. Proposed Provisions Related to Payment for Renal Dialysis Services Furnished by End Stage Renal Disease (ESRD) Facilities
- H. Private Contracts and Opt-Out Provision—Practitioner Definition
- I. Proposed Changes to Reassignment and Physician Self-Referral Rules Relating to Diagnostic Tests
- J. Supplier Access to Claims Billed on Reassignment
- K. Coverage of Bone Mass Measurement Tests
- L. Independent Diagnostic Testing Facility (IDTF) Issues
- 1. Proposed IDTF Changes in the Physician Fee Schedule Proposed Rule
- 2. Proposed Performance Standards for IDTFs
- 3. Supervision
- 4. Place of Service
- M. Independent Laboratory Billing for the Technical Component (TC) of Physician Pathology Services to Hospital Patients
- N. Public Consultation for Medicare Payment for New Outpatient Clinical Diagnostic Laboratory Tests
- O. Proposal To Establish Criteria for National Certifying Bodies That Certify Advanced Practice Nurses
- P. Chiropractic Services Demonstration
- Q. Promoting Effective Use of Health Information Technology
- R. Health Care Information Transparency Initiative
- III. Collection of Information Requirements
- IV. Response to Comments
- V. Regulatory Impact Analysis
- Regulation Text
- Addendum A—Explanation and Use of Addendum B
- Addendum B—2007 Relative Value Units and Related Information Used in Determining Medicare Payments for 2007
- Addendum C—Codes for Which We Received Practice Expense Review Committee (PERC) Recommendations on Practice Expense Direct Cost Inputs
- Addendum D—2007 Geographic Practice Cost Indices (GPCIs) by Medicare Carrier and Locality
- Addendum E—2007 Geographic Adjustment Factors (GAF)
- Addendum F—Proposed CPT/HCPCS Imaging Codes Defined by Section 5102(b) of the DRA

In addition, because of the many organizations and terms to which we refer by acronym in this proposed final rule, we are listing these acronyms and their corresponding terms in alphabetical order below:

- AADA American Academy of Dermatology Association
- AAH American Association of Homecare
- AAP Average acquisition price
- ACC American College of Cardiology
- ACG American College of Gastroenterology ACHPN Advanced Certified Hospice and Palliative Nurse

- ACOG American College of Obstetrics and Gynecology
- ACR American College of Radiology ADA American Dietetic Association
- AFROC Association of Freestanding Radiation Oncology Centers
- AGA American Gastroenterological Association
- AHRQ Agency for Healthcare Research and Quality
- AMA American Medical Association
- AMP Average manufacturer price
- ASA American Society of Anesthesiologists
 ASGE American Society of Gastrointestinal
 Endoscopy
- ASP Average sales price
- ASTRO American Society for Therapeutic Radiation Oncology
- ATA American Telemedicine Association
- AUA American Urological Association
- AWP Average wholesale price
- BBA Balanced Budget Act of 1997
- BBRA Balanced Budget Refinement Act of 1999
- BES (Bureau of the Census) Business Expenditure Survey
- BIPA Medicare, Medicaid, and SCHIP Benefits Improvement Protection Act of 2000
- BLS Bureau of Labor Statistics
- BMD Bone mineral density
- BMI Body mass index
- BMM Bone mass measurement
- BNF Budget neutrality factor
- BP Best price
- BSA Body surface area
- CAH Critical access hospital
- CAP College of American Pathologists
- CBSA Core-Based Statistical Area
- CCI Correct Coding Initiative
- CF Conversion factor
- CFR Code of Federal Regulations
- CMA California Medical Association CMS Centers for Medicare & Medicaid Services
- CNS Clinical nurse specialist
- CPEP Clinical Practice Expert Panel
- CPI Consumer Price Index
- CPO Care Plan Oversight
- CPT (Physicians') Current Procedural Terminology (4th Edition, 2002, copyrighted by the American Medical Association)
- CRNA Certified Registered Nurse Anesthetist
- CT Computed tomography
- CTA Computed tomographic angiography
- CY Calendar year
- DHS Designated health services
- DME Durable medical equipment
- DMERC Durable Medical Equipment Regional Carrier
- DRA Deficit Reduction Act
- DSMT Diabetes outpatient self-management training services
- DXA Dual energy x-ray absorptiometry
- E&M Evaluation and management
- EPO Erythopoeitin
- ESRD End stage renal disease
- FAX Facsimile
- FI Fiscal intermediary
- FR Federal Register
- GAF Geographic adjustment factor GAO General Accounting Office
- GAO General Accounting Office GDP Gross domestic product
- GPO Group purchasing organization

GPCI Geographic practice cost index
HCPAC Health Care Professional Advisory
Committee
HCPCS Healthcare Common Procedure

HCPCS Healthcare Common Procedure Coding System

HCRIS Healthcare Cost Report Information System

HSA Health Savings Account

HHA Home health agency

HHS (Department of) Health and Human Services

HIT Health information technology HOCM High osmolar contrast media

HPSA Health Professional Shortage Area

HRSA Health Resources Services
Administration (HHS)

HUD (Department of) Housing and Urban Development

IDTF Independent diagnostic testing facility IPF Inpatient psychiatric facility

IPPS Inpatient prospective payment system

IRF Inpatient rehabilitation facility ISO Insurance Services Office

IVIG Intravenous immune globulin

JCAAI Joint Council of Allergy, Asthma, and Immunology

JUA Joint underwriting association LCD Local coverage determination

LTCH Long-term care hospital LOCM Low osmolar contrast media

LOINC® Logical Observation Identifiers
Names and Codes

MA Medicare Advantage

MCAC Medicare Coverage Advisory Committee

MCG Medical College of Georgia MedPAC Medicare Payment Advisory Commission

MEI Medicare Economic Index MMA Medicare Prescription Drug, Improvement, and Modernization Act of

MNT Medical nutrition therapy

MRA Magnetic resonance angiography MRI Magnetic resonance imaging

MSA Metropolitan statistical area

NCD National coverage determination NCQDIS National Coalition of Quality

Diagnostic Imaging Services NDC National drug code

NECMA New England County Metropolitan Area

NECTA New England City and Town Area NP Nurse practitioner

NPP Nonphysician practitioners

NPWP Nonphysician Work Pool OBRA Omnibus Budget Reconciliation Act

OIG Office of Inspector General OMB Office of Management and Budget

OMB Office of Management and Budge OPD Outpatient Department

OPPS Outpatient prospective payment system

OSCAR Online Survey and Certification and Reporting

PA Physician assistant

PBM Pharmacy benefit managers

PC Professional component

PE Practice Expense

PEAC Practice Expense Advisory Committee

PERC Practice Expense Review Committee

PET Positron emission tomography

PFS Physician Fee Schedule

PLI Professional liability insurance

PPI Producer price index

PPO Preferred provider organization

PPS Prospective payment system

PRA Paperwork Reduction Act

PT Physical therapy

QCT Quantitative computerized tomography

RFA Regulatory Flexibility Act RIA Regulatory impact analysis

RN Registered nurse

RUC (AMA's Specialty Society) Relative (Value) Update Committee

RVU Relative value unit

SXA Single energy x-ray absorptiometry

SPA Single photon absorptiometry

SGR Sustainable growth rate

SMS (AMA's) Socioeconomic Monitoring System

SNF Skilled Nursing Facility

SNM Society for Nuclear Medicine

TA Technology AssessmentTC Technical Component

UAF Update adjustment factor
UPIN Unique Physician Identification

Number

WAC Wholesale acquisition cost WAMP Widely available market price

I. Background

[If you choose to comment on issues in this section, please include the caption "BACKGROUND" at the beginning of your comments.]

Since January 1, 1992, Medicare has paid for physicians' services under section 1848 of the Social Security Act (the Act), "Payment for Physicians" Services." The Act requires that payments under the physician fee schedule (PFS) be based on national uniform relative value units (RVUs) based on the resources used in furnishing a service. Section 1848(c) of the Act requires that national RVUs be established for physician work, practice expense (PE), and malpractice expense. Before the establishment of the resource-based relative value system, Medicare payment for physicians' services was based on reasonable charges.

A. Development of the Relative Value System

1. Work RVUs

The concepts and methodology underlying the PFS were enacted as part of the Omnibus Budget Reconciliation Act (OBRA) of 1989, Pub. L. 101–239, and OBRA 1990, (Pub. L. 101–508). The final rule, published November 25, 1991 (56 FR 59502), set forth the fee schedule for payment for physicians' services beginning January 1, 1992. Initially, only the physician work RVUs were resource-based, and the PE and malpractice RVUs were based on average allowable charges.

The physician work RVUs established for the implementation of the fee schedule in January 1992 were developed with extensive input from the physician community. A research team at the Harvard School of Public Health developed the original physician work RVUs for most codes in a cooperative agreement with the Department of Health and Human Services (HHS). In constructing the code-specific vignettes for the original physician work RVUs, Harvard worked with panels of experts, both inside and outside the Federal government, and obtained input from numerous physician specialty groups.

Section 1848(b)(2)(A) of the Act specifies that the RVUs for radiology services are based on relative value scale we adopted under section 1834(b)(1)(A) of the Act, (the American College of Radiology (ACR) relative value scale), which we integrated into the overall PFS. Section 1848(b)(2)(B) of the Act specifies that the RVUs for anesthesia services are based on RVUs from a uniform relative value guide. We established a separate conversion factor (CF) for anesthesia services, and we continue to utilize time units as a factor in determining payment for these services. As a result, there is a separate payment methodology for anesthesia services.

We establish physician work RVUs for new and revised codes based on recommendations received from the American Medical Association's (AMA) Specialty Society Relative Value Update Committee (RUC).

2. Practice Expense Relative Value Units (PE RVUs)

Section 121 of the Social Security Act Amendments of 1994 (Pub. L. 103–432), enacted on October 31, 1994, amended section 1848(c)(2)(C)(ii) of the Act and required us to develop resource-based PE RVUs for each physician's service beginning in 1998. We were to consider general categories of expenses (such as office rent and wages of personnel, but excluding malpractice expenses) comprising practice expenses.

Section 4505(a) of the Balanced Budget Act of 1997 (BBA) (Pub. L. 105–33), amended section 1848(c)(2)(C)(ii) of the Act to delay implementation of the resource-based PE RVU system until January 1, 1999. In addition, section 4505(b) of the BBA provided for a 4-year transition period from charge-based PE RVUs to resource-based RVUs.

We established the resource-based PE RVUs for each physician's service in a final rule, published November 2, 1998 (63 FR 58814), effective for services furnished in 1999. Based on the requirement to transition to a resource-based system for PE over a 4-year period, resource-based PE RVUs did not become fully effective until 2002.

This resource-based system was based on two significant sources of actual PE data: The Clinical Practice Expert Panel (CPEP) data and the AMA's Socioeconomic Monitoring System (SMS) data. The CPEP data were collected from panels of physicians, practice administrators, and nonphysicians (for example, registered nurses) nominated by physician specialty societies and other groups. The CPEP panels identified the direct inputs required for each physician's service in both the office setting and out-of-office setting. The AMA's SMS data provided aggregate specialtyspecific information on hours worked and practice expenses.

Separate PE RVUs are established for procedures that can be performed in both a nonfacility setting, such as a physician's office, and a facility setting, such as a hospital outpatient department. The difference between the facility and nonfacility RVUs reflects the fact that a facility receives separate payment from Medicare for its costs of providing the service, apart from payment under the PFS. The nonfacility RVUs reflect all of the direct and indirect practice expenses of providing a particular service.

Section 212 of the Balanced Budget Refinement Act of 1999 (BBRA) (Pub. L. 106-113) directed the Secretary of Health and Human Services (the Secretary) to establish a process under which we accept and use, to the maximum extent practicable and consistent with sound data practices, data collected or developed by entities and organizations to supplement the data we normally collect in determining the PE component. On May 3, 2000, we published the interim final rule (65 FR 25664) that set forth the criteria for the submission of these supplemental PE survey data. The criteria were modified in response to comments received, and published in the **Federal Register** (65 FR 65376) as part of a November 1, 2000 final rule. The PFS final rules published in 2001 and 2003, respectively, (66 FR 55246 and 68 FR 63196) extended the period during which we would accept these supplemental data.

3. Resource-Based Malpractice RVUs

Section 4505(f) of the BBA amended section 1848(c) of the Act to require us to implement resource-based malpractice RVUs for services furnished on or after 2000. The resource-based malpractice RVUs were implemented in the PFS final rule published November 2, 1999 (64 FR 59380). The malpractice RVUs were based on malpractice insurance premium data collected from commercial and physician-owned

insurers from all the States, the District of Columbia, and Puerto Rico.

4. Refinements to the RVUs

Section 1848(c)(2)(B)(i) of the Act requires that we review all RVUs no less often than every 5 years. The first 5-year review of the physician work RVUs went into effect in 1997, published on November 22, 1996 (61 FR 59489). The second 5-year review went into effect in 2002, published on November 1, 2001 (66 FR 55246). The next scheduled 5-year review is scheduled to go into effect in 2007.

In 1999, the AMA's RUC established the Practice Expense Advisory Committee (PEAC) for the purpose of refining the direct PE inputs. Through March of 2004, the PEAC provided recommendations to CMS for over 7,600 codes (all but a few hundred of the codes currently listed in the AMA's Current Procedural Terminology (CPT) codes).

In the November 15, 2004, PFS final rule (69 FR 66236), we implemented the first 5-year review of the malpractice RVUs (69 FR 66263).

5. Adjustments to RVUS Are Budget Neutral

Section 1848(c)(2)(B)(ii)(II) of the Act provides that adjustments in RVUs for a year may not cause total PFS payments to differ by more than \$20 million from what they would have been if the adjustments were not made. In accordance with section 1848(c)(2)(B)(ii)(II) of the Act, if adjustments to RVUs cause expenditures to change by more than \$20 million, we make adjustments to ensure that expenditures do not increase or decrease by more than \$20 million.

B. Components of the Fee Schedule Payment Amounts

To calculate the payment for every physician service, the components of the fee schedule (physician work, PE, and malpractice RVUs) are adjusted by a geographic practice cost index (GPCI). The GPCIs reflect the relative costs of physician work, PEs, and malpractice insurance in an area compared to the national average costs for each component.

Payments are converted to dollar amounts through the application of a CF, which is calculated by the Office of the Actuary and is updated annually for inflation.

The general formula for calculating the Medicare fee schedule amount for a given service and fee schedule area can be expressed as:

Payment = $[(RVU \text{ work} \times GPCI \text{ work}) + (RVU \text{ PE} \times GPCI \text{ PE}) + (RVU$

malpractice \times GPCI malpractice)] \times CF.

(Note: As discussed in the June 29, 2006 proposed notice for the Five-Year Review of Work Relative Value Units Under the Physician Fee Schedule and Proposed Changes to the Practice Expense Methodology (71 FR 37170), we have proposed to establish a separate budget neutrality adjustor that would be applied in the calculation of the work RVUs. Application of this budget neutrality adjustor would enable us to meet the budget neutrality provisions of section 1848(c)(2)(B)(ii) of the Act.)

C. Most Recent Changes to the Fee Schedule

The final rule with comment period that appeared in the **Federal Register** on November 21, 2005 (70 FR 70116) addressed Medicare Part B payment policy, including the physician fee schedule, that is applicable for calendar year (CY) 2006; and finalized certain provisions of the interim final rule to implement the Competitive Acquisition Program (CAP) for Part B Drugs.

It also revised Medicare Part B payment and related policies regarding: Physician work, practice expense and malpractice RVUs; Medicare telehealth services; multiple diagnostic imaging procedures; covered outpatient drugs and biologicals; supplemental payments to Federally Qualified Health Centers (FQHCs); renal dialysis services; coverage for glaucoma screening services; National Coverage Determination (NCD) timeframes; and physician referrals for nuclear medicine services and supplies to health care entities with which physicians have financial relationships.

In addition, the rule finalized the interim RVUs for CY 2005 and issued interim RVUs for new and revised procedure codes for CY 2006. The rule also updated the codes subject to the physician self-referral prohibition and discussed payment policies relating to teaching anesthesia services, therapy caps, private contracts and opt-out, and chiropractic and oncology demonstrations.

In accordance with section 1848(d)(1)(E)(i) of the Act, we also announced that the PFS update for CY 2006 would be -4.4 percent; the initial estimate for the sustainable growth rate for CY 2006 would be 1.7; and the CF for CY 2006 would be \$36.1770. However, subsequent to publication of the CY 2005 PFS final rule with comment period, section 5104 of the Deficit Reduction Act (DRA) of 2005 (Pub. L. 109–171, February 8, 2006), was enacted which amended section 1848(d)

of the statute to provide for a 0 percent update effective January 1, 2006.

We also note that the Five-Year Review of Work Relative Value Units Under the Physician Fee Schedule and Proposed Changes to the Practice Expense Methodology proposed notice appeared in the Federal Register on June 29, 2006 (71 FR 37170). In that notice, we proposed revisions to work RVUs affecting payment for physicians' services. The revisions reflect changes in medical practice, coding changes, and new data on relative value components that affect the relative amount of physician work required to perform each service, as required by the statute. We also proposed revisions to our methodology for calculating PE RVUs, including changes based on supplemental survey data for PE. This revised methodology would be used to establish payment for services beginning January 1, 2007.

As indicated in the June 29, 2006 proposed notice, we will respond to the comments received on that notice as part of the final Medicare PFS rule for CY 2007 scheduled for publication this fall. If adopted, the RVU revisions would be fully implemented for services furnished to Medicare beneficiaries on or after January 1, 2007. The PE revisions would be phased-in over a four-year period; although, as we gain experience with the new methodology, we will reexamine this policy beginning next year and propose necessary revisions through future rulemaking.

II. Provisions of the Proposed Rule

[If you choose to comment on issues in this section, please include the caption "PROVISIONS" at the beginning of your comments.]

A. Resource-Based Practice Expense (PE) RVU Proposals for CY 2007

Major changes to the PE methodology for 2007, as well as a detailed discussion of the current PE methodology, are discussed in the June 29, 2006 proposed notice (71 FR 37170 through 37430).

This proposed rule contains proposals for direct PE including clinical labor, medical supplies and medical equipment.

1. RUC Recommendations for Direct PE Inputs and Other PE Input Issues

The following discussions are proposals concerning direct PE inputs.

(a) RUC Recommendations

The AMA's Relative Value Update Committee (RUC) established a new committee, the Practice Expense Review Committee (PERC), to assist the RUC in recommending direct PE inputs (clinical staff, supplies, and equipment) for new and existing CPT codes.

The PERC reviewed the PE inputs for over 2000 existing codes, some of which were unresolved PE issues from the CY 2006 PFS final rule with comment period, at their meetings held in September 2005, February 2006 and April 2006. (A list of these reviewed codes can be found in Addendum C of this proposed rule.)

We have reviewed the PERC-submitted recommendations and propose to adopt all of them. We have worked with the AMA staff to make corrections for any typographical errors and to ensure that previously PEAC-accepted standards are incorporated in the recommendations.

The complete PERC recommendations and the revised PE database can be found on our Web site. (See the **SUPPLEMENTARY INFORMATION** section of this proposed rule for directions on accessing our Web site.)

(b) Standard Supplies and Equipment for 90-Day Global Codes

We are proposing to revise the CPEP supply and equipment inputs for those 90-day global procedures for which the RUC has only refined the clinical labor inputs. We are proposing to apply the standard supply and equipment inputs for the facility setting for 90-day global services to these remaining unrefined 90-day global procedure codes. As recommended by the RUC, for supplies, we propose to include one minimum supply visit package for each postoperative visit assigned to each code and a post-surgical incision care kit (suture, staples, or both) where appropriate, along with additional items recommended by the RUC for certain procedures. For equipment, we are proposing to include an exam table and light. However, there are several issues on which we need input before we finalize the recommended standards. For example, for many of the 90-day codes in question, the current supply input data contain supplies in far larger quantities than are contained in either the visit package or incision care kit. For other codes, the current data includes items that are not contained in the package or kit. In other cases, the recommendations from the RUC contain additional items in quantities that appear excessive. We plan to work with all the concerned specialties to ensure that the finalized inputs do represent the typical supplies needed to perform each procedure.

Because the application of the 90-day global standard supplies and equipment would result in the deletion of some original CPEP inputs, we are requesting that all the medical specialties examine the direct PE inputs on our Web site and let us know whether there are additional items from the original CPEP data that are a necessary part of the post-operative care and if the PE inputs listed are correct. (See the SUPPLEMENTARY INFORMATION section of this proposed rule for directions on accessing our Web site.)

2. Payment for Splint and Cast Supplies

In the PFS final rules published November 1999 (64 FR 59380) and November 2000 (65 FR 65376), we removed splint and cast supplies from the PE database for the CPT codes for fracture management and cast/strapping application procedures. Because splint and cast supplies could be separately billed using Healthcare Common Procedure Coding System (HCPCS) codes (Q4001–Q4051) that were established for payment of these supplies under section 1861(s)(5) of the Act, we did not want to make duplicate payment under the PFS for these items.

In the CY 2006 PFS proposed rule (70 FR 70116), we proposed to reinstate payment for all splints and cast supplies through the PE component of the PFS because we believed we may have unintentionally prohibited remuneration for these supplies when they are not used for reduction of a fracture or dislocation (covered under section 1861(s)(5) of the Act), but rather are provided (and covered) as "incident to" a physician service under section 1861(s)(2)(A) of the Act. This proposal was not finalized; however, in our final rule we asked the medical specialties and the PERC to determine the typical supplies for splints and casts necessary for each of the fracture management codes and the cast/strapping application codes because we wanted to make certain that the supply inputs were correct before we proceeded with rulemaking for the CY 2007 PFS. At its February 2006 meeting, the PERC reviewed and approved the supply inputs submitted by the AAOS for each CPT code for fracture management and cast/strapping application and these were forwarded to us as PERC recommendations. During this interim period we also reassessed the options for payment of materials for splints and casts.

We believe that the majority of the splint and cast supplies that are currently paid through the Q-codes are furnished in relationship to cast/strapping procedures for the management of fractures and dislocations. However, we did not intend for the medically necessary

splint and cast supplies used for other reasons (for example, serial casting, wound care, or protection) not to be paid. Because it may be difficult for the contractors to identify the purpose for the cast/strapping application procedure on a claim form, we believe that contractors may have been paying for the splint and cast supply Q-codes when the service is performed for other purposes than treatment of fractures and dislocations.

Since these splint and cast supplies can be covered under both sections 1861(s)(5) and 1861(s)(2)(A) of the Act, we are proposing to include payment for both statutory benefits using the separate HCPCS Q-codes. This would allow for payment for these medically necessary supplies whether based on sections 1861(s)(5) or 1861(s)(2)(A) of the Act, while ensuring that no duplicate payments are made. Physicians would continue to bill the HCPCS Q-codes, in addition to the cast/strapping application procedure codes, to be paid for these materials.

The following supplies would continue to be paid separately using the HCPCS Q-codes and would not be included in the PE database upon adoption of this proposal:

- Fiberglass roll.
- Cast padding.
- Cast shoe.
- Stockingnet/stockinette.
- Plaster bandage.
- Denver splint.
- Dome paste bandage.
- Cast sole.
- Elastoplast roll.
- Fiberglass splint.
- · Ace wrap.
- Kerlix.
- Webril.
- Malleable arch bars and elastics.
 The splint and cast supplies would not be included in the PEs for the following CPT codes:
 - 24500 through 24685
 - 25500 through 25695
 - 26600 through 26785
 - 27500 through 27566
 - 27750 through 27848
 - 28400 through 28675
 - 29000 through 29750.

We are requesting input, specifically from medical specialties and contractors on this proposal.

3. Medical Nutrition Therapy Services

In 2000, the Health Care Professional Advisory Committee (HCPAC) recommended that we assign work RVUs to three new medical nutrition therapy (MNT) CPT codes—97802 Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient,

each 15 minutes at 0.45 RVUs, 97803 Medical nutrition therapy; reassessment and intervention, individual, face-to-face with the patient, each 15 minutes at 0.37 RVUs, and 97804 Medical nutrition therapy; group (two or more individuals), each 30 minutes at 0.25 RVUs. However, during rulemaking for the CY 2001 PFS final rule, we indicated that MNT was not covered because there was yet no statutory benefit category that would allow medical nutritionists to bill these services. We also did not accept the HCPAC recommendations for work RVUs for these MNT services because the codes were designed for use only by nonphysicians. The following year, section 105(c) of the Medicare, Medicaid, and SCHIP Benefits Improvement Protection Act of 2000 (BIPA) provided for the coverage of MNT services when furnished by registered dietitians or nutritional professionals at 85 percent of the amount that a physician would be paid for the same services. As a result, we established values for these MNT services for the 2002 PFS. In keeping with our earlier decision, we did not assign the HCPAC-recommended work values. However, the associated work value for each code was utilized in the conversion of work to clinical labor time for MNTs as part of the PE component. At that time we received several comments, including one from the American Dietetic Association (ADA), urging us to adopt the work values recommended by the HCPAC.

More recently, the ADA has requested us to reconsider our decision not to accept the HCPAC recommended work RVUs. The ADA contends that the payment rate established by section 105(c) of BIPA, 85 percent of the PFS amount that would be paid for the same service if furnished by a physician, is based on the premise that work values are inherent to these MNT services. The ADA believes that without work RVUs, the payment for these services does not reflect 85 percent of what a physician would be paid for performing the same service. Because these MNT codes were created specifically for MNT professionals, the ADA compared the work associated with their services to physician E/M services of CPT 99203 and 99213, which have respective work RVUs of 1.34 and 0.67.

After reviewing the issues and relevant arguments raised by the ADA, we are persuaded that it would be appropriate to include work RVUs for the MNT services. Consequently, we are proposing to establish work RVUs for each code at the level previously

recommended by the HCPAC, as follows:

- CPT 97802 = 0.45 RVUs.
- CPT 97803 = 0.37 RVUs.
- CPT 97804 = 0.25.

Because we propose to add the work RVUs to these services, the MNT clinical labor time in the direct input database would be removed with the adoption of this proposal. Additionally, two HCPCS codes, G0270 MNT subs tx for change dx and G0271 Group MNT 2 or more 30 mins were created to track MNT services following the second referral in the same year. These HCPCS codes correspond to CPT codes 97803 and 97804, respectively. Therefore, we would also propose to add the same work RVUs to these HCPCS codes and to delete the clinical labor inputs from the PE database upon adoption of this policy. We encourage specialty societies and other professional groups to comment on this proposal.

4. Surgical Pathology Codes

We heard from the College of American Pathologists (CAP) regarding the equipment times assigned to CPT codes 88304 and 88305 in the basic surgical pathology family of codes. While all six codes in this family have been refined by the PEAC, this refinement occurred at 4 separate PEAC meetings. CPT codes 88304 and 88305 were refined at the first PEAC meeting in April 1999 before time standards were established for the equipment at subsequent PEAC meetings when the other four CPT codes 88300, 88302, 88307, and 88309 were reviewed. Using our proposed bottom-up PE methodology to value these codes, the lack of the equipment time standards for CPT codes 88304 and 88305 create a rank-order anomaly in this family. Consequently, CAP, after reviewing and applying current standards for the equipment times, submitted suggested revised equipment times to us. We are proposing to accept these times and the proposed times will be reflected in the PE database on our Web site (See the **SUPPLEMENTARY INFORMATION** section of this proposed notice for directions on accessing our Web site.)

5. Other PE Issues

In the CY 2006 PFS final rule with comment period (70 FR 70116), we explained that we were not implementing the PERC or other proposed PE changes for CY 2006 due to issues with the PE methodology. In this proposed rule, we are proposing that the PERC and other PE changes originally proposed for CY 2006 would be implemented and effective with the CY 2007 PFS. The following

subsections, (a) through (j), summarize the PE proposals from the CY 2006 PFS final rule with comment period that we are including in this proposed rule. Additionally, we are including several other items which concern inputs for PE that are discussed below in subsections (k) through (n).

(a) PE Recommendations on CPEP Inputs for CY 2006

We are proposing to use a clinical labor time of 167 minutes for the service period for CPT code 36522, Extracorporeal Photopheresis; maintain the nonfacility setting PE RVUs for CPT code 78350, single photon bone densitometry; and remove the PE inputs for the nonfacility setting for CPT codes 76975, GI endoscopic ultrasound, and 15852, Dressing change not for burn. (70 FR 70136 through 70137)

(b) Supply Items for CPT Code 95015 (Which Is Used for Intradermal Allergy Tests With Drugs, Biologicals, or Venoms)

We are proposing to implement the allergy and immunology specialty's recommendation to change the test substance in CPT code 95015 to venom, at \$10.70 (from single antigen, at \$5.18) and the quantity to 0.3 ml (from 0.1 ml). (See 70 FR 70138.)

(c) Flow Cytometry Services

Based on information from the society representing independent laboratories, we are proposing to implement the following direct PE inputs:

- Clinical Labor—We are proposing to change the staff type in the service (intra) period in both CPT codes 88184 and 88185 to cytotechnologist, at \$0.45 per minute (currently lab technician, at \$0.33 per minute).
- Supplies—We are proposing to change the antibody cost for both CPT codes 88184 and 88185 to \$8.50 (from \$3.544).
- Equipment—We are proposing to add the following equipment to CPT code 88184:
 - + Computer.
 - + Printer.
 - + Slide strainer.
 - Biohazard hood.
 - + Wash assistant.
 - + FAC loader.
- + We are proposing to add a computer and printer to the equipment for CPT code 88185 (70 FR 70138).

(d) Low Osmolar Contrast Media (LOCM) and High Osmolar Contrast Media (HOCM)

Because separate payment is available for both types of contrast media, we are proposing to delete LOCM and HOCM from the PE database with the CY 2007 PFS rule. (See 70 FR 70138).

(e) Imaging Rooms

We are proposing to implement the updates for the contents and prices of 5 "rooms" used in imaging procedures including—

- Basic radiology room;
- Radiographic-fluoroscopic room;
- Mammography room;
- Computed tomography (CT) room; nd
- Magnetic resonance imaging (MRI) room (See 70 FR 70139).

(f) Equipment Pricing for Select Services and Procedures

We are proposing to accept the following equipment pricing information provided by various specialty societies for select services and procedures as discussed in the CY 2006 PFS final rule with comment period. (See 70 FR 70139):

- Equipment pricing for certain radiology services received from the ACR as presented in Table 15 of the CY 2006 PFS proposed rule.
- Equipment pricing on the ultrasound color doppler transducers and vaginal probe received from the American College of Obstetrics and Gynecology (ACOG).
- For CPT 36522, extracorporeal photopheresis, equipment pricing information specific to this procedure.
- Pricing of EMG botox machine used in CPT code 92265 as presented by the American Academy of Ophthalmology.
- (g) Supply Item for In Situ Hybridization Codes (CPT Codes 88365, 88367, and 88368)

We are proposing to implement the Society for Clinical Pathologists' request to change the probe quantity for CPT code 88367 *In situ hybridization, auto* to 1.5, equal to that of the other two codes in the family.

(h) Supply Item for Percutaneous Vertebroplasty Procedures (CPT codes 22520 and 22525)

Based on documentation provided by the Society for Interventional Radiology, we are proposing to implement a new price of \$696.00 for the vertebroplasty kit, to replace a temporary price of \$660.50 that was a placeholder price from the CY 2006 PFS final rule with comment period. (See 70 FR 70139.)

(i) Clinical Labor for G-Codes Related to Home Health and Hospice Physician Supervision, Certification and Recertification

We are proposing to apply the refinements made to the PE inputs to

CPT codes 99375 and 99378 for home health and hospice supervision to 4 G-codes that are related to home health and hospice physician supervision, certification and recertification, G0179, GO180, GO181, and GO182. These G-codes are incorrectly valued for clinical labor. These G-codes are cross-walked from CPT codes 99375 and 99378, which underwent PEAC refinement in January 2003 for the CY 2004 PFS. However, at that time we inadvertently did not apply the new refinements to these specific G-codes. (See 70 FR 70139 through 70140.)

(j) Programmers for Implantable Neurostimulators and Intrathecal Drug Infusion Pumps

Although we had initially proposed, in the CY 2006 PFS proposed rule, to remove two programmers from the PE database (EQ208 for medication pump from two codes (CPT 62367 and 62368) and EQ209 for the neurostimulator from 8 codes (CPT 95970-97979)), based on comments received as discussed in the CY 2006 PFS final rule with comment period (see 70 FR 70140), we determined that we will retain these programmers in the database. In addition, we added "with printer" to the description of EQ208 based on comments received. We are proposing to implement these decisions for CY 2007.

(k) Cardiac Monitoring Services

We are requesting more specific PE information related to remote cardiac monitoring services because these services do not fit the direct PE model used for typical physician services. These services are overwhelmingly performed by specialized independent diagnostic testing facilities (IDTFs) that are paid under the PFS, but due to the characteristics of cardiac monitoring services, frequently maintain more extensive operating hours than the typical physician office. Specifically, we are looking for data to indicate the typical number and type of transmissions or other encounters per day between the beneficiary and the IDTF for each of the remote monitoring services. We would also like to know the number and type of clinical staff, as well as the corresponding time, that are necessary to ensure appropriate services are available for each patient. Additionally, we are interested in identifying any other direct PE inputs for typical supplies and equipment relating to these services, and any data that would reflect indirect PEs, such as overhead and non-clinical payroll expenses. We believe that the following codes represent atypical PE scenarios

and would like to receive PE information regarding these services:

- Cardiac event monitoring (CPT codes 93271, 93012 and 93270).
- Pacemaker monitoring (CPT codes 93733 and 93736).
- Holter monitoring (CPT codes 93232, 93226, 93231 and 93225).
- INR monitoring (HCPCS codes G0248 and G0249).

(l) Clarification With Respect to Non-Facility PE RVUs

In the CY 2006 PFS final rule with comment (70 FR 70335) we provided a clarification in Addendum A concerning use of "NA" in the PE RVU columns for Addendum B. Commenters requested that further clarification be made concerning the payment amount for procedures performed in the nonfacility setting if there is an "NA" in the non-facility PE RVU column. Our policy is that if the Medicare carrier pays for the service in the non-facility setting, the service will be paid at the facility PE RVU rate. In this proposed rule, we are proposing revisions to Addendum A to include this clarification.

(m) Supply for CPT Code 50384, Removal (via Snare/Capture) of Internally Dwelling Ureteral Stent Via Percutaneous Approach, Including Radiological Supervision and Interpretation

Upon review of the RUC-recommended direct PE inputs for CPT 50384, a new procedure for CPT 2006, we identified the inappropriate inclusion of a ureteral stent that we are proposing to delete for CY 2007. We believe that the addition of the ureteral stent, valued by the specialty at \$162, to CPT code 50384, which is the procedure for the removal of a stent, was an inadvertent error by the specialty during the April 2005 RUC meeting.

(n) Supply and Equipment Items Needing Specialty Input

We have identified certain supply and equipment items for which we were unable to verify the pricing information (see Table 1: Supply Items Needing Specialty Input for Pricing and Table 2: Equipment Items Needing Specialty Input for Pricing). During the CY 2006 rulemaking process, we listed both supply and equipment items for which

pricing documentation was needed from the medical specialty societies and, for many of these items, we received sufficient documentation in the form of catalog listings, vendor Web sites, invoices, and manufacturer quotes. We have accepted the documented prices for many of these items and these prices are reflected in the PE RVUs in Addendum B of this proposed rule. The items listed below in Tables 1 and 2 represent the outstanding items from CY 2006 and new items added from the current RUC recommendations. We are requesting that commenters provide pricing information on items in these tables along with acceptable documentation, as noted in the footnote to each table, to support recommended prices. For supplies or equipment that have previously appeared on this list, and for which we received no or inadequate documentation, we are proposing to delete these items unless we receive adequate information to support current pricing by the conclusion of the comment period for this proposed rule.

BILLING CODE 4120-01-P

Table 1: Supply Items Needing Specialty Input for Pricing

Code	2005/6 Description	Unit	Unit Price	Primary associated specialties	Associated *CPT code(s)	Prior Item Status on Table	Commenter response and CMS action	2007 Item Status refer to note(s)
SK105	blood pressure recording form, average	Item	0.31	Cardiology	93784, 93786, 93788	YES	Specialty to submit asap, per comment.	В, С
SJ072	Brush, disposable applicator	Item		Dermatology	17360	YES	Specialty to submit asap, per comment.	В
SD217	Diaphragm fitting set	Item	75.00	Ob-gyn	57170	YES	Documentation received: set is reusable. Propose deletion.	.
SD054	Electrode, EEG, tin cup (12 pack uou)	Item		Neurology	95812-13, 95816, 95819, 95822, 95950, 95954,	YES	Submitted price of \$18 for 12 pack Accepted price of \$18 for 12 pack (uou)	А
SC088	Fistula set, dialysis, 17g	Item		Dermatology	36522	YES	Specialty to submit asap, per comment.	В
SL193	Glycolic acid, 20 - 50%	ml		Dermatology	17360	YES	Specialty to submit asap, per comment.	В
SF044	Micro air burr	Item		Podiatry, Orthopedics	28740, 28750, 28755, 28760	YES	No comments received.	В, С
SJ076	Nose pads	Item		Optometry	92370	YES	Documentation received. Accept price of \$.79 per pair	A
SD140	pressure bag	item	8.925	Cardiology	93501, 93508, 93510, 93526	YES	No documentation Received.	В, С

Code	2005/6 Description	Unit	Unit Price	Primary associated specialties	Associated *CPT code(s)	Prior Item Status on Table	Commenter response and CMS action	2007 Item Status refer to note(s)
SL119	Sealant spray	ΟZ		Radiation Oncology	77333	YES	Inadequate documentation received. Need price per ounce.	В
SL200	Sodium bicarbonate spray, 8 oz	Item		Dermatology	17360	YES	<u> </u>	В
SA091	Tray, scoop, fast track system	tray	750.00	ENT	31730	YES	Documentation received-with tray contents. Accept price of \$750.00.	Α
SD213	tubing, sterile, non- vented (fluid administration)	item	1.99	Cardiology	93501, 93508, 93510, 93526	YES	Specialty to submit asap, per comment.	в, с

*CPT codes and descriptions only are copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

Note: Acceptable documentation includes--Detailed description (including system components), source, and current pricing information, such as copies of catalog pages, hard copy from specific web pages, invoices, and quotes (letter format okay) from manufacturer, vendors or distributors. Unacceptable documentation includes--phone numbers and addresses of manufacturer, vendors or distributors, website links without pricing information, etc.

- A. Submitted price or rationale accepted. Appropriate changes made to database.
- B. 2005/2006 price retained, on an interim basis. Forward acceptable documentation promptly as applicable.
- C. No/Insufficient documentation. Retained price in database, on an interim basis. Price is proposed to be removed from database if acceptable documentation is not received during comment period. Forward documentation promptly.
- D. Deleted, item is reusable.

Table 2: Equipment Items Needing Specialty Input for Pricing and Proposed Deletions

Code	2005/6 Description	2005/6 Price	Primary specialties associated with item	*CPT code(s) associated with item	Prior Status on Table	Commenter response and CMS Action	2007 Item Status refer to note(s)
EQ269	Ambulatory blood pressure monitor	3,000	Cardiology	93784, 93786, 93788	Yes	No comments received.	В, С
EQ100	dialysis access flow monitor	10,000	Nephrology	90940		Manufacturer/ Vendor documentation received. Price accepted at \$17,925	A
EQ008	ECG signal averaging system	8,250	Cardiology, IM	93278	Yes		B, C

Code	2005/6 Description	2005/6 Price	Primary specialties associated with item	*CPT code(s) associated with item	Prior Status on Table	Commenter response and CMS Action	2007 Item Status refer to note(s)
ER029	film alternator (motorized film viewbox)	27,500	Radiology	329 codes	Yes	Manufacturer/Vendor documentation received.	A
						Price accepted at \$30,900	
EQ131	Hyperbaric chamber	125,000	FP, IM, EM	99183	Yes	Manufacturer/ Vendor documentation received.	A
ER036	hyperthermia system, ultrasound, intracavitary	250,000	Radiation oncology	77620	Yes	\$128,000. Manufacturer/ Vendor documentation received. Price accepted at \$282,575	A
	Light assembly, photopheresis		Dermatology	36522	Yes	No comments received.	B, C
ER045	orthovoltage radiotherapy system	140,000	Radiation oncology	77401	Yes	Vendor/ distributor documentation received. Price accepted at \$251,450	A
ER008	OSHA ventilated hood	5,000	Radiation oncology	77334	Yes	No comments received.	B, C
	plasma pheresis machine w/UV light source	37,900	radiology, dermatology	36481, G0341	Yes	No comments received.	B, C
ER070	Portal imaging system (w/PC work station and software)	377,319	Radiation oncology	77421	No	Documentation Requested	В
EQ271	Radiuscope	1,595	ophthalmology, optometry	92310 – 92317	Yes	Manufacturer/ Vendor documentation received. Price accepted at \$1,595	A
EQ221	review master	23,500	pulmonary disease, neurology	95805, 95807-11, 95816, 95822, 95955-56		Documentation received from ACCP & AAN. Price accepted at \$5,000	A

*CPT codes and descriptions only are copyright 2006 American medical Association. All Rights Reserved. Applicable

Note: Acceptable documentation includes--Detailed description (including system components), source, and current pricing information, such as copies of catalog pages, hard copy from specific web pages, invoices, and quotes (letter format okay) from manufacturer, vendors or distributors. Unacceptable documentation includes—phone numbers and addresses of manufacturer, vendors or distributors, website links without pricing information, etc.

A. Submitted price or rationale accepted. Appropriate changes made to database.

B. 2005/2006 price retained, on an interim basis. Forward acceptable documentation promptly as applicable.

C. No/Insufficient documentation. Retained price in database, on an interim basis. Price is proposed to be removed from database if acceptable documentation is not received during comment period. Forward documentation promptly.

B. Geographic Practice Cost Indices (GPCI)

[If you choose to comment on issues in this section, please include the caption "GPCI" at the beginning of your comments.]

Section 1848(e)(1)(A) of the Act requires us to develop separate GPCIs to measure resource cost differences among localities compared to the national average for each of the three fee schedule components. While requiring that the PE and malpractice GPCIs reflect the full relative cost differences, section 1848(e)(1)(A)(iii) of the Act requires that the physician work GPCIs reflect only one-quarter of the relative cost differences compared to the national average.

Section 1848(e)(1)(C) of the Act requires us, in consultation with appropriate physician representatives, to review the GPCIs at least every 3 years and allows us to make adjustments based on our review. This section of the Act also requires us to phase-in the adjustment over 2 years,

implementing only one-half of any adjustment in the first year if more than 1 year has elapsed since the last GPCI revision. The GPCIs were first implemented in 1992. The first review and revision was implemented in 1995 and the last GPCI revision was implemented in 2005. The next update is scheduled to be implemented in January 2008.

We do not anticipate proposing significant changes to the GPCIs in response to changes in the source data. There have been no new Census data to affect the work GPCI, the PE GPCI will reflect any changes in the Department of Housing and Urban Development (HUD) rental data, and the malpractice GPCI (based on malpractice RVUs) will reflect the national claims-based premium data for 2004 and 2005. Details of the methodology, data sources, and adjustments to the GPCIs will be made available for public comment in the CY 2008 PFS proposed rule.

In addition, section 412 of the MMA amended section 1848(e)(1) of the Act to establish a floor of 1.0 for the work GPCI

for any locality where the GPCI would otherwise fall below 1.0 for purposes of payment for services furnished on or after January 1, 2004 and before January 1, 2007. Beginning on January 1, 2007, the 1.00 floor will be removed and the work GPCI will revert to the fully implemented value. The values for the work GPCI and subsequent changes to the Geographic Adjustment Factor (GAF) published in this proposed rule reflect the removal of the 1.0 floor. For many payment localities this change had no impact on the GAF; however, the GAFs for a number of payment localities were reduced due to this change. The impact of this change on the GAFs for those payment localities is shown below in Table 3.

The proposed GPCIs for 2007 are shown in Addendum D and the proposed GAFs for 2007 are shown in Addendum E. The GPCIs shown in Addendum D are fully implemented and reflect 2007 budget neutrality scaling coefficients provided by the Office of the Actuary.

TABLE 3.—PAYMENT LOCALITIES WITH NEGATIVE PERCENT CHANGE IN GAF 1 BETWEEN 2006 AND 2007 DUE TO REMOVAL OF THE 1.000 WORK FLOOR

Locality name	2006 GAF	2007 GAF	Percent change
Fort Worth, TX	0.998	0.996	-0.17
Rest of Michigan	0.986	0.984	-0.20
Rest of New York	0.952	0.950	-0.21
Rest of Maryland	0.982	0.978	-0.36
Metropolitan St. Louis, MO	0.978	0.974	-0.41
Rest of Pennsylvania	0.950	0.946	-0.44
Ohio	0.970	0.966	-0.44
Austin, TX	1.020	1.015	-0.47
New Hampshire	1.010	1.005	-0.50
Minnesota	0.980	0.975	-0.53
Galveston, TX	0.991	0.986	-0.54
Metropolitan Kansas City, MO	0.987	0.981	-0.56
Fort Lauderdale, FL	1.022	1.016	-0.59
Arizona	0.999	0.993	-0.65
Wisconsin	0.956	0.950	-0.65
Colorado	0.998	0.991	-0.67
East St. Louis, IL	1.003	0.996	-0.68
New Orleans, LA	0.984	0.977	-0.73
Rest of Washington	0.984	0.976	-0.77
Indiana	0.937	0.930	-0.79
Beaumont, TX	0.951	0.942	-0.96
Alabama	0.923	0.914	-0.99
Virginia	0.958	0.948	- 1.06
Southern Maine	0.992	0.981	- 1.09
Rest of Georgia	0.943	0.932	-1.14
Tennessee	0.933	0.921	- 1.27
Utah	0.960	0.948	- 1.30
South Carolina	0.930	0.917	-1.41
Rest of Illinois	0.952	0.938	- 1.43
Rest of Florida	0.982	0.968	- 1.45
West Virginia	0.942	0.928	- 1.47
North Carolina	0.951	0.936	- 1.55
New Mexico	0.947	0.932	- 1.57
Kansas*	0.934	0.919	- 1.60
Rest of Louisiana	0.936	0.919	- 1.78
Kentucky	0.932	0.915	- 1.80
Kansas*	0.936	0.919	- 1.81
Rest of Oregon	0.946	0.929	- 1.81

Table 3.—Payment Localities With Negative Percent Change in GAF ¹ Between 2006 and 2007 Due to Removal of the 1.000 Work Floor—Continued

Locality name	2006 GAF	2007 GAF	Percent change
Vermont	0.968 1.007	0.950 0.989	- 1.82 - 1.83
Rest of Texas	0.947 0.922	0.929	1.87 1.91
lowa	0.922	0.904 0.909	- 1.91 - 1.97
Rest of Maine	0.936	0.916	-2.14 -2.14
Oklahoma	0.913 0.919	0.893 0.898	-2.14 -2.31
Arkansas	0.905 0.905	0.884 0.883	-2.34 -2.44
Puerto Rico Nebraska	0.905	0.883	-2.44 -2.44
Wyoming	0.934	0.910	-2.55 -2.83
Montana* Rest of Missouri*	0.928 0.910	0.902 0.883	-2.83 -2.97
North Dakota	0.924	0.895	-3.16
South Dakota	0.922	0.891	-3.35

¹ Calculation for the GAF: (.52466*work gpci) + (.03865*mp gpci) + (.52466*pe gpci).

In the CY 2005 PFS proposed rule, published August 15, 2004, we discussed the issue of changes to the GPCI payment localities (69 FR 47504). In that proposed rule, we noted that we look for the support of a State medical society as the impetus for changes to existing payment localities. Because the GPCIs for each locality are calculated using the average of the county-specific data from all of the counties in the locality, removing high cost counties from a locality will result in lower GPCIs for the remaining counties. Therefore, because of this redistributive impact, we have refrained, in the past, from making changes to payment localities unless the State medical association provides evidence that any proposed change has statewide support.

We would be interested in receiving suggestions on alternative ways that we could administratively reconfigure payment localities that could be developed and proposed in future rulemaking. In addition, MEDPAC and the GAO have both expressed interest in studying the physician payment localities. CMS intends to work with both groups to study our current methodology and develop alternative options.

C. Medicare Telehealth Services

[If you choose to comment on issues in this section, please include the caption "TELEHEALTH" at the beginning of your comments.]

1. Requests for Adding Services to the List of Medicare Telehealth Services

Section 1834(m)(4)(F) of the Act defines telehealth services as professional consultations, office visits, and office psychiatry services (identified as of July 1, 2000 by CPT codes 99241 through 99275, 99201 through 99215, 90804 through 90809, and 90862) and any additional service specified by the Secretary. In addition, the statute requires us to establish a process for adding services to or deleting services from the list of telehealth services on an annual basis.

In the December 31, 2002 Federal Register (67 FR 79988), we established a process for adding services to or deleting services from the list of Medicare telehealth services. This process provides the public an ongoing opportunity to submit requests for adding services. We assign any request to make additions to the list of Medicare telehealth services to one of the following categories:

- Category #1: Services that are similar to office and other outpatient visits, consultation, and office psychiatry services. In reviewing these requests, we look for similarities between the proposed and existing telehealth services for the roles of, and interactions among, the beneficiary, the physician (or other practitioner) at the distant site and, if necessary, the telepresenter. We also look for similarities in the telecommunications system used to deliver the proposed service, for example, the use of interactive audio and video equipment.
- Category #2: Services that are not similar to the current list of telehealth services. Our review of these requests includes an assessment of whether the use of a telecommunications system to deliver the service produces similar diagnostic findings or therapeutic interventions as compared with the faceπtoπface "hands on" delivery of the same service. Requestors should submit

evidence showing that the use of a telecommunications system does not affect the diagnosis or treatment plan as compared to a face π to π face delivery of the requested service.

Since establishing the process, we have added the following to the list of Medicare telehealth services: psychiatric diagnostic interview examination; ESRD services with two to three visits per month and four or more visits per month (although we require at least one visit a month by a physician, CNS, NP, or PA to examine the vascular access site); and individual medical nutritional therapy.

Requests to add services to the list of Medicare telehealth services must be submitted and received no later than December 31 of each CY to be considered for the next proposed rule. For example, requests submitted before the end of CY 2005 are considered for the CY 2007 proposed rule. For more information on submitting a request for an addition to the list of Medicare telehealth services, visit our Web site at www.cms.hhs.gov/telehealth.

2. Submitted Requests for Addition to the List of Telehealth Services

We received the following requests for additional approved services in CY 2005: (1) Nursing facility care; (2) speech language pathology; (3) audiology; and (4) physical therapy services. The following is a discussion of the requests submitted in CY 2005.

Nursing Facility Care

The American Telemedicine Association (ATA) and an individual practitioner submitted a request to add the following services: Initial nursing facility care (as represented by HCPCS codes 99304 through 99306); subsequent nursing facility care (HCPCS codes 99307 through 99310); nursing facility discharge services (HCPCS codes 99315 and 99316); and other nursing facility services as described by HCPCS code 99318. The requestors explained that the primary purpose of using telehealth in the Skilled Nursing Facility (SNF) setting is to provide urgent consultation when the patient has a sudden change in his or her condition, and to provide increased availability to primary and specialty care on days when the physician is not present in the SNF or when traveling is a hardship. The requestors believe that the current list of Medicare telehealth services is not appropriate because the list does not include codes that are specifically intended for nursing facility residents.

CMS Review

Nursing Facility Care

Section 1834(m)(C)(ii) of the Act defines a telehealth originating site as a physician's or practitioner's office; or a hospital, critical access hospital (CAH), rural health clinic, or FQHC. SNFs are not defined in the statute as originating sites.

However, section 418 of the MMA required the Health Resources Services Administration (HRSA), a component of HHS, in consultation with CMS, to conduct an evaluation of demonstration projects under which SNFs, as defined in section 1819(a) of the Act, are treated as originating sites for Medicare telehealth services. The MMA also required the Secretary to submit a report to the Congress that includes recommendations on "mechanisms to ensure that permitting a SNF to serve as an originating site for the use of telehealth services or any other service delivered via a telecommunications system does not serve as a substitute for in-person visits furnished by a physician, or for in-person visits furnished by a physician assistant (PA), nurse practitioner (NP), or clinical nurse specialist (CNS), as is otherwise required by the Secretary" and provides the authority to include SNFs as a Medicare telehealth originating site, if the Secretary concludes in the report that it is advisable to do so and that mechanisms could be established to ensure that the use of a telecommunications system does not serve as a substitute for the required inperson physician or practitioner SNF visits. This report is currently under review in DHHS.

Given that SNFs are not defined in the statute as a telehealth originating site and the report to the Congress, as

discussed above, is currently being reviewed within DHHS, we cannot consider approving nursing facility care for telehealth at this time. We will review and consider the recommendations of the report to the Congress once it is issued. If it is determined that SNFs should be added as an originating site, this change will be considered in future rulemaking.

Speech Language Pathology, Audiology and Physical Therapy

The ATA and an individual practitioner submitted a request to add various speech therapy, audiology and physical therapy services to the list of Medicare telehealth services. The requestors also asked us to add physical therapists, speech language pathologists and audiologists to the list of approved telehealth practitioners.

CMS Review

Physical therapists, speech language pathologists and audiologists are not permitted under current law to provide and receive payment for Medicare telehealth services at the distant site. The statute permits only a physician, as defined by section 1861(r) of the Act or a practitioner as described in section 1842(b)(18)(C) of the Act (CNS, NP, PA, nurse midwife, clinical psychologist, clinical social worker, registered dietitian or other nutrition professional), to furnish Medicare telehealth services. Since speech language pathologists, audiologists and physical therapists are not permitted under current law to provide and receive payment for Medicare telehealth services at the distant site, we cannot fully consider the request to add speech therapy, audiology services and physical therapy to the list of Medicare telehealth services. We are exploring this issue as part of a report to the Congress (required by section 223(d) of BIPA) on additional sites and settings, geographic areas, and types of non-physician practitioners that could be reimbursed for the provision of telehealth services.

D. Miscellaneous Coding Issues

[If you choose to comment on issues in this section, please include the caption "Miscellaneous Coding Issues" at the beginning of your comments.]

The following sections address specific coding issues related to payment for services under the PFS.

1. Global Period for Remote Afterloading High Intensity Brachytherapy Procedures

CPT Code 77783, Remote afterloading high intensity brachytherapy; 9–12 source positions or catheters, resides in a family of codes with varying numbers of source positions. All of the codes in the family, CPT codes 77781–77784 are currently designated as 90-day global services. CPT codes 77781–77784 are used to treat many clinical conditions, but primarily patients with prostate cancer, breast cancer and sarcoma. Patients with any of these conditions usually receive several treatments (2–10) over a two to ten day period of time. Due to the increasing variability in treatment regimens, it is difficult to assign RVUs for a "typical" patient based on a global period of 90 days.

Therefore, we are proposing that this family of codes (CPT codes 77781, 77782, 77783 and 77784) be assigned a global period of "XXX", which will permit separate payment each time the services are provided and allow payment to be based on the actual service(s) provided. We will request that the RUC revalue the work RVUs and the PE inputs for these services if a change in the global period is finalized. However we are proposing, on an interim basis, to revise the work RVUs and PE inputs to reflect the removal of the postoperative visit, CPT code 99212, that is currently assigned to these services. The proposed interim work RVUs for these services would be as follows:

- 77781 = 1.21
- 77782 = 2.04
- 77783 = 3.27
- 77784 = 5.15

We are also proposing to delete the registered nurse (RN) time in the post-service period as well as the patient gowns for the post-service visit. We would also note that, to the extent that these services are performed as staged procedures, providers may make use of applicable modifiers.

2. Assignment of RVUs to CPT Codes for Proton Beam Treatment Delivery Services

We have received a request to assign PE inputs for the non-facility setting to Proton Beam treatment delivery services represented by CPT codes 77520 through 77525.

These services are currently carrier-priced; therefore, payment in the facility or non-facility setting is established by each carrier. To the extent that physicians and suppliers wish to have national RVUs assigned for these services, there is an established process utilizing the AMA–RUC to recommend work RVUs, as well as the direct PE inputs used to compute the PE RVUs, to CMS. We would strongly encourage the physicians and suppliers to use this established process, and would also be

interested in receiving comments on this issue.

E. Deficit Reduction Act (DRA) Related Proposals

[If you choose to comment on issues in this section, please include the caption "DRA PROPOSALS" at the beginning of your comments.]

The DRA of 2005 (Pub. L. 109–171), was enacted February 8, 2006 and included provisions that affect the Medicare program. The following section addresses the specific DRA provisions that are being addressed in this proposed rule.

1. Section 5102—Proposed Adjustments for Payments to Imaging Services

Section 5102 of the DRA includes two provisions that affect payment of imaging services under the Medicare physician fee schedule. The first provision addresses payment for certain multiple imaging procedures for CY 2007 and application of budget neutrality while the second provision addresses limiting the payment amount under PFS to the outpatient department (OPD) payment amount for the technical component (TC) of certain imaging services.

(a) Payment for Multiple Imaging Procedures for 2007

In general, Medicare prices diagnostic imaging procedures in the following three ways:

- The professional component (PC) represents the physician's interpretation (PC-only services are billed with the 26 modifier).
- The TC represents PE and includes clinical staff, supplies, and equipment (TC-only services are billed with the TC modifier).
- The global service represents both PC and TC.

As discussed in the CY 2006 PFS final rule with comment period (70 FR 70261), in the CY 2006 PFS proposed rule (70 FR 45764 through 46064), we had proposed to reduce payment for the TC of selected diagnostic imaging procedures belonging to one of eleven imaging families when the procedures are performed on contiguous body areas by 50 percent for CY 2006. However, in the final rule with comment period, we stated that we would phase-in the 50 percent reduction over two years, beginning with a 25 percent reduction in 2006. We also sought additional data and comments on the appropriateness of 50 percent as the final level of reduction. The reduction applies to the TC and the technical portion of the global service, but does not apply to the PC of the service. Currently, we make

full payment for the highest priced procedure and reduce payment for each additional procedure by 25 percent, when more than one procedure from the same imaging family is performed during the same session on the same

As described in the CY 2006 PFS final rule with comment period, at the time, the statute required us to make changes such as this in a budget neutral manner, meaning that the estimated savings generated by the application of the multiple imaging procedure payment reduction were used to increase payment for other physician fee schedule services. We increased the CY 2006 PE RVUs by 0.3 percent to offset the estimated savings generated by the multiple imaging payment reduction policy.

Subsequent to the publication of the CY 2006 PFS final rule with comment period, section 5102(a) of the DRA (Multiple Procedure Payment Reduction for Imaging Exempted From Budget Neutrality), required that "effective for fee schedules established beginning with 2007, reduced expenditures attributable to the multiple procedure payment reduction for imaging under the final rule published by the Secretary in the Federal Register on November 21, 2005 (42 CFR 405, et al.) insofar as it relates to the physician fee schedules for 2006 and 2007" are exempted from the budget neutrality provision. As a result, we are proposing to remove the 0.3 percent increase to the CY 2006 PE RVUs from the CY 2007 PE RVUs in accordance with the statute.

In addition, in response to our request for data on the appropriateness of the 50 percent reduction in the CY 2006 PFS final rule with comment period (70 FR 70261), the ACR provided information for 25 code combinations supporting a reduction of between 21 and 44 percent. Given the expected interaction between the multiple procedure imaging policy and the further imaging payment reductions mandated by section 5102(b) of the DRA described below, along with the new information we have received from the ACR on the multiple imaging procedure policy as it applies to common combinations of imaging services, we believe it would be prudent to maintain the multiple imaging payment reduction at its current 25 percent level while we continue to examine the appropriate payment levels. Therefore, we are proposing to continue the multiple imaging payment reduction for 2007 at the 25 percent level. We would proceed through future rulemaking in the event we determine that revisions to the policy are warranted.

(b) Reduction in TC for Imaging Services Under the PFS to OPD Payment Amount

Section 5102(b)(1) of the DRA amended section 1848 of the Act and requires that, with respect to imaging services, if—

- "(i) The technical component (including the technical component portion of a global fee) of the service established for a year under the fee schedule * * *, without application of the geographic adjustment factor * * *, exceeds,
- (ii) The Medicare OPD fee schedule amount established under the prospective payment system for hospital outpatient department services * * * for such service for such year, determined without regard to geographic adjustment * * *, the Secretary shall substitute the amount described in clause (ii), adjusted by the geographic adjustment factor [under the PFS] * * *, for the fee schedule amount for such technical component for such year."

As required by the statute, for imaging services (described below) furnished on or after January 1, 2007, we will cap the PFS payment amount for the year (prior to geographic adjustment) by the CY 2007 outpatient prospective payment system (OPPS) payment amount (prior to geographic adjustment). We will then apply the PFS geographic adjustment to the capped payment amount.

Section 5102(b)(2) of the DRA exempts the estimated savings from this provision from the PFS budget neutrality requirement. Section 5102(b)(1) of the DRA defines imaging services as "* * imaging and computer-assisted imaging services, including X-ray, ultrasound (including echocardiography), nuclear medicine (including positron emission tomography), magnetic resonance imaging, computed tomography, and fluoroscopy, but excluding diagnostic and screening mammography."

In order to apply section 5102(b) of the DRA, we needed to determine the CPT and alpha-numeric HCPCS codes that fall within the scope of "imaging services" defined by the DRA provision. In general, we believe that imaging services provide visual information regarding areas of the body that are not normally visible, thereby assisting in the diagnosis or treatment of illness or injury. We began by considering the CPT 7XXXX series codes for radiology services and then adding in other CPT codes and alpha-numeric HCPCS codes that describe imaging services. We then excluded nuclear medicine services that were either non-imaging diagnostic or treatment services. We also excluded all

codes for unlisted procedures, since we would not know in advance of any specific clinical scenario whether or not the unlisted procedure was an imaging service. We excluded all mammography services, consistent with the statute. We excluded radiation oncology services that were not imaging or computerassisted imaging services. We also excluded all HCPCS codes for imaging services that are not separately paid under the OPPS since there would be no corresponding OPPS payment to serve as a TC cap. We excluded any service where the CPT code describes a procedure for which fluoroscopy, ultrasound, or another imaging modality is either included in the code whether or not it is used or is employed peripherally in the performance of the main procedure, for example, 31622 for bronchoscopy with or without fluoroscopic guidance and 43242 for

upper gastrointestinal endoscopy with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s). In these cases, we are unable to clearly distinguish imaging from non-imaging services because, for example, a specific procedure may or may not utilize an imaging modality, or the use of an imaging technology cannot be segregated from the performance of the main procedure. Note that we included carrier priced services since these services are within the statutory definition of imaging services and are also within the statutory definition of PFS services (that is, carrier-priced TCs of PET scans).

Our proposed list of codes that identify imaging services defined by the DRA OPPS cap provision can be found in Addendum F to this proposed rule. Note that this is the list of imaging

services for which we propose to make the comparison between the PFS TC payment amount and the OPPS payment amount used to establish OPD payment. Payment for an individual service on this list would only be capped if the PFS TC payment amount exceeds the OPPS payment amount.

To the extent changes are made to codes for services already on the list, we propose to update the list through program instructions to our contractors. To the extent that the same imaging service is coded differently under the PFS and the OPPS, we propose to crosswalk the code under the PFS to the appropriate code under the OPPS that could be reported for the same service provided in the hospital outpatient setting. Our proposed list of crosswalks is below:

MFS code Descriptor		OPPS code	Desc
76093 76094 71555 73725	Mri angio, abdom w or w/o dye Magnetic image, breast Magnetic image, both breasts Mri angio chest w or w/o dye Mr ang lwr ext w or w/o dye Mr angio pelvis w/o & w/dye	C8905 C8908 C8909 C8912	MRI w/o fol w/cont, brst, un. MRI w/o fol w/cont, breast. MRA w/cont, chest. MRA w/cont, lwr ext.

(c) Interaction of the Multiple Imaging Payment Reduction and the OPPS Cap

For CY 2007 imaging services potentially subject to both the multiple

imaging reduction and the OPPS cap, we propose to first apply the multiple imaging payment reduction and then apply the OPPS cap to the reduced amount as illustrated in the following example.

HCPCS	Pre-OPPS cap MPFS rate	25% Mul- tiple imag- ing reduc- tion	OPPS cap rate	Final MPFS payment
7XXX1	\$341.89	\$256.42	\$316.55	\$256.42
	552.86	414.65	391.83	391.83

We considered first applying the OPPS cap and then applying the multiple procedure reduction. However, as indicated in the CY 2006 OPPS final rule, we received public comments suggesting that the OPPS payment rates may implicitly include at least some multiple imaging discount. While we continue to examine this issue, we believe the most appropriate policy is to apply the multiple imaging payment reduction prior to the application of the OPPS cap.

2. Section 5107—Revisions to Payments for Therapy Services

Section 1833(g) of the Act applies an annual per beneficiary combined cap beginning January 1, 1999, on outpatient physical therapy and speech-language

pathology services and a similar separate cap on outpatient occupational therapy services. These caps apply to expenses incurred for the respective therapy services under Medicare Part B, with the exception of outpatient hospital services. The caps were in effect from January 1, through December 31, 1999, from September 1, 2003 through December 7, 2003, and beginning January 1, 2006. In 2000 through 2002, and from December 8, 2003 through December 31, 2005, the Congress placed moratoria on implementation of the caps. Section 1833(g)(2) of the Act provides that, for 1999 through 2001, the caps were \$1500, and for years after 2001, the caps are equal to the preceding year's cap increased by the percentage increase in

the Medicare Economic Index (MEI) (except that if an increase for a year is not a multiple of \$10, it is rounded to the nearest multiple of \$10).

We implemented the separate statutory limits of \$1740 for outpatient physical therapy and speech-language pathology services and \$1740 for occupational therapy on January 1, 2006. The DRA of 2005 was enacted on February 8, 2006. Section 5107(a) of the DRA required the Secretary to develop an exceptions process for the therapy caps effective January 1, 2006. The exceptions process applies only to expenses incurred in 2006. Details of the exceptions process were published in a manual change on February 13, 2006 (CR4364). The change request

consists of three transmittals with current numbers of—

- Transmittal 855, CR 4364, Pub. L. 100–04;
- Transmittal 47, CR 4365, Pub. L. 100–02; and
- Transmittal 140, CR 4364, Pub. L.
 100–08.

The transmittals are available on our Web site at http://www.cms.hhs.gov/Transmittals/.

In accordance with the statute, the therapy caps will remain in effect, but without the exceptions process, with respect to expenses incurred beginning on January 1, 2007. The dollar amount of the therapy caps in 2007 will be the 2006 rate (\$1740) increased by the percentage increase in the MEI. As noted above, under current law, the exceptions process will not apply to therapy services incurred after December 31, 2006, but the therapy caps will remain inapplicable to therapy services provided in the outpatient hospital setting as provided in section 1833(g) of the Act.

Section 5107(b) of the DRA requires the Secretary to implement, by July 1, 2006, edits for clinically illogical combinations of procedure codes and other edits in order to limit inappropriate payment for therapy services. In January 2006, we implemented Correct Coding Initiative (CCI) edits for the therapy providers that bill to the fiscal intermediaries, thus, addressing the section 5107 of the DRA requirement with respect to edits for clinically illogical combinations of procedure codes. Adoption of these code edits ensures that these providers of outpatient Part B therapy services, including SNFs, comprehensive outpatient rehabilitation facilities, certain outpatient physical therapy and speech-language therapy providers (rehabilitation agencies) and home health agencies (HHAs) (where beneficiary is not under a Part A plan of care) meet the same CCI edit requirements as those that have been in place for physicians, private practice therapists, and OPPS hospitals. We are considering the implementation of other edits in the future to further address concerns about inappropriate payment for therapy services.

3. Section 5112-Proposed Addition of Ultrasound Screening for Abdominal Aortic Aneurysm (AAA)

Section 5112 of the DRA of 2005 amended section 1861 of the Act to provide for coverage under Part B of ultrasound screening for AAAs, effective for services furnished on or after January 1, 2007, subject to certain eligibility and other limitations. This screening test will be available even if the qualifying patient does not present signs or symptoms of disease or illness.

To conform the regulations to the statutory requirements of section 5112 of the DRA, we are proposing to include an exception in § 411.15(a)(1) to permit coverage for ultrasound screening for AAAs that meet the conditions for coverage that we are proposing to specify under new § 410.19(b) (Conditions for coverage of an ultrasound screening for abdominal aortic aneurysms). We are also adding a new § 411.15(k)(12).

As provided in the DRA, this new coverage allows payment for a one-time only screening examination. We are proposing to add new § 410.19(b) to provide for the coverage of the screening examinations for AAAs as specified in section 5112 of the DRA. We are also proposing to add new § 410.19(c) (Limitation on coverage of ultrasound screening for abdominal aortic aneurysms.) to provide the limitation on coverage for an individual who is not an eligible beneficiary as defined in proposed new § 410.19(a).

We are proposing definitions set forth in new § 410.19(a) of this proposed rule that would be included to implement the statutory provisions and to help the reader in understanding the provisions of this regulation. The proposed definitions include the following terms:

- Eligible beneficiary.
- Ultrasound screening for abdominal aortic aneurysms.

Specifically, section 5112(a)(1) of the DRA amended section 1861 of the Act to provide that coverage of ultrasound screening for AAAs will be available for an individual—(i) who receives a referral for such an ultrasound screening as a result of an initial preventive physical examination (as defined in section 1861(ww)(1) of the Act); (ii) who has not been previously furnished such an ultrasound screening under this title; and (iii) who has a family history of AAA or manifests risk factors included in a beneficiary category recommended for screening by the United States Preventive Services Task Force regarding AAAs.

Section 5112(a)(2) of the DRA also adds a definition of the term "ultrasound screening for an Abdominal Aortic Aneurysm" to mean, "(1) a procedure using sound waves (or other procedures using alternative technologies, of commensurate accuracy and cost, that the Secretary may specify) provided for the early detection of abdominal aortic aneurysm; and (2) includes a physician's interpretation of the results of the procedure."

In developing the proposed rule based on this provision, we reviewed the 2005 United States Preventive Services Task Force (USPSTF) recommendations and related material on ultrasound screening for AAAs. This includes—

• A recommendation for a one-time ultrasound screening for men aged 65 to 75 who have smoked at least 100 cigarettes in their lifetime;

 No recommendation for or against ultrasound screening for AAAs for men who have not smoked at least 100 cigarettes in their lifetime; and

• A recommendation against routine screening for AAAs in women.

Based on the statutory language and the USPSTF recommendations outlined above, we are proposing to define the term "eligible beneficiary" for coverage of ultrasound screening examinations for AAA to mean an individual who—

- Has received a referral for an ultrasound screening as a result of an initial preventive physical examination (as defined in section 1861(ww)(1) of the Act);
- Has not been previously furnished such a covered ultrasound screening examination under the Medicare program; and
- Is included in at least one of the following risk categories:
 - + Has a family history of an AAA; or
- + Is a man age 65 to 75 years who smoked at least 100 cigarettes in his lifetime; or
- + Is an individual who manifests other risk factors that are described in a benefit category recommended by the USPSTF regarding an AAA that has been determined by the Secretary through the NCD process.

To facilitate our consideration of possible expansions of coverage in the future for identifying (1) other risk factors in a benefit category recommended for screening for the early detection of AAAs by the USPSTF, and (2) alternative screening technologies to ultrasound screening for AAAs of commensurate accuracy and cost, we are proposing to add language to our regulations that would allow us to make determinations through the NCD process. The NCD process would allow the Secretary to expand coverage more quickly following an assessment of those subjects than is possible under the standard rulemaking process. We intend to use the NCD process, which includes an opportunity for public comments, for evaluating the medical and scientific issues relating to the coverage of alternative screening technologies and the identification of other risk factors for AAAs recommended by the USPSTF that may be brought to our attention in the future. Use of an NCD to establish

a change in the scope of benefits is authorized by section 1871(a)(2) of the Act. An aggrieved party can challenge an NCD under the procedures established by section 1869(f) of the Act. These proposed coverage provisions would be set forth in proposed new § 410.19 (a)(1)(i) and § 410.19(a)(2)(iii)(C).

Section 5112(b) of DRA also amended section 1861(ww)(2) of the Act (the initial preventive physical examination benefit) by adding the new ultrasound screening benefit to the list of preventive services for which physicians and other qualified nonphysician practitioners must provide "education, counseling and referral" to new beneficiaries who take advantage of the initial preventive physical examination benefit within the first 6 months after the effective date of their first Part B coverage period. Therefore, we are also proposing to amend § 410.16(a)(7) of the regulations so that it reflects the additional responsibilities that physicians and qualified nonphysician practitioners will have under the initial preventive physical examination benefit with respect to the new ultrasound screening benefit.

Beginning January 1, 2007, we are proposing to pay for ultrasound screening for AAAs through the use of a new HCPCS code GXXX1, Ultrasound, B-scan and/or real time with image documentation; for abdominal aortic aneurysm (AAA) screening. We are proposing that payment for this service be made at the same level as CPT code 76775 Ultrasound, retroperitoneal (e.g., renal, aorta, nodes), B-scan and/or real time with image documentation; limited. CPT code 76775 is used to bill for the service when it is provided as a diagnostic test, and we believe the service associated with the proposed HCPCS code reflects equivalent resources and work intensity to those contained in CPT code 76775.

In addition, since the DRA provides that the Medicare Part B deductible will not apply with respect to ultrasound screening for abdominal aortic aneurysm (as defined in section 1861(bbb) of the Act), we are proposing to revise § 410.160 to include an exception from the Medicare Part B deductible for the ultrasound screening for abdominal aortic aneurysm as described in proposed § 410.19. (Conditions for coverage of an ultrasound screening for abdominal aortic aneurysms.)

4. Section 5113—Proposed Non-Application of the Part B Deductible for Colorectal Cancer Screening Tests

Current Medicare policy requires that, with limited exceptions, incurred expenses for covered part B services are subject to, and count toward meeting the Part B annual deductible. Section 5113 of the DRA amended section 1833(b) of the Act to provide for an exception to the application of the Part B deductible with respect to colorectal cancer screening tests. Beginning January 1, 2007, colorectal cancer screening services, as described in section 1861(pp)(1) of the Act, are no longer subject to the Part B deductible. The conditions for and limitations on coverage for colorectal cancer screening tests under Medicare part B are described in § 410.37.

To conform our regulations to this statutory change, we are proposing to revise § 410.160 to include an exception from the Part B annual deductible for the colorectal cancer screening services described in § 410.37.

5. Section 5114—Proposed Addition of Diabetes Outpatient Self-Management Training Services (DSMT) and Medical Nutrition Therapy (MNT) for the FQHC Program

Section 5114 of the DRA amended section 1861(aa)(3) of the Act to add DSMT and MNT services to the list of Medicare covered and reimbursed services under the Medicare FQHC benefit, effective for services provided on or after January 1, 2006. Although this statutory change has already been implemented in administrative instructions, we are proposing to conform the regulations to the new statutory requirement.

FQHCs certified as DSMT and MNT providers have been allowed to bundle the cost of those services into their FOHC payment rates. But before the enactment of the DRA, the provision of these services would not generate a separate FQHC visit payment. Effective for services furnished on or after January 1, 2006, FQHCs that are certified providers of DSMT and MNT services can receive per visit payments for covered services furnished by registered dietitians or nutrition professionals. In other words, if all relevant program requirements are met, these services are included under the Medicare FQHC benefit as billable

In order to conform the regulations, we are proposing to amend § 405.2446(b) to expand the scope of FQHC services to include certified providers of DSMT and MNT services

by adding a new paragraph (10). We are also proposing to revise § 405.2463 by—

- Revising paragraph (a) to expand the definition of an FQHC visit to include certified providers of DSMT and MNT services under new sub-paragraph (a)(1)(ii)(B). We would also revise the definition of an RHC visit in new subparagraph (a)(1)(i) to include a face-to-face encounter between a patient and a clinical psychologist or clinical social worker to conform to statutory language at section 1861(aa)(1)(B) of the Act. We are also proposing to redesignate and revise paragraphs (b) and (c) as new paragraphs (a)(2) and (a)(3), respectively.
- We are proposing to incorporate paragraph (a)(2) into (a)(1), and to redesignate and revise current paragraph (a)(3) as new paragraph (b). We would also clarify that it is generally permissible for both FOHCs and Rural Health Clinics to furnish, when necessary, most types of medical and other health visits on the same day to the same patient. We are also proposing to amend this paragraph to permit a separate additional FQHC visit for DSMT and MNT services (which may occur on the same date of service when the beneficiary receives care from their FQHC physician or non-physician practitioner) when reasonable and necessary, consistent with the Congressional mandate under section 5114 of the DRA to provide coverage and adequate access to these services in the FQHC setting.
- We are proposing to redesignate and revise current paragraph (a)(4) as new paragraph (c).
- F. Proposed Payment for Covered Outpatient Drugs and Biologicals (ASP Issues)

[If you choose to comment on issues in this section, please include the caption "ASP Issues" at the beginning of your comments.]

Medicare Part B covers a limited number of prescription drugs and biologicals. For the purposes of this proposed rule, the term "drugs" will hereafter refer to both drugs and biologicals. Medicare Part B covered drugs not paid on a cost or prospective payment basis generally fall into the following three categories:

- Drugs furnished incident to a physician's service.
 - DME drugs.
- Drugs specifically covered by statute (certain immunosuppressive drugs, for example).

Beginning in CY 2005, the vast majority of Medicare Part B drugs not paid on a cost or prospective payment basis are paid under the ASP methodology. The ASP methodology is based on data submitted to us quarterly by manufacturers. In addition to the payment for the drug, Medicare currently pays a furnishing fee for blood clotting factors, a dispensing fee for inhalation drugs, and a supplying fee to pharmacies for certain Part B drugs.

In January 2006, the drug coverage available to Medicare beneficiaries expanded with the implementation of Medicare Part D. The Medicare Part D program does not change Medicare Part

B drug coverage.

This section of the preamble discusses proposed changes and issues related to the determination of the payment amounts for covered Part B drugs and furnishing blood clotting factor. This section also discusses proposed changes to how manufacturers calculate and report ASP data to us.

1. ASP Issues

Section 303(c) of the MMA amended Title XVIII of the Act by adding new section 1847A. This new section revised the payment methodology for the vast majority of drugs and biologicals not paid on a cost or prospective payment basis furnished on or after January 1, 2005. The ASP reporting requirements are set forth in section 1927(b) of the Act. Manufacturers must submit ASP data for each 11-digit National Drug Code (NDC) to us quarterly. The manufacturers' submissions are due to us not later than 30 days after the last day of each calendar quarter. The methodology for developing Medicare drug payment allowances based on the manufacturers' submitted ASP data is specified in the regulations in part 414, subpart K. We update the Part B drug payment amounts quarterly based on the data we receive.

In this section of the preamble, we discuss our intent to issue a final rule to implement the provisions in the MMA related to the calculation and submission of manufacturers' ASP data, and seek further comments on specific issues related to price concessions and certain fees.

On April 6, 2004, we published the Manufacturer's Submission of Average Sales Price Data for Medicare Part B Drugs and Biologicals (ASP) interim final rule with comment period (IFC) (69 FR 17935) to implement the ASP calculation and reporting requirements. Manufacturers were required to submit their initial quarterly ASP data to us shortly thereafter, beginning April 30, 2004. We received comments from drug manufacturers, pharmacies, physicians, national associations of the pharmaceutical industry, national associations of physicians, and

consultants. These comments addressed a variety of aspects of calculating and reporting ASPs. On September 16, 2004, we published the Manufacturer's Submission of Average Sales Price Data for Medicare Part B Drugs and Biologicals (ASP) final rule (69 FR 55763) addressing only the comments pertaining to the methodology for estimating lagged price concessions. We have also addressed ASP calculation and reporting requirements in other proposed and final rules and information collection notices, including rulemaking to implement the Competitive Acquisition Program for Part B Drugs and Biologicals (CAP). (See 70 FR 39069, 70 FR 45842, 70 FR 70215, and 70 FR 70477.) In addition, we posted official agency guidance, including responses to frequently asked questions, on our Web site to implement the ASP provisions in accordance with section 1847A(c)(5)(C) of the Act.

We intend to publish a final rule addressing comments on the April 6, 2004 IFC in the near future. We may publish the final rule as part of this rulemaking, or we may publish a separate final rule, in either case after the close of the comment period for this proposed rule. Because the comments received during the comment period in response to the April 6, 2004 IFC were made during the initial months of manufacturers' experience with calculating and reporting ASPs and prior to publication of payment amounts based on the ASP methodology, we believe there is good reason to provide the public with the opportunity for additional comments based on what is now more than a year and a half of experience with the ASP reporting requirements. Therefore, we seek comments on the ASP reporting provisions in the April 6, 2004 IFC. In particular, we seek comments on the issues discussed in the sections below.

We note that we received many comments in response to the April 6, 2004 interim final rule on the use and potential impacts of the ASP payment methodology. As noted above, we are reopening the comment period on the issue of ASP reporting. Thus, comments about the use or appropriateness of the ASP payment methodology are outside the scope of this rulemaking and the ASP reporting rule (CMS-1380-IFC). Therefore, comments about the appropriateness and use of 106 percent of ASP as the basis for the Medicare Part B drug payment rates will be outside the scope of the comments considered for the final ASP reporting rule we are preparing to publish.

a. Fees Not Considered Price Concessions

Section 1847A(c)(5)(A) of the Act states that the ASP is to be calculated by the manufacturer on a quarterly basis. As a part of that calculation, manufacturers are to take into account price concessions such as—

- Volume discounts;
- Prompt pay discounts;
- Cash discounts;
- Free goods that are contingent on any purchase requirement;
 - Chargebacks; and
- Rebates (other than rebates under the Medicaid drug rebate programs).

If the data on these price concessions are lagged, then the manufacturer is required to estimate costs attributable to these price concessions using the required ratio methodology as specified in 42 CFR part 414, subpart J, § 414.804(a)(3).

Among the comments from drug manufacturers and national associations representing wholesalers and distributors, we received requests for clarification and detailed guidance on the treatment of administrative fees, service fees and fees paid to pharmacy benefit managers (PBMs) in the ASP calculation. We posted guidance on our Web site (http://questions.cms.hhs.gov/ cgi-bin/cmshhs.cfg/php/enduser/ std_adp.php?p_faqid=3323&p_ created=1095344721& $p_sid = Ghuscgci \& p_accessibility = 0 \&$ p_lva=&p_sp=cF9zcmNoPTEmcF9zb3I 0X2J5P\$ZwX2dyaWRzb3J0 PSZwX3Jvd19jbnQ9M zEmcF9wcm9kcz04LD U2LDYwNCZwX2NhdHM9JnBfc HY9Mv42MDOmcF9idi0mcF9zZWFvY 2hfdHlwZT1hbnN3ZXJzLnNl YXJjaF9ubCZwX3BhZ2U9MQ**&p_li=& *p_topview=1*) to clarify that in the absence of specific guidance in the Social Security Act or Federal regulations, the manufacturer may make reasonable assumptions in its calculations of ASP, consistent with the general requirements and intent of the Social Security Act, Federal regulations, and its customary business practices. These assumptions should be submitted along with the ASP data. In December 2004, we posted further guidance on our website addressing service fees and administrative fees paid to buyers (http://questions.cms.hhs.gov/cgi-bin/ cmshhs.cfg/php/enduser/ std_adp.php?p_faqid=3318&p_ created=1095343992&p_sid=a2qUcgci &p_accessibility=0&p_lva=&p _sp=cF9zcmNoPTEmcF9zb3J0X2J5PSZ wX2dyaWRzb3J0PSZwX3Jvd19jbnQ9Mz EmcF9wcm9kcz04LDU2LDY wNCZwX2NhdHM9

InBfcHY9My42MDQmcF9jdj0 mcF9zZWFvY2hfdH lwZT1hbnN3ZXJzLnNlYXJ jaF9ubCZwX3BhZ2U9MQ**&p_li=&p _topview=1 and http:// questions.cms.hhs.gov/cgi-bin/ cmshhs.cfg/php/enduser/std_adp. php?p_faqid=4136&p _created=1109786814&p_sid=bxw-cgci &p_accessibility=0&p_lva=& $p_sp=cF9zcmNoPTE$ mcF9zb3J0X2J5PSZwX2 dyaWRzb3J0PSZwX3Jvd19jbn Q9MzEmcF9wcm9kcz04LDU2LDY wNCZwX2NhdHM9JnBfcHY9 My42MDQmcF9jdj0mcF9zZWFyY2hfd HlwZT1hbnN3ZXJzLnNlYXJjaF9 ubCZwX3BhZ2U9MQ**&р $_li=&p_topview=1).$

On July 6, 2005, we restated our guidance on service fees in the preamble of the Competitive Acquisition of Outpatient Drugs and Biologicals Under Part B (CAP) interim final rule with comment (70 FR 39069). Subsequently, we have received requests for clarification on how fees paid to entities such as group purchasing organizations (GPOs) or PBMs must be treated for purposes of the ASP calculation.

We propose to further clarify in the final ASP reporting rule that, beginning with the ASP reporting for sales during the first calendar quarter of 2007, bona fide service fees that are paid by a manufacturer to an entity, whether or not the entity takes title to the drug, are not considered price concessions under § 414.804(a)(2) insofar as, and to the extent that, they satisfy the definition of a bona fide service fee that we are proposing at § 414.802. In § 414.802, we propose to define bona fide service fees as fees paid by a manufacturer to an entity that represent fair market value for a bona fide, itemized service actually performed on behalf of the manufacturer that the manufacturer would otherwise perform (or contract for) in the absence of the service arrangement, and that are not passed on, in whole or in part, to a client or customer of an entity, whether or not the entity takes title to the drug. Our current guidance, which provides that bona fide service fees means expenses that would have generally been paid for by the manufacturer at the same rate had these services been performed by other entities, would continue unless we provide an alternative approach as discussed below. Further, we propose to clarify in the final ASP reporting rule that fees, including service fees, administrative fees and other fees, paid to GPOs or PBMs are not considered price concessions under § 414.804(a)(2) insofar as, and to the extent that, they satisfy the definition of a bona fide

service fee that we have proposed at § 414.802.

In comments on the April 6, 2004 IFC, groups representing wholesalers, distributors and specialty pharmacies provided some insight into the types of activities that are performed in the distribution of drugs. These commenters suggested that costs for handling, storage, inventory reporting, shipping, receiving, patient education, disease management and data should be borne by manufacturers and be excluded from the ASP calculation as bona fide services. However, these commenters did not provide detailed information about whether and how one would determine the extent to which these activities are bona fide services actually performed on behalf of the manufacturer or otherwise.

Because the scope of appropriate services may vary across categories of drugs, we are considering providing guidance on the types of services that may qualify as bona fide services for purposes of the ASP calculation. We are also considering providing further guidance on or revising the approach or methodology manufacturers must use to determine the fair market value of bona fide services performed on their behalf and whether the service fee paid was passed on in whole or in part. In either case, we may implement our policy through rulemaking or through program instruction or other guidance (consistent with our authority under section 1847A(c)(5)(C) of the Act).

We seek comments on the specific types of services entities perform on behalf of manufacturers that a manufacturer would otherwise perform (or contract for) and the necessity of those services in the efficient distribution of drugs. We also seek comments on activities that should not be considered bona fide services performed on behalf of manufacturers. To better understand which services may be considered bona fide services performed on behalf of the manufacturer that the manufacturer would otherwise perform (or contract for), we seek to understand the bona fide services that may be appropriate for all or specific types of products, as well as the specific services that may be applicable to unique products or circumstances. We also seek to understand the costs and relative costs of services performed on behalf of manufacturers.

To exclude a bona fide service fee from the ASP calculation, a manufacturer must determine whether the fee paid to an entity represents fair market value for a bona fide service actually performed on behalf of the manufacturer that the manufacturer

would otherwise perform (or contract for), and that the fee is not passed on, in whole or in part, to a client or customer of the entity. Our current guidance provides that bona fide service fees means expenses that would have generally been paid for by the manufacturer at the same rate had these services been performed by other entities. We seek comments on appropriate additional guidance or alternative methods for determining fair market value for purposes of identifying bona fide service fees that are excluded from the calculation of ASP, as well as comments on whether, and the extent to which, fees tied to performance of a service, fixed fee, revenue generated by product sales, or other basis may represent fair market prices for purposes of identifying bona fide service fees that are excluded from the calculation of ASP. In addition, we seek comments on the appropriate methods for determining whether a fee is passed on in whole or in part. We also seek comments on how Medicare's guidance on the treatment of service fees for ASP calculation purposes may differ with the treatment of service fees for financial accounting or other purposes, and any implications that this may have for manufacturers.

b. Estimation Methodology for Lagged Exempted Sales

Section 1847A(c)(2) of the Act requires manufacturers to exclude from the calculation of ASP those sales that are exempt from the Medicaid best price (BP) calculation (for example, Federal sales, sales to State pharmacy assistance programs, sales to a prescription drug plan for use under Medicare Part D). In the comments on the April 6, 2004 IFC, commenters requested more guidance on the method manufacturers should use to exclude exempted sales that are known on a lagged basis. Manufacturers identify exempted sales based on direct sales and through chargeback and rebate data that may not be sufficiently available at the time the ASP is calculated. In the absence of specific guidance on how to account for lagged exempted sales (that is, exempted sales identified through chargeback or rebate processes), manufacturers have relied upon assumptions in accordance with their customary business practices to develop their approach for excluding these sales from the ASP calculation. In our work with manufacturers that submit ASP data, we understand that some manufacturers have used a ratio methodology for estimating exempted sales known on a lagged basis which is similar to the ratio methodology manufacturers must use to estimate

price concessions known on a lagged basis.

To establish a uniform approach, in § 414.804(a)(4), we propose to require, in the final ASP reporting rule, that all manufacturers use a 12-month (or less, if applicable) rolling average ratio methodology to estimate exempted sales known on a lagged basis (through chargebacks or rebates) in order to more accurately exclude these sales from the ASP calculation. Specifically, for exempted sales known on a lagged basis, the manufacturer sums the lagged exempted sales for the most recent 12month period available (or the number of months the NDC has been sold for NDCs with less than 12 months of sales, except for redesignated NDCs as described in section d below). The manufacturer then calculates a percentage using this summed amount as the numerator and the sales (the number of units after non-lagged exempted sales have been subtracted from total sales) for the same period (12 months or less, if applicable) as the denominator. The result is a rolling average percentage estimate for lagged exempted sales that is applied to the sales (the number of units after nonlagged exempted sales have been subtracted from total sales) for the quarter being reported. The product that results from multiplying the rolling average percentage estimate of lagged exempted sales and sales (the number of units after non-lagged exempted sales have been subtracted from total sales) determines the number of lagged exempted sales (in units) to be excluded from the denominator of the ASP calculation. Manufacturers must make a corresponding adjustment to the numerator of the ASP calculation to ensure that the total in dollars for the reporting quarter does not include revenue related to lagged exempted sales excluded from the denominator using the proposed estimation methodology. Further, manufacturers must remove the dollar value of lagged exempted sales from their estimates of lagged price concessions by subtracting the dollar value of estimated lagged exempted sales from the denominator as specified in § 414.804(a)(3)(i).

Our proposed methodology for excluding lagged exempted sales is similar to the methodology manufacturers are required to use to estimate price concessions known on a lagged basis, and was recommended by manufacturers. We believe requiring similar methods to estimate both lagged exempted sales and lagged price concessions is reasonable and reduces potential errors in the manufacturers' ASP calculations, while ensuring that

exempted sales are appropriately removed from the ASP calculation. In addition, using an estimation methodology to remove lagged exempted sales reduces the likelihood of quarter to quarter variations in the ASP.

We seek comments on the proposed methodology for excluding exempted sales known on a lagged basis from the ASP calculation and estimate of lagged price concessions. We also solicit suggestions on appropriate alternative methodologies that may be less complex.

c. Nominal Sales

Section 1847A(c)(2)(B) of the Act requires manufacturers to exclude from the ASP calculation sales that are merely nominal in amount, as applied for purposes of section 1927(c)(1)(C)(ii)(III) of the Act, except as the Secretary may otherwise provide. Effective January 1, 2007, the DRA (Pub. L. 109-171) modifies section 1927(c)(1)(C)(ii)(III) of the Act. Limitations on nominal sales have been added in new section 1927(c)(1)(D) of the Act. The DRA also modified the average manufacturer price (AMP) calculation and frequency of AMP reporting. Therefore, we are proposing to clarify the method manufacturers must follow, beginning in 2007, to identify nominal sales for ASP reporting purposes and to exclude nominal sales from the calculation of the ASP. We also are seeking comments on whether we should establish an alternative definition of nominal sales for ASP purposes.

In the preamble to the ASP reporting interim final rule, we stated sales to an entity that are nominal in amount are defined in the Medicaid drug rebate agreement (see sample agreement at http://www.cms.hhs.gov/ MedicaidDrugRebateProgram/ downloads/rebateagreement.pdf). That is, for ASP purposes, a nominal sale is a sale at a price less than 10 percent of the AMP in the same quarter for which the AMP is computed. Effective January 1, 2007, the DRA revises the AMP calculation (to omit customary prompt pay discounts extended to wholesalers), added a monthly AMP reporting requirement, and established limitations on nominal sales (only sales to certain entities may qualify as nominal sales). Section 1927(c)(1)(D) of the Act limits the nominal sales exclusion to nominal sales made to the following entities:

- 340B covered entities as described in section 340B(a)(4) of the Public Health Services Act (PHS Act).
- Intermediate care facilities for the mentally retarded (ICFs/MR).

- State-owned or operated nursing facilities.
- Any other facility or entity that the Secretary determines is a safety net provider to which sales of such drugs at a nominal price would be appropriate based on the factors described in section 1927(c)(1)(D)(ii) of the Act.

Because section 1847A(c)(2)(B) of the Act requires manufacturers to exclude from the ASP calculation sales that are merely nominal in amount, as applied for purposes of section 1927(c)(1)(C)(ii)(III) of the Act, except as the Secretary may otherwise provide, the DRA changes will have implications for ASP reporting beginning January 1, 2007 (unless we provide an alternative policy for determining nominal sales as permitted under section 1847A(c)(2)(B) of the Act). One implication is that the limitations set forth in section 1927(c)(1)(D) of the Act will continue the exclusion of nominal sales to certain entities while requiring that sales to entities not identified under section 1927(c)(1)(D) of the Act are included in the ASP calculation, even if such sales are at very low prices. Another implication is the AMP calculation will exclude customary prompt pay discounts extended to wholesalers, yet prompt pay discounts will continue to be a type of price concession that manufacturers must include in their ASP calculations. The change in treatment of customary prompt pay discounts extended to wholesalers in the AMP calculation may result in a higher number of sales that are at less than 10 percent of the AMP than in past ASP reporting periods (notwithstanding the new limitation on what is considered a nominal sale under section 1927(c)(1)(D) of the Act). Still another implication is that the frequency of AMP reporting will include monthly reporting; thus, for ASP purposes, there is further need to clarify how nominal sales are to be identified in 2007. Separate Medicaid rulemaking will address the DRA provisions related to AMP reporting.

We believe the DRA modifications to section 1927 of the Act noted above will have minimal effect on reported ASPs. We would expect that the exclusion of customary prompt pay discounts extended to wholesalers from AMP would lead to a modest increase in AMP, and as a result a modest increase in the number of sales that would qualify as nominal under the current ASP reporting regulations. At the same time, we anticipate that the limitation on nominal sales in section 1927(c)(1)(D) of the Act will result in a modest reduction in the number of sales that qualify as nominal sales for

purposes of ASP reporting because we believe that the entities outlined in section 1927(c)(1)(D) of the Act generally represent the types of entities to which manufacturers may offer sales at a nominal amount. Consequently, we would expect these two countervailing changes would have a minimal overall impact on nominal sales that would be excluded from the ASP calculation. For 2007 and beyond, we propose to revise § 414.804(a)(4) to clarify that manufacturers must continue to use the Medicaid threshold (less than 10 percent of AMP) to determine nominal sales that are excluded (subject to the limitations in section 1927(c)(1)(D) of the Act) from the ASP calculation. Further, we propose that, in identifying nominal sales, manufacturers must use the AMP for the calendar quarter that is the same calendar quarter for the ASP reporting period. For these reasons, we are proposing to continue the current methodology for identifying and excluding nominal sales (that is, sales that are exempt from the Medicaid best price calculation under section 1927(c)(1)(C)(ii)(III) of the Act) from the manufacturer's calculation of the ASP. We believe this approach helps maintain continuity in the ASP calculation and minimizes manufacturers' reporting burden, as Medicare continues to follow the Medicaid approach for identifying nominal sales and manufacturers can use a single method for identifying nominal sales for both ASP and AMP purposes.

We seek comments on our proposal to continue use of the AMP as the basis for identifying nominal sales excluded from the ASP calculation and on whether an alternative threshold for identifying nominal sales for ASP calculation purposes is necessary or desirable to ensure the accuracy of the ASP payment methodology. Specifically, we seek comments on whether sales at less than 10 percent of the ASP (instead of the AMP) should be used to identify nominal sales for ASP purposes (with the new requirement in section 1927(c)(1)(D) of the Act allowing only sales to certain entities to be considered nominal sales still being applicable). We also seek comments on our belief that the new limitations on nominal sales and change to the AMP calculation will have minimal impact on reported ASPs.

Subsequent to the April 6, 2004 IFC, we received requests for clarification on a technical aspect related to the identification of nominal sales. Specifically, some manufacturers have asked whether nominal sales are identified by performing a series of calculations once or whether the

manufacturer repeats the series of calculations until no remaining ASP eligible sales are below the nominal threshold. Consistent with current Medicaid reporting, for 2005 and 2006, manufacturers must identify nominal sales by performing the following steps once:

- The manufacturer calculates the AMP for the reporting quarter to identify the dollar amount that represents 10 percent of the AMP for that reporting period.
- The manufacturer then identifies sales below this amount and excludes these sales from the ASP calculation.
- Beginning in 2007, the limitations in section 1927(c)(1)(D) of the Act must also be met to exclude the sale.

d. Other Price Concession Issues

In our ongoing work with manufacturers that submit ASP data, some manufacturers have posed questions or raised concerns about how the estimate of lagged price concessions is done prior to having 12 months of data for a NDC and, when a product is redesignated with a new NDC, whether price concessions from the prior NDC must be included in calculating the ASP for the new NDC. Manufacturers and other stakeholders have also asked us about how Medicare's ASP guidance concerning price concessions is to be applied when drugs are sold under bundling arrangements.

In response, we are proposing clarifications and seeking comment on these issues.

(1) Price Concessions for NDCs With Less Than 12 Months of Sales

To address situations when a NDC with price concessions known on a lagged basis has not been sold for a full 12 months, we propose to revise § 414.804(a)(3) to specify that the period used to estimate lagged price concessions is the total number of months the NDC has been sold. We propose to require that manufacturers use less than 12 months of data in the estimation methodology for lagged price concessions for NDCs with less than 12 months of sales (except when the manufacturer has redesignated the product's NDC, as discussed below). Manufacturers may include the current ASP reporting quarter in the most recent 12 month period (or less for NDCs with less than 12 months of sales) so long as the manufacturer follows this approach in calculating the ASP for all of its reported NDCs. Using less than 12 months in the estimation methodology for lagged price concessions is consistent with our proposal for

estimating lagged excluded sales described in section b. above.

(2) Redesignated NDCs

From time to time, a manufacturer may change the NDC assigned to a specific product and package size while continuing or offering price concessions that span across sales of the product under its prior and redesignated NDCs. For example, an NDC may be changed to reflect a change in the labeler code while lagged price concessions in place under the prior NDC remain in effect and carry over to the redesignated NDC. Another example would be a manufacturer that modifies its package design or other non-drug feature of the NDC and assigns a new NDC to reflect the revised packaging.

We propose to clarify in the final ASP reporting rule that, when an NDC is changed (except when a product is repackaged or relabeled by a different manufacturer or relabeler or is privately labeled) and lagged price concessions offered for the prior NDC remain in effect, the manufacturer must use 12 months (or the total number of months of sales of the prior and redesignated NDCs if the total number of months of sales is less than 12 months) of sales and price concession data from the prior and redesignated NDCs to estimate lagged price concessions applicable to the redesignated NDC. In establishing this methodology, we are relying on our authority under section 1847A(c)(5)(A) of the Act.

We seek comments on our proposed refinements to the estimation of lagged price concessions for NDCs with less than 12 months of sales and when a manufacturer redesignates the NDC assigned to a product. We also solicit suggestions for potentially clarifying these policies further.

(3) Bundled Price Concessions

We have heard a few concerns about how Medicare's ASP guidance concerning price concessions is to be applied when drugs are sold under bundling arrangements (for example, when a purchaser's price for one or more drugs is contingent upon the purchase of other drugs or items). We would like to better understand how bundling affects sales of Part B drugs and the ASP calculation, and any concerns stakeholders may have on this issue. Therefore, we are soliciting comments on a number of these issues. We note that we expect manufacturers of drugs reimbursed by Medicare Part B to comply with all applicable laws, regulations, and legal decisions including, but not limited to the Stark law, other relevant anti-kickback laws,

antitrust laws, and laws governing fair trade practices. Our discussion of this issue in this proposed rule should not be construed as an endorsement or authorization of any pricing practices that contravene any laws, legal decisions, or regulations.

Thus far, we have not provided specific guidance in the ASP context on the issue of apportioning price concessions across drugs that are sold under bundling arrangements. In the absence of specific guidance, the manufacturer may make reasonable assumptions in its calculations of ASP, consistent with the general requirements and the intent of the Social Security Act, Federal regulations, and its customary business practices. Manufacturers must include assumptions in their ASP submissions. We are now considering providing guidance, through rulemaking or through program instruction or other guidance (consistent with our authority under section 1847A(c)(5)(C) of the Act) on the methodology manufacturers must use for apportioning price concessions across Part B drugs sold under bundling arrangements for purposes of the calculation of ASP. As we consider this issue, our goal is to ensure that the ASP is an accurate reflection of market prices for Part B drugs and that the treatment of bundled price concessions in the ASP calculation does not create inappropriate financial incentives.

We are soliciting comments on a number of issues, including how frequently Part B drugs are sold under bundling arrangements, the different structures of bundling arrangements that may exist (for example, the number of products included in a bundling arrangement; whether the price concessions are contingent on the purchase of only one product, the purchase of multiple products, or the inclusion of one or more products on a formulary; and the timing of the price concessions), and the extent to which sales of Part B drugs are bundled with sales of non-Part B drugs or non-drug products. We also seek comment on what effect bundling arrangements may have on the ASP calculation, on beneficiary access to high quality appropriate care (including access to drugs that may not have clinical alternatives), and on costs to the Medicare program and beneficiaries. In addition, we seek comments on whether additional guidance on apportioning bundled price concessions for purposes of the calculation of ASP is needed and potential methodologies that Medicare could consider requiring. Furthermore, we seek comment on how variation in the structure of bundling arrangements

may affect the impact of potential apportionment methodologies on the ASP calculation.

2. Clotting Factor Furnishing Fee

Section 303(e)(1) of the MMA added section 1842(o)(5) of the Act which requires the Secretary, beginning in CY 2005, to pay a furnishing fee, in an amount the Secretary determines to be appropriate, to hemophilia treatment centers and homecare companies for the items and services associated with the furnishing of blood clotting factor. Section 1842(o)(5)(C) of the Act specifies that the furnishing fee for clotting factor for years after CY 2006 and subsequent years will be equal to the fee for the previous year increased by the percentage increase in the consumer price index (CPI) for medical care for the 12 month period ending with June of the previous year. In the CY 2006 PFS final rule, we announced that, based on the percentage increase in the CPI of 4.2 percent for the 12-month period ending June 2005, the furnishing fee is \$0.146 per unit clotting factor for CY 2006.

The CPI data for the 12-month period ending in June 2006 is not yet available. In the FY 2007 PFS final rule, we will include the actual figure for the percent change in the CPI for medical care for the 12-month period ending June 2006, and the updated furnishing fee for CY 2007 calculated based on that figure.

3. Widely Available Market Prices (WAMP) and AMP Threshold

Section 1847A(d)(1) of the Act states that "the Inspector General of HHS shall conduct studies, which may include surveys to determine the widely available market prices (WAMP) of drugs and biologicals to which this section applies, as the Inspector General, in consultation with the Secretary, determines to be appropriate." Section 1847A(d)(2) of the Act states that, "Based upon such studies and other data for drugs and biologicals, the Inspector General shall compare the ASP under this section for drugs and biologicals with—

• The widely available market price (WAMP) for these drugs and biologicals (if any); and

• The average manufacturer price (AMP) (as determined under section 1927(k)(1) of the Act for such drugs and biologicals."

Section 1847A(d)(3)(A) of the Act states that, "The Secretary may disregard the ASP for a drug or biological that exceeds the WAMP or the AMP for such drug or biological by the applicable threshold percentage (as defined in subparagraph (B))." The

applicable threshold is specified as 5 percent for CY 2005. For CY 2006 and subsequent years, section 1847A(d)(3)(B) of the Act establishes that the applicable threshold is "the percentage applied under this subparagraph subject to such adjustment as the Secretary may specify for the WAMP or the AMP, or both." In CY 2006, we specified an applicable threshold percentage of 5 percent for both the WAMP and AMP. We based this decision on the limited data available to support a change in the current threshold percentage.

For CY 2007, we propose to specify an applicable threshold percentage of 5 percent for the WAMP and the AMP. At present, the OIG is continuing its comparison of both the WAMP and the AMP. Since, at this time we do not have data that suggest another level is more appropriate, we believe that continuing the 5 percent applicable threshold percentage for both the WAMP and AMP is appropriate.

There are a number of operational issues associated with Medicare's authority to substitute a lower payment amount for a drug if the OIG finds and informs the Secretary, at such times as the Secretary may specify, that the ASP exceeds the WAMP or AMP by more than the established threshold (currently 5 percent). We would welcome public comment on operational issues such as the timing and frequency of the ASP, AMP, and WAMP comparisons and effective date and duration of the rate substitution.

4. Payment for Drugs Furnished During CY 2006 and Subsequent Years in Connection With the Furnishing of Renal Dialysis Services if Separately Billed by Renal Dialysis Facilities

In the November 21, 2005 PFS final rule (70 FR 70116), we stated that payment for a drug furnished during CY 2006 in connection with renal dialysis services and separately billed by freestanding renal dialysis facilities and hospital-based facilities would be based on section 1847A of the Act. We intended this to mean CY 2006 and subsequent years. Therefore, in this proposed rule, we are not proposing a policy change, but rather, we are clarifying that this policy will apply to CY 2006 and subsequent years until otherwise specified.

G. Proposed Provisions Related To Payment for Renal Dialysis Services Furnished by End-Stage Renal Disease (ESRD) Facilities

[If you choose to comment on issues in this section, please include the

caption "ESRD PROVISIONS" at the beginning of your comments.]

Since August 1, 1983, payment for dialysis services furnished by ESRD facilities has been based on a composite rate payment system that provides a fixed, prospectively determined amount per dialysis treatment, adjusted for geographic differences in area wage levels. In accordance with section 1881(b)(7) of the Act, separate composite rates have been established for hospital-based and independent ESRD facilities. The composite rate is designed to cover a package of goods and services needed to furnish dialysis treatments that include certain routinely provided drugs, laboratory tests, supplies, and equipment. Unless specifically included in the composite rate, other injectable drugs and laboratory tests medically necessary for the care of the dialysis patient are separately billable. The base composite rates per treatment, effective on August 1, 1983, were \$123 for independent ESRD facilities and \$127 for hospitalbased ESRD facilities. The Congress has enacted a number of adjustments to the composite rate since that time. The current 2006 base composite rates are \$130.40 for independent ESRD facilities and \$134.53 for hospital-based ESRD

Section 623 of the MMA amended section 1881 of the Act to require changes to the composite rate payment methodology, as well as to the pricing methodology for separately billable drugs and biologicals furnished by ESRD facilities.

Section 1881(b)(12) of the Act, as added by MMA, required the establishment of a basic case-mix adjusted prospective payment system (PPS) that would include the services comprising the composite rate and an add-on to the composite rate component for the difference between current payments for separately billed drugs and the revised drug pricing specified in the statute. In addition, section 1881(b)(12) of the Act required that the composite rate be adjusted for a limited number of patient characteristics (casemix) and section 1881(b)(12)(D) of the Act gave the Secretary discretion to revise the wage indices and the urban and rural definitions used to develop them. Finally, section 1881(b)(12)(E) of the Act imposed a budget neutrality requirement, so that aggregate payments under the basic case-mix adjusted composite payment system for 2005 would equal the aggregate payments that would have been made for the same period if section 1881(b)(12) of the Act did not apply.

Before January 1, 2005, payment to both independent and hospital-based facilities for the anti-anemia drug, Erythropoietin (EPO) was established pursuant to section 1881(b)(11) of the Act at \$10.00 per 1,000 units. For independent ESRD facilities, payment for all other separately billable drugs and biologicals was based on the lower of actual charges or 95 percent of the average wholesale price (AWP). Hospital-based ESRD facilities were paid based on the reasonable cost methodology for separately billed drugs and biologicals (other than EPO) furnished to dialysis patients. Changes to the payment methodology for separately billed ESRD drugs and biologicals that were established by the MMA and were effective January 1, 2005 are described in sections G.1. and G.2. below. These changes affected payments in both CYs 2005 and 2006.

1. CY 2005 Revisions

On November 15, 2004, we published the CY 2005 PFS final rule with comment period (69 FR 66319 through 66334), that revised payments to ESRD facilities based on changes enacted by the MMA. The November 15, 2004 final rule with comment period implemented section 1881(b) of the Act, as amended by section 623 of the MMA. Changes effective January 1, 2005, included implementation of a case-mix adjusted payment system that incorporates services that comprise the composite rate; an update of 1.6 percent to the composite rate component of the payment system; and a drug add-on of 8.7 percent to the composite rate for the difference between current payments for separately billable drugs and payments based on the revised drug pricing for 2005 which used acquisition costs. The final rule also implemented case-mix adjustments to the composite rate for a limited number of patient characteristics (age, low body mass index (BMI), and body surface area (BSA)), effective April 1, 2005.

In addition, to implement section 1881(b)(13) of the Act, we revised payments for drugs billed separately by independent ESRD facilities, paying for the top 10 ESRD drugs based on acquisition costs (as determined by the OIG) and for other separately billed drugs at the average sales price +6 percent (hereafter referred to as ASP+6 percent). Hospital-based ESRD facilities continued to receive cost-based payments for all separately billable drugs and biologicals except for EPO which was paid based on average acquisition costs.

2. CY 2006 Revisions

In the November 21, 2005 Federal Register (70 FR 70161), we published the CY 2006 PFS final rule with comment period (70 FR 70161) implementing additional revisions to payments to ESRD facilities under section 623 of the MMA. For CY 2006, we further revised the drug payment methodology applicable to drugs furnished by ESRD facilities. All separately billed drugs and biologicals furnished by both hospital-based and independent ESRD facilities are now paid based on ASP+6 percent.

We recalculated the 2005 drug add-on adjustment to reflect the difference in payments between the pre-MMA AWP pricing and the revised pricing based on ASP+6 percent. The recalculation did not affect the actual add-on adjustment applied to payments in 2005, but provided an estimate of what the adjustment would have been had the 2006 payment methodology been in effect in 2005. The drug add-on adjustment was then updated to reflect the expected growth in expenditures for separately billable drugs in CY 2006.

As of January 1, 2006, we also implemented a revised geographic adjustment authorized by section 1881(b)(12) of the Act. As part of that change, we—

- Revised the labor market areas to incorporate the new CBSA designations established by the Office of Management and Budget (OMB);
- Eliminated the wage index ceiling and reduced the floor to .8500; and
- Revised the labor portion of the composite rate to which the geographic adjustment is applied.

We also provided a 4-year transition from the previous wage-adjusted composite rates to the current wage-adjusted rates. For CY 2006, only 25 percent of the payment is based on the revised geographic adjustments, and the remaining 75 percent of payment is based on the old Metropolitan Statistical Area-based (MSA-based) payments.

In addition, section 5106 of the DRA (Pub. L. 109–171), provided for a 1.6 percent update to the composite rate component of the basic case-mix adjusted payment system, effective January 1, 2006. As a result, the current base composite rate is \$130.40 for independent ESRD facilities and \$134.53 for hospital-based facilities. The drug add-on adjustment (including the growth update) for 2006 is 14.5 percent.

3. Provisions of the Proposed Rule

For CY 2007, we are proposing the following provisions which are described in more detail below:

- A method to annually calculate the growth update to the drug add-on adjustment required by section 1881(b)(12) of the Act, as well as an estimated growth update adjustment to the add-on amount of 0.6 percent for CY 2007.
- An update to the wage index adjustments to reflect the latest hospital wage data, including a budget neutrality adjustment of 1.053069 to the wage index for CY 2007.
- 4. Proposed Growth Update to the Drug Add-On Adjustment to the Composite Rates

Section 623(d) of the MMA added section 1881(b)(12)(B)(ii) of the Act which required the establishment of an add-on to the composite rate to account for changes in the drug payment methodology stemming from enactment of the MMA. Section 1881(b)(12)(C) of the Act provides that the drug add-on must reflect the difference in aggregate payments between the revised drug payment methodology for separately billable ESRD drugs (acquisition costs in CY 2005; ASP+6 percent in CY 2006) and the AWP payment methodology in effect in CY 2004.

In addition, section 1881(b)(12)(F) of the Act requires that, beginning in CY 2006, we establish an annual update to the drug add-on to reflect estimated growth in expenditures for separately billable drugs and biologicals furnished by ESRD facilities. This growth update applies only to the drug add-on portion of the case-mix adjusted payment system.

The CY 2006 drug add-on adjustment to the composite rate is 14.5 percent. The drug add-on adjustment for CY 2006 incorporates an inflation adjustment of 1.4 percent. This computation is explained in detail in the CY 2006 PFS final rule with comment period (70 FR 70162). We note that the drug add-on adjustment of 14.7 percent that was published in November 21, 2005 PFS final rule with comment period did not account for the 1.6 percent update to the composite rate portion of the basic case-mix adjustment payment system that was subsequently enacted by the DRA, effective January 1, 2006. Since we compute the drug addon adjustment as a percentage of the weighted average base composite rate, the drug add-on percentage was decreased to account for the higher composite payment rate resulting in a 14.5 percent add-on adjustment for CY 2006. This adjustment was necessary to ensure that the total drug add-on dollars remained constant.

a. Estimating Growth in Expenditures for Drugs and Biologicals for CY 2007

In developing the growth update to the drug add-on for CY 2006 we conducted a trend analysis of prior years' ESRD drug expenditure data (2001 through 2004). All 4 years of data used for the trend analysis reflected expenditures associated with payment for separately billed drugs and biologicals under the AWP methodology. We could, therefore, develop growth estimates for CY 2006 using comparable historical expenditure data. To extend the trend analysis for CY 2007, we would need to include drug expenditure data from CY 2005. However, in CY 2005, section 1881(b)(13)(A)(ii) of the Act required that we use a different drug payment methodology, based on average acquisition costs, rather than the AWP methodology used in prior years. Therefore, ESRD drug expenditure data for CY 2005 are not comparable to expenditure data for CY 2001 through CÝ 2004 for trend analysis purposes. This data issue will extend to subsequent years' data as well, as we are now paying for separately billable drugs using ASP+6 percent. Because we do not have comparable data on which to base continuing trend analysis, we believe it is necessary to re-evaluate our methodology for updating the drug addon adjustment.

In order to address the issue of data comparability described above, we considered using available drug proxy measures to predict growth in ESRD drug expenditures for CY 2007. We note that section 1881(b)(12)(F) of the Act specifies that the drug update must reflect "the estimated growth in expenditures for drugs and biologicals that are separately billable * * *." By referring to "expenditures", we believe the statute contemplates that the update would account for both increases in drug prices as well as increases in utilization of those drugs.

One available proxy measure that reflects both price and utilization is the national health expenditure projection for prescription drugs that is developed by CMS. However, because of uncertainties regarding the impact of the Medicare Part D prescription drug program on expenditures, we are concerned that the current estimates for CY 2007 will likely change, as actual Part D expenditure data become available. Therefore, we do not believe this measure would be an appropriate proxy measure for this purpose.

Another widely recognized proxy measure is the producer price index (PPI) for prescription drugs. The PPI is

a good measure of drug pricing growth, but does not capture the growth in per patient drug utilization that must also be part of an accurate estimate of growth in ESRD drug expenditures. However, if the PPI is used in conjunction with an estimate of per patient growth in drug utilization, we believe this measure would provide a simple and accurate approach to updating the drug add-on that could be readily used in subsequent years. Moreover, using the PPI would significantly reduce any data bias that is inherent in using historical drug expenditure data that do not reflect current drug payment methodologies. As discussed in detail below, we are proposing to estimate growth in per patient utilization of drugs by using historical data from 2004 and 2005.

Another approach to estimating the growth in ESRD drug expenditures is to continue using historical trend analysis by making adjustments to the available data to permit year to year comparisons. This would be accomplished by making an adjustment to the CY 2005 data based on average acquisition price (AAP) using the weighted average difference between AWP prices and AAP prices. We would use trend analysis to project the growth in drug expenditures for CY 2007.

While we believe this approach is reasonably accurate for developing the CY 2007 growth estimates, since only one year of data would require adjustment, we are concerned about applying this methodology to future updates. Future year updates would require multiple year to year adjustments in prices. Moreover, historical AWP data does not provide an accurate measure of price changes for EPO under the revised drug payment methodology, since EPO pricing was held constant during that historical period.

In addition, our estimate of the weighted average difference between AAP prices and AWP prices (and ASP versus AWP prices in CY 2006) was based on a projection of price levels. It is likely that the weighted average difference would change based on actual pricing data for each of those years. To be consistent with the statute, we expect to update the established adjustment to reflect estimated growth in drug expenditures, but we do not anticipate re-computing the drug add-on adjustment annually. Adjusting our assumptions to estimate projected growth without changing the underlying assumptions in the add-on adjustment would create inconsistencies between the two elements. Therefore, we are proposing to discontinue use of older historical drug spending data to

estimate the growth update to the drug add-on adjustment. We will reconsider our methodology when we have sufficient historical data reflecting the revised drug payment methodology using ASP pricing.

For the reasons discussed above, we are proposing to develop an estimate of the growth in expenditures for ESRD drugs and biologicals using the PPI for prescription drugs as a measure of price increases in conjunction with two years of historical data from 2004 and 2005 as a basis for estimating utilization growth at the per patient level. We believe that this approach will best reflect the estimated growth in expenditures for ESRD drugs and biologicals.

b. Estimating Growth in Per Patient Drug Utilization

To isolate and project the growth in per patient utilization of ESRD drugs for CY 2007, we need to remove the enrollment and price growth components from historical drug expenditure data and consider the residual utilization growth. We propose to use total drug expenditure data from CYs 2004 and 2005 to estimate per patient utilization growth for CY 2007.

We first needed to estimate total drug expenditures. For this proposed rule, we used the final CY 2004 ESRD claims data and the latest available CY 2005 ESRD facility claims, updated through December 31, 2005, that is, claims with dates of service from January 1 through December 31, 2005, that were received, processed, paid, and passed to the National Claims History File as of December 31, 2005. For the final rule, we will use more updated CY 2005 claims with dates of service for the same time period. This updated CY 2005 data file will include claims that are received, processed, paid, and passed to the National Claims History File as of June 30, 2006.

While the December 2005 update of CY 2005 claims used in this proposed rule is the most recently available claims data, we recognize that it is not a fully complete year as claims with dates of service towards the end of the year have not all been processed. To more accurately estimate the update to the drug add-on, we need aggregate drug expenditures. Based on an analysis of the 2004 claims data, we inflated the CY 2005 drug expenditures to estimate the June 30, 2006 update of the 2005 claims file. We used the relationship between the December 2004 and the June 2005 versions of 2004 claims to estimate the more complete 2005 claims that will be available in June 2006. We applied that ratio to the 2005 claims data from the December 2005 claims file. We did this

for drug expenditures in aggregate, for each of top ten separately billable drugs, and within each for independent and hospital-based ESRD facilities. All components were then combined to estimate aggregate CY 2005 ESRD drug expenditures. The net adjustment to the CY 2005 claims data was an increase of 13 percent to the 2005 expenditure data. This adjustment allows us to more accurately compare the 2004 and 2005 data, to estimate utilization growth.

The next step is to remove the enrollment and price growth components from that total. As discussed earlier in this section, in developing the per patient utilization growth for this proposed rule, we limited our analysis to the latest 2 years of available ESRD drug data, that is, 2004 and 2005. We believe that per patient utilization growth between these years would be a better proxy for future growth, as it best represents current utilization trends. Furthermore, because of the implementation of the new EPO utilization monitoring policy that took effect on April 1, 2006 (Medicare Claims Processing Manual, Chapter 8, section 60-4ff, p. 51-53), we believe that per patient utilization of ESRD drugs will remain relatively stable or decline slightly in future years. We note that EPO accounts for nearly 70 percent of ESRD drug expenditures.

To calculate the per patient utilization growth, we removed the enrollment component by using the growth in enrollment data between 2004 and 2005. This was approximately 3 percent. To remove the price effect we used a twostep process. First we calculated a weighted average between EPO and non-EPO price growth factors to account for the growth in pre-MMA pricing between 2004 and 2005. Since EPO was priced at \$10 per thousand units prior to the enactment of the MMA, there is no growth for EPO. For the non-EPO drugs, we used the PPI as a proxy for the growth between the 2 years to maintain consistency with the established methodology for calculating the drug add-on adjustment which used the PPI to estimate the price growth in separately billable drugs (November 15, 2004, CY 2005 PFS final rule with comment period, 69 FR 66321). Next, we incorporated the estimated negative 13 percent weighted price difference between 2005 AWP and 2005 AAP pricing as was published in the CY 2005 PFS final rule with comment period (69 FR 66319 through 66334). This two-step process to account for the price effect from 2004 to 2005 led to an overall 12 percent reduction in price between 2004 and 2005.

After removing the enrollment and price effects from the expenditure data, we believe the residual growth would reflect the per patient utilization growth. To do this, we divided the product of the enrollment growth of 3 percent (1.03) and the price reduction of 12 percent (1.00 - .12 = .88) into the total drug expenditure decrease between 2004 and 2005 of 9 percent (1.00 - .09 = .91). The result is a utilization factor equal to 1.00 (.91/(1.03 * .88) = 1.00).

As we observed no growth in per patient utilization of drugs between 2004 and 2005, we are, therefore, projecting no growth in per patient utilization for GY 2007.

1. Applying the Proposed Growth Update to the Drug Add-on Adjustment

In CY 2006, we estimated the growth update by trending drug expenditures forward based on four years of AWP payment data (CY 2001 through CY 2004). We then applied the estimated growth update percentage to the total amount of drug add-on dollars established for CY 2005 to come up with a dollar amount for the CY 2006 growth update. In addition, we projected the growth in dialysis treatments for CY 2006 based on the projected growth in ESRD enrollment. We divided the projected total dialysis treatments for CY 2006 into the projected dollar amount of the CY 2006 growth to develop the per treatment growth update amount. This growth update amount, combined with the CY 2005 per treatment drug add-on amount, resulted in an average drug add-on amount per treatment of \$18.88 (or a 14.5 percent adjustment to the composite rate) for CY

Beginning in CY 2007, we are proposing to annually update the per treatment drug add-on amount of \$18.88 established in CY 2006 and convert the update to an adjustment factor as stipulated in section 1881(b)(12)(F) of the Act. As explained above, we believe this approach is more accurate than recalculating the per treatment add-on adjustment each year using an estimate of growth in treatments. We note that we had received comments that our projections of treatment growth used to calculate the CY 2006 adjustment may have been overstated, however, we believe that the use of enrollment data was and remains the best measure available to predict treatment growth. By proposing to apply the update to the CY 2006 per treatment add-on amount, this estimation component is eliminated for CY 2007 and future years.

2. Proposed Update to the Drug Add-On Adjustment

As discussed above, we estimate no growth in per patient utilization of ESRD drugs for CY 2007. Using the projected CY 2007 PPI for prescription drugs of 4.9 percent, we are projecting that the combined growth in per patient utilization and pricing for CY 2007 would result in an update equal to the PPI or 4.9 percent (1.0*1.049 = 1.049). This update factor would be applied to the CY 2006 average per treatment drug add-on amount of \$18.88 (reflecting a 14.5 percent adjustment in CY 2006), resulting in a proposed weighted average increase to the composite rate of \$.93 for CY 2007 or a 0.6 percent increase in the CY 2006 drug add-on percentage. Thus, the total proposed drug add-on adjustment to the composite rate for CY 2007, including the growth update, would be 15.2 percent (1.145*1.006 = 1.152).

In addition, we are proposing to continue to use this method to estimate the growth update to the drug add-on component of the case-mix adjusted payment system until we have at least three years worth of ASP-based historical drug expenditure data that could be used to conduct a trend analysis to estimate the growth in drug expenditures. Given the time lag in the availability of ASP drug expenditure data, we expect that the earliest we could consider using trend analysis to update the drug add-on adjustment would be 2010. We propose to reevaluate our methodology for estimating the growth update at that

c. OIG Report on New Drug Codes

Section 623(c)(1) of the MMA mandated that the OIG conduct two studies to determine the difference between the Medicare payment amount for separately billable ESRD drugs and the facilities" acquisition costs for these drugs, as well as estimating the growth rate of expenditures for these drugs. The initial study, "Medicare Reimbursement for Existing End Stage Renal Disease Drugs'' (OEI-03-04-00120) was completed in May 2004, and reported on existing ESRD drugs. This report was used to set the CY 2005 reimbursement rates for ESRD drugs billed by independent dialysis facilities (69 FR 66322). The second study ("Medicare Reimbursement for New ESRD Drugs' (OEI-03-06-00200)) focused on new drugs. New drugs for the purpose of this study were defined as an ESRD drug that did not have a BILLING CODE prior to January 1, 2004.

One drug, darbepoetin alfa (Aranesp) accounted for the majority of all payments for new drugs. Therefore, this was the only new ESRD drug studied. The OIG report found that use of this drug was limited to a small number of facilities (only 157 facilities reported using this drug with concentrated use in approximately 55 of these facilities). Because of the recent changes we made to the drug payment methodology and the lack of comparable historical data, the OIG report made no estimate of an expenditure growth rate for this drug.

Darbepoetin alfa (Aranesp) is currently paid as a separately billable drug at ASP+6 percent. Because of the recent (CY 2006) implementation of the ASP+6 percent drug reimbursement methodology, the small number of facilities using this drug for ESRD patients, and the lack of historical data for trending purposes, we have no data to indicate that any difference in payment methods for Aranesp (between 2004 and 2006) would affect our calculation of the drug add-on or of the growth update. Moreover, since Aranesp was approved in 2001 for use in ESRD patients, we believe that expenditures for Aranesp were reflected in the historical data used to establish the 2005 drug add-on under a generic drug code. Therefore, we are proposing to make no additional changes to the drug add-on adjustment for CY 2007.

5. Proposed Update to the Geographic Adjustments to the Composite Rates

Section 1881(b)(12)(D) of the Act, as amended by section 623(d) of the MMA, gave the Secretary the authority to revise the wage indexes previously applied to the ESRD composite rates. The wage indexes are calculated for each urban and rural area. The purpose of the wage index is to adjust the composite rates for differing wage levels covering the areas in which ESRD facilities are located.

a. Updates to CBSA Definitions

In the CY 2006 PFS final rule with comment period (70 FR 70167), we announced our adoption of the OMB's CBSA-based geographic area designations to develop revised urban/ rural definitions and corresponding wage index values for purposes of calculating ESRD composite rates. OMB's CBSA-based geographic area designations were described in Bulletin 03-04 originally issued June 6, 2003. On February 22, 2005 and December 5, 2005, OMB released Bulletins 05-02 and 06-01, respectively. Those bulletins contained updates to the metropolitan and micropolitan statistical area designations initially announced in

Bulletin 03–04. OMB's revisions had no effect on the classification of counties which comprise the urban and rural areas used to develop the ESRD wage index values. However, Bulletins 05–02 and 06–01 changed the titles of several of the MSAs and Metropolitan Divisions used in connection with the ESRD urban wage index. Table 5 below, which contains the proposed wage index values for the ESRD urban areas, includes all of the changes announced by OMB in the February 22, 2005 and December 5, 2005 bulletins.

b. Updated Wage Index Values

In the CY 2006 PFS final rule with comment period, we stated that we intended to update the wage index values annually (70 FR 70167). Current ESRD wage index values for CY 2006 were developed from FY 2002 wage and employment data obtained from the Medicare hospital cost reports. The values are calculated without regard to geographic reclassifications authorized under sections 1886(d)(8) and (d)(10) of the Act and utilize pre-floor hospital data that is unadjusted for occupational mix.

The methodology for calculating the CY 2006 wage index values was described in the CY 2006 PFS final rule with comment period (70 FR 70168). We propose to use the same methodology for CY 2007, with the exception that FY 2003 hospital data will be used to develop the CY 2007 ESRD wage index values. For a detailed description of the development of the proposed CY 2007 ESRD wage index values based on FY 2003 hospital data, see the FY 2007 IPPS proposed rule entitled, "Proposed Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 2007 Rates," (April 25, 2006, 71 FR 24080). Section III F. (Computation of the Proposed FY 2007 Unadjusted Wage Index) of the preamble to that proposed rule describes the cost report schedules, line items, data elements, adjustments, and wage index computations. The wage index data affecting ESRD composite rates for each urban and rural locale may also be accessed on the CMS website at: http://www.cms.hhs.gov/ AcuteInpatientPPS/WIFN/list.asp.

The wage data are located in the section entitled, "FY 2007 Proposed Rule Occupational Mix Adjusted and Unadjusted Average Hourly Wage and Pre-reclassified Wage Index by CBSA".

(1) Wage Index Values for Areas With No Hospital Data

In CY 2006, while adopting the CBSA designations, we identified a small number of ESRD facilities in both urban and rural geographic areas where there

is no hospital wage data on which to base the calculations of the CY 2006 ESRD wage index values. Our CY 2005 policy and CY 2006 proposal for each area are discussed separately below.

The first situation was rural Massachusetts. Because there were no reasonable proxies for rural data within Massachusetts, we used the prior year's acute care hospital wage index value for rural Massachusetts. For CY 2007, we propose to continue to use this value and request public input on an alternative methodology.

Since there may be additional rural areas in the future similarly impacted by a lack of hospital wage data on which to derive a hospital wage index, we are considering alternative methodologies for imputing a rural wage index for areas in States where no hospital wage data are available. We believe that an evaluation of alternative methodologies for imputing a rural wage index in these areas should adhere to four basic policy criteria. First, an alternative methodology should retain our current longstanding policy to use pre-floor, pre-reclassified hospital wage data to compute wage index values for post acute care facilities, including ESRD facilities. Second, any methodology to impute a rural wage index should use rural wage data to derive the rural wage index value. Third, any methodology to impute a rural wage index should be easy to evaluate. Fourth, any methodology to impute a rural wage index would be able to update wage data from year-to-year.

We arrived at one alternative that meets all of the above policy criteria. Under this alternative, we would impute a rural wage index value by using a simple average CBSA-based rural wage index value at the Census Division level. Census Divisions are defined by the U.S. Census Bureau and may be found at (www.census.gov/geo/ www/us_regdiv.pdf). As stated above, for CY 2007, hospital wage data are not available to compute a rural wage index for ESRD facilities in rural Massachusetts, and this alternative methodology could be applied in this case. Massachusetts is located in Census Division I (New England). The States in this Census Division, and their respective rural wage index values (using hospital cost report wage data for FY 2003) include—

- Connecticut (1.1753);
- Maine (0.8410);
- New Hampshire (1.0800);
- Vermont (0.9944)
- Rhode Island (all five counties classified as urban); and

Massachusetts.

Under this alternative methodology, the States in Census Division I for which rural wage index values are available, as shown above, would be used: this would result in a simple average rural wage index value of 1.0227 (1.0770 after applying budget neutrality factor (BNF)). Although this methodology would result in a rural Massachusetts wage index that is currently greater than the value under the current proposed policy (1.0216, 1.0758 after applying BNF), we believe this methodology may be able to accurately reflect future increases or decreases of wage data for the States within the applicable Census Division.

Rural Puerto Rico is similar to rural Massachusetts in that there are ESRD facilities where there are no acute care hospitals and, therefore, no hospital data. However, the situation for facilities in rural Puerto Rico is different in that the floor would be applied to rural Puerto Rico ESRD facilities. All areas in Puerto Rico that have an index are eligible for the floor because they have wage-index values that are below .8000. For CY 2007, we propose to apply the floor to rural Puerto Rico.

The third situation involves an urban area in Hinesville, GA (CBSA 25980). For CY 2006, we used a wage index value based on wage index values in all of the other urban areas within the same State to serve as a reasonable proxy for the urban areas without hospital wage index data. Specifically, we used the average wage index value for all urban areas within the State of Georgia as the urban wage index for purposes of calculating the value for Hinesville for CY 2006. For CY 2007, we are proposing to continue using this method for Hinesville, GA (CBSA 25980).

We solicit comments on maintaining our current policy for establishing wage index values for rural and urban areas without hospitals, the alternative approach outlined above in developing wage index values for rural areas without hospitals for CY 2007 and subsequent years, and other methods that meet the policy criteria for imputing wage index values. We will also continue to evaluate existing hospital wage data and, possibly, wage data from other sources, such as the Bureau of Labor Statistics, to determine if other methodologies of imputing a wage index value where hospital wage data are not available may be feasible.

(2) Second Year of the Transition

In the CY 2006 PFS final rule with comment period, we indicated that we would apply a 4-year transition period

to mitigate the impact on composite rates resulting from our adoption of CBSA-based geographic designations (70 FR 70169). Beginning January 1, 2006, during each year of the transition, an ESRD facility's wage-adjusted composite rate (that is, without regard to any case-mix adjustments) will be a blend of its old MSA-based wageadjusted payment rate and its new CBSA-based wage adjusted payment rate for the transition year involved. For each transition year, the share of the blended wage-adjusted base payment rate that is derived from the MSA-based and CBSA-based wage index values is shown in Table 4 below. In CY 2006, the first year of the transition, we implemented a 75/25 blend. CY 2007 is the second year of the 4-year transition period. Consistent with the transition blends announced in the November 21, 2005 PFS final rule with comment period (70 FR 70170), we are proposing a 50/50 blend between an ESRD facility's MSA-based composite rate, and its CY 2007 CBSA-based rate reflecting its revised wage index values.

In CY 2006, we also eliminated the wage index cap of 1.30, and stated that we would implement a gradual reduction in the wage index floor of .90. Prior to January 1, 2006, the wage indexes were restricted to values no less than .90 and no greater than 1.30, meaning that payments to facilities in areas where labor costs fell below 90 percent of the national average, or exceeded 130 percent of that average, were not adjusted beyond the 90 percent or 130 percent level. Although we stated that the ESRD wage index values should not be constrained by the application of floors and ceilings, we also expressed concern that the immediate elimination of the floor could adversely affect ESRD beneficiary access to care. Therefore, we reduced the floor to .85 in CY 2006.

For CY 2007, we are proposing to reduce the wage index floor to .80. As we stated in the CY 2006 PFS final rule with comment period, we intend to reassess the continuing need for a wage index floor in CY 2008 and CY 2009 (CY 2006 PFS final rule with comment period, November 21, 2005, 70 FR 70169 through 70170). The proposed wage index floors, caps, and blended shares of the composite rates applicable to all ESRD facilities during CYs 2007 through 2009 are shown in Table 4 below. They are identical to the values shown in Table 20 of the CY 2006 PFS final rule with comment period (70 FR 70170) for the applicable years.

CY payment	Floor	Ceiling	Old MSA (percent)	New CBSA (percent)
2007	.80 *	None	50	50
2008	Reassess	None	25	75
2009	Reassess	None	0	100

^{*}Each wage index floor is multiplied by a budget neutrality adjustment factor. For CY 2007 the budget neutrality adjustment is 1.053069 resulting in an actual wage index floor of 0.8425.

An example of how the wage-adjusted composite rates would be blended during CY 2007 and the two subsequent transition years follows.

Example: An ESRD facility has a wage-adjusted composite rate (without regard to any case-mix adjustments) of \$135.00 per treatment in CY 2006. Using CBSA-based geographic area designations, the facility's CY 2007 wage-adjusted composite rate, reflecting its wage index value as shown in Table 5 below, would be \$145.00. During the remaining 3 years of the four-year transition period to the new CBSA-based wage index values, this facility's blended rate through 2009 would be calculated as follows:

CY 2007 $.50 \times $135.00 + .50 \times 145.00 = \$140.00

CY 2008 $.25 \times \$135.00 + .75 \times \145.00 = \$142.50

CY 2009 0 × \$135.00 + 1.0 × \$145.00 = \$145.00

We note that this hypothetical example assumes that the calculated wage-adjusted composite rate of \$145.00 for CY 2007 does not change in CYs 2008 and 2009. In actuality, the wage-adjusted composite rate would change because of annual revisions to the wage index. However, the example serves only to demonstrate the effect on the composite rate of the CBSA-based wage index values which will be phased-in during the remaining 3 years of the transition period.

c. Budget Neutrality Adjustment

Section 1881(b)(12)(E)(i) of the Act, as added by section 623(d) of the MMA, requires that any revisions to the ESRD composite rate payment system as a result of the MMA provision (including the geographic adjustment) be made in a budget neutral manner. This means

that aggregate payments to ESRD facilities in CY 2007 should be the same as aggregate payments that would have been made if we had not made any changes to the geographic adjusters. We note that this budget neutrality adjustment only addresses the impact of changes in the geographic adjustments. A separate budget neutrality adjustment was developed for the case-mix adjustments, currently in effect. Since we are not proposing any changes to the case-mix measures for CY 2007, the current case-mix budget neutrality will remain in effect for CY 2007. For CY 2007, we again propose to apply a BNF directly to the ESRD wage index values, as we did in CY 2006. As we explained in the CY 2006 PFS final rule with comment period (70 FR 70170 through 70171), we believe this is the simplest approach because it allows us to maintain our base composite rates during the transition from the current wage adjustments to the revised wage adjustments described earlier in this section. Because the ESRD wage index is only applied to the labor-related portion of the composite rate, we computed the BNF adjustment based on that proportion (53.711 percent).

In order to compute the proposed CY 2007 wage index BNF, we used the wage index values in Tables 5 and 6 below, 2005 outpatient claims (paid and processed as of December 31, 2005), and geographic location information for each facility which may be found through Dialysis Facility Compare. Dialysis Facility Compare can be found by going to the following Web site: http://www.cms.hhs.gov/DialysisFacilityCompare/.

Using treatment counts from the 2005 claims and facility-specific CY 2006 composite rates, we computed the estimated total dollar amount each ESRD provider would have received in CY 2006 (the first year of the 4-year transition). The total of these payments became the target amount of expenditures for all ESRD facilities for CY 2007. Next, we computed the estimated dollar amount that would have been paid to the same ESRD facilities using the proposed ESRD wage index for CY 2007 (the second year of the 4-year transition). The total of these payments became the second year new amount of wage-adjusted composite rate expenditures for all ESRD facilities.

After comparing these two dollar amounts (target amount divided by second year new amount), we calculated an adjustment factor that, when multiplied by the applicable CY 2007 ESRD wage index shown in Tables 5 and 6 below, will result in payments to each facility that will remain within the target amount of composite rate expenditures when totaled for all ESRD facilities. The proposed budget neutrality adjustment factor for the CY 2007 wage index is 1.053069.

To ensure budget neutrality we also must apply the BNF to the wage index floor of 0.8000 which results in a proposed adjusted wage index floor of 0.8425 for CY 2007.

d. ESRD Wage Index Tables

The following two tables show the proposed CY 2007 ESRD wage index, including the BNF adjustment, for urban areas (Table 5) and rural areas (Table 6).

BILLING CODE 4120-01-P

Table 5: Proposed CY 2007 Wage Index For Urban Areas
Based On CBSA Labor Market Areas

CBSA Code	Urban Area (Constituent Counties)	Wage Index
10180	Abilene, TX Callahan County, TX Jones County, TX Taylor County, TX	0.8439
10380	Aguadilla-Isabela-San Sebastián, PR Aguada Municipio, PR Aguadilla Municipio, PR Añasco Municipio, PR Isabela Municipio, PR Lares Municipio, PR Moca Municipio, PR Rincón Municipio, PR San Sebastián Municipio, PR	0.8425
10420	Akron, OH Portage County, OH Summit County, OH	0.9097
10500	Albany, GA Baker County, GA Dougherty County, GA Lee County, GA Terrell County, GA Worth County, GA	0.9438
10580	Albany-Schenectady-Troy, NY Albany County, NY Rensselaer County, NY Saratoga County, NY Schenectady County, NY Schoharie County, NY	0.9199
10740	Albuquerque, NM Bernalillo County, NM Sandoval County, NM Torrance County, NM Valencia County, NM	0.9977

CBSA Code	Urban Area (Constituent Counties)	Wage Index
10780	Alexandria, LA Grant Parish, LA Rapides Parish, LA	0.8446
10900	Allentown-Bethlehem-Easton, PA-NJ Warren County, NJ Carbon County, PA Lehigh County, PA Northampton County, PA	1.0436
11020	Altoona, PA Blair County, PA	0.9190
11100	Amarillo, TX Armstrong County, TX Carson County, TX Potter County, TX Randall County, TX	0.9664
11180	Ames, IA Story County, IA	1.0296
11260	Anchorage, AK Anchorage Municipality, AK Matanuska-Susitna Borough, AK	1.2684
11300	Anderson, IN Madison County, IN	0.9256
11340	Anderson, SC Anderson County, SC	0.9434
11460	Ann Arbor, MI Washtenaw County, MI	1.1413
11500	Anniston-Oxford, AL Calhoun County, AL	0.8425
11540	Appleton, WI Calumet County, WI Outagamie County, WI	0.9975

CBSA Code	Urban Area (Constituent Counties)	Wage Index
11700	Asheville, NC Buncombe County, NC Haywood County, NC Henderson County, NC Madison County, NC	0.9576
12020	Athens-Clarke County, GA Clarke County, GA Madison County, GA Oconee County, GA Oglethorpe County, GA	1.0380
12060	Atlanta-Sandy Springs-Marietta, GA Barrow County, GA Bartow County, GA Butts County, GA Carroll County, GA Cherokee County, GA Clayton County, GA Cobb County, GA Coweta County, GA Dowson County, GA Dowson County, GA Douglas County, GA Fayette County, GA Forsyth County, GA Fulton County, GA Gwinnett County, GA Haralson County, GA Heard County, GA Henry County, GA Jasper County, GA Meriwether County, GA Newton County, GA Paulding County, GA Pickens County, GA Rockdale County, GA Spalding County, GA Walton County, GA Walton County, GA	1.0291
12100	Atlantic City, NJ Atlantic County, NJ	1.2375
12220	Auburn-Opelika, AL Lee County, AL	0.8540

CBSA Code	Urban Area (Constituent Counties)	Wage Index
12260	Augusta-Richmond County, GA-SC Burke County, GA Columbia County, GA McDuffie County, GA Richmond County, GA Aiken County, SC Edgefield County, SC	1.0192
12420	Austin-Round Rock, TX Bastrop County, TX Caldwell County, TX Hays County, TX Travis County, TX Williamson County, TX	0.9857
12540	Bakersfield, CA Kern County, CA	1.1168
12580	Baltimore-Towson, MD Anne Arundel County, MD Baltimore County, MD Carroll County, MD Harford County, MD Howard County, MD Queen Anne's County, MD Baltimore City, MD	1.0642
12620	Bangor, ME Penobscot County, ME	1.0235
12700	Barnstable Town, MA Barnstable County, MA	1.3228
12940	Baton Rouge, LA Ascension Parish, LA East Baton Rouge Parish, LA East Feliciana Parish, LA Iberville Parish, LA Livingston Parish, LA Pointe Coupee Parish, LA St. Helena Parish, LA West Baton Rouge Parish, LA West Feliciana Parish, LA	0.8529
12980	Battle Creek, MI Calhoun County, MI	1.0263

CBSA Code	Urban Area (Constituent Counties)	Wage Index
13020	Bay City, MI Bay County, MI	0.9763
13140	Beaumont-Port Arthur, TX Hardin County, TX Jefferson County, TX Orange County, TX	0.9067
13380	Bellingham, WA Whatcom County, WA	1.1714
13460	Bend, OR Deschutes County, OR	1.1333
13644	Bethesda-Gaithersburg-Frederick, MD Frederick County, MD Montgomery County, MD	1.1503
13740	Billings, MT Carbon County, MT Yellowstone County, MT	0.9191
13780	Binghamton, NY Broome County, NY Tioga County, NY	0.9265
13820	Birmingham-Hoover, AL Bibb County, AL Blount County, AL Chilton County, AL Jefferson County, AL St. Clair County, AL Shelby County, AL Walker County, AL	0.9392
13900	Bismarck, ND Burleigh County, ND Morton County, ND	0.8425
13980	Blacksburg-Christiansburg-Radford, VA Giles County, VA Montgomery County, VA Pulaski County, VA Radford City, VA	0.8664

CBSA Code	Urban Area (Constituent Counties)	Wage Index
14020	Bloomington, IN Greene County, IN Monroe County, IN Owen County, IN	0.9002
14060	Bloomington-Normal, IL McLean County, IL	0.9435
14260	Boise City-Nampa, ID Ada County, ID Boise County, ID Canyon County, ID Gem County, ID Owyhee County, ID	0.9917
14484	Boston-Quincy, MA Norfolk County, MA Plymouth County, MA Suffolk County, MA	1.2314
14500	Boulder, CO Boulder County, CO	1.0918
14540	Bowling Green, KY Edmonson County, KY Warren County, KY	0.8595
14740	Bremerton-Silverdale, WA Kitsap County, WA	1.1512
14860	Bridgeport-Stamford-Norwalk, CT Fairfield County, CT	1.3354
15180	Brownsville-Harlingen, TX Cameron County, TX	0.9947
15260	Brunswick, GA Brantley County, GA Glynn County, GA McIntosh County, GA	1.0633
15380	Buffalo-Niagara Falls, NY Erie County, NY Niagara County, NY	0.9986
15500	Burlington, NC Alamance County, NC	0.9150

CBSA Code	Urban Area (Constituent Counties)	Wage Index
15540	Burlington-South Burlington, VT Chittenden County, VT Franklin County, VT Grand Isle County, VT	0.9995
15764	Cambridge-Newton-Framingham, MA Middlesex County, MA	1.1497
15804	Camden, NJ Burlington County, NJ Camden County, NJ Gloucester County, NJ	1.0964
15940	Canton-Massillon, OH Carroll County, OH Stark County, OH	0.9527
15980	Cape Coral-Fort Myers, FL Lee County, FL	0.9856
16180	Carson City, NV Carson City, NV	1.0576
16220	Casper, WY Natrona County, WY	0.9647
16300	Cedar Rapids, IA Benton County, IA Jones County, IA Linn County, IA	0.9375
16580	Champaign-Urbana, IL Champaign County, IL Ford County, IL Piatt County, IL	1.0174
16620	Charleston, WV Boone County, WV Clay County, WV Kanawha County, WV Lincoln County, WV Putnam County, WV	0.9012

CBSA Code	Urban Area (Constituent Counties)	Wage Index
16700	Charleston-North Charleston, SC Berkeley County, SC Charleston County, SC Dorchester County, SC	0.9642
16740	Charlotte-Gastonia-Concord, NC-SC Anson County, NC Cabarrus County, NC Gaston County, NC Mecklenburg County, NC Union County, NC York County, SC	1.0072
16820	Charlottesville, VA Albemarle County, VA Fluvanna County, VA Greene County, VA Nelson County, VA Charlottesville City, VA	1.0681
16860	Chattanooga, TN-GA Catoosa County, GA Dade County, GA Walker County, GA Hamilton County, TN Marion County, TN Sequatchie County, TN	0.9439
16940	Cheyenne, WY Laramie County, WY	0.9558
16974	Chicago-Naperville-Joliet, IL Cook County, IL DeKalb County, IL DuPage County, IL Grundy County, IL Kane County, IL Kendall County, IL McHenry County, IL Will County, IL	1.1315
17020	Chico, CA Butte County, CA	1.1661

CBSA Code	Urban Area (Constituent Counties)	Wage Index
17140	Cincinnati-Middletown, OH-KY-IN Dearborn County, IN Franklin County, IN Ohio County, IN Boone County, KY Bracken County, KY Campbell County, KY Gallatin County, KY Grant County, KY Wenton County, KY Pendleton County, KY Brown County, OH Butler County, OH Clermont County, OH Hamilton County, OH Warren County, OH	1.0127
17300	Clarksville, TN-KY Christian County, KY Trigg County, KY Montgomery County, TN Stewart County, TN	0.8899
17420	Cleveland, TN Bradley County, TN Polk County, TN	0.8555
17460	Cleveland-Elyria-Mentor, OH Cuyahoga County, OH Geauga County, OH Lake County, OH Lorain County, OH Medina County, OH	0.9883
17660	Coeur d'Alene, ID Kootenai County, ID	0.9857
17780	College Station-Bryan, TX Brazos County, TX Burleson County, TX Robertson County, TX	0.9542
17820	Colorado Springs, CO El Paso County, CO Teller County, CO	1.0234
17860	Columbia, MO Boone County, MO Howard County, MO	0.9011

CBSA Code	Urban Area (Constituent Counties)	Wage Index
17900	Columbia, SC Calhoun County, SC Fairfield County, SC Kershaw County, SC Lexington County, SC Richland County, SC Saluda County, SC	0.8454
17980	Columbus, GA-AL Russell County, AL Chattahoochee County, GA Harris County, GA Marion County, GA Muscogee County, GA	0.8692
18020	Columbus, IN Bartholomew County, IN	0.9829
18140	Columbus, OH Delaware County, OH Fairfield County, OH Franklin County, OH Licking County, OH Madison County, OH Morrow County, OH Pickaway County, OH Union County, OH	1.0659
18580	Corpus Christi, TX Aransas County, TX Nueces County, TX San Patricio County, TX	0.9034
18700	Corvallis, OR Benton County, OR	1.2180
19060	Cumberland, MD-WV Allegany County, MD Mineral County, WV	0.9329
19124	Dallas-Plano-Irving, TX Collin County, TX Dallas County, TX Delta County, TX Denton County, TX Ellis County, TX Hunt County, TX Kaufman County, TX Rockwall County, TX	1.0629

CBSA Code	Urban Area (Constituent Counties)	Wage Index
19140	Dalton, GA Murray County, GA Whitfield County, GA	0.9542
19180	Danville, IL Vermilion County, IL	0.9776
19260	Danville, VA Pittsylvania County, VA Danville City, VA	0.8915
19340	Davenport-Moline-Rock Island, IA-IL Henry County, IL Mercer County, IL Rock Island County, IL Scott County, IA	0.9011
19380	Dayton, OH Greene County, OH Miami County, OH Montgomery County, OH Preble County, OH	0.9533
19460	Decatur, AL Lawrence County, AL Morgan County, AL	0.8656
19500	Decatur, IL Macon County, IL	0.8621
19660	Deltona-Daytona Beach-Ormond Beach, FL Volusia County, FL	0.9772
19740	Denver-Aurora, CO Adams County, CO Arapahoe County, CO Broomfield County, CO Clear Creek County, CO Denver County, CO Douglas County, CO Elbert County, CO Gilpin County, CO Jefferson County, CO Park County, CO	1.1528

CBSA Code	Urban Area (Constituent Counties)	Wage Index
19780	Des Moines-West Des Moines, IA Dallas County, IA Guthrie County, IA Madison County, IA Polk County, IA Warren County, IA	0.9621
19804	Detroit-Livonia-Dearborn, MI Wayne County, MI	1.0766
20020	Dothan, AL Geneva County, AL Henry County, AL Houston County, AL	0.8425
20100	Dover, DE Kent County, DE	1.0389
20220	Dubuque, IA Dubuque County, IA	0.9636
20260	Duluth, MN-WI Carlton County, MN St. Louis County, MN Douglas County, WI	1.0604
20500	Durham, NC Chatham County, NC Durham County, NC Orange County, NC Person County, NC	1.0365
20740	Eau Claire, WI Chippewa County, WI Eau Claire County, WI	1.0159
20764	Edison, NJ Middlesex County, NJ Monmouth County, NJ Ocean County, NJ Somerset County, NJ	1.1802
20940	El Centro, CA Imperial County, CA	0.9575
21060	Elizabethtown, KY Hardin County, KY Larue County, KY	0.9175
21140	Elkhart-Goshen, IN Elkhart County, IN	0.9943

CBSA Code	Urban Area (Constituent Counties)	Wage Index
21300	Elmira, NY Chemung County, NY	0.8649
21340	El Paso, TX El Paso County, TX	0.9550
21500	Erie, PA Erie County, PA	0.9166
21604	Essex County, MA Essex County, MA	1.0991
21660	Eugene-Springfield, OR Lane County, OR	1.1474
21780	Evansville, IN-KY Gibson County, IN Posey County, IN Vanderburgh County, IN Warrick County, IN Henderson County, KY Webster County, KY	0.9299
21820	Fairbanks, AK Fairbanks North Star Borough, AK	1.1667
21940	Fajardo, PR Ceiba Municipio, PR Fajardo Municipio, PR Luquillo Municipio, PR	0.8425
22020	Fargo, ND-MN Cass County, ND Clay County, MN	0.8704
22140	Farmington, NM San Juan County, NM	0.9061
22180	Fayetteville, NC Cumberland County, NC Hoke County, NC	0.9437
22220	Fayetteville-Springdale-Rogers, AR-MO Benton County, AR Madison County, AR Washington County, AR McDonald County, MO	0.9226

CBSA Code	Urban Area (Constituent Counties)	Wage Index
22380	Flagstaff, AZ Coconino County, AZ	1.2238
22420	Flint, MI Genesee County, MI	1.1571
22500	Florence, SC Darlington County, SC Florence County, SC	0.8868
22520	Florence-Muscle Shoals, AL Colbert County, AL Lauderdale County, AL	0.8425
22540	Fond du Lac, WI Fond du Lac County, WI	1.0616
22660	Fort Collins-Loveland, CO Larimer County, CO	1.0068
22744	Fort Lauderdale-Pompano Beach-Deerfield Beach, FL Broward County, FL	1.0690
22900	Fort Smith, AR-OK Crawford County, AR Franklin County, AR Sebastian County, AR Le Flore County, OK Sequoyah County, OK	0.8425
23020	Fort Walton Beach-Crestview-Destin, FL Okaloosa County, FL	0.9117
23060	Fort Wayne, IN Allen County, IN Wells County, IN Whitley County, IN	1.0008
23104	Fort Worth-Arlington, TX Johnson County, TX Parker County, TX Tarrant County, TX Wise County, TX	1.0096
23420	Fresno, CA Fresno County, CA	1.1547

CBSA Code	Urban Area (Constituent Counties)	Wage Index
23460	Gadsden, AL Etowah County, AL	0.8509
23540	Gainesville, FL Alachua County, FL Gilchrist County, FL	0.9806
23580	Gainesville, GA Hall County, GA	0.9450
23844	Gary, IN Jasper County, IN Lake County, IN Newton County, IN Porter County, IN	0.9774
24020	Glens Falls, NY Warren County, NY Washington County, NY	0.8782
24140	Goldsboro, NC Wayne County, NC	0.9675
24220	Grand Forks, ND-MN Polk County, MN Grand Forks County, ND	0.8425
24300	Grand Junction, CO Mesa County, CO	1.0199
24340	Grand Rapids-Wyoming, MI Barry County, MI Ionia County, MI Kent County, MI Newaygo County, MI	0.9973
24500	Great Falls, MT Cascade County, MT	0.9070
24540	Greeley, CO Weld County, CO	1.0129
24580	Green Bay, WI Brown County, WI Kewaunee County, WI Oconto County, WI	1.0324

CBSA Code	Urban Area (Constituent Counties)	Wage Index
24660	Greensboro-High Point, NC Guilford County, NC Randolph County, NC Rockingham County, NC	0.9199
24780	Greenville, NC Greene County, NC Pitt County, NC	0.9950
24860	Greenville, SC Greenville County, SC Laurens County, SC Pickens County, SC	1.0250
25020	Guayama, PR Arroyo Municipio, PR Guayama Municipio, PR Patillas Municipio, PR	0.8425
25060	Gulfport-Biloxi, MS Hancock County, MS Harrison County, MS Stone County, MS	0.9405
25180	Hagerstown-Martinsburg, MD-WV Washington County, MD Berkeley County, WV Morgan County, WV	0.9534
25260	Hanford-Corcoran, CA Kings County, CA	1.0680
25420	Harrisburg-Carlisle, PA Cumberland County, PA Dauphin County, PA Perry County, PA	0.9919
25500	Harrisonburg, VA Rockingham County, VA Harrisonburg City, VA	0.9572

CBSA Code	Urban Area	Wage
	(Constituent Counties)	Index
25540	Hartford-West Hartford-East Hartford, CT Hartford County, CT Litchfield County, CT Middlesex County, CT Tolland County, CT	1.1495
25620	Hattiesburg, MS Forrest County, MS Lamar County, MS Perry County, MS	0.8425
25860	Hickory-Lenoir-Morganton, NC Alexander County, NC Burke County, NC Caldwell County, NC Catawba County, NC	0.9500
25980	Hinesville-Fort Stewart, GA Liberty County, GA Long County, GA	0.9649
26100	Holland-Grand Haven, MI Ottawa County, MI	0.9694
26180	Honolulu, HI Honolulu County, HI	1.1654
26300	Hot Springs, AR Garland County, AR	0.9264
26380	Houma-Bayou Cane-Thibodaux, LA Lafourche Parish, LA Terrebonne Parish, LA	0.8428
26420	Houston-Sugar Land-Baytown, TX Austin County, TX Brazoria County, TX Chambers County, TX Fort Bend County, TX Galveston County, TX Harris County, TX Liberty County, TX Montgomery County, TX San Jacinto County, TX Waller County, TX	1.0558

CBSA Code	Urban Area (Constituent Counties)	Wage Index
26580	Huntington-Ashland, WV-KY-OH Boyd County, KY Greenup County, KY Lawrence County, OH Cabell County, WV Wayne County, WV	0.9491
26620	Huntsville, AL Limestone County, AL Madison County, AL	0.9531
26820	Idaho Falls, ID Bonneville County, ID Jefferson County, ID	0.9587
26900	Indianapolis-Carmel, IN Boone County, IN Brown County, IN Hamilton County, IN Hancock County, IN Hendricks County, IN Johnson County. IN Marion County. IN Morgan County, IN Putnam County, IN Shelby County, IN	1.0284
26980	Iowa City, IA Johnson County, IA Washington County, IA	1.0247
27060	Ithaca, NY Tompkins County, NY	1.0353
27100	Jackson, MI Jackson County, MI	1.0085
27140	Jackson, MS Copiah County, MS Hinds County, MS Madison County, MS Rankin County, MS Simpson County, MS	0.8726
27180	Jackson, TN Chester County, TN Madison County, TN	0.9340

CBSA Code	Urban Area (Constituent Counties)	Wage Index
27260	Jacksonville, FL Baker County, FL Clay County, FL Duval County, FL Nassau County, FL St. Johns County, FL	0.9522
27340	Jacksonville, NC Onslow County, NC	0.8683
27500	Janesville, WI Rock County, WI	1.0185
27620	Jefferson City, MO Callaway County, MO Cole County, MO Moniteau County, MO Osage County, MO	0.8790
27740	Johnson City, TN Carter County, TN Unicoi County, TN Washington County, TN	0.8485
27780	Johnstown, PA Cambria County, PA	0.9093
27860	Jonesboro, AR Craighead County, AR Poinsett County, AR	0.8425
27900	Joplin, MO Jasper County, MO Newton County, MO	0.9077
28020	Kalamazoo-Portage, MI Kalamazoo County, MI Van Buren County, MI	1.1292
28100	Kankakee-Bradley, IL Kankakee County, IL	1.0520
28140	Kansas City, MO-KS Franklin County, KS Johnson County, KS Leavenworth County, KS Linn County, KS Miami County, KS Wyandotte County, KS Bates County, MO Caldwell County, MO Cass County, MO	1.0019

CBSA Code	Urban Area (Constituent Counties)	Wage Index
	Clay County, MO Clinton County, MO Jackson County, MO Lafayette County, MO Platte County, MO Ray County, MO	
28420	Kennewick-Richland-Pasco, WA Benton County, WA Franklin County, WA	1.0911
28660	Killeen-Temple-Fort Hood, TX Bell County, TX Coryell County, TX Lampasas County, TX	0.9581
28700	Kingsport-Bristol-Bristol, TN-VA Hawkins County, TN Sullivan County, TN Bristol City, VA Scott County, VA Washington County, VA	0.8425
28740	Kingston, NY Ulster County, NY	0.9881
28940	Knoxville, TN Anderson County, TN Blount County, TN Knox County, TN Loudon County, TN Union County, TN	0.8702
29020	Kokomo, IN Howard County, IN Tipton County, IN	0.9962
29100	La Crosse, WI-MN Houston County, MN La Crosse County, WI	0.9943
29140	Lafayette, IN Benton County, IN Carroll County, IN Tippecanoe County, IN	0.9448

CBSA Code	Urban Area (Constituent Counties)	Wage Index
29180	Lafayette, LA Lafayette Parish, LA St. Martin Parish, LA	0.8733
29340	Lake Charles, LA Calcasieu Parish, LA Cameron Parish, LA	0.8425
29404	Lake County-Kenosha County, IL-WI Lake County, IL Kenosha County, WI	1.0958
29460	Lakeland, FL Polk County, FL	0.9367
29540	Lancaster, PA Lancaster County, PA	1.0156
29620	Lansing-East Lansing, MI Clinton County, MI Eaton County, MI Ingham County, MI	1.0638
29700	Laredo, TX Webb County, TX	0.8425
29740	Las Cruces, NM Dona Ana County, NM	0.9783
29820	Las Vegas-Paradise, NV Clark County, NV	1.2058
29940	Lawrence, KS Douglas County, KS	0.8796
30020	Lawton, OK Comanche County, OK	0.8509
30140	Lebanon, PA Lebanon County, PA	0.9156
30300	Lewiston, ID-WA Nez Perce County, ID Asotin County, WA	1.0395
30340	Lewiston-Auburn, ME Androscoggin County, ME	0.9633

CBSA Code	Urban Area (Constituent Counties)	Wage Index
30460	Lexington-Fayette, KY Bourbon County, KY Clark County, KY Fayette County, KY Jessamine County, KY Scott County, KY Woodford County, KY	0.9679
30620	Lima, OH Allen County, OH	0.9539
30700	Lincoln, NE Lancaster County, NE Seward County, NE	1.0647
30780	Little Rock-North Little Rock, AR Faulkner County, AR Grant County, AR Lonoke County, AR Perry County, AR Pulaski County, AR Saline County, AR	0.9379
30860	Logan, UT-ID Franklin County, ID Cache County, UT	0.9518
30980	Longview, TX Gregg County, TX Rusk County, TX Upshur County, TX	0.9270
31020	Longview, WA Cowlitz County, WA	1.0561
31084	Los Angeles-Long Beach-Glendale, CA Los Angeles County, CA	1.2376

CBSA Code	Urban Area (Constituent Counties)	Wage Index
31140	Louisville-Jefferson County, KY-IN Clark County, IN Floyd County, IN Harrison County, IN Washington County, IN Bullitt County, KY Henry County, KY Jefferson County, KY Meade County, KY Nelson County, KY Oldham County, KY Shelby County, KY Spencer County, KY Trimble County, KY	0.9620
31180	Lubbock, TX Crosby County, TX Lubbock County, TX	0.9086
31340	Lynchburg, VA Amherst County, VA Appomattox County, VA Bedford County, VA Campbell County, VA Bedford City, VA Lynchburg City, VA	0.9172
31420	Macon, GA Bibb County, GA Crawford County, GA Jones County, GA Monroe County, GA Twiggs County, GA	1.0023
31460	Madera, CA Madera County, CA	0.8603
31540	Madison, WI Columbia County, WI Dane County, WI Iowa County, WI	1.1306
31700	Manchester-Nashua, NH Hillsborough County, NH Merrimack County, NH	1.0806
31900	Mansfield, OH Richland County, OH	0.9780

CBSA Code	Urban Area (Constituent Counties)	Wage Index
32420	Mayagüez, PR Hormigueros Municipio, PR Mayagüez Municipio, PR	0.8425
32580	McAllen-Edinburg-Mission, TX Hidalgo County, TX	0.9254
32780	Medford, OR Jackson County, OR	1.1412
32820	Memphis, TN-MS-AR Crittenden County, AR DeSoto County, MS Marshall County, MS Tate County, MS Tunica County, MS Fayette County, TN Shelby County, TN Tipton County, TN	0.9858
32900	Merced, CA Merced County, CA	1.2021
33124	Miami-Miami Beach-Kendall, FL Miami-Dade County, FL	1.0352
33140	Michigan City-La Porte, IN LaPorte County, IN	0.9576
33260	Midland, TX Midland County, TX	1.0323
33340	Milwaukee-Waukesha-West Allis, WI Milwaukee County, WI Ozaukee County, WI Washington County, WI Waukesha County, WI	1.0779

CBSA Code	Urban Area (Constituent Counties)	Wage Index
33460	Minneapolis-St. Paul-Bloomington, MN-WI Anoka County, MN Carver County, MN Chisago County, MN Dakota County, MN Hennepin County, MN Isanti County, MN Ramsey County, MN Scott County, MN Sherburne County, MN Washington County, MN Wright County, MN Pierce County, WI St. Croix County, WI	1.1547
33540	Missoula, MT Missoula County, MT	0.9419
33660	Mobile, AL Mobile County, AL	0.8425
33700	Modesto, CA Stanislaus County, CA	1.2205
33740	Monroe, LA Ouachita Parish, LA Union Parish, LA	0.8436
33780	Monroe, MI Monroe County, MI	1.0241
33860	Montgomery, AL Autauga County, AL Elmore County, AL Lowndes County, AL Montgomery County, AL	0.8449
34060	Morgantown, WV Monongalia County, WV Preston County, WV	0.8886
34100	Morristown, TN Grainger County, TN Hamblen County, TN Jefferson County, TN	0.8425
34580	Mount Vernon-Anacortes, WA Skagit County, WA	1.1095

CBSA Code	Urban Area (Constituent Counties)	Wage Index
34620	Muncie, IN Delaware County, IN	0.8739
34740	Muskegon-Norton Shores, MI Muskegon County, MI	1.0485
34820	Myrtle Beach-Conway-North Myrtle Beach, SC Horry County, SC	0.9292
34900	Napa, CA Napa County, CA	1.4212
34940	Naples-Marco Island, FL Collier County, FL	1.0488
34980	Nashville-DavidsonMurfreesboro, TN Cannon County, TN Cheatham County, TN Davidson County, TN Dickson County, TN Hickman County, TN Macon County, TN Robertson County, TN Rutherford County, TN Smith County, TN Sumner County, TN Trousdale County, TN Williamson County, TN Wilson County, TN	1.0385
35004	Nassau-Suffolk, NY Nassau County, NY Suffolk County, NY	1.3354
35084	Newark-Union, NJ-PA Essex County, NJ Hunterdon County, NJ Morris County, NJ Sussex County, NJ Union County, NJ Pike County, PA	1.2521
35300	New Haven-Milford, CT New Haven County, CT	1.2609

CBSA Code	Urban Area (Constituent Counties)	Wage Index
35380	New Orleans-Metairie-Kenner, LA Jefferson Parish, LA Orleans Parish, LA Plaquemines Parish, LA St. Bernard Parish, LA St. Charles Parish, LA St. John the Baptist Parish, LA St. Tammany Parish, LA	0.9328
35644	New York-White Plains-Wayne, NY-NJ Bergen County, NJ Hudson County, NJ Passaic County, NJ Bronx County, NY Kings County, NY New York County, NY Putnam County, NY Queens County, NY Richmond County, NY Rockland County, NY Westchester County, NY	1.3909
35660	Niles-Benton Harbor, MI Berrien County, MI	0.9405
35980	Norwich-New London, CT New London County, CT	1.2587
36084	Oakland-Fremont-Hayward, CA Alameda County, CA Contra Costa County, CA	1.6238
36100	Ocala, FL Marion County, FL	0.9354
36140	Ocean City, NJ Cape May County, NJ	1.1047
36220	Odessa, TX Ector County, TX	1.0656
36260	Ogden-Clearfield, UT Davis County, UT Morgan County, UT Weber County, UT	0.9489

CBSA Code	Urban Area	Wage
	(Constituent Counties)	Index
36420	Oklahoma City, OK Canadian County, OK Cleveland County, OK Grady County, OK Lincoln County, OK	0.9323
	Logan County, OK McClain County, OK Oklahoma County, OK	
36500	Olympia, WA Thurston County, WA	1.1689
36540	Omaha-Council Bluffs, NE-IA Harrison County, IA Mills County, IA Pottawattamie County, IA Cass County, NE Douglas County, NE Sarpy County, NE Saunders County, NE Washington County, NE	0.9969
36740	Orlando-Kissimmee, FL Lake County, FL Orange County, FL Osceola County, FL Seminole County, FL	0.9922
36780	Oshkosh-Neenah, WI Winnebago County, WI	0.9827
36980	Owensboro, KY Daviess County, KY Hancock County, KY McLean County, KY	0.9228
37100	Oxnard-Thousand Oaks-Ventura, CA Ventura County, CA	1.2206
37340	Palm Bay-Melbourne-Titusville, FL Brevard County, FL	0.9949
37460	Panama City-Lynn Haven, FL Bay County, FL	0.8516

CBSA Code	Urban Area (Constituent Counties)	Wage Index
37620	Parkersburg-Marietta-Vienna, WV-OH Washington County, OH Pleasants County, WV Wirt County, WV Wood County, WV	0.8425
37700	Pascagoula, MS George County, MS Jackson County, MS	0.8667
37860	Pensacola-Ferry Pass-Brent, FL Escambia County, FL Santa Rosa County, FL	0.8439
37900	Peoria, IL Marshall County, IL Peoria County, IL Stark County, IL Tazewell County, IL Woodford County, IL	0.9476
37964	Philadelphia, PA Bucks County, PA Chester County, PA Delaware County, PA Montgomery County, PA Philadelphia County, PA	1.1603
38060	Phoenix-Mesa-Scottsdale, AZ Maricopa County, AZ Pinal County, AZ	1.0852
38220	Pine Bluff, AR Cleveland County, AR Jefferson County, AR Lincoln County, AR	0.8844
38300	Pittsburgh, PA Allegheny County, PA Armstrong County, PA Beaver County, PA Butler County, PA Fayette County, PA Washington County, PA Westmoreland County, PA	0.9146
38340	Pittsfield, MA Berkshire County, MA	1.0830

CBSA Code	Urban Area (Constituent Counties)	Wage Index
38540	Pocatello, ID Bannock County, ID Power County, ID	0.9917
38660	Ponce, PR Juana Díaz Municipio, PR Ponce Municipio, PR Villalba Municipio, PR	0.8425
38860	Portland-South Portland-Biddeford, ME Cumberland County, ME Sagadahoc County, ME York County, ME	1.0453
38900	Portland-Vancouver-Beaverton, OR-WA Clackamas County, OR Columbia County, OR Multnomah County, OR Washington County, OR Yamhill County, OR Clark County, WA Skamania County, WA	1.2043
38940	Port St. Lucie-Fort Pierce, FL Martin County, FL St. Lucie County, FL	1.0374
39100	Poughkeepsie-Newburgh-Middletown, NY Dutchess County, NY Orange County, NY	1.1492
39140	Prescott, AZ Yavapai County, AZ	1.0376
39300	Providence-New Bedford-Fall River, RI-MA Bristol County, MA Bristol County, RI Kent County, RI Newport County, RI Providence County, RI Washington County, RI	1.1377
39340	Provo-Orem, UT Juab County, UT Utah County, UT	1.0061
39380	Pueblo, CO Pueblo County, CO	0.9006

CBSA Code	Urban Area (Constituent Counties)	Wage Index
39460	Punta Gorda, FL Charlotte County, FL	0.9921
39540	Racine, WI Racine County, WI	0.9680
39580	Raleigh-Cary, NC Franklin County, NC Johnston County, NC Wake County, NC	1.0403
39660	Rapid City, SD Meade County, SD Pennington County, SD	1.0900
39740	Reading, PA Berks County, PA	1.0151
39820	Redding, CA Shasta County, CA	1.3923
39900	Reno-Sparks, NV Storey County, NV Washoe County, NV	1.2620
40060	Richmond, VA Amelia County, VA Caroline County, VA Charles City County, VA Chesterfield County, VA Cumberland County, VA Dinwiddie County, VA Goochland County, VA Hanover County, VA Henrico County, VA King and Queen County, VA King William County, VA Louisa County, VA New Kent County, VA Powhatan County, VA Prince George County, VA Colonial Heights City, VA Hopewell City, VA Petersburg City, VA Richmond City, VA	0.9681
40140	Riverside-San Bernardino-Ontario, CA Riverside County, CA San Bernardino County, CA	1.1514

CBSA Code	Urban Area (Constituent Counties)	Wage Index
40220	Roanoke, VA Botetourt County, VA Craig County, VA Franklin County, VA Roanoke County, VA Roanoke City, VA Salem City, VA	0.9122
40340	Rochester, MN Dodge County, MN Olmsted County, MN Wabasha County, MN	1.1858
40380	Rochester, NY Livingston County, NY Monroe County, NY Ontario County, NY Orleans County, NY Wayne County, NY	0.9483
40420	Rockford, IL Boone County, IL Winnebago County, IL	1.0538
40484	Rockingham County-Strafford County, NH Rockingham County, NH Strafford County, NH	1.0717
40580	Rocky Mount, NC Edgecombe County, NC Nash County, NC	0.9340
40660	Rome, GA Floyd County, GA	0.9810
40900	SacramentoArden-ArcadeRoseville, CA El Dorado County, CA Placer County, CA Sacramento County, CA Yolo County, CA	1.4083
40980	Saginaw-Saginaw Township North, MI Saginaw County, MI	0.9361

CBSA Code	Urban Area (Constituent Counties)	Wage Index
41060	St. Cloud, MN Benton County, MN Stearns County, MN	1.0931
41100	St. George, UT Washington County, UT	0.9774
41140	St. Joseph, MO-KS Doniphan County, KS Andrew County, MO Buchanan County, MO DeKalb County, MO	1.0674
41180	St. Louis, MO-IL Bond County, IL Calhoun County, IL Clinton County, IL Jersey County, IL Macoupin County, IL Madison County, IL Monroe County, IL St. Clair County, IL Crawford County, MO Franklin County, MO Jefferson County, MO Lincoln County, MO St. Charles County, MO St. Louis County, MO Warren County, MO Washington County, MO St. Louis City, MO	0.9491
41420	Salem, OR Marion County, OR Polk County, OR	1.1012
41500	Salinas, CA Monterey County, CA	1.5226
41540	Salisbury, MD Somerset County, MD Wicomico County, MD	0.9445
41620	Salt Lake City, UT Salt Lake County, UT Summit County, UT Tooele County, UT	0.9918

CBSA Code	Urban Area (Constituent Counties)	Wage Index
41660	San Angelo, TX Irion County, TX Tom Green County, TX	0.8822
41700	San Antonio, TX Atascosa County, TX Bandera County, TX Bexar County, TX Comal County, TX Guadalupe County, TX Kendall County, TX Medina County, TX Wilson County, TX	0.9330
41740	San Diego-Carlsbad-San Marcos, CA San Diego County, CA	1.1978
41780	Sandusky, OH Erie County, OH	0.9814
41884	San Francisco-San Mateo-Redwood City, CA Marin County, CA San Francisco County, CA San Mateo County, CA	1.5871
41900	San Germán-Cabo Rojo, PR Cabo Rojo Municipio, PR Lajas Municipio, PR Sabana Grande Municipio, PR San Germán Municipio, PR	0.8425
41940	San Jose-Sunnyvale-Santa Clara, CA San Benito County, CA Santa Clara County, CA	1.6105
41980	San Juan-Caguas-Guaynabo, PR Aguas Buenas Municipio, PR Aibonito Municipio, PR Arecibo Municipio, PR Barceloneta Municipio, PR Barranquitas Municipio, PR Bayamón Municipio, PR Caguas Municipio, PR Camuy Municipio, PR Canóvanas Municipio, PR Carolina Municipio, PR Cataño Municipio, PR Cayey Municipio, PR	0.8425

CBSA Code	Urban Area (Constituent Counties)	Wage Index
	Ciales Municipio, PR Cidra Municipio, PR Comerío Municipio, PR Corozal Municipio, PR Dorado Municipio, PR Florida Municipio, PR Guaynabo Municipio, PR Gurabo Municipio, PR Hatillo Municipio, PR Humacao Municipio, PR Juncos Municipio, PR Las Piedras Municipio, PR Las Piedras Municipio, PR Manatí Municipio, PR Manatí Municipio, PR Maunabo Municipio, PR Maunabo Municipio, PR Naguabo Municipio, PR Naguabo Municipio, PR Naranjito Municipio, PR Quebradillas Municipio, PR San Juan Municipio, PR San Lorenzo Municipio, PR Toa Alta Municipio, PR Trujillo Alto Municipio, PR Vega Alta Municipio, PR Vega Alta Municipio, PR Vega Baja Municipio, PR Vega Baja Municipio, PR	
42020	Yabucoa Municipio, PR San Luis Obispo-Paso Robles, CA	1.2236
	San Luis Obispo County, CA	
42044	Santa Ana-Anaheim-Irvine, CA Orange County, CA	1.1893
42060	Santa Barbara-Santa Maria, CA Santa Barbara County, CA	1.1663
42100	Santa Cruz-Watsonville, CA Santa Cruz County, CA	1.6355
42140	Santa Fe, NM Santa Fe County, NM	1.1418
42220	Santa Rosa-Petaluma, CA Sonoma County, CA	1.5258
42260	Sarasota-Bradenton-Venice, FL Manatee County, FL Sarasota County, FL	1.0410

CBSA Code	Urban Area (Constituent Counties)	Wage Index
42340	Savannah, GA Bryan County, GA Chatham County, GA Effingham County, GA	0.9569
42540	ScrantonWilkes-Barre, PA Lackawanna County, PA Luzerne County, PA Wyoming County, PA	0.8973
42644	Seattle-Bellevue-Everett, WA	1.2062
42680	Sebastian-Vero Beach, FL Indian River County, FL	1.0099
43100	Sheboygan, WI Sheboygan County, WI	0.9522
43300	Sherman-Denison, TX Grayson County, TX	0.8969
43340	Shreveport-Bossier City, LA Bossier Parish, LA Caddo Parish, LA De Soto Parish, LA	0.9352
43580	Sioux City, IA-NE-SD Woodbury County, IA Dakota County, NE Dixon County, NE Union County, SD	0.9706
43620	Sioux Falls, SD Lincoln County, SD McCook County, SD Minnehaha County, SD Turner County, SD	1.0096
43780	South Bend-Mishawaka, IN-MI St. Joseph County, IN Cass County, MI	1.0204
43900	Spartanburg, SC Spartanburg County, SC	0.9678
44060	Spokane, WA Spokane County, WA	1.1020

CBSA Code	Urban Area (Constituent Counties)	Wage Index
44100	Springfield, IL Menard County, IL Sangamon County, IL	0.9378
44140	Springfield, MA Franklin County, MA Hampden County, MA Hampshire County, MA	1.0615
44180	Springfield, MO Christian County, MO Dallas County, MO Greene County, MO Polk County, MO Webster County, MO	0.8934
44220	Springfield, OH Clark County, OH	0.8911
44300	State College, PA Centre County, PA	0.9266
44700	Stockton, CA San Joaquin County, CA	1.2070
44940	Sumter, SC Sumter County, SC	0.8528
45060	Syracuse, NY Madison County, NY Onondaga County, NY Oswego County, NY	1.0224
45104	Tacoma, WA Pierce County, WA	1.1382
45220	Tallahassee, FL Gadsden County, FL Jefferson County, FL Leon County, FL Wakulla County, FL	0.9792
45300	Tampa-St. Petersburg-Clearwater, FL Hernando County, FL Hillsborough County, FL Pasco County, FL Pinellas County, FL	0.9646

CBSA Code	Urban Area (Constituent Counties)	Wage Index
45460	Terre Haute, IN Clay County, IN Sullivan County, IN Vermillion County, IN Vigo County, IN	0.9121
45500	Texarkana, TX-Texarkana, AR Miller County, AR Bowie County, TX	0.8549
45780	Toledo, OH Fulton County, OH Lucas County, OH Ottawa County, OH Wood County, OH	1.0108
45820	Topeka, KS Jackson County, KS Jefferson County, KS Osage County, KS Shawnee County, KS Wabaunsee County, KS	0.9210
45940	Trenton-Ewing, NJ Mercer County, NJ	1.1454
46060	Tucson, AZ Pima County, AZ	0.9708
46140	Tulsa, OK Creek County, OK Okmulgee County, OK Osage County, OK Pawnee County, OK Rogers County, OK Tulsa County, OK Wagoner County, OK	0.8534
46220	Tuscaloosa, AL Greene County, AL Hale County, AL Tuscaloosa County, AL	0.9100
46340	Tyler, TX Smith County, TX	0.9295
46540	Utica-Rome, NY Herkimer County, NY Oneida County, NY	0.8848

CBSA Code	Urban Area (Constituent Counties)	Wage Index
46660	Valdosta, GA Brooks County, GA Echols County, GA Lanier County, GA Lowndes County, GA	0.8787
46700	Vallejo-Fairfield, CA Solano County, CA	1.5969
47020	Victoria, TX Calhoun County, TX Goliad County, TX Victoria County, TX	0.9030
47220	Vineland-Millville-Bridgeton, NJ Cumberland County, NJ	1.0372
47260	Virginia Beach-Norfolk-Newport News, VA-NC Currituck County, NC Gloucester County, VA Isle of Wight County, VA James City County, VA Mathews County, VA Surry County, VA York County, VA Chesapeake City, VA Hampton City, VA Newport News City, VA Norfolk City, VA Poquoson City, VA Portsmouth City, VA Suffolk City, VA Virginia Beach City, VA Williamsburg City, VA	0.9272
47300	Visalia-Porterville, CA Tulare County, CA	1.0516
47380	Waco, TX McLennan County, TX	0.9107
47580	Warner Robins, GA Houston County, GA	0.8839
47644	Warren-Troy-Farmington Hills, MI Lapeer County, MI Livingston County, MI Macomb County, MI Oakland County, MI St. Clair County, MI	1.0663

CBSA Code	Urban Area (Constituent Counties)	Wage Index
47894	Washington-Arlington-Alexandria, DC-VA-MD-WV District of Columbia, DC Calvert County, MD Charles County, MD Prince George's County, MD Arlington County, VA Clarke County, VA Fairfax County, VA Fauquier County, VA Prince William County, VA Spotsylvania County, VA Stafford County, VA Warren County, VA Fairfax City, VA Fairfax City, VA Fairfax City, VA Fredericksburg City, VA Manassas City, VA Manassas Park City, VA Jefferson County, WV	1.1662
47940	Waterloo-Cedar Falls, IA Black Hawk County, IA Bremer County, IA Grundy County, IA	0.8869
48140	Wausau, WI Marathon County, WI	1.0257
48260	Weirton-Steubenville, WV-OH Jefferson County, OH Brooke County, WV Hancock County, WV	0.8507
48300	Wenatchee, WA Chelan County, WA Douglas County, WA	1.0915
48424	West Palm Beach-Boca Raton-Boynton Beach, FL Palm Beach County, FL	1.0169
48540	Wheeling, WV-OH Belmont County, OH Marshall County, WV Ohio County, WV	0.8425

CBSA Code	Urban Area (Constituent Counties)	Wage Index
48620	Wichita, KS Butler County, KS Harvey County, KS Sedgwick County, KS Sumner County, KS	0.9561
48660	Wichita Falls, TX Archer County, TX Clay County, TX Wichita County, TX	0.8768
48700	Williamsport, PA Lycoming County, PA	0.8557
48864	Wilmington, DE-MD-NJ New Castle County, DE Cecil County, MD Salem County, NJ	1.1271
48900	Wilmington, NC Brunswick County, NC New Hanover County, NC Pender County, NC	1.0376
49020	Winchester, VA-WV Frederick County, VA Winchester City, VA Hampshire County, WV	1.0645
49180	Winston-Salem, NC Davie County, NC Forsyth County, NC Stokes County, NC Yadkin County, NC	0.9786
49340	Worcester, MA Worcester County, MA	1.1311
49420	Yakima, WA Yakima County, WA	1.0389

CBSA Code	Urban Area (Constituent Counties)	Wage Index
49500	Yauco, PR Guánica Municipio, PR Guayanilla Municipio, PR Peñuelas Municipio, PR Yauco Municipio, PR	0.8425
49620	York-Hanover, PA York County, PA	0.9914
49660	Youngstown-Warren-Boardman, OH-PA Mahoning County, OH Trumbull County, OH Mercer County, PA	0.9285
49700	Yuba City, CA Sutter County, CA Yuba County, CA	1.1319
49740	Yuma, AZ Yuma County, AZ	0.9609

TABLE 6.—PROPOSED CY 2007 ESRD WAGE INDEX FOR RURAL AREAS BASED ON CBSA LABOR MARKET AREAS

	CBSA code	Nonurban area	Wage index
1.		Alabama	0.8425
2 .		Alaska	1.1247
		Arizona	0.9398
4 .		Arkansas	0.8425
		California	1.1902
-		Colorado	0.9838
-		Connecticut	1.2377
		Delaware	1.0239
-		Florida	0.9051
		Georgia	0.8425
		Hawaii	1.1022
		Idaho	0.8566
_		Illinois	0.8769
		Indiana	0.8927
_		lowa	0.9159
_		Kansas	0.8425
		Kentucky	0.8425
_		Louisiana	0.8425
		Maine	0.8856
		Maryland	0.9417
		Massachusetts	1.0758
		Michigan	0.9532
_		Minnesota	0.9653
			0.8425
_		Mississippi	
		Missouri	0.8425 0.9062
		Montana	
_		Nebraska	0.9154
_		Nevada	0.9435
		New Hampshire	1.1373
-		New Jersey	0.0700
		New Mexico	0.8790 0.8688
		New York	
		North Carolina	0.9055
		North Dakota	0.8425
		Ohio	0.9134
-		Oklahoma	0.8425
		Oregon	1.0288
		Pennsylvania	0.8774
		¹ Rhode Island	0.0405
		South Carolina	0.8425
_		South Dakota	0.9038
		Tennessee	0.8425
_		Texas	0.8425
_		Utah	0.8587
		Vermont	1.0472
		Virgin Islands	0.8425
		Virginia	0.8425
		Washington	1.0827
-		West Virginia	0.8425
-		Wisconsin	0.9970
53		Wyoming	0.9805

¹ All counties in the States of New Jersey and Rhode Island are urban.

H. Private Contracts and Opt-Out Provision—Practitioner Definition

[If you choose to comment on issues in this section, please include the caption "PRIVATE CONTRACTS AND OPT-OUT" at the beginning of your comments.]

Section 4507 of the BBA of 1997 amended section 1802 of the Act to permit certain physicians and practitioners to opt-out of Medicare if certain conditions were met, and to provide through private contracts services that would otherwise be covered by Medicare. Before enactment of BIPA (Pub.L. 106–554), section 1802(b)(5)(C) of the Act, which refers to the definition of "practitioner" at section 1842(b)(18)(C) of the Act, did not include registered dietitians or nutrition professionals among the practitioners who may choose to opt-out of Medicare. Section 105(d) of BIPA amended the definition of practitioner located at section 1842(b)(18)(c) of the Act to include registered dietitians or nutrition professionals. Because section 1802(b)(5)(C) of the Act references section 1842(b)(18)(c) of the Act in order to define the term practitioner for

purposes of opting out of Medicare, current law permits registered dietitians or nutrition professionals to opt-out of Medicare. Because the definition of practitioner located in the current regulations at § 405.400 does not include registered dietitians or nutrition professionals, we are proposing to amend that section so that it is consistent with section 1802(b)(5)(C) of the Act.

I. Proposed Changes to Reassignment and Physician Self-Referral Rules Relating to Diagnostic Tests

[If you choose to comment on issues in this section, please include the caption "REASSIGNMENT AND PHYSICIAN SELF-REFERRAL" at the beginning of your comments.]

Historically, Medicare rules have prohibited the markup of the TC of certain diagnostic tests that are performed by outside suppliers and billed to Medicare by a different individual or entity. In addition, Medicare rules restrict who may bill Medicare for the PC (hereafter, also referred to as the "interpretation") of diagnostic tests. Recent changes to our rules on reassignment of the right to receive Medicare payment may have led to some confusion as to whether the anti-markup and purchased interpretation requirements apply to certain situations where a reassignment has occurred pursuant to a contractual arrangement.

Likewise, we are concerned about the existence of certain arrangements that are not within the intended purpose of our physician self-referral rules, which allow physician group practices to bill for services furnished by a contractor physician in a "centralized building." We are concerned that allowing physician group practices or other suppliers to purchase or otherwise contract for the provision of diagnostic tests and then to realize a profit when billing Medicare may lead to patient and program abuse in the form of overutilization of services and result in higher costs to the Medicare program.

Therefore, we are proposing to amend our reassignment regulations to clarify how the purchased test and purchased test interpretation rules apply in the case of a reassignment made under the contractual arrangement exception set forth at § 424.80(d)(2). Specifically, in our reassignment regulations, we propose to incorporate provisions similar to those that currently appear in § 414.50 of our regulations on purchased tests, and we are considering incorporating provisions on purchased test interpretations that currently appear in our manual instructions. In addition, we are proposing to change the definition of "centralized building" at § 411.351 of the physician self-referral regulations to place certain restrictions on what types of space ownership or leasing arrangements will qualify for purposes of the physician self-referral in-office ancillary services exception and physician services exception.

Our proposals regarding the reassignment regulations are based on

existing requirements for purchased tests and purchased test interpretations. Section 1842(n) of the Act contains certain limitations on billing for the TC of diagnostic tests described in section 1861(s)(3) of the Act (other than clinical diagnostic laboratory tests paid under section 1833(a)(2)(D) of the Act, which are subject to the special rules set forth in section 1833(h)(5)(A) of the Act). Section 1842(n)(1)(A) of the Act provides that if the test was not performed by the billing physician and also was not performed or supervised by a physician with whom the billing physician shares a practice, Medicare payment is the lower of the costs (net of any discount) charged by the performing supplier to the billing physician, or the performing supplier's reasonable charge (or other applicable limit). This is commonly known as the anti-markup provision. Section 1842(n)(2) of the Act further provides that a physician may not bill a beneficiary any amount other than the amount specified in section 1842(n)(1)(A) of the Act and any applicable deductible and coinsurance. Under section 1842(n)(3) of the Act, if a physician knowingly, willfully, and repeatedly bills a Medicare beneficiary for more than the amount allowed under section 1842(n)(2) of the Act, he or she is subject to civil monetary penalties and assessments, and exclusion from Medicare and Medicaid for up to 5 years. Our regulations implementing section 1842(n) of the Act appear at § 414.50 and § 402.1(c)(15).

In addition, our Claims Processing Manual (Pub. 100–4) outlines certain conditions regarding who can submit a claim for purchased diagnostic test intepretations. As set forth in Chapter 1, Section 30.2.9.1 of the Claims Processing Manual, the following requirements must be satisfied in order to submit a claim for a purchased diagnostic test interpretation:

• The test must be ordered by a physician or medical group that is independent of the person or entity performing the TC of the test, and also must be independent of the physician or medical group performing the interpretations.

• The physician or medical group performing the interpretations does not see the patient.

• The purchaser (or employee, partner, or owner of the purchaser) performs the TC of the test, and the interpreting physician must be enrolled in the Medicare program.

Section 1842(b)(6) of the Act generally prohibits Medicare payment to anyone other than the Medicare beneficiary or the physician or other person who performed the service for the beneficiary. However, section 1842(b)(6) of the Act, also provides exceptions, known as the reassignment exceptions, to this general rule. These exceptions allow us to make payment to an individual or an entity other than the beneficiary or the physician or other person who performed the service for the beneficiary. For example, the reassignment exceptions allow us to make payment to an employer of a physician, such as a group practice or a hospital, to which the physician employee has reassigned his or her right to payment.

Prior to the MMA, a physician or other individual supplier could reassign his or her right to bill and receive payment under a contractual arrangement, rather than an employeeemployer relationship, only if the services being paid for were performed on the premises of the contracting hospital, critical access hospital, clinic, or other facility. Section 952 of the MMA, however, amended section 1842(b)(6)(A)(ii) of the Act to extend the reassignment exception to contractual arrangements regardless of whether the services are performed on the premises of the billing entity. Section 952 of the MMA permits us to recognize this type of reassignment to the extent that the contractual arrangement between the physician or other individual supplier and the billing entity (excluding a billing agent, which cannot receive reassigned benefits) meets program integrity and other safeguards as the Secretary may determine to be appropriate. A motivating factor behind the passage of section 952 of the MMA appears to have been the desire by the Congress to permit us to allow hospital emergency department staffing companies that employ physicians on a contract basis to bill Medicare (if the staffing companies enroll in Medicare).

Our proposed implementation of section 952 of the MMA appeared in the Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2005 proposed rule, 69 FR 47488, 47524 through 47525 (August 5, 2004). We proposed program safeguards, whereby the parties to the contractual arrangement would have joint and several liability for any Medicare overpayments, and the physician or other individual supplier would have unrestricted access to billings submitted on his or her behalf by the entity receiving reassigned payments. In that proposed rule, we stated our awareness that the changes to the reassignment rules authorized by section 952 of the MMA may create new fraud and abuse vulnerabilities, which may not become apparent until the program has

experience with new contractual arrangements. We solicited comments on these potential program vulnerabilities and on possible additional safeguards to protect against such vulnerabilities.

Comments submitted in response to the CY 2005 PFS proposed rule expressed concern over the recent growth of "pod" or "condo" laboratories (hereinafter "pod labs"). In a typical pod lab arrangement involving pathology services, an entity leases space in a medical building and then subdivides the space into separate areas or cubicles, which are equipped with microscopes and a minimal amount of other laboratory equipment. The entity subleases each space to a physician group practice, even though the space may be located many miles away from any medical office of the group practice and is often located in a different state. The entity hires a histologist who performs the TC of the pathology service, by preparing a microscopic slide of each specimen for review by a pathologist. The entity also makes arrangements with a pathologist, who performs the PC of the pathology service and who also supervises the pod lab.

In one type of arrangement, the pathologist and histologist perform their services for the different group practices by moving from cubicle to cubicle. Each group practice pays the pathologist a fee for every slide reviewed and pays the entity a management fee, which covers the rental of the pod lab and the histologist's salary. The group practice then bills Medicare for the entire pathology service, typically at a markup from what the group practice paid the pathologist for the professional service and the entity for its services. In another common arrangement, the histologist performs the TC of the pathology service for the entity and the entity bills Medicare for that service, while the group practice bills for the interpretation that was performed by its independent contractor pathologist, who has reassigned to the group practice his or her right to receive Medicare payment.

The commenters stated that pod lab arrangements are subject to fraud, waste and abuse, including, but not limited to the following:

- Generation of medically unnecessary biopsies.
 - Kickbacks.
 - Fee-splitting.
- Referrals that would otherwise be prohibited under the physician selfreferral statute.

The commenters provided several suggestions. One commenter suggested that we prohibit a physician from

reassigning benefits to another physician if the physicians do not practice in substantially the same medical specialty. Some commenters also stated that our regulations need to state more clearly that all requirements of the purchased diagnostic test rules and purchased test interpretation rules need to be met.

In the CY 2005 PFS final rule, we responded that we shared the commenters concerns, although we declined to incorporate the suggested revisions at that time. We said that we would be paying close attention to this issue, and that we might initiate future rulemaking to address arrangements that are fraudulent or abusive. (See 69 FR 66316, November 15, 2004.) In that final rule, we amended our reassignment regulation at § 424.80(a) to state that nothing in § 424.80 alters an individual's or entity's obligations under other Medicare statutes or rules, including, but not limited to, the physician self-referral law (section 1877 of the Act), the anti-kickback statute (section 1128B(b)(1) of the Act), the regulations regarding purchased diagnostic tests, and the regulations regarding services and supplies provided incident to a physician's service.

At about the same time as we published our proposed rule for implementing section 952 of the MMA, we published an IFC concerning exceptions to the physician self-referral law in section 1877 of the Act (69 FR 16054). Section 1877 of the Act prohibits a physician from making referrals for DHS, as defined in section 1877(h)(6) of the Act, payable by Medicare to an entity with which he or she (or an immediate family member) has a financial relationship (ownership or compensation), and it prohibits the entity from billing Medicare, another payor, or the beneficiary for those referred services, unless an exception applies. The statute establishes a number of specific exceptions to these prohibitions and grants the Secretary the authority to create regulatory exceptions for financial relationships that pose no risk of fraud or abuse.

One significant exception is at § 411.355(a) for the provision of "physician services" as defined in § 410.20(a). Under this exception, professional physician services that are DHS must be furnished personally by another physician who is a member of the referring physician's group practice, or by a physician in the same group practice as the referring physician, or by someone under the supervision of one of these physicians. A "member" of a group practice is a physician owner, a

physician employee, a locum tenens physician, or an on-call physician while the physician is providing on-call services for members of the group practice. "Physician in the group practice" means a member of the group practice, as well as an independent contractor physician during the time the independent contractor is furnishing patient care services for the group practice to the group practice's patients in the group practice's facilities. (See § 411.351.)

Another significant exception, at § 411.355(b), is for the provision of inoffice ancillary services. This exception allows group practice physicians to refer patients for DHS to other members of their group or to nonphysician staff, provided that certain supervision, location, and billing requirements are satisfied. Specifically, the DHS must be furnished personally by the referring physician, a member of the group practice, or an individual who is supervised by the referring physician or by a physician in the group practice. In addition, the DHS must be furnished in—(1) the "same building" where group physicians perform a certain amount of physician services (as set forth in § 411.355(b)(2)), including physician services unrelated to the provision of DHS; or (2) in a "centralized building." We define "centralized building," in pertinent part, as all or part of building that is owned or leased on a full-time basis 24 hours per day, 7 days per week. In the "Phase II" physician self-referral IFC, we reaffirmed our earlier position, set forth in the "Phase I" final rule with comment period that, a group practice may have more than one centralized building (69 FR at 16075).

In response to the Phase II IFC, several commenters strongly criticized the centralized building prong of the inoffice ancillary services exception. They requested that the rule be changed to require full-time use of the facility and the addition of a commercially reasonable test. According to the commenters, the Phase II IFC encourages numerous abusive arrangements that are designed solely to permit medical groups to bill in circumvention of the prohibition in section 1877 of the Act. Commenters objected to medical groups establishing satellite DHS facilities, sometimes in different States, specifically to capture ancillary income. Several commenters identified pod labs that rent space to urology groups as among the types of abusive arrangements that are proliferating. Several other commenters requested clarification that the in-office ancillary services exception did not

override our policies on reassignment and purchased diagnostic tests. According to the comments, some of the arrangements do not satisfy the rules regarding purchased diagnostic tests. On the other hand, a professional association complained that the requirement that the centralized building be occupied exclusively by the medical group is too restrictive.

As noted above, we stated, in response to the comments on the proposed rule implementing section 952 of the MMA, that we might address suspect arrangements in a future rulemaking. After additional consideration, including consideration of the comments we received in response to the Phase II IFC, we are now proposing to amend our regulations on reassignment and physician self-referral in this proposed rule.

We are proposing to amend § 424.80 of our regulations to clarify that any reassignment pursuant to the contractual arrangement exception is subject to program integrity safeguards that relate to the right to payment for diagnostic tests. First, we would amend § 424.80 of our regulations to provide that if the TC of a diagnostic test (other than clinical diagnostic laboratory tests paid under section 1833(a)(2)(D) of the Act, which are subject to the special rules set forth in section 1833(h)(5)(A) of the Act) is billed by a physician or medical group (the "billing entity") under a reassignment involving a contractual arrangement with a physician or other supplier who performs the service, the amount billed to Medicare by the billing entity, less the applicable deductibles and coinsurance, may not exceed the lowest of the following amounts:

- The physician or other supplier's net charge to the billing physician or medical group.
- The billing physician's or medical group's actual charge.
- The fee schedule amount for the service that would be allowed if the physician or other supplier billed directly.

Second, we would also require that, in order to bill for the TC, the billing entity would be required to perform the interpretation. Third, we are considering further amendments to § 424.80(d) that would impose certain conditions on when a physician or medical group can bill for a reassigned PC of a diagnostic test. We are considering the following conditions:

• The test must be ordered by a physician that is financially independent of the person or entity performing the test and also of the

physician or medical group performing the interpretation.

- The physician or medical group performing the interpretation does not see the patient.
- The physician or medical group billing for the interpretation must have performed the TC of the test.

We believe that we are comfortably within our authority to place the proposed restrictions on reassignments made before a contractual arrangement, in order to guard against patient and program abuse, and we also believe that we would be within our authority to adopt the conditions on billing for a reassigned PC before a contractual arrangement that we continue to consider.

We note that there is no right to effect a reassignment under section 1842(b)(6) of the Act (rather, this section allows, but does not require us to make payment to someone other than the beneficiary or the physician or other person who performed the service), and that section 952 of the MMA permits us to recognize reassignments under the contractual arrangement exception only to the extent that the arrangement meets program integrity and other safeguards as the Secretary may determine to be appropriate. Moreover, we believe that our current rules on purchased diagnostic tests generally should be applicable to both situations in which the billing entity is purchasing the test without a formal reassignment as well as situations in which the physician performing the test has reassigned his or her right to Medicare payment to the billing physician or medical group.

Although we welcome comments on all aspects of our proposals, we are particularly interested in soliciting comments on the amendments we have proposed, as well as those we are still considering involving reassigned interpretations, to § 424.80(d). In particular, we are soliciting comments as to whether diagnostic tests in the DHS category of radiology and certain other imaging services should be excepted from any those provisions; whether the proposal in whole or in part should apply only to pathology services; whether any of these provisions should apply to services performed on the premises of the billing entity and if so, how to define the premises appropriately. We are also soliciting suggested regulatory text for the proposal under consideration involving purchased test interpretations, as well as any other comments regarding the appropriate scope of the provisions under consideration.

In addition, we are soliciting comments on whether an anti-markup

provision should apply to the reassignment of the PC of diagnostic tests performed under a contractual arrangement, and if so, how to determine the correct amount that should be billed to the Medicare program

In addition to our proposed changes to the reassignment rules, we are proposing to change the definition of "centralized building" in § 411.351 for purposes of our physician self-referral regulations. We are persuaded by the commenters who responded to the Phase II IFC that our present definition may encourage the unnecessary ordering of ancillary services. Section 1877(b)(1) of the Act, in conjunction with section 1877(h)(4)(vi) of the Act, states that the Secretary may define by regulation what constitutes a "group practice" for purposes of the physician services exception. Similarly, section 1877(b)(2) of the Act authorizes the Secretary to determine additional terms and conditions relating to the supervision and location requirements of the in-office ancillary services exception as may be necessary to prevent a risk of program or patient abuse. Accordingly, we propose to modify the definition of "centralized building" to include a minimum square footage requirement of 350 square feet. Our modified definition would be relevant to both the physician services exception and the in-office ancillary services exception. That is because, under § 411.351, a "physician in the group practice" includes an independent contractor physician during the time he or she is providing services to the group's patients in the group's facilities. Thus, to the extent that an independent contractor physician would qualify as a "physician in the group" on the basis of furnishing services to a group's patients in a centralized building, the space owned or leased by the group would need to comply with the proposed modification to the definition of "centralized building" in order for the group to rely on the physician services exception or the in-office ancillary services exception when billing Medicare for services furnished by the independent contractor

Ålthough we believe that the arrangements we seek to address through our proposed change to the definition of "centralized building" primarily involves independent contractor physicians, the proposed definition would also apply to services performed by physicians who are employees of a group practice.

The proposed minimum square footage requirement would not apply to

space owned or rented in a building in which no more than three group practices own or lease space in the 'same building,'' as defined in § 411.351 (that is, in a building with the same street address) and share the same 'physician in the group practice'' (as defined in § 411.351). The purpose of the square foot minimum and the exception is to prevent abusive arrangements such as pod labs, while not disqualifying legitimate, stand-alone physician offices that are unusually small. The following examples are intended to illustrate how the proposed exception might apply:

+ Example 1—A space of 200 square feet located in a building in which only two other group practices lease space could qualify as a centralized building, irrespective of whether all three group practices contract with the same individual as a "physician in the group

practice."

+ Example 2—A space of 200 square feet is located in a building in which seven other group practices lease space. Dr. Jones has a contractual relationship with three group practices as a "physician in the group practice." Dr. Smith also has a contractual relationship with three group practices. No physician has a contractual relationship as a "physician in the group practice" with four or more group practices that are located in that building. The space could qualify as a "centralized building."

We would also require the space to contain, on a permanent basis, the necessary equipment to perform substantially all of the DHS that are performed in this space, in order to meet the definition of a "centralized building." That is, we wish to prevent the situation in which an entity would routinely move equipment as needed from one group's space to another group's space (for example, from cubicle to cubicle). We believe these situations are abusive and contrary to the purpose of concept of the "centralized building" concept, but we recognize that there may be an occasional need to bring specialized equipment into the space on a temporary basis.

We believe that the proposed clarification to our reassignment rules, in tandem with our proposed changes to the definition of "centralized building" for purposes of our physician selfreferral rules would prevent abusive arrangements while preserving legitimate small physician offices. In particular, we anticipate that restrictions on marking up the TC of diagnostic tests as well as the limits we are considering for who can bill for the PC of diagnostic tests, combined with

square footage limits and requirements of having necessary equipment on site would make it not financially feasible for pod labs to exist.

With respect to our proposed change to the definition of "centralized building," we seek comments on whether there should be a minimum square foot requirement, and if so, whether the minimum should be 350 square feet or an amount more or less than that. In addition, we seek comments regarding whether there should be an exception to any minimum square foot requirement, and if so, the circumstances under which an exception should apply.

With respect to our proposal that the "centralized building" permanently contain the necessary equipment to perform substantially all of the DHS that is furnished in the "centralized building," we seek comments on whether this test should be imposed, and whether at least 90 percent or some other minimum percentage or measurement is appropriate. We are also considering whether to require that, for space to qualify as a "centralized building," the group practice must employ, in that space, a nonphysician employee or independent contractor who will perform services exclusively for the group for at least 35 hours per week. We seek comments on whether we should have this requirement or similar requirement, or whether this requirement would be unduly burdensome on a small group practice, and whether this requirement would be likely to reduce the number of existing pod labs and to discourage the development of new pod labs. Finally, we seek comments on whether a group practice should be allowed to maintain a "centralized building" in a State different from the State(s) in which it has an office that meets the criteria of § 411.355(b)(2)(i), and if so, whether space that is located in a different State must be within a certain number of miles from an office of the group practice that meets the criteria of $\S411.355(b)(2)(i)$, in order to qualify as a "centralized building."

J. Supplier Access to Claims Billed on Reassignment

Section 1833(e) of the Act provides that, "no payment shall be made to any provider of services or other person under this part unless there has been furnished such information as may be necessary in order to determine the amounts due such provider or other person under this part for the period with respect to which the amounts are being paid or for any prior period.' Section 1842(b)(6) of the Act generally

provides that payment may not be made to anyone other than the beneficiary or the physician or other person who provided the service. There are certain exceptions to this prohibition whereby payment may be made to others. These are commonly referred to as the reassignment exceptions and are found at section 1842(b)(6)(A) of the Act.

Taking these two statutory provisions together, we are permitted, but not required, to make payment to someone other than the beneficiary, or the physician or other person who furnished the service, but only if we have determined that Medicare has received all necessary information to determine the amounts due the provider. Where Medicare makes payment to an entity rather than to the physician or other person who furnished the service, there is a heightened concern that payment may not be correct. By allowing physicians and other individual suppliers who reassign benefits to an entity such as a group practice to have access to the billing information concerning the services they allegedly furnish, we believe we will reduce the risk of

inappropriate billing.
Moreover, as noted in section I.2. of this proposed rule, section 952 of the MMA amended section 1842(b)(6)(A)(ii) of the Act to allow a physician or other person who was in a contractual arrangement rather than in an employee-employer relationship to reassign his or her right to bill and receive payment, irrespective of whether the services were performed on the premises of the entity. Section 952 of the MMA permits reassignment to the extent that the contractual arrangement between the physician or other individual supplier and the billing entity meets program integrity and other safeguards that the Secretary may

determine to be appropriate.

In the FY 2005 Physician Fee Schedule proposed rule, published August 5, 2005 (69 FR 47488, 47524 through 47525), we stated our awareness that changes in the reassignment rules based on section 952 of the MMA may create new fraud and abuse vulnerabilities, which may not become apparent until the program has experience with new contractual arrangements. We proposed program safeguards, whereby the parties to the contractual arrangement would have joint and several liability for any Medicare overpayments, and the physician or other individual supplier would have unrestricted access to billings submitted on their behalf by the entity receiving reassigned payments. In response to the August 5, 2005 proposed rule, we received a comment that questioned the need for the two program integrity safeguards (joint and several liability and unrestricted access to billing records) as a requirement for a reassignment of claims involving a contractual arrangement. The commenter believed that it was premature for CMS to implement these program safeguards, that CMS already imposes joint and several liability through Medicare participation agreements and the signing of the enrollment form for billing reassigned claims (the CMS-855-R form), and questioned why the program safeguards applied only to independent contractors and not to employees. (69 FR 66316 through 66317 (November 15, 2004).)

In response to the commenter, we stated that those program integrity safeguards were necessary to monitor the billings of entities with which we have had billing problems (for example, billing for services never furnished and upcoding resulting in Medicare overpayments) in the past, and that the reason the safeguards applied to independent contractors and not to employees, was that the billing problems identified thus far involved certain entities (which, for the most part, contracted with, rather than employed, emergency room (ER) physicians). We also stated that we would study whether the same program integrity safeguards applicable to independent contractors should also apply to employees.

Prior to January 1, 2005, the effective date of the program integrity safeguards for the contractual arrangement reassignment exception, we received public inquiries asking why employees do not have unrestricted access to billing records. Since the January 1, 2005 effective date of the program integrity safeguards, we have received an inquiry from an ER physician employee of a medium-sized ER physician staffing company, who was denied access to billing records for services that he claims to have furnished, and who had his employment terminated. We also note that the MMA Conference Report, in its discussion of section 952 of the MMA, states that the Conference Committee supports appropriate program integrity efforts for any entities billing the Medicare program, including entities with independent contractors as well as employees. Having reconsidered the issue, we find no valid reason why an employee should not have access to records on billings for services furnished by that employee. Therefore, we are proposing to change the title of § 424.80(d) and amend § 424.80(d)(2) of

our regulations to state that the supplier who reassigns his or her right to bill and receive Medicare payment to an entity has unrestricted access to claims information submitted by that entity for services supposedly furnished by the individual supplier, irrespective of whether the supplier is an employee or independent contractor of the entity. If adopted, our proposal would also mean that if an entity receiving the reassigned benefits were to refuse to provide the billing information to the employee supplier requesting the information, the entity's right to receive reassigned benefits may be revoked under 42 CFR 424.82(c)(3) (which is currently the case with respect to an entity's refusal to provide billing information to an independent contractor supplier).

K. Coverage of Bone Mass Measurement (BMM) Tests

[If you choose to comment on issues in this section, please include the caption "BONE MASS MEASUREMENT TESTS" at the beginning of your comments.]

In an IFC entitled "Medicare Coverage of and Payment for Bone Mass Measurements" published in the Federal Register on June 24, 1998 (63 FR 34320), we implemented section 4106 of the BBA by establishing a new regulatory section, 42 CFR 410.31 (Bone Mass Measurement: Conditions for Coverage and Frequency Standards). Section 4106 of the BBA statutorily defined BMM and individuals that are qualified to receive a BMM. The June 24, 1998 IFC, under the "reasonable and necessary" provisions of 1862(a)(1)(A) of the Act, also established conditions for coverage of the tests that must be ordered by physicians or nonphysician practitioners. Lastly, as directed by section 4106 of the BBA, we established frequency standards governing the time period when qualified individuals would be eligible to receive covered BMMs.

1. Provisions of the June 24, 1998 IFC

As stated earlier in this section, the June 24, 1998 IFC implemented section 4106 of the BBA by establishing conditions for coverage and frequency standards for BMMs to ensure that they are paid for uniformly throughout the Medicare program and that they are reasonable and necessary for Medicare beneficiaries who are eligible to receive these measurements. This section summarizes the provisions discussed in the June 24, 1998 IFC.

 a. Coverage Conditions and Frequency Standards

We established conditions for coverage and frequency standards for medically necessary BMMs for five categories of Medicare beneficiaries in § 410.31.

In § 410.31(a), we defined "bone mass measurement" based on the statutory definition in section 4106 of the BBA. In accordance with the "reasonable and necessary" provisions of section 1862(a)(1)(A) of the Act, we established the conditions for coverage of BMMs in § 410.31(b) of the regulations. Consistent with § 410.32 (Diagnostic x-ray tests, diagnostic laboratory tests, and diagnostic tests: Conditions), we provided that coverage be available for the BMM only if it is ordered by the physician or a qualified nonphysician practitioner (as defined in § 410.32(a)) treating the beneficiary following an evaluation of the beneficiary's need for the test, including a determination as to the medically appropriate procedure to be used for the beneficiary. We believed that BMMs were not demonstrably reasonable and necessary unless (among other things) they are ordered by the physician treating the beneficiary following a careful evaluation of the beneficiary's medical need, and they are employed to manage the beneficiary's care.

To ensure that the BMM is performed as accurately and consistently in accordance with appropriate quality assurance guidelines as possible, we required that it be performed under the appropriate supervision of a physician as defined in § 410.32(b)(3). To ensure that the BMM is medically appropriate for the five categories specified in the law, we provided that it be reasonable and necessary for diagnosing, treating, or monitoring the condition of the beneficiary who meets the coverage requirements specified in § 410.31(d).

Furthermore, in § 410.31(c), we set forth limitations on the frequency for covering a BMM. Generally, we cover a BMM for a beneficiary if at least 23 months have passed since the month the last BMM was performed. However, we allow for coverage of follow-up BMMs performed more frequently than once every 23 months when medically necessary. We listed the following examples of situations where more frequent BMMs procedures may be medically necessary to include:

- Monitoring beneficiaries on longterm glucocorticoid (steroid) therapy of more than 3 months.
- Allowing for a confirmatory baseline bone mass measurement (either central or peripheral) to permit

monitoring of beneficiaries in the future if the initial test was performed with a technique that is different from the proposed monitoring method.

b. Beneficiaries Who May Be Covered

In § 410.31(d), we amended our regulations to conform to the statutory requirement that the following categories of beneficiaries may receive Medicare coverage for a medically necessary BMM:

- A woman who has been determined by the physician or a qualified nonphysician practitioner treating her to be estrogen-deficient and at clinical risk for osteoporosis, based on her medical history and other findings.
- An individual with vertebral abnormalities as demonstrated by an x-ray to be indicative of osteoporosis, osteopenia, or vertebral fracture.
- An individual receiving (or expecting to receive) glucocorticoid (steroid) therapy equivalent to 7.5 mg of prednisone, or greater, per day, for more than 3 months.
- An individual with primary hyperparathyroidism.
- An individual being monitored to assess the response to or efficacy of an FDA-approved osteoporosis drug therapy.

c. Waiver of Liability

Section 410.31(e) provides that Medicare payment would be denied for a BMM in accordance with section 1862(a)(1)(A) of the Act if the regulatory standards are not satisfied. Existing regulations concerning limitation on liability are set forth in §§ 411.400 through 411.406 and are applicable to denial of BMMs under § 410.31.

d. Payments for BMMs

Medicare payments for covered BMMs are paid for under the PFS (42) CFR part 414) as required by statute. In the June 24, 1998 IFC, we revised the definition of "physician services" in § 414.2 to include bone mass measurements. When BMM procedures are furnished to hospital inpatients and outpatients, the TCs of these procedures are payable under existing payment methods for hospital services. These methods include payments under the prospective payment system, on a reasonable cost basis, or under a special provision for determining payment rates for hospital outpatient radiology services.

In the June 24, 1998 IFC, we revised § 414.50(a), regarding physician billing for purchased diagnostic tests, to clarify that the section does not apply to payment for BMMs.

e. Conforming Changes

In the June 24, 1998 IFC, to allow for appropriate placement in the CFR of the BMM coverage requirements, we redesignated § 410.31 (Prescription drugs used in immunosuppressive therapy) as § 410.30.

2. Additional Scientific Evidence

In 2004, the Surgeon General issued a report, Bone Health and Osteoporosis (U.S. Department of Health and Human Services, Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General, 2004). This report provides scientific evidence related to the prevention, assessment, diagnosis, and treatment of bone disease. The report states that identification of those at risk of bone disease and fracture is important so that appropriate interventions can be implemented. However, as the report states, "Assessing the risk of bone disease and fracture remains a challenge. Not all of the risk factors have been identified, and the relative importance of those that are known remains unclear."

As bone strength is not measured directly, bone mineral density (BMD) remains the single best predictor of fracture risk, with the most widely accepted method for measuring BMD being the dual energy x-ray absorptiometry (DXA) for a bone density study at the axial skeleton (for example, hips and spine). As there are many sources of variability in the measurement of BMD, a quality control system related to both the methodology and reporting of test results is important to ensure the validity of DXA analysis.

In addition to DXA of the axial skeleton, bone mass can also be measured using other techniques. These other techniques include DXA bone density study for the appendicular skeleton (for example, radius, wrist, heel); quantitative computerized tomography (QCT), bone mineral density study for the axial skeleton or appendicular skeleton; radiographic absorptiometry (photodensitometry, radiogrammetry); single-photon absorptiometry (SPA); single energy xray absorptiometry (SXA) for the appendicular skeleton; and ultrasound bone mineral density study for the appendicular skeleton. With regard to these techniques (except for SPA which was not discussed), the 2004 Surgeon General report states, "While these methods do assess bone density and may provide an indication of fracture risk, it is important to note that the WHO [World Health Organization]

recommendations and other guidelines for using BMD and interpreting BMD results for diagnosis are based on DXA measurements of the hip or spine." The report further states, "Incorporating these techniques for bone assessment into future clinical trials and observational studies will help in better understanding their appropriate use as a means of predicting the risk of bone disease and fracture."

3. Proposed Changes to the June 24, 1998 IFC.

We received 18 public comments on the June 24, 1998 IFC. The majority of the comments had specific recommendations for changes to the IFC. In addition to responding to comments that we may receive on our proposed revisions to § 410.31, it is our intent to address all these previous comments in the CY 2007 PFS final rule.

Based on the comments received on the IFC, the Surgeon General's report, and other evidence, we are proposing changes to § 410.31. We encourage comments on these proposals.

a. Proposed "BMM" Definition (§ 410.31(a))

We are proposing to revise the definition of "bone mass measurement" at $\S 410.31(a)(2)$ to remove coverage for the use of SPA, which uses isotope sources to measure BMD. Many medical experts indicate that SPA has largely been replaced by the newer techniques of DXA, which are believed to be superior in accuracy and precision. Medicare claims data in recent years continue to show a steady decline in the use of the SPA procedure by the beneficiary population. Further, there is a lack of evidence to support continued use of SPA, an older procedure where the metrics have not been correlated with fracture rate.

We are proposing to revise the definition of a "bone mass measurement" to read, "Is performed with either a bone densitometer (other than a single-photon or dual-photon absorptiometry) or with a bone sonometer system that has been cleared for marketing for this use by the FDA under 21 CFR part 807, or approved for marketing by the FDA for this use under 21 CFR part 814."

We are specifically requesting comments on this proposal regarding the evidence of benefit for SPA, particularly in comparison with other alternatives.

b. Conditions for Coverage (§ 410.31(b))

We are proposing to revise the conditions for coverage for BMMs in

§ 410.31(b) by requiring that for a medically necessary BMM to be covered for an individual being monitored to assess the response to or efficacy of an FDA-approved osteoporosis drug therapy (§ 410.31(d)(5)) the individual would be required to meet the present conditions for coverage under § 410.31(b), and the monitoring would have to be performed by the use of an dual energy x-ray absorptiometry system (axial system).

We recognize that in the June 24, 1998 IFC, we allowed the physician or qualified nonphysician practitioner treating the beneficiary more flexibility in ordering those diagnostic measurements, but we are proposing to limit that flexibility with respect to the type of BMM that is used for monitoring individuals receiving osteoporosis drug therapy and other purposes (as discussed later in this section) because of new evidence and other information received since publication of the June 24, 1998 IFC that supports the need for requiring the use of the DXA measurement (axial skeleton) in those circumstances. In addition to the 2004 Surgeon General's Report that recognized the superiority of the DXA (axial skeleton) for measuring bone mass over time, the International Society for Clinical Densitometry currently recommends that if an individual has a low bone mass using a peripheral measurement (appendicular skeleton) he or she should have a DXA (axial skeleton) performed for monitoring or confirmatory diagnostic purposes.

Therefore, we are also proposing to revise § 410.31(b) by adding a requirement that in the case of any individual who qualifies for a bone mass measurement as provided for in § 410.31(d) and who receives a confirmatory baseline BMM to permit monitoring in the future, Medicare may cover a medically necessary BMM for that individual, if the present conditions for coverage under § 410.31(b) are met, and the BMM is performed by a dual energy x-ray absorptiometry system (axial skeleton) (if the initial measurement was not performed by this system).

As indicated previously, the most widely accepted method for measuring bone mineral density (BMD) is the use of DXA (Surgeons General's Report 2004) at axial skeletal sites. DXA (axial skeleton) measures BMD at the hip and spine (sites likely to fracture in patients who have osteoporosis). DXA is precise, safe, and low in radiation exposure, and permits more accurate and reliable monitoring of individuals over time. DXA of the femoral neck is the best validated test to predict hip fracture and

is comparable to forearm measurements for predicting fractures at other sites (Evidence Report/Technology Assessment No 28, Agency for Healthcare Research and Quality (AHRQ), January 2001).

c. Bone Mass Measurement: Standards on Frequency of Coverage (§ 410.31(c))

To conform the examples of a BMM exception to the standards on frequency of coverage in § 410.31(c)(2) to the regulation change we are proposing in § 410.31(b)(3), we are proposing to revise the confirmatory baseline test example in § 410.31(c)(2)(ii) to read, "Allowing for a confirmatory baseline measurement to permit monitoring of beneficiaries in the future if the requirements of paragraph (b)(3) of this section are met."

d. Bone Mass Measurement: Beneficiaries Who May Be Covered (§ 410.31(d))

The Congress has recognized that individuals receiving long-term glucocorticoid steroid therapy are qualified individuals for purposes of section 1861(rr)(1) of the Act. Therapy to prevent bone loss in most patients beginning long-term therapy has been recommended at a prednisone equivalent of ≥ 5 mg/day for at least 3 months (McIlwain, 2003). Based on our review of the current evidence, we are proposing to reduce the dosage equivalent in § 410.31(d)(3) from an average of 7.5 mg/day of prednisone for at least 3 months to an average of 5.0 mg/day of prednisone for the same period.

e. Use of the NCD Process (§ 410.31(f))

To facilitate future consideration of coverage of additional BMM systems for purposes of proposed paragraphs § 410.31(b)(2) and (b)(3), which would limit coverage of BMMs for monitoring individuals receiving osteoporosis drug therapy and for performing confirmatory baseline measurements, we are proposing to allow CMS, through the NCD process, to identify additional BMM systems for those purposes. By using the NCD process, we could conduct a timely assessment of FDAapproved BMMs. Use of an NCD to add coverage of effective BMM systems for these purposes is authorized by the reasonable and necessary provision of sections 1862(a)(1)(A) and 1871(a)(2) of the Act.

In summary, in view of the 18 comments and our review of the post-1998 medical literature, we have decided to propose several revisions to § 410.31 relative to the definition of the term "Bone Mass Measurement"

(§ 410.31(a)(2)), the conditions for coverage (§ 410.31(b)), the examples of exceptions to the standards on frequency of coverage (§ 410.31(c)(2)), the category of individuals receiving (or expecting to receive) glucocorticoid (steroid) therapy (§ 410.31(d)(3)), and the addition of a new subparagraph (§ 410.31(f)) on use of the NCD process.

L. Independent Diagnostic Testing Facility (IDTF) Issues

[If you choose to comment on issues in this section, please include the caption "IDTF ISSUES" at the beginning of your comments.]

1. Proposed IDTF Changes in the Physician Fee Schedule Proposed Rule

During the course of a national review in 2003–2004, the Office of Inspector General (OIG) found a potential \$71 million in improper payments made to IDTFs (Review of Claims Billed by Independent Diagnostic Testing Facilities for Services Provided to Medicare Beneficiaries During Calendar Year 2001 (A-03-03-00002)). The OIG found that erroneous payments were made as the result of poor or missing documentation or the lack of medical necessity. Moreover, in recent years, CMS and its contractors have determined that a number of IDTFs in California and other States are perpetrating schemes to defraud the Medicare program.

Since 2000, the number of IDTFs in California has increased by 40 percent, which is a far greater percentage increase than the Medicare population in that State. The number of IDTFs billing Medicare in California alone increased more than 400 percent from 2000 to 2005. The increased use of IDTF services has not lowered the use of diagnostic testing within other settings. The increased rates of utilization within IDTFs is likely to be unrealistic due to an increase in the need of diagnostic testing within California's Medicare population. Also, these IDTFs are growing at a rate faster than CMS can survey these facilities. The actual growth of IDTFs is not a problem, however, the results of the OIG audit make it clear that we need to closely monitor IDTFs and establish standards to ensure quality care for Medicare beneficiaries. To address the erroneous payments identified by the OIG above, we are proposing to establish IDTF supplier standards similar to those we adopted for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Suppliers on October 11, 2000 (see 42 CFR 424.57).

We are proposing that each IDTF be required to be in compliance with the proposed fourteen suppler standards discussed in section L.2. below in order to obtain or retain enrollment in the Medicare program. Accordingly, at proposed § 410.33(h), we are proposing that if an IDTF fails to meet one or more of the proposed standards at the time of enrollment or at the time of reenrollment, then its enrollment application would be denied. Also, if at any time we determine that an enrolled IDTF no longer meets the proposed supplier standards, its billing privileges would be revoked.

We believe that these supplier standards are needed to ensure that minimum quality standards are met to protect beneficiaries as well as the Medicare Trust Fund. These standards are merely good business practices which will help to ensure that suppliers are providing a quality care to Medicare beneficiaries. Examples of the kind of standards are a primary business phone number and address. Another example is a posting of standards for review by patients and the public.

We are proposing to adopt, for IDTFs, a number of standards we adopted for DMEPOS suppliers, including supplier standard number 6 which requires a supplier to maintain a comprehensive liability insurance policy of \$300,000 or 20 percent of its average annual Medicare billings, whichever amount is greater, that covers both the place of business and all customers and employees of the IDTF.

Furthermore, we are proposing in the new performance standard number 7 that an IDTF agrees not to directly solicit patients. This provision does not preclude the IDTF from public advertisement or marketing its services to physicians and other suppliers, however it does prohibit recruitment of beneficiaries through direct solicitation.

Additionally, the IDTF would be required to grant CMS, or its designated fee-for-service contractors, including our agents, to have access to the IDTF physical location, all equipment, and beneficiary medical records during normal business hours. For portable equipment, an IDTF would be required to maintain a catalog of portable equipment and be able to produce the cataloged equipment within two business days. If the IDTF denies this access, the IDTF's Medicare enrollment would be immediately revoked.

To ensure that equipment used by an IDTF is maintained and operates properly, we are seeking public comment regarding IDTF supplier standard number 11, which would require that an IDTF must have its testing equipment calibrated per equipment instructions or in

compliance with applicable industry standards. Specifically, we are seeking public comment regarding the organizations or entities that may currently establish testing specifications for diagnostics equipment. Further, if these organizations or entities do not exist, we invite public comment regarding establishment of a supplier standard that relies on the manufacturer's maintenance and calibration standards.

While we understand that these proposed additional standards could lead certain IDTFs to withdraw from the Medicare program rather than comply with the new standards, we believe that legitimate businesses would not oppose these changes. Moreover, we emphasize that services provided by an IDTF are also readily available to beneficiaries through other avenues such as physicians' offices, outpatient laboratories, outpatient radiology facilities, and outpatient clinics. We believe that the implementation of these proposed standards would improve the quality of services provided to Medicare beneficiaries by IDTFs without any associated access concerns.

2. Proposed Performance Standards for IDTFs

The IDTF would be required to meet the following standards as of January 1, 2007 and any newly or reenrolling IDTF would be required to certify in its enrollment application that it meets and would continue to meet the standards. At § 410.33, we are proposing to revise the regulation to specify that the IDTF would be required to—

• Operate its business in compliance with all applicable Federal, State, and local licensure and regulatory requirements with regard to the health and safety of patients;

- Provide complete and accurate information on its enrollment application as stated in the "Requirements for Providers and Suppliers to Establish and Maintain Enrollment final rule" (April 21, 2006 (42 FR 20754)). Any change in enrollment information would be required to be reported to the designated fee-for-service contractor on the Medicare enrollment application within 30 calendar days;
- Maintain a physical facility on an appropriate site. For the purposes of this proposed standard, a post office box or commercial mailbox would not be considered a physical facility. The physical facility would be required to contain space for equipment appropriate to the services designated on the enrollment application, facilities for hand washing, adequate patient privacy

accommodations, and the storage of both business records and current medical records;

- · Have all applicable testing equipment available at the physical site, excluding portable equipment. A catalog of portable equipment, including equipment serial numbers, would be maintained at the physical site. In addition, portable equipment would be made available for inspection within two business days of our inspection request. The IDTF would be required to maintain a current inventory of the equipment (including serial/registration numbers), provide this information to the designated fee-for-service contractor and notify the contractor of any changes in equipment;
- Maintain a primary business phone under the name of the business. The business phone would be located at the designated site of the business. The telephone number or toll free numbers would be available in a local directory and through directory assistance;
- Have a comprehensive liability insurance policy of at least \$300,000 or 20 percent of its average annual Medicare billings, whichever amount is greater, that covers both the place of business and all customers and employees of the IDTF. The insurance policy would be carried by a non-relative owned company. The policy would be required to list the serial numbers of any and all equipment used by the IDTF;
- Agree not to directly solicit patients, which includes, but is not limited to, a prohibition on telephone, computer, or in-person contracts. The IDTF would accept only those patients referred for diagnostic testing by an attending physician, who is furnishing a consultation or treating a beneficiary for a specific medical problem and who uses the results in the management of the beneficiary's specific medical problem. Nonphysician practictioners may order tests as set forth in § 410.32(a)(3);
- Answer beneficiaries' questions and respond to their complaints. Documentation of those contacts would be maintained at the physical site;
- Openly post these standards for review by patients and the public;
- Disclose to the government, any person having ownership, financial or control interest, or any other legal interest in the supplier at the time of enrollment or within 30 days of a change;
- Have its testing equipment calibrated per equipment instructions and in compliance with applicable national standards;

 Have technical staff on duty with the appropriate credentials to perform tests. The IDTF would be required to produce the applicable Federal or State licenses and/or certifications of the individuals performing these services;
 Have proper medical record storage

 Have proper medical record storage and be able to retrieve medical records upon request from CMS or its designated fee-for-service contractor within 2 business days; and

• Permit CMS, including its agents or its designated fee-for-service contractors, to conduct unannounced, on-site inspections to confirm the IDTF's compliance with these proposed standards. The IDTF would be required to provide access, during regular business hours, to CMS and beneficiaries, as well as maintain a visible sign posting the normal business hours of the IDTF.

3. Supervision

To ensure quality care is provided to Medicare beneficiaries, we are proposing to revise § 410.33(b)(1) to read that physicians will be limited to providing supervision to "no more than three (3) IDTF sites."

4. Place of Service

In addition to proposing the establishment of specific supplier standards for IDTFs, at proposed § 410.33(i), we are proposing to define the "point of the actual delivery of service" as the correct "Place of Service" for the claim form in the case of diagnostic testing performed outside the IDTF's physical location. For example, when an IDTF performs a diagnostic test at a beneficiary's residence, we believe that it is reasonable to establish the beneficiary's residence as the "Place of Service." Previously, there has been no set procedure, so therefore, we believe that the information is gathered at the collection point from the beneficiary, and this is the point service. While most diagnostic tests are performed in an office setting, we are seeking public comment regarding the types of services that can be safely and appropriately used in a residential setting.

M. Independent Laboratory Billing for the TC of Physician Pathology Services to Hospital Patients

[If you choose to comment on issues in this section, please include the caption "INDEPENDENT LAB BILLING" at the beginning of your comments.]

The TC of physician pathology services refers to the preparation of the slide involving tissue or cells that a pathologist will interpret. (In contrast, the pathologist's interpretation of the slide is the PC service. If this service is furnished by the hospital pathologist for a hospital patient, it is separately billable. If the independent laboratory's pathologist furnishes the PC service, it is usually billed with the TC service as a combined service.)

In the "Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2000" final rule published in the Federal Register on November 2, 1999 (64 FR 59380 and 59408 through 59409), we stated that we would implement a policy to pay only the hospital for the TC of physician pathology services furnished to hospital patients. Before that proposal, any independent laboratory could bill the carrier under the PFS for the TC of physician pathology services for hospital patients. As pointed out in the November 2, 1999 final rule, this policy has contributed to the Medicare program paying twice for the TC service, first through the inpatient prospective payment rate to the hospital where the patient is an inpatient and again to the independent laboratory that bills the carrier, instead of the hospital, for the TC service.

Therefore, in that final rule at § 415.130, we provided that, for services furnished on or after January 11, 2001, the carriers would no longer pay claims to the independent laboratory under the physician fee schedule for the TC of physician pathology services for hospital patients.

Ordinarily, the provisions in the final PFS are implemented in the following year. However, in this case, the change to § 415.130 was delayed one year (until January 1, 2001), at the request of the industry, to allow independent laboratories and hospitals sufficient time to negotiate arrangements.

Moreover, our full implementation of § 415.130 was further delayed through CY 2006.

We continue to believe, however, that hospital prospective payment amounts already compensate hospitals for the TC of physician pathology tests and that additional payment under the PFS is inappropriate. Therefore, we are proposing to amend § 415.130 to provide that, for services furnished after December 31, 2006, an independent laboratory may not bill the carrier for physician pathology services furnished to a hospital inpatient or outpatient. Under proposed § 415.130(d), we would pay under the PFS for the TC of a physician pathology service furnished by an independent laboratory for services provided to an inpatient or outpatient of a "covered hospital" on or before December 31, 2006. A "covered hospital" is defined in § 415.130(a)(1).

N. Public Consultation for Medicare Payment for New Outpatient Clinical Diagnostic Laboratory Tests

[If you choose to comment on issues in this section, please include the caption "CLINICAL DIAGNOSTIC LAB TESTS" at the beginning of your comments.]

Section 1833(h) of the Act requires the Secretary to establish fee schedules for clinical laboratory tests under Medicare Part B. In this section of the preamble, we are proposing to implement section 942(b) of the MMA which specifies annual procedures for consulting the public on how to establish payment for new clinical laboratory test codes to be included in the annual update of the clinical laboratory fee schedule.

1. BIPA (Pub. L. 106-554)

Section 531(b) of BIPA mandated that we establish, no later than 1 year after the date of enactment, procedures that permit public consultation for payment determinations for new clinical diagnostic laboratory tests under Medicare Part B in a manner consistent with the procedures established for implementing ICD-9-CM coding modifications. In the November 23, 2001 Federal Register (66 FR 58743), we specified the procedures to implement section 531(b) of BIPA.

These procedures were most recently used to determine the payments for new 2006 clinical laboratory fee schedule codes. First, we convened a public meeting to solicit expert input on the nature of the new tests before rate determinations were made. We have held these meetings each year since 2002 to receive this expert input on the next year's codes. Our most recent meeting was announced in the Federal **Register** on May 27, 2005 (70 FR 30734) and occurred on July 18, 2005. In that meeting, we requested that presenters address the new test codes, each test's purpose, method, cost, and a recommendation for one of two methods (crosswalking or gapfilling) for determining payment for the new clinical laboratory codes. Crosswalking and gapfilling are discussed below in section N.2.d.

Following the public meeting, we posted, on our Website, a summary of the new codes and the payment recommendations that were presented during the public meeting. The summary also displayed our tentative payment determinations and indicated a comment period for interested parties to submit written comments. After reviewing the comments received, we issued Medicare Transmittal 750, 2006 Annual Update for Clinical Laboratory

Fee Schedule, which provided all instructions and final rate determinations for the 2006 clinical laboratory fee schedule including the new codes and fees, on November 18, 2005.

2. Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) (Pub. L. 108–173)

Further legislation affecting public consultation for new clinical laboratory tests was enacted at section 942(b) of the MMA (Pub. L. 108–173), which added section 1833(h)(8) to the Act. Section 1833(h)(8)(A) of the Act requires the Secretary to establish by regulation procedures for determining the basis for and amount of payment for a clinical diagnostic laboratory test that is assigned a new or substantially revised Healthcare Common Procedure Coding System (HCPCS) code on or after January 1, 2005. We refer to these tests as "new tests."

Section 1833(h)(8)(B) of the Act provides that determinations of payment amounts for new tests shall be made only after the Secretary—

- Makes available to the public (through an Internet Web site and other appropriate mechanisms) a list that includes codes for which establishment of a payment amount is being considered for the next calendar year;
- On the same day the list of codes is made available, publishes a Federal Register notice of a meeting to receive public comments and recommendations (and data on which recommendations are based) on the appropriate basis for establishing payment amounts for the list of codes made available to the public;
- Not less than 30 days after publication of the notice in the Federal Register, convenes a meeting that includes representatives of CMS officials involved in determining payment amounts, to receive public comments and recommendations (and data on which the recommendations are based); and
- Taking into account the comments and recommendations (and accompanying data) received at the public meeting, develops and makes available to the public (through an Internet Web site and other appropriate mechanisms)—
- + A list of proposed determinations with respect to the appropriate basis for establishing a payment amount for each code, together with an explanation of the reasons for each determination, the data on which the determinations are based, and a request for public written comments on the proposed determination; and

+ A list of final determinations of the payment amounts for tests, together with the rationale for each determination, the data on which the determinations are based, and responses to comments and suggestions from the public.

We believe that our current process for providing for public consultation on the establishment of payment amounts for new clinical laboratory tests is consistent with the requirements of section 1833(h)(8)(B) of the Act. We currently make available to the public through a posting on the CMS Web site a list of new laboratory test codes for the next calendar year. We publish a Federal Register notice of a meeting to receive public comments and recommendations and convene the meeting with appropriate CMS officials in attendance. We take into account the input received at the public meeting and we make available to the public on the CMS Web site a list of the proposed determinations and seek comment. We then make available to the public our final determinations in the instructions that we provide to our claims processing contractors to implement the Medicare Part B clinical laboratory fee schedule each year.

The most significant change required by section 1886(h)(8)(A) of the Act with respect to our procedures for public consultation is that we codify this process in regulations. Therefore, in this proposed rule, we are proposing to codify our current process for public consultation for new clinical diagnostic laboratory tests paid under the Medicare Part B clinical laboratory fee schedule at proposed new Subpart F—Payment for New Clinical Diagnostic Laboratory Tests (§ 414.402 through § 414.406).

a. Proposed Basis and Scope (§ 414.400)

This proposed new subpart would implement provisions of section 1833(h)(8) of the Act—procedures for determining the basis for, and amount of, payment for a new clinical diagnostic laboratory test with respect to which a new or substantially revised Healthcare Common Procedure Coding System code is assigned on or after January 1, 2005.

b. Proposed Definition (§ 414.402)

As specified in section 942(b) of the MMA, we propose to define the term "Substantially Revised Healthcare Common Procedure Coding System Code" to mean a code for which there has been a substantive change to the definition of the test or procedure to which the code applies (such as a new analyte or a new methodology for

measuring an existing analyte specific test).

c. Proposed Procedures for Public Consultation for Payment for a New Clinical Diagnostic Laboratory Test (§ 414.406)

For a clinical laboratory test that is assigned a new or substantially revised code on or after January 1, 2005, we would establish a local fee schedule amount only after the following:

- We make available to the public (through an Internet Web site and other appropriate mechanisms) a list that includes codes for which establishment of a payment amount is being considered for the next calendar year.
- We publish a **Federal Register** notice of a meeting to receive public comments and recommendations (and data on which recommendations are based) on the appropriate basis, as specified in proposed new § 414.408, for establishing payment amounts for the list of codes made available to the public.
- Not less than 30 days after publication of the notice in the **Federal Register**, we convene a meeting, that includes representatives of CMS officials involved in determining payment amounts, to receive public comments and recommendations (and data on which the recommendations are based).
- Taking into account the comments and recommendations (and accompanying data) received at the public meeting, we develop and make available to the public (through an Internet Web site and other appropriate mechanisms)—
- + A list of proposed determinations with respect to the appropriate basis for establishing a payment amount for each code, together with an explanation of the reasons for each determination, the data on which the determinations are based, and a request for public written comments on the proposed determination within a specified time period; and
- + A list of final determinations of the payment amounts for tests, together with the rationale for each determination, the data on which the determinations are based, and responses to comments and suggestions from the public.
- d. Proposed Payment for a New Clinical Diagnostic Laboratory Test— Crosswalking and Gapfilling (§ 414.408)

We are proposing to add a new § 414.408 to indicate when, in establishing the payment amount for a new clinical laboratory test, one of two payment methods can be utilized. The

first payment method, called "crosswalking," is used if a new test is determined to be comparable to an existing test, multiple existing test codes, or a portion of an existing test code. We propose that a new test code would be assigned the related existing local fee schedule amounts and national limitation amount.

In new § 414.408, we propose to use the second method, called "gapfilling," when no comparable, existing test is available. Currently when using this method, manual instructions are provided to each Medicare carrier to determine a payment amount for its geographic area(s) for use in the first year, and the carrier-specific amounts are used to establish a national limitation amount for following years. Consistent with our current process, the sources of information carriers examine in determining gapfill amounts, if available, include-

- Charges for the test and routine discounts to charges;
- Resources required to perform the
- · Payment amounts determined by other payers; and
- Charges, payment amounts, and resources required for other tests that may be comparable or otherwise relevant.

Currently, our manual instructions allow carriers to consider other sources of information as appropriate, including clinical studies and information provided by clinicians practicing in the area, manufacturers, or other interested parties. Carriers are also instructed to establish carrier specific amounts on or before March 31 of the year and to revise their carrier specific amount, if necessary, on or before September 1 of the year. In this manner, a carrier may revise its carrier specific amount based on additional information, but there is also a specific time frame to perform this revision so that we have adequate time to receive and use the carrier specific amounts for the calculation of the next year's clinical laboratory fee schedule.

Currently for new gapfilled laboratory tests, the payment amount beginning in the second year is based on the lower of the carrier specific amount determined in the first year or the national limitation amount. In accordance with section 1833(h) of the Act, the national limitation amount is set at the median of the carrier-specific amounts.

In light of new MMA provisions, however, we are proposing, in new § 414.408, to prospectively eliminate payment of new gapfilled tests at a carrier specific amount after the first year. Section 1833(h)(8)(A) of the Act gives the Secretary authority to establish procedures for determining the payment amount for laboratory tests for which new or substantially revised HCPCS codes were established on or after January 1, 2005. Under this authority, we propose, in new § 414.408(b), to pay for a new gapfilled laboratory test under our existing methodology for the first year (the carrier would establish a gapfill amount.) Beginning in the second year, the test would be paid at the national limitation amount. This would result in consistent payment in geographic areas for a new test using the median of the carrier gapfill amounts.

3. Other Laboratory Issues

This section discusses other laboratory issues related to quality and glucose monitoring in SNFs.

a. Quality

In addition to providing payments, Medicare's clinical laboratory fee schedule for both new and existing tests should foster the provision of quality care and the prevention of avoidable health care costs. We are exploring the development of measures related to the quality and efficiency of care, including those involving clinical laboratory fee schedule services. Physicians' decisions are central to the health care their patients receive and are informed by appropriate clinical laboratory testing. We want to work with physicians, providers and the clinical laboratory community to identify ways to promote utilization decisions that clearly increase the quality of care while avoiding unnecessary costs for beneficiaries and the Medicare program.

As part of its strategies to improve quality of care, CMS could require those who perform laboratory tests to submit laboratory values using common vocabulary standards, such as those found in the Logical Observation Identifiers Names and Codes (LOINC®) database.

The LOINC® database currently contains about 41.000 observational terms, of which nearly 31,000 are observational terms related to laboratory testing. The laboratory subset of the LOINC® database provides universal names and codes for identifying the results of clinical laboratory tests and it facilitates the exchange and pooling of clinical laboratory results for clinical care, outcomes management and research. Note that LOINC® describes the test result, but does not provide it. It is, therefore, only one possible component of a comprehensive system of collecting clinical laboratory fee test results. Each LOINC® record corresponds to a single test result or

panel. The following are some examples of LOINC records:

LOINC code LOINC name (component: property: timing: specimen: scale)

2951-2 SODIUM:SCNC:PT:SER/ PLAS:ON

2955-2 SODIUM:SCNC:PT:UR:QN SODIUM:SRAT:24H:UR:QN 2956 - 12164-2CREATININE RENAL

CLEARANCE:VRAT:24H:UR:ON 1514-9 GLUCOSEA2H POST 100 G **GLUCOSE**

PO:MCNC:PT:SER/PLAS:QN

3665-7 GENTAMICIN∧ TROUGH:MCNC:PT:SER/PLAS:ON 17863–2 CALCIUM.IONIZED:

MCNC:PT:SER/PLAS:ON 2863-9 ALBUMIN:MCNC:PT:SNV: QN:ELECTROPHORESIS

The parts of the LOINC® name refer to different aspects of the test result. The component is the analyte (for example, sodium). The property is the characteristic of the analyte that is measured, evaluated or observed (for example SCNC = substance concentration). Timing indicates whether the measurement is an observation at a moment of time, or an observation integrated over an extended duration of time (for example, PT = point in time). The specimen is the type of sample (for example, SER/PLAS = serum or plasma). The scale is the type of scale (for example QN = quantitative). For further detail, please see the LOINC® Web site at http:// www.loinc.org.

On September 23, 2005 (70 FR 55900-56025), we published the proposed rule "HIPAA Administrative Simplification: Standards for Electronic Health Care Claims Attachments." This rule proposed standards for electronically requesting and supplying particular types of additional health care information in the form of an electronic attachment to support submitted health care claims data. The proposed rule specified a standard attachment form for reporting laboratory results (among other standards) and proposed adoption of LOINC® as the standard code set for reporting such results.

While the laboratory claims attachment standard and use of LOINC® could provide a means for reporting test result data, we recognize that there are significant operational and other challenges that would need to be addressed before Medicare could begin to collect laboratory values in a comprehensive fashion using common vocabulary standards and that these challenges need to be met in partnership with the clinical laboratory community.

We look forward to working

collaboratively with the clinical laboratory community on these issues.

b. Blood Glucose Monitoring in SNFs

In response to inquiries regarding our policy on blood glucose monitoring in SNFs, we are taking this opportunity to restate our long-standing policy on coverage of blood glucose monitoring services and to propose to codify physician certification requirements for blood glucose monitoring in SNFs.

Generally, section 1862(a)(1)(A) of the Act requires that a service be reasonable and necessary for diagnosis and treatment in order to be eligible for coverage by Medicare. Our regulations at § 410.32(a) already require that, for any diagnostic test, including a clinical diagnostic laboratory test, to be considered reasonable and necessary, it must be both ordered by the physician and the ordering physician must use the result in the management of the beneficiary's specific medical problem. Tests not ordered by the physician who is treating the beneficiary are not reasonable and necessary.

In the context of blood glucose monitoring, we most recently stated this policy in Transmittal AB–00–108, "Glucose Monitoring", which is available on our Web site at http://www.cms.hhs.gov/transmittals/downloads/ab00108.pdf. This interpretation of § 410.32 is also the basis for our policy in Chapter 7 of the Medicare Claims Processing Manual ("Skilled Nursing Facility Part B Billing" available on our Web site at http://www.cms.hhs.gov/manuals/downloads/clm104c07.pdf.)

In addition, section 1835(a)(2)(B) of the Act provides that, in the case of certain "medical and other health services" (including clinical diagnostic laboratory services), payment may be made for Part B services that are furnished by a provider of services only if a physician certifies—and recertifies where those services are furnished over a period of time, with such frequency, and accompanied by such supporting material, as may be provided by regulation—that those services were medically necessary. The regulations currently implementing this provision at § 424.24 do not specifically address the issue of blood glucose monitoring in SNFs. Therefore, we are proposing to amend § 424.24 to provide that, for each blood glucose test furnished to a resident of a SNF, the physician must certify that the test is medically necessary. We are also proposing to amend § 424.24 to clarify that a physician's standing order is not sufficient to order routine blood glucose monitoring.

c. Other Lab Issues—Proposed Clinical Diagnostic Laboratory Date of Service (DOS) for Stored Specimens

We are proposing to add a new § 414.410 to address concerns that have been raised regarding the date of service of a clinical diagnostic laboratory test that use a stored (or "archived") specimen. In the final rule of coverage and administrative policies for clinical diagnostic laboratory services that we published on November 23, 2001 (66 FR 58792), we adopted a policy under which the date of service for clinical diagnostic laboratory services generally is the date the specimen is collected. For laboratory tests that use an archived specimen, however, the date of service is the date the specimen was obtained from the storage. In 2002, we issued Program Memorandum AB-02-134 which permitted contractors discretion in making determinations regarding the length of time a specimen must be stored to be considered archived. In response to comments requesting that we issue a national standard to clarify when a stored specimen can be considered "archived," in the Procedures for Maintaining Code Lists in the Negotiated National Coverage Determinations for Clinical Diagnostic Laboratory Services final notice, published in the Federal Register on February 25, 2005 (70 FR 9355), we defined an "archived" specimen as a specimen that is stored for more than 30 calendar days before testing. The date of service for these archived specimens is the date the specimen was obtained from storage. Specimens stored 30 days or less have a date of service of the date the specimen was collected. The February 25, 2005 final notice also clarified that the date of service for tests when the collection spanned more than two calendar days is the date the collection ended. Instructions that implemented these policies were added to Chapter 16, section 40.8 of the Medicare Claims Processing Manual (Pub. 100–04) with the issuance of Transmittal 800 (CR 4156), on December 30, 2005.

Recently, we have received correspondence that expressed concern that our policies have created some unintended consequences, especially in situations in which a specimen is taken in a hospital setting, but then later used for a test after the patient has left the hospital. Under the current manual instructions, if the specimen used for a test ordered subsequent to the beneficiary's discharge is obtained less than 31 calendar days following the date the specimen was collected, the date of service of the test is the date of

collection. The date of service of a test may affect payment because, if the date of service falls during an inpatient stay or on a day on which the beneficiary had an outpatient procedure, payment for the laboratory test usually is bundled with the hospital service. To address these concerns, we are proposing to change our current policy so that the date of service would be the date the specimen is obtained from storage, even if the specimen is obtained less than 31 days from the date it was collected, without violating the unbundling rules as long as the following conditions are met:

- The test is ordered by the patient's physician at least 14 days following the date of the patient's discharge from the hospital.
- The test could not reasonably have been ordered while the patient was hospitalized.
- The procedure performed while the beneficiary is a patient of the hospital is for purposes other than collection of the specimen needed for the test.
- The test is reasonable and medically necessary.

These conditions are consistent with the guidance in Chapter 16, sec 40.3 of the Claims Processing Manual, which states that "When the hospital obtains laboratory tests for outpatients under arrangements with clinical laboratories or other hospital laboratories, only the hospital can bill for the arranged services."

In addition, Chapter 3 of the Program Integrity Manual contains instructions for additional documentation if further development of laboratory claims for pre-or postpay are required. Although we believe these changes will help to maintain beneficiary access to care, we are concerned about the potential for these policy changes creating inappropriate incentives in the development of technology and the implications for the unbundling of services. We solicit comment on the proposed changes and these concerns.

O. Proposal to Establish Criteria for National Certifying Bodies That Certify Advanced Practice Nurses

[If you choose to comment on issues in this section, please include the caption "Criteria for National Certifying Bodies-Advanced Practice Nurses" at the beginning of your comments.]

Federal regulatory qualifications for nurse practitioners (NPs) at 42 CFR 410.75 require that an individual be certified as an NP by a recognized national certifying body that has established standards for NPs. Similarly, Federal regulatory qualifications for clinical nurse specialists (CNSs) at 42 CFR 410.76 require that an individual be certified as a CNS by a national certifying body that has established standards for CNSs and that is approved by the Secretary.

Currently, there is not a list of recognized or approved national certifying bodies for NPs and CNSs in regulations. However, Chapter 15, section 200 of the Benefit Policy Manual, Pub. 100-02 contains a list of national certifying bodies that are recognized by Medicare as being appropriate for certification of NPs. Although the manual provision regarding CNS services at Chapter 15, section 210 of the Benefit Policy Manual lists only the American Nurses Credentialing Center as an approved national certifying body for CNSs, we indicated that the list of recognized certifying bodies in the manual provision for NP services would also apply for CNSs in the "Revisions to Payment Policies Under the CY 2003 Physician Fee Schedule and Inclusion of Registered Nurses in the Personnel Provision of the Critical Access Hospital **Emergency Services Requirement for** Frontier Areas and Remote Locations: Payment Policies final rule (December 31, 2002, 67 FR 79987). The national certifying bodies that are listed under the manual instruction at section 200, and that currently apply for both NPs and CNSs (collectively, advanced practice nurses) are as follows:

- American Academy of Nurse Practitioners;
- American Nurses Credentialing
 Center:
- National Certification Corporation for Obstetric, Gynecologic and Neonatal Nursing Specialties;
- National Certification Board of Pediatric Nurse Practitioners and Nurses:
- Oncology Nurses Certification Corporation;
- Critical Care Certification Corporation.

In the December 31, 2002 final rule, in response to a public comment, we stated, "it is not the agency's intention to be overly restrictive in our program requirements and consequently prevent qualified CNSs who specialize in areas of medicine other than those certified by the American Nurses Credentialing Center (ANCC) from participating under the CNS benefit and from rendering care to patients in need of specialized services. Furthermore, the intent of the revision to the certification requirement for CNSs is to recognize all appropriate national certifying bodies for CNSs as the program does for NPs." Accordingly, in an effort to recognize all appropriate national certifying bodies for CNSs and

NPs, we added, at that time, the Oncology Nurses Certification Corporation (ONCC) and the Critical Care Certification Corporation (CCCC) to the list of recognized national certifying bodies for advanced practice nurses.

The National Board on Certification of Hospice and Palliative Care Nurses (NBCHPN) has requested that we now follow the same course of action as we did for the ONCC and the CCCC by adding its name to the list of recognized national certifying bodies. That is, NBCHPN believes that it is an appropriate national certifying body based on its certification experience, principles, services, and the certification exam that it administers to advanced practice nurses who specialize in palliative care for hospice patients.

The NBCHPN stated in information it sent to the agency that its organization is a well-established certification body with more than 12-years history of certification and that it has been certifying advanced practice hospice and palliative nurses since 2003 in partnership with the ANCC. Starting in 2005, the NBCHPN became sole proprietor of the Advanced Certified Hospice and Palliative Nurse (ACHPN) examination. Master's level nurse practitioners and clinical nurse specialists sit for this ACHPN examination that is based on a role delineation study for the advanced practice level of hospice and palliative nursing. Additionally, the NBCHPN stated that it has met the requirements of the American Board of Nursing Specialties and is an active member of the Board of Specialties, as is the ANCC. The Executive Director of the NBCHPN stated that she believes that the absence of the NBCHPN from the current list of recognized national certifying bodies presents a barrier for advanced practice nurses in the hospice palliative care specialty because they are denied enrollment on the basis that they do not meet the certification qualification requirement. The Web site for the NBCHPN can be found at www.nbchpn.com.

We are soliciting public comments on whether it would be appropriate to include the NBCHPN under the list of recognized and approved national certifying bodies for NPs and CNSs under manual instructions for both NPs and CNSs. We are also soliciting public comments on criteria or standards that we could use to determine whether an organization is an appropriate national certifying body for advanced practice nurses. CMS realizes that the agency may receive other requests in the future from organizations that wish to be to be

added to the list of recognized or approved national certifying bodies. In anticipation of those requests, the agency is interested in developing certification standards that would facilitate the process for making these decisions.

P. Chiropractic Services Demonstration

[If you choose to comment on issues in this section, please include the caption "Chiropractic Services Demonstration" at the beginning of your comments.]

In the FY 2006 PFS final rule (November 21, 2005), we included a discussion of the 2-year demonstration authorized by section 651 of the MMA to evaluate the feasibility and advisability of covering chiropractic services under Medicare. These services extend beyond the current coverage for manipulation to care for neuromusculoskeletal conditions typical among eligible beneficiaries, and cover diagnostic and other services that a chiropractor is legally authorized to perform by the State or jurisdiction in which the treatment is provided. The demonstration is being conducted in four sites, two rural and two urban. The demonstration must be budget neutral as the statute requires the Secretary to ensure that the aggregate payment made under the Medicare program does not exceed the amount which would be paid in the absence of the demonstration.

Ensuring budget neutrality requires that the Secretary develop a strategy for recouping funds should the demonstration result in costs higher than those that would occur in the absence of the demonstration. As we stated in the FY 2006 PFS, we would make adjustments in the national chiropractor fee schedule to recover the costs of the demonstration in excess of the amount estimated to yield budget neutrality. We will assess budget neutrality by determining the change in costs based on a pre/post comparison of costs and the rate of change for specific diagnoses that are treated by chiropractors and physicians in the demonstration sites and control sites. We will not limit our analysis to reviewing only chiropractor claims, because the costs of the expanded chiropractor services may have an impact on other Medicare costs.

Any needed reduction would be made in the 2010 and 2011 physician fee schedules as it will take approximately 2 years to complete the claims analysis. If we determine that the adjustment for budget neutrality is greater than 2 percent of spending for the chiropractor fee schedule codes (comprised of the 3

currently covered CPT codes 98940, 98941, and 98942), we would implement the adjustment over a 2-year period. However, if the adjustment is less than 2 percent of spending under the chiropractor fee schedule codes, we would implement the adjustment over a 1-year period. We will include the detailed analysis of budget neutrality and the proposed offset during the 2009 rulemaking process. PT services performed by chiropractors under the demonstration are subject to the PT therapy cap. These services are included under the cap because chiropractors are subject to the same rules as medical doctors for therapy services under the demonstration.

Q. Promoting Effective Use of Health Information Technology (HIT)

(If you choose to comment on issues in this section, please include the caption "Promoting Effective Use of HIT" at the beginning of your comment.)

We recognize the potential for health information technology (HIT) to facilitate improvements in the quality and efficiency of health care services. One recent RAND study found that broad adoption of electronic health records could save more than \$81 billion annually and, at the same time, improve quality of care. The largest potential savings that the study identified was in the hospital setting because of shorter hospital stays promoted by better coordinated care; less nursing time spent on administrative tasks; better use of medications in hospitals; and better utilization of drugs, laboratory services, and radiology services in hospital outpatient settings. The study also identified potential quality gains through enhanced patient safety, decision support tools for evidencebased medicine, and reminder mechanisms for screening and preventive care. Despite these large potential benefits, the study found that only about 20 to 25 percent of hospitals have adopted HIT systems.

It is important to note the caveats to the RAND study. The projected savings are across the health care sector, and any Federal savings would be a reduced percentage. In addition, there are significant assumptions made in the RAND study. National savings are projected in some cases based on one or two small studies. Also, the study assumes patient compliance, in the form of participation in disease management programs and following medical advice. For these reasons, extreme caution should be used in interpreting these results.

In summary, there are mixed signals about the potential of HIT to reduce costs. Some studies have indicated that HIT adoption does not necessarily lead to lower costs and improved quality. In addition, some industry experts have stated that factors such as an aging population, medical advances, and increasing provider expenses would make any projected savings impossible.

In his 2004 State of the Union Address, the President announced a plan to ensure that most Americans have electronic health records within 10 years.² One part of this plan involves developing voluntary standards and promoting the adoption of interoperable HIT systems that use these standards. The 2007 Budget states that "The Administration supports the adoption of health information technology (IT) as a normal cost of doing business to ensure patients receive high quality care."

Over the past several years, we have undertaken several activities to promote the adoption and effective use of HIT in coordination with other Federal agencies and with the Office of the National Coordinator for Health Information Technology. One of those activities is promotion of data standards for clinical information, as well as for claims and administrative data.

As noted above, the Administration supports the adoption of HIT as a normal cost of doing business. The adoption and use of HIT may contribute to improved processes and outcomes of care, including shortened illnesses and the avoidance of adverse drug reactions.

R. Health Care Information Transparency Initiative

(If you choose to comment on issues in this section, please include the caption "Health Care Information Transparency Initiative" at the beginning of your comment.)

The United States (U.S.) faces a dilemma in health care. Although the rate of increase in health care spending slowed last year, costs are still growing at an unsustainable rate. The U.S. spends \$1.9 trillion on health care, or 16 percent of the gross domestic product (GDP). By 2015, projections are that health care will consume 20 percent of GDP. As indicated in the 2006 Annual Report of the Boards of Trustees, the

Medicare program alone consumes 3.2 percent of the GDP and by 2040, it will consume 8.0 percent of the GDP.

Part of the reason health care costs are rising so quickly is that most consumers of health care—the patients—are frequently not aware of the actual cost of their care. Health insurance shields them from the full cost of services, and they have only limited information about the quality and costs of their care. Consequently, consumers do not have the incentive or means to carefully shop for providers offering the best value. Thus, providers of care are not subject to the competitive pressures that exist in other markets for offering quality services at the best possible price. Reducing the rate of increase in health care prices and avoiding health services of little value could help to stem the growth in health care spending, and potentially reduce the number of individuals who are unable to afford health insurance. Part of the President's health care agenda is to expand Health Savings Accounts (HSAs), which would provide consumers with greater financial incentives to compare providers in terms of price and quality, and choose those that offer the best value.

In order to exercise those choices, consumers must have accessible and useful information on the price and quality of health care items and services. Typically, health care providers do not publicly quote or publish their prices. Moreover, list prices, or charges, generally differ from the actual prices negotiated and paid by different health plans. Thus, even if consumers were financially motivated to shop for the best price, it would be very difficult at the current time for them to access usable information.

For these reasons, DHHS is launching a major health care information transparency initiative in 2006. This effort builds on steps taken by CMS to make quality and price information available. For example, Medicare has provided unprecedented information about drug prices in the Medicare drug benefit, and is now adding to these efforts in other areas. Medicare payment information for common elective procedures and other common admissions for all hospitals by county has been posted on our Web site at: http://www.cms.hhs.gov/ HealthCareConInit/01 Overview.asp#TopOfP.

We will post geographically-based Medicare payment information for common elective procedures for ambulatory surgery centers this summer and for common hospital outpatient and physician services this fall.

¹RAND News Release: Rand Study Says Computerizing Medical Records Could Save \$81 Billion Annually and Improve the Quality of Medical Care, September 14, 2005, available at http://rand.org/news/press.05/09.14.html.

² Transforming Health Care: The President's Health Information Technology Plan, available at: http://www.whitehouse.gov/infocus/technology/economic_policy200404/chap3.html.

In addition, a number of tools providing usable healthcare information are already available to Medicare beneficiaries. Supported by the public-private quality alliances, consumers can access "Compare" Web sites through www.medicare.gov where they can evaluate important aspects of their health care options for care at a hospital, nursing home, home health agency, and dialysis facility, as well as compare their costs and coverage when choosing

a prescription drug plan. We are developing a project with the goals of providing more comprehensive information on quality and costs, including more complete measures of health outcomes, satisfaction, and volume of services that matter to consumers, and more comprehensive measures of costs for entire episodes of care, not just payments for particular services and admissions. We intend for the project to combine public and private health care data to measure cost and quality of care information at the physician and hospital levels. Quality, cost, pricing, and patient information will be reported to consumers and purchasers of health care in a meaningful and transparent way.

III. Collection of Information Requirements

Under the Paperwork Reduction Act of 1995, we are required to provide 60-day notice in the **Federal Register** and solicit public comment before a collection of information requirement is submitted to the Office of Management and Budget (OMB) for review and approval. In order to fairly evaluate whether an information collection should be approved by OMB, section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires that we solicit comment on the following issues:

- The need for the information collection and its usefulness in carrying out the proper functions of our agency.
- The accuracy of our estimate of the information collection burden.
- The quality, utility, and clarity of the information to be collected.
- Recommendations to minimize the information collection burden on the affected public, including automated collection techniques.

We are soliciting public comment on each of these issues for the following sections of this document that contain information collection requirements:

Section 410.33 Independent Diagnostic Testing Facility

Section 410.33(e)(1) imposes a recordkeeping requirement on multistate entities. Specifically, an independent diagnostic testing facility

(IDTF) that operates across State boundaries must maintain documentation that its supervising physicians and technicians are licensed and certified in each of the States in which it operates. The burden associated with this requirement is the time and effort it takes the IDTF to collect and maintain the aforementioned information.

While subject to the PRA, we believe this information collection requirement is exempt as defined in 5 CFR 1320.3(b)(2), because the time, effort, and financial resources necessary to comply with the requirement would be incurred by persons in the normal course of their activities (for example, in compiling and maintaining business records) and is considered to be usual and customary.

Section 410.33(g) discusses the application certification standards that an IDTF must meet. An IDTF must complete an enrollment application and certify the information contained in the application. The certification is part of an application that is subject to the PRA. The burden associated with this requirement is the time and effort necessary to complete the application. This requirement is currently approved in OMB No. 0938–0685, with a current expiration date of April 30, 2009.

If you comment on these information collection and recordkeeping requirements, please mail copies directly to the following:

Centers for Medicare & Medicaid Services, Office of Strategic Operations and Regulatory Affairs, Regulations Development Group, Attn: William N. Parham, III, [CMS– 1321–P], Room C4–26–05, 7500 Security Boulevard, Baltimore, MD 21244–1850; and

Office of Information and Regulatory Affairs, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503, Attn: Carolyn Lovett, CMS Desk Officer, [CMS–1321–P], carolyn_lovett@omb.eop.gov. Fax (202) 395–6974.

IV. Response to Comments

Because of the large number of public comments we normally receive on Federal Register documents, we are not able to acknowledge or respond to them individually. We will consider all comments we receive by the date and time specified in the DATES section of this preamble, and, when we proceed with a subsequent document, we will respond to the comments in the preamble to that document.

V. Regulatory Impact Analysis

[If you choose to comment on issues in this section, please include the caption "IMPACT" at the beginning of your comments.]

We have examined the impact of this rule as required by Executive Order 12866 (September 1993, Regulatory Planning and Review), the Regulatory Flexibility Act (RFA) (September 19, 1980 Pub. L. 96–354), section 1102(b) of the Social Security Act, the Unfunded Mandates Reform Act of 1995 (Pub. L. 104–4), and Executive Order 13132.

Executive Order 12866 (as amended by Executive Order 13258, which merely reassigns responsibilities of duties) directs agencies to assess all costs and benefits of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects, distributive impacts, and equity). A regulatory impact analysis must be prepared for proposed rules with economically significant effects (that is, a proposed rule that would have an annual effect on the economy of \$100 million or more in any one year, or would adversely affect in a material way the economy, a sector of the economy, productivity, competition, jobs, the environment, public health or safety, or State, local, or tribal governments or communities). As indicated in more detail below, we estimate that the PFS provisions included in this proposed rule will redistribute more than \$100 million in one year. We are considering this proposed rule to be economically significant because its provisions are estimated to result in an increase, decrease or aggregate redistribution of Medicare spending that will exceed \$100 million. Therefore, this proposed rule is a major rule and we have prepared a regulatory impact analysis.

The RFA requires that we analyze regulatory options for small businesses and other entities. We prepare a regulatory flexibility analysis unless we certify that a rule would not have a significant economic impact on a substantial number of small entities. The analysis must include a justification concerning the reason action is being taken, the kinds and number of small entities the rule affects, and an explanation of any meaningful options that achieve the objectives with less significant adverse economic impact on the small entities.

Section 1102(b) of the Act requires us to prepare a regulatory impact analysis for any proposed rule that may have a significant impact on the operations of a substantial number of small rural hospitals. This analysis must conform to the provisions of section 603 of the RFA. For purposes of section 1102(b) of the Act, we define a small rural hospital as a hospital that is located outside a Metropolitan Statistical Area and has fewer than 100 beds. We have determined that this proposed rule would have minimal impact on small hospitals located in rural areas. Of the 222 hospital-based ESRD facilities located in rural areas, only 40 are affiliated with hospitals with fewer than 100 beds.

For purposes of the RFA, physicians, nonphysician practitioners, and suppliers are considered small businesses if they generate revenues of \$6 million or less. Approximately 95 percent of physicians are considered to be small entities. There are about 980,000 physicians, other practitioners and medical suppliers that receive Medicare payment under the PFS.

For purposes of the RFA, approximately 80 percent of clinical diagnostic laboratories are considered small businesses according to the Small Business Administration's size standards.

In addition, most ESRD facilities are considered small entities, either based on nonprofit status or by having revenues of \$29 million or less in any year. We consider a substantial number of entities to be affected if the proposed rule is estimated to impact more than 5 percent of the total number of small entities. Based on our analysis of the 927 nonprofit ESRD facilities considered small entities in accordance with the above definitions, we estimate that the combined impact of the proposed changes to payment for renal dialysis services included in this proposed rule would have a 0.9 percent increase in overall payments relative to current overall payments.

IDTFs are suppliers under the Medicare program. For purposes of the RFA, suppliers with annual sales of \$6 million or less are considered to be small entities. (Individuals and States are not included in the definition of a small entity.) We believe that our proposed standards for IDTFs will help bar fraudulent suppliers from participating in the Medicare program and provide an added level of protection to Medicare beneficiaries. Therefore, we expect to have an impact on an unknown number of persons and entities who will effectively be prevented from practicing their aberrant billing activities. The vast majority of suppliers would not be significantly affected by this proposed rule. The reduction in program overpayments and the added level of protection to beneficiaries that we expect to achieve as a result of this proposed rule justifies the relatively small burden this proposed rule would impose on all small entities.

The analysis and discussion provided in this section, as well as elsewhere in this proposed rule, complies with the RFA requirements.

Section 202 of the Unfunded Mandates Reform Act of 1995 also requires that agencies assess anticipated costs and benefits before issuing any rule that may result in expenditures in any year by State, local, or tribal governments, in the aggregate, or by the private sector, of \$120 million. Medicare beneficiaries are considered to be part of the private sector for this purpose.

We have examined this proposed rule in accordance with Executive Order 13132 and have determined that this regulation would not have any significant impact on the rights, roles, or responsibilities of State, local, or tribal governments. A discussion concerning the impact of this rule on beneficiaries is found later in this section.

We have prepared the following analysis, which, together with the information provided in the rest of this preamble, meets all assessment requirements. The analysis explains the rationale for and purposes of this proposed rule; details the costs and benefits of the rule; analyzes alternatives; and presents the measures we propose to use to minimize the burden on small entities. As indicated elsewhere in this proposed rule, we propose to change our methodology for calculating resource-based PE RVUs and make a variety of other changes to our regulations, payments, or payment policies to ensure that our payment systems reflect changes in medical practice and the relative value of services. We provide information for each of the policy changes in the relevant sections of this proposed rule. We are unaware of any relevant Federal rules that duplicate, overlap or conflict with this proposed rule. The relevant sections of this proposed rule contain a description of significant alternatives if applicable.

A. Resource Based PE RVU Proposals for CY 2007 and Section 5102 of the DRA-Proposed Adjustments for Payments for Imaging Services

As required by section 5102(a) of the DRA and described earlier in section II.E.1. of this proposed rule, we are removing, from the PE RVUs under the PFS the 0.3 percent increase made to the PE RVUs in the CY 2006 PFS final rule with comment period to ensure the

budget neutrality of the impact of the multiple imaging policy adopted for CY 2006. Section 5102(a) of the DRA exempts the CY 2006 and 2007 impact of the multiple imaging policy from budget neutrality. Because we are proposing to maintain the current 25 percent payment reduction for multiple imaging procedures in CY 2007, there is no additional impact resulting from our proposals for CY 2007. Section 5102 of the DRA also exempts the estimated savings from the application of the OPPS-based payment limitation on PFS imaging services from the PFS budget neutrality requirement. We estimate that the combined impact of the budget neutrality exemptions in section 5102 of the DRA would reduce PFS expenditures by approximately 1.3 percent in CY 2007.

Table 7 below shows the specialtylevel impact of section 5102 of the DRA and our most recent estimate (-5.1percent) of the CY 2007 Medicare PFS update. For reference purposes, we have also included the specialty-level impacts using the methodology from the separate June 29, 2006 proposed notice (71 FR 37170), which solicited comments on proposed changes to the PE methodology as well as changes to work RVUs for certain services based on the agency's completion of a five-year review of work RVUs. The CY 2007 impact of the PE input changes described in section II.A. of this proposed rule that were not included in the June 29, 2006 proposed notice are minimal at the specialty level. Additionally, the impacts in this proposed rule reflect the use of updated physician time data from the AMA-ŘÚC.

Our estimates of changes in Medicare revenues for PFS services compare payment rates for CY 2006 with proposed payment rates for CY 2007 using CY 2005 Medicare utilization for all years. We are using CY 2005 Medicare claims processed and paid through March 30, 2005, that we estimate are 98 percent complete. To the extent that there are year-to-year changes in the volume and mix of services provided by physicians, the actual impact on total Medicare revenues will be different than those shown here. The payment impacts reflect averages for each specialty based on Medicare utilization. The payment impact for an individual physician would be different from the average, based on the mix of services the physician provides. The average change in total revenues would be less than the impact displayed here because physicians furnish services to both Medicare and non-Medicare patients

and specialties may receive substantial Medicare revenues for services that are not paid under the PFS. For instance, independent laboratories receive approximately 80 percent of their Medicare revenues from clinical laboratory services that are not paid under the PFS.

Table 7 shows only the payment impact on PFS services. The following is an explanation of the information represented in Table 7:

- Specialty—The physician specialty or type of practitioner/supplier.
- Allowed Charges—Allowed charges are the Medicare Fee Schedule amounts for covered services and include copayments and deductibles (which are
- the financial responsibility of the beneficiary.) These amounts have been summed across all services provided by physicians, practitioners, or suppliers with a specialty to arrive at the total allowed charges for the specialty.
- Impact of Work and PE RVU Changes using the June 29, 2006 proposed notice methodology—For references purposes, the combined CY 2007 percentage increase or decrease in allowed charges attributed to changes in the work and PE RVUs described in and republished from the June 29, 2006 proposed notice methodology.
- Impact of section 5102 of the DRA—The CY 2007 percentage decrease

- in allowed charges attributed to section 5102 of the DRA.
- Combined impact of the June 29, 2006 proposed notice methodology and section 5102 of the DRA.
- CY 2007 Update—The percentage decrease in allowed charges attributed to the most recent estimate of the CY 2007 PFS conversion factor update (-5.1 percent).
- Combined impact with CY 2007 update—The CY 2007 percentage decrease in allowed charges attributed to the June 29, 2006 proposed notice methodology, section 5102 of the DRA, and the CY 2007 update.

TABLE 7: Combined CY 2007 Total Allowed Charge Impact for the Five-Year Review of Work RVUs and Practice Expense Changes, DRA 5102, and the CY 2007 Update

Specialty	1	llowed harges (mil)	Impact of Work and PE RVU Changes using June 29 proposed Notice Methodology	Impac t of DRA 5102	Combined Impact June 29 Proposed Notice Methodology and DRA 5102	CY ¹ 2007 Updat e	Combined Impact With CY 2007 Update
Total	\$	74,749	0%	-1%	-1%	5%	-6%
ALLERGY/IMMUNOLOGY	\$	167	3%	0%	3%	5%	-3%
ANESTHESIOLOGY	\$	1,710	-7%	0%	-7%	-5%	-12%
CARDIAC SURGERY	\$	389	2%	0%	2%	-5%	-3%
CARDIOLOGY	\$	7,462	-1%	-1%	-2%	-5%	-7%
COLON AND RECTAL SURGERY	\$	120	0%	0%	0%	-5%	-5%
CRITICAL CARE	\$	171	4%	0%	4%	-5%	-1%
DERMATOLOGY	\$	2,145	-2%	0%	-2%	-5%	-7%
EMERGENCY MEDICINE	\$	1,989	7%	0%	7%	-5%	2%
ENDOCRINOLOGY	\$	319	6%	-1%	5%	-5%	0%
FAMILY PRACTICE	\$	4,809	5%	0%	5%	-5%	0%
GASTROENTEROLOGY	\$	1,734	0%	0%	0%	-5%	-5%
GENERAL PRACTICE	\$	1,016	3%	-1%	2%	-5%	-3%
GENERAL SURGERY	\$	2,321	0%	-1%_	-1%	-5%	-6%
GERIATRICS	\$	132	2%	0%	2%	-5%	-3%
HAND SURGERY	\$	76	-2%	0%	-2%	-5%	-7%
HEMATOLOGY/ONCOLOGY	\$	1,761	3%	0%_	2%	-5%	-3%
INFECTIOUS DISEASE	\$	450	9%	0%	9%	-5%	3%

Specialty	C	llowed harges (mil)	Impact of Work and PE RVU Changes using June 29 proposed Notice Methodology	Impac t of DRA 5102	Combined Impact June 29 Proposed Notice Methodology and DRA 5102	CY ¹ 2007 Updat e	Combined Impact With CY 2007 Update
INTERNAL MEDICINE	\$	9,510	5%	0%	5%	-5%	0%
INTERVENTIONAL		222					
RADIOLOGY	\$	233	-6%	-3%	-9%	-5%	-14%
NEPHROLOGY	\$	1,585	-1%	0%	-1%	-5%	-6%
NEUROLOGY	\$	1,331	2%	-1%	1%	-5%	-4%
NEUROSURGERY	\$	571	-2%	-1%	-2%	-5%	-7%
NUCLEAR MEDICINE	\$	86	-7%	-2%	-9%	-5%	-14%
OBSTETRICS/GYNECOLOGY	\$	623	1%	0%	1%	-5%	-4%
OPHTHALMOLOGY	\$	4,786	-3%	0%	-3%	-5%	-8%
ORTHOPEDIC SURGERY	\$	3,265	-2%	-1%	-3%	-5%	-8%
OTOLARNGOLOGY	\$	892	0%	0%	0%	-5%	-5%
PATHOLOGY	\$	934	-5%	0%	-5%	-5%	-10%
PEDIATRICS	\$	73	2%	0%	1%	-5%	-4%
PHYSICAL MEDICINE	\$	785	2%	0%	2%	-5%	-4%
PLASTIC SURGERY	\$	279	-1%	0%	-1%	-5%	-6%
PSYCHIATRY	\$	1,128	-2%	0%	-2%	-5%	-7%
PULMONARY DISEASE	\$	1,580	6%	0%	5%	-5%	0%
RADIATION ONCOLOGY	\$	1,448	-1%	0%	-1%	-5%	-7%
RADIOLOGY	\$	5,365	-5%	-6%	-11%	-5%	-16%
RHEUMATOLOGY	\$	469	2%	-1%	2%	-5%	-4%
THORACIC SURGERY	\$	442	1%	-1%	1%	-5%	-5%
UROLOGY	\$	1,949	1%	-1%	0%	-5%	-5%
VASCULAR SURGERY	\$	606	-1%	-6%	-6%	-5%	-11%
AUDIOLOGIST	\$	31	-1%	0%	-1%	-5%	-6%
CHIROPRACTOR	\$	774	-8%	0%	-8%	-5%	-13%
CLINICAL PSYCHOLOGIST	\$. 554	-9%	0%	-9%	-5%	-14%
CLINICAL SOCIAL WORKER	\$	362	-9%	0%	-9%	-5%	-14%
NURSE ANESTHETIST	\$	651	-8%	0%	-8%	-5%	-13%
NURSE PRACTITIONER	\$	710	0%	0%	0%	-5%	-5%
OPTOMETRY	\$	838	-3%	0%	-3%	-5%	-8%
ORAL/MAXILLOFACIAL	Ψ	030	-370	070	-3%	-3%	-8%
SURG	\$	37	-1%	0%	-1%	-5%	-6%
PHYS/OCC THERAPY	\$	1,593	-4%	0%	-4%	-5%	-9%
PHYSICIANS ASSISTANT	\$	537	1%	0%	1%	-5%	-4%
PODIATRY	\$	1,541	-1%	0%	-1%	-5%	-7%
DIAGNOSTIC TESTING			,		(- 1		
FACILITY	\$	1,214	-2%	-17%	-19%	-5%	-25%
INDEPENDENT LABORATORY	\$	665	4%	0%	4%	-5%	-2%
PORTABLE X-RAY SUPPLIER	\$	87	1%	0%	1%	-5%	-4%

¹ It is our standard policy to use the latest historical data available for compensation, prices, and economy-wide multifactor productivity when determining the Medicare Economic Index (MEI) used for the fee schedule update. The CY07 update will be no different. Beginning in April 2006, the BLS' Employment Cost Indexes (ECI) and economy-wide multifactor productivity (MFP) estimates will use the North American Industrial Classification System (NAICS), instead of the Standard Industrial Codes (SIC), which will no longer exist. Additional information on this issue can be found in the fact sheet which is posted with this proposed rule (CMS -1321-P) on our website at http://www.cms.hhs.gov/PhysicianFeeSched/PFSFRN/list.asp#TopOfPage

spectrum of physician specialties. There are separate columns that show the change in the facility rates and the nonfacility rates. For an explanation of

facility and nonfacility PE refer to Addendum A of this proposed rule. If we change any of the proposed provisions following the consideration of public comments, these figures may change.

Table 8: Impact of Proposed Rule on and Estimated Physician Update on 2007 Payment For Selected Procedures

СРТ/	MOD	Description		Facility		Non-facility		
HCPCS		Description	Old	New	Percent Change	Old	New	Percent Change
11721		Debride nail, 6 or more	31.08	28.77	-7%	39.79	38.84	-2%
17000		Destroy benign/premlg lesion	44.34	43.52	-2%	60.64	61.14	1%
27130		Total hip arthroplasty	1399.55	1202.66	-14%	1399.55	NA	NA
27244		Treat thigh fracture	1137.68	1103.04	-3%	1137.68	NA	NA
27447		Total knee arthroplasty	1511.35	1385.00	-8%	1511.35	NA	NA
33533		CABG, arterial, single	1933.53	2078.04	7%	1933.53	NA	NA
35301		Rechanneling of artery	1128.97	1086.49	-4%	1128.97	NA	NA
43239		Upper GI endoscopy, biopsy	162.20	157.17	-3%	334.26	319.37	-4%
66821		After cataract laser surgery	230.80	251.03	9%	248.61	267.58	8%
66984		Cataract surg w/iol, 1 stage	683.67	643.41	-6%	683.67	NA	NA
67210		Treatment of retinal lesion	574.15	559.97	-2%	600.30	582.99	-3%
71010		Chest x-ray	28.04	NA	NA	28.04	25.89	-8%
71010	26	Chest x-ray	9.47	8.99	-5%	9.47	8.99	-5%
76091		Mammogram, both breasts	97.40	NA	NA	97.40	97.10	0%
76091	26	Mammogram, both breasts	45.10	42.80	-5%	45.10	42.80	-5%
76092		Mammogram, screening	85.65	NA	NA	85.65	80.92	-6%
76092	26	Mammogram, screening	36.38	34.53	-5%	36.38	34.53	-5%
77427		Radiation tx management, x5	172.05	163.64	-5%	172.05	163.64	-5%
78465	26	Heart image (3d), multiple	76.93	74.81	-3%	76.93	74.81	-3%

СРТ/	MOD	IOD Description		Facility		Non-facility		
HCPCS MOI		Description	Old	New	Percent Change	Old	New	Percent Change
88305	26	Tissue exam by pathologist	42.07	38.84	-8%	42.07	38.84	-8%
90801		Psy dx interview	143.63	133.43	-7%	152.73	147.81	-3%
90862		Medication management	48.89	46.03	-6%	51.92	51.43	-1%
90935		Hemodialysis, one evaluation	73.14	68.33	-7%	73.14	NA	NA
92012		Eye exam established pat	37.14	34.89	-6%	65.18	61.14	-6%
92014		Eye exam & treatment	60.64	56.82	-6%	96.26	90.63	-6%
92980		Insert intracoronary stent	830.71	807.77	-3%	830.71	NA	NA
93000		Electrocardiogram, complete	26.91	24.10	-10%	26.91	24.10	-10%
93010		Electrocardiogram report	9.10	8.63	-5%	9.10	8.63	-5%
93015		Cardiovascular stress test	108.01	102.14	-5%	108.01	102.14	-5%
93307	26	Echo exam of heart	49.27	47.83	-3%	49.27	47.83	-3%
93510	26	Left heart catheterization	257.70	246.00	-5%	257.70	246.00	-5%
98941		Chiropractic manipulation	31.45	29.85	-5%	36.38	34.17	-6%
99203		Office/outpatient visit, new	72.38	68.33	-6%	97.02	91.71	-5%
99213		Office/outpatient visit, est	35.62	43.16	21%	52.68	59.70	13%
99214		Office/outpatient visit, est	59.12	67.97	15%	82.62	90.63	10%
99222		Initial hospital care	112.93	121.92	8%	112.93	NA	NA
99223		Initial hospital care	157.27	178.03	13%	157.27	NA	NA
99231		Subsequent hospital care	34.11	36.68	8%	34.11	NA	NA
99232		Subsequent hospital care	55.71	65.46	17%	55.71	NA	NA
99233		Subsequent hospital care	79.21	93.51	18%	79.21	NA	NA
99236		Observ/hosp same date	223.22	210.03	-6%	223.22	NA	NA
99239		Hospital discharge day	96.64	96.75	0%	96.64	NA	NA
99243		Office consultation	93.99	95.31	1%	122.79	123.00	0%
99244		Office consultation	138.70	148.89	7%	173.19	180.90	4%
99253		Initial inpatient consult	98.91	111.13	12%	98.91	NA	NA
99254		Initial inpatient consult	142.12	160.04	13%	142.12	NA	NA
99283		Emergency dept visit	62.15	62.22	0%	62.15	NA	NA
99284		Emergency dept visit	97.02	114.01	18%	97.02	NA	NA
99291		Critical care, first hour	207.68	213.99	3%	256.95	259.31	1%
99292		Critical care, addÏl 30 min	104.22	107.53	3%	114.07	116.53	2%
99348		Home visit, est patient	72.01	NA	NA	72.01	67.61	-6%
99350		Home visit, est patient	164.48	NA	NA	164.48	153.57	-7%
G0008		Admin influenza virus vac	-18.57	NA	NA	18.57	19.06	3%
G0317		ESRD related svs 4+mo 20+yrs	308.11	286.64	-7%	308.11	286.64	-7%
G0344		Office/outpatient visit, new	72.38	68.69	-5%	97.02	92.07	-5%
G0366		Electrocardiogram, complete	26.91	24.10	-10%	26.91	24.10	-10%
G0367		Electrocardiogram, tracing	17.81	NA	NA	17.81	15.46	-13%
G0368		Electrocardiogram report	9.10	8.63	-5%	9.10	8.63	-5%

B. Geographic Practice Cost Indices (GPCI)—Payment Localities

As discussed in section II.B. of the preamble to this proposed rule, we are proposing new GPCIs for 2007. In the November 15, 2004 PFS final rule, we published 2005 and 2006 GPCI and GAF values reflecting the 2 year phase-in of

updated GPCI data. In 2007, the proposed GPCI and GAF values will reflect new budget neutrality scalers (developed by the Office of the Actuary) and the removal of the 1.000 MMA floor from the physician work GPCI. The negative impact of these changes on a number of payment localities is shown

in 4 of section II.B. in this proposed rule.

C. Global Period for Remote Afterloading High Intensity Brachytherapy Procedures

As discussed in section II.D.1. of this proposed rule, we are proposing changes to the global period for these

services. We do not anticipate this proposed change will have a significant impact on Medicare expenditures.

D. DRA 5112—Proposed Addition of the Ultrasound Screening for Abdominal Aortic Aneurysm to Welcome to Medicare Benefit

As discussed earlier in section II.E.3. of this preamble, section 5112 of the DRA authorizes coverage of an ultrasound screening for abdominal aortic aneurysms effective January 1, 2007, subject to certain eligibility and other limitations. We estimate that this new benefit would result in an increase in Medicare expenditures to physicians and other practitioners and suppliers of ultrasound services and related followup tests and treatment that may be required as a result of the coverage of these screening examinations. However, this is not expected to have a significant cost impact on the Medicare program.

E. DRA 5113—Proposed Colorectal Screening Exemption From Part B Deductible

As discussed earlier in section II.E.4. of this preamble, beginning January 1, 2007, colorectal cancer screening services as described in section 1861(pp)(1) of the Act are no longer subject to the Part B deductible. While waiver of this deductible will be beneficial to Medicare beneficiaries, we do not anticipate that this change will have a significant cost impact on the Medicare program.

F. Section 5114—Proposed Addition of Diabetes Outpatient Self-Management Training Services (DSMT) and Medical Nutrition Therapy (MNT) for the FQHC Program

As discussed earlier in section E.4. of this preamble, section 5114 of the DRA amended section 1861(aa)(3) the Act to

add DSMT and MNT to the list of Medicare covered and reimbursed services under the Medicare FQHC benefit, effective for services provided on or after January 1, 2006. Although this statutory change has already been implemented in administrative instructions, we are proposing to conform the regulations to meet the new statutory requirement. FQHCs certified as DSMT and MNT providers have been allowed to bundle the cost of those services into their FQHC payment rates. But before the enactment of the DRA, the provision of these services would not generate a separate FOHC visit payment. Effective for services furnished on or after January 1, 2006, FQHCs that are certified providers of DSMT and MNT services can receive per visit payments for covered services furnished by registered dietitians or nutrition professionals. In light of the fact there are a limited number of qualified centers for DSMT and MNT services, the increase in Medicare expenditures should be negligible.

G. Proposed Payment for Covered Outpatient Drugs and Biologicals (ASP Issues)

The proposed changes discussed in section II.F. of this proposed rule, with respect to payment for covered outpatient drugs and biologicals, are estimated to have no impact on Medicare expenditures. However, we believe the changes will assist in clarifying existing policy with respect to ASP payment.

H. Proposed Provisions Related to Payment for Renal Dialysis Services Furnished by End State Renal Disease (ESRD) Facilities

The ESRD related provisions in this proposed rule are discussed in section

II.G. of this preamble. In order to understand the impact of the proposed changes affecting payments to different categories of ESRD facilities, it is necessary to compare estimated payments under the current year (current 2006 payments) to estimated payments under the proposed revisions to the composite rate payment system as discussed in II.G. of this proposed rule (proposed 2007 payments). To estimate the impact among various classes of ESRD facilities, it is imperative that the estimates of current payments and proposed payments contain similar inputs. Therefore, we simulated payments only for those ESRD facilities that we are able to calculate both current 2006 payments and proposed 2007 payments.

Due to data limitations, we are unable to estimate current and proposed payments for 226 facilities that bill for ESRD dialysis treatments. ESRD providers were grouped into the categories based on characteristics provided in the Online Survey and Certification and Reporting (OSCAR) file and the most recent cost report data from the Healthcare Cost Report Information System (HCRIS). We also used the December 2005 update of CY 2005 National Claims History file as a basis for Medicare dialysis treatments and separately billable drugs and biologicals. While the December 2005 update of the 2005 claims file is not complete, we wanted to use the most recent data available, and plan to use an updated version of the 2005 claims file for the final rule.

BILLING CODE 4120-01-P

Table 9: Impact of CY 2007 Proposed Changes in Payments to Hospital Based and Independent ESRD Facilities
[Percent change in composite rate payments to ESRD facilities (both program and beneficiaries)]

1	2	3	4	5
	Number Of facilities	Number of Dialysis Treatments (in millions)	Effect of Proposed Changes in Wage Index 1/	Overall Effect 2/
All	4,360	. 30.4	0.0	0.6
Independent	3,756	27.0	-0.1	0.6
Hospital Based	604	3.4	0.4	1.1
By Facility Size:				
Less than 5000 treatments	1,705	5.0	-0.3	0.3
5000 to 9999 treatments	1,768	12.8	0.0	0.6
Greater than 9999 treatments	887	12.6	0.1	0.7
By Type of Ownership				
Profit	3,433	24.5	-0.1	0.5
Nonprofit	927	5.9	0.3	0.9
By Geographic Location:				
Rural	1,205	6.3	-0.6	0.0
Urban	3,155	24.1	0.1	0.7
By Region:				
New England	143	1.1	1.3	1.8
Middle Atlantic	539	4.0	0.7	1.3
East North Central	675	4.7	-0.5	0.1
West North Central	335	1.6	-0.4	0.3
South Atlantic	977	6.9	0.0	0.6
East South Central	348	2.2	-1.1	-0.5
West South Central	594	4.2	-0.7	-0.1
Mountain	230	1.4	0.2	0.8
Pacific	492	3.8	1.1	1.7
Puerto Rico 1/ This column shows the effect	27	0.4	-1.7	-1.1

^{1/} This column shows the effect of proposed wage changes to ESRD providers. Composite rate payments computed using the current wage index are compared to composite rate payments using the CY 2007 wage index changes.

^{2/} This column shows the percent change between CY 2007 and CY 2006 composite rate payments to ESRD facilities. The CY 2007 payments include the CY 2007 wage adjusted composite rate, and the 15.2 percent drug add-on times treatments. The CY 2006 payments to ESRD facilities include the CY 2006 wage adjusted composite rate and the 14.5 percent drug add-on times treatments.

indicates the number of ESRD facilities for each type, and the third column indicates the number of dialysis treatments.

The fourth column shows the effect of CY 2007 proposed changes to the ESRD wage index as it affects the composite rate payments to ESRD facilities. The fourth column compares aggregate ESRD wage adjusted composite rate payments in the second year of the transition (CY 2007) to aggregate ESRD wage adjusted composite rate payments in first year of the transition (CY 2006). In the second year of the transition (CY 2007), ESRD facilities receive 50 percent of the CBSA wage adjusted composite rate and 50 percent of the MSA adjusted composite rate. In the first year of the transition, ESRD facilities receive 25 percent of the CBSA wage adjusted composite rate and 75 percent of the MSA adjusted composite rate. The overall effect to all ESRD providers in aggregate is zero because the proposed CY 2007 ESRD wage index has been multiplied by a budget neutrality factor to comply with the statutory requirement that any wage index revisions be done in a manner that results in the same aggregate amount of expenditures as would have been made without any changes in the wage index. The decreases shown among census regions is primarily due to reducing the wage index floor, as there were areas in these areas with wage index values below the proposed floor.

The fifth column shows the overall effect of the proposed changes in composite rate payments to ESRD providers. The overall effect is measured as the difference between CY 2007 proposed payment with all changes as proposed in this rule and CY 2006 current payment. This amount is computed by multiplying the wage adjusted composite rate with the drug add-on for each provider times dialysis treatments from 2005 claims. The CY 2007 proposed payment is transition year two wage adjusted composite rate for each provider (with the proposed 15.2 percent drug add-on) times dialysis treatments from 2005 claims. The CY 2006 current payment is transition year one wage adjusted composite rate for each provider (with the current 14.5 percent drug add on) times dialysis treatments from 2005 claims.

The overall impact to ESRD providers in aggregate is 0.6 percent. This increase corresponds to the proposed 0.6 percent increase to the drug add-on. The variation seen in column 5 is due to variation in change in the wage index (column 4). All provider types receive the same 0.6 percent increase to the drug add on.

I. Private Contracts and Opt-Out Provision

The changes discussed in this proposed rule, with respect to private contracts and the opt-out provision, are currently estimated to have no significant impact on Medicare expenditures.

J. Proposals Related to Physician Self Referral Prohibitions

As discussed in section II.I of this proposed rule, we would clarify in regulations at § 424.80(d) under the contractual arrangement reassignment exception that, if a physician or other individual supplier reassigns his or her right to bill for the TC of a diagnostic test, the entity to which the reassignment is made may not be paid more than the physician or other individual supplier would have been paid for the TC. In addition, in order to bill for the TC of the diagnostic test, the entity to which the reassignment is made must perform the PC. We also propose that, in order to bill for the PC of a diagnostic test following a reassignment, the billing entity must meet current requirements in our manual instructions.

In addition, as discussed in section II.I., we also propose to revise §§ 424.80(b) and (d) to provide that a physician or other individual supplier who reassigns his or her right to benefits has a right to review the bills for his or her services, irrespective of whether the individual is an employee or an independent contractor of the entity to which the reassignment is made.

We also propose the following changes to the physician self-referral provisions:

• A "centralized building" for purposes of the physician services exception and the in-office ancillary services exception at §§ 411.355(a) and (b), respectively, would have to measure at least 350 square feet and include permanent placement of the equipment used in the provision of substantially all of the designated health services. We believe that these changes would have little effect on Medicare expenditures.

K. Supplier Access to Claims Billed on Reassignment

The reassignment provisions discussed in section II.J.2. of this preamble are currently estimated to have no significant impact on Medicare expenditures.

L. Proposed Coverage of Bone Mass Measurement

As discussed in section II.K. of this preamble, we have decided to propose several revisions to § 410.31 relative to

the definition of the term "Bone Mass Measurement" (§ 410.31(a)(2)), the conditions for coverage (§ 410.31(b)), the examples of exceptions to the standards on frequency of coverage $(\S 410.31(c)(2))$, and the category of individuals receiving glucocorticoid (steroid) therapy (§ 410.31(d)(3)). We are also proposing the addition of a new paragraph (f) that would allow CMS, through the NCD process, to identify additional BMM systems for monitoring individuals receiving osteoporosis drug therapy and for performing confirmatory baseline measurements. We do not expect that this addition would have a significant cost impact on the Medicare program in the next several years.

Based on the projected impact of the first three changes that would place greater reliance on the use of the more expensive DXA (axial skeleton) devices, we estimate that this revised benefit would result in an increase in Medicare payments for providers who use the DXA (axial skeleton) devices and a somewhat smaller decrease in payments to providers who use QCT (axial skeleton) and peripheral devices. However, we do not expect that these changes would have a significant cost impact on the Medicare program due to the fact that at present a very small percentage of our total Medicare payments for bone mass measurements are being made to providers who use QCT or peripheral devices. In addition, we estimate that lowering the eligibility standard for coverage of individuals on steroid therapy from 7.5 mg/day to 5.0 mg/day of prednisone (the fourth change) would result in an increase in Medicare payment for testing of additional patients, but this modest lowering of the steroid standard is not expected to have a significant cost impact on the program.

M. Proposed IDTF Changes

The costs associated with these proposed changes would be as follows:

1. Liability Insurance Requirement (§ 424.57(c)(10))

We estimate that only 10 percent of IDTFs do not already have liability insurance that meets this requirement. Based on Medicare data as of June 2005, 10 percent of the total number of IDTFs is approximately 559 suppliers. Using the previously highest estimate received (\$1,800 annually), results in an approximate additional liability insurance cost of \$1 million annually (559 times \$1,800) to the IDTF industry due to this proposed rule.

2. Primary Business Telephone Listed Under the Name of the Business Locally or Toll-free for Beneficiaries Proposed Requirement (§ 424.57(c)(9))

We estimate that only 1 percent of IDTFs do not already meet this requirement. Based on Medicare data as of June 2005, we determined that 1 percent of IDTFs is approximately 56 suppliers. Therefore, 56 times the approximate \$600 annual cost of telephone service results in an additional cost of \$33,600 annually. Total Cost = \$1 Million + \$33,600 = approximately \$1.04 million annually.

N. Independent Lab Billing for TC Component of Physician Pathology Services for Hospital Patients

The most current information on the number of affected hospitals and the impact on laboratories and hospitals comes from a report issued by the General Accounting Office (GAO) in September 2003.

The GAO estimated that approximately 95 percent of the total of all Medicare hospitals on the prospective payment system, as well as CAHs sent the TC of physician pathology services to independent laboratories and the independent laboratories billed the carrier under the PFS

The GAO estimated that the median number of services sent by each hospital to outside independent laboratories was small, approximately 81 services. The GAO was unable to identify the number of laboratories billing for the TC service because a single laboratory may submit claims under multiple provider numbers. In general, the impact on the individual hospital is small; however, we do not know the impact on the individual independent laboratory

If the independent laboratories had not received payments from the carriers for these TC services for hospital patients, the GAO estimates that Medicare spending would have been \$42 million less in 2001 and beneficiary cost sharing obligations for inpatient and outpatient services would have been reduced by \$2 million.

Based on what they learned from the hospital industry, the GAO thought that Medicare beneficiaries' access to pathology services would not likely be affected if independent laboratories could not longer bill the carrier for these services. Hospital representatives indicated that they would likely continue to use independent laboratories to provide TC pathology services.

In is unclear if the hospitals contracting with independent

laboratories would pay the laboratories at the same rates that the laboratories received by billing the Medicare carriers under the physician fee schedule.

O. Public Consultation for Medicare Payment for New Outpatient Clinical Diagnostic Laboratory Tests

This codification of our process for public consultation for new clinical diagnostic laboratory tests paid under the Medicare Part B clinical laboratory fee schedule, if adopted, would not increase or decrease payment amounts for existing clinical diagnostic laboratory tests because it would not alter our current methodology for calculating payment amounts for existing clinical diagnostic laboratory tests. For new tests, this proposal would primarily codify an existing process for the determination of payment amounts. Because any new laboratory tests to be gapfilled are unknown to us at the current time, we do not have any data to estimate the impact of our proposal to pay for new gapfilled lab tests at the median of the local carrier amounts for all carriers rather than the lower of that amount and the local carrier amount.

P. Alternatives Considered

This proposed rule contains a range of policies, including some proposals related to specific MMA provisions. The preamble provides descriptions of the statutory provisions that are addressed, identifies those policies when discretion has been exercised, presents rationale for our decisions and, where relevant, alternatives that were considered.

Q. Impact on Beneficiaries

There are a number of changes made in this proposed rule that would have an effect on beneficiaries. In general, we believe these proposed changes, particularly the DRA provisions that provide for an exception to the application of the Part B deductible with respect to colorectal cancer screening tests and coverage of an ultrasound screening for the early detection of AAAs, as part of the Initial Preventive Physical Examination benefit (referred to as the Welcome to Medicare benefit) would improve beneficiary access to services that are currently covered or expand the Medicare benefit package to include new services. As explained in more detail below, the regulatory provisions may affect beneficiary liability in some cases. Any changes in aggregate beneficiary liability from a particular provision would be a function of the coinsurance (20 percent if applicable for the particular provision after the beneficiary has met the deductible) and the effect of the

aggregate cost (savings) of the provision on the calculation of the Medicare Part B premium rate (generally 25 percent of the provision's cost or savings).

To illustrate this point, as shown in Table 8, the 2006 national payment amount in the nonfacility setting for CPT code 99203 (Office/outpatient visit, new), is \$97.02 which means that currently a beneficiary is responsible for 20 percent of this amount, or \$19.40. Based on the June 29, 2006 proposed notice (71 FR 37170) and this proposed rule, the 2007 national payment amount in the nonfacility setting for CPT code 99203, as shown in Table 8, is \$91.71 which means that, in 2007, the beneficiary coinsurance for this service would be \$18.34.

Very few of the changes we are proposing impact overall payments and, therefore, would affect Medicare beneficiaries' coinsurance liability. Proposals discussed above that do affect overall spending, such as DRA 5102 imaging provisions, would similarly impact beneficiaries' coinsurance.

R. Accounting Statement

As required by OMB Circular A–4 (available at http://www.whitehouse.gov/omb/circulars/a004/a–4.pdf), in Table 10 below, we have prepared an accounting statement showing the classification of the expenditures associated with the provisions of this proposed rule. This table includes the impact of the proposed changes in this rule on providers and suppliers.

Expenditures are classified as transfers to Medicare providers/or suppliers (that is, ESRD facilities and physicians, other practitioners, clinical laboratories and medical suppliers that receive payment under the physician fee schedule or Medicare Part B). Based on the proposals contained in this proposed rule, there would be an estimated decrease in expenditures from CY 2006 to 2007. This is a result of the CY 2007 increased payment to ESRD facilities the reduction to the payments for imaging services under the PFS required by section 5102 of the DRA and the -5.1 percent Medicare PFS conversion factor update required by the statutory update formula.

TABLE 10.—ACCOUNTING STATEMENT: CLASSIFICATION OF ESTIMATED EX-PENDITURES, FROM CY 2006 TO THE CY 2007 (IN MILLIONS)

Category	Transfers
Annualized Monetized Transfers.	Estimated decrease in expenditures of \$3,600

TABLE 10.—ACCOUNTING STATEMENT: PART 405—FEDERAL HEALTH CLASSIFICATION OF ESTIMATED EX-PENDITURES, FROM CY 2006 TO THE CY 2007 (IN MILLIONS)-Continued

Category	Transfers
From Whom To Whom?	Federal Government To ESRD Medicare Providers; physicians, other practitioners and suppliers who receive payment under the Medicare Physician Fee Schedule; and Medicare Suppliers billing for Part B drugs.

In accordance with the provisions of Executive Order 12866, this final rule was reviewed by the Office of Management and Budget.

List of Subjects

42 CFR Part 405

Administrative practice and procedure, Health facilities, Health professions, Kidney diseases, Medical devices, Medicare, Reporting and recordkeeping requirements, Rural areas, X-rays.

42 CFR Part 410

Health facilities, Health professions, Kidney diseases, Laboratories, Medicare, Reporting and recordkeeping requirements, Rural areas, X-rays.

42 CFR Part 411

Kidney diseases, Medicare, Physician Referral, Reporting and recordkeeping requirements.

42 CFR Part 414

Administrative practice and procedure, Health facilities, Health professions, Kidney diseases, Medicare, Reporting and recordkeeping.

42 CFR Part 415

Health facilities, Health professions, Medicare, Reporting and recordkeeping requirements.

42 CFR Part 424

Emergency medical services, Health facilities, Health professions, Medicare, Reporting and recordkeeping requirements.

For the reasons set forth in the preamble, the Centers for Medicare & Medicaid Services proposes to amend 42 CFR chapter IV as set forth below:

INSURANCE FOR THE AGED AND DISABLED

1. The authority citation for part 405 continues to read as follows:

Authority: Secs. 1102, 1861, 1862(a), 1871, 1874, 1881, and 1886(k) of the Social Security Act (42 U.S.C. 1302, 1395x, 1395y(a), 1395hh, 1395kk, 1395rr, and 1395ww(k)), and sec. 353 of the Public Health Service Act (42 U.S.C. 263a).

Subpart D—Private Contracts

2. Section 405.400 is amended by revising the definition of "Practitioner" to read as follows:

§ 405.400 Definitions.

Practitioner means a physician assistant, nurse practitioner, clinical nurse specialist, certified registered nurse anesthetist, certified nurse midwife, clinical psychologist, clinical social worker, registered dietitian or nutrition professional, who is currently legally authorized to practice in that capacity by each State in which he or she furnishes services to patients or clients.

Subpart X—Rural Health Clinic and **Federally Qualified Health Center Services Payment for Rural Health** Clinic and Federally Qualified Health **Center Services**

3. Section 405.2446 is amended by adding paragraph (b)(10) to read as follows:

§ 405.2446 Scope of services.

* * (b) * * *

(10) Medical nutrition therapy services as specified in part 410, subpart G of this chapter, and diabetes outpatient self-management training services as specified in part 410, subpart H of this chapter.

4. Section 405.2463 is revised to read as follows:

§ 405.2463 What constitutes a visit.

- (a) Visit—(1) General. (i) For RHCs, a visit is a face-to-face encounter between a clinic or center patient and a physician, physician assistant, nurse practitioner, nurse midwife, visiting nurse, clinical psychologist, or clinical social worker.
- (ii) For FQHCs, a visit means— (A) A face-to-face encounter, as described in paragraph (a)(1)(i) of this section: or
- (B) A face-to-face encounter between a patient and a qualified provider of

- medical nutrition therapy services as defined in part 410, subpart G of this chapter; or a qualified provider of outpatient diabetes self-management training services as defined in part 410, subpart H of this chapter.
- (2) Medical visit. For purposes of this section, a medical visit is a face-to-face encounter between a clinic or center patient and a physician, physician assistant, nurse practitioner, nurse midwife, or a visiting nurse; and for FQHCs only, a medical visit also includes a separately billable medical nutrition therapy visit or a diabetes outpatient self-management training visit.
- (3) Other health visit. For purposes of this section, a other health visit is a face-to-face encounter between a clinic or center patient and a clinical psychologist, clinical social worker, or other health professional for mental health services.
- (b) Encounters. Encounters with more than one health professional and multiple encounters with the same health professional that take place on the same day and at a single location constitute a single visit, except when one of the following conditions exist:
- (1) After the first encounter, the patient suffers illness or injury requiring additional diagnosis or treatment.
- (2) The patient has a medical visit and other health visit(s), as defined in paragraph (a) of this section.
- (c) Payment. Medicare pays for more than one visit per day when the conditions in paragraph (b) of this section are met or a separate visit under paragraph (a)(1)(ii)(B) of this section is made.

PART 410—SUPPLEMENTARY **MEDICAL INSURANCE (SMI) BENEFITS**

5. The authority citation for part 410 continues to read as follows:

Authority: Secs. 1102, 1834, and 1871 of the Social Security Act (42 U.S.C. 1302, 1395m, and 1395hh).

Subpart B-Medical and Other Health **Services**

6. Section 410.16 is amended in paragraph (a) by revising paragraph (7) of the definition of "Initial preventive physical examination" to read as follows:

§ 410.16 Initial preventive physical examination: Conditions for and limitations on coverage.

(a) * * *

Initial preventive physical examination * * *

* * * * *

(7) Education, counseling, and referral, including a written plan such as a checklist provided to the beneficiary for obtaining the appropriate screening and other preventive services that are covered as separate Medicare Part B benefits as described in section 1861(s)(10), section 1861(jj), section 1861(nn), section 1861(oo), section 1861(pp), section 1861(qq)(1), section 1861(rr), section 1861(uu), section 1861(vv), section 1861(xx)(1), section 1861(yy), and section 1861(bbb) of the Act.

7. A new § 410.19 is added to read as follows:

§ 410.19 Ultrasound screening for abdominal aortic aneurysms: Condition for and limitation on coverage.

- (a) *Definitions:* As used in this section, the following definitions apply: *Eligible beneficiary* means an individual who—
- (1) Has received a referral for an ultrasound screening for an abdominal aortic aneurysm as a result of an initial preventive physical examination (as defined in section 1861(ww)(1) of the Act):
- (2) Has not been previously furnished an ultrasound screening for an abdominal aortic aneurysm under the Medicare program; and

(3) Is included in at least one of the following risk categories:

(i) Has a family history of an abdominal aortic aneurysm.

(ii) Is a man age 65 to 75 who has smoked at least 100 cigarettes in his lifetime.

(iii) Is an individual who manifests other risk factors in a beneficiary category recommended for screening by the United States Preventive Services Task Force regarding abdominal aortic aneurysms, as specified by the Secretary through a national coverage determination process.

Ultrasound screening for abdominal aortic aneurysms means the following services furnished to an asymptomatic individual for the early detection of an abdominal aortic aneurysm:

- (1) A procedure using soundwaves (or other procedures using alternative technologies of commensurate accuracy and cost, as specified by the Secretary through a national coverage determination process) provided for the early detection of abdominal aortic aneurysms.
- (2) Includes a physician's interpretation of the results of the procedure.

- (b) Conditions for coverage of an ultrasound screening for abdominal aortic aneurysms. Medicare Part B pays for one ultrasound screening for an abdominal aortic aneurysm provided to eligible beneficiaries, as described in this section, after a referral from a physician or a qualified nonphysician practitioner as defined in § 410.16(a).
- (c) Limitation on coverage of ultrasound screening for abdominal aortic aneurysms. Payment may not be made for an ultrasound screening for an abdominal aortic aneurysm that is performed for an individual who is not an eligible beneficiary, as described in the definition of "Eligible beneficiary" in this section.
- 8. Section 410.31 is revised to read as follows:

§ 410.31 Bone mass measurement: Conditions for coverage and frequency standards.

(a) *Definition*. As used in this section unless specified otherwise, the following definition applies:

Bone mass measurement means a radiologic, radioisotopic, or other procedure that meets the following conditions:

(1) Is performed for the purpose of identifying bone mass, detecting bone loss, or determining bone quality.

(2) Is performed with either a bone densitometer (other than single-photon or dual-photon absorptiometry) or with a bone sonometer system that has been cleared for marketing for this use by the FDA under 21 CFR part 807, or approved for marketing by the FDA for this use under 21 CFR part 814.

(3) Includes a physician's interpretation of the results of the procedure.

(b) Conditions for coverage. (1) Medicare covers a medically necessary bone mass measurement if the following conditions are met:

(i) Following an evaluation of the beneficiary's need for the measurement, including a determination as to the medically appropriate procedure to be used for the beneficiary, it is ordered by the physician or a qualified nonphysician practitioner (as these terms are defined in § 410.32(a)) treating the beneficiary.

(ii) It is performed under the appropriate level of supervision of a physician (as set forth in § 410.32(b)).

- (iii) It is reasonable and necessary for diagnosing and treating the condition of a beneficiary who meets the conditions described in paragraph (d) of this section.
- (2) Medicare covers a medically necessary bone mass measurement for an individual defined under paragraph

(d)(5) of this section if the conditions under paragraph (b)(1) of this section are met and the monitoring is performed by the use of a dual energy x-ray absorptiometry system (axial skeleton).

(3) Medicare covers a medically necessary confirmatory baseline bone mass measurement for an individual defined under paragraph (d) of this section, if the conditions under paragraph (b)(1) of this section are met and the confirmatory baseline bone mass measurement is performed by a dual energy x-ray absorptiometry system (axial skeleton) and the initial measurement was not performed by a dual energy x-ray absorptiometry system (axial skeleton).

(c) Standards on frequency of coverage—(1) General rule. Except as allowed under paragraph (c)(2) of this section, Medicare may cover a bone mass measurement for a beneficiary if at least 23 months have passed since the month the last bone mass measurement

was performed.

(2) Exception. If medically necessary, Medicare may cover a bone mass measurement for a beneficiary more frequently than allowed under paragraph (c)(1) of this section. Examples of situations where more frequent bone mass measurement procedures may be medically necessary include, but are not limited to the following medical circumstances.

(i) Monitoring beneficiaries on longterm glucocorticoid (steroid) therapy of

more than 3 months.

(ii) Allowing for a confirmatory baseline measurement to permit monitoring of beneficiaries in the future if the requirements of paragraph (b)(3) of this section are met.

(d) Beneficiaries who may be covered. The following categories of beneficiaries may receive Medicare coverage for a medically necessary bone mass measurement:

(1) A woman who has been determined by the physician (or a qualified nonphysician practitioner) treating her to be estrogen-deficient and at clinical risk for osteoporosis, based on her medical history and other findings.

(2) An individual with vertebral abnormalities as demonstrated by an x-ray to be indicative of osteoporosis, osteopenia, or vertebral fracture.

(3) An individual receiving (or expecting to receive) glucocorticoid (steroid) therapy equivalent to an average of 5.0 mg of prednisone, or greater, per day for more than 3 months.

(4) An individual with primary

hyperparathyroidism.

(5) An individual being monitored to assess the response to or efficacy of an

FDA-approved osteoporosis drug therapy.

(e) Denial as not reasonable and necessary. If CMS determines that a bone mass measurement does not meet the conditions for coverage in paragraphs (b) or (d) of this section, or the standards on frequency of coverage in paragraph (c) of this section, it is excluded from Medicare coverage as not "reasonable" and "necessary" under section 1862(a)(1)(A) of the Act and § 411.15(k) of this chapter.

(f) Use of the National Coverage Determination Process. For the purposes of paragraphs (b)(2) and (b)(3) of this section, CMS may determine through the National Coverage Determination process that additional bone mass measurement systems are reasonable and necessary under section 1862(a)(1) of the Act for monitoring and confirming baseline bone mass measurements.

9. Section 410.33 is amended by—

A. Revising paragraph (b)(1).

B. Revising paragraph (e).

C. Adding paragraphs (g), (h), and (i). The revision and additions read as follows:

§ 410.33 Independent diagnostic testing facility.

- (b) Supervising physician. (1) Each supervising physician must be limited to providing supervision to no more than three (3) IDTF sites. The IDTF supervising physician is responsible for the overall operation and administration of the IDTFs, including the employment of personnel who are competent to perform test procedures, record and report test results promptly, accurately and proficiently, and for assuring compliance with the applicable regulations.
- (e) Multi-State entities. (1) An IDTF that operates across State boundaries must-
- (i) Maintain documentation that its supervising physicians and technicians are licensed and certified in each of the States in which it operates; and
- (ii) Operate in compliance with all applicable Federal, State, and local licensure and regulatory requirements with regard to the health and safety of patients.
- (2) The point of the actual delivery of services is the Place of Service on the claim form. When an IDTF performs a diagnostic test at the beneficiary's residence, the beneficiary's residence is the Place of Service.

- (g) Application certification standards. The IDTF must certify in its enrollment application that it meets the following standards:
- (1) Operate its business in compliance with all applicable Federal and State licensure and regulatory requirements.
- (2) Provide complete and accurate information on their enrollment application. Any change in enrollment information must be reported to the designated fee-for-service contractor on the Medicare enrollment application within 30 calendar days of the change.
- (3) Maintain a physical facility on an appropriate site. For the purposes of this standard, a post office box or commercial mail box is not considered a physical facility. The physical facility must contain space for equipment appropriate to the services designated on the enrollment application, facilities for hand washing, adequate patient privacy accommodations, and the storage of both business records and current medical records.
- (4) Have all applicable testing equipment available at the physical site excluding portable equipment. A catalog of portable equipment, including equipment serial numbers, must be maintained at the physical site. In addition, portable equipment must be available for inspection within two business days of a CMS inspection request. The IDTF must maintain a current inventory of the equipment, including serial and registration numbers, provide this information to the designated fee-for-service contractor upon request, and notify the contractor of any changes in equipment within 90

(5) Maintain a primary business phone under the name of the designated business. The business phone must be located at the designated site of the business. The telephone number or toll free numbers must be available in a local directory and through directory assistance.

(6) Have a comprehensive liability insurance policy of at least \$300,000 or 20 percent of its average annual Medicare billings, whichever amount is greater, that covers both the place of business and all customers and employees of the IDTF. The policy must be carried by a non-relative owned company and list the serial numbers of any and all equipment used by the

(7) Agree not to directly solicit patients through any means including, but not limited to, a prohibition on telephone, computer, or in-person contacts. The IDTF must accept only those patients referred for diagnostic testing by an attending physician, who

- is furnishing a consultation or treating a beneficiary for a specific medical problem and who uses the results in the management of the beneficiary's specific medical problem. Nonphysician practictioners may order tests as set forth in § 410.32(a)(3).
- (8) Answer beneficiaries' questions and respond to their complaints. Documentation of those contacts must be maintained at the physical site.

(9) Openly post these standards for review by patients and the public.

(10) Disclose to the government any person having ownership, financial, or control interest or any other legal interest in the supplier.

(11) Have its testing equipment calibrated per equipment instructions and in compliance with applicable

national standards.

(12) Have technical staff on duty with the appropriate credentials to perform tests. The IDTF must be able to produce the applicable Federal or State licenses or certifications of the individuals performing these services.

(13) Have proper medical record storage and be able to retrieve medical records upon request from CMS or its fee-for-service contractor within 2 business days.

- (14) Permit CMS, including its agents, or its designated fee-for-service contractors, to conduct unannounced, on-site inspections to confirm the IDTF's compliance with these standards. The IDTF must be accessible during regular business hours to CMS and beneficiaries and must maintain a visible sign posting the normal business hours of the IDTF.
- (h) Failure to meet standards. If an IDTF fails to meet one or more of the standards in paragraph (g) of this section at the time of enrollment, its enrollment will be denied. CMS will revoke a supplier's billing privileges if and IDTF is found not to meet the standards in paragraph (g) or (b)(1) of this section.

(i) Definition. For purposes of this section, the following definition applies:

Point of actual delivery of service. The point of the actual delivery of service means the Place of Service on the claim form. When an IDTF performs a diagnostic test at the beneficiary's residence, the beneficiary's residence is the Place of Service.

Subpart I—Payment of SMI Benefits

10. Section 410.160 is amended by adding paragraphs (b)(7) and (b)(8) to read as follows:

§ 410.160 Part B annual deductible.

(b) * * *

- (7) Beginning January 1, 2007, colorectal cancer screening tests as described in § 410.37.
- (8) Beginning January 1, 2007, ultrasound screening for abdominal aortic aneurysms described in § 410.19.

PART 411—EXCLUSIONS FROM MEDICARE AND LIMITATIONS ON MEDICARE PAYMENT

11. The authority citation for part 411 is amended to read as follows:

Authority: Secs. 1102, 1860D–1 through 1860D–42, 1871, and 1877 of the Social Security Act (42 U.S.C. 1302, 1395w–101 through 1395w–152, 1395hh, and 1395nn).

Subpart A—General Exclusions and Exclusion of Particular Services

- 12. Section 411.15 is amended by—
- A. Revising paragraph (a)(1).
- B. Adding a new paragraph (k)(12).
- C. Revising paragraph (o).
- The revisions and addition read as follows:

§ 411.15 Particular services excluded from coverage.

* * * * * * (a) * * *

- (1) Examinations performed for a purpose other than treatment or diagnosis of a specific illness, symptoms, complaint, or injury, except for screening mammography, colorectal cancer screening tests, screening pelvic exams, prostate cancer screening tests,
- exams, prostate cancer screening tests, glaucoma screening exams, initial preventive physical examinations, or ultrasound screening for abdominal aortic aneurysms that meet the criteria specified in paragraphs (k)(6) through

(k)(12) of this section.

* * * * * *

(k) * * *

- (12) In the case of ultrasound screening for abdominal aortic aneurysms, with the goal of early detection of abdominal aortic aneurysms, subject to the conditions and limitation specified in § 410.19 of this chapter.
- (o) Experimental or investigational devices, except for certain devices—
- (1) Categorized by the FDA as a Category A or B device defined in § 405.201(b) of this chapter; and
- (2) Furnished in accordance with the CMS clinical research policy.

Subpart J—Financial Relationships Between Physicians and Entities Furnishing Designated Health Services

13. Section 411.351 is amended by-

A. Revising the definition "Centralized building".

B. Revising the definition "Physician in the group practice".

The revisions read as follows:

§ 411.351 Definitions.

* * * * *

Centralized building means all or part of a building, including, for purposes of this subpart only, a mobile vehicle, van, or trailer that is owned or leased on a full-time basis (that is, 24 hours per day, 7 days per week, for a term of not less than 6 months) by a group practice and that is used exclusively by the group practice. Space in a building or a mobile vehicle, van, or trailer that is shared by more than one group practice, by a group practice and one or more solo practitioners, or by a group practice and another provider or supplier (for example, a diagnostic imaging facility) is not a centralized building for purposes of this subpart. This definition does not preclude a group practice from providing services to other providers or suppliers (for example, purchased diagnostic tests) in the group practice's centralized building. A group practice may have more than one centralized building. A centralized building does not include space that is owned or leased by a group practice if that space is less than 350 square feet. This limitation does not apply to space owned or rented in a building where no more than three group practices own or lease space in the "same building" (as defined in this section) and share the same "physician in the group practice" (as defined in this section). A centralized building does not include space owned or leased by a group practice if equipment needed to perform substantially all (at least 90 percent) of the designated health services furnished in that space in any given calendar year is not permanently located in that space. That is, equipment needed to perform more than 10 percent of the designated health services furnished in that space in a calendar year cannot be temporarily moved into that space from another space in the "same building" or from outside the "same building" (as defined in this section).

Physician in the group practice means a member of the group practice, as well as an independent contractor physician during the time the independent contractor is furnishing patient care services (as defined in this section) for the group practice under a contractual arrangement with the group practice to provide services to the group practice's patients in the group practice's facilities. The contract must contain the

same restrictions on compensation that apply to members of the group practice under § 411.352(g) (or the contract must fit in the personal services exception in § 411.357(d)), and the independent contractor's arrangement with the group practice and must comply with the reassignment rules at § 424.80(d)(3) of this chapter or section 30.2.9.1 of the CMS Internet-only manual, publication 100-04, Claims Processing Manual, chapter 1 on general billing requirements (as amended or replaced from time to time). Referrals from an independent contractor who is a physician in the group practice are subject to the prohibition on referrals in § 411.353(a), and the group practice is subject to the limitation on billing for those referrals in § 411.353(b).

PART 414—PAYMENT FOR PART B MEDICAL AND OTHER HEALTH SERVICES

14. The authority citation for part 414 continues to read as follows:

Authority: Secs. 1102, 1871, and 1881(b)(1) of the Social Security Act (42 U.S.C. 1302, 1395hh, and 1395rr(b)(1).

15. A new subpart F is added as follows:

Subpart F—Payment for New Clinical Diagnostic Laboratory Tests

Sec.

414.400 Basis and scope.

414.402 Definitions.

414.404 [Reserved]

- 414.406 Procedures for public consultation for payment for a new clinical diagnostic laboratory test.
- 414.408 Payment for a new clinical diagnostic laboratory test.
- 414.410 Clinical Diagnostic Laboratory Date of Service for Specimens

Subpart F—Payment for New Clinical Diagnostic Laboratory Tests

§ 414.400 Basis and scope.

This subpart implements provisions of 1833(h)(8) of the Act procedures for determining the basis for, and amount of, payment for a new clinical diagnostic laboratory test with respect to which a new or substantially revised Healthcare Common Procedure Coding System code is assigned on or after January 1, 2005.

§414.402 Definitions.

For purposes of this subpart— Substantially Revised Healthcare Common Procedure Coding System Code means a code for which there has been a substantive change to the definition of the test or procedure to which the code applies (such as a new analyte or a new methodology for measuring an existing analyte specific test).

§414.404 [Reserved]

§ 414.406 Procedures for public consultation for payment for a new clinical diagnostic laboratory test.

For a new clinical diagnostic laboratory test that is assigned a new or substantially revised code on or after January 1, 2005, CMS determines the payment after the performance of the following:

- (a) CMS makes available to the public (through an Internet Web site and other appropriate mechanisms) a list that includes codes for which establishment of a payment amount is being considered for the next calendar year.
- (b) CMS publishes a **Federal Register** notice of a meeting to receive public comments and recommendations (and data on which recommendations are based) on the appropriate basis, as specified in § 414.408, for establishing payment amounts for the list of codes made available to the public.
- (c) Not fewer than 30 days after publication of the notice in the **Federal Register**, CMS convenes a meeting that includes representatives of CMS officials involved in determining payment amounts, to receive public comments and recommendations (and data on which the recommendations are based).
- (d) Taking into account the comments and recommendations (and accompanying data) received at the public meeting, CMS develops and makes available to the public (through an Internet Web site and other appropriate mechanisms)—
- (1) A list of proposed determinations with respect to the appropriate basis for establishing a payment amount for each code, with an explanation of the reasons for each determination, the data on which the determinations are based, and a request for public written comments within a specified time period on the proposed determination; and
- (2) A list of final determinations of the payment amounts for tests, with the rationale for each determination, the data on which the determinations are based, and responses to comments and suggestions from the public.

§ 414.408 Payment for a new clinical diagnostic laboratory test.

For a new clinical diagnostic laboratory test that is assigned a new or substantially revised code on or after January 1, 2005, CMS determines the payment amount based on either of the following:

- (a) Crosswalking. Crosswalking is used if it is determined that a new test is comparable to an existing test, multiple existing test codes, or a portion of an existing test code.
- (1) CMS assigns to the new test code, the local fee schedule amounts and national limitation amount of the existing test.
- (2) Payment for the new test code is made at the lesser of the local fee schedule amount or the national limitation amount.

(b) *Gapfilling*. Gapfilling is used when no comparable existing test is available.

- (1) Carrier-specific amounts are established for the new test code for the first year using the following sources of information to determine gapfill amounts, if available:
- (i) Charges for the test and routine discounts to charges;
- (ii) Resources required to perform the test;
- (iii) Payment amounts determined by other payers; and
- (iv) Charges, payment amounts, and resources required for other tests that may be comparable or otherwise relevant.
- (2) In the second year, the test code is paid at the national limitation amount, which is the median of the carrier-specific amounts.

§ 414.410 Clinical Diagnostic Laboratory Date of Service for Specimens.

The date of service for a laboratory test is as follows:

(a) Except as provided under paragraph (b) of this section, the date of service of the test shall be the date the specimen was collected.

(b)(1) If a specimen is collected over a period that spans two calendar days, then the date of service shall be the date the collection ended.

(2) If a specimen was stored for more than 30 calendar days before testing (otherwise known as "an archived specimen"), the date of service of the test shall be the date the specimen was obtained from storage.

(3) If a specimen was stored for less than or equal to 30 calendar days from the date it was collected, the date of service of the test must be the date the specimen was obtained from storage if—

(i) The test is ordered by the patient's physician at least 14 days following the date of the patient's discharge from the hospital.

(ii) The test could not reasonably have been ordered while the patient was hospitalized.

(iii) The procedure performed while the beneficiary is a patient of the hospital is for purposes other than collection of the specimen needed for the test. (iv) The test is reasonable and medically necessary.

Subpart J—Submission of Manufacturer's Average Sales Price Data

16. Section 414.802 is amended by adding the definition of "Bona fide service fees" in alphabetical order to read as follows:

§ 414.802 Definitions.

* * * * *

Bona fide service fees means fees paid by a manufacturer to an entity, that represent fair market value for a bona fide, itemized service actually performed on behalf of the manufacturer that the manufacturer would otherwise perform (or contract for) in the absence of the service arrangement, and that are not passed on in whole or in part to a client or customer of an entity, whether or not the entity takes title to the drug.

17. Section 414.804 is amended by revising paragraphs (a)(1), (a)(2), (a)(3), and (a)(4).

The revisions read as follows:

§ 414.804 Basis of Payment.

(a) * *

- (1) The manufacturer's average sales price for a quarter for a drug represented by a particular 11-digit National Drug Code must be calculated as the manufacturer's sales to all purchasers in the United States for that particular 11digit National Drug Code (after excluding sales as specified in paragraph (a)(4) of this section and then deducting price concessions as specified in paragraphs (a)(2) and (a)(3) of this section) divided by the total number of units sold by the manufacturer in that quarter (after excluding units associated with sales as specified in paragraph (a)(4) of this section).
- (2) Price concessions. (i) In calculating the manufacturer's average sales price, a manufacturer must deduct price concessions. Price concessions include the following types of transactions and items:
 - (A) Volume discounts.
 - (B) Prompt pay discounts.
 - (C) Cash discounts.
- (D) Free goods that are contingent on any purchase requirement.
- (E) Chargebacks and rebates (other than rebates under the Medicaid program).
- (ii) For the purposes of paragraph (a)(2)(i), bona fide services fees are not considered price concessions.
- (3) To the extent that data on price concessions, as described in paragraph (a)(2) of this section, are available on a

lagged basis, the manufacturer must estimate this amount in accordance with the methodology described in this

paragraph.

(i)(A) For each National Drug Code with at least 12 months of sales (including products for which the manufacturer has redesignated the National Drug Code for the specific product and package size and has 12 months of sales across the prior and current National Drug Codes), after adjusting for exempted sales, the manufacturer calculates a percentage equal to the sum of the price concessions for the most recent 12month period available associated with sales subject to the average sales price reporting requirement divided by the total in dollars for the sales subject to the average sales price reporting requirement for the same 12-month period.

(B) For each National Drug Code with less than 12 months of sales, the calculation described in paragraph (i)(A) of this section is performed for the time period equaling the total number of

months of sales.

(ii) The manufacturer multiplies the applicable percentage described in paragraph (a)(3)(i)(A) or (a)(3)(i)(B) of this section by the total in dollars for the sales subject to the average sales price reporting requirement (after adjusting for exempted sales) for the quarter being submitted. (The manufacturer must carry a sufficient number of decimal places in the calculation of the price concessions percentage in order to round accurately the net total sales amount for the quarter to the nearest whole dollar.) The result of this multiplication is then subtracted from the total in dollars for the sales subject to the average sales price reporting requirement (after adjusting for exempted sales) for the quarter being submitted.

(iii) The manufacturer uses the result of the calculation described in paragraph (a)(3)(ii) of this section as the numerator and the number of units sold in the quarter (after adjusting for exempted sales) as the denominator to calculate the manufacturer's average sales price for the National Drug Code for the quarter being submitted.

(iv) Example. After adjusting for exempted sales, the total lagged price concessions (discounts, rebates, etc.) over the most recent 12-month period available associated with sales for National Drug Code 12345-6789-01 subject to the ASP reporting requirement equal \$200,000, and the total in dollars for the sales subject to the average sales price reporting requirement for the same period equals

\$600,000. The lagged price concessions percentage for this period equals 200,000/600,000 = .33333. The total in dollars for the sales subject to the average sales price reporting requirement for the quarter being reported, after accounting for nonlagged price concessions, equals \$50,000 for 10,000 units sold. The manufacturer's average sales price calculation for this National Drug Code for this quarter is: \$50,000 - (0.33333) $\times 50,000$ = \$33,334 (net total sales amount); \$33,334/10,000 = \$3.33(average sales price).

(4) Exempted sales. (i) In calculating the manufacturer's average sales price, a manufacturer must exclude sales that are exempt from the Medicaid best price calculation under sections 1927(c)(1)(C)(i) and 1927(c)(1)(C)(ii)(III) of the Act as limited by section

1927(c)(1)(D) of the Act.

(ii) In determining nominal sales exempted under section 1927(c)(1)(C)(ii)(III) of the Act, the manufacturer calculates the average manufacturer price as defined in section 1927(k) of the Act and then identifies sales that are eligible to be considered a nominal sale under section 1927(c)(1)(D) of the Act and are at less than 10 percent of the average manufacturer price. To identify nominal sales, the manufacturer must use the average manufacturer price for the calendar quarter that is the same calendar quarter as the average sales price reporting period.

(iii) For exempted sales under section 1927(c)(1)(C)(i) of the Act known on a lagged basis because of chargebacks or rebates, manufacturers must estimate such lagged exempted sales using the ratio methodology specified in this paragraph to exclude lagged exempted sales before accounting for price concessions as specified in paragraphs

(a)(2) and (a)(3) of this section.

(A) For each National Drug Code with at least 12 months of sales (including products for which the manufacturer has redesignated the Nation Drug Code and has 12 months of sales across the prior and current National Drug Codes), the manufacturer calculates a percentage using the sum of lagged exempted sales (in units) for the most recent 12 month period available as the numerator and the sales (the number of units after non-lagged exempted sales have been subtracted from total sales) for the same 12 month period as the denominator. The result is a rolling average percentage estimate of lagged exempted sales that is applied to the sales (the number of units after nonlagged exempted sales have been subtracted from total sales) for the

quarter being submitted. The product that results from the multiplication of the rolling average percentage estimate of lagged exempted sales and the sales for the quarter determines the estimated lagged exempted sales in units to subtract from the denominator of the average sales price calculation. Manufacturers must make a corresponding adjustment to the numerator of the average sales price calculation to ensure that the total in dollars for the reporting quarter does not include revenue related to lagged exempted sales removed from the denominator using the estimation methodology.

- (B) For National Drug Codes with less than 12 months of sales, the calculation described in paragraph (4)(iii)(A) of this section is calculated based on the sales and exempted sales (lagged and nonlagged) for the period equaling the total number of months of sales.
- (C) Manufacturers must exclude lagged exempted sales (as calculated using the ratio methodology in paragraph (a)(4)(iii)(A) of this section) from their estimates of lagged price concessions described in paragraph (a)(3) of this section.

Subpart K—Payment for Drugs and **Biologicals Under Part B**

18. Section 414.904 is amended by revising paragraphs (d)(2)(iii) and (d)(3) to read as follows:

§ 414.904 Average sales price as the basis for payment.

(d) * * *

(2) * * *

- (iii) Effective for drugs and biologicals furnished in CY 2006 and subsequent calendar years, the payment for such drugs and biologicals furnished in connection with renal dialysis services and separately billed by freestanding and hospital-based renal dialysis facilities not paid on a cost basis is 106 percent of the average sales price.
- (3) Widely available market price and average manufacturer price. If the Inspector General finds that the average sales price exceeds the widely available market price or the average manufacturer price by 5 percent or more in CY 2007, the payment limit in the quarter following the transmittal of this information to the Secretary is the lesser of the widely available market price or 103 percent of the average manufacturer price.

PART 415—SERVICES FURNISHED BY PHYSICIANS IN PROVIDERS, SUPERVISING PHYSICIANS IN TEACHING SETTINGS, AND RESIDENTS IN CERTAIN SETTINGS

19. The authority citation for part 415 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

Subpart C—Part B Carrier Payments for Physician Services to Beneficiaries in Providers

20. Section 415.130 is amended by revising paragraph (d) to read as follows:

§ 415.130 Conditions for payment: Physician pathology services.

* * * * *

(d) Physician pathology services furnished by an independent laboratory. The technical component of physician pathology services furnished by an independent laboratory to a hospital inpatient or outpatient on or before December 31, 2006 may be paid to the laboratory by the carrier under the physician fee schedule if the Medicare beneficiary is a patient of a covered hospital as defined in paragraph (a)(1) of this section. For services furnished after December 31, 2006, an independent laboratory may not bill the carrier for physician pathology services furnished to a hospital inpatient or outpatient.

PART 424—CONDITIONS FOR MEDICARE PAYMENT

21. The authority citation for part 424 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

Subpart B—Certification and Plan of Treatment Requirements

- 22. Section 424.24 is amended by—
- A. Redesignating paragraph (f) as paragraph (g).
 - B. Adding a new paragraph (f). The addition reads as follows:

§ 424.24 Requirements for medical and other health services furnished by providers under Medicare Part B.

* * * * *

(f) Blood glucose monitoring in skilled nursing facilities. For each blood glucose test furnished to a resident of a skilled nursing facility, the physician must certify that the test is medically necessary. A physician's standing order

is not sufficient to order a series of blood glucose tests.

* * * * *

Subpart F—Limitations on Assignment and Reassignment of Claims

- 23. Section 424.80 is amended by—
- A. Revising the heading of paragraph (d).
 - B. Revising paragraph (d)(2)
 - C. Adding a new paragraph (d)(3).

The revisions and addition read as follows:

§ 424.80 Prohibition of reassignment of claims by suppliers.

(d) Pagasian mant to as

(d) Reassignment to an entity under an employer-employee relationship or under a contractual arrangement: Conditions and limitations. (1) * * *

- (2) Access to records. The supplier who furnishes the service has unrestricted access to claims submitted by an entity for services provided by that supplier. This paragraph applies irrespective of whether the supplier is an employee or whether the service is provided under a contractual arrangement. If an entity refuses to provide, upon request, the billing information to the supplier performing the service, the entity's right to receive reassigned benefits may be revoked under § 424.82(c)(3).
- (3) Contractual arrangements for provision of diagnostic test services. If a physician or medical group bills for the technical component of a diagnostic test covered under section 1861(s)(3) of the Act and paid for under part 414 of this chapter (other than clinical diagnostic laboratory tests paid under section 1833(a)(2)(D) of the Act, which are subject to the special rules set forth in section 1833(h)(5)(A) of the Act), following a reassignment involving a contractual arrangement with the physician or other supplier who performed the technical component, each of the following conditions must be met:
- (i) The payment to the billing physician, or medical group, less the applicable deductibles and coinsurance, may not exceed the lowest of the following amounts:
- (A) The physician or other supplier's net charge to the billing physician or medical group.
- (B) The billing physician's or medical group's actual charge.
- (C) The fee schedule amount for the service that would be allowed if the physician or other supplier billed directly.
- (ii) The physician or medical group billing for the test must identify the

physician or other supplier that performed the test and indicate the supplier's net charge for the test. If the physician or medical group billing for the test fails to provide this information, CMS will not make any payment to the physician or medical group billing for the test and the billing physician or medical group can not bill the beneficiary.

(iii) In order to bill for the technical component of the service, the physician or medical group must directly perform the professional component of the service.

(Catalog of Federal Domestic Assistance Program No. 93.774, Medicare— Supplementary Medical Insurance Program)

Dated: June 29, 2006.

Mark B. McClellan,

Administrator, Centers for Medicare & Medicaid Services.

Approved: August 3, 2006.

Michael O. Leavitt,

Secretary.

Note: These addenda will not appear in the Code of Federal Regulations.

Addendum A: Explanation and Use of Addenda B

The addenda on the following pages provide various data pertaining to the Medicare fee schedule for physicians' services furnished in 2007. Addendum B contains the RVUs for work, nonfacility PE, facility PE, and malpractice expense, and other information for all services included in the PFS.

In previous years, we have listed many services in Addendum B that are not paid under the PFS. To avoid publishing as many pages of codes for these services, we are not including clinical laboratory codes or the alphanumeric codes (Healthcare Common Procedure Coding System (HCPCS) codes not included in CPT) not paid under the PFS in Addendum B.

Addendum B—2007 Relative Value Units and Related Information Used in Determining Medicare Payments for 2007

This addendum contains the following information for each CPT code and alphanumeric HCPCS code, except for: alphanumeric codes beginning with B (enteral and parenteral therapy), E (durable medical equipment), K (temporary stcodes for nonphysicians' services or items), or L (orthotics); and codes for anesthesiology. Please also note the following:

• An "NA" in the "Non-facility PE RVUs" column of Addendum B means that CMS has not developed a PE RVU in the non-facility setting for the service because it is typically performed in the hospital (for example, an open heart surgery is generally performed in the hospital setting and not a physician's office). If there is an "NA" in the non-facility PE RVU column, and the contractor determines that this service can be performed in the non-facility setting, the service will be paid at the facility PE RVU rate.

• Services that have an "NA" in the "Facility PE RVUs" column of Addendum B are typically not paid using the PFS when provided in a facility setting. These services (which include "incident to" services and the technical portion of diagnostic tests) are generally paid under either the outpatient hospital prospective payment system or bundled into the hospital inpatient prospective payment system payment.

1. CPT/HCPCS code. This is the CPT or alphanumeric HCPCS number for the service. Alphanumeric HCPCS codes are included at the end of this addendum.

2. Modifier. A modifier is shown if there is a technical component (modifier TC) and a professional component (PC) (modifier –26) for the service. If there is a PC and a TC for the service, Addendum B contains three entries for the code. A code for: the global values (both professional and technical); modifier –26 (PC); and, modifier TC. The global service is not designated by a modifier, and physicians must bill using the code without a modifier if the physician furnishes both the PC and the TC of the service.

Modifier-53 is shown for a discontinued procedure, for example, a colonoscopy that is not completed. There will be RVUs for a code with this modifier.

3. Status indicator. This indicator shows whether the CPT/HCPCS code is in the PFS and whether it is separately payable if the service is covered.

Å = Active code. These codes are separately payable under the PFS if covered. There will be RVUs for codes with this status. The presence of an "A" indicator does not mean that Medicare has made a national coverage determination regarding the service. Carriers remain responsible for coverage decisions in the absence of a national Medicare policy.

B = Bundled code. Payments for covered services are always bundled into payment for other services not specified. If RVUs are shown, they are not used for Medicare payment. If these services are covered, payment for them is subsumed by the payment for the services to which they are incident (an example is a telephone call from a

hospital nurse regarding care of a patient).

C = Carriers price the code. Carriers will establish RVUs and payment amounts for these services, generally on an individual case basis following review of documentation, such as an operative report.

 $D^* = Deleted/discontinued code.$

E = Excluded from the PFS by regulation. These codes are for items and services that CMS chose to exclude from the fee schedule payment by regulation. No RVUs are shown, and no payment may be made under the PFS for these codes. Payment for them, when covered, continues under reasonable charge procedures.

F = Deleted/discontinued codes. (Code not subject to a 90-day grace period.) These codes are deleted effective with the beginning of the year and are never subject to a grace period. This indicator is no longer effective beginning with the 2005 fee schedule as of January 1, 2005.

G = Code not valid for Medicare purposes. Medicare uses another code for reporting of, and payment for, these services. (Codes subject to a 90-day grace period.) This indicator is no longer effective with the 2005 PFS as of January 1, 2005.

 H^* = Deleted modifier. For 2000 and later years, either the TC or PC component shown for the code has been deleted and the deleted component is shown in the database with the H status indicator.

I = Not valid for Medicare purposes. Medicare uses another code for the reporting of, and the payment for these services. (Codes not subject to a 90-day grace period.)

L = Local codes. Carriers will apply this status to all local codes in effect on January 1, 1998 or subsequently approved by central office for use. Carriers will complete the RVUs and payment amounts for these codes.

M = Measurement codes, used for reporting purposes only. There are no RVUs and no payment amounts for these codes. Medicare uses them to aid with performance measurement. No separate payment is made. These codes should be billed with a zero ((\$0.00) charge and are denied) on the MPFSDB.

N = Non-covered service. These codes are noncovered services. Medicare payment may not be made for these codes. If RVUs are shown, they are not used for Medicare payment.

R = Restricted coverage. Special coverage instructions apply. If the service is covered and no RVUs are shown, it is carrier-priced.

T = There are RVUs for these services, but they are only paid if there are no other services payable under the PFS billed on the same date by the same provider. If any other services payable under the PFS are billed on the same date by the same provider, these services are bundled into the service(s) for which payment is made.

X = Statutory exclusion. These codes represent an item or service that is not within the statutory definition of "physicians' services" for PFS payment purposes. No RVUs are shown for these codes, and no payment may be made under the PFS. (Examples are ambulance services and clinical diagnostic laboratory services.)

4. Description of code. This is an abbreviated version of the narrative description of the code.

5. Physician work RVUs. These are the RVUs for the physician work for this service in 2007. As stated in the June 29, 2006 proposed notice, the RVUs for codes with a 10- or 90-day global period reflect the application of the RUC-recommended values for the E/M services that are included as part of the global period for the service.

Note: The separate budget neutrality adjustor is *not* reflected in these physician work RVUs.

- 6. Fully implemented non-facility practice expense RVUs. These are the fully implemented resource-based PE RVUs for non-facility settings.
- 7. Transitional Non-facility practice expense RVUs. These are the 2007 resource-based PE RVUs for non-facility settings.
- 8. Fully implemented facility practice expense RVUs. These are the fully implemented resource-based PE RVUs for facility settings.
- 9. Transitional facility practice expense RVUs. These are the 2007 resource-based PE RVUs for facility settings.
- 10. Malpractice expense RVUs. These are the RVUs for the malpractice expense for the service for 2006.
- 11. *Non-facility total*. This is the sum of the work, fully implemented nonfacility PE, and malpractice expense RVUs.
- 12. Transitional non-facility total. This is the sum of the work, 2007 transitional non-facility PE, and malpractice expense RVUs.
- 13. Facility total. This is the sum of the work, fully implemented facility PE, and malpractice expense RVUs.
- 14. Transitional facility total. This is the sum of the work, 2007 transitional facility PE, and malpractice expense RVUs.
- 15. Global period. This indicator shows the number of days in the global period for the code (0, 10, or 90 days).

An explanation of the alpha codes follows:

MMM = Code describes a service furnished in uncomplicated maternity cases including antepartum care, delivery, and postpartum care. The usual global surgical concept does not apply. See the 1999 Physicians' Current Procedural Terminology for specific definitions.

XXX = The global concept does not

apply.

YYY = The global period is to be set by the carrier (for example, unlisted surgery codes).

ZZZ = Code related to another service that is always included in the global period of the other service. (Note: Physician work and PE are associated with intra service time and in some instances in the post service time.

*Codes with these indicators had a 90-day grace period before January 1, 2005.

Addendum B.—Relative Value Units (RVUS) and Related Information Used in Determining Medicare Payments For 2007

Global	*************************************
Year 2007 Transi- tional Fa- cility Total	88888888888888888888888888888888888888
Illy Im- ement- Facil- Total	8888888888888888888888888888888888888
Year 2007 Transi- pie tional lon-Fa- ity collity Total	0.0000000000000000000000000000000000000
Fully Implemented Non-Facility Total	0.000000000000000000000000000000000000
Mal-Practice RVUs	800000000000000000000000000000000000000
Year 2007 Transi- tional Fa- cility PE RVUs	80000000000000000000000000000000000000
Fully Important Pacific Forms of Pacific	88888888888888888888888888888888888888
Year 2007 Transi- tional Non-Fa- cility PE RVUs	0.0000000000000000000000000000000000000
Fully Implemented Non-Facility PE RVUs	0.0000000000000000000000000000000000000
Physician Work RVUs	888888888888888888888888888888888888888
Description	Cervicography
Mod Status	000000000000000000000000000000000000000
Mod	26 26 7C
CPT ¹ / HCPCS ²	0003T 0008T 0016T 0011T 0011T 0021T 0022T 0022T 0023T 0030T 0041T 0044T 0044T 0044T 0045T 0065T 0065T 0065T 0067T

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	
Year 2007 Transitional Facility Total	888888888888888888888888888888888888888
Fully Im- plement- ed Facil- ity Total	800000000000000000000000000000000000000
Year 2007 Transi- tional Non-Fa- cility Total	
Fully Implemented Non-Facility Total	
Mal-Practice RVUs	888888888888888888888888888888888888888
Year 2007 Transi- tional Fa- cility PE RVUs	888888888888888888888888888888888888888
Fully Im- plement- ed Facil- ity PE RVUs	888888888888888888888888888888888888888
Year 2007 2007 Transi- tional Non-Fa- cility PE RVUs	
Fully Implemented Non-Facility PE RVUs	
Physician plement- round Non-Facility PE RVUs PERVUS PERVUS FULIS IN DELEMBRING MEDICARE FATMENTS FOR PATMENTS FOR PATM	888888888888888888888888888888888888888
Description	Endovasc visc extnsn repr Endovasc sort repr rad s&i Endovasc sort repr rad s&i Endovasc visc extnsn s&i Stereotactic rad delivery Stereotactic rad delivery Stereotactic rad delivery Stereotactic rad delivery Lumpa prostate urethral stent Temp prostate urethral stent Temp prostate urethral stent Temp prostate urethral stent Temp prostate urethral stent Retigraphy testing, 3-day Cervical artific disc Lumbar artific disc Artific disc addl Cervical artific disc Artific discectomy addl Rev cervical artific disc Rev artific disc addl Rev artific disc addl Rev artific disc addl Rev cervical artific disc Rev artific disc addl Rev arti
l H	000000000000000000000000000000000000000
Mod St	28 28
CPT ¹ / HCPCS ²	000877 000817 000817 000817 00087 00087 00087 00097 00097 00097 01007 01107 01

***************************************	222 010 022 000 000 000 000 000 000
0.000000000000000000000000000000000000	0.62 0.43 0.75 0.93 0.93 1.69 1.69
0.00 0.00	0.62 0.74 0.74 0.74 1.57 1.57 1.67 0.94 0.94 0.04 0.04 0.04
0.00 0.00	0.78 1.89 1.58 1.58 1.59 1.64 1.64 1.64 1.65 1.65 1.65 1.65 1.65 1.65 1.65 1.65
0.000 0.0000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.	0.83 0.47 1.71 1.71 2.36 2.83 3.28 3.28 3.25 3.25
000000000000000000000000000000000000000	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
0.000 0.000	0.19 0.79 0.21 0.23 0.25 0.25 0.41 0.48
0.000000000000000000000000000000000000	0.19 0.20 0.27 0.37 0.25 0.20 0.20 0.30 0.30
0.00 0.00	0.35 0.16 0.16 1.20 1.20 1.68 1.38 1.38 1.38
0000 0000 0000 0000 0000 0000 0000 0000 0000	0.40 0.16 0.16 1.17 1.17 1.06 1.39 1.16 1.17
0.00 0.00	0.41 0.02 0.03 0.05 0.085 1.06 0.09 0.09 1.14
CCTA w/wo, quan calcium CCTA w/wo, strx CCTA w/wo, strx CCTA w/wo, strx CCTA w/wo, strx quan calc CCTA w/wo, disease strx CCTA	Biopsy, skin add-on Removal of skin tags Removes skin tags add-on Shave skin lesion
000000000000000000000000000000000000000	<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
26 26 70 26 70 70 70 70 70 70 70 70 70 70 70 70 70	
	11 00 00 11 12 22 23 33 33 33 43 74 75 75 75 75 75 75 75 75 75 75 75 75 75
01487 01487 01487 01487 01487 01497 01507 01507 01507 01507 01507 01507 01507 01507 01607 01	11101 11200 11201 11300 11302 11303 11305 11306

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Iued Global a- fal	1.58 0000 0000 0000 0000 0000 0000 0000 0
Year Year 2007 Transitional Facility Total	
Fully Implemented Facility Total	$\begin{array}{c}$
Year 2007 Transitional Non-Fa-cility Total	2.22.28.29.29.29.29.29.29.29.29.29.29.29.29.29.
Fully Implement-	21.2 20.2 20.2 20.2 20.2 20.2 20.2 20.2
Mal-Practice RVUs	0.000.000.000.000.000.000.000.000.000.
Year 2007 Transitional Facility PE RVUs	0.000 0.000
Fully Implemented Facility PE RVUs	0.000011111100011111000111100000000000
Year 2007 Transitional Non-Fa-cility PE RVUs	1. 1. 1. 1. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.
Fully Implemented Non-Facility PERVUS	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1
Physician plement- Transi- Work ed Non-Fa- RVUs PERVUS PERVUS FULLY IN- 2007 Fully Im- 2007 Fully Im- 2007 Image of Non-Fa- ity PE RVUs PERVUS FACILITY Non-Fa- ity PE RVUs RVUs FACILITY PERVUS FACILITY PER	0.1.1.0.1.1.0.8.0.1.1.0.8.4.8.4.9.4.8.4.1.0.9.9.8.8.4.1.9.9.8.8.4.1.9.9.8.8.4.1.9.9.8.8.4.1.9.9.8.8.4.1.9.9.8.8.4.1.9.9.8.8.4.1.9.9.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8
RELATIVE VALUE UNITS (HVUS) AND Description	Shave skin lesion Exc tr-ext b9+marg 0.5 < cm Exc tr-ext b9+marg 0.6-1 cm Exc tr-ext b9+marg 0.1-2 cm Exc tr-ext b9+marg 1.1-2 cm Exc tr-ext b9+marg 2.1-3 cm Exc tr-ext b9+marg 0.6-1 Exc h-f-nk-sp b9+marg 0.5 < cm Exc h-f-nk-sp b9+marg 0.1-2 Exc h-f-nk-sp b9+marg 2.1-3 Exc h-f-nk-sp b9+marg 2.1-3 Exc h-f-nk-sp b9+marg 2.1-3 Exc h-f-nk-sp b9+marg 2.1-3 cm Exc face-mm b9+marg 0.6-1 cm Exc face-mm b9+marg 0.1-2 cm Exc face-mm b9+marg 0.1-2 cm Exc face-mm b9+marg 0.1-2 cm Exc face-mm b9+marg 0.1-3 cm Exc face-mm b9+marg 0.5 < cm Exc face-mm b9+marg 0.5 < cm Exc face-mm b9+marg 0.5 < cm Exc face-mm h9+marg 0.5 < cm Exc face-mm h9+marg 0.5 < cm Exc tr-ext mig+marg 0.5 < cm Exc face-mm malig+marg 0.6-1 Exc face-mm malig+marg 0.1-2 Exc face-mm malig+marg 0.6-1 Exc face-mm malig+marg 0.6-1 Exc face-mm malig+marg 0.1-2 Exc face-mm malig+marg 0.1-2 Exc
	q
ADDENDUM B.	
ADDI CPT¹/ HCPCS²	11310 11311 11312 11400 11400 11400 11400 11420 11421 11421 11421 11421 11420 11440 11441 11441 11441 11441 11441 11441 11441 11600

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2	4 4 4 4 6 6 9 9 4 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9
4 + + + + + + + + + + + + + + + + + + +	7.6.4.0.0.9.6.4.0.0.8.4.4.4.0.0.9.7.7.4.0.0.8.8.8.8.8.8.9.7.6.4.4.6.0.9.7.7.4.0.0.8.8.8.8.8.8.8.9.7.8.8.8.8.8.8.8.8.8.8.8
6.9.9.6.1. 4.6.7.6.7. 4.6.7.6.7. 4.	AN N S S S S S S S S S S S S S S S S S S
6.8.6.7.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4	2.4.4.2.2.4.4.4.2.2.4.4.2.2.4.4.4.2.2.4.4.4.2.2.4.4.4.2.2.4.4.4.2.2.4.4.4.2.2.4.4.4.4.2.2.4
0.000000000000000000000000000000000000	2.000000000000000000000000000000000000
2.00.1.2.2.0.0.0.1.1.0.0.0.0.0.0.0.0.0.0	2.00
6.20 6.20 6.20 6.20 6.20 6.20 6.20 6.20	2.00.1.1.0000.0000.0000.0000.0000.0000.
8 8 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	2. 4. 4. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6.
3.2.6.9 3.2.6.9 3.2.6.9 3.6.0.0.9 3.6.0.9 3.6.0.9 3.6.0.9 3.6.0.9 3.6.0.9 3.6.0.9 3.6.0.9 3.6.0.0.9 3.6.0.0.9 3.6.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.	2. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.
2.0.0.9 2.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0	- 7 7 8 8 4 - 1 7 8 8 4 7 7 7 7 8 8 7 7 7 8 8 7 7 8 8 7 7 8 8 8 7 8 8 8 8 7 8
Reconstruction of nail bed Excision of nail fold, toe Removal of pilonidal lesion Norrect skin color defects Correct skin color defects Correct skin color defects Therapy for contour defects Therapy for	Repair superficial wound(s) Layer closure of wound(s) Repair of wound or lesion
auil bed	Repair superficial wound(s) Layer closure of wound(s) Repair of wound or lesion
Reconstruction of nail bed Excision of nail fold, toe Removal of pilonidal lesion raped of pilonidal lesion singertion into skin lesions injection Dornect skin color defects Correct skin color defects Therapy for contour defect Therapy for contour defect Inserapy for contour defect Inserapy for contour defect Replace tissue expander (S) Remove tissue expander (S) Remove tissue expander (S) masert contraceptive cap Removal of contraceptive cap Removal of contraceptive cap Removal of contraceptive cap Removal fusion for the state of the	Repair superficial wound(s) Layer closure of wound(s) Repair of wound or lesion
Recond Excision Remov Remov Injection Correc Correc Correc Therap Therap Therap Therap Therap Therap Therap Therap Therap Therap Therap Therap Insert t Remov Insert t Remov R	Repair Repair Repair Repair Repair Repair Closurra Closurra Layer Layer Layer Layer Layer Layer Layer Layer Layer Layer Layer Layer Repair Repair Repair Repair Repair Repair
11765 11770 11770 11900 11920 11950 11951 11951 11970 11980 11980 11983 11983 11983 11983	

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Physician Phys		-				\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \			ָרָי . 		Vest Ve	1007		
2.19 1.82 1.70 0.94 1.01 0.03 4.19 4.07 4.89 4.89 4.89 4.89 4.10 0.03 4.19 4.07 4.84 5.31 3.13 0.31 0.01 0.04 1.01 0.04 4.60 4.56 6.32 1.98 1.94 0.08 1.10 0.24 4.60 4.56 6.75 8.73 0.04 1.01 0.24 4.60 4.56 7.56 8.73 0.04 1.01 0.24 4.60 4.56 7.56 8.73 0.04 1.01 0.24 4.60 4.56 7.56 8.73 0.04 1.01 0.24 4.00 4.56 7.56 8.94 8.94 8.95 0.05 1.84 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1	Status		Description	Physician Work RVUs	Fully Implemented Non-Facility PE RVUs	zooz Transi- tional Non-Fa- cility PE RVUs		Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Prac- tice RVUs	Fully Implemented Non-Facility Total	Year 2007 Transi- tional Non-Fa- cility Total	Fully Implemented Facility Total	Year 2007 Transi- tional Fa- cility Total	Global
4.44 5.35 4.54 3.17 3.13 0.31 10.10 9.89 6.32 7.31 6.35 3.77 1.10 0.24 4.60 4			Repair wound/lesion add-on		1.82	1.70	0.94	1.01	0.18	4.19	4.07	3.31	3.38	ZZZ
6.32 7.31 6.35 3.77 1.0 0.04 1400 1307 6.38 1.39 1.90 0.04 1400 0.04 1400 1307 6.78 8.78 1.94 1.04 1.04 1.04 1.04 1.05 9.52 10.29 9.78 7.04 7.14 1.54 1.04 1.04 1.04 1.78 9.79 8.91 7.04 6.57 0.08 1.124 1.04			Repair of wound or lesion		5.35	4.94	3.11	3.13	0.31	10.10	9.69	7.86	7.88	010
11.75			Repair of wound or lesion		7.31	6.35	3.77	3.97	0.40	14.03	13.07	10.49	10.69	010
6.76 6.76 6.76 6.76 6.76 16.40 16.41 16.43 16.44 16.4			Late closure of wound		2 N	Z Z	7.07	7.14	1.54	P Z	g ₹	20.37	20.44	060
9.52 9.73 9.74 7.75 0.82 2124 20.12 1.10 9.73 9.74 6.70 6.71 0.82 21.24 22.45 1.10 9.22 9.74 9.84 9.87 0.08 1.64 22.45 1.23 9.24 9.84 9.59 0.73 0.86 1.97 1.86 1.37 1.34 1.12.30 9.84 9.59 0.76 28.75 26.49 1.37 1.34 1.28 9.84 9.59 0.76 28.75 26.49 1.37 1.34 1.08 9.24 9.19 1.16 27.50 1.16 27.50 1.16 27.50 26.94 27.50 1.16 27.50 26.94 27.90 27.50 <td< td=""><td></td><td></td><td>Skin tissue rearrangement</td><td></td><td>8.78</td><td>8.08</td><td>5.92</td><td>5.58</td><td>0.59</td><td>16.13</td><td>15.43</td><td>13.27</td><td>12.93</td><td>060</td></td<>			Skin tissue rearrangement		8.78	8.08	5.92	5.58	0.59	16.13	15.43	13.27	12.93	060
1.10			Skin tissue rearrangement		0.90	9.78	7.40	7.15 6.57	0.82	18.01	20.12	17.74	17.49	060
18.36 9.92 9.08 6.77 7.09 0.62 18.90 18.06 18.59 9.40 8.94 9.59 6.77 7.09 0.62 18.90 18.06 18.58 9.44 19.30 9.84 7.31 0.68 26.45 26.45 18.59 9.40 9.84 7.31 0.68 10.7 26.45 26.45 10.73 NA NA 6.92 7.09 1.34 NA NA 10.73 1.08 1.73 0.68 1.07 1.66 26.49 1.09 1.73 26.49 1.09 1.74 1.70 22.89 1.06 1.09			Skin tissue rearrangement		12.13	10.52	8.40	8.31	0.8	24.04	22.43	20.31	20.22	060
1259 13,17 11,24 9,03 8,76 0,73 26,49 24,56 13,58 14,41 12,30 9,84 7,73 0,73 26,49 24,56 13,58 14,41 12,30 9,84 7,10 1,16 7,59 1,34 8,43 10,73 N,44 12,30 9,84 7,10 1,16 9,84 3,99 1,16 8,78 1,90 8,78 8,69 1,16 8,69 1,17 1,16 8,78 1,10 2,14 1,10 2,14 1,10 2,29 2,29 1,11 1,17 1,14 1,17 2,14 1,10 2,29			Skin tissue rearrangement		9.92	90.6	6.77	7.09	0.62	18.90	18.06	15.75	16.07	060
13.58 9.40 8.94 7.31 0.68 1907 1861 13.58 14.44 18.94 9.84 7.31 0.68 1907 1861 13.71 13.26 11.66 9.24 9.99 0.68 1.16 27.59 25.99 10.00 3.66 1.15 0.35 0.40 0.14 1.70 2.29 2.00 3.86 4.19 0.35 0.40 0.14 1.70 2.29 1.00 3.86 4.19 0.73 2.07 3.28 2.59 2.08 1.22 2.59 2.08 1.22 2.59 2.08 1.22 2.59 2.08 1.22 2.59 2.08 1.22 2.59 2.08 1.22 2.59 1.44 1.44 1.44 1.44 2.44 2.44 3.47 4.24 1.33 1.77 0.88 1.31 1.16 2.23 2.88 1.44 1.44 2.44 2.44 2.44 2.44 2.44 2.44			Skin tissue rearrangement		13.17	11.24	9.03	8.76	0.73	26.49	24.56	22.35	22.08	060
13.38 14.41 12.30 9.84 9.59 1.0 6.64 2.65 2.66 1.0			Skin tissue rearrangement		9.40	8.94	6.94	7.31	0.68	19.07	18.61	16.61	16.98	060
13.17 13.26 11.06 9.24 9.19 1.16 2.59 9.19 1.16 2.59 9.19 1.16 2.59 9.19 1.16 2.59 9.19 1.16 2.59 9.19 1.16 2.59 9.19 1.16 2.59 9.19 1.16 2.59 9.19 1.16 2.59 9.19 1.16 2.59 9.19 1.16 2.59 9.19 1.16 2.59 9.19 1.16 2.59 9.19 1.16 2.59 9.19 1.16 0.24 4.77 2.59 9.29 1.10 0.24 4.77 2.59 9.29 1.16 6.68 1.21 1.20 0.20 2.29 1.29			Skin tissue rearrangement		14.41	12.30	9.84	9.59	0.76	28.75	26.64	24.18	23.93	060
10.73 NA			Skin tissue rearrangement		13.26	11.66	9.24	9.19	1.16	27.59	25.99	23.57	23.52	060
2.00 3.89 1.73 2.00 0.24 0.74 2.00 3.86 1.73 0.35 0.40 0.54 0.74 0.43 2.00 3.86 1.39 1.03 1.11 0.24 6.10 6.63 9.66 9.84 11.09 6.73 7.55 1.28 20.78 2.236 1.85 0.89 1.023 6.50 6.88 1.31 21.05 22.36 1.85 0.89 1.19 0.64 0.75 1.18 20.78 2.236 1.18 0.12 0.49 0.64 0.75 1.16 22.36 22.36 2.50 1.22 1.49 0.64 0.75 1.16 2.34 2.14 2.23 2.67 1.18 1.14 0.39 1.06 0.33 4.05 2.236 2.67 1.18 1.23 1.71 0.36 6.20 2.06 1.14 1.76 2.236 2.68 1.12			Skin tissue rearrangement		A S	A C	6.92	7.09	45.0	NA 14	Z Z	18.99	9.16	060
2.00 3.86 4.39 1.03 1.11 0.24 6.10 6.23 2.00 3.86 4.39 1.03 1.11 0.24 4.47 5.28 1.082 3.84 1.023 6.50 6.88 1.31 12.96 5.28 1.082 3.89 1.023 6.50 6.88 1.31 21.05 22.36 1.13 9.16 9.21 0.89 1.06 0.24 4.47 5.39 1.13 9.16 9.21 0.89 1.06 0.33 3.00 3.20 2.50 1.28 0.79 0.58 0.16 0.30 3.00 3.22 2.28 1.31 1.70 0.36 4.05 2.28 1.24 2.14			Wound prep, 1st 100 sq cm		4.74	3.90	2.7. 2.8.0	70.0	4 5 5	4 70	8.43 00.0	0.70	0.00	227
5.29 7.68 7.10 5.02 5.09 1.35 1.26 1.26 1.27 1.35 1.28 1.29 1.28 1.29 1.28 1.29 1.28 1.29 1.28 1.29 1.28 1.29 1.28 1.29 1.28 1.29 1.28 1.29 1.28 1.29 1.28 1.29 1.28 1.29 1.28 1.29 1.28 1.29 1.28 1.29 1.28 1.29 1.28 1.29 1.28 1.29 1.28 1.29 1.29 1.29 1.29 1.29 1.29 <th< td=""><td></td><td></td><td>Harvest cultured skin craft</td><td></td><td>98.6</td><td>2 4</td><td>20.0</td><td>1.5</td><td>0.0</td><td>0.5</td><td>6.23</td><td>3.72</td><td>. c.</td><td>100</td></th<>			Harvest cultured skin craft		98.6	2 4	20.0	1.5	0.0	0.5	6.23	3.72	. c.	100
9.66 9.84 11.00 6.73 7.55 1.28 20.78 22.84 1.72 2.51 3.43 0.87 7.55 1.19 0.24 4.47 5.39 1.82 0.89 1.19 0.64 0.75 0.28 20.78 22.84 1.13 9.16 0.89 1.19 0.64 0.75 0.29 20.78 20.78 1.08 0.89 1.19 0.64 0.75 0.98 1.19 20.28 20.38 4.05 20.38 20.7			Skin pinch graft	20.1	7.65	7.53	. r.	- 60	0.57	13.51	12.96	10.88	10.95	060
1,72 2,51 3,43 0.87 1,10 0.24 4,47 5,39 1,082 8,89 1,102 6,68 1,31 21,06 22,36 1,082 8,91 1,12 6,68 7,18 0,33 3,00 1,13 9,16 9,21 6,68 7,78 0,33 2,14 21,49 2,50 1,12 1,49 0,89 7,06 0,33 2,14 21,49 2,67 3,47 4,24 1,33 1,77 0,38 6,50 7,27 2,67 3,47 4,24 1,33 1,71 0,38 6,50 7,22 1,50 0,68 0,68 0,64 0,20 0,21 2,44 2,149 1,50 0,68 0,68 0,68 0,64 0,53 0,64 0,20 1,70 1,50 0,68 0,68 0,68 0,64 0,53 0,64 0,21 2,44 1,76 2,50 1,09 <td< td=""><td></td><td></td><td>Skin solt arft. trnk/arm/lea</td><td>99.6</td><td>9.84</td><td>11.90</td><td>6.73</td><td>7.55</td><td>1.28</td><td>20.78</td><td>22.84</td><td>17.67</td><td>18.49</td><td>060</td></td<>			Skin solt arft. trnk/arm/lea	99.6	9.84	11.90	6.73	7.55	1.28	20.78	22.84	17.67	18.49	060
10.82 8.92 10.23 6.50 6.88 1.31 21.05 22.36 1.85 9.89 1.19 6.68 7.75 1.16 21.44 21.49 1.18 9.16 9.11 6.68 7.76 1.16 21.44 21.49 2.50 1.12 1.18 1.084 7.32 7.67 1.16 23.22 22.88 1.08 1.118 1.084 7.32 7.67 1.16 23.22 22.88 1.08 1.118 1.084 7.32 7.67 1.16 23.22 22.88 1.50 0.70 0.98 0.54 0.77 0.97 1.67 1.77 0.36 6.50 7.27 1.08 0.70 0.98 7.84 1.23 1.74 2.14 2.14 2.14 1.08 0.74 0.58 0.61 0.20 0.33 1.74 0.78 1.74 0.78 1.74 0.78 1.74 0.78 0.78 1.74			Skin splt grft t/a/l, add-on		2.51	3.43	0.87	1.10	0.24	4.47	5.39	2.83	3.06	777
1.85 0.89 1.19 0.64 0.75 0.26 3.00 3.30 1.13 2.16 9.21 6.68 7.18 1.15 21.44 21.49 1.0.8 1.12 1.49 0.89 1.06 0.33 4.05 22.88 1.0.8 1.118 1.084 7.32 7.67 1.16 23.22 22.88 2.67 3.47 4.24 1.33 1.71 0.36 6.50 7.27 1.08 9.41 0.52 0.64 0.20 2.38 2.54 1.50 0.06 0.52 0.64 0.20 2.38 2.54 1.50 0.06 0.63 0.64 0.20 2.38 2.54 1.50 0.06 0.63 0.64 0.20 2.38 2.54 1.50 0.06 0.64 0.20 2.38 2.54 1.77 2.00 0.90 1.21 2.47 2.182 2.24 2.38 2.54			Epidrm autogrft trnk/arm/leg		8.92	10.23	6.50	6.88	1.31	21.05	22.36	18.63	19.01	060
11.13 9.16 9.21 6.68 7.18 1.15 21.44 21.49 2.50 1.22 1.49 0.89 7.67 1.06 0.33 4.05 2.28 10.88 1.11 0.09 0.64 0.20 2.241 2.69 7.33 8.03 9.40 5.64 6.17 0.97 16.33 17.70 10.83 9.41 5.64 6.17 0.21 2.41 2.69 10.83 9.44 6.26 6.47 0.20 2.38 2.54 10.83 9.44 6.28 7.84 1.23 2.44 2.69 1.50 0.09 0.84 0.53 0.64 0.20 2.38 2.54 9.24 7.22 8.15 5.92 6.78 1.01 0.28 3.49 2.00 0.90 1.21 0.74 0.87 1.01 0.20 2.38 2.54 2.00 1.00 1.41 0.87 0.81 <			Epidrm autogrft t/a/l add-on		0.89	1.19	0.64	0.75	0.26	3.00	3.30	2.75	2.86	222
2.50 1.22 1.49 0.89 1.06 0.33 4.05 4.32 2.67 3.47 1.38 1.71 2.22.88 4.05 7.27 2.67 3.44 1.33 1.77 0.36 6.50 7.27 1.50 0.70 0.98 0.52 0.61 0.21 2.41 2.69 1.50 0.70 0.98 0.52 0.61 0.21 2.41 2.69 1.50 0.70 0.99 0.72 0.84 0.20 2.38 2.54 2.00 0.90 1.21 0.70 0.81 0.28 3.49 2.50 1.08 1.24 0.70 0.81 0.20 2.38 2.54 2.00 1.09 1.21 0.70 0.81 0.36 4.29 4.58 2.00 1.03 1.04 0.70 0.81 0.36 4.29 4.58 2.00 1.03 1.07 1.08 1.18 0.36 4.29			Epidrm a-grft face/nck/hf/g		9.16	9.21	89.9	7.18	1.15	21.44	21.49	18.96	19.46	060
10.88 11.18 10.84 7.32 7.67 1.16 23.22 22.88 7.33 8.07 0.98 0.52 0.51 0.27 1.23 1.77 0.36 6.50 7.27 1.50 0.70 0.98 0.52 0.64 0.20 2.44 2.69 1.50 0.68 0.84 0.53 0.64 0.20 2.38 2.54 2.20 0.90 1.21 0.70 0.81 1.76 1.85 2.50 1.08 0.63 0.64 0.20 2.38 2.54 2.00 1.09 1.21 0.70 0.81 1.05 1.86 4.29 2.00 1.08 1.24 0.87 1.01 0.28 3.49 4.29 2.50 1.37 1.67 1.07 1.28 0.36 4.29 4.58 2.00 1.37 1.67 1.07 1.28 0.39 4.76 5.06 2.75 1.14 0.			Epidrm a-grft f/n/hf/g addl		1.22	1.49	0.89	1.06	0.33	4.05	4.32	3.72	3.89	777
2.67 3.47 4.24 1.33 1.71 0.36 6.50 7.27 7.33 8.03 9.40 5.64 6.17 0.36 6.50 7.27 1.50 0.70 0.98 0.56 6.98 7.84 1.23 2.147 2.182 1.50 0.68 0.84 0.53 0.64 0.20 2.38 2.54 1.50 0.68 0.84 0.53 0.64 0.20 2.38 2.54 2.00 0.90 1.21 0.70 0.81 0.28 3.49 2.54 2.50 0.99 1.21 0.77 0.81 1.05 1.864 1.831 4.79 2.75 1.18 1.47 0.98 1.18 0.36 4.76 5.06 2.75 1.18 1.47 0.98 1.18 0.39 4.76 5.06 2.75 1.67 1.07 1.28 0.39 4.29 4.58 2.99 3.66 3.7			Skn splt a-grft fac/nck/hf/g		11.18	10.84	7.32	7.67	1.16	23.22	22.88	19.36	19.71	060
7.33 8.03 9.40 5.64 6.17 0.97 16.33 17.70 10.83 9.41 0.28 6.36 6.17 0.97 16.33 17.70 10.83 9.41 9.76 6.98 7.84 1.23 2.44 2.69 10.83 9.44 0.53 0.64 0.20 2.38 2.54 2.50 0.90 1.21 0.70 0.81 0.20 2.38 2.54 2.50 1.08 1.44 0.87 1.01 0.35 3.49 3.49 2.50 1.08 1.47 0.89 1.18 0.39 4.29 4.58 2.75 1.18 1.47 0.98 1.18 0.36 4.29 4.58 2.75 1.18 1.47 0.98 1.18 0.36 4.76 5.06 2.75 1.18 1.47 0.99 1.18 0.39 4.76 5.06 2.79 0.81 0.59 0.59			Skn splt a-grft f/n/hf/g add		3.47	4.24	1.33	1.71	0.36	6.50	7.27	4.36	4.74	222
1.50 0.70 0.98 0.05 0.21 2.41 2.08 1.50 0.68 0.89 0.84 0.20 2.38 2.69 1.50 0.68 0.84 0.20 0.28 3.18 2.50 2.00 0.90 1.21 0.70 0.81 0.28 3.38 2.59 2.00 0.90 1.24 0.70 0.81 0.28 3.39 4.29 2.00 1.08 1.44 0.96 1.18 0.36 4.29 4.58 2.75 1.18 1.47 0.98 1.18 0.36 4.29 4.58 2.75 1.18 1.47 0.98 1.18 0.36 4.29 4.58 2.75 1.10 1.28 0.36 4.76 5.06 4.58 2.89 3.65 3.75 3.94 0.82 14.05 14.19 2.99 3.65 3.75 3.94 0.82 14.05 14.19 2.99 </td <td></td> <td></td> <td>Derm autograft, trnk/arm/leg</td> <td></td> <td>8.03</td> <td>9.40</td> <td>5.64</td> <td>6.17</td> <td>0.97</td> <td>16.33</td> <td>17.70</td> <td>13.94</td> <td>14.47</td> <td>090</td>			Derm autograft, trnk/arm/leg		8.03	9.40	5.64	6.17	0.97	16.33	17.70	13.94	14.47	090
10.05 3.41 9.70 0.36 7.84 1.25 2.14 2.182 9.24 7.22 8.15 5.92 6.31 1.14 17.60 18.53 2.54 2.00 1.21 0.70 0.81 0.28 3.18 3.49 2.00 1.08 1.44 0.87 1.01 0.35 3.33 4.29 2.50 1.08 1.44 0.87 1.01 0.36 3.49 4.29 2.50 1.08 1.44 0.87 1.01 0.36 4.29 4.29 2.75 1.18 1.47 0.89 1.01 0.36 4.76 5.06 5.99 7.60 0.51 0.59 0.39 4.76 5.06 2.75 1.18 1.47 0.87 1.03 0.39 4.76 5.06 5.99 2.76 0.51 0.59 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79			Derm autograft t/a/l add-on	1.50	0.70	0.98	0.52	0.61	L 2.0	2.41	2.69	2 2 2	7 22	777
1.50 0.084 0.03 0.04 0.20 9.24 7.22 8.15 0.23 0.04 1.14 1.76 1.50 2.00 0.90 1.21 0.70 0.81 0.28 3.18 3.49 2.50 1.08 1.44 0.87 1.01 0.35 3.93 4.29 2.50 1.08 1.44 0.87 1.01 0.35 3.93 4.29 2.50 1.08 1.47 0.98 1.18 0.36 4.29 4.58 3.00 1.37 1.67 1.09 1.18 0.36 4.76 5.06 5.99 3.65 3.79 2.36 2.36 0.55 10.19 10.33 2.00 1.50 0.67 0.51 0.59 0.19 2.41 10.33 2.45 1.07 1.10 0.51 0.29 3.81 3.84 2.59 2.21 0.59 0.61 0.79 0.82 14.05 14			Derm autograft face/nck/ht/g	10.83	9.41	9.76	86.0	48.7		74.12	21.82	19.04	19.90	080
2.50 0.09 1.21 0.05 0.01 1.14 0.05 0.01 1.14 0.05 0.01 1.14 0.05 0.01 1.14 0.05 0.01 1.10 0.035 0.05 <t< td=""><td></td><td></td><td>Derm autograft, I/n/ni/g add</td><td>00.00</td><td>0.08</td><td>40.0</td><td>0.50 0.00</td><td>9.0</td><td>0.20</td><td>1.30</td><td>7.04 4.07</td><td>, k</td><td>4.0</td><td>777</td></t<>			Derm autograft, I/n/ni/g add	00.00	0.08	40.0	0.50 0.00	9.0	0.20	1.30	7.04 4.07	, k	4.0	777
2.50 1.08 1.21 0.77 0.62 1.08 1.09 2.50 2.50 1.08 1.47 0.87 1.01 0.36 4.29 4.58 2.75 1.18 1.47 0.98 1.18 0.36 4.29 4.58 3.00 1.37 1.67 1.07 1.28 0.36 4.76 5.06 5.99 3.65 3.79 0.51 0.59 0.19 2.39 4.76 5.06 7.99 5.24 5.38 3.75 3.94 0.82 14.05 14.19 10.33 2.41 8.90 9.85 9.51 0.59 0.79 0.89 19.73 19.39 2.41 19.39 2.41 19.39 2.41 19.39 2.41 19.39 2.41 19.39 2.41 19.39 2.41 19.39 2.41 19.39 2.41 19.39 2.41 19.39 2.41 19.39 2.41 19.39 2.41 19.39 2.42 <td< td=""><td></td><td></td><td>Cult epiderm grit varmineg</td><td>9.24</td><td>77.7</td><td>00.</td><td>25.92</td><td>5.0</td><td>4 00</td><td>09.7</td><td>0.03</td><td>0.30</td><td>00.00</td><td>030</td></td<>			Cult epiderm grit varmineg	9.24	77.7	00.	25.92	5.0	4 00	09.7	0.03	0.30	00.00	030
9.99 7.00 7.77 6.29 6.78 1.05 18.64 18.15 2.75 1.18 1.47 0.96 1.18 0.36 4.76 5.06 3.00 1.37 1.67 1.07 1.28 0.39 4.76 5.06 5.99 3.65 3.79 2.36 2.36 0.19 2.39 2.44 6.06 0.65 0.61 0.95 0.19 2.39 2.44 7.89 9.85 9.51 6.29 6.29 0.39 14.19 10.33 1.32 2.11 2.45 0.61 0.95 0.29 3.81 3.84 8.90 9.85 9.51 6.29 0.99 3.81 14.19 10.33 1.32 2.11 2.24 6.51 6.64 0.84 18.91 18.14 18.14 18.14 18.14 18.14 18.34 18.34 18.34 18.34 18.34 18.34 18.34 18.34 18.34 18			Cult epiderm graft 1/2/1 ±%	2 6	0.00	3. 1	0.70	5.5	0.20	3 . 6	0.4	2.30	20.0	777
2.75 1.18 1.47 0.38 1.18 0.36 4.29 4.58 3.00 1.37 1.67 1.07 1.28 0.39 4.76 5.06 5.99 3.65 3.79 2.36 2.36 0.55 10.19 10.33 1.55 0.65 0.67 0.51 0.59 0.79 4.76 5.06 2.45 1.07 1.10 0.81 0.82 14.05 14.19 2.45 1.07 1.10 0.81 0.82 14.05 14.19 1.32 2.11 2.45 0.56 0.61 0.19 3.81 3.84 8.90 9.85 9.51 6.29 6.22 0.98 19.73 19.39 1.32 2.11 2.45 0.56 0.61 0.19 3.62 3.96 1.32 1.17 3.64 6.51 6.64 0.94 18.91 18.14 1.03 1.128 8.64 6.51 0.94			Cult epiderm graft f/n/hf/a	00.0	7.60	777	0.0 20.0	22.0	1.05	18.64	12.41	17.20	17.82	0.00
3.00 1.37 1.07 1.08 0.39 4.76 5.06 5.99 3.65 3.79 2.36 2.36 0.55 10.19 10.33 1.55 0.65 0.67 0.51 0.59 0.19 2.39 2.41 2.45 1.07 1.10 0.81 0.95 0.95 0.39 3.84 8.90 9.85 9.61 0.29 3.81 3.84 8.90 9.85 9.51 0.50 0.61 0.19 3.84 1.32 2.11 2.45 0.56 0.61 0.19 3.82 3.94 1.30 9.85 9.51 0.50 0.61 0.19 3.84 3.84 1.30 1.24 0.56 0.61 0.19 3.62 3.96 1.19 2.01 2.24 0.50 0.65 0.16 3.86 1.10 2.24 0.50 0.65 0.19 3.86 3.56 1.10 2.24 <td></td> <td></td> <td>Cult epidem out f/n/hfa add</td> <td>0.00</td> <td>20.7</td> <td>1 47</td> <td>0.53</td> <td>2.5</td> <td> %</td> <td>0.0</td> <td>2.0.7</td> <td>25.7</td> <td>20. 7</td> <td>777</td>			Cult epidem out f/n/hfa add	0.00	20.7	1 47	0.53	2.5	 %	0.0	2.0.7	25.7	20. 7	777
5.99 3.65 3.79 2.36 0.55 10.19 10.33 7.99 5.24 5.38 3.75 3.94 0.65 0.67 0.51 0.59 0.19 2.39 2.41 7.99 5.24 1.10 0.81 0.59 0.19 2.31 14.19 10.33 8.90 9.86 9.51 0.29 0.29 3.81 3.84 1.32 2.45 0.56 0.61 0.19 3.62 3.96 1.32 2.21 2.45 0.56 0.61 0.19 3.62 3.96 1.32 2.21 2.45 0.56 0.61 0.19 3.62 3.96 1.32 10.21 9.44 6.51 6.64 0.84 18.14 18.14 1.19 2.01 2.24 0.50 0.55 0.16 3.36 21.53 1.86 2.51 2.46 0.79 0.88 0.22 4.60 4.55 1.28 <td< td=""><td></td><td></td><td>Cult epiderm orft f/n/hfa +%</td><td>0.00</td><td>1.37</td><td>1.67</td><td>1 07</td><td>7</td><td>0.39</td><td>4 76</td><td>5.06</td><td>4 46</td><td>4 67</td><td>12</td></td<>			Cult epiderm orft f/n/hfa +%	0.00	1.37	1.67	1 07	7	0.39	4 76	5.06	4 46	4 67	12
1.55 0.65 0.67 0.51 0.59 0.19 2.39 2.41 7.99 5.24 5.38 3.75 3.94 0.82 14.05 14.19 2.45 1.07 1.10 0.81 0.95 0.29 3.81 3.84 8.90 9.86 9.51 0.56 0.61 0.19 3.62 14.19 7.86 10.21 2.44 6.51 6.64 0.84 18.91 18.14 1.19 2.01 2.24 0.50 0.55 0.16 3.36 3.59 10.03 11.73 10.58 8.64 0.84 18.91 18.14 1.86 2.01 2.24 0.50 0.55 0.16 22.68 21.53 1.129 1.263 10.82 9.02 8.69 0.69 24.61 22.80 1.20 2.21 2.46 0.79 0.88 0.23 4.60 4.55 1.129 2.75 1.12 1.33			Acell graft trunk/arms/legs	5.99	3.65	3.79	2.36	2.36	0.55	10.19	10.33	8.90	8.90	060
7.99 5.24 5.38 3.75 3.94 0.82 14.05 14.19 2.45 1.07 1.10 0.81 0.95 0.29 3.81 3.84 8.90 9.85 9.51 6.29 0.96 0.99 3.81 3.84 1.32 2.11 2.45 0.66 0.61 0.19 3.62 3.81 1.03 10.21 2.24 0.50 0.64 0.84 18.91 18.14 1.03 11.73 10.58 8.64 0.16 3.36 2.153 1.04 11.73 10.58 8.64 8.12 0.92 2.461 4.55 11.29 12.63 10.8 0.29 4.60 4.55 1.13 11.29 12.63 1.12 1.12 1.26 8.69 0.69 2.461 2.16 2.23 2.91 2.75 1.12 1.33 0.21 2.51 2.10 4.65 3.36 3.24 2.10			Acell graft t/arm/leg add-on	1.55	0.65	0.67	0.51	0.59	0.19	2.39	2.41	2.25	2.33	222
2.45 1.07 1.10 0.81 0.95 0.29 3.81 3.84 8.90 9.85 9.51 6.29 6.22 0.98 19.73 19.39 1.32 2.11 2.45 6.51 6.64 0.84 19.73 19.39 1.03 10.21 2.44 6.51 6.64 0.84 19.73 19.39 10.03 11.73 10.24 0.56 0.61 0.92 3.86 3.59 10.03 11.73 10.58 8.64 8.12 0.92 22.68 21.53 11.29 12.63 10.82 9.02 8.69 0.69 24.61 22.80 2.23 2.24 0.79 0.88 0.69 0.69 24.61 22.80 2.23 2.24 0.79 0.88 0.21 5.35 5.19 4.65 3.36 3.24 0.34 0.39 0.14 1.61 1.61 5.36 3.75 3.65 2.32 <td></td> <td></td> <td>Acellular graft. f/n/hf/g</td> <td></td> <td>5.24</td> <td>5.38</td> <td>3.75</td> <td>3.94</td> <td>0.82</td> <td>14.05</td> <td>14.19</td> <td>12.56</td> <td>12.75</td> <td>060</td>			Acellular graft. f/n/hf/g		5.24	5.38	3.75	3.94	0.82	14.05	14.19	12.56	12.75	060
8.90 9.85 9.51 6.29 6.22 0.98 19.73 19.39 1.32 2.11 2.45 0.56 0.61 0.19 3.62 3.96 1.38 10.21 2.24 0.56 0.61 0.19 3.62 3.96 1.03 11.73 10.58 8.64 0.61 0.84 3.36 3.59 10.03 11.73 10.58 8.64 0.12 0.26 2.2.68 21.53 1.86 2.51 2.46 0.79 0.88 0.23 4.60 4.55 1.12 12.63 10.82 9.02 8.69 0.69 24.61 22.80 2.23 2.91 2.75 1.12 1.33 0.21 5.35 5.19 2.23 2.24 0.79 0.89 0.69 0.69 6.51 8.38 1.00 0.47 0.47 0.21 2.24 0.50 8.38 1.50 0.68 0.69 0.69			Acell graft, f/n/hf/g add-on		1.07	1.10	0.81	0.95	0.29	3.81	3.84	3.55	3.69	222
1.32 2.11 2.45 0.56 0.61 0.19 3.62 3.96 7.86 10.21 9.44 6.51 6.64 0.84 18.91 18.14 1.19 2.01 2.24 0.50 0.55 0.16 3.36 3.59 10.03 11.73 10.58 8.64 8.89 0.23 4.60 4.55 11.29 12.63 10.82 9.02 8.69 0.69 24.61 22.80 2.23 2.91 2.75 1.12 1.33 0.21 5.35 5.19 4.65 3.36 3.24 2.10 2.20 0.49 8.50 8.38 1.00 0.47 0.47 0.34 0.39 0.14 1.61 1.61 5.36 3.75 2.32 2.48 0.58 9.69 9.69 1.50 0.68 0.69 0.57 0.21 2.39 2.40 1.50 0.68 0.69 0.57 0.21			Skin full graft, trunk		9.85	9.51	629	6.22	0.98	19.73	19.39	16.17	16.10	060
7.86 10.21 9.44 6.51 6.64 0.84 18.91 18.14 1.19 2.01 2.24 0.50 0.55 0.16 3.36 3.59 10.03 11.73 10.58 8.64 8.12 0.92 22.68 21.53 11.29 12.63 10.68 0.23 4.60 4.55 11.29 12.63 0.69 24.61 22.88 2.23 2.91 2.75 1.12 1.33 0.21 5.35 5.19 4.65 3.36 3.24 2.10 2.20 0.49 8.50 8.38 4.65 3.36 3.24 2.10 2.20 0.49 8.50 8.38 5.36 3.75 2.76 0.34 0.39 0.14 1.61 1.61 5.36 3.75 3.65 2.48 0.58 9.69 9.59 1.50 0.68 0.60 0.57 0.21 2.39 2.40 3.09			Skin full graft trunk add-on		2.11	2.45	0.56	0.61	0.19	3,62	3.96	202	21.0	777
1.19 2.01 2.24 0.50 0.55 0.16 3.36 3.59 10.03 11.73 10.58 8.64 8.12 0.92 22.68 21.53 11.29 12.51 2.46 0.79 0.88 0.23 4.60 4.55 11.29 12.63 10.82 9.02 8.69 0.69 24.61 22.80 2.23 2.91 2.75 1.12 1.33 0.21 5.35 5.19 4.65 3.36 3.24 0.34 0.39 0.14 1.61 1.61 5.36 3.75 3.65 2.32 2.48 0.58 9.69 9.59 1.50 0.68 0.69 0.57 0.21 2.39 2.40 3.75 3.14 3.18 1.90 2.14 0.49 7.62 7.66 3.69 3.75 3.62 2.24 0.67 0.21 2.39 2.40 3.69 3.76 0.69 0.60			Skin full graft sch/arm/leg		10.01	9 4 6	6.51	664	0.84	18.91	18.14	15.21	15.34	060
10.03 11.73 10.58 8.64 8.12 0.92 22.68 21.53 1.86 2.51 2.46 0.79 0.88 0.23 4.60 4.55 2.23 2.91 2.75 1.12 1.33 0.21 5.35 5.19 2.23 2.91 2.75 1.12 1.33 0.21 5.35 5.19 4.65 3.36 3.24 0.39 0.49 8.50 8.38 1.00 0.47 0.47 0.34 0.39 0.14 1.61 1.61 5.36 3.75 3.65 2.32 2.48 0.58 9.69 9.59 1.50 0.68 0.69 0.57 0.21 2.39 2.40 3.99 3.14 3.18 1.90 2.94 0.49 8.69 9.69 3.60 3.75 3.65 0.57 0.57 0.21 2.39 2.40 3.60 3.75 3.65 0.50 0.57 0.			Okin full graft add-on		100	20.0	0.50	0.0	9.0	- 60.00	0.00	7.7	5 6	777
1.29			Okin full orth face/depit/hf		11 73	10.52	0.00 0.00	ο α 5 τ	9 0	99.00	21.00	05.01	10.02	100
11.29 12.63 10.82 9.02 8.69 0.69 24.61 22.80 2.23 2.91 2.75 1.12 1.33 0.21 5.35 5.19 4.65 3.36 3.24 2.10 2.20 0.49 8.50 8.38 1.00 0.47 0.47 0.34 0.39 0.14 1.61 1.61 5.36 3.75 3.69 0.50 0.57 0.21 2.49 9.69 1.50 0.68 0.69 0.50 0.57 0.21 2.39 2.40 3.09 3.14 3.18 1.90 2.14 0.49 5.66 7.66			Skin full graft add-on		5.7.0	2.30	62.0	2 . 0	0.02	4 60	4.55	0.00	20.0	777
2.23 2.91 2.75 1.12 1.33 0.21 5.35 5.19 4.65 3.36 3.24 2.10 2.20 0.49 8.50 8.38 1.00 0.47 0.47 0.34 0.39 0.14 1.61 1.61 5.36 3.75 3.65 2.32 2.48 0.58 9.69 9.59 1.50 0.68 0.69 0.57 0.21 2.39 2.40 3.09 3.14 3.18 1.90 2.14 0.49 7.62 7.66			Skin full graft een & lips		12.63	10.82	20.6	8,69	69.0	24.61	22.80	21.00	20.67	060
4.65 3.36 3.24 2.10 2.20 0.49 8.50 8.38 1.00 0.47 0.47 0.34 0.39 0.14 1.61 1.61 5.36 3.75 3.65 2.32 2.48 0.58 9.69 9.59 1.50 0.68 0.69 0.57 0.21 2.39 2.40 3.09 3.14 3.18 1.90 2.04 2.04 2.04			Skin full graft add-on		2.91	2.75	1.12	1.33	0.21	5.35	5.19	3.56	3.77	777
1.00 0.47 0.47 0.34 0.39 0.14 1.61 1.61 5.36 3.75 3.65 2.32 2.48 0.58 9.69 9.59 1.50 0.68 0.69 0.50 0.57 0.21 2.39 2.40 2.39 2.48 0.59 0.57 0.51 2.39 2.40 3.14 3.18 1.90 2.04 2.04 2.62 7.66			Apply skinallogrft, t/arm/lg		3.36	3.24	2.10	2.20	0.49	8.50	8.38	7.24	7.34	060
5.36 3.75 3.65 2.32 2.48 0.58 9.69 9.59 1.50 0.68 0.69 0.50 0.57 0.21 2.39 2.40 3.39 3.14 3.18 1.90 2.14 0.49 7.66			Apply sknallogrft t/a/l addl		0.47	0.47	0.34	0.39	0.14	1.61	1.61	1.48	1.53	222
1.50 0.68 0.69 0.50 0.57 0.21 2.39 2.40 1.30 2.39 2.40 1.30 2.40 2.40 2.40 2.40 2.40 2.40 2.40 2.4			Apply skin allogrft f/n/hf/g		3.75	3.65	2.32	2.48	0.58	69.6	9.59	8.26	8.45	060
4.09 3.14 3.18 1.90 2.14 0.49 7.02 7.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00			Aply sknallogrtt f/n/htg add		0.68	0.69	0.50	0.57	0.21	2.39	2.40	2.21	2.28	777
			Aply acell alogrit Varm/leg		4	3.18	08	2.7	0.49	1.62	1.60	6.38	0.62	030

																											-									-											_		_
090 ZZZ 010	090	060 ZZZ	060	760	ZZZ	ZZZ	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	000	000	060	060	060	010	760	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	XX 000
2.18 6.87	7.39	7.80	8.72	9.16	2.31	0.00	17.97	17.57	19.25	16.81	0.00 0.00	7.78	8.40	9.22	33.55	8.5 5.5 5.0	32.90	20.57	23.04	61.27	90.19	17.62	16.34	5.87	8.75 16.05	10.57	10.92	8.92	8. c	5.43	10.10	6.19	8.02	11.90	12.68	9.22	14.94	20.02	21.04	21.20	24.92	18.51	17.45	5. 5. 5. 5. 5. 5.	25.61	42.62	67.92	23.91	1.12
2.11	7.41	7.80	8.48	9.21	2.23	0.00	17.74	17.70	18.57	16.44	8. r.	7.72	8.42	9.21	32.74	20.45 20.00 20.00	31.92	21.16	22.86	59.63	57.30	17.30	16.25	6.17	7. 7. 86. 86.	10.65	10.08	9.45	3.36	5.86	10.67	5.45	7.19	11.67	12.45	8.99	14.83	22.53	20.20	21.23	22.12	18.69	16.26	17.66	24.54	41.16	66.49	23.51	1.16
8.50 8.08 9.08	8.73 8.73	9.11	9.03	10.20	3.00	0.00	22.35	20.63	22.28	19.74	9.20	11.34	11.24	12.12	38.82	36.63	38.50	22.98	Y :	Α <u>2</u> 2	4 4 Z Z	20.51	ΑΝ	8.52	11.26	12.47	14.40	11.67	5.59	9.34	13.43	9.02	10.02	13.27	14.24	10.52	16.33	ζ 4		Z Z	AN	AN S	19.09	20 44	Z Z	A A	¥:	A C	2.51
8.45 2.35 7.92	8.61 8.61	8.96	9.70	10.39	2.91	0.00	21.64	20.82	22.04	19.55	0.40	10.25	11.13	12.03	36.32	33.08	35.54	25.21	∢ : Z	Ψ < Z Z	۷ ۵ ۲ ۲	20.60	Ν	7.97	10.23	13.61	14.09	12.39	5.90	10.63	14.11	8.84	9.46	12.89	13.77	10.15	16.13	(d	(∢ 2 Z	ΥZ	ΥZ	A S	19.27	20.87	Z Z	A		A S	2.25
0.55	0.00 0.43 4.30	0.46	0.47	0.52	0.21	00.00	1.34	1.20	1.20	0.87	0.27	0.35	0.34	0.42	1.99	2.61	2.65	0.63	1.42	4.61	3.69 4.23	0.85	1.05	0.52	0.72	0.9	0.34	0.28	0.11		0.20	0.13	0.19	0.97	0.45	0.37	0.50	1.73	. 49	1.61	1.60	45.5	1.18	0.30	.32	2.54	4.93	0.81	0.00
2.35 0.55 2.74	3.09	3.19	3.93	3.81	0.60	00.0	69.9	6.49	7.57	6.76	3.30	3.86	4.16	4.21	11.94	10.90	11.39	8.46	8.98	20.02	20.35	7.16	9.65	1.40	2.50	5.39	6.27	4.36	1.30	3.53	4.99	4.20	4.10	7.03	5.64	4.41	6.40	0.50	7.93	7.70	7.61	6.84	6.97	6.34	9.62	14.51	22.44	9.17	0.29
2.06 0.48 2.72 0.47	3.11	3.19	3.69	3.86	0.52	0.0	6.46	6.62	6.89	6.39	3 03	3.80	4.18	4.20	11.13	9 95 9 95	10.41	9.02	8.80	18.38	16.03	6.84	92.9	1.70	1.61	5.47	5.43	4.89	2 5	3.66	5.56	3.46	3.27	5.25	5.41	4.18	6.29	0.0 0.0 0.0	20.2	7.73	7.81	7.02	5.78	00.4	8.55	13.05	21.01	8.77	0.18
3.45 0.70 3.95	4.43 4.83	4.50	4.24	4.85	1.29	0.00	11.07	9.55	10.60	9.69	7.02 4.91	7.42	7.00	7.11	17.21	17.12	16.99	10.87	₹ Z	▼ < Z Z	₹ 4 2 2	10.05	Ν	4.05	5.01	7.29	9.75	7.11	3.45	21.7	8.32	7.03	6.10 N	6.85	7.20	5.71	6/:/	(ζ ∢ Ζ Ζ	ΥZ	ΥZ	A S	8.61	4 N N	Z Z	Z A	Y S	Z Y	1.59
3.40 0.72 3.79	4.31	4.35	4.91	5.04	1.20	0.00	10.36	9.74	10.36	9.50	5.7.8 5.7.8	6.33	6.89	7.02	14./1	13.77	14.03	13.10	Y Z	Ψ < Z Z	ξ Δ Ζ Ζ	10.14	NA	3.50	3.98	8.43	9.44	7.83	3.76	8.43	9.00	6.85	5.54	6.47	6.73	5.34	7.59 VIV	(d 2 Z	Z Z	ΥZ	ΥZ	A S	8.79	0 40	Z Z	N A	Z :	Ϋ́ Ϋ́	1.33
4.50 1.43 3.72	3.87	4.15 1.45	4.32	4.83	1.50	0.00	9.94	9.88	10.48	9.18	- S- C	3.57	3.90	4.59	19.62	9.52	18.86	11.48	12.64	36.64	36.85	9.61	8.64	3.95	5.53	4.84	4.31	4.28	2.03	60.5	4.91	1.86	3.73	6.07	6.59	4.44	8.04	19.57	11.62	11.89	12.71	10.33	08.90	0.00	14.67	25.57	40.55	13.93	0.86
Apply acell graft, fruhfig add Apply acell graft substitute Apply outli skin substitute Apply acell and add and a substitute Apply outly skin substitute Apply outly skin substitute Apply outly skin sub add-on																																															Flap for face nerve palsy		
addute	t/a/l	/n/hf/g	t/a/l	nf/g	g add	add	55.0							flap	ad/neck	¥ (aff	e graft	crovasc	Free Skin IIap, microvasc Free fascial flan microvasc			grafts	grafts	skin	skin	skin	е С	apiderm	dermal	cial	ıal	<u></u>	<u>i</u>	plid	ilid	tissue	tissue	tissue	tissue	tissue	tissue	lissue	alsv	alsý	, isy	iir, face	Removal of sutures
Apply acell graft, f/n/hf/g adAply acell grft f/n/hf/g adApply cult skin substitute	t derm sub, a	t derm sub f t derm f/hf/a	n xenograft,	n xgraft, f/n/l	xgrft f/n/hf/	ellular xeriog ellular xoraft	n pedicle flap	pedicle flag	n pedicle flap	pedicie flap				skin pedicle	din graff, hed	kin grali, irui kin oraft am	kin graft, led kin graft, led	dicle flap gra	cular pedicle	/skin tlap mi	nap, microvial flan micr	e skin graft	t-fascia grafl	splant punch	splant punch	treatment of	treatment of	treatment of	lesion, sing	peel face.	peel, face,	peel, nonfa	peel, nonta	ngery, neck of lower eve	of lower eye	of upper eye	ot upper eye	Cessive skir	cessive skir	cessive skir	cessive skir	cessive skir	cessive skir	cessive skir	face nerve p	face nerve p	ace nerve pa	muscle repa	or surures . of sutures .
Apply ace Apply acell Apply acell Apply acell Apply cult	Apply cult	Apply cult	Apply skii	Apply ski	Apply skr	Apply ace	Form skir	Form skir	Form skir	Form skir	Skin gran	Skin graft	Skin graft	Transfer	Muscle-s	Muscle-si Muscle-si	Muscle-s	Island be	Neurovas	Free myo	Free SKIN	Composit	Derma-fa	Hair trans	Hair trans	Abrasion	Abrasion	Abrasion	Abrasion,	Chemical	Chemical	Chemical	Chemical	Revision	Revision	Revision	Hevision	TXCISE EX	Excise ex	Excise ex	Excise ex	Excise ex	Excise ex	Excise ex	Graft for 1	Graft for t	Flap for fa	Skin and	Removal
4444																																																	
								-											:									-				-				-					:	-				-	-		
15335 15336 15340				5420	5421	5431	2	5572	5574	15576	15610	5620	5630	2650	5/32	5736	5738	5740	750		5758	5760	2220		9//6	5781	5782		5/86	2 8	5789		15793	5820	15821		5823	5830			5835	5836	5837		5840	15841	15842	15845	15851

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Status Dressing of Test for black f				Year		,00			,00			
val contract the state of the s	Description	Physician Work RVUs	Fully Implemented Non-Facility PE RVUs	2002 2003 Transi- tional Non-Fa- cility PE RVUs	Fully Im- plement- ed Facil- ity PE RVUs	Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Prac- tice RVUs	Fully Implemented Non-Facility Total	Year 2007 Transi- tional Non-Fa- cility Total	Fully Im- plement- ed Facil- ity Total	Year 2007 Transi- tional Fa- cility Total	Global
oval coval c	Dressing change not for burn	0.86	1.62 NA	1.79 NA	0.25	0.31	0.09	2.57 NA	2.74 NA	1.20	1.26	000
ove so ov	Removal of tail bone ulcer	8.06	Y Z	Y Z	5.83	5.62	1.04	Y Z	Y Z		14.72	060
ove s ove s ove s ove h ove h ove t ove t ov ove t ove	Hemoval of tall bone uicer	9.89	Z Z	Z Z	5.55	7.16	1.42	X X	¥ Z		16.79	060
s your s source s source s source s source s source s source thouse the safdeb	acrum pressure sore	11.49	NA	NA	7.34	7.72	1.52	A	N		20.73	060
ove s ove h ove h ove t ove t ove t ove t s/deb	sacrum pressure sore	13.45	Y Z	Y S	7.61	7.93	1.78	Y Z	Z Z		23.16	060
tove s tove h tove h tove t tove t t tove t tove t t tove t tove t t t t tove t t t t t t t t t t t t t t t t t t t	sacrum pressure sore	12.96	Z Z	Z Z	7.49	8.04	1.76	Z Z	Z Z		22.76	060
hove hove hove hove hove hove hove hove	sacrum pressure sore	14.91	N N	Z Z	8.96	9.61	2.06	A A	N A		26.58	060
n ove h nove th nove th nove th nove th nove th soldeb	hip pressure sore	10.05	Y S	Z S	5.84	6.09	1.31	Ϋ́	Y S		17.45	060
nove h nove th nove th nove th nove th nove th nove th	hip pressure sore	12.13	₹ \$ Z Z	∀	8.51	9.22	1.66	∢ < Z Z	₹ ₹		23.07	060
nove the novel call treated as when the novel call treated the novel call treat	Remove hip pressure sore	13.45	Z Z	₹	9.24	0.0	1.63	4 Z	ζ Δ Ζ Ζ		22.32 24.81	060
nove the move the movel of all treats.	Remove hip pressure sore	23.72	ZZ	 	13.95	14.27	3.16	Z Z	. ∠ . ∠		41.15	060
nove the novel call treat call treat ss/deb	Remove thigh pressure sore	7.83	Z	Z	5.40	5.41	1.04	Ϋ́Z	Z		14.28	060
move the move the move the move the move the moval of ial treat	Remove thigh pressure sore	11.30	N	Ϋ́	8.00	7.90	1.49	A	AN		20.69	060
move the move the move the move the move the moval call is a factor of the movel of	Remove thigh pressure sore	12.03	Y Y	Υ V	7.77	7.76	1.60	ΥZ	A A		21.39	060
move tr move th moval c ial treat	Remove thigh pressure sore	13.27	Υ S	Υ S	9.10	9.05	1.79	₹ Z	¥ ;		24.08	060
moval c moval c ial treat ess/deb	Remove thigh pressure sore	16.46	₹	∀ < Z Z	9.66	10.49	72.2	∀ < Z Z	₹ ₹		29.16	060
tial treat ess/deb	Removal of pressure sore	0.42			00.00	0.00	00.0		200		00.0	26°
deb/sse	Initial treatment of burn(s)	0.89	0.73	0.83	0.24	0.26	0.08	1.70	1.80		1.23	000
	Dress/debrid p-thick burn, s	0.80	- -	1.25	0.56	0.58	0.08	1.99	2.13		1.46	000
ress/deb	Dress/debrid p-thick burn, m	1.85	1.61	1.72	0.88	0.94	0.19	3.65	3.76		2.98	000
ress/deb	rid p-thick burn, I	2.08	1.98	2.12	0.96	9 5	0.24	4.30	44.4		3.40	000
ncision of	Incision of burn scab, initi	4.7.5	Ψ < Z	¥	12.1	05.1	0.46	₹ ₹	¥ \$ 2		5.70	080
Destroy be	Destroy benjan/premla lesion	000	136	107	0.43	0.58	0.20	66	1 20		12.7	010
Sestroy le	sions, 2–14	0.07	0.10	0.11	0.03	0.06	0.01	0.18	0.19		0.14	ZZZ
Jestroy le	Destroy lesions, 15 or more	1.58	2.23	2.28	1.20	1.49	0.11	3.92	3.97		3.18	010
Destruction	Destruction of skin lesions	4.58	4.56	4.59	3.18	3.29	0.35	9.49	9.52		8.22	060
Destruction	Destruction of skin lesions	9.15	7.08	7.17	5.01	5.34	0.63	16.86	16.95		15.12	060
Jestruction 15	Destruction of skin lesions	13.18	9.19	9.24	90.0	14.7	9.00	22.91	22.90		21.13	080
Destruct le	Destruct lesion 15 or more	9.0	10	5. 5	9.5	1 88		4 C	25.3		- t	0.00
Chemical	Chemical cautery tissue	0.50	132	1 2 5	0.38	0.35	0.0	1.88	181		16.0	000
Destruction	Destruction of skin lesions	0.91	1.37	1.30	0.68	0.67	0.04	2.32	2.25		1.62	010
Destruction of	οf skin lesions	1.17	2.42	1.81	1.02	0.88	0.05	3.64	3.03		2.10	010
Destruction	Destruction of skin lesions	1.58	2.74	2.10	1.22	1.07	0.06	4.38	3.74		2.71	010
Destruction of	of skin lesions	1.79	2.97	2.28	1.31	1.15	0.07	4.83	4.14		3.01	010
Destruction of	of skin lesions	1.94	3.17	2.46	88.1	1.19	0.08	5.19	4.48		12.8 12.1 12.1	010
Destruction of	of skin lesions	45.74 45.04	24.6	K./3	4.0.	ان ان	0.09	0.80	0.10		3.73 2.73	0.00
Destruction of	skin lesions	32.1	2.30	1.87	- 1	0.92	0.03	3.7.3 1.1.3	3.24		2.29	0.00
Destruction of	skin lesions	t	0.20	1.97		50.	0.06	4 5 6	3.32		0.20 0.00	010
Destruction of	skin lesions	7/:- GO C	2.00	2.2	5	1 27	0.0	4.7 A	20.4		9.50	5 6
Destruction of	skin lesions	2.03	9 6	24.0		, i.	9.0	9.53	7.49		01.5	0 0
Destruction of	of skin lesions	3.20	3.78	3.15	16:1	1.74	0.16	7.14	6.51		5.10	010
Destruction of	of skin lesions	1.17	2.29	1.78	66.0	0.86	0.05	3.51	3.00		2.08	010
Destruction of		1.72	2.65	2.09	1.28	1.14	0.07	4.44	3.88		2.93	010
Destruction of	of skin lesions	2.04	3.04	2.37	1.43	1.29	0.08	5.16	4.49		3.41	010
Destruction of	of skin lesions	2.64	3.45	2.77	1.70	1.54	0.11	6.20	5.52		4.29	010
Destruction of a	of skin lesions	3.21	3.86	3.16	3.65	1.80	0.13	7.20	6.50		5.14	010
stage m	Destruction of skill lesions	7.45	11.63	20.0	3.58	3.57	0.23	19.52	16.98		11.46	200

0000 00000 0000	00000000000000000000000000000000000000
8 ± 8 4 7 8 8 1 2 8 2 1 8 8 2 8 8 8 8 8 8 8 8 8 8	
4 4 4 4 1 1 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	17.00 & 0.04 & 0.00 & 0
4 4 4 4 1 1 2 2 0 1 1 2 1 2 1 2 1 2 1 2 1 2 1 2	17.07 19.70 19.24 3.71 0.00 3.90 6.03 15.15 15.15 6.23 8.77
25.7.7.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2	N N N A N N N N N N N N N N N N N N N N
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	NA NA NA 0.00 0.00 0.00 0.00 17.7 11.41 13.76 NA
0.000000000000000000000000000000000000	1.29 1.144 1.162 1.30 1.30 1.23 1.23 1.23 1.24 1.24 1.24 1.24 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25
+ + + + + + + + + + + + + + + + + + +	6.88 7.89 7.89 1.05 1.05 1.68 1.89 1.80 1.80 1.80 1.80 1.80 1.80 1.80 1.80
4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	6.86 7.74 7.74 7.74 1.24 0.00 1.53 1.53 1.85 1.85 1.85 1.85 1.85 1.85 1.85 1.85
444410666666666666666666666666666666666	NA NA NA 1.94 0.00 2.72 2.72 3.55 NA NA NA
8.6.9.9.1 9.9.9.1 9.9.9.1 9.9.9.2 9.9.9.2 9.9.9.3 9.9.3	N N N N N N N N N N N N N N N N N N N
8 8 8 8 9 9 9 9 9 8 9 8 9 9 9 9 9 9 9 9	8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9
2 stage mohs, up to 5 spec 3 stage mohs, up to 5 spec Mohs addl stage up to 5 spec Mohs any stage > 5 spec each Cyotherapy of skin Skin peel therapy Skin itssue procedure Drainage of breast lesion Incision of breast lesion Bx breast percut w/o image Biopsy of breast, open Bx breast percut w/device Nipple exploration Excise breast duct fistula Removal of breast lesion Excision, addl breast lesion Excision, breast lesion Excision, breast lesion Excision, breast stasue Partial mastectomy P-mastectomy P-masteromy P-masteromstruction Breast reconstruction	Surgery of breast capsule Removal of breast capsule Revise breast reconstruction Design custom breast implant Breast surgery procedure Incision of abscess Incision of deep abscess Explore wound, neck Explore wound, abdomen Explore wound, extremity Explore wound, extremity Explore wound, extremity Explore wound, abdomen
2 stage moths, 3 stage moths, 3 stage moths, 3 stage moths, Mohs any stag Cryotherapy of Skin peed by Cryotherapy of Skin issue pro Drainage of bru Bw breast perc Brosson, addle browal of bre Excision, hose Excision, addle Removal of bre Brace breast reconst Breast recons	Surgery Removal Rewise b Design c Breast st Incision (Incision (Explore v Explore v Explore v Explore v
444440444444444444444444444444444444444	
17305 17306 17307 17340 17340 17340 19000 19000 19000 19100 19110 19110 19110 19110 19120 19120 19120 19120 19120 19120 19120 19120 19120 19120 19120 19120 19120 19220 19230 19230 19230 19230 19230 19330 19330 19330 19330 19330 19330 19330 19330 19330	19370 19371 19380 19380 19499 20000 20000 20100 20100 20102 20103 20103

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Physical part Physical par	Profession Pro	
1.46 3.87 3.07 0.74 0.03 6.48 6.45 6.56 6.59 2.89 1.69 3.26 6.19 0.64 0.64 0.64 6.56 6.	2.36 3.87 3.87 3.87 3.87 3.87 3.87 3.87 3.87 3.87 3.87 3.87 3.87 3.87 3.87 3.87 3.87 3.78 6.54 6.78 <td< th=""><th>Status Description</th></td<>	Status Description
127 128	1.27 2.71 4.10 0.65 0.67	A Muscle biopsyA Deep muscle biopsy
157 1516 1516 100 111 100 152 15	187 187	
8.72 NA NA 5.74 6.24 0.04 NA 5.74 8.71 NA NA 5.79 6.24 1.02 NA NA 5.74 8.71 NA NA 5.74 1.15 NA NA 9.90 9.71 1.22 1.30 2.22 2.26 1.36 0.12 2.06 3.17 1.04 9.90 9.74 0.72 0.22 0.22 0.22 0.24 0.04 3.16 4.89 3.57 1.10 9.74 0.86 0.89 0.24 0.04 0.11 1.89 3.10 1.10 9.75 0.88 0.27 0.28 0.27 0.24 0.09 1.41 1.60 1.10 9.75 0.66 0.67 0.29 0.28 0.27 0.09 1.44 1.50 1.10 9.78 0.79 0.70 0.70 0.70 0.09 0.70 1.11 1.10 1.10 1	322 NA NA 2.79 6.34 1.01 NA NA 5.77 6.40 NA NA 6.00 9.72 1.02 1.02 1.03 NA NA 9.72 1.03 1.03 1.03 1.04	
5.14 NA NA 3.74 3.56 1.02 NA NA 1.75 3.56 NA NA 1.74 3.56 NA NA 1.02 NA 1.02 NA 1.02 NA 1.03 1.04 <td< td=""><td>5.11 NA 3.74 3.96 1.15 NA 9.75 9.7</td><td></td></td<>	5.11 NA 3.74 3.96 1.15 NA 9.75 9.7	
1567 10A NA NA NA NA 115 NA 102 122 13A 235 227 0.24 0.25 0.04 0.15 1.04 1.04 13A 7.09 883 2.24 2.62 0.04 0.	1567 NA	
1.55 2.55 2.55 2.75 0.24 0.25 0.04 2.55 0.04 2.55 0.04 0.05 0.04 0.05 0.04 0.05 0.04 0.05 0.04 0.05 0.04 0.05 0.04 0.05 0.04 0.05 0.04 0.05 0.04 0.05 0.04 0.05 0.04 0.05 0.04 0.05 0.04 0.05	1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,	
185 2.59 2.83 1.44 1.68 0.21 1.65 4.89 3.50 0.94 7.09 8.63 2.20 0.21 1.69 0.61 1.69 1.263 0.50 0.75 0.68 0.69 0.69 0.24 0.01 1.89 1.263 1.12 0.75 0.66 0.67 0.69 0.23 0.04 1.47 1.50 1.12 0.66 0.67 0.69 0.23 0.04 1.47 1.50 1.12 0.66 0.67 0.69 0.23 0.04 1.47 1.50 1.16 0.69 0.67 0.69 0.23 0.04 1.47 1.50 1.16 0.79 0.70 0.70 0.71 0.72 0.23 0.04 1.47 1.50 1.16 0.79 0.70 0.70 0.71 0.72 0.23 0.04 1.44 1.50 1.16 0.79 0.70 0.71 0.7	186 259 288 144 168 0.51 1109 1263 3.74 1109 1263 3.74 1109 1263 3.74 1109 1263 3.74 1109 1263 3.74 1109 1263 3.74 1109 1263 3.74 1109 1263 3.74 1263 1263 3.74 1263 1263 3.74 1263 1263 1263 3.74 1263	
0.549 0.829 0.849 0.824 0.849 1.240 0.849 1.240 0.849 1.240 0.849 <td< td=""><td>0.54 0.09 0.20 0.21 1.09 0.29 0.44 0.29 0.24 0.29 0.40 0.09 1.40 0.59 0.60 0.09 1.47 1.53 1.12 1.16 0.55 0.09 0.00 0.09 1.47 1.53 1.12 1.16 0.09 <td< td=""><td></td></td<></td></td<>	0.54 0.09 0.20 0.21 1.09 0.29 0.44 0.29 0.24 0.29 0.40 0.09 1.40 0.59 0.60 0.09 1.47 1.53 1.12 1.16 0.55 0.09 0.00 0.09 1.47 1.53 1.12 1.16 0.09 <td< td=""><td></td></td<>	
0.75 0.64 0.69 0.29 0.24 0.09 147 1,53 1,12 0.66 0.75 0.64 0.69 0.29 0.27 0.09 147 1,59 1,19 1,11 0.66 0.78 0.78 0.78 0.79 0.09 0.29 0.29 0.09 1,14 1,17 1,10 0.09 0.09 0.09 0.09 0.10 1,14 1,10 0.09 <td>0.75 0.64 0.69 0.29 0.09 1.47 1.53 1.12 1.16 0.75 0.69 0.75 0.69 0.22 0.09 1.44 1.50 0.99 0.99 0.75 0.68 0.77 0.29 0.29 0.09 1.44 1.40 1.00 0.99 0.99 0.09 0.04 0.22 0.09 1.44 1.40 1.00 0.99 0.99 0.09 0.04 0.22 0.09 1.44 1.40 1.00 0.99 0.99 0.09 0.09 0.09 1.44 1.40 1.00 0.99 0.09 0.09 0.09 0.09 1.44 1.44 1.70 0.09<</td> <td></td>	0.75 0.64 0.69 0.29 0.09 1.47 1.53 1.12 1.16 0.75 0.69 0.75 0.69 0.22 0.09 1.44 1.50 0.99 0.99 0.75 0.68 0.77 0.29 0.29 0.09 1.44 1.40 1.00 0.99 0.99 0.09 0.04 0.22 0.09 1.44 1.40 1.00 0.99 0.99 0.09 0.04 0.22 0.09 1.44 1.40 1.00 0.99 0.99 0.09 0.09 0.09 1.44 1.40 1.00 0.99 0.09 0.09 0.09 0.09 1.44 1.44 1.70 0.09<	
0.67 0.68 0.69 0.62 0.03 0.04 1.44 1.50 1.12 0.06 0.07 0.07 0.08 0.07 0.02 0.07 0.02 0.07 0.02 0.07 0.07	0.75 0.054 0.054 0.025 0.023 0.03 1.29 1.14 1.29 1.14 1.15 1.16 1.10 1.11 1.11 1.11 1.11 1.14 1.15 1.15 1.15 1.15 1.10 1.11 1.11 1.14 1.15 1.15 1.16	
0.75 0.65 0.78 0.27 0.03 0.03 0.04 1.44 1.50 1.06 0.08 0.74 0.76 0.33 0.35 0.08 1.41 1.40 1.06 0.09 0.70 0.77 0.76 0.33 0.35 0.01 1.50 1.51 1.12 1.00<	0.75 0.65 0.78 0.02 0.04 144 157 1.06 107 0.78 0.79 0.76 0.03 0.34 0.04 144 157 1.06 108 0.79 0.77 0.76 0.33 0.35 0.06 150 1.51 1.09 1.19 1.19 1.15 1.09 1.11 1.09 1.10 1.00 1.11 1.00 1.11 1.10	
0.066 0.067 0.070 0.034 0.034 0.034 1.41 1.40 1.05 0.076 0.076 0.077 0.076 0.035 0.036 1.50 1.52 1.09 0.076 1.07 0.08 0.04 0.03 0.01 1.50 1.52 1.09 2.28 2.57 3.31 1.41 1.73 0.03 5.05 6.49 6.24 4.02 2.28 2.51 2.40 1.48 1.53 0.03 6.04 6.04 6.04 1.05 1.05 1.05 1.09 <t< td=""><td>0.66 0.74 0.76 0.33 0.34 0.08 1.40 1.05 1.08 0.78 0.77 0.77 0.76 0.35 0.34 0.08 1.40 1.05 1.11 1.12 1.08 0.79 0.70 0.77 0.71 1.02 0.35 0.01 1.50 1.51 1.12 1.15 1.08 1.30 1.32 1.32 1.08 1.15 1.09 1.11<</td><td></td></t<>	0.66 0.74 0.76 0.33 0.34 0.08 1.40 1.05 1.08 0.78 0.77 0.77 0.76 0.35 0.34 0.08 1.40 1.05 1.11 1.12 1.08 0.79 0.70 0.77 0.71 1.02 0.35 0.01 1.50 1.51 1.12 1.15 1.08 1.30 1.32 1.32 1.08 1.15 1.09 1.11<	
0.79 1.07 0.98 0.40 0.42 0.11 1.97 1.88 1.07 0.98 0.40 0.42 0.11 1.97 1.88 1.07 0.08 0.10 1.50 1.51 1.12 <td< td=""><td>0.79 1.07 0.38 0.40 0.42 0.11 1.97 1.18 1.30 1.35 1.31 1.38 1.30 1.35 1.31 1.38 1.31 1.31 1.38 4.07 1.35 0.20 5.20 5.79 3.89 4.07 1.35 0.20 5.79 3.89 4.07 1.36 1.35 0.20 5.79 3.89 4.07 1.38 4.07 1.38 4.07 1.38 4.07 1.38 4.07 1.38 4.07 1.38 4.07 1.38 4.07 1.38 4.07 1.38 1.39 1.40 1.39 6.49 6.40 4.07 1.03 1.08 6.40 4.07 1.03 1.08 6.40 4.07 1.03 1.08 4.07 1.03 1.08 4.07 1.03 1.09 1.09 1.09 1.09 1.09 1.09 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 <td< td=""><td></td></td<></td></td<>	0.79 1.07 0.38 0.40 0.42 0.11 1.97 1.18 1.30 1.35 1.31 1.38 1.30 1.35 1.31 1.38 1.31 1.31 1.38 4.07 1.35 0.20 5.20 5.79 3.89 4.07 1.35 0.20 5.79 3.89 4.07 1.36 1.35 0.20 5.79 3.89 4.07 1.38 4.07 1.38 4.07 1.38 4.07 1.38 4.07 1.38 4.07 1.38 4.07 1.38 4.07 1.38 4.07 1.38 1.39 1.40 1.39 6.49 6.40 4.07 1.03 1.08 6.40 4.07 1.03 1.08 6.40 4.07 1.03 1.08 4.07 1.03 1.08 4.07 1.03 1.09 1.09 1.09 1.09 1.09 1.09 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 <td< td=""><td></td></td<>	
0.70 0.71 0.32 0.35 0.10 1.51 1.12 2.23 2.51 2.44 1.44 1.73 0.20 5.20 5.79 3.89 2.23 2.51 2.40 1.44 1.50 1.58 0.50 6.49 6.24 4.60 5.66 NA NA A.86 5.36 0.56 NA NA 11.50 6.18 NA NA 4.86 6.09 5.14 NA NA 11.50 9.78 NA NA NA 8.13 7.31 1.26 0.19 2.87 4.60 1.31 1.38 1.96 0.97 1.26 0.19 2.87 4.76 1.74 6.70 1.08 0.97 1.26 0.19 8.70 4.76 5.54 NA NA 4.26 0.20 0.28 0.44 4.00 5.64 0.09 5.18 0.19 0.84 4.00 1.04 4.02 </td <td>0.70 0.71 0.32 0.35 0.10 1.50 1.15 1.15 2.28 2.51 2.40 1.48 1.53 0.31 5.05 4.94 4.02 4.07 5.06 NA NA 6.00 5.18 1.14 NA NA 1.15 1.15 1.15 1.15 1.15 1.15 1.15 4.07 4.07 4.07 1.18 1.58 0.59 6.49 4.94 4.02 4.07 4.07 1.08 1.18</td> <td></td>	0.70 0.71 0.32 0.35 0.10 1.50 1.15 1.15 2.28 2.51 2.40 1.48 1.53 0.31 5.05 4.94 4.02 4.07 5.06 NA NA 6.00 5.18 1.14 NA NA 1.15 1.15 1.15 1.15 1.15 1.15 1.15 4.07 4.07 4.07 1.18 1.58 0.59 6.49 4.94 4.02 4.07 4.07 1.08 1.18	
2.23 2.71 2.40 1.41 1.73 0.20 5.20 5.79 3.89 2.23 2.51 2.40 1.48 1.50 0.31 5.06 4.90 6.24 4.00 6.18 NA NA 4.86 5.98 0.56 6.49 6.24 4.00 6.18 NA NA 4.86 5.98 0.56 6.49 6.24 4.00 6.18 NA NA 4.86 5.98 0.56 NA NA 11.62 1.31 1.38 1.96 0.97 1.08 0.19 2.88 3.46 2.00 1.31 1.38 1.96 0.97 1.06 0.19 2.88 3.70 1.31 1.38 1.96 0.97 1.06 0.19 2.88 3.46 2.00 1.34 1.39 1.38 0.19 0.28 3.70 1.02 3.70 1.34 1.39 0.19 0.19 0.10 <	2.55 2.51 2.40 1.44 1.73 0.20 9.79 9.78 4.68 5.06 NA NA 4.86 5.36 0.59 6.49 4.09 4.68 4.68 4.68 4.68 4.68 4.68 4.68 4.68 4.68 4.68 4.68 4.68 4.68 6.24 4.09 4.68 4.68 6.24 4.08 4.68 6.24 4.08 4.68 6.24 4.08 4.68 6.24 4.08 4.68 6.24 4.08 1.28 6.24 4.09 1.138 1.148	
2.51 3.39 3.14 1.50 1.58 0.59 6.49 6.24 4.60 6.18 NA NA 4.85 5.36 0.56 NA NA 11.20 6.18 NA NA 4.85 5.36 0.56 NA NA 11.62 1.31 1.38 1.96 0.97 1.74 NA NA 11.62 1.34 1.38 1.96 0.97 1.26 0.19 2.88 3.46 2.70 1.74 8.20 0.64 0.73 1.68 2.00 0.28 8.72 1.05 1.05 6.40 NA NA 2.27 2.45 0.56 1.462 1.05 1.04 1.05 6.40 NA NA 2.27 2.45 0.59 NA NA 1.143 6.40 NA NA 2.27 2.45 0.59 NA NA 1.143 6.40 NA NA 2.27 <t< td=""><td>251 339 314 1.50 1.58 0.59 6.49 6.24 4.60 1.18 6.16 NA NA 6.06 NA NA 1.69 1.18 1.11 1.18 1.11 1.11 1.11</td><td></td></t<>	251 339 314 1.50 1.58 0.59 6.49 6.24 4.60 1.18 6.16 NA NA 6.06 NA NA 1.69 1.18 1.11 1.18 1.11 1.11 1.11	
5.56 NA NA 6.00 5.18 1.14 NA NA 11.59 1.14 NA NA 11.59 1.15 11.59	5.06 NA NA 4.86 5.35 0.56 NA NA 1.14 NA 1.14 NA 1.15 1.138 5.54 NA NA NA 4.86 5.35 0.56 NA NA 11.50 11.38 5.54 NA NA 8.13 7.31 1.74 NA 11.62 11.39 11.38 1.74 6.70 10.36 0.97 1.26 0.98 3.46 2.76 11.39 1.74 6.70 10.33 1.68 2.00 0.28 8.72 12.35 3.70 4.02 5.86 8.20 8.64 4.10 3.82 0.56 1.05 NA NA 11.58 11.20 11.39 6.40 NA NA 2.27 2.45 0.59 NA NA 10.24 10.24 6.40 NA NA 2.27 2.45 0.59 NA 10.74 11.10 6.40 NA	
5.54 NA NA 5.45 9.33 9.35 9.35 NA NA 11.38 1.31 1.38 1.38 1.36 0.97 1.26 0.19 2.88 3.46 2.47 1.34 0.33 1.36 0.97 1.26 0.19 2.88 3.46 2.47 5.58 NA NA 4.16 2.27 2.45 0.59 NA 10.54 10.54 5.91 NA NA 4.26 0.59 NA NA 10.74 10.23 3.70 5.91 NA NA 2.27 2.45 0.59 NA NA 10.74 10.23 11.56 2.47 5.91 NA NA 4.16 3.82 0.56 NA NA 10.74 10.74 10.74 10.74 10.74 10.74 10.74 10.74 10.74 10.74 10.74 10.74 10.74 10.74 10.74 10.74 10.74 10.74 10.74 </td <td>5.16 NA NA 5.14 4.93 0.93 NA NA 1.13 1.20<td></td></td>	5.16 NA NA 5.14 4.93 0.93 NA NA 1.13 1.20 <td></td>	
9.78 NA NA 8.13 7.31 1.74 NA 1966 1.34 1.38 1.96 0.97 1.26 0.19 2.88 3.46 2.47 1.74 6.70 10.33 1.96 0.97 1.26 0.19 2.88 3.46 2.47 1.74 6.70 10.33 1.06 0.97 2.45 0.56 14.62 15.06 10.52 1.74 6.70 1.08 2.27 2.45 0.56 14.62 15.06 10.74 1.74 0.08 8.20 0.56 14.62 10.88 2.47 1.10 0.09 0.28 0.56 14.62 10.74 10.74 1.10 0.09 0.09 0.70 0.70 0.86 0.71 10.23 11.43 1.10 0.09 0.71 0.73 0.74 0.70 10.74 10.74 10.74 1.10 0.00 0.71 0.72 0.74 0.70	9.78 NA NA 8.13 7.31 1.74 NA NA 19.6 0.19 2.88 3.46 19.65 18.83	
1.31 1.38 1.96 0.97 1.26 0.19 2.28 3.46 2.47 1.74 6.70 10.33 1.68 2.27 2.45 0.59 1.05 NA NA 10.24 5.86 NA NA NA 2.27 2.45 0.59 NA NA 10.74 6.40 NA NA 2.27 2.45 0.59 NA NA 10.74 6.40 NA NA 2.27 2.45 0.59 NA NA 10.74 6.40 NA NA A.15 NA NA NA 10.74 6.41 NA NA 2.27 2.45 0.59 1.05 NA NA 6.49 6.41 NA NA A.13 8.6 1.05 NA NA 11.43 6.51 NA NA NA A.13 A.13 NA NA 10.42 8.62 NA NA NA NA NA NA NA 10.69 9.10 NA <td< td=""><td>1.31 1.38 1.96 0.97 1.26 0.19 2.88 3.34 3.46 2.77 2.76 1.38 3.63 0.97 1.26 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.9</td><td></td></td<>	1.31 1.38 1.96 0.97 1.26 0.19 2.88 3.34 3.46 2.77 2.76 1.38 3.63 0.97 1.26 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.9	
5.86 8.20 8.64 4.10 3.82 0.56 14.62 15.62 10.52 3.63 NA NA 2.27 2.45 0.59 NA NA 6.49 4.15 5.37 NA NA 4.54 5.29 0.98 NA NA 10.74 4.15 5.37 NA NA 4.54 5.20 0.98 NA NA 6.49 4.16 5.37 NA NA 24.05 3.62 0.73 11.66 10.74 5.100 NA NA 24.05 32.22 4.84 NA NA 11.43 5.100 NA NA 24.05 32.22 4.84 NA NA 11.43 5.100 NA NA 24.05 32.22 4.84 NA NA 11.43 5.100 NA NA A.136 4.136 4.13 0.09 NA NA 11.43 5.100 NA NA A.14 0.09 NA NA 10.00 5.100 NA	5.86 8.20 8.64 4.10 3.82 0.56 14.62 15.06 10.22 10.24 10.23 14.62 15.06 10.23 14.62 15.06 10.23 14.62 10.52 10.24 10.23 14.62 10.52 10.24 10.23 10.23 10.24 10.23 10.23 10.24 6.77 10.24 10.23 11.66 10.74 11.10 4.15 5.37 6.70 3.56 2.1.73 3.81 0.71 10.23 11.56 8.72 8.78 6.70 8.78 9.71 10.23 11.15 8.78 8.78 8.78 8.78 9.71 11.10 11.11 11.12 11	
363 NA NA 2.27 2.45 0.59 NA NA 6.49 6.40 NA NA 3.29 3.65 1.05 NA NA 10.74 6.40 NA NA 4.54 5.22 0.09 NA NA 10.74 4.15 5.37 6.70 3.66 3.82 0.71 10.23 11.56 8.42 51.00 NA NA 24.05 32.22 4.84 NA NA 10.42 62.63 NA NA 24.05 32.22 4.84 NA NA 11.43 51.00 NA NA 24.05 32.22 4.84 NA NA 11.43 51.00 NA NA NA A.18 A.18 NA NA 11.43 51.00 NA NA NA A.18 A.18 NA NA 11.43 51.00 NA NA NA A.18 A.52	3.63 NA 2.27 2.45 0.59 NA NA 6.49 6.67 6.40 NA NA 3.29 2.65 1.05 NA NA 11.10 5.91 NA NA 4.52 3.65 1.05 NA NA 11.10 4.15 5.37 6.70 3.56 3.92 0.71 10.23 11.56 8.42 8.79 62.63 NA NA A.14 NA 11.43 12.11 11.10 62.63 NA NA A.14 NA NA 11.11 11.11 80.64 NA NA NA NA 10.68 8.79 8.70 80.65 A.14 NA NA NA NA 10.68 11.08 91.64 NA NA NA NA NA 10.64 11.10 92.30 NA NA NA NA NA 10.64 11.10 92.14	
4.15 5.37 NA 4.56 3.92 0.98 NA 10.74 4.15 5.37 NA 4.56 3.92 0.98 NA NA 11.56 4.15 5.37 NA 4.52 3.81 NA NA 70.02 5.100 NA NA 2.595 32.22 4.84 NA NA 70.02 6.263 NA NA A.18 A.18 A.52 NA NA 70.02 8.663 NA NA A.18 A.18 NA NA 70.02 8.630 NA NA A.18 A.18 NA NA 70.02 8.630 NA NA A.18 A.18 NA NA 70.02 8.630 NA NA A.18 A.18 NA NA 70.02 8.640 NA NA A.18 NA NA 70.02 8.650 A.29 33.33 3.66 NA NA 70.02 8.690 A.38 6.60 4.99 <td< td=""><td>5.34 NA 5.25 5.00 NA NA 1.10 NA 1.10 4.15 5.37 NA NA 5.22 0.98 NA NA 11.43 12.11 4.16 5.37 6.70 3.56 3.92 0.71 10.23 11.56 8.42 8.78 5.10 NA NA 22.05 3.92 0.71 10.23 11.56 8.42 8.78 5.10 NA NA 24.05 22.73 3.81 NA NA 11.24 11.10 88.06 5.63 NA NA 22.24 31.50 4.18 NA NA 10.84 8.06 61.38 11.08 11.08 11.08 11.08 11.08 11.08 11.08 11.08 11.08 11.08 11.10 11.10 11.08 11.10 11.08 11.10 11.08 11.10 11.08 11.10 11.08 11.10 11.10 11.08 11.10 11.08 11.10<td></td></td></td<>	5.34 NA 5.25 5.00 NA NA 1.10 NA 1.10 4.15 5.37 NA NA 5.22 0.98 NA NA 11.43 12.11 4.16 5.37 6.70 3.56 3.92 0.71 10.23 11.56 8.42 8.78 5.10 NA NA 22.05 3.92 0.71 10.23 11.56 8.42 8.78 5.10 NA NA 24.05 22.73 3.81 NA NA 11.24 11.10 88.06 5.63 NA NA 22.24 31.50 4.18 NA NA 10.84 8.06 61.38 11.08 11.08 11.08 11.08 11.08 11.08 11.08 11.08 11.08 11.08 11.10 11.10 11.08 11.10 11.08 11.10 11.08 11.10 11.08 11.10 11.08 11.10 11.10 11.08 11.10 11.08 11.10 <td></td>	
4.15 5.37 6.70 3.56 3.92 0.71 10.23 11.56 8.42 42.16 NA NA 24.95 3.22 4.84 NA NA 70.02 51.00 NA NA 25.95 32.22 4.84 NA NA 70.02 51.00 NA NA 25.95 32.22 4.84 NA NA 70.02 26.30 NA NA 22.24 31.50 NA NA 106.29 31.64 NA NA 22.24 31.50 NA NA 106.20 31.64 NA NA 22.24 31.50 A.18 A.52 NA NA 52.72 31.64 NA NA 22.24 31.50 A.18 NA NA 52.72 31.64 NA NA 22.24 31.50 A.61 NA NA 52.72 31.64 NA NA 25.97 33.33 3.66	4.15 5.37 6.70 3.56 3.92 0.71 10.23 11.56 8.42 8.78 42.16 NA NA 24.05 22.22 4.84 NA 70.02 67.70 67.00 NA NA 24.05 22.22 4.84 NA 70.02 67.70 67.00 NA NA 24.53 34.48 4.52 NA NA 108.28 110.85 26.30 NA NA 22.24 31.50 A.18 NA NA 60.69 70.04 26.30 NA NA A.18 A.61 NA NA 60.69 70.04 31.64 NA NA A.26 34.48 4.52 NA NA 70.02 61.98 31.64 NA NA A.26 31.50 A.18 A.61 NA NA 60.69 70.10 31.64 NA NA NA NA NA NA NA 70.10 <td></td>	
42.16 NA NA 24.06 21.73 3.81 NA NA 70.02 62.63 NA NA NA 25.96 21.73 3.81 NA NA 70.02 26.30 NA NA NA 22.24 31.50 4.18 NA NA 108.28 26.30 NA NA 22.24 31.50 4.18 NA NA 60.69 27.12 NA NA 22.24 31.50 4.61 NA NA 60.69 27.12 NA NA 22.24 31.50 4.61 NA NA 60.69 27.12 NA NA 22.24 31.50 4.61 NA NA 60.69 27.12 NA NA 23.90 33.35 4.61 NA NA 52.72 28.90 9.33 8.66 4.95 5.49 0.94 15.96 10.48 29.91 NA NA 4.62 5.04 0.71 NA NA 10.66 20.32 NA NA </td <td>42.16 NA NA 24.05 21.73 3.81 NA NA 67.00 67.70 62.63 NA NA 24.05 22.22 4.84 NA NA 70.02 67.70 62.63 NA NA 24.48 4.52 NA NA 70.04 70.04 26.30 NA NA 22.24 31.50 4.18 NA 70.04 70.04 26.30 NA NA 22.24 31.50 4.18 NA NA 70.04 27.12 NA NA 22.24 31.50 4.61 NA 70.04 70.04 27.12 NA NA 23.90 33.38 3.66 NA NA 57.19 60.69 70.10 27.12 NA NA 13.65 20.12 1.12 NA NA 57.19 60.69 70.10 27.12 NA NA 13.66 1.30 NA NA 17.04 10.0</td> <td></td>	42.16 NA NA 24.05 21.73 3.81 NA NA 67.00 67.70 62.63 NA NA 24.05 22.22 4.84 NA NA 70.02 67.70 62.63 NA NA 24.48 4.52 NA NA 70.04 70.04 26.30 NA NA 22.24 31.50 4.18 NA 70.04 70.04 26.30 NA NA 22.24 31.50 4.18 NA NA 70.04 27.12 NA NA 22.24 31.50 4.61 NA 70.04 70.04 27.12 NA NA 23.90 33.38 3.66 NA NA 57.19 60.69 70.10 27.12 NA NA 13.65 20.12 1.12 NA NA 57.19 60.69 70.10 27.12 NA NA 13.66 1.30 NA NA 17.04 10.0	
62.63 NA NA 24.53 34.48 4.52 NA NA 108.28 13.50 NA NA 22.24 31.50 NA NA 22.24 31.50 NA NA 22.24 31.50 NA NA 22.24 31.50 NA NA 22.22 NA NA NA 22.24 31.50 NA NA 52.02 NA NA 52.02 NA NA 52.02 NA NA 52.03 NA NA 52.03 NA NA 52.04 0.94 15.96 NA NA 10.88 NA NA 4.26 0.66 NA NA 10.88 NA NA 10.88 NA NA 10.89 0.70 15.00 15.00 12.44 NA NA 10.89 0.70 15.00 15.00 12.44 NA NA 10.89 0.70 15.00 15.00 12.44 NA NA 10.89 0.70 15.00 NA NA 10.89 0.70 15.00 15.00 15.00 12.75 NA NA NA 10.89 0.70 15.00 NA NA 10.88 0.54 NA NA 4.26 0.66 NA NA 10.38 0.54 NA NA 10.32 NA NA 10.34 NA 10.35 NA NA 10.36 0.54 NA NA 4.38 NA 10.34 NA 4.32 NA NA 10.35 NA NA 10.36 NA NA NA 10.36 NA NA 10.36 NA NA NA 10.36 NA NA 10.36 NA NA 10.36 NA NA 10.36 NA NA NA 10.36 NA NA NA 10.36 NA NA NA NA NA 10.36 NA	62.63 NA NA 38.79 41.36 6.86 NA NA 10.82 110.85 26.30 NA NA 24.53 34.48 4.52 NA NA 108.28 110.85 26.30 NA NA 22.24 31.50 4.18 NA 60.69 70.64 26.30 NA NA 22.24 31.50 4.61 NA NA 60.69 70.10 27.12 NA NA A.51 NA NA 57.19 60.69 70.10 27.12 NA NA NA NA 57.19 61.86 64.11 5.69 9.33 8.66 4.95 5.49 0.94 15.96 11.58 12.12 5.69 9.33 8.66 4.95 5.49 0.71 NA NA 15.04 15.82 5.33 NA NA 4.67 5.51 0.69 NA 11.08 10.28 5.34	
31.64 NA NA 22.24 31.48 4.52 NA 60.69 26.30 NA NA 22.24 31.50 4.18 NA NA 60.69 31.64 NA NA NA 22.24 31.50 4.18 NA NA 60.69 27.12 NA NA 22.24 31.50 4.11 NA NA 62.02 27.12 NA NA 13.65 20.12 1.12 NA NA 54.68 5.69 9.33 8.66 4.95 5.49 0.94 15.96 11.58 7.90 NA NA 4.62 5.04 0.71 NA NA 15.04 8.34 NA NA 4.62 5.04 0.71 NA NA 15.04 8.34 NA A.62 5.04 0.71 NA NA 10.66 8.34 NA A.62 5.04 0.71 NA NA 10.66 8.35 NA NA 4.36 4.26 0.66 NA	31.64 NA NA 24.53 34.48 4.52 NA NA 50.69 70.64 26.30 NA NA 22.24 33.53 34.61 NA NA 60.69 70.64 31.64 NA NA 22.24 33.53 3.66 NA NA 62.02 70.10 27.12 NA NA 23.90 33.33 3.66 NA NA 62.02 70.10 27.12 NA NA 13.65 20.12 1.12 NA NA 62.02 70.10 5.69 9.33 8.66 4.95 5.49 0.94 15.96 15.29 11.58 12.12 7.90 NA NA 4.67 5.61 0.69 NA NA 15.02 11.68 8.69 4.96 5.51 0.69 NA NA 10.66 11.08 8.69 4.96 5.51 0.69 NA NA 10.28 11.28 8.69 4.96 5.51 0.69 NA NA 10.28 11.89 </td <td></td>	
31.64 NA NA 25.77 33.85 4.61 NA NA 62.02 27.12 NA NA 62.02 27.12 NA NA 25.77 33.85 4.61 NA NA 62.02 27.12 NA NA 62.03 33.33 3.66 NA NA 62.03 11.58 15.29 NA NA 62.03 NA NA 62.04 15.06 NA NA 15.04 17.00 15.02 17.44 16.53 NA NA 6.653 NA NA 6.653 NA NA 6.653 NA NA 6.653 NA NA NA 6.653 NA NA NA 6.653 NA NA 6.6	31.64 NA NA 25.77 33.85 4.61 NA NA 62.02 70.10 27.12 NA NA 25.77 33.85 4.61 NA NA 62.02 70.10 27.12 NA NA 13.65 20.12 1.12 NA NA 54.68 64.11 27.14 NA NA 4.62 5.04 0.71 NA NA 11.70 12.54 27.15 NA NA 4.67 5.51 0.69 NA NA 10.38 10.28 27.16 NA NA 4.67 5.51 0.69 NA NA 10.38 10.28 27.17 NA NA 4.67 5.51 0.69 NA NA 10.38 10.28 27.18 NA NA 4.41 4.67 0.87 NA NA 10.92 11.18 27.9 NA NA 1.16 1.36 0.54 NA NA 4.82 5.12 27.9 NA NA 1.16 0.89 0.20 5.65 7.64 2.84 2.85 11.38 27.9 NA NA 1.16 0.89 0.20 5.65 7.64 2.85 11.38	
27.12 NA NA 23.90 33.33 3.66 NA NA 54.68 4.242 NA NA 13.65 20.12 1.12 NA NA 57.19 7.90 NA NA 4.62 1.30 NA 15.04 5.33 NA NA 4.62 5.04 0.71 NA NA 15.04 5.33 NA NA 4.67 5.51 0.69 NA NA 11.70 5.34 NA NA 4.67 5.51 0.69 NA NA 10.66 6.34 NA A.36 4.89 0.70 15.00 15.02 12.44 6.53 NA NA 4.41 4.67 0.87 NA 10.56 6.53 NA NA 4.41 4.67 0.87 NA 10.92 6.53 NA	27.12 NA NA 23.90 33.33 3.66 NA NA 54.68 64.11 42.42 NA 13.65 20.12 1.12 NA 54.68 64.11 5.69 9.33 8.66 5.49 0.94 15.96 15.29 11.58 12.12 7.90 NA NA 4.62 5.04 0.71 NA NA 15.82 12.12 5.33 NA A.62 5.04 0.71 NA NA 15.82 11.08 12.12 6.34 NA A.62 5.04 0.71 NA NA 11.08 11.08 11.08 6.34 NA A.46 5.51 0.69 NA 11.70 12.24 12.37 6.78 7.54 4.96 4.89 0.70 15.00 15.00 15.04 11.38 6.54 NA NA <t< td=""><td></td></t<>	
5.69 9.33 8.66 4.95 5.04 0.94 15.96 15.29 15.89 15.96 15.99 15	42.42 NA 13.83 A MA 13.83 13.13 A MA 15.89 15.12	
7.90 NA NA 5.84 6.62 1.30 NA NA 15.04 5.33 NA NA 4.62 5.04 0.71 NA 10.66 6.34 NA A.67 5.51 0.69 NA 11.70 5.36 NA A.96 4.89 0.70 15.00 15.02 6.53 NA NA 4.96 4.89 0.70 15.00 12.44 6.53 NA NA 4.41 4.67 0.87 NA NA 10.92 6.53 NA NA 4.41 4.67 0.87 NA NA 10.92 1.81 NA NA 0.69 0.64 NA A.482 2.79 NA NA 1.16 1.46 0.64 NA A.482	7.90 NA NA 5.84 6.62 1.30 NA NA 15.82 5.33 NA NA 4.62 5.04 0.71 NA NA 15.82 6.34 NA A.62 5.04 0.71 NA NA 10.66 11.08 6.34 NA A.62 5.04 0.71 NA NA 10.66 11.08 6.34 NA A.62 5.51 0.69 NA 10.38 10.28 7.5 7.5 4.96 4.89 0.70 15.00 15.02 12.44 12.37 8.53 NA NA 4.41 4.67 0.87 NA NA 10.28 1.81 NA NA 4.41 4.67 0.87 NA NA 4.69 1.31 NA NA 1.36 0.87 NA NA 4.48 4.69 1.32 NA NA 1.46 0.84 NA 4.48	
6.34 NA NA 4.62 5.04 0.71 NA NA 10.66 NA 10.66 NA 10.66 NA 10.66 NA 11.70 NA 10.65 NA NA 11.70 NA NA 10.68 NA NA 11.70 NA NA 10.88 NA NA 10.87 NA	5.33 NA NA 4.62 5.04 0.71 NA NA 10.66 11.08 6.34 NA NA A.67 5.51 0.69 NA NA 10.56 11.08 6.34 NA NA A.67 5.51 0.69 NA NA 10.28 1.02 1.32 NA NA 4.49 4.89 0.70 15.00 15.02 12.44 12.37 1.03 1.04 NA NA 1.04 NA NA 12.57 13.23 1.04 NA NA 4.41 4.67 0.87 NA NA 10.92 11.18 1.04 NA NA 1.04 0.87 NA NA 10.92 11.18 1.04 NA 1.04 0.87 NA NA 4.42 4.69 1.04 NA 1.04 0.87 NA NA 4.42 4.69 1.04 NA 1.04 0.87 NA 1.04 NA 4.48 5.12 1.05	
6.78 7.52 NA NA 4.36 4.89 0.70 15.00 15.02 12.44 6.78 7.54 4.96 4.89 0.70 15.00 15.02 12.44 6.53 NA NA 6.41 4.67 0.87 NA NA 10.32 1.81 NA NA 1.16 1.46 0.64 NA NA 4.82 2.79 NA NA 1.16 1.46 0.64 NA NA 4.82	5.36 NA NA 4.26 0.66 NA NA 10.38 10.28 6.53 NA NA 5.00 5.66 1.04 NA NA 12.57 5.64 NA NA 6.69 0.87 0.43 NA NA 10.92 11.18 7.54 NA NA 6.69 0.87 0.43 NA NA 10.92 11.18 7.55 NA NA 1.09 1.36 0.54 NA NA 10.92 11.18 7.56 NA NA 1.09 1.36 0.54 NA NA 10.92 11.18 7.57 NA NA 1.16 1.46 0.64 NA NA 4.42 4.69 7.58 NA NA 1.16 1.46 0.64 NA NA 4.82 5.12 7.59 NA NA 1.16 1.36 0.20 5.65 7.64 2.34 2.34	
6.78 7.52 7.54 4.96 4.89 0.70 15.00 15.02 12.44 6.53 NA NA 5.00 5.66 1.04 NA NA 12.57 5.64 NA NA 0.69 0.87 0.87 NA NA 2.93 2.79 NA NA 1.16 1.46 0.64 NA NA 4.82 3.02 NA NA 1.16 1.46 0.64 NA NA 4.82	6.53 NA NA 5.00 5.66 1.04 NA NA 10.92 12.37 13.23 5.64 NA NA 5.00 5.66 1.04 NA NA 10.92 11.18 7.75 NA NA 1.09 1.36 0.87 0.43 NA NA 10.92 11.18 7.79 NA NA 1.09 1.36 0.54 NA NA 4.42 4.65 7.79 NA NA 1.10 1.36 0.54 NA NA 4.42 4.69 7.70 NA NA 1.10 1.36 0.54 NA NA 4.42 4.69 7.70 NA NA 1.10 1.36 0.50 0.20 5.65 7.64 2.34 2.34 7.70 NA NA 1.26 NA NA 1.36 0.36 0.20 5.65 7.64 2.34 2.34	
6.53 NA NA 5.00 5.66 1.04 NA NA 12.57 5.64 NA NA 0.69 0.87 NA NA 1.16 1.46 NA NA 1.16 1.46 NA NA 1.16 3.02 NA NA 1.16 1.46 0.64 NA NA 4.82	6.53 NA NA 5.00 5.66 1.04 NA NA 12.57 13.23 5.64 NA NA NA 4.41 4.67 0.87 NA NA 10.92 11.18 2.79 NA NA 1.09 1.36 0.54 NA NA 4.42 4.69 3.02 NA NA 1.16 1.46 0.64 NA NA 4.82 5.12 1.26 4.19 6.18 0.88 0.96 0.20 5.65 7.64 2.34 2.34	
5.64 NA NA 4.41 4.67 0.87 NA NA 10.92 1.81 NA NA 10.69 0.69 0.54 NA NA 2.93 3.02 NA NA 1.16 1.46 0.64 NA NA 4.82	5.64 NA NA A 441 4.67 0.87 NA NA 10.92 11.18 1.81 NA NA 0.69 0.87 0.43 NA NA 2.93 3.11 2.79 NA NA 1.09 1.36 0.54 NA NA 4.42 4.69 3.02 NA NA 1.16 1.46 0.64 NA NA 4.82 5.12 1.26 4.19 6.18 0.98 0.90 0.20 5.65 7.64 2.34 2.42	
2.79 NA NA 1.09 1.36 0.54 NA NA 4.82 3.02 NA NA 1.16 1.46 0.64	2.79 NA NA 1.16 1.46 0.64 NA NA 4.82 5.12 1.26 4.19 6.18 0.38 0.96 0.20 5.65 7.64 2.34 2.42	
3.02 NA NA 1.16 1.46 0.64 NA NA 4.82	3.02 NA NA 1.16 1.46 0.64 NA NA 4.82 5.12 1.26 4.19 6.18 0.88 0.96 0.20 5.65 7.64 2.34 2.42	
7000	1.20 4.19 0.10 0.30 0.30 0.30 7.04 2.34 2.42	

Column C																			_	_																	_			_	_	_	_	_
A	060	060	000	000	200	. ↓ ↓ ↓ 060	060	060	060	060	060	060	060	060	060	060	060	060	060	010	060	060	060	060	060	010	060	060	060	060	000	060	060	060	060	060	060	060	060	060	060	060	060	060
March State Browning and part mercentary March State Sta	67.51 71.55 68.28 70.97	74.83 69.21	1.26	4.76	10.84	18.71	11.06	21.49	15.97	10.22	7.19	30.67	9.99 25.55	31.32	27.53	28.05	32.59	22.04	16.57	24.09	60.83	40.39	41.29	37.85	40.14	16.24	45.32	0.00	0.00	15.16	1.17	16.27	17.96	23.16	22.69	18.75	23.68	34.59	34.47	35.23	41.37	42.53	51.20	26.08
March State Bright State Brig	22.87 28.57 38.65 57.04	70.95 36.98	37.42 1.22	4.59	0.58	0.00	10.53	20.99	15.41	9.95	7.08	28.31	3 4.95	39.62	27.32	27.48	59.64	21.09	19.73 15.86	20.19	50.56	38.02	34.53	32.37	33.48	13.83	37.14	0.00	0.00	16.31	1.09	6.03	17.22	22.60	21.38	17.68	22.91	32.95	32.75	31.17	96.96	11.43	12.78	94.68
Particle Date of Bull																																												_
A before born graft inforcation A before born graft inforcation A before born graft inforcation A before graft	ZZZZZ	222	Z #:	Z	- 6	9 Z	Z	24.6	18.4	11.8	- c	34.0	-	Z	Z		Z	Z	<u>.</u>	26.6	66.3	51.0	46.3	39.7	45.3	18.1	2, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5,	0.0	0.0	16.9	4.1	18.4	Z	200	67.7	Z	Z Z	zz	Z	z z	: Z	Z	2 2	Z
A Ribble box grift incrorate A A Britanch Control	X X Z Z Z	Z Z Z	NA 1.72	NA V	91.16	0.00 V	A A	24.79	18.40	12.46	9.78	31.97	12.53 NA	A A	ΥZ Z	Z Z	AN	¥ Z	ΣZ	23.24	56.51	38.81 44.23	40.22	38.07	40.22	16.80	41.17	0.00	0.00	19.68	3.31	19.12	A :	AN ac oa	100.4	Ν	Z Z	Z Z	A :	A Z	Z Z	Y S	(NA NA
Figure 2009 of part incroases	7.01	6.60	5.54	0.51	0.69	1.00 1.100	0.70	1.32	0.94	0.54	0.48	1.7	1.54	1.52	1.85	1.76	1.59	1.47	1.27	1.99	4.55	3.15	3.20	3. 1	2 5	1.27	9. 6. 1. 44.	0.00	0.00	0.72	0.06	06.0	1.07	1.40	1.52	1.32	1.74	2.35	2.38	1.66	3.09	1.84	2.30	2.48
A Ribe bore graft microase 40	22.72 23.75 19.06 25.21	24.09 19.84	22.63	1.65	2.88	0.00	4.83	9.18	6.83	4.94	3.58 84.8	11.87	4. 4 1. 6	11.77	11.83	11.94	12.04	9.13	 15.0 14.0 14.0 14.0 14.0 14.0 14.0 14.0 14	8.70	22.58	16.83	15.24	13.90	15.48	5.98	16.60	0.00	0.00	8.74	0.30	7.74	8.38	10.62	9.06	7.37	9.27	13.11	12.25	12.96	13.86	14.68	20.14	22.65
Fibule borne graft, inforease	18.08 20.77 19.43 21.28	20.21	15.05	1.48	2.62	0.00 5.85	4.30	8.68 8.68	6.27	4.67	3.37	9.51	4.67 7.48	10.01	11.62	11.37	60.6	8.18	6.15	4.80	12.31	8.28 9.22 22.32	8.48	8.42 7.91	8.82	3.57	8.83 8.82 8.83	0.00	0.00	68.6	0.22	7.50	7.64	10.06	7.70	6.30	8.50 8.49	11.47	10.53	8.90	9.45	13.58	11.72	21.25
Fibula bone graft, microvasc 39.90		ZZZ	NA 0.77	NA 77	103.0	0.00 V	Z A	12.30	9.34	6.54	5.52	15.23	0.6 A N	Z Z	Z Z	₹ ₹ Z	Ϋ́	Y S	 {	11.23	28.06	19.46	20.27	18.04	20.71	7.85	20.96	0.00	0.00	10.49	3.86	9.95	Ą.	NA 82	53.79	ΑN	 V Z	Z Z	Ą.	A N	 (A S	Z Z	_ V
High bone graft, microvasc		(0.99	NA 82	83.20	0.0 V V	N A	12.48	9.26	7.18	6.07	13.17	52.7 A N	A A	Y S	¥ Z	Y V	Υ <u>Σ</u>	 {	7.85	18.26	15.43	14.17	14.12	15.56	6.54	12.85	0.00	0.00	13.26	2.44	10.59	¥ :	NA 00 00	86.74	AN	 V Z	Z Z	₹ Z	 ∀	 {	 ₹ 2	 { Z Z	_ V
444444444444444444444444444444444444	39.90 40.79 42.17 39.21	44.14	46.83 0.62	2.60	7.27	10.82	5.53	10.99	8.20	4.74	3.24	17.09	12.53	18.03	13.85	14.35	18.96	11.44	 8.44 	13.40	33.70	25.06	22.85	20.84	22.48	8.99	24.88	0.00	0.00	5.70	0.81	7.63	8.51	11.14	12.16	10.06	12.67	19.13	19.84	20.61	24.42	26.01	28.76	30.95
444444444444444444444444444444444444				-		-		-		-					-		-	-			-			-		-					-		-	-		-	_			_		_		_
444444444444444444444444444444444444																																												
444444444444444444444444444444444444	vasc asc	rest tarsal	toe	ation	perq	yı	mor	er jaw	e(s) lesion	9 tumor .	andible axilla	nlg tumor	n Iesion		st compley	complex.	/repair	0.001	naye	sthesis	sthesis							sthesis	sthesis		ay			ا	aw bone			lefort		lefort	lefort			lefort
444444444444444444444444444444444444	graft, microraft, microvitt, micr	raft, illiac o raft, illiac o raft, metal	raft, great	ne stimul	tumor(s)	letal surge aw joint	f facial tur	oone, low	ace bone	zygoma b	ostosis, m ostosis, m	zygoma r	alble lesio jaw hone	w surgery	ndible cys	xilla cvst	aw cyst w	jaw joint .	י שטווור ל onoid pro	e/oral pros	e/oral pros							e/oral pros	e/oral pros Fixation	ixation	v joint x-ra	ion of chir	ion of chir	ion of chir	n, lower j n, lower i	f forehead	f forehead	midface,	midface,	midface,	midface,	midface,		
444444444444444444444444444444444444	bula bone gic bone grapher bone grapher bone	ne/skin g ne/skin g ne/skin g	ne/skin g ectrical bo	ectrical bo	late, bone	usculoske sision of is	section o	cision of I	ntour of f	cise max/	move exc	cise max/	cise man	tensive ja	move ma	cise iwi ja move ma	cis uppr j	moval of	ifficive jaw imove cor	epare fac	epare fac	epare rac epare fac	epare fac	epare faci	epare fac	epare fac	epare laci epare faci	epare fac	epare tac	erdental f	ection, jav	construct	construct	construct	gmentatic	duction o	duction o	construct	construct	construct	construct	construct	construct	construct
	<u> </u>	<u> </u>	<u> </u>	₫ =	5€:	ΞΞ		<u> </u>	<u> </u>	й (ž &	ш	v g	<u> </u>	<u> </u>	 	Щ	<u> </u>	 	<u> </u>	4	֓֞֞֝֟֝ <u>֞</u>	4	בֿ בֿ	<u>.</u>	4	<u> </u>	<u>.</u>	בֿ בֿ	트	<u>=</u> 6	ž &	<u>~</u>	- R	₹ ₹	R		- B	<u>۾</u> .	<u> </u>	<u> </u>	<u> </u>		_ #
				∢ ⊲						-													-	-							∢ <		-				∢ ⊲							⋖
209556 209567 209576 209577 209577 209577 209577 209577 2097																																	•											
	20955 20956 20957 20962	20970 20972 20972	20973 20974	20975	20982	20999	21015	21025	21029	21030	21032	21034	21040	21045	21046	21048	21049	21050	21070	21076	21077	210/9	21081	21082	21084	21085	21087	21088	21089	21110	21116	21121	21122	21123	21127	21137	21138	21141	21142	21143	21146	21147	21151	21154

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Perfolio	Perform Profile Perform Profile Perform Perf
2.8.88 NA NA 13.45 21.28 664 NA NA 67.29 NA	2.8.8 IMA IMA 1.57.2 2.5.8 6.64 IMA IMA 6.62 6.62 6.63 6.64 6.65 <th< th=""></th<>
### 88	46 88 9 NA NA 231,1 25.88 4.18 NA NA 74.78 22 47 NA NA NA 13.34 2.58 4.18 NA NA 74.09 7.78 22 47 NA NA NA 13.29 13.77 4.88 NA NA 14.19 4.47 22 47 NA NA NA 13.29 13.77 4.88 NA NA 14.19 4.47 22 47 NA NA NA NA NA 14.19 4.47 NA NA 14.19 4.47 22 47 NA NA NA 14.14 12.94 NA NA 14.19 4.47 NA NA 14.19 14.19 14.19 14.19 1
23.9.77 NA NA 13.59 16.77 3.55 NA NA 45.77 5.57 NA A 55.12 5.47 5.47 5.59 NA NA 45.77 5.50 NA NA 45.12 5.47 5.78 1.00 </td <td>33.37 NA NA 12.25 13.77 3.55 NA NA 45.77</td>	33.37 NA NA 12.25 13.77 3.55 NA NA 45.77
23.47 NA NA 12.69 15.67 4.68 NA NA 54.77 54.89 NA NA 4.15.99 15.67 4.89 NA NA 4.15.99 15.67 4.89 NA NA 4.15.99 15.67 8.87 8.87 3.87 9.	23.47 NA NA 10.59 16.57 4.88 NA A 55.46 54.77 54.77 NA 4.88 NA A 56.46 54.77 54.77 NA 4.88 7.99 16.57 A 7.99 NA A 46.89 8.87 3.84 NA 4.88 9.99 9.87 9.84 9.87 9.88 9.99 9.87 9.87 9.88 9.99 9.87 9.87 9.88 9.99 9.87 9.87 9.88 9.87 9.88 9.87 9.88 9.87 9.88 9.89
2.44 NA NA 13.04 14.34 2.89 NA NA 13.05 14.34 15.34 18.35 18	2.44 NA NA 1309 14.34 2.89 NA 1309 14.34 2.89 NA 1309 14.34 2.89 NA 1309 14.34 2.89 NA 14.89 14.
22.38 NA 706 737 736 736 737 736 736 737 736 736 736 736 736 736 736 736 736 736 736 736 <td> 1975 </td>	1975 1975
32.39 NA NA 14.29 17.91 2.90 NA NA 49.48 53.10 NA 14.29 17.91 2.90 NA NA 49.48 53.10 NA NA 21.02 2.91 NA NA 11.29 17.10 2.93 NA NA 11.48 11.48 11.49 4.47 NA NA 65.46 56.44 56.44 11.49 NA NA 11.48 11.49 2.77 11.49 14.45 11.49 14.	32.39 NA NA 14.29 17.91 2.80 NA NA 49.48 53.10 NA 48.48 53.10 NA NA 21.02 17.78 5.70 NA NA 65.46 53.10 NA NA 14.29 17.88 19.49 4.47 NA NA 65.46 55.46 55.40 NA NA 11.02 17.28 15.70 NA NA 53.04.9 56.46 55.40 NA 11.02 17.28 15.70 NA NA 53.04.9 56.46 55.40 NA 11.02 17.28 15.70 NA NA 53.04.9 56.40 56.40 17.20 17.20 17.20 17.20 NA NA 53.04.9 56.40 56.40 17.2
3.55 NA NA 15.48 19.49 NA NA 65.46 59.47 NA 8.56 18.55 NA NA 14.82 19.49 18.50 NA NA 14.82 19.50 19.40 NA 14.82 19.50 19	3.55 NA NA 15.48 NA 14.82 NA NA 15.48 NA NA 15.49 NA 15.49 NA 15.49 NA NA 15.49 NA NA 15.49 NA NA 15.49 NA N
22.91 NA NA 1132 1738 198 NA NA 39.02 22.92 NA NA 39.02 22.93 NA NA 11.05 11.0	22.91 NA 1482 17.86 17.87 17.87 17.87 17.87 17.87 17.87 17.87 17.86 17.86 17.86 17.86 17.86 17.86 17.87 17.82 17.86 17.87 17.82 17.82 17.82 17.82 17.82 17.82 17.82 17.82 17.
218.55 NA NA 10.06 13.18 2.22 NA NA 30.04 32.78 218.45 NA NA 11.06 11.31 15.4 NA NA 33.67 34.84 20.44 NA 11.02 11.22 11.44 11.06 12.29 NA NA 35.67 34.84 15.24 NA NA 11.02 11.22 11.44 NA 12.29 18.84 36.96 12.78 </td <td>11855 NA NA 1106 113.18 2.22 NA NA 30.64 32.78 118.55 NA NA 11.06 11.18 11.06 <t< td=""></t<></td>	11855 NA NA 1106 113.18 2.22 NA NA 30.64 32.78 118.55 NA NA 11.06 11.18 11.06 <t< td=""></t<>
2.1.43 NA NA 13.58 143.18 1.64 NA NA 36.63 2.0.44 NA 11.45 14.45 1.64 NA NA 36.63 15.20 NA NA 11.05 12.20 1.44 NA 23.75 34.84 15.27 NA 11.05 12.29 1.44 NA 23.75 34.84 11.02 22.43 12.26 1.30 0.05 15.95 19.87 34.88 29.12 37.58 11.02 22.43 1.30 0.05 15.95 19.89 19.27 19.89 19.27 36.89 19.28 19.28 19.28 19.28 19.29 19.44 29.39 19.29 19.44 29.75 36.89 19.28 19.28 19.28 19.28 19.28 19.29 19.44 19.39 19.29 19.44 19.39 19.29 19.44 19.39 19.29 19.29 19.29 19.29 19.29 19.29 19.29	1.72 NA
20,41 NA NA 13,25 15,27 2.04 NA NA 27,28 1,24 NA NA 27,28 1,24 NA NA 27,18 1,15 1,15 1,15 1,14 NA NA 27,18 1,15 1,15 1,16 1,16 1,16 20,12	20,44 NA NA 13,25 15,27 2.07 NA NA 25,28 1.54 NA NA 25,28 1.54 NA NA 27,28 1.56 NA NA 27,28 1.56 NA NA 27,18 27,18 1.56 NA NA 27,18 27,18 27,18 1.56 NA NA 27,18 27,18 1.56 NA NA 27,18 28,18 28,17 28,18 28,17 27,18 28,18
15.27 NA	15.99 NA NA 11.05 12.29 1.44 NA NA 27.88 29.12 1.39 NA NA 27.78 29.13 NA NA 27.78 29.11 1.39 NA NA 27.78 29.12 1.39 NA NA 27.78 29.13 1.39 NA NA 27.78 29.43 1.11 27.70 39.11 1.39 20.69 19.54 1.57 28.48 21.23 21.43 22.74 42.74 29.11 1.30 66.64 27.77 28.94 1.50 20.69 19.54 15.78 28.48 21.23 20.69 19.54 15.78 28.48 21.23 20.69 21.22 22.44 42.10 20.28 21.22 22.44 42.10 20.28 20.59 20.28 20.59 20.28 20.52 20.28 20.28 20.28 20.28 20.28 20.28 20.28 20.28 20.28 20.28 20.28 20.28 20.28 20.28 20.28
16.55 NA NA 16.75 1.39 NA NA 24.74 26.48 11.02 324.3 24.86 7.71 9.11 1.09 44.55 36.98 19.87 26.48 11.02 324.3 24.86 7.70 9.11 1.09 44.55 36.98 19.87 21.28 11.02 A.384 29.11 7.70 9.81 1.53 9.92 66.40 21.34 22.37 11.02 NA NA 10.21 1.72 1.99 9.02 66.40 21.34 22.37 11.02 NA NA 10.41 11.87 2.24 NA 1.40 16.27 11.02 NA NA 11.22 11.80 1.25 1.74 1.75 1.75 1.74 1.75 1.75 1.76 1.76 1.76 1.76 1.76 1.76 1.76 1.76 1.76 1.76 1.76 1.76 1.76 1.76 1.76 1.76 1.7	16.56 NA NA 16.75 18.26 1.39 NA A 7.77 1.39 NA A 7.77 A 7.71 1.39 NA A 7.77 2.64 A 7.77 A 7.77 1.09 26.64 1.57 2.64 1.29 1.29 1.65 36.98 1.95 2.64 1.50 2.65 2.65 2.65 2.65 2.64
15.27 32.43 24.86 7.15 12.26 1.33 NA 1.57 12.88 1.33 NA 1.57 1.28 NA 1.57 1.29 1.30 1.55 1.57 1.58 1.57 1.58 1.57 1.58 1.57 1.58 1.57 1	11.02 3.24.8
7.45 7.77 7.71 1.00 20.89 19.24 1.25 1.12 1.25 <	7.40 7.41 7.51 0.90 20.69 19.50 17.
11.28 43.84 29.61 7.70 8.94 1.30 56.42 42.19 20.28 21.52 11.82 86.57 53.05 7.70 8.94 1.53 96.42 42.19 20.28 21.52 11.82 98.57 6.89 6.28 0.61 1.53 1.66 42.19 20.28 22.37 15.66 NA NA 10.84 11.29 1.78 1.76 1.24 1.87 20.28 20.28 15.66 NA 10.84 11.29 1.78 1.78 1.74 1.70 1.28 1.41 1.41 1.41 1.70 1.28 NA NA 20.28 <td> 11.28 43.84 29.61 770 8.94 1.30 56.42 42.19 20.28 21.35 11.05 </td>	11.28 43.84 29.61 770 8.94 1.30 56.42 42.19 20.28 21.35 11.05
11.82 86.57 53.05 7.39 9.02 1.53 99.92 66.40 21.34 22.37 11.00 NA NA 10.54 11.29 11.29 NA NA 10.54 11.29 11.29 NA NA 10.54 11.29 11.29 NA NA 20.52 22.70 23.89 11.29 NA NA 10.57 11.20 11.25 NA NA 20.52 22.50 11.20 NA NA 10.57 11.20 11.25 NA NA 20.52 22.50 11.20 NA NA 13.59 11.30 11.30 NA NA 20.72 22.50 11.20 NA NA 13.59 11.35 NA NA 20.72 22.50 11.20 NA NA 13.59 11.35 NA NA 20.72 22.50 11.30 NA NA 13.59 11.35 NA NA 20.72 22.50 11.30 NA NA 20.72 22.50 11.30 NA NA 13.59 11.35 NA NA 20.72 22.50 11.30 NA NA 13.59 11.35 NA NA 20.72 22.50 11.30 NA NA 14.88 12.18 22.34 NA NA 20.71 22.34 12.30 NA NA 14.88 12.18 22.34 NA NA 20.91 22.35 11.35 NA NA 20.91 22.35 NA NA 15.74 11.35 20.35 NA NA 15.74 11.30 NA NA 20.50 20.35 11.35 NA NA 15.74 11.30 11.30 NA NA 20.50 20.35 11.30 NA NA 20.51 11.	1182 8657 5305 7.99 9.02 1.53 99.92 6640 21.34 22.37 1100 7.21 9.70 9.81 1.83 11.87 1.24 NA NA S. 6.29 1.25 NA NA S. 6.29 1.50 7.21 9.70 9.81 1.83 11.87 1.24 NA NA S. 6.29 1.25 NA NA S. 6.29 1.20 NA NA S. 6.29 1.25 NA
1.00 NA	7.7.1 7.7.2 9.7.8 7.7.7 1.2.9 NA 6.94 7.7.7 1.2.9 NA NA 6.94 7.7.7 1.1.8 1.2.4 NA NA 1.9.23 1.9.7 1.1.9 2.2.4 NA NA 2.0.06 14.20 NA NA 11.31 11.37 1.7.2 2.2.4 NA NA 2.0.06 23.83 NA NA 10.93 11.80 1.7.8 NA 2.0.06 2.0.76 23.83 NA NA NA 1.2.6 NA NA 2.0.06
15.65 NA NA 11.31 11.87 2.24 NA NA 26.62 27.27 NA NA 26.62 27.27 NA NA 10.64 11.29 1.78 NA NA 26.62 27.27 NA NA 10.64 11.29 1.28 NA NA 26.62 27.27 NA NA 10.64 11.29 1.28 NA NA 26.62 27.27 NA NA 10.64 11.29 1.28 NA NA 26.62 27.27 12.70 NA NA 10.69 1.49 1.26 1.26 1.26 2.36 1.41 2.83 NA NA 26.71 26.26 27.21 26.29 1.26 1.26 1.26 7.51 8.83 1.55 2.66 1.26 26.26 27.27 22.59 1.27 2.39 NA NA 26.27 2.39 NA NA 26.27 2.39 NA NA 26.27 2.39 1.36 1.36 NA NA 26.27 2.39 1.36 NA NA 26.27 2.39 1.36 NA NA 14.88 21.89 3.42 NA NA 26.29 1.36 1.36 1.36 NA NA 15.74 19.99 3.65 NA NA 26.29 1.37 1.36 1.36 1.36 NA NA 15.74 19.99 3.65 NA NA 26.29 1.37 1.36 1.36 1.36 NA NA 26.20 2.36 1.37 1.36 1.36 1.37 1.39 1.30 1.30 1.30 1.30 1.30 1.30 1.30 1.30	15.65 NA NA 11.31 11.87 2.24 NA NA 26.52 27.27 NA NA 15.50 29.30 11.20 NA NA 15.77 11.87 2.24 NA NA 26.52 27.27 NA NA 10.64 11.29 1.25 NA NA 26.52 27.27 NA NA 10.64 11.29 1.25 NA NA 26.52 27.27 NA NA 10.53 11.80 1.25 NA NA 26.52 27.34 28.11 2.25 NA NA 26.52 27.35 NA NA 10.53 11.80 NA NA 13.33 11.54 2.88 NA NA 26.52 27.51 28.30 11.35 NA NA 26.52 27.34 28.10 27.30 24.30 11.24 28.30 11.25 NA NA 26.52 27.31 27.32 22.34 11.35 NA NA 26.52 27.31 27.32 27.34 28.10 27.32 27.32 27.34 28.10 27.32 27.32 27.34 28.10 27.32 27.32 27.34 28.10 27.32 27.32 27.34 28.10 27.32 27.32 27.34 28.10 27.32 27.32 27.34 2
14.20 NA 11.29 1.78 NA NA 10.64 11.29 1.78 NA NA 27.27	14.20 NA NA 11.29 1.78 1.78 NA A 2.85 27.27
23.83 NA NA 15.77 17.02 3.25 NA NA 42.85 44.10 13.23 13.24 10.93 11.90 11.25 NA NA 26.28 44.10 12.70 NA NA 16.57 9.39 11.90 12.5 NA NA 26.28 22.50	23.83 NA NA 15.77 17.02 3.25 NA A 42.86 44.10 12.78 NA NA 11.80 1.12 NA NA 42.86 44.10 12.78 NA NA 16.33 11.80 1.12 NA A 6.28 44.10 12.70 NA 18.39 1.36 1.44 7.99 9.39 1.19 27.34 28.11 21.96 23.60 12.70 NA NA 1.35 16.41 1.26 2.48 37.10 37.54 30.91 32.97 12.70 NA NA 1.33 1.54 1.50 NA A 6.25 22.50 22.50 18.00 NA NA 1.33 1.54 1.50 NA A 6.25 22.50 22.50 22.50 22.50 22.50 22.50 22.50 22.50 22.50 22.50 22.50 22.50 22.50 22.50 22.50 22.50 22.50 22.50
12.23	12.23 13.74 14.14 7 10.93 11.39 1.15 27.34 28.14 20.25 22.54 12.50 NA NA 20.72 22.50 NA NA 13.57 14.14 7 10.93 11.39 11.39 NA NA 20.72 22.50 NA NA 13.57 14.36 12.50 NA NA 20.73 22.34 28.15 12.50 NA NA 20.73 22.35 22.74 20.50 NA NA 20.73 22.35 22.74 20.50 NA NA 20.73 20.85 20.74 20.50 NA NA 20.73 20.85 20.74 20.50 NA NA 20.73 20.85 20.74 20.70 12.50 NA NA 20.73 20.85 20.70 12.50 NA NA 20.73 20.85 20.70 12.50 NA NA 20.73 20.85 20.74 20.70 12.50 NA NA 20.73 20.85 20.70 12.50 NA NA 20.73 20.85 20.70 NA NA 20.73 20.85 20.70 12.50 NA NA 20.73 20.85 20.70 NA NA 20.73 20.85 20.74 NA NA 20.73 20.85 20.70 NA NA 20.73 20.85 20.74 NA NA 20.73 20.73 20.85 20.74 NA NA 20.73 20.
12.70 NA NA 13.59 16.41 2.83 NA NA 20.72 22.50 18.00 NA NA 13.59 16.41 2.83 NA NA 15.50 16.41 2.83 NA NA 15.30 17.10 NA NA 14.88 21.89 3.42 NA NA 14.17 17.32 NA NA 14.17 17.25 NA NA 14.17 17.26 NA NA 14.17 17.26 NA NA 14.17 17.27 NA NA 14.17 17.20 NA NA 16.14 18.86 17.00 NA NA 16.14 17.07 18.09 17.07 17.07 18.09 17.07 18.09 17.07 17.07 18.09 17.07 18.09 17.07 17.07 18.09 17.07 17.07 18.09 17.07 17.07 18.09 17.07 17.07 18.09 17.07 17.07 18.09 17.07 17.07 18.09 17.07 17.07 18.09 17.07 17.	12.70 NA NA 13.59 16.41 2.83 NA NA 20.72 22.50 16.41 2.83 NA NA 13.59 16.43 37.10 37.54 30.91 32.97 17.62 NA NA 14.88 21.89 3.42 NA NA 14.89 21.89 3.42 NA NA 14.17 17.25 NA NA 17.38 18.74 17.37 18.26 NA NA 17.38 18.74 17.37 18.26 NA NA 17.38 18.74 17.37 18.26 NA NA 17.38 18.74 18.75 NA NA 17.38 18.75 NA N
23.91 NA NA 13.59 16.41 2.83 NA 40.33 43.15 12.46 12.26 7.51 8.93 1.55 26.61 26.26 22.94 18.49 16.13 16.57 9.94 12.00 2.38 NA 37.54 30.91 32.97 18.00 NA NA 13.36 1.56 0.97 NA NA 28.80 30.18 17.02 NA NA 11.36 0.97 NA NA 28.80 30.18 17.06 NA NA 11.36 0.97 NA NA 28.80 30.18 30.60 NA NA 12.60 NA A7.39 51.07 20.35 NA NA 11.70 NA NA 40.91 30.60 NA NA 11.70 NA A7.39 51.07 20.35 NA NA 11.36 1.70 NA A8.19 40.91 <td< td=""><td>23.91 NA 13.59 16.41 2.83 NA 40.33 43.15 12.46 12.80 12.25 7.51 8.93 1.55 26.61 26.26 22.94 18.49 16.13 16.57 9.98 11.36 1.59 NA NA A.83.71 37.54 30.91 32.97 18.00 NA NA 19.38 11.36 1.50 NA NA 33.71 35.81 32.97 17.02 NA NA 19.88 11.36 1.50 NA NA 33.71 35.81 32.97 30.60 NA NA 14.17 17.85 2.62 NA NA 47.39 30.18 30.60 NA NA 14.17 17.85 2.62 NA NA 47.39 51.07 30.60 NA NA 14.17 17.85 2.62 NA NA 47.39 51.07 20.56 NA NA 17.91 17.</td></td<>	23.91 NA 13.59 16.41 2.83 NA 40.33 43.15 12.46 12.80 12.25 7.51 8.93 1.55 26.61 26.26 22.94 18.49 16.13 16.57 9.98 11.36 1.59 NA NA A.83.71 37.54 30.91 32.97 18.00 NA NA 19.38 11.36 1.50 NA NA 33.71 35.81 32.97 17.02 NA NA 19.88 11.36 1.50 NA NA 33.71 35.81 32.97 30.60 NA NA 14.17 17.85 2.62 NA NA 47.39 30.18 30.60 NA NA 14.17 17.85 2.62 NA NA 47.39 51.07 30.60 NA NA 14.17 17.85 2.62 NA NA 47.39 51.07 20.56 NA NA 17.91 17.
12.46 12.25 7.51 8.93 1.55 26.61 26.26 22.34 18.40 16.57 9.94 12.00 2.48 37.10 37.54 30.91 32.97 18.40 NA NA 13.33 15.44 15.74 15.35 16.60 NA NA 16.14 18.86 17.70 NA NA 20.29 20.85 17.07 18.09 17.09	12.46 12.25 7.51 8.93 1.55 26.61 26.26 22.94 18.49 16.13 16.57 9.94 12.00 2.48 37.10 37.54 30.91 32.97 18.00 NA NA 13.33 15.48 12.00 2.48 37.10 37.54 30.91 32.97 18.00 NA NA 11.36 0.97 NA NA 28.80 30.18 33.66 NA NA 11.36 0.97 NA NA 28.80 30.18 30.60 NA NA 14.88 21.89 3.42 NA A7.39 51.07 20.35 NA NA 14.73 17.85 26.91 30.18 40.91 20.35 NA NA 14.73 17.85 26.91 17.07 18.09 20.35 NA NA 14.73 17.84 5.90 0.72 20.34 40.91 11.59 NA NA
10.49 10.15	10.00
17.32 NA NA 9.98 11.36 NA NA 28.18 30.18 30.18 30.8 3.66 NA NA 14.17 17.85 2.66 NA NA 47.39 51.07 20.35 NA NA 16.14 18.86 1.70 NA NA 47.39 51.07 20.35 NA NA 16.14 18.86 1.70 NA NA 46.05 49.40 10.46 11.17 11.53 5.89 6.91 0.72 22.35 22.71 17.07 18.09 10.46 11.17 11.53 5.89 6.91 0.72 22.35 22.71 17.07 18.09 11.59 NA NA 5.84 5.90 0.26 NA NA 8.57 8.74 1.78 NA NA 5.84 5.90 0.00 0.00 0.00 0.00 0.00 0.00 0.00	17.32 NA 9.98 11.36 1.50 NA NA 28.14 30.18 17.66 NA NA 9.98 11.36 1.50 NA NA 28.30 30.18 33.66 NA NA 14.88 21.89 3.42 NA NA 28.14 30.58 30.60 NA NA 14.17 17.85 2.62 NA NA 47.39 51.07 20.60 NA NA NA 14.17 17.85 2.62 NA NA 49.40 51.07 20.60 NA NA NA 16.99 3.65 NA NA 46.05 58.97
17.66 NA NA 9.51 11.95 0.97 NA NA 51.96 58.97 33.66 NA NA 14.78 21.89 3.42 NA NA 51.96 58.97 20.56 NA NA 14.17 17.85 2.62 NA NA 46.05 58.97 20.56 NA NA 14.17 11.53 5.89 6.91 0.72 22.35 22.71 17.07 18.09 10.46 11.17 11.53 5.89 6.91 0.72 22.35 22.71 17.07 18.09 10.46 11.17 11.53 5.89 6.91 0.72 22.35 22.71 17.07 18.09 10.46 11.17 11.53 5.84 5.90 0.42 NA NA 4.49 4.90 10.46 NA NA 2.22 5 0.42 NA NA 4.49 5.08 6.84 NA 7.44 5.05 <td>17.66 NA NA 9.51 11.95 0.97 NA NA 51.96 58.97 33.66 NA NA 14.88 21.89 3.42 NA NA 51.96 58.97 30.60 NA NA 14.17 17.85 2.62 NA NA 47.39 51.07 20.55 NA NA 16.14 18.86 1.70 NA NA 46.05 58.97 20.66 NA NA 16.44 18.86 1.70 NA NA 46.05 58.97 20.66 NA NA NA 1.78 0.72 22.35 22.71 17.07 18.09 10.46 11.17 11.53 5.89 6.91 0.72 22.35 22.71 17.07 18.09 11.59 NA NA 7.44 4.43 0.26 NA NA 4.56 4.49 4.61 NA NA 2.62 NA NA 4.49</td>	17.66 NA NA 9.51 11.95 0.97 NA NA 51.96 58.97 33.66 NA NA 14.88 21.89 3.42 NA NA 51.96 58.97 30.60 NA NA 14.17 17.85 2.62 NA NA 47.39 51.07 20.55 NA NA 16.14 18.86 1.70 NA NA 46.05 58.97 20.66 NA NA 16.44 18.86 1.70 NA NA 46.05 58.97 20.66 NA NA NA 1.78 0.72 22.35 22.71 17.07 18.09 10.46 11.17 11.53 5.89 6.91 0.72 22.35 22.71 17.07 18.09 11.59 NA NA 7.44 4.43 0.26 NA NA 4.56 4.49 4.61 NA NA 2.62 NA NA 4.49
33.66 NA NA 14.88 21.89 3.42 NA NA 51.96 58.97 30.00 NA NA 14.17 17.85 2.62 NA NA NA 14.79 51.07 NA NA 14.79 51.07 NA NA 15.74 19.09 3.66 NA NA 20.29 20.85 11.15 NA NA 2.61 2.55 0.16 NA NA 4.55 4.49 11.10 0.00 0.00 0.00 0.00 0.00 0.00 0.	33.66 NA NA 14.88 21.89 3.42 NA NA 51.96 58.97 20.35 NA NA 15.74 19.09 3.65 NA NA 46.05 51.07 20.66 NA NA 15.74 19.09 3.65 NA NA 46.05 51.07 10.46 11.17 11.53 5.89 6.91 0.72 22.35 22.71 17.07 18.09 11.59 NA NA 2.61 2.55 0.16 NA NA 4.55 4.49 1.78 NA NA 2.61 2.55 0.16 NA NA 4.55 4.49 1.78 NA NA 5.46 5.05 0.00 0.00 0.00 0.00 0.00 0.00 1.85 4.65 NA NA 6.72 1.25 1.25 1.65 0.14 6.08 5.98 3.26 1.85 A.05 NA NA 7.44 9.15 0.25 NA NA 17.33 18.74 1.86 NA NA 8.16 9.25 NA NA 17.33 18.74 15.30 1.87 NA NA 1.65 NA NA 1.65 NA NA 11.04 12.47 16.26 1.88 NA NA 1.25 N.54 NA NA 11.04 12.47 16.26 1.89 NA NA 1.65 NA NA 1.65 NA NA 11.04 12.47 16.26 1.80 NA NA 1.65 NA NA 1.65 NA NA 11.04 12.47 16.26 1.80 NA NA 1.65 NA NA 1.65 NA NA 11.04 12.47 16.26 1.80 NA NA 1.65 NA NA 1.65 NA NA 11.04 12.47 16.26 1.80 NA NA 1.65 NA NA 1.65 NA NA 11.04 12.47 16.26 1.80 NA NA 1.65 NA NA 1.65 NA NA 11.04 12.47 16.26 1.80 NA NA 1.65 NA NA 1.65 NA NA 11.04 12.47 16.26 1.80 NA NA 1.65 NA NA 1.65 NA NA 11.04 12.47 16.26 1.80 NA NA 1.65 NA NA 1.65 NA NA 11.04 12.47 16.26 1.80 NA NA 1.65 NA NA 1.65 NA NA 11.04 12.47 16.26 1.80 NA NA 1.65 NA NA 1.65 NA NA 11.04 12.47 16.26 1.80 NA NA 1.65 NA NA 1.65 NA NA 11.04 12.47 16.26 1.80 NA NA 1.65 NA NA 1.65 NA NA 11.04 12.47 16.26 1.80 NA NA 1.65 NA NA 1.65 NA NA 11.04 16.26 NA NA 11.04 NA
20.35 NA NA 14.17 11.53 5.89 6.91 0.72 22.35 22.71 17.07 18.09 11.59 NA NA 15.74 19.09 3.66 NA NA 20.29 20.85 11.59 NA NA 2.61 2.55 0.16 NA NA 4.55 4.49 11.10 0.00 0.00 0.00 0.00 0.00 0.00 0.	20.35 NA NA 14.17 11.53 5.89 6.91 0.72 22.35 22.71 17.07 18.09 10.04 11.59 NA NA 15.74 19.09 3.65 NA NA 16.75 18.09 11.59 NA NA 15.74 19.09 3.65 NA NA 46.05 49.40 11.59 NA NA 42.6 6.91 0.72 22.35 22.71 17.07 18.09 11.59 NA NA 42.6 4.43 0.26 NA NA 4.55 4.49 10.00 0.00 0.00 0.00 0.00 0.00 0.00 0.
26.66 NA NA 15.74 19.09 3.65 NA NA 46.05 10.00 11.53 5.89 6.91 3.65 NA NA 46.05 10.00 11.59 NA NA 5.84 6.91 0.72 22.35 22.71 17.07 18.09 11.59 NA NA 5.84 5.90 0.42 NA NA 13.10 13.16 NA NA 2.61 2.55 0.16 NA NA 4.55 4.49 1.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00	26.66 NA NA 15.74 19.09 3.65 NA NA 46.05 49.40 11.59 NA NA 46.05 11.17 11.53 5.89 6.91 0.72 22.35 22.71 17.07 18.09 11.59 NA NA 46.05 10.00 0.42 NA NA 46.05 10.00 20.85 10.00 0.00 0.00 0.00 0.00 0.00 0.00 0.
11.17 11.53 5.89 6.91 0.72 22.35 22.71 17.07 18.09 NA NA 5.84 5.90 0.42 NA NA 20.29 20.85 NA NA 2.61 2.55 0.16 NA NA 4.55 4.49 NA NA 5.46 5.05 0.00 0.00 0.00 0.00 0.00 0.00 0.28 1.84 0.28 0.27 0.13 2.83 0.74 0.77 4.46 4.29 1.65 1.85 0.18 6.08 5.98 3.28 3.56 NA NA NA 6.72 8.15 0.31 NA NA 11.04 12.47 NA NA NA 1.4 0.56 NA NA 13.62 15.32 NA NA NA 146 9.55 0.74 NA NA 15.71 16.26 NA NA NA 146 1.53 0.18 0.31 NA NA 15.71 16.26 NA NA NA 146 1.53 0.18 0.56 NA NA 15.71 16.26 NA NA NA 146 1.54 0.55 NA NA 15.71 16.26	11.17 11.53 5.89 6.91 0.72 22.35 22.71 17.07 18.09 NA NA 5.84 5.90 0.42 NA NA 20.29 20.85 NA NA 2.61 2.55 0.16 NA NA 4.55 4.49 NA NA 5.46 5.05 0.00 0.00 0.00 0.00 0.00 0.28 1.84 0.28 0.27 0.13 1.13 2.69 1.13 1.12 1.97 2.20 0.11 0.14 0.05 2.69 1.13 1.12 1.05 3.95 1.25 1.53 0.18 6.08 5.98 3.28 3.72 NA NA NA 6.72 8.15 0.31 NA NA 17.33 18.74 NA NA 8.16 9.25 0.55 NA NA 17.33 18.74 NA NA 8.16 9.25 0.55 NA NA 17.33 18.74 NA NA 8.16 9.25 0.55 NA NA 17.33 18.74
NA NA NA 7.41 7.97 1.29 NA NA 20.29 20.85 NA NA NA 5.84 5.90 0.42 NA NA 8.74 NA 20.29 20.85 NA NA NA 2.61 2.55 0.06 NA NA 4.55 4.49 NA NA 10.41 10.00 0.00 0.00 0.00 0.00 0.00 0.	NA NA 7.41 7.97 1.29 NA NA 20.29 20.85 NA NA NA 5.64 5.90 0.42 NA NA 13.10 13.16 NA NA 2.61 2.55 0.16 NA NA 4.55 4.49 NA NA 5.46 5.05 0.34 NA NA 10.41 10.00 0.00 0.00 0.00 0.00 0.00 0.
NA N	NA NA 5.84 5.90 0.42 NA NA 13.10 13.16 NA NA NA 13.10 NA
NA N	NA NA 5-46 5.05 0.16 NA NA 4.29 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
NA NA NA S.46 5.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00	NA NA 5.46 5.29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0
1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00	1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.58	0.58
0.58 1.97 2.20 0.11 0.14 0.05 2.60 2.83 0.74 0.77 1.76 4.46 4.29 1.65 1.82 0.14 6.36 6.19 3.55 3.72 4.01 NA NA 6.72 0.15 0.14 6.36 6.19 3.55 3.72 4.01 NA NA 6.72 8.15 0.31 NA 11.04 12.47 5.62 NA NA 7.44 9.14 0.56 NA NA 17.33 18.74 6.46 NA NA 8.16 0.74 0.75 NA 17.33 18.74	0.58 1.97 2.20 0.11 0.14 0.05 2.60 2.83 0.74 0.77 1.76 4.46 4.29 1.65 1.82 0.14 6.36 6.19 3.55 3.72 1.85 4.05 3.95 1.25 1.53 0.18 6.08 5.98 3.28 3.56 1.24 1.04 1.05 1.05 1.05 1.05 1.05 1.05 1.05 1.05
1.76 4.46 4.29 1.65 1.82 0.14 6.36 6.19 3.55 3.72 3.72 1.85 4.05 3.95 1.25 1.53 0.18 6.08 5.98 3.28 3.56 4.01 NA 6.72 8.15 0.31 NA NA 6.72 8.15 0.31 NA NA 17.44 9.15 0.74 NA 17.31 18.74 6.46 NA NA 8.16 9.25 NA NA 15.77 16.28	1.76 4.46 4.29 1.65 1.82 0.14 6.36 6.19 3.55 3.72 1.85 4.05 3.95 1.25 1.53 0.18 6.08 5.98 3.28 3.56 4.01 NA NA 6.72 8.15 0.31 NA NA 11.04 12.47 5.62 NA NA 7.74 9.15 0.56 NA NA 13.62 15.32 8.85 NA NA 8.16 9.25 0.55 NA NA 15.77 16.26
1.85 4.05 3.95 1.25 1.53 0.18 6.08 5.98 3.28 3.56 3.56 4.01 NA NA 6.72 8.15 0.31 NA NA 11.04 12.47 12.47 5.62 NA NA 7.74 9.15 0.74 NA 17.33 18.74 8.85 NA NA 15.17 16.28	1.85 4.05 3.95 1.25 1.53 0.18 6.08 5.98 3.28 3.56 4.01 NA NA 6.72 8.15 0.31 NA NA 11.04 12.47 5.62 NA NA 7.44 9.14 0.56 NA NA 17.32 8.85 NA NA 7.74 9.15 0.74 NA NA 17.33 18.74 6.46 NA NA 15.17 16.26
4.01 NA NA 6.72 8.15 0.31 NA NA 11.04 12.47 15.32 8.88 NA NA 7.74 9.15 0.74 NA NA 15.32 18.74 8.85 NA NA 8.16 9.25 NA NA 15.17 16.26 NA NA 15.17 16.26 NA NA 15.17 16.26	4.01 NA NA 6.72 8.15 0.31 NA NA 11.04 12.47 5.62 NA NA 7.44 9.14 0.56 NA NA 13.62 15.32 8.85 NA NA 7.74 9.15 0.74 NA 17.33 18.74 6.46 NA NA 15.17 16.26
5.62 NA NA 7.44 9.14 0.56 NA NA 13.62 15.32 8.85 NA NA 7.74 9.15 0.74 NA NA 15.31 18.74 6.46 NA NA 8.16 9.25 0.55 NA NA 15.17 16.26	5.62 NA NA 7.44 9.14 0.56 NA NA 13.62 15.32 15.32 8.85 NA NA 7.74 9.15 0.74 NA NA 17.33 18.74 6.46 NA NA 8.16 9.25 0.55 NA NA 15.17 16.26
0.00 NA NA 8.16 9.25 0.75 NA NA 15.17 16.26	6.46 NA NA 8.16 9.25 0.55 NA NA 15.17 16.26

The control of the																																		_	_		_
A	060 060 060	060	090	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	000	060	060	060	060	060	010	060	060	060	060	060	060	060	060
A	7.00 20.45 22.37 20.54 30.21	16.56 24.26 29.79	29.70	13.45	31.94	17.10	19.55 19.52	24.73	7.28	16.41	22.69 14.90	17.31	17.84	17.37	34.12	50.24 10.11	15.15	10.86	7.43	14.00	22.57	23.68	0.86	13.03	15.60	12.87	7.95	13.74	3.94	8.15	15.07	13.80	18.05	13.76	14.25	33.00 32.79	25.26
The transmitted fracture S.70 S.7 S.6 S.6 S.5 S.6 S.5 S.6 S.6 S.7	6.84 17.18 19.92 19.76 27.99	15.67 23.18 26.32	26.18 7.60 9.02	12.94	31.20	16.06	18.27 18.96	23.80	6.99	15.68	21.96 15.39	16.34	17.70	16.71	32.67	11.21	15.33	15.62	8.39	13.53	22.52 25.09	22.52	0.85	14.17	16.46	13.99	7.66	13.09	3.95	8.31	14.37	13.84	17.13	21.45	13.74	32.03	23.64
Treat rease fraction floatine mean transfer mean transfe	0. 46. N N N N N N N N N N N N N N N N N N N	19.49 NA NA	10.68	Z Z	(₹ ₹ ?	A A	A A	11.69	₹ ₹	NA 16.45	₹ S	₹ ₹	Α Δ Ζ Ζ	Z Z	11.48	17.15	16.24	15.21	2 Y	38.58 43.24	Z Z	2.38	14.21	₹ ₹ Z Z	14.18	10.65	Ψ Ψ Z Z	5.98	10.47 NA	₹ Z	4 4 Ζ Ζ	₹ Z	 ∢	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	▼	_ V
A Treat ness septimed fracture B 37	0.0 Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	19.38 NA NA	10.21	2 Z Z	((▼ Z Z	NA 4	11.10	ζ ζ Z Z	NA 18.52	Y S	ζ ζ Ζ	Z Z	Z Z	13.89	19.20	14.21	14.27	N A	51.16	Z	2.18	17.19	ξ Z Z	16.81	10.65	Y Y	6.50	10.66 NA	Y Z	Z Z	Y S		\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	4 4 2 2	– V
A Treat nasothmod fracture 6.70 NA NA 1.05	0.28 0.82 0.96 1.15 1.47	0.92	0.34 48.48	0.74	2.49	0.97	0:90	1.44 4.5	0.38	0.94	0.73	0.99	0.70	0.81	1.98	93.00 93.00	0.78	0.63	0.27	0.82	0.98	1.50	0.06	0.51	0.46	0.50	0.43	0.97	0.16	0.56	1.08	3.07	1.45	1.86 0.98	1.02	2.58	1.06
A Treat neasethmol fracture 3.7 6.06	3.52 12.93 13.08 8.14 14.73 15.64	6.87 11.84 15.03	9.94 3.36	5.76	11.09	6.73	7.61	8.71	. 8.39 60.00	9.83 6.62	8.64	7.76	9.48	7.84	12.22	17.26	8.43	7.06 8.71	4.93	6.11	12.64	9.42	0.19	8.04	8.23 8.71	8.02	3.72	5.42	1.72	3.25 4.08	5.12	5.75	6.38	7.80	6.13	10.74	9.43
A Treat reasothmed fracture 8.32 NA	3.36 9.66 10.63 7.36 12.51	5.98 10.76 11.56	6.42 3.00 9.00	5.25	10.35	5.69	7.25	7.78	3.10	5.89	7.91 8.96	6.79	9.34	7.18	10.77	7.63	8.61	9.63	5.89	5.64	12.59	8.26	0.18	9.18	9.57	9.14	3.43	4.77	1.73	3.41	4.42	5.79 8.13	5.46	7.15	5.62	9.62	7.81
A Treat ness/ proper fracture 8.00	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	9.80 NA NA	0.08	Z Z	(₹ ₹ ;	Ψ Ψ Z Z	N 6	7.80	₹ ₹	10.02	₹ ₹	ζ ∢ Ζ Ζ	▼	₹ Z	NA 7.90	10.43	8.14 10.25	12.71	* 4 * Z	31.32	4	1.7.1	9.22	₹ ₹ Z Z	9.33	6.42	A A	3.76	5.57 NA	Z Z	Δ Δ Ζ Ζ	₹ Z		Z Z	▼	– V V
Treat nasolethoid fracture		9.69 NA AN	5.61	2 Z Z	(₹ ₹ :	Ψ Ψ Z Z	NA VZ	7.21	₹ ₹ 2 Z	12.09	₹ \$ 2 2	₹ ₹	▼	₹ Z	10.31	12.48	10.41	11.77	† 4 ? Z	41.23	₹ Z Z	1.51	12.20	₹ ₹ 2 Z	11.96	6.42	A A	4.28	5.76 NA	Z Z	Δ Δ Ζ Ζ	₹ Z		Z Z	▼	– V V
<u></u>	8.33 11.25 14.01	8.77 11.21 13.29	17.28 4.26 4.64	6.95	18.36	9.40	9.94	14.58	3.51	8.85	12.61	8.56	7.66	8.72 26.05	19.92	29.89 3.20	5.94	3.47	2.23	7.07	8.95 10.65	12.76	0.61	4.48	6.43	4.35	3.80	7.35	2.06	4 r 46 r 47 r	8.87	7.06	10.22	12.44	7.10	18.90	14.77
<u></u>	ture stare star stare star star star star star star star star		ure	ure	ure		rre	Te					ure	Jre	ure	ure	nre	Φ Φ	0 0	о Ф	Φ Φ	0 0	Φ.		ıre	q				hest	hest			Ves		gery	ension
<u></u>	nasal septal fracinasoethmoid fracinasoethmoid fracinent of nose fracient of sinus fracinent of sinus fracinant of sinus fracinant of sinus fracinant and sinus fracinant and sinus fracinant and sinus fracinant and sinus fracinative sinus frac	nose/jaw fracture nose/jaw fracture nose/jaw fracture	nose/jaw fracture cheek bone fract	cheek bone fract	cheek bone fract	eye socket fractu	eye socket fractu eye socket fractu	eye socket fractu	eye socket fractu	eye socket macu eye socket fractu	eye socket fractu mouth roof fractu	mouth roof fractu	oraniofacial fracti	craniofacial fracti	craniofacial fracti	craniotacial tracti dental ridge fract	dental ridge fract	ower jaw fractur ower jaw fractur	ower jaw fractur	ower jaw fractur	ower jaw fractur ower jaw fractur	ower jaw fractur	ower Jaw rractur dislocated jaw .	dislocated jaw .	disiocated jaw nyoid bone fractu	ental wiring	neck/chest lesion	chest lesion	of neck/chest	ve lesion, neck/c	ve tumor, neck/c	removal of rib .	val of rib	val of rib and ner	I debridement	sive sternum surg sive sternum surg	myotomy & susp
	Treat	Treat Treat Treat	Treat C	Treat	Treat	Treat	Treat	Treat	Treat	Treat	Treat	Treat	Treat	Treat	Treat	Treat (Treat	Treat I	Treat	Treat	Treat	Treat	Reset	Reset	Treat	Interde	Drain	Draina	Biopsy	Remo	Remo	Partial	Remo	Remo	Sterns	Extens	Hyoid
	44444	444	444	< <	< <	٠ ◄ ٢	∢ ∢	∢ ⊲	< <	< <	∢ ∢	⋖ <	< <	∢	< <	∢ ∢	< <	∢ ∢	∢	< <	∢ ∢	< <	∢ ∢	⋖ <	∢ ∢	∢ C) «	∢ ∢	< <	∢ ⊲	< ∢	∢ ∢	< ✓	۷ ۵	∶∢•	∢ ∢	4
																									21490 .					21555 .	21557			21616	21627	21630	21685 .

BELATIVE VALUE UNITS (BVUS) AND BELATED INFORMATION USED IN DETERMINING MEDICABE PAYMENTS FOR 2007-

ADE	ADDENDUM B		-RELATIVE VALUE UNITS (RVUS) AND	RELATED	INFORMATION U	ഗ	ed In Det	ETERMINING	MEDICAR	RE PAYMENTS	ENTS FOR	2007	Continued	-
CPT¹/ HCPCS²	Mod	Status	Description	Physician Work RVUs	Fully Implemented Non-Facility	Year 2007 Transi- tional Non-Fa- cility PE RVUs	Fully Im- plement- ed Facil- ity PE RVUs	Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Prac- tice RVUs	Fully Implemented Non-Facility Total	Year 2007 Transi- tional Non-Fa- cility Total	Fully Im- plement- ed Facil- ity Total	Year 2007 Transi- tional Fa- cility Total	Global
21705		44	Revision of neck muscleRevision of neck muscle/rib	6.18	Y Y Z	Y Y	3.93	4.31	0.32	Y Z Z	Y Y	10.43	10.81	060
21720		4 4	Revision of neck muscle Revision of neck muscle	7.04	A A	Z Z	4.32	2.93 5.23	1.21	Z Z	A A		9.51 13.48	060
21740		. ∢ (Reconstruction of sternum	17.43	Y Y	N A	8.77	8.58	2.36	Y Y	Y Y		28.37	060
21742		ပပ	Repair stern/nuss w/o scope	00.0	00.0	00.0	00.0	00.0	00.0	00.0	00.0		00.0	060
		۰ ک	Repair of sternum separation	11.33	Y N	AN.	5.45	5.95	1.63	Z S	A S		18.91	060
21800		∢ ∢	I reatment of rib fracture	0.96	SE.T NA	1.34 NA	3.56	3.29	0.09	2.40 NA	2.39 NA		2.41 6.42	060
		∢.	Treatment of rib fracture(s)	6.85	A S	AN.	5.27	5.05	0.94	A S	AN S		12.84	060
21820		4 4	I reat sternum fracture	7.58	08.L NA	1.82 NA	1.87	6.16	1.16	3.24 NA	3.26 NA		3.23	060
21899		0 <	Neck/chest surgery procedure	0.00	0.00	0.00	0.0	0.00	0.00	0.00	0.00		0.00	χ.
21925		< <	Biopsy soft tissue of back	4.48	5.50	5.25	3.45	3.29	0.60	10.58	10.33		3.76 8.37	060
		< •	Remove lesion, back or flank	4.99	6.05	5.80	3.77	3.49	0.66	11.70	11.45		9.14	060
22010		∢ ∢	Remove tumor, back	18.29	Z Z	A Z	8.56	9.30	2.47	A A	A A		30.75 21.06	060
		. ⋖	I&d, p-spine, I/s/Is	12.38	Z	¥ Z	8.02	8.62	1.71	Z	Z Z		22.71	060
22100		∢ ⊲	Remove part of neck vertebra	10.72	A A	A Z	8.01	7.65	2.13	V Z	¥ Z		20.50	060
22102		< ∢	Remove part, lumbar vertebra	10.80	Z Z	Z Z	7.24	7.89	1.87	Z Z	Y Z	19.91	20.56	060
22103		∢ •	Remove extra spine segment	2.34	Y S	Y Z	0.89	1.13	0.44	Y S	Y S	3.67	3.91	ZZZ
22110		∢ ∢	Remove part of neck vertebra	13.72	Z Z	A Z	9.09	9.70	2 2.7	A A	A A	25.57	25.62	060
22114			Remove part, lumbar vertebra	13.79	Z Z	N N	9.08	9.21	2.63	A A	A A	25.50	25.63	060
22116			Remove extra spine segment	2.32	Z Z	¥ S	0.87	1.10	0.50	Y S	Y S	3.69	3.92	ZZZ
22212			Revision of thorax spine	20.64	ZZ	ZZ	12.49	13.08	3.90	Z Z	Z Z	37.03	37.62	060
			Revision of lumbar spine	20.67	Z Z	Y S	12.59	13.51	3.91	A S	Z Z	37.17	38.09	060
22220			Revise, extra spine segment	6.03	Y Y	¥ ¥ Z Z	13.42	13.57	5.06	Z Z	¥ ×	9.69	10.26	777
			Revision of thorax spine	22.74	Y :	A :	12.19	11.40	4.12	Y :	¥:	39.05	38.26	060
22224		∢ ⊲	Revision of lumbar spine	22.74	Y Z	Y Z	13.17	13.96	4.18	₹ Z	A A	40.09	40.88	060
22305		< ∢	Treat spine process fracture	2.05	2.16	2.27	1.81	1.89	0.39	4.60	4.71	4.25	4.33	060
22310		∢ <	Treat spine fracture	3.61	2.99	2.85	2.50	2.39	0.50	7.10	6.96	6.61	6.50	060
22318		(∢	Treat odontoid fx w/o graft	22.46	S N	S Z	13.25	13.35	5.28	AN AN	82:3 AN	40.99	41.09	060
		∢ <	Treat odontoid fx w/graft	25.07	Y S	Y S	14.00	14.53	6.03	Y Z	Y S	45.10	45.63	060
22326		< <	Treat neck spine fracture	20.56	Z Z	¥ ¥ Z Z	12.13	12.56	4.42	Y Y	₹ ₹ Z Z	37.11	37.54	060
		∢.	Treat thorax spine fracture	20.42	¥.	Y Z	12.07	12.29	3.98	Y Z	Y S	36.47	36.69	060
22328		∢ ⊲	I reat each add spine TX	1.87	Z Z	A Z	8. 6	2.75	0.94	A Z	A A	4. c.	3.20	010
		ζ∢.	Percut vertebroplasty thor	9.15	44.71	57.42	4.39	4.92	1.71	55.57	68.28	15.25	15.78	010
•		∢ ⊲	Percut vertebroplasty lumb	8.58	45.98 NA	53.47 NA	4.20	4.76	1.60	56.16 NA	63.65 NA	14.38	14.94	010
22523		< <	Percut kyphoplasty, thor	9.19	ZY	Z	4.75	5.61	1.71	Z Z	Z Z	15.65	16.51	010
22524		∢ <	Percut kyphoplasty, lumbar	8.79	Y Z	Y Z	4.60	5.42	1.60	Y Z	Y Z	14.99	15.81	010
22532		(∢	Lat thorax spine fusion	25.73	ZZ	ZZ	13.79	14.56	4.34	Z Z	Z Z	43.86	44.63	060
22533		∢ <	Lat lumbar spine fusion	24.53	Z Z	Y Z	13.43	13.55	3.15	Z Z	Y S	41.11	41.23	060
22548		< 4	Neck spine fusion	26.78	Z Z	Z Z Z Z	15.08	15.62	5.59	Z Z Z Z	Z Z Z Z	47.45	47.99	060

000N00000	NONOO	0000	10000	NNN	NNNO	0 N 0 0	> o > o	0000	000	000	000	000	000	00	000		000
060 060 060 060 060	ZZ 6 Z 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	00000	178881		8 2 2 2	8888	`\$8`\$8	86558	8685	00 10 00	6 6 6 6 6	60	000	60	n o o	200	600
33.87 43.08 39.25 9.39 39.53 37.54 37.54 40.84	10.95 39.89 8.88 35.34 56.72	65.77 47.84 53.85 58.41	221.11 21.38	22.56 27.78 20.48	21.28 23.37 10.12 34.28	18.60 11.36 17.78 28.79	0.00	18:00 6:77 5:80	18.75 14.87 4.11	8.67 4.50 14.31	30.42 12.59 11.67	16.57	14.61	15.71 13.14	16.06	16.74 20.52 17.55	13.94 14.10 19.55
32.67 41.83 37.93 8.86 39.36 37.37 37.37 32.12 31.40	39.17 39.17 8.39 34.12 54.15	62.40 46.00 51.28 55.93	20.47 20.47 20.14	21.55 21.55 26.07 19.34	20.07 22.11 9.51 33.19	18.24 10.77 17.36 28.50	0.00 10.41 0.00	6.40 5.43 5.43	17.95 14.24 71.4	8.38 4.47 41.41	30.12 12.21 11.11	15.82	13.89 14.4	14.94 12.84	16.52	19.09 19.79 16.83	13.23 13.12 18.75
4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	4 4 4 4 4 Z Z Z Z Z	4 4 4 4 2 2 2 2 2	4 4 4 4 5 2 2 2 2	4 4 4 4 2 2 2 2	4 4 4 4 2 2 2 2	4 4 4 4 2 2 2 2	0.00 NA 0.00	N 1.1.0	N N S	2.46 NA NA	4 4 4 2 2 2	4 4 5 2 2 3	4 4 4 2 2 2	Y Y	 &	4 4 4 2 2 2	4 4 4 2 2 2
							0 00	2 = 2	4)	74 0							
4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	4 4 4 4 4 2 2 2 2 2	4 4 4 4 2 2 2 2 2	Z Z Z Z	4 4 4 2 2 2 2	4 4 4 2 2 2 2	4 4 4 4 2 2 2 2	0.00 NA 0.00	10.31 9.73	N N S.38	12.50 6.47 NA	4 4 4 Z Z Z	Y Y Z	4 4 4 2 2 2	Z Z	A A S	4 4 4 2 2 2	A A A
ស្ ង្គ ស ស្សខ្	ထွပ္ျပည္လ	\$ \$ 0 0 8 L	ი დ დ დ <u>:</u>	4	က္က တက္က	400.5	0000	3 4 12 9 1	040	ŭ 4 ω	ŭ 4 ô	200	2 22 22	0 8	ත සී දි 		0 - 20
4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	8.4.1.8.9.	0.4.0.0.0	9. 5. 5. 5.	7 9 9 9	9. 9. - 8.	2. – – e 9. 4. 8. 8)	0.000	0.0	0	0.0	2. L. 0.	4.0.4		<u>+</u> +	4.00	 - : : : :	
11.24 12.85 13.27 13.27 11.28 13.88	3.14 3.36 2.50 2.37 8.74	7.57 5.69 7.50 9.23	9.32 7.75 6.08	6.27 8.18 5.69	5.93 6.60 2.98 1.37	6.87 3.17 6.65	0.00 3.31 0.00	2.78	6.22 1.64	3.89 1.77 5.50	0.11 5.53 5.14	6.87	6.22	6.87	7.04 6.83	6.71 8.09 7.14	5.79 5.96 8.10
10.74 13.07 11.53 2.09 13.10 12.61 11.28 10.88	2.49 12.64 2.01 11.15	18.20 13.85 14.93 16.75	19.65 19.45 7.11 4.84	6.47 6.47 6.55	4.72 5.34 2.37 10.28	6.51 2.58 6.23 9.28	0.00 3.56 0.00	6.51 2.23 2.23	6.80 5.59 1.70	3.60 1.74 5.33	9.81 5.15 4.58	6.12	5.50	6.10 4.82	5.83	6.42 6.42	5.08 4.98 7.30
	4444 ZZZZZ			4 4 4 4 2 2 2 2			0 A 0 0 8	N 7 7 8 8	2 A A 6		4 4 4 Z Z Z	4 4 5 2 2 2	4 4 4 2 2 2	4 4 2 2			
							0 0 8	7 /	7	~ ღ							
	4 4 4 4 4 2 2 2 2 2	4 4 4 4 Z Z Z Z Z	4 4 4 4 2 2 2 2	4 4 4 4 2 2 2 2	4 4 4 4 2 2 2 2	4 4 4 4 2 2 2 2	0.00 NA 0.00 7.833	6.32 6.53 6.53	2.91 2.91 2.91	7.72 3.74 NA	4 4 4 Z Z Z	A A S	4 4 4 2 Z Z	A A	 &		 & & & & Z Z Z
24.42 23.25 5.52 1.48 20.36 NA 20.36 NA 17.12 NA 17.00 NA 17.00 NA																	
24.48 23.25 5.52 20.38 20.38 17.00 22.50	21.81 5.22 19.22 31.83	37.22 27.23 31.22 33.90	39.12 39.10 11.07 12.52	13.44 16.42 11.94	12.40 13.78 5.99 19.02	9.69 6.70 9.24 15.71	0.00 6.09 0.00 4.35	9.16 3.42 2.74	9.55 9.55 2.27	4.15 2.39 7.68	17.98 6.02 5.57	8.28 5.95	7.16 7.16	7.54 6.94	9.20	8.71 10.63 8.91	7.03 7.13 9.80
24.48 23.25 5.52 20.38 20.38 17.00 22.50	21.81 5.22 19.22 31.83	37.22 27.23 31.22 33.90	39.12 39.10 11.07 12.52	13.44 16.42 11.94	12.40 13.78 5.99 19.02	9.69 6.70 9.24 15.71	0.00 6.09 0.00 4.35	9.16 3.42 2.74	9.55 9.55 2.27	4.15 2.39 7.68	17.98 6.02 5.57	8.28 5.95	7.16 7.16	7.54 6.94	9.20	8.71 10.63 8.91	7.03 7.13 9.80
24.48 23.25 5.52 20.38 20.38 17.00 22.50	21.81 5.22 19.22 31.83	37.22 27.23 31.22 33.90	39.12 39.10 11.07 12.52	13.44 16.42 11.94	12.40 13.78 5.99 19.02	9.69 6.70 9.24 15.71	0.00 6.09 0.00 4.35	9.16 3.42 2.74	9.55 9.55 2.27	4.15 2.39 7.68	17.98 6.02 5.57	8.28 5.95	7.16 7.16	7.54 6.94	9.20	8.71 10.63 8.91	7.03 7.13 9.80
24.48 23.25 5.52 20.38 20.38 17.00 22.50	21.81 5.22 19.22 31.83	37.22 27.23 31.22 33.90	39.12 39.10 11.07 12.52	13.44 16.42 11.94	12.40 13.78 5.99 19.02	9.69 6.70 9.24 15.71	0.00 6.09 0.00 4.35	9.16 3.42 2.74	9.55 9.55 2.27	4.15 2.39 7.68	17.98 6.02 5.57	8.28 5.95	7.16 7.16	7.54 6.94	9.20	8.71 10.63 8.91	7.03 7.13 9.80
24.48 23.25 5.52 20.38 20.38 17.00 22.50	21.81 5.22 19.22 31.83	37.22 27.23 31.22 33.90	39.12 39.10 11.07 12.52	13.44 16.42 11.94	12.40 13.78 5.99 19.02	9.69 6.70 9.24 15.71	0.00 6.09 0.00 4.35	9.16 3.42 2.74	9.55 9.55 2.27	4.15 2.39 7.68	17.98 6.02 5.57	8.28 5.95	7.16 7.16	7.54 6.94	9.20	8.71 10.63 8.91	7.03 7.13 9.80
24.48 23.25 5.52 20.38 20.38 17.00 22.50	21.81 5.22 19.22 31.83	37.22 27.23 31.22 33.90	39.12 39.10 11.07 12.52	13.44 16.42 11.94	12.40 13.78 5.99 19.02	9.69 6.70 9.24 15.71	0.00 6.09 0.00 4.35	9.16 3.42 2.74	9.55 9.55 2.27	4.15 2.39 7.68	17.98 6.02 5.57	8.28 5.95	7.16 7.16	7.54 6.94	9.20	8.71 10.63 8.91	7.03 7.13 9.80
17.48 17.48 19.00 19.00 19.00 19.00 17.12 17.12 19.00 17.00 10.00	21.81 5.22 19.22 31.83	37.22 27.23 31.22 33.90	39.12 39.10 11.07 12.52	13.44 16.42 11.94	12.40 13.78 5.99 19.02	9.69 6.70 9.24 15.71	0.00 6.09 0.00 4.35	9.16 3.42 2.74	9.55 9.55 2.27	4.15 2.39 7.68	17.98 6.02 5.57	8.28 5.95	7.16 7.16	7.54 6.94	9.20	8.71 10.63 8.91	7.03 7.13 9.80
A Thorax spine fusion	Spine fusion, extra segment 6.43 Lumbar spine fusion 21.81 Spine fusion, extra segment 5.22 Fusion of spine 19.22 Fusion of spine 13.23	A Fusion of spine 37.22 A Fusion of spine 27.23 A Fusion of spine 31.22 A Fusion of spine 33.90	Kyphectomy, 1–z segments 34-12 Kyphectomy, 3 or more 39-10 Exploration of spinal fusion 11.07 Insert spine fixation device 12.52	Insert spine fixation device	Insert spine fixation device	Apply spine fixation device	Spine surgery procedure 0.00 Remove abdominal wall lesion 6.09 Abdomen surgery procedure 0.00 Removal of calcium denosits 4.35	Release shoulder joint 9.16 Drain shoulder lesion 3.42 Drain shoulder bursa 2.74 Drain shoulder bursa 8 0.6	Exploratory shoulder surgery 9.55 Exploratory shoulder surgery 7.41 Biopsy shoulder tissues 2.27	Biopsy shoulder tissues 4.15 Removal of shoulder lesion 2.39 Removal of shoulder lesion 7.68	Remove tumor of shoulder	Remove shoulder joint lining	Explore treat shounder joint	Remove shoulder bone, part 7.54 Removal of bone lesion 6.94	Removal of bone lesion 9.20 Removal of bone lesion 7.88 Premoval of bremoval colors	Hemoval of numerus lesion 10.63	A Remove collar bone lesion
Neck spine fusion	A Spine fusion, extra segment 6.43 A Lumbar spine fusion 21.81 A Spine fusion, extra segment 5.22 A Fusion of spine 19.22 A Fusion of spine 31.83	A Fusion of spine 37.22 A Fusion of spine 27.23 A Fusion of spine 31.22 A Fusion of spine 33.30	Kyphectomy, 1–z segments 34-12 Kyphectomy, 3 or more 39-10 Exploration of spinal fusion 11.07 Insert spine fixation device 12.52	Insert spine fixation device	Insert spine fixation device	Apply spine fixation device	A Remove abdominal wall lesion 0.00 C Abdomen surgery procedure 0.00 C Abdomen congeny procedure 0.00 A Removal of calcium denosits 4.35	A Prain shoulder bursa A Drain shoulder bursa	Exploratory shoulder surgery 9.55 Exploratory shoulder surgery 7.41 Biopsy shoulder tissues 2.27	Biopsy shoulder tissues 4.15 Removal of shoulder lesion 2.39 Removal of shoulder lesion 7.68	Remove tumor of shoulder	Remove shoulder joint lining	Explore treat shounder joint	A Remove shoulder bone, part	A Removal of bone lesion	Hemoval of numerus lesion 10.63	Remove collar bone lesion
A Neck spine fusion	A Spine fusion, extra segment 6.43 A Lumbar spine fusion 21.81 Spine fusion, extra segment 5.22 A Fusion of spine 19.22 A Fusion of spine 31.83	A Fusion of spine 37.22	A Kyphedorffy, 1–2 segfrients 34.12 A Kyphoration of spinal fusion 11.07 A Kyphoration of spinal fusion 11.07 A Insert spine fixation device 12.52	Insert spine fixation device 12.50	New Taylor fixation device 12.40 New Taylor fixation device 12.40 New Taylor fixation device 12.78 New Taylor fixation device 5.99 New Taylor fixation 19.02 New Taylor fixation New Taylor fixation	A Remove spine fixation device 9.69	C Spine surgery procedure 0.00	Release shoulder joint	A Exploratory shoulder surgery 9.55	A Biopsy shoulder tissues	A Remove tumor of shoulder	New Shoulder joint lining 8.28 Remove shoulder joint		A Remove shoulder bone, part	A Removal of bone lesion	A Removal of humerus lesion	A Remove collar bone lesion
A Thorax spine fusion	A Spine fusion, extra segment 6.43 Lumbar spine fusion 21.81 Spine fusion, extra segment 5.22 A Pusion of spine 19.22 A Fusion of spine 31.83	A Fusion of spine 37.22 A Fusion of spine 27.23 A Fusion of spine 31.22 A Fusion of spine 33.90	A Kyphedoriny, 1–2 segments 34-12	12.50 12.5	12.40 12.40 12.40 12.40 12.40 12.40 12.40 13.78 13.7	A Remove spine fixation device		A Release shoulder joint 9.16	A Exploratory shoulder surgery 9.55 Exploratory shoulder surgery 7.41 Biopsy shoulder tissues 2.27	A Biopsy shoulder tissues	A Remove tumor of shoulder	New Shoulder joint lining 8.28 Remove shoulder joint	A Partial removal, collar bone	A Remove shoulder bone, part	New York A Removal of bone lesion 9.20 1.88 1.88 1.89	3150 A Hemoval of numerus lesion	A Remove collar bone lesion

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Description
collar bone lesion
louider blade lesion imerus lesion
oval of scapula
f collar bone
f shoulder blade
loval of humerus
oval of humerus
Remove shoulder foreign body
noulder foreign body
r shoulder x-ray
nsfer,shoulder/arm
nsters
tendon & muscle
on(s) & muscle(s)
ttor cuff, acute
shoulder ligament
houlder
sps tendon
ansplant tendon
Repair shoulder capsule Repair shoulder capsule
ulder capsule
ulder capsule
ulder capsule
t shoulder joint
x shoulder joint
Revision of collar bone
Revision of collar bone
Reinforce shoulder bones
ole fracture
clavicle fiacture
de dislocation
ale dislocation
cle dislocation
Treat clavicle dislocation
de dislocation
de dislocation
lder blade fx
Ider blade fx
ula fracture
erus fracture
numerus fracturehumerus fracture
humerus fracture
Transfer of the street

The state of the control of the co						_												_		_														_			
The filtren of the following statement 7.5 miles 7.4 miles 7.5 miles	060 060 060	060	010	060	060	۲۲ 010	010	060	090	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	010	060	000	060	060	060	060	060	060	060
A	8.78 15.07 6.45 9.42 14.96	15.91 12.71 19.81	5.07 26.55	35.11	11.35	0.00	4.14	12.15	18.52 4.02	10.08	12.03	21.13	12.87	16.01 8.51	15.07	22.80	13.49	16.40	13.08	16.43	19.49	16.50	29.57	25.56	19.01	17.79	15.74	3.53	9.37	9.97	19.69	15.04	19.82	18.76	15.44	15.98 18.32	20.68
The thrusts finding decoration 7.00 7.	8 50 14 36 6 48 6 48 14 40 6 43	15.20 12.21 18.99	4.88 24.40	34.37	11.20	0.00	3.82	11.68	4.12	9.94	11.83	10.05	12.23	15.23 8.25	14.32	21.75	12.96	15.80	12.41	15.27	16.27	15.18	29.00	24.47	17.93	17.30	14.94	3.34	8.98	1.82	18.69	14.25	19.50	17.83	14.67	15.24	19.62 17.34
Track Therebes fraction	9.41 NA NA NA NA NA	13.71 NA	4 4 4 Z Z Z	Z Z Z	X Z S	0.00 9.36	7.59 NA	¥:	5.68	14.78	Y Z	ς ς Z Z	Y S	Z Z	Y Z	¥ ¥ Z Z	¥ S	X X Z Z	ĕ ĕ Z Z	Ž Ž	A A	Y Z	¥ ¥ Z Z	Y S	Z Z	Ψ Φ Z Z	Z Z	5.21	14.61	/ V N	A :	Y Y	₹ Z	— 4 4 2 2	Y S	Ψ Z Z	 &
Treat hurren's fination Treat hurren's f	9.03 NA NA NA NA	13.21 NA	4 4 4 Z Z Z	(Z Z (0.00 8.37	6.41 NA	Y :	0.33	14.33	Z :	Z Z	Y Z	ς ς Z Z	A S	4 4 2 2	Y S	Z Z	Z Z	Z Z	ς ς Z Z	Y Z	X Z	Y S	Z Z	Z Z	Z Z	4.74	13.19	4.03 AA	Y Z	Y Y	₹ Z		Z	 {	 V V Z Z
Treat blumets fracture	0.67	1.36	2.35	. 8. 6 8. 6 8. 6	0.78	0.00	0.28	0.97	0.17	0.80	0.95	1.72	1.03	0.61	1.28	2.05	1.10	1.16	1.04	1.38	1.34	1.25	2.34	2.32	1.48	0.74	1.30	0.20	0.72	0.08	1.66	1.15	1.73	1.60	1.23		1.85
Treat humens fracture	6.40 6.40 2.77 4.17 6.19	6.60 5.66 7.84	9.70	11.46	5.03	0.00	2.07	5.25	1.77	3.37	4.79	7.55	5.72	6.60	6.41	7.12 8.72	5.75	6.82	5.80	0.83	7.51 8.63	7.62	11.43	9.63	7.37	5.41	6.62	5.56	4.10	0.44 5.58	7.85	6.45	7.43	7.57	6.52	7.82	8.17
A Trade humants fracture 7.40	3.91 5.69 2.80 7.1.7 5.63	5.89 5.16 7.02	7.55	10.72	4.88 6.90	0.00	1.75	4.78	1.87	3.94	4.59	6.96 4.28	5.08	v. 4 28.0.4 40.4	5.66	7.67	5.22	6.22	5.13	5.67	6.71	6.30	10.86	8.54	6.29	4.92	5.82	1.38	3.71	5.18	6.85	5.66	7.11	6.64	5.75	6.00 7.52	7.11
Teat humens fracture	48.7 8.8 8.8 8.8 8.8 8.8 8.8 8.8 8.8 8.8	6.66 NA NA	4 4 4 2 2 2	(X	0.00	5.52 NA	¥ ż	3.43	8.78	Z	Z Z	₹ Z	▼	Z Z	₹ ₹ Z Z	₹ S	₹ ₹	Z Z	Z Z	▼	₹ S	₹ ₹ 2 Z	₹ S	Z	Z Z	₹ Z	3.25	9.34	3.38 NA	¥:	4 4 Ζ Ζ	₹ Z		Y S	 {	 &
Treat humerus fracture A Treat shoulder dislocation A Treat shoulder dislocation A Treat shoulder dislocation A Treat dislocation/fracture A Muputation of shoulder joint A Muputation follow-up surgery A Maputation follow-up surgery A Muputation follow-up surgery A Palease elbow joint lining A Biopsy armelbow soft tissue A Biopsy armelbow	44.4 AN 2.6 AN AN A AN A AN A	0.16 N A N	4 4 4 Z Z Z	(Z Z (0.00	4.34 AA	Y :	4.08	8.33	Z	Ψ	Y S	4 4 2 2	Y S	4 4 2 2	Y S	Z Z	Y Z	Z Z	Ψ Z Z	Y S	ζ <u>ζ</u> Ζ Ζ	Y 2	ZZ	Y Z	Z Z	2.78	7.92	2.64 NA	Z :	Ψ Ψ Ζ Ζ	Y Z	 &	Α <u>ς</u>	 {	 &
<u>4444444444444444444444444444444444444</u>	3.92 7.40 3.38 4.56 7.48	7.95 6.04 10.22	2.52 14.50	20.47	5.54	0.00	1.79	5.93	9.54 2.08	5.20 3.91	6.29	11.86 4.92	6.12	30.88 30.08 3.60	7.38	12.03	6.64	8.42	6.24	8.22	9.35	7.63	15.80	13.61	10.16	11.64	7.82	1.76	4.55	3.74	10.18	7.44	10.66	9.59	7.69	7.88 9.14	10.66
<u>4444444444444444444444444444444444444</u>	e e e e e e e tribular di	ure ure ure	nt	girdle	surgery	seduren	a lesion	gery	t tissue	t tissue	sion	ı/elbow	int	ningsa	on	sionsion	CO	sion	adius	lesion	esion	ius	wodl	ırgery	ery	ery	nplant	Implant	ın body	aynesth		ng		es Po		onejser	ndonw/tiss
<u>4444444444444444444444444444444444444</u>	Treat humerus fractur Treat humerus fractur Treat shoulder disloca Treat shoulder disloca Treat shoulder disloca	Treat dislocation/fracti Treat dislocation/fracti Treat dislocation/fracti	Fixation of shoulder Fusion of shoulder join	Amputation of arm & o	Amputation follow-up	Shoulder surgery proc Drainage of arm lesion	Drainage of arm bursa Drain arm/elbow bone	Exploratory elbow sur	Helease elbow joint Biopsy arm/elbow soft	Biopsy arm/elbow soft	Remove arm/elbow le	Remove tumor of arm Biopsy elbow joint linit	Explore/treat elbow jo	Remove elbow joint lir Removal of elbow bur	Remove humerus lesi	Remove/graft bone les	Remove elbow lesion	Remove/graft bone les	Removal of head of re	Remove radius bone I	Hemove elbow bone I Partial removal of arm	Partial removal of radi	Radical resection of e	Extensive humerus su	Extensive radius surge	Extensive radius surge	Remove elbow joint in	Remove radius head I Removal of arm foreic	Removal of arm foreig	Injection for elbow x-ra Manipulate elbow w/a	Muscle/tendon transfe	Arm tendon lengthenir Revision of arm tendo	Repair of arm tendon	Revision of arm musc Revision of arm musc	Tenolysis, triceps	Hepair of biceps terior Repair arm tendon/mu	Repair of ruptured ten Repr elbow lat ligmnt
															< <																						⋖ ⋖
23653 23653 23653 23653 23655 23665 23666 23667 23867																																					
	23625 23630 23650 23655 23660 23665	23670 23675 23680	23700	23900	23921	23929	23931 23935	24000	24006 24065	24066	24076	24077 24100	24101	24102 24105	24110	24115	24120	24126	24130	24136	24138 24140	24145	24149	24150	24152	24153	24160	24164 24200	24201	24220	24301	24305 24310	24320	24330 24331	24332	24340 24341	24342 24343

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Head						Year 2007 Transi-	Fully Im-	Year 2007
NA NA NA 552 539 1176 128 NA NA 1727 1887 1887 1887 1887 1887 1887 1887	Description					ransi- tional Non-Fa- ility Total	premented Facility Total	Transi- tional Fa- cility Total
NA NA NA 5292 539 110 NA NA 1757 1136 1137 NA NA 1757 1136 1137 NA NA NA 5292 539 110 NA NA 1757 1136 1137 NA NA NA 5292 539 110 NA NA 1757 1136 1137 NA NA NA 5292 539 110 NA NA 1757 1136 1137 NA NA NA 5292 539 110 NA NA 1757 1136 1137 NA NA 1757 1136 1137 NA NA 1757 1136 1136 1136 1137 NA NA 1757 1136 1136 1136 1136 1136 1136 1136 113	Reconstruct elbow lat ligmnt		1.16	2.36	A A	Z Z	27.27	28.37
NA NA 528 594 100 NA 1130 1152 NA NA 1130 NA 1130 NA NA 528 594 100 NA NA 1226 1136 1136 NA NA 1226 NA 1236 NA NA 1226 NA 1236 NA NA 1226 NA NA 1226 NA 1236 NA NA 1226 NA N	Reconstruct elbow med ligmnt		.02	2.33	Z :	Y Z	27.24	28.20
NA NA 522 594 1170 NA NA 1275 11346 NA NA 522 696 1170 NA NA 1276 11346 NA NA 1226 1101 2.018 NA NA 1310 11384 NA NA 1226 1132 NA NA 1310 11384 NA NA 523 6166 1171 NA NA 1310 11384 NA NA 523 6166 1171 NA NA 1310 11384 NA NA 523 6166 218 NA NA 1510 11384 NA NA 632 6166 1141 NA NA 1510 1152 NA NA 888 210 62 27 NA NA 2650 2656 NA NA NA 646 1132 1132 NA NA 2650 2656 NA NA NA 646 1132 1132 NA NA 1664 1751 NA NA 646 1132 1132 NA NA 1664 1751 NA NA 646 1132 1132 NA NA 1664 1751 NA NA 866 643 1146 1168 1168 1168 1169 1169 11761 NA NA NA 657 666 643 1168 1168 1169 1169 11761 NA NA NA 657 643 1168 1168 1168 1169 1169 11761 NA NA 866 643 1161 1181 1181 1181 1181 1181 1181 118	Repair of tennis elbow		41 5.69	1.02	4	₹ <u>₹</u>	11.93	12.61
NA NA 522 6.95 1.10 NA NA 12.02 6.00 NA NA 12.10 13.44 NA 12.02 6.00 NA NA 12.02	Repair of tennis elbow		5.94	1.10	Y :	Ž:	12.75	13.46
NA NA 8.787 9.10 2.05 NA NA 22.45 23.59 NA NA NA 22.45 23.50 NA NA NA NA 22.45 23.50 NA NA NA 22.45 23.50 NA NA NA NA 22.45 23.50 NA NA NA NA 22.45 23.50 NA NA 22.55 23.50 NA NA 22.45 23.50 NA NA 22.45 23.50 NA 22.45 23.50 NA NA 22.45 23.50 NA 22.45 NA NA 22.45 23.50 NA 22.45 NA NA 22.55 23.55 NA NA 22.45 23.50 NA 22.45 23	Revision of tennis elbow		5.03 5.06	1.17	ξ ζ Z Z	¥ X Z Z	12.79	13.47
NA NA 9:30 9:36 2:68 NA NA 25:14 25:44 NA NA 9:30 9:30 2:68 NA NA 55:44 25:44 1 NA NA 9:30 9:30 3:41 1:22 NA NA 55:44 1:70 1:70 3:70 1:70 1:70 3:70 1:70 1:70 3:70 1:70 1:70 1:70 1:70 1:70 1:70 1:70 1	Reconstruct elbow joint		9.10	2.05	A :	¥:	22.46	23.59
NA NA 528 638 301 NA NA 576 88 634 118 NA NA 566 98 57 18 18 NA NA 6648 118 NA 6648 118 NA 6648 118 NA 6648 118 NA NA 6648 118	Reconstruct elbow joint		0.13 9.86	2.18 2.60	▼	₹ Z Z	25.14 26.99	26.49
NA NA 6.39	Replace elbow joint		3.35	3.01	A :	Y :	37.66	38.75
NA NA NA SA	Reconstruct head of radius		5.89	1.41	Δ Z	A Z	15.79	16.74
NA NA NA B 832 10.06 2.57 NA NA 26.75 22.74 NA NA NA B 832 10.06 2.57 NA NA 26.50 26.83 NA NA NA B 832 10.06 1.48 NA NA 26.50 26.83 NA NA NA C 848 2.00 1.48 NA 16.09 17.64 NA NA NA C 848 2.00 1.48 NA 16.09 17.64 NA NA NA C 848 2.00 1.48 NA 16.09 17.64 NA NA NA C 848 2.00 1.44 1.48 1.22 NA NA NA C 848 1.24 1.48 1.24 1.28 1.44 NA NA NA C 848 1.24 1.24 1.24 1.24 NA NA NA C 848 1.24 1.24 1.24 1.24 NA NA NA C 848 1.24 1.24 1.24 1.24 NA NA NA C 848 1.24 1.24 1.24 1.24 NA NA NA C 848 1.24 1.24 1.24 NA NA NA C 848 1.24 1.24 1.24 NA NA NA C 848 1.24 1.24 NA NA NA C 848 1.24 1.24 NA NA NA C 848 1.24 1.24 NA NA C 848 1.26 NA NA C	Revision of humerus		3.54	1.92	Z Z	Z	20.64	21.56
NA NA 6.36 9.66 2.27 NA NA 26.50 22.88 NA NA 6.446 NA NA 6.446 8.82 1.18 NA NA 6.446 4.75 3.80 9.66 3.71 0.50 11.32 11.33 11.3	Revision of humerus		0.06	2.57	Z Z	Z Z	26.75	27.49
NA NA 686 1063 227 NA NA 1667 2754 NA NA 668 823 118 NA NA 1660 1764 1761 NA NA 668 823 118 NA NA 1609 1764 1761 NA NA 668 823 118 NA NA 1609 1764 1761 NA NA 668 823 118 NA NA 2198 2230 1132 NA NA 771 876 202 NA NA 2198 2239 1132 NA NA 772 872 873 164 NA NA 772 872 873 164 NA NA 1986 2077 NA NA 1986 1951 NA NA 1986 2077 NA NA 1986 1951 NA NA 1986	Repair of humerus		9.63	2.21	Z Z	Z Z	26.50	26.83
NA NA 668 8.23 1.18 NA NA 16.09 17.64 NA NA 16.09 17.64 NA NA NA 7.75 8.88 1.18 14.86 15.63 13.90 14.47 14.47 NA NA 7.22 8.38 1.64 NA NA 21.72 22.35 NA NA NA 7.24 8.32 1.64 NA NA 20.07 14.47 NA NA 8.24 4.37 2.38 1.24 NA NA 20.07 14.47 1.86 1.86 6.42 1.34 1.34 1.34 1.34 1.34 1.34 1.34 1.34	Repair humerus with graft		0.63	2.27	Ψ Δ Ζ Ζ	4 Z	26.77	27.54
NA NA 7.75 8.88 2.06 NA NA 27.89 23.02 NA NA 7.75 3.89 2.06 NA NA 27.18 2.30 S87 6.42 4.90 5.27 0.89 11.32 12.47 10.98 22.37 NA NA 7.71 8.09 5.00 8.00 6.20 NA A 21.28 11.32 11.42 11.42 6.82 7.59 5.86 6.43 1.18 1.48 15.63 11.47 11.44 1	Decompression of forearm		3.23	1.18	Z Z	Z Z	16.09	17.64
5.87 6.82 6.82 6.82 6.82 6.82 6.82 6.82 6.82 6.82 6.83 6.83 6.83 6.83 6.83 6.84 6.82 6.83 6.83 6.83 6.84 6.83 6.84 6.85 6.84 6.85	Reinforce humerus		3.88	2.06	N N	NA AA	21.89	23.02
NA NA 8.09 9.06 2.02 NA NA 21.98 22.95 NA NA 4.74 5.09 5.86 6.43 1.18 14.86 15.63 18.90 14.47 NA NA 7.24 8.15 1.84 NA NA 7.24 8.15 1.84 NA NA 19.86 20.77 NA NA NA 7.27 8.80 9.15 12.34 12.90 14.47 NA	humerus fract		5.27	0.89	11.92	12.47	10.95	11.32
4.74 5.09 4.00 4.03 0.57 8.80 9.15 8.06 8.00 8.00 8.00 8.00 8.00 8.00 8.00	Treat humerus fracture		9.06	2.02	₹ Z	Y Z	21.98	22.95
6.82 7.59 5.86 6.43 1.18 14.86 15.63 13.90 14.47 NA NA NA NA 18.40 19.51 NA NA 7.24 8.33 1.64 NA 18.40 19.51 4.05 4.37 3.38 3.24 0.44 7.29 7.61 6.62 6.48 5.86 6.42 4.97 7.86 1.30 17.34 17.34 17.34 NA NA NA NA 20.92 1.48 NA 20.05 6.48 1.86 0.39 1.29 1.48 NA 20.05 17.34 11.48 17.34 NA NA 1.88 1.29 1.48 NA 20.05 17.34 17.34 17.34 NA NA 1.88 1.48 1.48 NA 19.48 20.16 17.44 17.34 NA NA 1.48 NA 1.48 NA 1.48 1.4	Treat humerus fracture		1.03	0.57	8.80	9.15	8.06	8.09
NA N	Treat humerus fracture		5.43	1.18	14.86	15.63	13.90	14.47
NA NA 9.50 10.87 2.73 NA NA 28.14 29.51 5.86 6.42 4.97 5.38 10.44 7.29 7.61 6.62 6.48 5.86 6.42 4.97 5.38 1.34 12.90 11.45 11.86 NA NA NA NA NA 17.04 17.94 11.46 11.86 6.01 6.70 5.08 5.65 0.95 12.77 8.00 7.04 17.94 6.01 6.70 5.08 5.65 0.95 12.74 13.43 11.81 12.38 6.01 6.70 5.08 5.65 0.95 12.74 13.43 11.81 12.38 6.01 6.70 5.08 10.76 2.64 NA NA 17.77 22.49 NA NA 8.21 10.61 2.52 NA NA 17.84 11.86 NA NA 8.59 10.61 2.64	Treat humerus fracture		3.15 3.15	2 24	Y Y Z Z	Z Z	19.86	20.77
5.00 5.30 5.24 0.74 7.29 7.29 17.06 17.06 17.04 17.06 17.06 17.04 17.06 17.06 17.04 17.06 17.06 17.04 17.06 17.04 17.06 17.06 17.04 17.06 17.04 17.06 17.04 17.06 17.04 17.06 17.04 17.06 17.04 17.06 17.04 17.06 17.04 17.06 17.04 17.06 17.04 17.06 17.04 17.06 17.04 17.06 17.04 17.06 17.04 17.06 17.04 17.06 17.04 17.06 17.04	humerus fracture		0.87	2.73	N N	NA NA	28.14	29.51
NA NA 6.97 7.86 1.30 NA NA 17.05 17.94 NA NA 7.27 8.12 1.86 NA NA 20.07 20.92 NA NA 7.87 8.59 2.02 NA NA 21.77 22.49 NA NA NA 8.21 1.61 2.52 NA NA 21.77 22.49 NA NA NA 6.59 3.24 0.89 NA NA 11.26 NA NA NA 10.23 13.10 2.28 NA NA 13.52 14.10 NA NA NA 10.23 13.10 2.28 NA NA 13.52 14.10 NA NA NA 6.59 0.80 0.35 5.95 6.21 5.51 NA NA NA 6.59 0.80 0.30 0.41 NA NA NA 6.59 0.30 0.41 NA NA NA 6.59 0.30 0.41 NA NA 6.59 0.60 1.07 NA NA 6.59 0.30 0.281 0.30 NA NA 6.59 0.30 0.30 0.30 NA NA 6.59 0.30 0.30 0.30 NA NA 6.59 0.30 0.41 NA NA 6.59 0.30 0.41 NA NA 6.59 0.60 0.30 NA NA 6.59 0.50 0.30 NA NA 6.59 0.30 0.41 NA NA 6.59 0.30 0.41 NA NA 6.59 0.60 0.80 0.40 NA NA 6.59 0.50 0.50 NA NA 6.59 0.50 0.50 NA NA 6.59 0.50 0.50 NA NA 6.58 0.60 0.81 NA NA 6.58 0.81 NA NA 6.58 0.82 NA NA 6.68 0.87 NA	Treat humerus fracture		5.38	0.93	12.34	12.90	11.45	11.86
4.45	humerus fracture		7.86	1.30	₹ Z	Y Z	17.05	17.94
6.01 6.70 5.08 5.65 0.95 12.74 13.43 11.81 12.38 NA NA 7.87 8.59 2.02 NA NA 27.57 22.49 NA NA 9.36 10.61 2.52 NA NA 27.55 28.95 2.016 NA NA 9.36 10.61 2.52 NA NA 27.45 28.95 28.95 NA NA 10.61 2.52 NA NA 13.52 14.10 NA NA 10.23 13.10 2.28 NA NA 13.52 14.10 NA NA 10.23 13.10 2.28 NA NA 13.52 14.10 NA NA 6.53 13.00 2.28 13.00 0.12 2.80 3.07 2.12 2.12 3.44 3.70 3.00 2.81 0.35 5.20 3.00 2.81 0.35 5.20 3.00 2.81 0.35 5.30 3.00 2.81 0.35 5.30 3.00 3.45 0.30 3.45 0.30 3.41 0.20 10.85 3.44 3.70 3.00 2.81 0.25 NA NA 16.07 16.81 NA NA 6.53 4.50 4.41 4.70 0.70 10.29 10.85 9.50 9.79 10.85	Treat humerus fracture		3.72	0.46	7.77	8.00	7.06	7.04
NA NA NA 9.36 1.48 NA NA 27.45 28.95 NA NA 15.74 2.249 NA NA 9.36 1.48 NA NA 27.45 28.95 NA NA 9.37 10.61 2.52 NA NA 27.45 28.95 28.95 NA NA 17.84 18.76 NA NA 13.52 14.10 NA NA 17.56 0.80 0.80 0.12 2.80 3.70 2.81 1.35 14.10 NA NA 6.53 0.80 0.80 0.12 2.80 3.70 2.81 1.35 19.08 19.08 NA NA 6.53 1.4.10 NA NA 6.54 1.55 1.55 1.28 NA NA 16.85 1.7.10 NA NA 6.58 1.7.10 NA NA 6.59 1.7.10 NA NA 6.58 1.7.10 NA NA 6.5	humerus fracture		5.65	0.95	12.74	13.43	1.81	12.38
NA NA S.	Treat humerus fracture		 3.89	2.02 1.48	ξ ς Z Z	¥ ¥ Z Z	19.48	20.16
NA NA NA 6-59 (2.74	Treat elbow fracture		9.76	2.64	Ϋ́ Z	Y S	27.55	28.95
NA NA 659 751 160 NA NA 17.84 18.76 NA NA 10.23 13.10 2.28 NA NA 17.84 18.76 1.48 1.75 0.80 0.80 0.12 2.80 3.07 2.12 5.20 5.76 4.41 4.70 0.70 10.29 10.85 9.50 9.79 NA NA 10.2 3.16 3.09 0.41 6.69 6.97 6.11 6.04 5.30 5.81 4.50 4.85 0.81 10.82 11.35 10.02 10.37 NA NA 6.48 0.81 1.63 NA NA 16.85 17.63 NA NA 6.48 0.89 NA 16.85 17.63 NA NA 16.89 NA 16.85 17.63 NA NA 16.89 NA 16.85 17.63	reat elbow fracture		3.45	0.50	8.59	NA 9.33	27.45 8.01	28.69
NA NA 659 751 160 NA NA 17.84 18.76 NA NA 10.23 13.10 2.28 NA 17.84 18.76 1.48 1.75 0.80 0.80 0.12 2.80 3.07 2.12 5.20 5.76 4.41 4.70 0.70 10.29 10.85 9.50 NA NA 6.53 7.27 1.41 NA 18.28 19.08 3.74 4.02 3.16 3.09 0.41 6.69 6.97 6.11 6.04 5.30 5.81 0.82 0.81 10.82 11.35 10.02 10.37 NA NA 6.48 0.81 10.82 11.35 10.02 10.37 NA NA 6.48 0.87 1.63 NA NA 16.85 17.63 NA NA 6.58 1.28 NA NA 16.85 17.63	Treat elbow dislocation		5.26	0.89	N A	N A	11.26	11.56
NA N	Treat elbow dislocation		7.51	1.60	Y Z	Y Z	17.84	18.76
1.48 1.75 0.80 0.80 0.12 2.80 3.07 2.12 2.12 2.12 2.12 2.12 2.12 2.13 3.04 3.70 2.81 0.35 5.95 6.21 5.51 5.32 3.70 3.00 2.81 0.70 10.29 10.85 9.50 9.79 10.81 10.82 10.08 10.0	Treat elbow fracture		3.10	2.28	Z Z	Z Z	25.98	28.85
3.44 3.70 3.00 2.81 0.35 5.95 6.21 5.51 5.32 5.20 5.20 5.76 4.41 4.70 0.70 10.29 10.85 9.50 9.79 9.79 10.81 10.82 10.82 10.82 10.82 10.83 10.82 10.83 10.82 10.83 10.82 10.83 10.82 10.83 10.83 10.83 10.82 10.83	Treat elbow dislocation		08.0	0.12	2.80	3.07	2.12	2.12
3.74 A 0.2 5.30 5.30 5.30 5.30 5.30 5.30 5.30 5.30	Treat radius fracture		2.81	0.35	5.95	6.21	5.51	5.32
NA NA 7.00 7.80 1.62 NA NA 18.28 19.08 15.20 NA NA 16.85 NA NA NA NA 16.85 NA	Treat radius fracture		1.70	0.70	92.0L	10.85 NA	9.50	9.79
3.74 4.02 3.16 3.09 0.41 6.69 6.97 6.11 6.04 10.37 NA NA 0.55 0.05 0.05 0.05 0.05 0.05 0.05 0.0	Treat radius fracture		.80	1.62	¥ Z Z	Z Z	18.28	19.08
5.30 5.83 4.50 4.85 0.81 10.82 11.35 10.02 10.37 NA NA NA 0.55 0.00 0.00 0.00 0.00 0.00 0.00 0.0	Treat ulnar fracture		3.09	0.41	69.9	6.97	6.11	6.04
NA NA 7.66 8.47 1.63 NA NA 20.47 21.28	Treat ulnar fracture		4.85 7.26	0.81	10.82 NA	11.35 NA	10.UZ 16.85	10.37
	Fusion of elbow joint		3.47	1.63	Ψ.	Y Z	20.47	21.28

4444400444444444444444444444444444444									_	_	_									_																	_	_		_	_	_	
A	060	060	060	060	060	060	060	060	060	030	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	000	060	060	060	060	060	060	060	060	060	060	060
A miputation of upper nm	18.39 14.06 19.23	21.48 26.57	00.0	10.34 8.31	15.74	19.28	29.23	12.07	21.12	15.45 4.04	11.42	9.92	22.53	13.04	11.06	13.69	16.46	8.46	10.29	24.20	10.50	14.16	20.35	20.76	15.06	13.32	16.09	20.35	13.30	17.40	11.86	2.02	13.88	18.50	9.94	21.27	24.57	17.94	19.83 22.62	17.36	19.88	18.69	18.19 17.41
A Angulation of upper arm 9.85	17.95 18.01 13.21 18.22	23.36 27.23	0.0	8.98	13.74	19.08	28.52	10.23	17.59	04.4C	10.22	9.18	20.18	11.78	10.26	12.58	15.57	8.01	9.76	21.33	9.67	12.85	17.28	17.59	14.02	12.52	14.72	17.20	12.35	15.96	10.97	2.02	12.42	17.59	9.50	18.20 17.95	21.34	14.84	16.51	16.55	16.76	15.68	17.24 16.41
Appropriation of opport ann	<u> </u>	Δ Z Z Z	0.00	Α	Z Z	X X	Y Z	Σ Z	A S	NA 5.60	N S S S	₹ S	Z Z	¥ S	Y Y Z Z	Y Z	Z Z	Z Z	A :	 &	Y Z	Z Z	Z Z	Z Z	Z Z	Y Z	Z Z	Y Z	Y Y Z Z	Y S	▼	4.80	Ψ Ψ Z Z	Z Z	Υ S	▼ 4 Z Z	Y Y	Y Z	 4	N A	 V V	Z Z	 ∢
A Amputation of upper arm		ĕ ĕ Z Z	0.00	▼	₹ ₹	 ₹ Z Z	Z Z	 {		NA 6,33	Z Z	Z Z	Z Z	Y S	ζ ζ Z Z	Y :	Z Z	Z Z	Y :	 &	₹ Z	Z Z	Z Z	Z Z	Z Z	Z Z	Z Z	Y S	ζ Z Z	A :	ς ς Z Z	4.24	A A	Z Z	A S	Z Z	 { Z Z	 Y	 {	Z V		 { Z Z	 4
A Appropriation of upper arm 98	1.53	1.89 2.13	0.00	0.55	0.93	1.36	1.82	0.03	1.24	1.15 0.15	0.64	0.55	1.42	0.85	0.75	0.92	0.00 0.00	0.53	0.70	- F	0.68	0.96	1.06	1.27	1.02		- -	1.18	0.88	1.19	0.79	0.09	0.72	1.26	0.62	0. 1. 0. 4.	1.47	0.95	1.1.	1.31	1.08	1.00	1.26
A	6.91 6.82 5.80 6.91	6.35 8.24	00.0	6.42	8.90	7.40	9.74	7.31	12.41		9.99	5.64	11.30	6.70	5.63	6.93	8.05	4.55	5.07	13.08	5.46	7.17	11.82	11.95	7.16	6.33	7.75	11.67	6.48	8.27	5.85 6.53	0.48	8.03 5.91	7.62	5.58	12.29	13.23	1.00	11.69	7.31	13.54	11.15	8.14 7.73
A Apputation of upper arm with colors up surgery 0.50	6.47 6.45 4.95 5.90	8.23 8.90	00.0	3.85	6.90	7.20	9.03	5.47	88.0	08.4 09.40	5.46	4.90	8.95	5.4	4.83	5.82	7.16	4.10	4.54	10.21	4.63	5.86	8.75	8.78	6.12	5.53	6.38	8.52	5.53	6.83	5.27	0.48	6.57	6.71	5.14	9.25 9.25 9.05	10.00	7.90	8.37 9.20	6.50	8.47	8.14	7.19 6.73
A Apputation of upper amm	4 4 4 4 2 Z Z Z Z	4 4 Z Z	0.00		Z Z	Z Z	Y S	 {	A S	3.46	Y Y	₹ S	Z Z	₹ S	Z Z	Y :	Z Z	¥ 2 Z	A :		Y Y	Z Z	Z Z	Z Z	Z Z	Z Z	Z Z	Y S	ξ	Y :	Ψ Z Z Z	3.26	Z Z	¥ Z	Z Z	∀	Z Z	 V 2	Z Z	Z Y	Z Z	Z Z	4 4 Z Z
A Amputation of upper arm Amputation of upper arm Amputation of upper arm Amputation follow-up surgary A Amputation follow-up surgary A Amputation follow-up surgary C C Hoper arm-follow surgary A Pevision of amputation floated and spaces A Decompress foream a spaces A Decompress foream a spaces A Decompress foream buse A Decompress foream solitissues A Biopsy foream soft itssues A Removal foream lesion A Remove wrist fendon lesion A Remove wrist fendon selon A Remove wrist tendon A Remove wrist tendon selon A Remove wrist tendon A Remove wrist tendon A Remove wrist tendon selon A Remove wri	4 4 4 4 2 2 2 2 :	ς ς Z Z	00:0	Y Z	Z Z	Υ Υ Υ Υ Υ Υ	¥ S	 {	Y Z	AN 4	, A	₹ Z Z	Z Z	Y S	¥ Z Z	¥ :	A A	Z Z	Y :	 &	Z	A A	Z Z	A A	Z Z	▼ A	Z Z	₹ Z	Υ Σ Ζ Ζ	Y S	▼	2.70	Z Z	Z Z	Y S	Z Z	Z Z	A S	 {	Z Y	 V Z	 {	 ∢
<u>4444400444444444444444444444444444444</u>	9.95 9.95 7.12 10.65	13.24 16.20	00:0	3.37	5.91	10.52	17.67	4.13	7.47	 දුව ල	4.12	3.73	9.81	5.49	4.68	5.84	7.42	 8	4.52	9.81	4.36	6.03	7.47	7.54	6.88	2.96 9.89	7.20	7.50	5.94	7.94	5.22	1.45	5.13	9.62	3.74	7.79	9.87	2.99	7.U3 8.74	8.74	7.21	6.54	8.79 8.39
<u></u>	ırm surgery	k implantn	lery	ath	1 space	spaces	2 spaces	ursa	sion	rt	sense	on subcu	m/wrist	le	±	ng	tilage	lesion	n lesion	lesion	neath	a	lesion	lesion	lesion	lesion		ns	gery	Se	us	,	gn body	thesis	esthes	//muscle/nuscle	/muscle	/muscle	/muscle/nuscle	sheath	endon	tendon	vrist
<u></u>	on of upper a on of upper a on follow-up a on follow-up a	upper arm & of amputation	of upper arm m/elbow surg	of tendon she xor carpi radi	ess forearm	ess forearm ?	ess forearm ?	of forearm b	earm bone le	reat wrist join rearm soft tis	rearm soft tis	forearm lesic	tumor, forear	of wrist capsu	reat wrist join	wrist joint lini	wrist joint car	wrist tendon	e wrist tendo	wrist/forearm wrist/forearm	rist tendon sh	moval of ulna of forearm le	graft forearm	graft forearm of wrist lesio	& graft wrist	& graft wrist forearm bone	moval of ulna	moval of radi	of wrist bone	of wrist bone	moval of radi moval of ulna	for wrist x-ray	forearm torei	of wrist prost	te wrist w/and	rearm tendor rearm tendor	rearm tendor	rearm tendor	rearm tendor rearm tendor	rearm tendor	rist/forearm t	wrist/forearm	tendons at v tendons at v
<u></u>	Amputati Amputati Amputati Amputati	Amputate Revision	Revision Upper an	Incision of Incise flex	Decompr	Decompr	Decompr	Drainage	Treat fore	Explore/t	Biopsy fo	Removal	Remove	Incision c	Explore/ti	Remove	Remove	Remove	Reremov	Remove	Excise w	Partial re Bemoval	Remove/	Remove/	Remove	Remove	Partial re	Partial re	Removal	Removal	Partial re	Injection	Remove	Removal	Manipula	Repair to	Repair fo	Repair fo	Hepair ic Repair fo	Repair fo	Revise w	Release	Fusion o
																						∢ ላ	(∢																				∢∢
									-			-							-						_	· 				-						:							
					25020		•	: :	25035			25075	25077	•			•		25112	25115 25116	5118		5125	•		25136	:5150	25151		25215			25248	25251		25260	25265	•		25275	25280	25295	25300 25301

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Year 2007 Transitional Facility Total	2
Fully Implemented Facility Total	28
Year Year 2007 Transitional Non-Fa-cility Total	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
Fully Implement- ed Non- Facility Total	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
Mal-Practice RVUs	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Physician plement- from definity in per RVUs PERVUS	1 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1
Fully Implemented Facility PE RVUs	8 8 9 9 0 0 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
Year 2007 Transitional Non-Fa- cility PE RVUs	44444444444444444444444444444444444444
Fully Implemented Non-Facility PE RVUS	ZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZ
Physician Work RVUs	8 9 9 5 5 7 5 1 5 1 5 1 5 1 5 1 5 1 5 1 5 1 5
MELATIVE VALUE UNITS (HVUS) AND Description	Transplant forearm tendon Transplant forearm tendon Revise palsy hand tendon(s) Revise palsy hand tendon(s) Repair/revise wrist joint Realignment of hand Reconstruct ulna/radioulnar Revision of radius Revision of ulna Revision radius & ulna Repair radius or ulna Repair radius or ulna Repair radius or ulna Repair graft radius or ulna Repair/graft radius or ulna Reconstruct wrist joint Revision of wrist joint Treat fracture of radius Treat fracture of radius Treat fracture of ulna Treat fracture of ulna Treat fracture radius & ulna
. Statı	
ADDENDOM B	
ADDI CPT¹/ HCPCS²	25310 25316 25317 25318 25320 25330 25330 25330 25330 25330 25330 25330 25330 25330 25330 25330 25330 25330 25330 25340 25440 25441 25441 25442 25443 25444 25444 25446 25446 25446 25446 25447 25446 25446 25447 25446 25446 25446 25447 25446 25446 25446 25447 25446 25446 25447 25446 25446 25447 25446 25447 25446 25447 25448 25488 25588

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0060 0060 0060 0060 0060 0060 0060 006
6.19 6.19	7.66 6.66 8.00 9.67 9.67 9.07 1.98 1.57 1.57 1.57 1.57 1.57
8.60 0 0 8.00 0 4.00 1.00 0 0 1.00 0 0 1.00 0 0 1.00 0 0 1.00 0 0 1.00 0 0 1.00 0 0 1.00 0 0 1.00 0 0 1.00 0 0 1.00 0 0 1.00 0 0 1.00 0 0 1.00	7.72 7.72 7.72 9.29 7.76 7.76 8.65 11.65 16.01 17.20 11.20 11.20 12.25 12.25
Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
N N 8 8 8 N N N N N N N N N N N N N N N	,
4.4.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0	0.45 0.48 0.68 0.63 0.63 0.53 0.53 0.63 0.70 0.70 0.94 0.92
8.8.7. 8.4. 9.0. 9.4. 9.0. 9.4. 9.0. 9.0. 9.0. 9	2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2
8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8	3.3.0.6 3.0.0.6 3.0.0.0.6 3.0.0.0.6 3.0.0.6 3.0.0.6 3.0.0.6 3.0.0.6 3.0.0.6 3.0.0.6 3.0.0.6 3.
X X 4.0	2
S S S S S S S S S S S S S S S S S S S	%
$\begin{array}{c} 0.88 \ 9.44 \ 0.034 \ 1.034 $	2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2
Treat fracture radius/ulna Treat wrist bone fracture Treat wrist dislocation Treat wrist dislocation Treat wrist dislocation Treat wrist fracture Amputation of forearm Amputation follow-up surgery Amputation follow-up surgery Amputation follow-up surgery Torearm or wrist surgery Amputation follow-up surgery Torearm or wrist surgery Torearm or wrist surgery Torearm or wrist surgery Torearm or wrist surgery Toreat hand bone lesion Drainage of finger abscess Drainage of finger abscess Drainage of finger abscess Drainage of palm bursa. Belease palm contracture Release palm contracture Release palm contracture Release palm contracture	Incise Inger tendon snearn Incision of finger tendon Explore/treat hand joint Explore/treat finger joint Biopsy hand joint lining Biopsy finger joint lining Biopsy finger joint lining Removal hand lesion, deep Removal hand lesion, deep Release palm contracture
Treat fracture radius/ulna Treat wrist bone fracture Treat wrist dislocation Treat wrist dislocation Treat wrist dislocation Treat wrist dislocation Treat wrist fracture Treat wrist fisocation Fusion of hard bones with graft Eusion/graft of wrist joint Fusion of forearm Amputation follow-up surgery Forearm or wrist surgery Drainage of finger abscess Drainage of finger abscess Drainage of finger abscess Drainage of finger abscess Drainage of falm bursa. Decompress fingers/hand Decompress fingers/hand Release palm contracture Release palm contracture Proceed for to the adden to the a	Indison of finger tendon sneam Indison of finger tendon
25621 25622 25622 25622 25623 25624 25626 25635 25635 25635 25635 25630	

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

					, co								
•,	Status	Description	Physician Work RVUs	Fully Implemented Non-Facility	Teal 2007 Transi- tional Non-Fa- cility PE RVUs	Fully Im- plement- ed Facil- ity PE RVUs	Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Prac- tice RVUs	Fully Implemented Non-Facility	Year 2007 Transi- tional Non-Fa- cility Total	Fully Implemented Facility Total	Year 2007 Transi- tional Fa- cility Total	Global
< <		Bemove tendon sheath lesion	3.40	9.02	11.53	3.92	4.07	0.49	12.91	15.42	7.81	7.96	060
_ <		Removal of finger tendon	5.17	Y Z	Z Z	4.30	5.25		₹ Z	Z Z	10.72	11.20	060
۹		Remove finger bone	6.24	AN	Ν	5.81	5.98		AN	A	12.86	13.03	060
۹ ۹		Remove hand bone lesion	5.50	Ϋ́ Z	Y ?	4.58	5.16		Ϋ́ Z	Y Z	10.96	11.54	060
ጚ <		Hemove/graft bone lesion	7.75	∢	Υ < Ζ Ζ	5.85	6.63		∀	¥ S	14.80	15.58	060
Įα		Bemove/graft finger lesion	7.09	(4 Z Z	ζ 4	4.7. 7.53	6.12		(4 2 Z	ζ	13.60	14 19	060
、⋖		Partial removal of hand bone	6.32	ΥZ	ΥZ	5.01	5.69		ΥZ	₹ Z	12.34	13.02	060
. ⋖		Partial removal, finger bone	6.18	Ϋ́Z	A N	4.96	5.60		Ϋ́Z	AN	12.09	12.73	060
⋖		Partial removal, finger bone	5.31	Y V	A N	4.55	5.13		Y V	AN	10.67	11.25	060
◂		Extensive hand surgery	7.54	∀ Z	A A A	5.21	6.13		ΥZ	₹ Z	13.82	14.74	060
⋖		Extensive hand surgery	12.71	ΥN	A A	8.39	9.13		Ϋ́	Y N	22.78	23.52	060
◂		Extensive finger surgery	7.02	Y N	A N	5.36	5.98		Y N	AN	13.39	14.01	060
◂		Extensive finger surgery	9.20	Y N	A A	6.88	6.35		Y N	Y N	17.22	16.69	060
◂		Partial removal of finger	5.66	Y N	A A	4.66	5.16		Y N	Y N	11.20	11.70	060
◂		Removal of implant from hand	3.97	Y N	A A	3.78	4.18		Y N	Y N	8.34	8.74	060
◂		Manipulate finger w/anesth	2.50	Y N	A A	4.60	4.81		Y N	Y N	7.49	7.70	060
◂		Repair finger/hand tendon	5.98	A N	A V	9.45	13.32		Y V	Y N	16.36	20.23	060
a.		Repair/graft hand tendon	79.7	A N	A V	10.04	14.03		Y V	Y N	18.84	22.83	060
◂		Repair finger/hand tendon	10.06	Ϋ́	A V	13.68	17.20		Y V	Υ Ζ	24.95	28.47	060
a.		Repair finger/hand tendon	8.57	Y V	AN	10.26	14.29		Y V	Y N	20.16	24.19	060
		Repair/graft hand tendon	9.13	Ϋ́	A V	10.81	15.18		Y V	Υ Ζ	21.32	25.69	060
		Repair finger/hand tendon	7.10	ΥN	A A	9.50	13.71		Ϋ́	Y N	17.72	21.93	060
		Repair/graft hand tendon	8.81	∢ Z	A N	10.48	15.02		₹ Z	A A	20.69	25.23	060
		Repair finger/hand tendon	8.21	A N	A A	10.16	14.57		A N	₹ Z	19.60	24.01	060
◂		Revise hand/finger tendon	9.24	∢ Z	Υ Υ	9.08	12.23		₹ Z	Y Y	19.72	22.87	060
◂		Repair/graft hand tendon	10.30	₹ Z	A N	11.02	15.30		ΨZ	₹ Z	22.89	27.17	060
⋖		Repair hand tendon	4.62	A N	A N	7.56	10.85		A N	¥ N	12.91	16.20	060
⋖		Repair/graft hand tendon	6.30	ΥN	A A	8.57	12.10		Ϋ́	Y N	15.84	19.37	060
◂		Excision, hand/finger tendon	8.33	A N	A A	6.71	10.51		Y V	Υ N	16.02	19.82	060
⋖		Graft hand or finger tendon	9.36	A N	A N	8.70	13.12		A N	Y N	18.85	23.27	060
◂		Repair finger tendon	4.24	A N	A N	8.07	11.26		A N	Y Y	12.98	16.17	060
◂		Repair/graft finger tendon	9.76	A N	A V	8.75	12.41		Y V	₹ Z	16.58	20.24	060
◂		Repair finger/hand tendon	6.14	A N	Ϋ́	8.52	12.00		A N	Y N	15.61	19.09	060
◂		Repair/graft finger tendon	7.20	Ϋ́	A V	9.19	12.69		Ϋ́	¥Z	17.48	20.98	060
⋖		Repair finger tendon	4.01	ΥN	AN	6.71	9.37		ΑN	Ϋ́Z	11.36	14.02	060
◂		Repair finger tendon	4.55	Ν	AN	6.93	9.83		ΝA	Ϋ́Z	12.20	15.10	060
◂		Repair/araft finger tendon	90.9	A V	AN	7.87	10.62		A V	Ϋ́	14.88	17.63	060
◂		Realignment of tendons	5.81	A N	Ϋ́	7.71	10.61		A V	Ϋ́	14.41	17.31	060
◂		Release palm/finger tendon	5.01	A V	AN	8.43	12.18		A V	Ϋ́	14.19	17.94	060
◂		Release palm & finger tendon	9.40	A V	AN	11.61	14.86		A V	Ϋ́	22.21	25.46	060
◂		Release hand/finger tendon	4.30	A N	Ϋ́	8.10	11.88		A V	Ϋ́	13.05	16.83	060
⋖		Release forearm/hand tendon	8.24	ΑN	Ž	11.30	14.65	1.06	Ν	AN N	20.60	23.95	060
⋖		Incision of palm tendon	3.66	Ϋ́	¥Z	5.11	6.78	0.59	A V	Ž	9.36	11.03	060
◂		Incision of finger tendon	3.63	Ν	AZ	5.07	6.73	0.58	AN	₹Z	9 28	10.94	060
. ⋖		Incise hand/finger tendon	3.45	AN	Z Z	50.5	6.61	0.55	Ą	₹Z	6	10.61	060
. ⋖		Fusion of finder tendons	5.72	A Z	Z Z	7.66	10.35	0 88	A Z	₹Z	14.26	16.95	060
, ⋖		Fusion of finder tendons		Ą	Z Z	7 48	10 41	0.76	A Z	₹Z	13.55	16 48	060
. •		Tendon lengthening		A Z	Z Z	7.39	10.05	0.79	A Z	Z Z	13.35	16.01	060
◂		Tendon shortening		A Z	Z Z	7 47	10.16	0.81	A Z	₹Z	13.42	16.11	060
		I anothening of hand tendon		ζ Δ	Z Z	7 67	10.80	50.0	ζ Δ	₹ Z	14.36	17.49	060
ι <		Shortoning of hand tendon		2 2	Z 2	7.66	10.80	0.00	2 2	2 2	14.30	24.71	000
1 <		Transplant hand tendon		(<u> </u>	ζ <u> </u>	0 67	12.67	1 0.92	(< 2 2	¥	14.51	17.24	080
1 <		Transplant/anoft bond tondon		ζ < 2 2	ζ <u> </u>	9.57	13.07	20.1	ζ < Ζ 2	2 2	17.71	5.1.5	000
		Transplant grant nand tendon	0.70	₹ < Z Z	¥	0.22	2.4.	07.7	₹ ~	¥ \$ 2	19.70	23.72	000

000000000000000000000000000000000000000	060 060 060	00000	06000	060 060	060 060 060	060	00000	060000	06000	060 060 060	060 060 060	
22.22 23.65 23.65 23.22 23.50 70.00 70.00	22.28 17.37 19.36 20.28 17.68	16.61 19.47 22.72 77	18.81 13.68 15.95	9.76 16.84 18.31 22.19	18.85 19.14 25.98 21.05	40.35 85.81 72.27 99.02	23.96 23.96 34.86	18.71 18.85 24.67 34.66	24.83 34.29 12.51 16.36	5.56 6.95 12.23 11.34	7.85 9.20 13.07 14.98	9, 29 4, 09 6, 94 10, 91 10, 9
21.21 18.50 20.78 18.75 20.39 27.56	19.04 14.60 16.60 17.29 17.33	16.46	14.90 13.15 22.21	9.98 16.46 15.39	15.92 16.28 23.27 18.00	77.76 70.48 85.54	23.22 69.70 13.31 21.76	15.63 16.00 32.69	24.24 31.72 9.99 13.81	6.18 6.84 11.10 10.93	9.00 9.00 12.27 14.42 7.03	25.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
	4 4 4 4 4 2 2 2 2 2	Z Z Z Z	(4 4 4 4 2 2 2 2 2	X	X	(4 4 4 4 4 2 2 2 2 2	6.37 7.78 NA NA NA	0.10 NA NA 1.5 1.5	0.01 2.00 2.4 A A A A A A A A A A A A A A A A A A A
4 4 4 4 4 4 5 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	4 4 4 4 4 2 2 2 2 2	Z Z Z Z	(4 4 4 4 2 2 2 2	4 4 4 4 2 2 2 2 2 2	X	X	4 4 4 4 5 2 2 2 2 2	4 4 4 4 4 Z Z Z Z Z	6.53 7.43 NA NA NA	9.69 NA NA NA NA	0.00 N A N N S S S S S S S S S S S S S S S S
1.28	1.35 0.90 1.13 0.98	0.70 1.10 78	0.80 0.81 0.81 71.04	0.71 0.96 0.99 1.28	1.05 1.20 1.20 1.20	7.96 7.96 9.41	2.57 0.85 1.45	1.00 1.04 1.04 1.04 1.04	1.53 2.77 0.48 0.78	0.30 0.49 0.88 0.88	0.39 0.94 0.39	0.77 1.29 1.24 0.35 0.91 0.24
2 4 4 8 6 2 2 4 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	11.96 10.52 11.10 10.70	0.10 0.10 0.40 0.40 0.40 0.40 0.40 0.40	25.51 26.52 26.68 26.68 88.68	3.82 9.52 10.90 12.30	11.06 11.18 11.83	29.76 29.76 22.08 33.04	29.46 9.12 11.61	0.11 1.00 12.98	9.02 13.09 8.78 10.28	2.86 3.61 5.92 6.00 5.16	6.42 6.43 6.43 6.43	86. 14. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6.
9.029 9.77 9.04 1.148	8.72 8.34 8.59	8 7.56 9.22 9.21	8.81 5.43 6.15	9.14 9.14 9.04	8.13 8.32 11.42 8.78	21.71 20.29 19.56	7.09 7.09 13.88	7.90 8.15 10.13	8.43 10.52 6.26 7.73	3.48 3.50 4.88 5.25 4.75	3.52 3.93 5.62 2.96	4 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
4 4 4 4 4 4 4 5 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	4	Z Z Z Z	(4 4 4 4 2 2 2 2	4 4 4 4 2 2 2 2 2 2	X	1 4 4 4 4 2 2 2 2 2	4 4 4 4 2 2 2 2 2 2	4 4 4 4 4 Z Z Z Z Z	3.67 NA NA A A A	5.03 NA NA 0.68	2.3.2 N N N N N N N N N N N N N N N N N N N
4 4 4 4 4 4 4 5 2 Z Z Z Z Z Z Z	4 4 4 4 4 2 2 2 2 2	Z Z Z Z	(4 4 4 4 2 2 2 2 2	X		(4 4 4 4 2 2 2 2 2	3.83 4.09 8.04 8.09 8.09 8.09	4.17 4.62 NA 3.55	2. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4.
0 8 0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	8.97 5.95 7.13 7.46	5.42 7.14 8.88	5.32 6.68 7.90 7.90	6.36 6.42 8.61	6.77 6.91 10.41 8.02	48.09 47.78 56.57	49.27 5.37 10.90	6.73 6.81 9.07 19.40	14.28 18.43 5.30 843 843	2.40 5.35 5.35 5.35	3.93 4.40 7.65 3.68	84 .c. v. v. v. 4 .c. v.
Transplant/graft palm tendon Revise thumb tendon Trandon transfer with graft Hand tendon/muscle transfer Revise thumb tendon Finger tendon transfer Finger tendon transfer	Revision of finger Hand tendon reconstruction Hand tendon reconstruction Hand tendon reconstruction Release frumb contracture	Thumb tendon transfer Fusion of knuckle joint Fusion of knuckle joints	Release Knuckle contracture Release finger contracture Revise Knuckle joints Revise Knuckle joint implant	Revise finger joint Revise/implant finger joint Repair hand joint	Repair hand joint with graft	Great toe-hand transfer Single transfer, toe-hand Double transfer, toe-hand	Toshiorial change of intiger Toe joint transfer Repair of web finger Repair of web finger	Correct metacarpal flaw Correct finger deformity Lengthen metacarpal/finger Repair hand deformity	Heconstruct extra tinger Repair finger deformity Repair muscles of hand Release muscles of hand Assisson constricting itssue	Treat metacarpal fracture	reat thumb dislocation Treat thumb fracture Treat thumb fracture Treat thumb fracture Treat thumb fracture	Ireat hand dislocation Pin hand dislocation Treat hand dislocation Treat hand dislocation Treat knuckle dislocation Pin knuckle dislocation Treat knuckle dislocation Treat knuckle dislocation Treat finger fracture, each
Transk Revise Tendo Hand t Revise Finger	Revisi Hand 1 Hand 1 Hand 1	Thumk Fusion Fusion Fusion	Releas Releas Revise Revise	Revise Revise Repair Repair	Repair Recon Repair Recon	Great Great Single Double	Tosin Toe jo Repair Repair Benair	Correc Correc Correc Length Repair	Hecon Repair Repair Releas Excisio	Treat I Treat I Treat I	Treat t Treat t Treat t Treat t Treat t	Treat I Treat I Treat I Treat I Pin kn
444444												
	26499 26500 26502 26504					26551 26553 26553 26554			26587 26590 26591 26593 26593			26675 26676 26676 26686 26700 26715 26715 26715 26720

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Global	08000000000000000000000000000000000000
Year 2007 Transitional Facility Total	75748758600000000000000000000000000000000000
Fully Implemented Facility Total	721-4 8 1-4 8 6 6 8 8 6 6 6 6 6 6 6 6 7 7 7 7 6 7 7 7 7
AYMEN IS FOR Year 2007 2007 In tional lity Non-Fa-	A A 2 2 2 4 4 5 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
ည ≧ဋိသစ္ကြ	A N N N N N N N N N N N N N N N N N N N
Mal-Practice RVUs	9.99 9.99 9.99 9.99 9.99 9.99 9.99 9.9
Physician plement- Transi- 2007 Physician plement- Transi- Address and Nork Facility Nork Facility Nork Facility Nork RVUs RVUs RVUs RVUs RVUs RVUs RVUs RVUs	8. 4. 4. 5. 5. 5. 4. 4. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.
Fully Implemented Facility PE RVUs	7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7
Year 2007 Transitional Non-Fa-cility PE RVUs	X X & 4 X Z & 4 X X X X X X X X X X X X X X X X X X
Fully Implemented Non-Facility PE RVUs	X X 9 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
Physician Work RVUs	22.6.2.1. 88.6.1. 88.6.8. 88.6.8. 88.6.8. 88.6.8. 88.6
RELATIVE VALUE UNITS (RVUS) AND Description	Treat finger fracture, each Treat finger dislocation Treat finger dis
.	
ADDENDUM B	
ADDI CPT¹/ HCPCS²	26727 26742 26742 26745 26746 26756 26756 26776 26776 26841 26842 26841 26842 26841 26842 26843 26841 26843 26841 26843 26841 26843 26844 26861 26861 26861 26861 26861 26861 26861 26861 26862 26861 26861 26861 27000 27000 27001 27004 27004 27004 27004 27004 27004 27004 27004 27004 27004 27004 27006

										_																														_		_	_	_	_	_	_	—	_	_
060 060	060	060	060	060	000	000	96	060	060	060	060	060	060	060	060	080	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	280	060	060	060	060	060	060	060	060
60.91 41.94 70.59	26.31 25.79	12.47	16.41	21.88	06:1	2.16	12.81	16.58	21.31	22.38	24.71	33.66	29.12	29.32	33.44	44.57	39.57	41.18	23.70	33.38	28.28 88.28	45.59	33.98	32.26	35.69	17.14	23.73	29.04	23.15	27.58	19.29	26.29	. o	4.29	23.74	19.30	27.79	35.73	13.24	25.67	25.96	44.03 	11.61	20.35	24.01	27.81	11.49	30.67	37.70	9.85
58.97 40.62 68.59	25.45 24.27	12.39	3.86 15.66	20.87	1.87	2.14	17.01	15.03	20.36	21.46	24.33	32.54	27.96	28.62	31.14	43.02	38.01	39.57	22.50	32.34	37.30	43.70	31.14	31.00	34.80	16.49	23.17	28.14	23.03	27.30	18.67	25.09	11.66	4.36	19.55	18.89	27.53	35.74	12.90	24.57	26.85	42.6z 48.74	11.47	19.47	22.96	26.35	11.15	29.62	35.99	9.48
4 4 4 2 2 2	Z Z	AN S	0.49 NA	₹ Z	5.55	6.86	5.38 NA	 ₹ Z	¥ X	¥.	Υ ·	4 4 2 2	Υ Z	A A	Υ ?	₹ < Z Z	ζ ζ Ζ	Z Z	A A	Υ S	₹ 4 Z Z		Z Z	¥.	₹ Z Z	ζ	A A	¥:	Υ Z	 {	A A	A S	98.11 9N	4.31	A A	Α ·	A A	X X	13.33	¥:	 Z 2	 4	11.94	Z Z	¥.		 ∀	 ζ	. ∠	9.84
4 4 4 2 2 2	Ψ Ψ Z Z	A S	os.c V	Y Z	4.52	5.37	4.02 V V	 	A A	Y :	Υ S	Y Y	A N	ΑN	Ψ.	¥ < Z	ζ ζ Ζ	A N	A N	Υ S	¥ 4 Z Z	 ₹ ₹	Ϋ́	Y S	₹ S	ζ	A A	¥ :	Y Z	 	N A	A C	11.53	4.21	A A	Α S	4 4 2 2	Ϋ́Z	13.00		 V 2	 &	11.54	- V	N A		 & Z Z	 {	 {	9.44
5.64 3.70 6.12	2.22 1.94	0.93	1.35	1.94	0.13	0.14	0.08	0.95	1.85	1.72	2.18	- 60 4 00	2.61	2.54	3.50	4. 4	3.67	3.84	2.11	2.96	3.5/	2.4	3.16	2.94	3.10	1.46	2.22	2.61	2.08	1.57	2.39	2.37	0.96 65	0.28	1.06	1.97	2 63	3.48	1.07	2.19	2.48	4.05 4.66	0.95	1.85	2.11	2.71	0.89	2.10	3.52	0.81
18.56 14.07 21.99	9.65 9.04	4.80	6.41	8.45	0.47	0.52	0.33	6.51	8.34	8.85	8.99	2.08	10.65	10.39	12.54	12.12	13.41	13.85	9.01	11.78	12.92	15.43	10.03	11.68	12.62	6.45	8.82	10.59	8.38	10.11	7.31	9.92	5.01	2.17	15.47	6.94	16.9 87.9	11.40	5.52	09.6	8.11	14.91	5.05	6.88	9.10	10.56	5.03	10.90	13.17	4.31
16.62 12.75 19.99	8.79 7.52	4.72	5.66	7.44	9.0	0.50	0.33	6.96	7.39	7.93	8.61	10.79	9.49	69.6	10.24	13.57	11.85	12.24	7.81	10.74	461	13.54	7.19	10.42	11.73	9.02 5.80	8.26	69.6	8.26 5.6		69.9	8.72	87.4	2.24	11.28	6.53	6 8 7 0 7 0	11.41	5.18	8.50	9.00	13.44 44.03	5.6.4	00.9	8.05	9.10	4.69	0.10	11.46	3.97
4 4 4 Z Z Z	Ψ Ψ Z Z	AN,	4.36 NA	Y Z	4.12	5.22	3.90 AN		¥ X	¥ ?	Υ S	4 4 2 2	ΥZ	A V	Υ ?	4 < Z Z	(4 2 Z	A Z	Y Z	Υ S	₹	(4 2 Z	Ϋ́Z	¥.	₹ S	ζ	A A	¥ :	Y Z	 ₹ Z	A A	A S	86.4 8 A A	2.19	AN	Υ ?	Z Z	Ϋ́	5.61	¥:	 & 2 2	 4	5.38	Y Y	¥ X	 V 2		 { Z Z	. Υ Υ	4.33
	Ψ Z Z Z	N S	0.7 NA 0	▼	3.09	3.73	7.54 VA	Z Z	A A	A :	A S	Z Z	A A	A V	¥ :	₹ < Z Z	ζ 4 Ζ Ζ	A Z	A A	A S	¥ Z	ζ ζ Ζ	A N	A :	₹ S	ζ	A A	¥ :	Y Z	Y X	N A	A L	4.65 VA	2.09	N A	¥ ż	A A	Z Z	5.28	¥:	A S		4.98	Y Y	A N	 V 2	A Z	Σ Z	Z Z	3.93
36.71 24.17 42.48	14.44 14.81	6.74	8.65	11.49	1.30	1.50	04 00-	9.03	11.12	11.81	13.54	19.00	15.86	16.39	17.40	25.41	22.49	23.49	12.58	18.64	23.84	25.95	20.79	17.64	19.97	04.7	12.69	15.84	12.69	15.90	9.59	14.00	5.92	. 1 8. 1 8. 1	7.21	10.39	15.65	20.85	9.65	13.88	15.37	25.13	5.61	11.62	12.80	14.54	5.57	17.00	21.01	4.70
Extensive hip surgery	Extensive hip surgery	one	Remove hip foreign body	Removal of hip prosthesis	Injection for hip x-ray	Injection for hip x-ray	Inject sacrolliac joint	Transfer tendon to pelvis	ninal muscle	muscle	of iliopsoas muscle	hin socket	hip socket	Partial hip replacement	asty	Total nip arthroplasty	placement	Revise hip joint replacement	Transplant femur ridge	əe	Revision of hip bone	nes		f femur	Incision/fixation of femur	nead/neckhvsis	Treat slipped epiphysis	hysis	Treat slipped epiphysis	hvsis	Revision of femur epiphysis	es		cture	cture	ıre(s)	pelvic ring fracture	racture	racture	hip socket fracture	hip wall fracture	hip fracture(s)	thigh fracture	9	thigh fracture	90	90 (D 0	J (D)	
Extensive hip sur Extensive hip sur Extensive hip sur	ctensive hip sure ctensive hip sure	emoval of tail bo	emove nip loreig emove hip foreig	emoval of hip pr	jection for hip x	jection for hip x	Inject sacrolliac joint Bevision of hin tend	ansfer tendon to	Transfer of abdominal muscle	Transfer of spinal muscle	Transfer of illopso	Transfer of Illopsoas muscle Beconstruction of hin socket	Reconstruction of hip socket	artial hip replace	Total hip arthroplasty	otal nip arthropia	Revise hip joint replacement	evise hip joint re	ansplant femur	cision of hip bor	Revision of hip bone	evision of hip bo	evision of pelvis	cision of neck o	cision/fixation of	epair/gran rennu eat slipped epir	eat slipped epip	eat slipped epip	eat slipped epip	eat slipped epic	evision of femur	Reinforce hip bones	Treat pelvic ring fracture	Treat tail bone fracture	Treat tail bone fracture	Treat pelvic fracture(s)	Treat pelvic ring fracture	Treat pelvic ring fracture	Treat hip socket fracture	Treat hip socket f	Treat hip wall frac	Treat hip tracture	Treat thigh fracture	Treat thigh fracture	Treat thigh fractur	Treat thigh fracture	Treat thigh fracture	Freat thigh fracture	Treat thigh fracture	Treat thigh fracture
																																																		<u> </u>
444	4 4	, ·		Q Q		-		LQ		٩,	Q •			٩ :::	4 ·		L Q		٩	Q •		. 4		-		Į		٩.	-	. 4		-		. 4		Q •		. 4		٩,	`	. 4			-	-		. 4	١٩	/
		-	<u> </u>	-		-				-	-			:	: -	_			-	-	-			-	-			-	-			:			:	-	-		:	-	: -	: :				- - -	: - !	-		_: _:
27075 27076 27077	27078 27079	27080		27090	27093	27095	27097		27100	27105	•	27120		27125	27130	27132					2/14/	27156	27158			27175			27178	27181	27185	7187	27193		27202		27216	27218	27220	•	27226	27227 27228				27236	27238	27240	27245	27246
0 0 0	ผู้ผู	20 6	v N	0,0	ı öğ	SI C	N O	1 0	เพี	8	o '	N 0	ΙŃ	Ñ	ci b	N 0	1 0	เพิ	ò	ω b	N 0	1 0	ιώ	Ö	co c	ν'n	ιÑ	20	0, 0	1 (1	Ŋ	cv c	N 0	1 (1)	2	o b	א מ	ı	2	0 6	מ ל	N 0	1 (1)	ιώ	2	SO C	0 0	10	1 (1)	Ś

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

ADI	ADDENDOM B		RELATIVE VALUE UNITS (HVUS) AND	MELAIEU	INTORMA MADE	INFORMATION USED IN DETERMINING MEDICARE PAYMENTS	Ü. Ν Γ		NIEUICA	Π Τ Α ὶ Ιν	EN OF VE	_ / 2007 }	Confined	5
CPT¹/ HCPCS²	Mod	Status	Description	Physician Work RVUs	Fully Implemented Non-Facility	Year 2007 Transi- tional Non-Fa- cility PE RVUs	Fully Im- plement- ed Facil- ity PE RVUs	Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Prac- tice RVUs	Fully Implemented Non-Facility Total	Year 2007 Transi- tional Non-Fa- cility Total	Fully Im- plement- ed Facil- ity Total	Year 2007 Transi- tional Fa- cility Total	Global
27248		A	Treat thigh fracture	10.73	NA	AN	7.01	7.91	1.81	NA	NA	19.55	20.45	060
27250		⋖ <	Treat hip dislocation	7.12	Z Z	Y S	4.27	4.53	0.62	Y S	¥ ž	12.01	12.27	060
27253		∢ ∢	Treat hip dislocation	13.38	Z Z	4 4 2 2	8 28	02. 6	2.50	Y Y	4 4 2 Z	23.88	25.02	060
		< <	Treat hip dislocation	18.71	N N	Z A	10.56	11.66	3.17	A A	¥	32.44	33.54	060
27256		∢ •	Treat hip dislocation	4.23	2.39	3.24	1.39	1.91	0.46	7.08	7.93	6.08	6.60	010
27257		∢ ⊲	Treat his dislocation	5.33	A N	Z Z	2.57	10.52	0.69	A Z	Υ Z	8.59	20 11	010
27259		(∢	Treat hip dislocation	22.95	ΣŽ	Z Z	12.91	13.82	3.74	Z Z	Z Z	39.60	40.51	060
27265		⋖	Treat hip dislocation	5.04	Z Z	Z Y	3.98	4.59	0.63	A A	¥ Z	9.65	10.26	060
27266		∢ <	Treat hip dislocation	7.60	Z Z	Z Z	5.55	6.14	1.29	¥ ž	¥ S	14.44	15.03	090
27280		(<	Fusion of sacroiliac joint	14.39	Z Z	Z Z	9.05	96.6	2.53	Z Z	Z Z	25.97	26.88	060
27282		∢.	Fusion of pubic bones	11.62	Y :	Y :	7.83	7.96	1.86	A :	¥:	21.31	21.44	060
27284		< <	Fusion of hip joint	24.85	∀ \$ 2	▼	12.86	14.29	3.92	Κ <u>Υ</u>	Υ Υ	41.63	43.06	060
27290		₹ 4	Amplitation of leg at hip	24.89	(4 4 Z Z	12.53	13.68	3. c 43.	Z Z	ζ	40.23	43.22	060
27295		. ≺	Amputation of leg at hip	19.46	Ϋ́Z	Ą Z	9.79	10.93	2.95	Ą Z	Ą Z	32.20	33.34	060
27299		<u>ن</u>	Pelvis/hip joint surgery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	\\\ \
27301		< <	Drain thigh/knee lesion	0.60	8.23	9.61	4.66	5.02	40.5	15.87	17.25	12.30	12.66	060
27305		₹ 4	Drainage of bone lesion	6.03	₹ 4 Z Z	4 4 Z Z	6.07 4 63	0.70	. 5	Z Z	4 4 Ζ Ζ	11.67	10.03	060
		< <	Incision of thigh tendon	4.61	Z	A Z	4.07	4.56	0.85	ΥZ	A Z	9.53	10.02	060
27307		⋖	Incision of thigh tendons	5.91	Ϋ́Z	Y Y	4.81	5.24	1.04	A A	Y Y	11.76	12.19	060
27310		< <	Exploration of knee joint	08.6	₹ S	Ψ Z Z	6.83	7.39	1.61	Z Z	Υ <u>Υ</u>	18.24	18.80	060
27320		∢ ∢	Partial removal, triigh herve	20. 9	Z Z	4 4 2 2	4.0.4	2.07	90	Z Z	K K	12.55	12.18	060
		< <	Biopsy, thigh soft tissues	2.28	4.09	3.66	1.87	1.88	0.24	6.61	6.18	4.39	4.40	010
27324		∢ •	Biopsy, thigh soft tissues	4.89	NA S	AN S	3.85	4.10	0.75	AN S	¥ ;	9.49	9.74	060
27327		∢ <	Removal of third lesion	4.46	80.9	10.9 VN	3.61	99.5	0.64	8 L.T.L	L.T.	10.47	8.79	060
27329		< <	Remove tumor, thigh/knee	15.60	(ζ ζ Ζ Ζ	8.58	9.9	2.5	Z Z	ζ ∢ Ζ Ζ	26.32	26.65	060
27330		< <	Biopsy, knee joint lining	4.96	NA	N A	4.12	4.46	0.86	A A	A A	9.94	10.28	060
27331		۷.	Explore/treat knee joint	5.87	₹ Z	₹ Z	4.84	5.35	1.02	A :	Y Z	11.73	12.24	060
27332		∢ <	Removal of knee cartilage	8.26	∀	▼	6.15	6.88	1.43	Ψ < Z Z	Ψ « Z Z	15.84	16.57	060
27334		۲ ۷	Remove knee joint lining	66.8	(₹ ₹ 2 Z	6.49	7.18	15.	ζ	ζ	16.99	17.68	060
		. ≺	Remove knee joint lining	10.35	Ϋ́	A N	7.06	7.93	1.74	ΥZ	Ą Z	19.15	20.02	060
27340		∢ •	Removal of kneecap bursa	4.17	₹ Z	Ϋ́ Z	4.05	4.43	0.72	¥:	Υ :	8.94	9.32	060
27345		∢ <	Removal of knee cyst	19.0 19.0	∀	¥	4.89 7.89	ъ. т 44.	00.1	4 < Z Z	¥ \$	11.80	12.35	060
27350		< <	Removal of kneecap	8.46	Z Z	 ∠ Z	6.29	7.00	1.41	ξ ζ Ζ	Z Z	16.16	16.87	060
		۷	Remove femur lesion	7.82	Ϋ́Z	Ϋ́	5.87	6.55	1.32	ΥZ	A N	15.01	15.69	060
27356		⋖ <	Remove femur lesion/graft	68.6	¥ S	Y S	6.86	7.60	1.65	¥ ž	¥ ž	18.40	19.14	060
27357		< ⊲	Remove remur lesion/graft	0.93	₹ ₹	₹ 4 Z Z	45.7	0.37	- 92	۲ م ۲ ک	Ψ Φ Ζ Ζ	20.42	22.12	080
27360		< <	Partial removal, leg bone(s)	11.26	{	 ₹ Z	8.13	9.20	1.83	Z Z	Z Z	21.22	22.29	060
27365		۷	Extensive leg surgery	17.85	Ϋ́Z	Ą V	10.52	11.39	2.79	NA	Y V	31.16	32.03	060
27370		⋖ ·	Injection for knee x-ray	96.0	2.82	3.50	0.33	0.32	0.08	3.86	4.54	1.37	1.36	000
27372		∢ <	Removal of foreign body	5.06	8.34 NA	9.62 NA	4.05	4.53	0.84	14.24 NA	15.52 NA	9.95	10.43	060
27381		(∢	Repair/oraft kneecap tendon	10.56	Z Z	Z Z	7.56	8.71	1.79	Z Z	Z Z	19.91	21.06	060
27385		< <	Repair of thigh muscle	7.93	Ž	Z A	6.36	7.31	1.36	A A	Y Y	15.65	16.60	060
27386		∢.	Repair/graft of thigh muscle	10.90	₹ Z	₹ Z	7.98	9.13	1.85	¥:	Y :	20.73	21.88	060
27390		∢ ⊲	Incision of thigh tendon	5.38	A N	Z Z	4.57	4.98 8.98	0.92	V Z	Ψ Z	10.87	11.28	060
		ς	יייייייייייייייייייייייייייייייייייייי	į			5	2	<u>.</u>	-		2	5)

State A Complement of their means of the state A Complement of their means of their me					نَـــ						_	_					_		۰							_										
A	060 060 060 060	060	060	060	060	060	060 060	060	060 060	060	060		060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060
A Brigation of the pipe records 8-45 NA NA 510 675 110 NA NA 110 110 110 NA NA 110 110 110 110 NA NA NA NA 110 110 110 NA NA NA NA NA NA NA N	18.37 13.17 17.04 23.04 16.04 23.09 17.42	16.79 17.62 20.31	43.30	21.83	19.53	11.43	18.75	31.96	19.37 20.57	17.23	18.98	20.13	21.50	29.78	38.51	26.95	24.91	25.70	31.21	31.06	33.73	19.15	17.59	37.25	31.42	30.00	14.03	15.51	12.08	12.58	20.75	34.75	26.18 12.35	16.89	18.21 26.91	35.86
March Marc	17.72 12.55 16.27 22.04 15.24 22.62 16.61	15.97 16.83 19.07	42.44 35.90	20.86	18.62 18.66	10.82	17.92 27.78	31.15	18.54 19.98	16.48	19.86	20.72 22.04	20.51	28.35	36.44	25.65	23.80	24.45	29.95	24.30 29.88	32.26	18.34	16.72	35.94	30.40	28.72	13.47	15.07	16.53	12.26	19.86	33.57	24.95 12.04	15.85	17.47 25.34	34.34
A complement of the produces 6 45				 ∢ ∢ Z Z	4 4 Z Z	(4 :	 ∢ ∢ Z Z	_	 {	 ∢	Α :		 Z	Ç Q	4 4 Z Z	₹ ₹ ₹	₹ ₹	Z Z	Z Z	₹ ₹ 2 Z	∢ ∢ Z Z	∀ ₹	ξ	₹ S	ζ ζ Z Z	Z Z	ζ ζ Ζ Ζ	Y S	13.12	12.91	 &	₹ 2 2	13.24 13.24	Z Z	 {	
Mail			 {	 V V	Y Z	 { Z Z	 &		 {		Y S	 &	Z Z	 {	Α Α Ζ Ζ	Z Z	Z Z	Z Z	Z Z	X X Z Z	ς ς Z Z	Z Z	Z Z	Y S	Z Z	Z Z	Z Z	Y S	12.61	12.35	 &	Z Z	NA 12 68		 &	 V V V V
Page 1975 Page	1.57 1.10 2.04 1.34 1.32 1.31	44.1 1.5.1 1.78	4.35	1.88	1.70	0.90	1.63	2.70	1.69	1.49	1.81	1.88 2.09	1.90	2.80	3.79	2.42	2.24	2.34	2.77	2.79	3.07	1.73	1.53	3.36	2.74	2.71	1.15	1.24	1.02	1.03	1.78	3.03	2.42 0.97	1.34	1.53	3.12
Lengthening of thigh rendons 6.44 NA	7.37 5.63 6.96 8.99 8.73 8.89 6.98	6.91 7.23 7.91	14.52	8.58	7.82	5.32	7.53	12.14	7.72 8.28	6.99 8.30	6.28	6.91 8.63	8.39	10.80	13.91	10.15	9.51	9.51	14.1	11.40	12.19	7.46	7.11	13.05	11.36	10.98	5.24	5.81	6.57	5.27	7.81	12.39	9.43	7.61	7.08	13.37
A Innesion of their bendons 6.44	6.72 6.19 7.99 5.93 6.17 6.17	6.09 6.44 6.67 74	13.66	7.61	6.91	4.71	6.70	11.33	7.69	6.24	7.16	7.50	7.40	9.37	11.84 7.43	8.85	8.40	8.26	10.15	10.22	10.72	6.65	6.24	11.74	10.34	9.70	4.68	5.37	5.83 4.65	4.95	6.92	11.21	8.20	6.57	6.34 9.11	11.85
A Lengthening of thigh tendons			ZZ	 ∢ ∢ Z Z	4 4 Z Z	(4 ;	 &		 {		Z Z			(4 : 2 Z	Z Z	₹ 2 2	Z Z	Z Z	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	ξ ζ Ζ Ζ	Ζ Z	Y S	Z Z	Y S	X X	Z Z	Z Z	Z Z	5.95	5.60	 V V	Z Z	- NA	Y S	 {	 &
Lengthening of thigh tendons			 Z Z	 V V V V	Z Z	(&		 &	 4	Y Z		Z Z	ζ ζ Ζ	4 4 Z Z	ZZZ	Z Z	Ψ Z Z Z	Z Z	ξ ζ Z Z	ς ς Z Z	Y Z	ζ <u>Ψ</u>	₹ <u>₹</u>	ζ ∢ Ζ Ζ	∀ ₹ ₹	Z Z	Y S	5.44 	5.04		Y S	NA 2	- X	Z Z	 V V V V
<u> </u>	9.43 6.44 8.61 12.01 7.97 9.13	8.44 8.88 10.62	24.43	11.37	10.01	5.21	9.59	17.12	9.96 10.60	8.75	10.89	11.34	11.21	16.18	11.40	14.38	13.16	13.85	17.03	16.87	18.47	9.96	8.95	20.84	17.32	16.31	7.64	8.46	9.23 6.15	6.28	11.16	19.33	14.33 6.00	7.94	9.60 13.86	19.37
444444444444444444444444444444444444			ieet	dr. dr.	de de					<u>+</u>																9	φ φ	9.	Φ.							
444444444444444444444444444444444444	igh tendons of thigh tendor of thigh tendor of thigh tendon of thigh tendon of thigh tendon	ee cartilage ee ligament ee ligament	cyte implant kn al knee allogra	nerated kneeca instable kneeca	Instable kneecs	ar release oper	on, knee	on, knee	high muscies nee joint	cap	rnee joint	rnee joint	rnee joint	rnee joint	rthroplasty ich	igh of thick bono	of knee	of knee	of thigh bone	men migns	of thigh	top leg growth	top leg growth	ce knee joint	ce kriee joint knee prosthesis	ghgt thigh/kng	ion of thigh/kne	ion of thigh/kne	ion of thigh/kne thigh fracture	thigh fracture	thigh fracture	thigh fracture	thigh fracture	thigh fracture	thigh fracture thigh fracture	thigh fracture thigh fracture
444444444444444444444444444444444444	Incision of the Lengthening Lengthening Lengthening Transplant of Transplants Revise thigh	Repair of kn Repair of kn Repair of kn	Autochondro Osteochondr	Repair deger Revision of u	Revision of u	Lat retinacul	Reconstructi Reconstructi	Reconstructi	Revision of the Incision of kr	Revise knee	Revision of P	Revision of Revision of R	Revision of P	Revision of F	Total knee a	Incision of th	Realignment	Realignment Shortening o	Lengthening	Repair of thi	Repair/graft Surgery to st	Surgery to st	Surgery to st	Revise/repla	Removal of I	Reinforce thi	Decompress	Decompress	Decompress Treatment of	Treatment of	Treatment of Treatment of	Treatment of	Treatment of	Treatment of	Treatment or Treatment of	Treatment of Treatment of
										-														· 				-								
			:									. : - a			. ~			٠.							 . m			m .							· ·	ω4 · · ·

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

ADL	ADDENDOM D	ı	UNIA (SOVI) SIINIO EVALUE VAILA	DELATED INFORMATION OSED IN DETERMINING MEDICARE L'ATMENTS	לאור) לאור	20 00	ו ד ן		ואורעיט	- 1		1007		5
CPT¹/ HCPCS²	Mod	Status	Description	Physician Work RVUs	Fully Implemented Non-Facility	Year 2007 Transi- tional Non-Fa- cility PE RVUs	Fully Im- plement- ed Facil- ity PE RVUs	Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Prac- tice RVUs	Fully Im- plement- ed Non- Facility Total	Year 2007 Transi- tional Non-Fa- cility Total	Fully Im- plement- ed Facil- ity Total	Year 2007 Transi- tional Fa- cility Total	Global
27516		۷ ۵	Treat thigh fx growth plate	5.36	5.69 NA	6.19 NA	5.05	5.40	0.81	11.86 NA	12.36 NA	11.22	11.57	060
		⋖ •	thigh fx growth plate	15.72	A ;	A Z	98.6	11.16	2.55	N S	NA 12	28.15	29.43	060
27524		∢ ∢	Treat kneecap fracture	10.17	4 N	4.4 V AN	6.98	3.46	1.74	44. AN	NA NA	18.89	19.83	060
•		< <	Treat knee fracture	3.89	4.83	5.19	4.27	4.38	0.65	9.37	9.73	8.8	8.92	060
27535		∢ ∢	Treat knee fracture	11.72	0.43 NA	NA.	5.67 8.26	9.65	2:00	0.00 NA	15.7 AN	21.98	23.37	060
27536		∢.	Treat knee fracture	17.11	N	NA.	10.29	11.28	2.73	A N	¥.	30.13	31.12	060
27538 27540		⋖ ⋖	knee tracture knee fracture	13.38	5.54 NA	2.98 NA	8.02	5.12 9.14	0.84	11.24 NA	11.68 NA	10.62	10.82	060 060
27550		∢.	Treat knee dislocation	5.75	5.31	5.84	4.59	4.85	0.76	11.82	12.35	11.10	11.36	060
27552		∢ ⊲	Treat knee dislocation	7.95	A Z	A Z	6.12	6.74	1.36	A N	A A	15.43	16.05 28.44	060
		< <	Treat knee dislocation	17.22	Z Z	Z Z	10.58	12.49	2.97	Z Z	Z Z	30.77	32.68	060
27558		∢ <	Treat knee dislocation	17.93	NA 0 6	NA F3	10.62	12.44	3.08	Α V	NA Ca	31.63	33.45	060
27562		(∢	Treat kneecap dislocation	5.78	NA NA	- AN	4.45	4.69	0.94	- A V	NA NA	11.17	11.41	060
27566		∢•	Treat kneecap dislocation	12.51	Y :	Y :	7.85	8.95	2.12	¥ ?	Y :	22.48	23.58	060
27580		∢ ⊲	Fixation of knee joint	20.82	Z Z	A Z	1.62	1./3	0.30	A A	A A	36.53	38.38	010
27590		< ∢	Amputate leg at thigh	13.27	Z Z	N N	6.14	6.54	1.74	Z Z	Z Z	21.15	21.55	060
27591		∢ <	Amputate leg at thigh	13.74	Z S	¥ S	7.43	8.34	2.02	¥ ž	¥ ż	23.19	24.10	060
27594		∢ ⊲	Amputate leg at mign	7.09	₹	A Z	5.50 4.76	6.00	. 45	Z Z	4 4 2 2	12.87	13.23	060
27596		(∢	Amputation follow-up surgery	11.06	ZZZ	Z Z	90.9	6.62	1.57	Z Z	Z Z	18.69	19.25	060
27598		∢ (Amputate lower leg at knee	10.99	N	NA.	6.34	6.85	1.65	NA.	¥	18.98	19.49	060
27599		ပ ⊲	Leg surgery procedure	0.00	0.00 NA	0.00 NA	0.00	0.00	0.00	0.00 NA	0.00 NA	0.00	0.00	\ \ \
27601		(∢	Decompression of lower leg	5.87	ZZ	ZZ	4.26	4.70	0.80	Z Z	Z Z	10.93	11.37	060
27602		∢•	Decompression of lower leg	7.64	A N	AN I	4.39	4.95	1.10	AN S	A I	13.13	13.69	060
27603		∢ ∢	Drain lower leg lesion	5.05	6.47	6.38	3.90	3.83	0.74	12.84	13.17	9.69	58. 80 80. 80	060
		< ∢	Incision of achilles tendon	2.87	5.28	7.08	1.78	2.19	0.41	8.56	10.36	5.06	5.47	010
27606		∢ <	Incision of achilles tendon	4.13	Z S	¥ S	2.67	3.19	0.69	¥ ž	¥ ż	7.49	8.01	010
27610		∢ ∢	reat lower leg bone lesion Explore/treat ankle joint	8.93	Z Z	¥ ¥ Z Z	6.17	6.79	1.3	ξ Z	4 4 2 Z	16.50	17.12	060
27612		. ∢	Exploration of ankle joint	7.92	Z Z	Z Z	5.35	5.91	1.13	A N	A N	14.40	14.96	060
27613		∢ <	Biopsy lower leg soft tissue	2.17	3.81	3.38	1.72	1.78	0.20	6.18	5.75	4.09	4.15	010
27615		(∢	Remove tumor, lower leg	12.84	S N	N A	8.08	9.05	1.83	Z Z	2 Z	22.71	23.72	060
27618		∢ •	Remove lower leg lesion	5.08	6.40	6.11	3.77	3.94	0.72	12.20	11.91	9.57	9.74	060
27620		∢ ∢	Remove lower leg lesion	8.39	0.08 NA	9.65 AN	5.29	5.25	0.97	19.72 NA	19.29 NA	11.55	12.19	060
		< <	Remove ankle joint lining	8.29	NA	N A	5.59	6.24	1.28	A A	N A	15.16	15.81	060
27626		∢ •	Remove ankle joint lining	8.90	N S	NA	5.95	6.68	1.48	A I	A S	16.33	17.06	060
27635		∢ ∢	Removal or tendon lesion	7.83	86.7 8 A	/9./ AN	3.80	4.24 6.47	1.31	13.51 NA	13.20 NA	14.81	15.61	060
		< <	Remove/graft leg bone lesion	10.08	Z V	N A	7.16	8.01	1.66	A A	A A	18.90	19.75	060
27638		∢ <	Remove/graft leg bone lesion	10.79	Z Z	Y S	6.98	7.96	1.84	Y S	Y S	19.61	20.59	060
27641		< <	Partial removal of fibula	9.65	Z Z	ξ Z Z	6.19	9.78	46.	X X	X X	17.89	19.06	060
27645		. ∢	Extensive lower leg surgery	14.69	Z Z	Z Z	9.51	11.42	2.41	A N	A N	26.61	28.52	060
27646		∢ <	Extensive lower leg surgery	13.12	Z Z	¥ S	8.41	10.38	2.05	¥ ź	₹ Ş	23.58	25.55	060
27648		< <	Extensive anime/neel surgery	0.96	2.71	3.32	0.31	0.33	0.08	3.75	4.36	1.35	1.37	000

								Ť																-																		
060 060	060	060	060	060	060	060	060	060	222	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060
18.66 19.90 18.67	10.16	13.46 9.74	11.13	16.41	13.65	15.02	12.35	19.33	3.07	13.20 15.83	17.57	16.31	30.35	14.50	20.32	27.55	28.41	23.21	23.14	34.14	26.92	15.38	16.26	18.69	19.92	7.56	14.71	23.24	7.10	11.23	6.30	9.69	14.83	9.73	15.86	6.99	21.11	6.72	11.31	27.41	7.15	18.73
17.75 18.71 17.78	9.67	12.88 9.29	10.78 13.03	15.69	12.79	14.19	11.77	18.55	2.92	12.55	16.81	15.90	29.23	14.58	19.37	28.91	27.24	20.83	22.34	32.62	25.61	14.54	16.20	17.68	19.05	7.48	14.19	22.41	7.17	10.84	6.39	9.46	14.19	9.4	15.10	6.99	20.15	99.9	10.78	25.94	7.14	17.37
4 4 4 2 2 2	13.66 NA	∢ ∢ Z Z	4 4 Z Z	Α 4 Ζ Ζ	Z	2 Z Z Z	Z Z	 { Z Z	Z Z	Z Z	Y Z	Y S	Z Z	Y :	Y 2	Z Z	Z Z	4 4 2 2	Y Z	Z Z	Z Z	Y S	Z Z	Z Z	Z Z	8.39	S Z	Z Z	8.07	12.23	7.17	10.48	NA 7 66	10.66	Z	7.99	e AN	7.61	12.45 NA	Z Z	7.57	▼
 &	13.31 NA	A A	 ∢	Z Z	N S	0.28 NA	Z Z	ς <u>ς</u> Σ Ζ	Y S	ς ς Z Z	ΑN	Y S	₹ ₹ 2 Z	Y :	Y Z	ζ ∢ Ζ Ζ	Y Z	4 4 2 Z	Ϋ́	Z Z	X Z	Y S	Z Z	Z Z	Z Z	8.07	N A	Y Z	7.78	11.67	6.95	10.09	NA 7	10.18	Y Y	7.69	Y V	7.35	11.75 NA	ZZ	7.33	Z Z Z Z
1.59	0.69	1.09	0.89	1.37	1.15	1.24	1.00	. t 3 9.	0.32	1.05	1.47	1.30	2.76	1.27	1.80	1.73	2.47	2.49	2.05	3.16	2.43	1.72	1.35	1.62	1.75	0.55	1.17	2.03 38	0.48	0.85	0.41	0.73	1.23	0.74	1.32	0.46	1.85	0.43	0.82	2.25	0.45	1.47
7.21 7.64 6.85	3.74	5.45 4.40	4.85 5.49	6.51	5.63	6.21	5.12	7.50	0.88	5.65	69.9	5.55	10.03	5.62	7.86	8.58	10.35	9.09	8.87	11.86	06.6	6.14	6.26	7.66	7.88	3.82	6.29	8.90 0.00	3.61	5.14	3.24	4.57	6.26	4.55	6.71	3.70	8.24	3.40	5.00	10.98	3.56	8.37
6.30 6.45 5.96	3.65	4.87 3.95	4.50 4.75	5.79	4.77	5.38 86.3	4.54	6.72	0.73	5.00	5.93	5.14	9.83	5.70	6.91	9.94 9.94	9.18	7.97	8.07	10.34	8.59	5.30	6.20	6.65	7.01	3.74	5.77	8.07	3.68	4.75	3.33	4.34	2.62	4.26	5.95	3.70	7.28	3.36	4.47	9.51	3.55 4.84	7.01
ZZZ	8.41 AA	ς ς Z Z	▼	A A	NA NA) A V	Y S	 (Y S	Z Z	A A	Y Z	₹ ₹ 2 Z	¥.	Y Z	Z Z	Y Z	4 4 2 2	A A	A A	Z Z	Y S	Z Z	Z Z	Z Z	4.65	N A	Y Z	4.58	6.14	4 11.4	5.36	NA NA	5.48	Y V	4.70	0.0 V	4.29	6.14 AN	Z Z	3.98	▼ 4 Z Z
 &	8.06 NA	Ψ Ψ Z Z	Ψ Ψ Z Z	Y Y	Z C	9.82 NA	Υ S	 {	¥ S	▼	A A	¥ ž	4 4 2 2	¥ :	Α Δ Ζ Ζ	Z Z	Y S	▼	A A	▼	₹ ₹ 2 Z	₹ Z	Z Z	∀	Υ Z	4.33	N A	V Z	4.29	5.58	3.89	4.97	A V	5.00	¥ Z	4.40 7.40	N A A	4.03	5.44 NA	ξ ∀ [3.74	A A
9.86 10.55 10.24	4.56	6.92 4.58	5.39	8.53	6.87	7.57	6.23	10.19	1.87	6.50 8.38	9.41	9.46	16.69	7.61	10.66	17.24	15.59	15.27	12.22	19.12	14.59	7.52	8.65	9.41	10.29	3.19	7.25	12.31	3.01	5.24	2.65	4.39	7. c	4.44	7.83	2.83	11.02	2.89	5.49 12.04	14.18	3.14 6.54	8.89 15.65
Repair achilles tendon	Repair leg fascia defect		oh.	don	dons	don			nop	9			D‡	t		Incision of tibia & fibula		Revision of lower leg			Repair of lower leg		es			Treatment of tibia fracture	υ Φ	• • • • • • • • • • • • • • • • • • •	ıre	lre	<u> </u>	ıre	I're	<u> </u>		I're		ıre	17e	Treatment of ankle fracture		
Repair achilles tendon Repair/graft achilles tend Repair of achilles tendon	Repair leg fascia defect Repair of leg tendon, ead	g tendon, eac g tendon, eac	g tendon, eac r leg tendons	r leg tendons ower leg ten	ower leg tend	lower leg ten r leg tendons	calf tendon	r leg tendon	tional leg ten	ıkle ligament ıkle ligament	ikle ligament	ankle joint	ankle jolint ion. ankle ioii	ankle implan	bia	bia & fibula.	t of lower leg	lower leg	of tibia	of tibia	wer leg	via epiphysis	r leg epiphys	g epiphyses	g cpipingees Dia	of tibia fracture	if tibia fractur	of tibia fracture of tibia fracture	of ankle fractu	f ankle fractu	ii ariikie iractu if fibula fractu	of fibula fractu	of fibula fractu	if ankle fractu	f ankle fractu	of ankle fractu	of ankle fractu	of ankle fractu	of ankle fractu	f ankle fractu	leg fracture . leg fracture .	lower leg fracture . Iower leg fracture .
≔ ⊭ ૠ	eg f of le	o t o t o t o	r of le r lowe	r lowe	se of	e lowe	ion of	se lowe	se addi	airotai airofar	air of ar	ion of	nstruct	oval of	sion of t	ision of ti	alignmen	vision of pair of tib	epair/graft	epair/graft	epair of lo	epair of tik	lepair lowe	Repair of le	Reinforce til	reatment c	eatment c	reatment c	eatment c	eatment c	eatment c	eatment c	eatment c	eatment c	eatment c	eatment c	atment c	atment c	eatment c	atment c	eat lower	Treat lower Treat lower
Repair act Repair/gra Repair of	Repair I Repair o	Repair	Repai Repai	Repai	Relea	Revis	Revis	Review	Bev.	Rep	Rep	Revis	2 G	Ren		= =	2 2	ž	ď	<u> </u>	čč	œ ò	ш.	ш ц	- ш	⊢ ⊦	F	FF	Ė	<u>,</u> ,	==	Ě	ĚĖ	Ė	Ĕ	ĚĖ	===	<u>ٿ</u>	<u> </u>	<u> </u>	2 2	<u> </u>
A Repair act Repair/gra A Repair of 6																																										
<u> </u>	⋖ ⋖ ·				< <		∢ <				< <			⋖ ·	< <		⋖ <		< <	∢		∢ <		∢				∢		< <		∢.	∢		⋖			۷.	∢			۷ ۷
444	44	< <	44	⋖	<	4	4 <	T T	∢ •	۷ ۷	< <	∢ <	€	4	∢ <	<	4 <	∢ ∢	< <	∢ ₫	X 4	∢ <	X A	∢ ◊	< <	∢ <	< <	∢ ◊	(∢	∢ <	۲ ح	∢ •	∢ ◊	₹ ₹	4	∢ ◊	< <	∢ •	4 4	< <	∢ ∢	۷ ۷
<u> </u>	4 4 ·	4 4	∢ ∢	⋖	<	4	∢ <	4	4 •	۷ ۷	₹	∢ <	< <	Α	∢ <	< <	4 •	∢ ∢	< <	∢ ₫	4	∢ <	< <	∢ ◊	4	∢ <	< <	∢ ◊	X	4 •	۲ ح	4 ·	∢	<	Α	∢ ◊	< <	₹ .	∢	(4	∢ ∢	۷ ۷

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	000000000000000000000000000000000000
Year 2007 Transi- tional Fa- cility Total	34.65 36.65 37
Fully Im- plement- ed Facil- ity Total	23.25. 24.25. 25.
Year 2007 Transi- tional Non-Fa- cility Total	ANN 80 80 80 80 80 80 80 80 80 80 80 80 80
Fully Im- plement- ed Non- Facility Total	A N N N N N N N N N N N N N N N N N N N
Mal-Prac- tice RVUs	2.000.000.000.000.000.000.000.000.000.0
Year 2007 Transi- tional Fa- cility PE RVUs	£1.00.00
Fully Im- plement- ed Facil- ity PE RVUs	\$\frac{7}{2} \cdot \text{C} \t
Year 2007 Transi- tional Non-Fa- cility PE RVUs	A A C A A A A A A A A A A A A A A A A A
Fully Implemented Non-Facility PE RVUs	A N N N N N N N N N N N N N N N N N N N
Physician Work RVUs	87.8.4.0.4.0.0.1. 87.8.4.0.4.0.0.1. 87.8.6.9.8.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0
Description	Treat lower leg fracture Treat lower leg dislocation Treat lower leg dislocation Treat lower leg dislocation Treat ankle joint, open Fusion of ankle joint, open Fusion of the lower leg Amputation of lower leg Decompression of lot infection Treatment of foot infection Treatment of foot infection Treatment of foot infection Treatment of toot infection Treatment of foot infection Treatment of foot infection Treatment of foot infection Treatment of foot lesion Exploration of foot lesion Excise foot tendon sheath Excise foot tendon shea
Status	
Mod	
CPT1/ HCPCS ²	27828 27828 27829 27831 27842 27844 27844 27844 27844 27844 27846 27848 27884 27884 27884 27884 27884 27884 27884 27884 27884 27886 28002 28002 28002 28003 28003 28004 28005 28005 28005 28005 28006

060 060 060 060	000000000000000000000000000000000000000	060 060 060	060	090 010 090	060 060 060	060 060	060 060 060	060 060	060	060 060	060000	060000	000000000000000000000000000000000000000
7.87 7.80 9.24 8.59 10.81 15.12	11.06 9.77 13.59	6.87 16.99 12.49 7.83	6.85 7.46 16.50	10.52 3.63 8.78 10.30	8.68 12.19 8.21 11.14	8.43 10.23 6.97 8.74	8.26 6.98 7.08 13.63	8.29 10.77 14.08 21.48	30.16 18.96 9.03 7.05	8.58 8.32 11.23	14.72 11.01 15.21 14.33	15.69 13.88 18.67	7.55 7.70 10.79 10.79 10.79 8.20 8.20 8.20 8.20 8.20 8.20 8.20
7.69 7.71 9.00 8.39 11.08 21.22 15.30	9.68 9.68 10.32 13.27	6.63 12.04 7.64	7.01 7.19 16.44 77.71	10.47 3.52 8.46 10.09	8.46 11.89 8.13	8.18 9.64 6.86 8.42	7.69 6.52 6.86 13.21	7.93 10.51 13.88 20.80	29.35 18.02 8.83 6.91	9.51 8.54 8.17	14.44 10.45 19.06 25.70	15.25 15.91 13.56 18.45	16.68 15.57 10.56 11.70 9.81
9.73 10.27 11.27 13.07 24.98	13.47 11.97 13.84 15.71	8.62 NA 15.27 9.85	8.91 9.24 NA 18.00	12.90 5.73 11.04	10.76 15.22 10.23 13.71	10.21 11.96 8.84 10.45	9.87 8.71 8.88 16.37	10.02 12.82 16.05 23.56	33.60 20.40 10.78 8.85	12.44 10.51 13.00	17.42 13.22 17.71 23.80	18.95 19.89 16.71 21.91	NA 13.91 17.88 17.88 12.27
11.10 11.63 13.04 12.40 14.89 26.34 19.47	14.79 13.36 17.01 12.22	9.96 NA 15.79	10.35 10.63 NA 18.94	14.01 6.22 12.03 13.83	12.15 15.83 11.67 14.74	11.54 13.23 10.20 12.11	11.12 9.81 10.12 17.24	11.40 14.22 17.80 25.19	35.20 22.44 12.34 10.12	13.32 11.94 11.66	18.57 14.71 19.93 26.69	20.08 20.08 18.28 23.31	20.05 NA NA 15.08 13.93 NA
0.53 0.67 0.61 0.63 1.42	0.84 0.70 0.98 0.98	0.45 1.26 0.92 0.53	0.47	0.73 0.22 0.61 0.73	0.61 0.91 0.81	0.57 0.69 0.46 0.58	0.55 0.44 0.44 1.06	0.58 0.82 1.14	2.59 1.54 0.62 0.46	0.73 0.59 0.65	0.82 0.91 1.13	1.19	2. 1. 1. 1. 2.7 1. 2.7 1. 2.7 1. 2.7 1. 2.7 1. 2.7 1. 2.7 1. 3. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4.
3.19 3.57 3.55 3.55 4.40 8.36 8.36	3.69 3.69 4.30 3.61 3.61	2.91 6.51 1.65 2.22	2.73 3.24 5.40 5.06	3.69 1.45 3.54 3.85	3.48 4.39 3.27 3.99	3.34 2.93 3.64	3.48 3.16 3.28 4.79	3.36 4.04 7.08	10.64 6.97 3.66 2.80	3.20 3.20 4.85	5.67 4.54 6.32 6.32	6.03 6.03 6.99	6.59 6.59 6.44 6.44 7.00 7.00 7.00 7.00
3.01 3.10 3.33 3.33 4.67 8.31	3.60 3.98 4.83 3.47	2.67 5.91 4.16 3.03	2.89 2.97 5.34 68	3.52 3.22 3.64	3.26 4.09 3.19	3.09 3.34 3.32 3.32	2.91 2.70 3.06 4.37	3.00 3.78 4.73 6.40	9.83 6.03 3.46 2.66	3.60 3.37 4.74	5.39 3.98 6.19 6.97	5.36 5.36 7.73 7.45	2.7.2 5.0.9 5.0.9 3.87 4.48 8.3.83
5.05 5.66 6.55 6.18 6.66 12.07	6.68 5.89 7.27 5.45	4.66 NA 7.39	4.79 5.02 NA 191	6.07 3.55 5.80 6.05	5.56 7.42 5.29 6.56	5.12 5.66 4.73 5.35	5.09 4.89 5.08 7.53	5.09 6.09 6.90 9.16	14.08 8.41 5.41 4.60	6.53 5.23 6.62	8.37 6.75 8.20 11.71	8.53 9.34 7.73 9.23	8.35 NA 7.22 10.66 6.29 NA
6.42 7.02 7.37 7.31 8.48 13.43	8.00 7.28 8.14 8.57 6.82	6.00 NA 7.91 6.46	6.23 6.41 N A 8.85	7.18 4.04 6.79 7.38	6.95 8.03 6.73 7.59	6.93 6.93 7.01	6.34 6.32 8.40	6.47 7.49 8.65 10.79	15.68 10.45 6.97 5.87	7.41 6.77 6.54 8.69	9.52 8.24 10.42 14.60	9.30 9.30 10.63	9.57 9.57 8.39 9.57 9.57
4.15 6.00 5.00 6.78 11.49 8.86	5.95 5.38 7.57 7.46	3.51 9.22 6.96 4.08	3.65 3.73 9.77 8.97	6.10 1.96 4.63 5.72	6.89 6.89 6.34 6.34	4.52 3.65 4.52	4.23 3.38 3.36 7.78	4.35 5.91 8.01	16.93 10.45 4.75 3.79	5.18 4.58 5.73	8 .03 2 .05 2 .05 2 .05 2 .05	9.23 9.23 7.93 11.31	9 9 55 9 9 55 10 54 10 54 10 58 10 5
Removal of toe lesions Part removal of metatarsal Part removal of metatarsal Part removal of metatarsal Part removal of metatarsal Removal of metatarsal Removal of metatarsal Revision of foot	- PC			ody ody ody		of foot tendon of foot tendons of foot tendons of foot tendons of foot tendons	Incision of foot tendon(s) Incision of foot tendon Incision of foot tendon Evision of foot tendon	Release of big toe	Revision of foot and ankle	Je	Repair hallux rigidus Correction of bunion Correction of bunion Correction of bunion Correction of bunion		Incision of ankle bone Incision of ankle bone Incision of midroot bones Incision of metatarsal Incision of metatarsal Incision of metatarsal Incision of metatarsal
of toe lesions oval of metatarse oval of metatarse oval of metatarse oval of metatarse of metatarse of foot	of heel bone of heel spur oval of ankle/hee moval of foot bor moval of toe	moval of toe of ankle bone of metatarsal of toe	moval of toe moval of toe e foot surgery e foot surgery	e foot surgery of foot foreign b of foot foreign b of foot foreign b	foot tendon foot tendon aft of foot tendor	of foot tendon of foot tendons . of foot tendon of foot tendons .	of foot tendon(s) of toe tendon of foot tendon of foot tendon	of big toe of foot fascia of midfoot joint . of foot tendon	of foot and ankle of midfoot joint. of foot contractur of toe joint, each	f toes	allux rigidus n of bunion n of bunion n of bunion	n of bunion n of bunion n of bunion	of treet botte of ankle bone of midfoot bones aft midfoot bones of metatarsal of metatarsal of metatarsal of metatarsal
Removal Part rem Part rem Part rem Part rem Removal	Removal Removal Part rem Partial re Partial re	Partial re Removal Removal Removal	Partial re Partial re Extensive Extensive	Extensive Removal Removal Removal	Repair of Repair/gi Repair of Repair/gr	Release Release Release Release	Incision (Incision c Incision c Revision	Release Revision Release Revision	Revision Release Release Release	Fusion o Repair of Repair of Partial re	Repair h Correctio Correctio Correctio	Correctio Correctio Correctio Correctio	Incision of Incisi
444444	4444	⋖ ⋖⋖⋖	444	4444	444	444	444	444	444	< < < < ·	বববব	<<<<<<<	
		28126 28130 28140 28150					28230 28232 28234 28238				28289 28290 28292 28293		
ביז ניז ניז ניז ניז ניז ניז ניז (י		ניו ניו ניו ניו	CA CA CA CA	ניו ניו ניו ניו		ניז ניז ניז ניז	ניו ניו ניו מ	ניו ניו ניו ניו	ניו ניו ניו ניו				4 CA CA CA CA CA CA CA

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Status	וממני	ביים היים ביים	.	TELATIVE VACOE CIVILO (110 CO) AND	ורוח -		5	֓֞֝֜֝֝֓֞֜֝֝֝֓֜֜֝֓֓֓֓֓֜֜֜֜֜֜֜֓֓֓֓֓֓֜֜֜֜֜֓֓֓֓֓֜֜֜֜֜֓֓֓֜֜֜֜	;,,,,,,,	TIEFATED IN OTHER OF THE PROPERTY OF THE PROPE) -) - [1007		5
A Previous of teaching between colors A Previous of teaching A Previou	7.7 CS2	Mod	Status	Description	Physician Work RVUs	Fully Implemented Non-Facility PE RVUs	Year 2007 Transi- tional Non-Fa- cility PE RVUs		Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Practice RVUs	Fully Implemented Non-Facility	Year 2007 Transi- tional Non-Fa- cility Total	Fully Implemented Facility Total	Year 2007 Transi- tional Fa- cility Total	Global
A Reported of Search of			4	Revision of toe	4.54	7.41	5.93	3.24	3.53		12.58	11.10	8.41	8.70	060
A Repart of sealand bords				Repair deformity of toe		7.39	5.80	3.67	4.54		13.12	11.53	9.40	10.27	060
A Resect entinged to entingers 6 1				Removal of sesamoid bone		6.74 4 N	5.35 VA	3.25	3.3.3 18.6		22.21 NA	10.83	8.73	8.79 17.08	060
A Resect entriged to be issue 6.97 8.00 6.68 4.07 4.70 10.84 15.89				Repair of metatarsals		10.03	9.39	5.48	6.12		19.63	18.99	15.08	15.72	060
A Repeat entrols A Resolt entrols A Resolt entrols A Repeat A				Resect enlarged toe tissue		8.08	6.85	4.07	4.20		15.89	14.66	11.88	12.01	060
A Repair water block)				Resect enlarged toe		8.70	7.37	4.47	4.73		18.23	16.90	14.00	14.26	060
Maintained to the place Maintained to th				Repair extra toe(s)		0.83	6.01	3.19	3.52		11.59	10.77	7.95	8.28	060
A Treatment of lose fracture 2.16 3.15 3.57 2.83 3.17 3.75 4.41 0.035 5.90				Repair webbed toe(s)		7.8Z	0.00	3.89 9.89 9.89	84.48		2.53 VA	13.31 NA	10.60	96.32	080
A Treatment of heal fracture 4.55 4.56 4.57 4.76 5.75 4.76 4.76 4.76 4.76 4.76 4.76 4.76 4.76 4.77			< <	Treatment of heel fracture	2.16	3.39	3.57	2.93	3.02		5.90	6.08	5.44	5.53	060
Treat need fracture			- ≺	Treatment of heel fracture	4.56	4.53	4.76	3.76	4.41		9.82	10.05	9.05	9.70	060
A Treat/graft hele fracture 17.44 NA 10.22 12.24 2.66 NA A Treat/graft hele fracture 3.29 3.15 3.59 3.57 3.58 3.57 3.54 3.55 3.57 3.54 3.55 3.57 3.54 3.55 3.57 3.54 3.55 3.57 3.54 3.55 3.57 3.54 3.55 3.57 3.54 3.55 3.54 3.55 3.54 3.55 3.54 3.55 3.54 3.55 3.54 3.55 3.54 3.55 3.54 3.55 3.54 3.55 3.55 3.54 3.55 3.55 3.55 3.55			⋖	Treatment of heel fracture	6.36	Ϋ́Z	AN	5.69	6.52		٧Z	AN	13.16	13.99	060
A Treatment of ankle fracture 1699			⋖	Treat heel fracture	17.44	₹ Z	₹ Z	10.92	12.69		₹ Z	Y Y	31.02	32.79	060
Treatment of ankle fracture	:		< •	Treat/graft heel fracture	16.98	Z Z	A S	10.21	12.24		Υ ι V ι	A C	29.99	32.02	060
Treatment of ankle fracture			< <	of ankle fracture	2.09	3.15	3333	2.59	2.57		5.55	5.73	4.99	4.97	060
A Treat ankle fracture 15			< ⊲	of ankle fracture	5.39	0.70 NA	0.03 AN	5.07	5.57		0 / · /	ω / . / Φ / Z	10.7	11.19	060
A Treat midrot fracture, each 1.90 2.65 3.4 3.65 3.24 0.24 5.13			< <	Treat ankle fracture	16.99	Z Z	Z Z	9.79	10.72		Z Z	₹ Z	29.36	30.29	060
A Treat midroot fracture, each 3.09 3.66 3.49 3.05 3.29 7.21 A Treat midroot fracture, each 2.06 NA 3.65 6.01 1.10 NA A Treat midroot fracture 2.97 2.84 3.05 2.56 6.01 1.10 NA A Treat metafarsal fracture 2.97 3.18 3.29 2.46 3.05 2.60 6.01 1.10 NA A Treat metafarsal fracture 5.07 NA NA 4.75 5.22 0.36 6.01 1.10 NA A Treat big to fracture 5.07 NA A 7.52 2.94 2.26 6.06 1.10 1.18 A Treat big to fracture 5.07 NA A 7.72 7.99 2.90 3.75 0.04 4.26 A Treat big to fracture 5.07 NA 4.6 2.25 1.9 3.26 1.99 1.99 1.14 2.99 2			<	Treat midfoot fracture, each	1.90	2.95	3.07	2.44	2.46		5.13	5.25	4.62	4.64	060
A Treat metiatrical fracture 2.68 NA NA 3.65 4.02 0.44 NA A Treat metiatrical fracture 2.97 3.18 3.05 2.40 2.43 0.30 5.13 A Treat metiatrical fracture 2.97 3.18 3.05 2.50 2.43 0.30 5.13 A Treat metiatrical fracture 5.70 NA NA 4.87 5.22 0.94 6.59 A Treat big toe fracture 1.09 2.11 2.04 1.89 2.02 0.50 0.14 2.89 A Treat big toe fracture 1.09 2.11 2.04 1.89 2.05 1.89 2.05 0.93 0.14 3.34 A Treat big toe fracture 1.09 2.11 2.04 2.24 1.89 2.89 2.89 2.89 2.89 2.89 2.99 3.99 2.90 0.14 1.89 1.18 1.18 1.18 1.18 1.18 1.18 1.18			⋖	Treat midfoot fracture, each	3.09	3.68	3.49	3.05	3.33		7.21	7.02	6.58	98.9	060
A Treat metatarsal fracture and hold fracture			⋖	Treat midfoot fracture	2.68	Ϋ́Z	A N	3.63	4.02		Ϋ́Z	¥ Z	6.75	7.14	060
A Treat metatarsal fracture			< -	Treat midfoot fracture, each	7.06	₹ Z	A A	5.09	6.01		∢ Z	A N	13.25	14.17	060
Treat metatarisal fracture			< •	metatarsal fracture	1.99	2.84	3.05	2.40	2.43		5.13	5.34	4.69	4.72	060
Treat big toe fracture			(⊲	metatarsal fracture	78.8	0 P	0.23 A N	4.35	3.03 4 82		90.00 V	0.70	90.80	0.40	060
A Treat big toe fracture 109 211 204 169 165 014 334 A Treat big toe fracture 2.33 2.42 7.99 1.29 0.04 4.26 A Treat big toe fracture 1.08 7.53 7.96 1.29 0.04 4.26 A Treat big toe fracture 1.08 1.64 1.25 1.98 1.84 1.89 0.14 2.81 A Treat ment of toe fracture 1.06 2.25 1.98 1.84 1.88 0.18 3.89 A Treat sessmoold bone fracture 1.06 2.25 1.98 1.84 1.88 0.14 2.85 A Treat sessmoold bone fracture 2.04 2.75 2.66 2.42 0.04 1.07 A Treat sessmoold bone fracture 2.04 2.57 2.06 2.32 3.30 0.49 1.07 1.42 0.04 1.07 A Treat sessmoold bone fracture 2.04 2.69 2.84			< <	metatarsal fracture	5.70	Z Z	Z Z	4.57	5.22		Z Z	Υ Z	11.10	11.75	060
A Treat big toe fracture 1.58 2.48 2.25 1.88 2.02 0.20 4.26 A Treat big toe fracture 3.80 7.53 7.96 3.28 3.75 0.69 1.189 A Treat big toe fracture 1.09 1.68 1.57 1.61 1.55 0.14 1.89 1.89 1.84 1.89 0.14 1.189 A Treat not for fracture 1.06 1.65 1.49 1.37 2.92 3.30 0.49 10.74 A Treat seasmold bone fracture 2.04 2.78 2.50 2.33 0.49 10.74 A Treat seasmold bone fracture 2.04 2.78 2.50 2.33 2.38 0.26 0.49 10.74 A Treat seasmold bone fracture 2.04 2.78 2.50 2.33 2.38 0.26 0.49 10.74 A Treat toot dislocation 2.04 2.78 2.50 2.33 2.38 0.26 2.48 1.41 <td>-</td> <td></td> <td>⋖</td> <td>Treat big toe fracture</td> <td>1.09</td> <td>2.11</td> <td>2.04</td> <td>1.69</td> <td>1.65</td> <td></td> <td>3.34</td> <td>3.27</td> <td>2.92</td> <td>2.88</td> <td>060</td>	-		⋖	Treat big toe fracture	1.09	2.11	2.04	1.69	1.65		3.34	3.27	2.92	2.88	060
A Treat big toe fracture 2.33 7.22 7.99 2.90 3.12 0.36 1.99 A Treat big toe fracture 1.09 1.68 1.57 1.61 1.55 0.14 2.91 A Treat big toe fracture 1.09 1.68 1.57 1.61 1.55 0.14 2.91 A Treat sesamoid bone fracture 2.47 5.84 6.91 2.13 2.08 0.74 0.74 A Treat sesamoid bone fracture 2.47 5.84 6.91 2.13 2.08 0.26 0.14 2.85 A Treat foot dislocation 2.47 2.84 2.50 2.33 2.38 2.56 2.66 2.42 0.04 A Treat foot dislocation 2.45 3.25 2.57 2.66 2.42 0.04 0.77 0.25 1.44 A Treat foot dislocation 3.16 3.86 3.76 3.26 2.57 2.66 2.89 3.76 0.25 1.04 1.72 A Treat foot dislocation 3.10 3.26 3.26 <td>-</td> <td></td> <td>⋖・</td> <td>Treat big toe fracture</td> <td>1.58</td> <td>2.48</td> <td>2.25</td> <td>1.88</td> <td>2.02</td> <td></td> <td>4.26</td> <td>4.03</td> <td>3.66</td> <td>3.80</td> <td>060</td>	-		⋖・	Treat big toe fracture	1.58	2.48	2.25	1.88	2.02		4.26	4.03	3.66	3.80	060
Treat by the fracture 1.09 1.68 1.79 1.61 1.55 1.02 1.03			< <	Tract big too fracture	2.33	7.22	7.99	2.90	3.12		9.9	10.68	5.59	5.87	060
A Treatment of toe fracture 1.46 2.25 1.98 1.84 1.88 0.16 3.89 10.74 A Treat sesamoid bone fracture 1.06 1.65 1.49 1.38 1.32 0.49 10.74 A Treat sesamoid bone fracture 2.47 5.84 6.91 2.13 2.08 0.34 8.65 A Treat foot dislocation 2.45 3.25 2.57 2.66 2.42 0.14 2.85 A Treat foot dislocation 2.45 3.25 2.57 2.66 2.42 0.37 6.07 A Treat foot dislocation 2.45 3.25 2.46 2.40 0.37 6.07 A Treat foot dislocation 2.45 3.25 2.46 2.45 0.52 1.141 A Treat foot dislocation 2.47 3.88 3.89 3.68 3.71 0.56 8.25 A Treat foot dislocation 2.77 3.76 2.40 2.61 0.27 2.25 A Treat foot dislocation 2.77 3.76 3.28 3.16 3.13 0.40 0.87 A Treat foot dislocation 2.77 3.76 3.28 3.16 3.13 0.40 0.87 A Treat foot dislocation 2.77 3.76 3.28 3.16 3.13 0.40 0.87 A Treat foot dislocation 2.77 3.76 3.28 3.16 3.13 0.40 0.87 A Treat foot dislocation 2.77 3.76 3.28 3.16 3.13 0.40 0.87 A Treat foot dislocation 2.77 3.76 3.28 3.16 0.20 3.86 A Treat foot dislocation 2.77 3.76 3.28 3.16 0.40 0.87 A Treat foot dislocation 3.11 2.27 2.08 3.28 3.16 0.40 0.87 A Treat foot dislocation 3.11 2.27 2.08 3.28 0.99 0.20 3.86 A Treat foot dislocation 3.11 3.75 3.75 3.75 3.75 3.75 3.75 A Treat foot dislocation 3.11 3.75 3.75 3.75 3.75 3.75 3.75 A Treat foot dislocation 3.11 3.75 3.75 3.75 3.75 3.75 3.75 A Treat foot dislocation 3.12 3.14 3.20 3.25 3.75 3.75 3.75 A Treat foot dislocation 3.12 3.14 3.20 3.25 3.7			۲ ۵	Treatment of toe fracture	00.5	1.03	1.30	1 61	2.73			2.32	, c 48. c	0	060
A Treat toe fracture 3.32 6.93 7.37 2.92 3.30 0.49 10.74 A Treat sesamed bone fracture 2.47 5.84 6.91 2.13 2.08 0.49 10.74 A Treat sesamed bone fracture 2.45 5.84 6.91 2.13 2.08 0.34 8.65 A Treat foot dislocation 2.45 3.26 2.57 2.66 2.42 0.37 6.07 A Treat foot dislocation 6.35 9.82 2.66 2.40 2.76 2.76 2.46 2.00 2.38 0.26 5.08 A Treat foot dislocation 3.31 4.38 3.89 3.68 3.71 0.56 8.25 A Treat foot dislocation 4.40 NA 4.01 4.11 4.11 0.56 1.24 0.52 0.26 0.26 8.25 A Treat foot dislocation 4.40 NA 4.01 4.11 0.56 0.52 0.02 0.03 </td <td></td> <td></td> <td>< <</td> <td>Treatment of toe fracture</td> <td>1.46</td> <td>2.25</td> <td>1.98</td> <td>. 1 8:</td> <td>8.</td> <td></td> <td>3.89</td> <td>3.62</td> <td>3.48</td> <td>3.52</td> <td>060</td>			< <	Treatment of toe fracture	1.46	2.25	1.98	. 1 8:	8.		3.89	3.62	3.48	3.52	060
A Treat sesamoid bone fracture 1.06 1.65 1.49 1.36 1.42 0.14 2.85 A Treat sesamoid bone fracture 2.47 2.84 6.91 2.33 2.98 0.34 8.65 A Treat foot dislocation 2.45 3.25 2.57 2.66 2.42 0.37 6.07 A Treat foot dislocation 6.35 9.82 2.86 2.42 0.52 11.41 A Treat foot dislocation 1.66 2.59 2.46 2.00 2.25 0.23 2.48 A Treat foot dislocation 3.31 4.38 3.89 3.69 5.49 1.04 17.21 A Treat foot dislocation 8.10 9.98 7.99 5.49 5.70 1.25 19.33 A Treat foot dislocation 8.10 9.98 7.99 5.29 5.70 1.25 1.25 A Treat foot dislocation 8.80 NA A.31 4.60 NA 4.71			. ⋖	Treat toe fracture	3.32	6.93	7.37	2.92	3.30		10.74	11.18	6.73	7.11	060
A Treat sesamoid bone fracture 2.47 5.84 6.91 2.13 2.08 0.34 8.65 A Treat toot dislocation 2.45 3.27 2.57 2.69 2.47 5.89 0.26 2.49 5.08 A Treat foot dislocation 6.35 9.82 9.88 4.96 5.49 1.04 17.21 A Repair foot dislocation 1.66 2.59 2.46 2.00 2.25 0.25 0.33 4.48 A Treat foot dislocation 3.31 4.38 3.89 3.68 3.71 0.56 8.25 A Treat foot dislocation 1.89 3.68 3.71 0.56 8.25 A Treat foot dislocation 1.89 3.06 2.87 2.40 2.71 3.76 3.28 3.16 0.52 19.33 A Treat foot dislocation 1.89 3.06 2.87 5.70 1.25 0.26 6.87 A Treat too dislocation 1.91			⋖	Treat sesamoid bone fracture	1.06	1.65	1.49	1.36	1.42		2.85	2.69	2.56	2.62	060
A Treat foot dislocation 2.74 2.78 2.50 2.33 2.38 0.26 5.05 A Treat foot dislocation 3.26 2.75 2.66 2.42 0.75 11.41 A Treat foot dislocation 6.35 9.82 9.88 4.96 5.49 1.04 17.21 A Treat foot dislocation 1.66 2.59 2.46 2.00 2.25 0.23 4.48 A Treat foot dislocation 4.00 NA NA 4.01 4.13 0.69 NA A Treat foot dislocation 8.10 9.98 7.99 5.29 5.70 1.25 19.33 A Treat foot dislocation 4.80 NA A.41 4.01 4.01 4.01 0.69 NA A Treat foot dislocation 4.80 3.06 2.87 2.40 2.61 0.25 1.24 A Treat toe dislocation 4.80 NA NA 7.00 7.78 1.04			< •	Treat sesamoid bone fracture	2.47	5.84	6.91	2.13	2.08		8.65	9.72	4.94	4.89	060
A Treat toot dislocation 3.245 3.52 7.59 2.57 2.92 7.59 7.51 2.50 2.54 0.07<			< <	Treat foot dislocation	40.2	2.78	2.50	2.33	85.4		5.08	08.4	4.63	89.4	060
A Frequency dislocation 6.35 9.81 4.96 5.49 1.04 17.21 A Treat foot dislocation 1.66 2.59 2.46 2.00 2.25 0.23 4.48 A Treat foot dislocation 8.10 9.98 7.99 5.29 5.70 1.25 19.33 A Treat foot dislocation 1.89 3.06 2.87 2.40 2.61 0.27 5.22 A Treat foot dislocation 2.71 3.76 3.28 3.16 3.13 0.40 6.87 A Treat foot dislocation 4.89 NA NA 4.31 4.60 0.82 NA A Fepair foot dislocation 4.89 NA NA 4.31 4.60 0.82 4.44 A Treat toot dislocation 1.91 2.77 4.89 NA NA 7.78 1.30 NA A Treat too dislocation 1.91 2.77 4.38 4.00 2.05 2.48			(<	Treat foot dislocation	24.5	2.63	711	3.45	4 15 4 15		11 41	10.83	7 17	7.87	060
A Treat foot dislocation 1.66 2.59 2.46 2.00 2.25 0.23 4.48 A Treat foot dislocation 3.31 4.38 3.89 3.68 3.71 0.56 8.25 A Treat foot dislocation 8.10 9.98 7.99 5.29 5.70 1.25 19.33 A Treat foot dislocation 1.89 NA 4.31 4.60 0.87 5.22 A Treat foot dislocation 2.71 3.76 3.28 3.16 3.13 0.40 6.87 A Treat foot dislocation 4.89 NA NA 4.31 4.60 0.82 NA A Treat toot dislocation 1.70 1.96 1.67 0.95 0.99 0.20 3.86 A Treat toot dislocation 2.77 4.38 4.00 2.05 0.99 0.20 3.86 A Treat too dislocation 2.77 4.38 4.00 2.05 2.48 0.44			< <	Repair foot dislocation	6.35	9.82	9.88	4.96	5.49		17.21	17.27	12.35	12.88	060
A Treat foot dislocation 3.31 4.38 3.68 3.71 0.56 8.25 A Treat foot dislocation 4.40 NA 4.01 4.13 0.69 NA A Treat foot dislocation 1.89 3.06 2.87 2.40 2.61 0.27 5.22 A Treat foot dislocation 2.71 3.76 3.28 3.16 0.40 6.87 A Treat toot dislocation 4.89 NA NA 4.31 4.60 0.82 NA A Treat toot dislocation 1.70 1.96 1.67 0.99 0.20 3.86 A Treat too dislocation 2.77 4.38 4.00 2.05 0.99 0.20 3.86 A Treat too dislocation 2.77 4.38 4.00 2.05 2.44 4.44 A Treat too dislocation 2.77 4.38 4.00 2.05 2.48 0.44 A Treat too dislocation 4.21			<	Treat foot dislocation	1.66	2.59	2.46	2.00	2.25		4.48	4.35	3.89	4.14	060
A Treat foot dislocation 4.40 NA NA 4.01 4.13 0.69 NA A Repair foot dislocation 1.89 3.06 2.87 2.61 0.27 5.22 A Treat foot dislocation 2.71 3.76 3.28 3.16 3.13 0.40 6.87 A Treat foot dislocation 2.71 3.76 3.28 3.16 3.18 0.40 6.87 A Treat toot dislocation 1.70 1.96 1.67 0.95 0.99 0.20 3.86 A Treat too dislocation 1.70 1.96 1.67 0.95 0.99 0.20 3.86 A Treat toe dislocation 2.77 4.38 4.00 2.05 2.48 0.44 A Repair toe dislocation 4.21 6.90 5.44 3.20 3.25 0.57 11.68 A Treat toe dislocation 1.22 1.33 1.44 0.26 4.44 A Treat toe d			⋖	Treat foot dislocation	3.31	4.38	3.89	3.68	3.71		8.25	7.76	7.55	7.58	060
A Repair foot dislocation 8.10 9.98 7.99 5.29 5.70 1.25 19.33 A Treat foot dislocation 1.89 3.06 2.87 2.40 2.61 0.27 5.22 A Treat foot dislocation 4.89 NA NA 4.31 4.60 0.82 NA B A Treat toot dislocation 8.88 NA NA 7.00 7.78 1.30 NA B A Treat toe dislocation 1.70 1.96 1.67 0.95 0.99 0.20 3.86 A Treat toe dislocation 2.77 4.38 4.00 2.05 2.48 0.44 A Treat toe dislocation 2.77 4.38 4.00 2.05 2.48 0.44 A Treat toe dislocation 4.21 6.90 5.44 3.20 3.25 0.57 11.68 A Treat toe dislocation 1.22 1.34 1.41 0.26 2.44 <td< td=""><td></td><td></td><td>⋖ -</td><td>Treat foot dislocation</td><td>4.40</td><td>Υ Z</td><td>Y Y</td><td>4.01</td><td>4.13</td><td></td><td>₹ Z</td><td>A N</td><td>9.10</td><td>9.25</td><td>060</td></td<>			⋖ -	Treat foot dislocation	4.40	Υ Z	Y Y	4.01	4.13		₹ Z	A N	9.10	9.25	060
A Treat foot dislocation 1.89 3.06 2.87 2.40 2.01 5.22 A Treat foot dislocation 4.89 NA A.31 4.60 0.87 NA A Treat toot dislocation 8.88 NA 7.00 7.78 1.30 NA A Treat toot dislocation 1.70 1.96 1.67 0.95 0.99 0.20 3.86 A Treat too dislocation 2.77 4.88 4.04 4.44 7.58 A Treat too dislocation 2.77 4.88 4.24 3.20 2.48 0.44 A Treat too dislocation 4.21 6.90 5.44 3.20 3.25 0.57 11.68 A Treat too dislocation 1.22 1.31 1.27 0.79 0.79 0.79 0.57 1.68 A Treat too dislocation 2.92 1.85 1.54 1.41 0.26 4.03 A Treat too dislocation 2.92 <td< td=""><td></td><td></td><td>< •</td><td>Repair foot dislocation</td><td>8.10</td><td>9.98</td><td>7.99</td><td>5.29</td><td>5.70</td><td></td><td>19.33</td><td>17.34</td><td>14.64</td><td>15.05</td><td>060</td></td<>			< •	Repair foot dislocation	8.10	9.98	7.99	5.29	5.70		19.33	17.34	14.64	15.05	060
A Treat loot dislocation 2.71 3.70 3.13 3.13 0.40 0.82 NA A Treat toot dislocation 8.88 NA NA 4.31 4.60 0.82 NA A Treat too dislocation 1.70 1.96 1.67 0.95 0.99 0.20 3.86 A Treat too dislocation 2.77 4.38 4.00 2.08 1.48 0.26 4.44 A Treat too dislocation 4.21 6.90 5.44 3.20 3.25 0.57 11.58 A Treat too dislocation 1.23 1.31 1.27 0.79 0.79 0.79 0.71 2.67 A Treat too dislocation 2.66 NA 1.85 1.54 1.41 0.26 4.03 A Treat too dislocation 2.66 NA 1.84 0.79 0.79 0.79 0.79 A A Treat too dislocation 2.66 NA 1.87 1.41 <td< td=""><td>-</td><td></td><td>< <</td><td>Treat foot dislocation</td><td>1.89</td><td>3.06</td><td>2.87</td><td>2.40</td><td>2.61</td><td></td><td>5.22</td><td>5.03</td><td>4.56</td><td>4.77</td><td>060</td></td<>	-		< <	Treat foot dislocation	1.89	3.06	2.87	2.40	2.61		5.22	5.03	4.56	4.77	060
A Treat too dislocation A Treat too disl				Treat foot dislocation		0.70 VIV	3.20 VIV	3.10	3.13		0.07 VIV	95.0 V	10.07	10.24	080
A Treat toe dislocation 1.70 1.96 1.67 0.95 0.99 0.20 3.86				Repair foot dislocation		(4 2 Z	(4 2 Z	7.00	7.78		(4 2 Z	¥ 2	17.18	17.96	060
A Treat toe dislocation 1.91 2.27 2.08 1.33 1.48 0.26 4.44 A Treat toe dislocation 2.77 4.38 4.00 2.05 2.48 0.43 7.58 A Treat toe dislocation 1.23 1.31 1.27 0.79 0.79 0.79 0.13 2.67 A Treat toe dislocation 2.66 NA 1.84 1.92 2.48 0.79 <t< td=""><td></td><td></td><td></td><td>Treat toe dislocation</td><td></td><td>1.96</td><td>1.67</td><td>0.95</td><td>0.99</td><td></td><td>3.86</td><td>3.57</td><td>2.85</td><td>2.89</td><td>010</td></t<>				Treat toe dislocation		1.96	1.67	0.95	0.99		3.86	3.57	2.85	2.89	010
A Treat toe dislocation 2.77 4.38 4.00 2.05 2.48 0.43 7.58 A Repair toe dislocation 4.21 6.90 5.44 3.20 3.25 0.57 11.68 A Treat toe dislocation 1.92 1.85 1.54 1.34 1.41 0.26 4.03 A Treat toe dislocation 2.66 NA 1.92 2.42 0.43 NA A Repair of toe dislocation 2.92 6.72 7.04 2.87 3.23 0.45 10.09				Treat toe dislocation		2.27	2.08	1.33	1.48		4.44	4.25	3.50	3.65	010
A Repair toe dislocation 4.21 6.90 5.44 3.20 3.25 0.57 11.68 A Treat toe dislocation 1.23 1.31 1.27 0.79 0.79 0.13 2.67 A Treat toe dislocation 2.66 NA 1.92 2.41 0.26 4.03 A Repair of toe dislocation 2.92 6.72 7.04 2.87 3.23 0.45 10.09				Treat toe dislocation		4.38	4.00	2.05	2.48		7.58	7.20	5.25	2.68	010
A Treat toe dislocation 1.23 1.51 1.27 0.79 0.13 2.57 A Treat toe dislocation 2.96 N A 1.92 2.42 0.43 N A A Repair of toe dislocation 2.92 6.72 7.04 2.87 3.23 0.45 10.09	:			Repair toe dislocation		6.90	5.44	3.20	3.25		11.68	10.22	7.98	8.03	000
A Treat toe dislocation 2.66 NA NA 1.92 2.42 0.43 NA 1.92 2.87 3.23 0.45 10.09				Treat toe dislocation		 - 88	1.27	1.79	1.79		4.03	3.72	3.52	2 50	010
A Repair of toe dislocation 2.92 6.72 7.04 2.87 3.23 0.45 10.09				Treat toe dislocation		Z Z	Z Z	1.92	2.42		2 Z	Z Z	5.01	5.51	010
				Repair of toe dislocation		6.72	7.04	2.87	3.23		10.09	10.41	6.24	09.9	060

060 060 060 060		000000000000000000000000000000000000000	300000000000000000000000000000000000000	
35. 4 25. 53. 4 22. 12. 4 21. 24 21. 24 16. 59 16. 59 15. 90 16. 38 15. 38 15. 38	16.99 1.09 1.09 1.09 1.09 1.09 1.09 1.09 1	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4		2.27
33.89 25.02 20.70 20.62 20.62 16.27 15.37 15.37 14.79	19.67 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43	80.4 4.08 1.44 1.56 1.57 1.57 1.52 1.52	1.32 1.32 1.32 1.04 1.16 1.16 1.16 1.16 1.16 1.16 1.16 1.1	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
22.1.0 N N N N N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N N	6 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	2.00 2.00 1.00 1.30 1.31 1.31 1.31 1.31 1.31 1	3.3.2.2.2.2.3.3.3.3.3.3.3.3.3.3.3.3.3.3
21.19 20.32 19.968 NA	NA 13.21 13.21 13.21 13.27 13.27 13.28 15.88 15.88 15.88 16.06 16.	6.21 6.45 7.04 7.05 5.00 2.73 2.23 2.27 2.09	123 123 123 124 125 126 127 127 128	3.5.5 3.7.4 3.7.4 3.7.4 3.6.7
3.08 2.16 1.86 1.70 1.147 1.13 1.05 1.15	0.08 0.05 0.00 0.00 0.04 0.04 0.08 0.08 0.08	0.35 0.42 0.13 0.13 0.15 0.15 0.07	0.07 0.09 0.09 0.09 0.09 0.03 0.03	0.25 0.25 0.25 0.20 0.20 0.27 0.08 0.09 0.09 0.09 0.09 0.09 0.09 0.09
2.02 9.45 7.92 8.31 7.61 6.63 6.48 6.48 8.54 7.54 7.51	2.74 3.74 3.74 3.74 3.74 3.74 0.00 1.76 1.57 1.75 1.75	1.5.1 2.0.2 2.0.2 2.5.5 1.4.3 0.5.5 0.50 0.50	0.47 0.25 0.34 0.33 0.33 0.33 0.40 0.60 0.60 0.60 0.60 0.60 0.60 0.60	1.08 1.08 1.08 1.08 1.03 1.03 1.03 1.03 1.03 1.03 1.03 1.03
7.77 8.854 6.99 6.99 6.99 6.13 6.04 6.13 7.85 8.13 7.85 8.13 8.13 8.13 8.13 8.13 8.13 8.13 8.13	6.02 3.60 3.60 3.16 2.31 0.00 1.85 1.33 1.48 1.48 1.59	1.50 1.66 1.31 1.31 0.68 0.69 0.69	0.48 0.48 0.18 0.35 0.35 0.39 0.37 1.61	0.34 0.34 0.34 0.36 0.36 0.36 0.37 0.38 0.39 0.30 0.30 0.30 0.30
N N N N N N N N N N N N N N N N N N N	NA NA 7.61 7.05 7.05 9.34 9.30 3.30 3.30 3.30 3.30 3.30 3.30 3.30	2.9.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.	0.70 0.70 0.70 0.70 0.70 0.72 0.72 0.73 3.36 3.36 3.36	1.74 2.06 2.06 1.64 1.22 1.23 1.23 1.16 0.87 0.81 0.81 0.67 0.67 0.67 0.63 0.63
N N N N N N N N N N N N N N N N N N N	NA NA 7.78 7.23 7.23 9.00 9.33 9.37 3.37 3.62 3.37 3.62 3.63 3.63 3.63 3.63 3.63 3.63 3.63	3.63 3.98 3.98 1.13 1.25 1.25 1.03 1.10	0.97 0.62 0.62 0.62 0.62 0.67 0.65 0.65 0.65 0.65 0.65 0.65 0.65 0.65	1.64 2.06 1.58 1.54 1.54 1.62 1.62 1.63 0.65 0.65 0.65 0.65 0.65 0.67 0.67 0.67 0.67 0.67 0.67 0.67 0.67
		2.2 2.2 2.1.2 2.1.4 3.1.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3	0.55 0.55 0.65 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.7	1.45 1.45 1.18 1.18 1.18 1.18 1.18 1.18 1.18 1.1
Fusion of foot bones Fusion of foot foot foot foot foot foot foot	Amputation thru metatarsal Amputation toe & metatarsal Amputation of toe Partial amputation of toe Footboes surgery procedure Application of body cast	Application of body cast Application of body cast Application of body cast Application of figure eight Application of shoulder cast Application of shoulder cast Application of forearm cast Application of forearm cast Apply hand/wrist cast Apply finger cast Apply finger cast Apply forearm cast	Apply forgarm splint Apply forgarm splint Application of finger splint Application of finger splint Strapping of chest Strapping of shoulder Strapping of shoulder Strapping of shoulder Strapping of shoulder Strapping of hand or finger Application of hip cast Application of hip cast	Application of long leg cast Application of long leg cast Apply long leg cast tapply short leg cast Apply rigid leg cast Apply rigid leg cast Application of leg cast Application lower leg splint Application lower leg splint Strapping of knee Strapping of ankle and/or ft Strapping of ankle and/or tt Strapping of toes Application of paste boot Application of paste boot Application of splint Removal/revision of cast Removal/revision of cast
foot bones foot bones foot bones foot bones foot bones of foot bones of foot bones foot bone foot both foot bones foot of midfoon on of midfoo	on thru mete on toe & me on toe & me on of toe and toe of toe and toe of toe and to body con of body con or of body con or of body con or	on of body con of figure of the conference of the conf	grams priming a spiring a	Application of long leg cadapply long leg acadapply short leg cast brace. Apply short leg cast brace and part leg cast leg cast brace and part leg cast leg
Fusion o Fusion o	Amputati Amputati Amputati Amputati Partial an Pigh ene Foot/toee Applicati Applicati Applicati Applicati Applicati Applicati	Applicati Applicati Applicati Applicati Applicati Applicati Applicati Applicati Apply fin	Apply for Apply for Application Application Strapping Strapping Strapping Strapping Strapping Strapping Strapping Application	Applicati Applicati Applicati Apply sh Apply sh Apply si Apply rig Applicati
বৰৰৰৰৰৰৰৰ	. ব ব ব ব ব ర ర ব ব ব ব ব	⋖⋖⋖⋖⋖⋖⋖⋖ ⋖	(বেববববববববব	
28705 28715 28725 28730 28737 28740 28750 28750 28760				29345 29385 29385 29385 29385 29405 29440 29440 29440 2945 29450 29450 29450 2950 2950 2950 2950 2950 2950 2950 2950 2950 2950 2950 2950
., ., ., ., ., ., ., ., ., ., ., .,			,	4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 -

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	000000000000000000000000000000000000000
Year 2007 Transi-tional Fa-cility Total	4 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
ZUU / — (44.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.
AYMENTS FOR Year 2007 2007 in tional ity Non-Fa- cility Total	0 0.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0
TAYMIN IIN IIN IIN IIN IIN IIN IIN IIN IIN	0 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
Mal-Practice RVUs	00000000000000000000000000000000000000
Physician plement Transi ed Racile Work RVUs Facility Non-Far Paculty Non-Far cility PE RVUs PE RVUs RVUs RVUs RVUs RVUs RVUs RVUs RVUs	0.000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Fully Implemented Facility PERVUS	0.000000000000000000000000000000000000
Year 2007 Transitional Non-Fa- cility PE RVUs	0000000000000000000000000000000000000
Fully Implemented Non-Facility PERVUS	
Physician Work RVUs	0.000 0.0000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.
RELATIVE VALUE UNITS (HVUS) AND Description	Removal/revision of cast Wedging of cast Wedging of cast Wedging of clubfoot cast Casting/strapping procedure Jaw arthroscopy/surgery Shoulder arthroscopy/surgery Wrist arthroscopy/surgery Tibial arthroscopy/surgery Hip arthroscopy/surgery Hip arthroscopy/surgery Hip arthroscopy/surgery Hip arthroscopy/surgery Hip arthroscopy/surgery Hip arthroscopy/surgery Knee arthroscopy/surgery
.	
ADDENDOM B	
ADDE	29715 29716 29720 29730 29730 29730 29730 29730 29730 29800 29800 29800 29801 29801 29802 29802 29803 29803 29804 29803 29804 29803 29804

00000000000000000000000000000000000000	00000000000000000000000000000000000000
26 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2.560 2.60 2.60 2.60 2.60 2.60 2.60 2.60 2.
5. 84 5. 85	270 4 4 8 4 1 9 9 9 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9
Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	4.24 4.24 4.26 6.08 6.08 6.06 6.06 6.06 6.06 6.06 6.0
A N N N N N N N N N N N N N N N N N N N	NA NA NA NA NA NA NA NA NA NA NA NA NA N
1.30 88 1.13 1.13 1.13 1.13 1.13 1.13 1.13 1	0.889 0.570 0.577 0.651 0.09 0.16 0.13 0.17 0.20 0.20 0.280 0.09 0.00 0.00
6.66 6.66	5.52 4.78 8.64 7.73 7.33 1.93 0.31 0.69 1.07 6.47 8.76 0.00 0.00
6. 7. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6.	4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	7.87. NA 1.32 1.33
ANN	8.15 7.47 NA NA 1.20 3.07 3.03 8.96 NA NA NA NA NA NA NA NA NA NA NA NA NA
8 9 9 9 4 7 7 9 9 9 9 9 7 7 7 1 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2	6.68 6.01 5.36 7.11 1.03 1.21 1.54 1.97 1.97 1.97 1.97 1.26 0.00
Knee arthroscopy/surgery Knee arthroscopy/surgery Knee arthroscopy/surgery Knee arthroscopy/surgery Knee arthroscopy/surgery Ankle arthroscopy/surgery Mcp joint arthroscopy, surg Mcp joint arthroscopy surg Mcp joint arthroscopy, surg Mcp joint arthroscopy surg Mcp joint arthr	Repair upper jaw fistula Repair mouth/nose fistula Intranasal reconstruction Repair nasal septum defect Ablate inf turbinate, superf Cauterization, inner nose Control of nosebleed Control of nosebleed Control of nosebleed Repeat control of nosebleed Ligation, nasal sinus artery Ther fx, nasal inf turbinate Nasal surgery procedure Irrigation, maxillary sinus
urgery	fistula fistula rotion superf nose d d d d d d sartery artery artery sinus
arthroscopy/surgery oint arthroscopy/surgery arthroscopy/surgery arthroscopy/surgery oint arthroscopy/surgery arthroscopy/surgery oint arthroscopy/surgery wall of nose lesion age of nose lesion and of nose lesion and of nose lesion and of nose art inferior turbinate I removal of nose art inferior turbinate I removal of nose artuction of nose astruction	per jaw fi varantana yang per jaw fi yang per jaw fi yang per jaw yang per jaw yang per jaw yang per jaw yang per jaw yang per jaw yang per jaw
Knee arthroscopy/surge Knee arthroscopy/surge Knee arthroscopy/surge Knee arthroscopy/surge Anke arthroscopy/surge Ankle arthroscopy, and Mcp joint arthroscopy, and Mcmonal of nose lesion McConstruction of nose Mconstruction of nos	Repair up Repair mo Intranasal Repair na Abutate inf Abutate inf Abutate of Control of Control of Control of Control of Ingation, r Ingation, r Ther fx, n Nasal surg
4 ω ω μ ω μ ω μ μ μ μ ω ω μ η ω ω μ ω μ ω	0000-01-00-00-0
29884 29886 29886 29887 29889 29889 29899 29899 29899 29899 29899 29899 29899 29899 29899 29899 29899 29899 29899 29899 29899 29899 30100 30110 30117 30120	30580 30600 30620 30630 30801 30801 30902 30908 30906 30909 30915 30915 30915 30915 30915 30930

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Prescription Profit Prof	1
1.39	Description
10 10 10 10 10 10 10 10	Irrigation, sphenoid sinus
9.656 NA NA NA 6.64 9.704 NA NA 1150 NA NA 1154 NA NA 1154 NA NA 6.67 9.69 NA NA NA 1156 NA NA 1156 NA NA NA 1166 NA NA NA 1167 N	y sinusy
5.77 NA NA 6.72 NA NA 11.00 0.89 NA NA 11.00 1.00	/e polyps
7.71 NA NA 7.68 5.97 0.08 NA NA 15.82	d sinus
9.33 NA NA 9.58 9.58 NA NA 1156 12.75 NA	ery
12	Sinus
1439	nus
15.56 NA	inus
14.08 NA NA 10.89 12.07 14.0 NA NA 22.84 24.28 10.07 NA NA 10.89 12.07 14.0 NA NA 10.89 12.0 NA NA 10.80 12.1 NA NA 10.80 1	snu.
14.32 NA NA 12.29 12.07 NA NA 26.45 27.83 14.32 NA NA 12.29 12.07 NA NA 12.29 12.07 NA NA 12.29 14.01 NA NA 12.29 14.01 NA NA 12.29 11.29 0.99 NA NA 12.29 14.01 NA NA 12.29 11.29 0.99 1.36 1.39 1.30 1.30 1.30 1.30 1.30 1.30 1.30 1.30	snui
4.06 NA NA 7.22 8.74 NA NA 7.24 8.74 NA NA 7.24 8.74 NA NA 7.25 8.74 NA NA 7.24 8.75 9.74 1.12 1.12 NA NA 4.25 1.24 1.25 NA NA 4.25 1.24 1.25 NA NA 4.25 1.25	snu
NA N	sinus
10.40	sinus
NA 1628 17.44 1.59 NA NA 49.23 3.34 3.37 0.69 0.09 0.09 4.53 4.56 1.88 50.39 3.34 3.37 0.69 0.083 0.09 4.53 4.56 1.88 50.39 4.21 0.09 0.02 0.20 6.32 4.56 1.88 50.39 4.21 0.09 0.02 0.20 6.32 4.56 1.88 5.02 4.21 0.09 0.02 0.02 NA NA 6.09 17.38 NA NA 1.72 1.57 0.28 NA NA 6.09 17.38 NA NA 1.31 1.91 0.33 NA NA 6.70 11.35 NA NA NA 1.82 2.21 0.39 NA NA 6.70 11.35 NA NA NA 1.82 2.21 0.39 NA NA 6.70 1.29 NA NA 1.82 2.21 0.39 NA NA 6.70 1.29 NA NA 1.82 2.21 0.39 NA NA 6.70 1.29 NA NA 1.32 1.53 1.53 1.53 1.53 NA NA 1.32 1.33 1.33 1.33 NA NA 1.32 2.22 1.23 NA NA 6.70 1.29 NA NA 1.32 1.33 1.33 1.33 NA NA 1.32 2.22 1.23 NA NA 6.70 1.29 NA NA 1.32 1.33 1.33 1.33 NA NA 1.32 2.22 1.33 NA NA 6.70 1.33 1.33 NA NA 1.32 2.22 1.23 NA NA 1.32 1.33 1.33 NA NA 1.32 2.22 1.23 NA NA 1.32 1.33 1.33 NA NA 1.32 2.22 1.23 NA NA 1.32 1.33 1.33 NA NA 1.32 2.22 1.23 NA NA 1.32 1.33 1.33 NA NA 1.32 2.22 2.20 NA NA 1.32 1.33 1.33 NA NA 1.32 2.22 2.20 NA NA 1.32 1.33 1.33 NA NA 1.32 2.22 2.20 NA NA 1.32 1.33 1.33 NA NA 1.32 2.22 2.23 NA NA NA 6.30 1.31 1.31 1.37 NA NA 6.30 1.31 1.31 1.37 NA NA 6.30 1.31 1.31 1.31 1.31 1.31 1.31 1.31 1	sinus
3.34 3.37 0.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00	Removal of upper jaw
394 4.21 0.99 1.36 0.20 6.32 6.59 3.37 3.74 4.47 4.28 4.47 4.29 1.36 0.22 0.28 7.77 8.28 4.48 4.49 4.47 4.47 1.32 1.32 1.32 1.32 0.28 7.77 8.28 4.48 4.49 4.49 1.32 1.32 1.32 0.24 1.38 0.24 1.38 0.24 1.38 0.24 1.38 0.24 1.38 1.30 1.30 1.30 1.30 1.30 1.30 1.30 1.30	hemoval of upper Jaw
4.28 4.75 1.12 1.57 0.26 7.18 7.65 4.02 4.47 1.41 1.22 1.52 0.22 1.37 0.28 7.77 8.28 4.48 4.48 1.38 1.39 0.27 7.96 8.56 4.08 1.73 1.39 0.24 1.43 1.35 1.34 1.31 1.31 0.23 1.39 0.24 1.44 1.45 1.35 1.39 1.39 1.39 1.39 1.39 1.39 1.39 1.39	py, dx
4.51 5.02 1.22 1.72 0.28 7.77 8.28 4.48 4.98 4.48 NA NA 6.27 0.02 NA NA 1.05 0.24 NA NA 16.08 17.35 NA NA 1.12 1.58 0.24 NA NA 1.05 1.35 NA NA 1.31 1.31 0.33 NA NA 1.25 1.35 NA NA NA 1.48 2.21 0.39 NA NA 12.32 NA NA NA 1.52 0.00 0.00 0.00 0.00 0.00 NA NA NA 1.53 1.55 0.00 0.00 0.00 0.00 0.00 NA NA NA 1.53 1.55 0.00 0.00 0.00 0.00 0.00 0.00 NA NA 1.53 1.53 1.55 0.00 0.00 0.00 0.00 0.00 0.00 0.00	Nasal/sinus endoscopy, dx
NA NA 1.12	py, surg
NA NA 1.12 1.58 0.24 NA NA 6.79 7.65 NA NA 1.02 1.135 NA NA 1.03 1.039 NA NA 1.03 1.03 NA NA 1.03 1.03 1.03 NA NA 1.03 1.03 1.03 NA NA NA 1.03 1.03 NA NA 1.03 1.03 NA NA 1.03 1.03 NA NA 1.03 1.03 NA NA NA 1.03 1.03 NA NA 1.03 1.03 NA NA NA 1.03 1.03 1.03 NA NA 1.03 1.03 NA NA 1.03 1.03 NA NA 1.03 1.03 1.03 NA NA NA 1.03 1.03 1.03 1.03 NA NA NA 1.03 1.03 1.03 1.03 NA NA 1.03 1.03 1.03 NA NA 1.03 1.03 1.03 NA NA 1.03 1.03 1.03 1.03 NA NA 1.03 1.03 1.03 1.03 NA NA NA 1.03 1.03 1.03 NA NA 1.03 1.03 1.	Nasal/sinus endoscopy, surg
NA NA 1.70 2.56 0.45 NA NA 1.02 1.35 NA NA 1.03 NA NA 1.35 NA NA NA 1.35 NA NA 1.35 NA	py, surg
3.29 NA NA 1.32 2.34 1.37 0.73 NA NA 4.92 5.55 5.45 NA NA 1.92 2.96 0.55 NA NA 7.92 8.95 5.45 NA NA 1.92 2.96 0.95 NA NA 7.92 8.95 3.91 NA NA 1.46 NA NA 1.263 14.32 4.57 NA NA 1.66 NA NA 7.92 8.95 15.75 NA NA NA NA 1.263 30.90 14.32 15.75 NA NA NA NA 2.78 6.51 6.51 17.32 NA NA NA A.93 30.90 30.90 30.90 15.75 NA NA NA A.94 30.24 30.90 30.90 15.75 NA NA A.94 A.94 A.94 A.94 A.94 A.94 A.94 A.95 20.16 NA NA NA A.94 </td <td>Revision of ethmoid sinus</td>	Revision of ethmoid sinus
5.45 NA 1.92 2.96 0.55 NA NA 7.92 8.95 8.84 NA NA 1.92 2.96 0.55 NA NA 7.92 8.95 9.91 NA NA 1.67 2.21 0.66 0.92 NA NA 7.92 8.95 19.41 NA NA 1.67 1.50 1.68 NA NA 2.76 7.56 19.41 NA NA 1.67 1.68 NA NA 2.78 8.95 19.41 NA NA 1.68 NA NA 6.70 7.56 10.42 NA NA 1.68 NA NA 2.96 32.59 10.50 NA NA 1.68 1.28 NA NA 2.67 20.16 NA NA 1.69 1.79 NA NA 2.67 10.50 NA NA 1.69 1.70 NA NA 2.67 10.50 NA NA 1.73 1.68 NA	Sinus
8.84 NA NA 2.87 4.56 0.92 NA NA 17.67 2.21 0.39 NA NA 17.56 14.32 14.32 14.32 14.32 14.32 14.32 14.32 14.32 14.32 14.32 14.32 14.32 14.32 14.32 14.36 17.34 NA NA NA NA NA NA NA NA 14.32 14.32 14.46 NA NA NA 14.32 14.32 14.46 NA NA NA 14.32 14.32 14.46 NA NA NA 14.32 14.33	/ sinus
3.91 NAA NAA 1.48 2.22 0.39 NAA NA 6.76 7.56 18.45 NAA NAA 1.67 2.53 0.46 NAA NA 6.70 7.56 18.45 NAA NAA 7.20 11.50 1.68 NAA NA 27.85 30.90 19.41 NAA NAA 7.20 11.50 1.68 NAA NAA 27.85 30.90 15.75 NAA NAA 7.20 11.50 1.21 NAA NAA 27.85 30.90 20.13 NA NA NA 1.21 NAA NAA 27.85 30.90 20.00 0.00	ırgical
NA NA NA 11.04 11.04 1.07 NA NA 27.85 30.09 NA NA NA 8.60 11.50 11.64 1.40 NA NA 27.85 30.09 NA NA NA 8.72 10.49 1.28 NA NA 27.85 30.09 NA NA NA 17.39 16.89 1.38 NA NA 46.00 0.00 NA NA NA 19.22 21.25 1.72 1.74 NA NA 46.09 NA NA NA 19.22 20.08 1.63 NA NA 46.09 NA NA NA 19.22 20.08 1.63 NA NA 46.09 NA NA NA 22.29 23.86 2.23 NA NA 46.46 47.33 NA NA NA 25.53 27.61 2.46 2.23 NA NA 46.46 47.35 NA NA NA 22.29 23.86 2.23 NA NA 83.65 19.63 NA NA NA 25.53 27.61 2.43 NA NA 25.53 27.61	ppy, surg
NA NA NA 19.26 20.09	py, surg
NA NA 7.20 9.76 1.21 NA NA 24.16 26.72 0.00 NA NA 13.43 1.23 NA NA 26.42 29.09 NA NA 13.43 14.59 1.17 NA NA 15.18 16.03 NA NA 19.32 21.25 1.78 NA NA 48.21 56.38 NA NA NA 20.11 21.72 1.74 NA NA 48.96 50.58 NA NA NA 20.11 21.72 1.74 NA NA 48.96 50.57 NA NA S2.29 20.09 1.63 NA NA 48.96 50.58 NA NA 20.11 21.72 1.74 NA NA 48.96 50.58 NA NA 20.11 21.72 1.74 NA NA 48.96 50.58 NA NA 20.11 21.72 1.74 NA NA 48.96 50.58 NA NA 20.11 21.72 1.74 NA NA 48.96 50.57 NA NA 20.11 21.72 1.74 NA NA 48.96 50.57 NA NA 20.11 21.31 1.67 NA NA 63.24 64.81 NA NA 20.29 23.86 2.38 NA NA NA 63.24 64.81 NA NA 20.29 23.86 2.38 NA NA NA 63.24 64.81 NA NA 20.30 20.11 0.83 NA NA 23.65 25.41 NA NA NA 20.30 20.31 NA NA 23.65 25.41 NA NA 20.30 20.31 NA NA 23.65 20.31 NA NA 20.30 20.31 NA NA 23.65 25.41 NA NA 20.30 20.31 NA NA 23.65 25.41 NA NA 20.30 20.30 NA NA 23.65 25.41 NA NA 20.30 NA NA 23.65 25.41 NA NA 20.30 20.30 NA NA 23.65 25.41 NA NA NA 20.30 20.30 NA NA 23.65 25.41 NA NA NA 20.30 NA NA 23.65 25.41 NA NA 20.30 N	ργ, surg
NA NA NA S2.29 22.09 NA NA 63.24 25.09 NA	Nasal/sinus endoscopy, surg
NA NA NA 25.53 NA NA NA NA 25.541	Nasal/sinus endoscopy, surg
NA NA 13.43 14.59 1.17 NA NA 15.18 16.03 1.39 1.39 NA NA 19.22 21.25 1.74 NA NA 19.22 21.25 1.74 NA NA 20.11 21.72 NA NA 20.14 21.31 1.67 NA NA 20.15 21.31 1.67 NA NA 20.15 21.31 1.67 NA NA 20.15 21.31 1.67 NA NA 20.19 21.31 1.60 NA NA 20.10 20.	ppy, surg
NA NA 17.39 16.89 1.38 NA NA 46.00 45.50 NA NA 19.32 21.25 1.774 NA NA 22.12 24.65 20.09 NA NA 19.22 20.09 1.63 NA NA 20.11 21.72 NA NA 20.11 21.72 NA NA 20.14 1.830 20.18 1.70 NA NA 20.29 23.86 2.38 2.39 NA NA 20.29 23.86 2.39 NA NA 20.29 23.86 2.29 23.86 2.29 NA NA 20.29 23.61 24.81 NA NA 20.29 23.81 27.61 24.81 27.81 NA NA 20.29 23.81 27.61 27.81 NA NA 20.29 23.81 27.61 27.81 NA NA 20.29 23.81 27	Removal of larvnx lesion
NA NA 17.39 16.89 1.38 NA NA 46.00 45.50 NA NA 19.55 20.16 1.97 NA NA 22.12 24.65 2.00 NA NA 22.12 24.65 2.00 NA NA 19.22 21.25 1.74 NA NA 20.11 21.72 1.74 NA NA 48.96 50.57 NA NA 19.22 20.09 1.63 NA NA 46.46 47.33 NA NA 22.29 23.86 2.29 NA NA 83.65 25.51 24.8 NA NA 25.53 27.61 2.48 NA NA 25.53 27.61 2.48 NA NA 25.53 27.61 2.48 NA NA 23.65 25.41 NA NA NA 25.53 27.61 2.48 NA NA 23.65 25.41 NA N	Diagnostic incision, larynx
NA NA 19.55 20.16 1.97 NA NA 56.37 56.98 NA NA 22.12 24.65 2.20 NA NA 68.21 50.14 NA NA 20.11 21.72 1.74 NA NA 48.96 50.57 NA NA 19.22 20.09 1.63 NA NA 46.46 47.33 NA NA 22.29 23.86 2.23 NA NA 63.24 64.81 NA NA 25.53 27.61 2.48 NA NA 63.65 25.41 NA NA NA 25.53 27.61 2.48 NA NA 23.65 25.41 NA NA NA 25.53 27.61 2.48 NA NA 23.65 25.41 NA NA NA 25.53 27.61 2.48 NA NA 23.65 25.41 NA NA NA 25.53 27.61 2.48 NA NA 23.65 25.41	Removal of larynx
NA NA 19.32 21.25 1.76 NA NA 48.21 50.14 NA NA 19.22 24.65 2.20 NA NA 48.26 50.57 NA NA 19.22 24.65 2.20 NA NA 48.96 50.57 NA NA 19.22 20.09 1.63 NA NA 45.71 46.99 NA NA 22.29 23.86 2.23 NA NA 83.65 53.109 NA NA 25.53 27.61 2.48 NA NA 25.53 27.61 2.48 NA NA 25.53 27.61 2.48 NA NA 25.63 27.61 2.11 2.48 NA NA 25.63 27.61 2.48 NA NA 25.63 27.63	
NA NA 22.12 24.65 2.20 NA NA 58.05 60.58 NA NA 19.22 20.09 1.63 NA NA 46.46 47.33 NA NA 22.29 22.39 NA NA 63.24 64.81 NA NA 22.29 22.39 NA NA 63.24 64.81 NA NA 22.53 27.61 2.48 NA NA 77.35 73.43 NA	Partial removal of larynx
NA NA 22.29 23.86 2.23 NA NA 63.24 64.81 NA	rynx
NA NA 22.29 23.86 2.23 NA NA 63.24 64.81 NA	Partial removal of larynx
NA NA 22.29 23.86 2.23 NA NA 63.24 64.81 NA	Partial removal of larynx
NA NA 25.29 23.86 2.23 NA NA 63.24 64.81 NA NA 25.53 27.61 2.48 NA NA 71.35 73.43 NA	Partial removal of larvnx
NA NA 25.53 27.61 2.48 NA NA 71.35 73.43 NA NA 23.65 25.41 NA NA 0.43 0.63 NA NA 0.43 0.63 0.63 NA NA 0.43 0.63 0.63 NA NA 0.43 0.63 0.63 0.63 0.63 0.63 0.63 0.63 0.6	Removal of larynx & pharynx
. 11.40 NA NA 11.42 13.18 0.83 NA NA 23.65 25.41 . 11.25 NA NA O.43 O.53 O.43 NA NA 0.03 0.03 0.03	Reconstruct larynx & pharynx
NA NA 7.82 9.11 0.83 NA NA 19.90 2.1.19	Revision of larynx
	Removal of epiglottis

00000000000000000000000000000000000000	000 000 000 000 000 000 000 000 000 00
96.0-1 96.0-1	6.37 1.50 1.86 5.27 6.27 6.97 7.32 7.32 7.15
0.01 0.02 0.02 0.03	6.09 1.45 5.04 5.04 5.08 6.05 6.91 7.4
A 2 3 3 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	2.03 9.79 0.79 N N N N N N N N N N N N N N N N N N N
A 1 1 2 3 3 4 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4	9 9 9 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	0.34 0.16 0.24 0.31 0.35 0.35 0.35
86.7.1.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2	1.67 0.29 0.38 1.36 1.66 0.53 1.93 1.78
0.00 0.00	0.34 0.34 0.34 0.37 0.45 0.45 0.15 0.15 0.15
A 1.1. 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
2.2.98 3.0.2.33 3.0.0.2.33 3.0.0.2.33 3.0.0.3.3.3.3.3.3.3.3.3.3.3.3.3.3.3.	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0.00 0.00	7.53 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1
Change of windpipe airway Diagnostic laryngoscopy Laryngoscopy with biopsy Removal of larynx lesion Injection into vocal cord Laryngoscopy whoper scope Laryngoscopy whoper scope Laryngoscopy whoper scope Laryngoscopy who diation Laryngoscopy who a cope Laryngoscopy who gosp Laryngoscopy who socope Laryngoscop who socope	Bronchoscopy, dilate w/stent Bronchoscopy/lung bx, addll Bronchoscopy/lung bx, addll Bronchoscopy, w/fb removal Bronchoscopy, stent add-on Bronchoscopy, revise stent Bronchoscopy, treat blockage Bronchoscopy, treat blockage Diag bronchoscope/catheter
ndpipe aliway with biopsy with biopsy yin body, lary yinx lesion for aspiratio phy, newborn phy wchor is and dilation and dilation with se op so with se op se with se	', dilate w/ste '/lung bx, adc '/needle bx a 'w/fb remova ', stent add-c', stent add-c', revise sten ', treat blocka ', treat blocka
Change of windpipe airway Diagnostic laryngoscopy with biopsy. Remove foreign body, laryn Remove foreign body, laryn Remove of larynx lesion miniection into vocal cord minection into vocal cord minection into vocal cord minection into vocal cord minection with open so Laryngoscopy with emovel Laryngoscopy with emovel Laryngoscopy with emovel Laryngoscopy with emovel Laryngoscopy with experimentaryngoscopy with experimentaryngoscopy with experimentaryngoscopy with experimentaryngoscopy with experimentaryngoscopy with sopely laryngoscopy with sopely remove to lesion wiscope Remove to lesion wiscope Remove to lesion with sopely. Laryngoscopy with biopsy. Remove to lesion with biopsy. Removed of larynx lesion of larynx lesion. Indigenostic laryngoscopy with biopsy. Revision of larynx racture minesion of larynx merve surgery minesion of windpipe minesion of windp	Bronchoscopy, dilate w/stent Bronchoscopy/lung bx, addll Bronchoscopy w/b removal . Bronchoscopy, bronch stents Bronchoscopy, revise stent . Bronchoscopy, rewise stent Bronchoscopy, treat blockage Bronchoscopy, treat blockage Bronchoscopy, treat blockage Diag bronchoscope/catheter
444444444444444444444444444444444444444	
	31631 31632 31633 31635 31636 31640 31641

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	00000000000000000000000000000000000000
Year 2007 Transitional Facility Total	4 4 6 6 6 6 7 7 8 8 8 8 7 7 8 8 8 8 7 7 8 8 8 8
Fully Im- plement- ed Facil- ity Total	4 2 3 3 4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Im- Year 2007 on- tional lity Non-Fa- al cility Total	8 7 9 8 8 7 7 8 8 8 7 7 8 8 8 8 7 8 8 8 8
AYMI	80 87 7 8 8 8 8 8 9 9 9 9 9 9 9 9 9 9 9 9
Mal-Practice RVUs	0.000000000000000000000000000000000000
Physician plement to Non-Fa- RVUs PE RVUs PERVUs PERVUS PERVUS RVUs PERVUS RVUs RVUs RVUs RVUs RVUs RVUs RVUs RVUs	8 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
Fully Implemented Facility PERVUS	0.000000000000000000000000000000000000
Year 2007 Transitional Non-Fa-cility PE RVUs	0.4.0.9.2.2.2.0.9.2.0.0.2.0.9.2.0.0.9.2.0.0.9.2.0.0.9.2.0.9.2.0.9.2.0.9.2.0.9.2.0.9.2.0.9.2.0.9.2.0.9.2.0.9.2.0.0.0.0
Fully Implemented Non-Facility PE RVUS	4. 4. 8. 9. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.
AELATED Physician Work RVUs	6. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.
Description	Bronchoscopy, dear airways Bronchoscopy, reclear airway Bronchoscopy, reclear airway Bronchoscopy, in for x-ray Insertion of airway catheter Injection for bronchus x-ray Bronchial brush biopsy Glearance of airways Glearance of airways Intro, windpipe wire/fube Repair of windpipe Reconstruct windpipe Reconstruct windpipe Reconstruct windpipe Repair of windpipe lesion Repair of windpipe scar Airways sugical procedure Drainage of chest Treat lung lining chemically Insert pleural catheter Drainage of chest Exploration of chest wall Explo
.	
ADDENDOM B	
ADDR CPT¹/ HCPCS²	31645 31646 31656 31700 31700 31700 31700 31700 31725 31725 31726

																					_			_	_	_
000000000000000000000000000000000000000	2ZZ 080 080 080	0600	0000	000	060	060	060	060	060	060	060	060	060	060	{	060	060	803	000	060	060	060	060	060	ZZZ 080	060
55.97 59.06 40.78 43.37 36.47 48.13 50.02	39.54 6.83 50.30	35.54 8.54 9.27	11.96	12.86	25.34 36.08 28.97	23.96	23.91	28.72	27.59 32.98	23.83	24.88 24.15	36.85	81.20	93.50	0.00	36.30	33.34	8.35	3.22	3.27 14.04	23.36	34.53	26.75	36.97	7.09 7.09	19.98
54.86 60.75 39.51 42.10 34.62 47.12 49.27	38.70 6.70 6.70 7.75 7.75 7.75	36.00 8.36 9.07	13.10	12.63	25.23 35.71 29.75	23.58	18.94	27.25	26.40 31.59	22.92 27.18	24.67 23.85	36.54	74.19	80.33 87.42	0.00	35.93	44.46 32.73	8.05	3.40	3.49 14.14	23.18	34.33	26.59	36.50	23.50 7.04 23.85	19.84
	2 4 4 5 5 2 2 2 2 2	 (4 4 5 Z Z Z	▼	4 4 2 Z Z	4 4 4 Z Z Z	 (4 4 Z Z	∢ ∢ Z Z	∢ ∢ Z Z	▼	₹ ₹ ₹ Z Z :	4 4 6	00.0	(4 4 2 2	3.70 NA	0 Z	▼	Z Z	4 4 Z Z	Z Z	 {	 {	Z V V
	((4 4 4 2 2 2	Z Z Z	4 4 4 4 Z Z Z Z	4 4 4 2 Z Z	Ψ Ψ <u>Ψ</u>	(4	₹ ₹ Z Z	ς ς Z Z	4 4 5 Z Z :	4 4 5 Z Z 2	4 4 6	00.0	(ξ Z Z Z	3.59 NA	0.00 V V	ς ς Z Z	A A	4 4 Z Z	Z Z	 {	 {	- V
3.84 3.66 3.66 3.03 3.03 3.03 3.03	3.25 0.65 7.37	2.07 0.80 0.87	1.25	22.58	2.72	 	- 1 - 1 69 - 69 - 69 - 69 - 69 - 69 - 69 - 69 -	2.08	2.72	2.32	1.98	3.27	0.30 0.00 0.00	7.20	000	3.15	2.88	0.55	0.00	0.15	1.79	2.83	2.1.0	3.00 9.00 9.00	0.69	1.36
14.39 11.64 12.49 12.90 13.53	4.38 4.38 4.38	9.79 2.29 2.45	3.02	3.25	10.02 7.23	7.12	6.92	8.99 7.40	8.42	7.33	7.34	12.09	30.83	32.70	0.00	10.01	9.27	1.81	0.00	0.88 4.98	6.72	9.46	7.79	9.95	1.57	6.54
13.28 16.31 11.22 8.92 11.89 12.78	10.63 1.37 12.31	2.11	3.08	3.02	9.65 9.65 1.04	6.74 6.04	5.64	7.52	7.23	6.42 7.66	7.13	15.43	23.82	26.62	0.00	9.6	8.66	1.51	1.02	1.10 5.08	6.54	9.26	7.63	9.79	1.52	6.40
	X		4 4 4 2 2 2 2	4 4 4 Z Z Z	4 4 4 4 Z Z Z Z	 ∢ ∢ ∢ Z Z Z	4 4 4 Z Z Z	 (Z Z	Z Z	∢ ∢ Z Z	▼	₹ ₹ ₹ Z Z :	▼	00:0	(₹	0.7.0 A A O	0 Z	▼	- ч Z Z	∢ ∢ Z Z	ZZ	 {	 {	N A
	X	 {		4 4 4 2 Z Z	4 4 4 4 Z Z Z Z	▼	4 4 4 Z Z Z	 (Z Z	Z Z	▼	∀	▼	▼	00:0	(₹	1.59 A A	0 Z	▼	 ∢ ∢ Z Z	▼ 4 Z Z	ZZ	 {	 {	N A
37.74 40.73 25.65 27.22 22.67 31.72 32.69	24.42 4.68 31.55	23.68 5.45 5.95	7.80 8.77 6.92	10.73	23.34 19.86	14.95 13.14	11.61	17.65	17.00	14.18	15.56	37.94 22.27	44.37	53.60	00.0	23.14	21.19	1.84 5.99	2.24	2.24 8.41	14.85	22.24	16.82	24.02	4.83	12.08
Sleeve pneumonectomy Removal of lung Partial removal of lung Bilobectomy Segmentectomy Sleeve lobectomy Completion pneumonectomy																										
a of lung of lung why will be seen that the seen that the seen that the seen that the seen th	of lungs add-on	g lesion diagnostic	diagnostic diagnostic	diagnostic	surgical surgical	surgical surgical surgical	surgical surgical	surgical surgical surgical	surgical	surgical surgical	niasr er drainage	fistulaururur ured chest	, single with bypass .	; double with bypass .	lung, single lung, double	chest wall	cnest wall	eumothorax je	procedure art sac	e of heart sac t sac	t sact	of heart sac	irt sac lesion .	ır lesion ır lesion	er procedurer er procedure .	rt pacemaker
eeve pneumo antial removal lobectomy eeven lobector propertor pre	artial removal spair bronchu sect apical lu	emoval of lungorated processing the contract of the contract o	oracoscopy,	noracoscopy,	noracoscopy, noracoscopy, noracoscopy,	noracoscopy, noracoscopy, noracoscopy,	noracoscopy,	oracoscopy, noracoscopy, noracoscopy.	oracoscopy,	noracoscopy,	epair lung her ose chest afte	ose bronchial econstruct inju	ing transplant ing transplant	ing transplant ing transplant	epare donor	evise & repair	evise & repair evision of lung	nerapeutic pne otal lung lavag	nest surgery prainage of hea	epeat drainag cision of hear	cision of hear cision of hear	artial removal	emoval of hea	emoval of hea	eart revascura eart tmr w/oth sertion of hea	sertion of hea
												11		11		 			1 1		 			 		
	32500 32501 32503 32503	240	32603 32604 32605	: : :	32651 32652 32653	355 356	32657 32658	360 361	32662	364 365	300	32815 32820	32851 32852	32853 32854	32856	305	940	32960 32997	33010	33011 33015)20	33030		33120 33130	3140 3141 3200	3201
32445 32445 32480 32482 32484 32484 32486 32488	32500 32500 32501 32503	32540 32601 32602	32603 32604 32605	32606	32651 32652 32653	32654 32655 32656	32657	32660 32660 32661	32662 32663	32664 32665	32800 32810	32815 32820	32851	32853	32856	32905	32906	32960	330	33011	33020 33025	33030	33050	331	33140 33141 33200	332

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

ADL	ADDENDOM B	l <u>.</u>	RELATIVE VALUE UNITS (HVUS) AND	RELAIEU	INTORINA	JON COL	UN U		INFORMATION OSED IN DETERMINING MEDICARE PAYMENTS FOR	ME LAIN	5 - 0 - N	_/007	Confined	5
CPT1/ HCPCS ²	Mod	Status	Description	Physician Work RVUs	Fully Implemented Non-Facility	Year 2007 Transi- tional Non-Fa- cility PE RVUs	Fully Im- plement- ed Facil- ity PE RVUs	Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Prac- tice RVUs	Fully Im- plement- ed Non- Facility Total	Year 2007 Transi- tional Non-Fa- cility Total	Fully Im- plement- ed Facil- ity Total	Year 2007 Transi- tional Fa- cility Total	Global
33206		4	of heart	7.28	Y Z	Y.	5.13	4.63	0.52	Y:	Y Z	12.92	12.42	060
33207		∢ <	Insertion of heart pacemaker	9.03	Y Z	Y Z	5.78	4.94	0.59	Y Z	Υ Z	15.40	14.56	060
33210		< <	heart	3.30	Z Z	Z Z	1.70	1.36	0.18	Z Z	Z Z	5.18	4.84	000
33211		∢.	heart electrode	3.39	¥ :	Y :	1.67	1.40	0.21	¥.	¥ :	5.27	5.00	000
33212		< <		5.51	Υ S	Υ S	3.75	3.46	0.43	∀ \$ 2 2	Υ S	9.69	9.40	060
33214		∢ ∢	Insertion of pulse generator	0.30	Y Y	4 4 2 2	7 - 7	5.03	0.43	Z Z	4 4 2 2	13.70	13.33	060
33215		< <		4.87	A Z	A N	3.52	3.27	0.37	Y Y	Y Y	8.76	8.51	060
33216		∢.	Insert lead pace-defib, one	5.77	¥ :	Y :	4.58	4.30	0.36	¥.	¥ :	10.71	10.43	060
•		∢ <	Insert lead pace-defib, dual	5.74	¥ Z	Y Z	4.50	4.30	0.39	Υ Z	Υ Δ Ζ	10.63	10.43	060
33220		(∢	Repair lead pace-defib, dual	6.01	ZZ	Z Z	. 4 . 89 . 89	4.43	0.37	Z Z	Z Z	11.27	10.81	060
33222		∢.	Revise pocket, pacemaker	4.95	Y :	Y :	4.33	4.30	0.42	A :	Y :	9.70	9.67	060
33223		∢ <	Revise pocket, pacing-detib	6.45	4 <	¥ ×	4.97	4.69	0.45	₹ < Z Z	₹ < Z Z	11.8/	11.59	060
33225		(∢	L ventric pacing lead add-on	8.33	ζ	Z Z	2.03	3.55	0.45	Z Z	Z Z	13.23	12.33	ZZZ
33226		<	Reposition I ventric lead	89.8	AN	Ą Z	4.87	4.08	0.59	₹ Z	₹ Z	14.14	13.35	000
33233		⋖ ·	Removal of pacemaker system	3.29	Y :	₹ Z	3.29	3.28	0.22	¥.	¥.	6.80	6.79	060
33234		< <	Removal of pacemaker system	7.81	Υ S	Z Z	5.52	5.06	0.56	∀ \$ 2	∀ \$ 2	13.89	13.43	060
33236		∢ ⊲	Remove electrode/thoracotomy	12.83	4 4 2 2	4 4 Z Z	6.70	0.94 7.25	0.73 1.88	Z Z	4 4 2 2	06. 7 96. 06	1.57	060
		< <	Remove electrode/thoracotomy	13.69	Z Z	Υ Z	7.68	7.76	1.59	ΖZ	Z Z	22.96	23.04	060
		⋖	Remove electrode/thoracotomy	15.20	AN	A N	8.35	8.24	2.02	NA	AN	25.57	25.46	060
33240		∢ •		7.59	Y ?	ΨZ.	5.34	4.77	0.41	Υ ·	Ψ.	13.34	12.77	060
33241		۷ ۵	Remove pulse generator	23.24	A Z	4 4 2 2	40.5	11.35	0.78 0.09	A A	A A	0.40 36.45	36.80	060
		< <	Remove eltrd, transven	13.74	Z Z	Z Z	9.53	9.05	0.99	Z Z	A Z	24.26	23.78	060
33245		∢.	Insert epic eltrd pace-defib	16.82	¥ :	Y :	7.96	7.92	2.01	¥.	₹	26.79	26.75	060
33246		< <		23.11	Υ S	▼	10.73	10.39	2.63	∀ \$ 2 2	∀ \$ 2 2	36.47	36.13	060
33250		۷ ۵	Ahlate heart dysrhythm focus	25.75	A Z	4 4 2 2	10.33	28.85	3 .7	A A	Z Z	30.00	39.74	060
33251		< <	Ablate heart dysrhythm focus	28.77	A Z	A N	11.15	11.53	3.59	Y Y	Y Y	43.51	43.89	060
		⋖	Reconstruct atria	31.33	AN	A N	12.15	13.40	4.52	A A	A A	48.00	49.25	060
33261		⋖ •	Ablate heart dysrhythm focus	28.77	Υ S	ΨZ Z	11.33	11.66	3.45	¥ ž	Y S	43.55	43.88	060
33282		∢ ⊲	Remove nat-active ht record	99.4	4 4 2 2	¥ 2	4 5.29 0 4 6	4.09 50.4	0.23	¥ Z	¥ Z	9.9	8.98	060
33300		< <	Repair of heart wound	29.93	ζ ζ Ζ	 ₹ Z	11.14	9.71	2.65	(∢ Z Z	(∢ 2 Z	43.72	42.29	060
33305		⋖	Repair of heart wound	33.67	AN	A N	12.24	11.02	3.12	A A	A A	49.03	47.81	060
•		∢ <		20.19	¥ ž	Υ S	8.83	9.39	2.58	Y S	Y S	31.60	32.16	060
33320		< ⊲	Exploratory fleart sulgery	18 43	(4 2 Z	₹ ₹ 2 Z	8,69	0.70	20.07	Z Z	4 4 2 2	26.73	40.07 28 84	060
		< <	Repair major vessel	20.67	Z Z	A N	10.28	9.91	2.90	Ą Z	Ą Z	33.85	33.48	060
33322		⋖	Repair major blood vessel(s)	24.27	Y Y	₹ Z	9.83	10.23	2.85	A S	A N	36.92	37.35	060
33330		< <	Insert major vessel graft	25.14	Υ S	Ψ S	9.80	10.15	2.81	Y S	Y S	37.75	38.10	060
33332		< <	Insert major vessel graft	24.42	4 < 2 2	¥ < Z	9.65	10.30	3.02	₹ < Z Z	₹ < Z Z	37.09	37.74	080
33400		(∢	Repair of aortic valve	39.23	Z Z	ζ	14.57	15.39	4.10	Z Z	Z Z	57.90	58.72	060
		< <	Valvuloplasty, open	24.33	A N	Ą Z	9.83	12.58	3.56	A A	A A	37.72	40.47	060
33403		⋖ ·	Valvuloplasty, w/cp bypass	25.31	Y :	₹ :	10.53	13.36	3.54	¥.	¥.	39.38	42.21	060
33404		∢ <	Prepare heart-aorta conduit	31.22	Υ S	▼	12.26	13.97	4.32	∀	Υ S	47.80	49.51	060
33406		(∢	Replacement of aortic valve	48.87	ζ	₹ ₹ 2 Z	17.72	18.77	5.43	X X	ζ	72.02	73.07	060
33410		< <	Replacement of aortic valve	38.69	Y Y	Ą Z	14.63	16.09	4.68	¥ V	¥ X	58.00	59.46	060
33411		∢ •	Replacement of aortic valve	57.11	Y S	Z Z	20.12	19.09	5.46	¥ ż	¥ ż	82.69	81.66	060
33412		≤	Replacement of aortic valve	43.7	¥ 2	Z Z	/6.01	44.	0.3/	Z Z	Z	00.00	26.80	060

Second control of the control of t															_																												_	_			_	_	_	
A Broad of unity with with a black of the control of the control of the control of unity with a black of uni	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	ZZZ	060	060	060	060	222	777	ZZZ	777	777	ZZZ	060	060	060	060	060	090	760	060	060	060	060	060	060	060	060	060
A	82.22 58.23 45.63	54.48 46.46	36.83	55.84	63.02 67.45	72.55	42.63	29.99 48.24	50.83	50.91	32.47	35.43	40.25	62.39	40.70	43.77	43.02	29.56	35.27	33.93	53.27	57.23	48.56	0.45	53.30	60.27	61.68	62.64	3.00	7.13	10.44	13.79	20.52	8.61	57.78	60.47	63.75	49.92	61.89	66.57	47.01	45.61	49.03	50.34	48.75	53.52	53.01	60.65	75.19	43.31
Registerated of motify who was part of the control of the contro	81.11 59.03 44.97	54.58 45.36	36.30 46.01	56.93	65.18 65.18	73.64	42.39	47.20	50.56	52.15	31.01	33.94	41.16	66.27	40.56	42.26	42.73	29.54	33.96	34.59	52.73	57.94	47.16	0.45	50.66	58.11	29.69	60.64	3.75	7.05	10.33	13.65	20.34	8.52	55.93	58.24 62.17	61.51	49.66	61.77	64.49	46.96	46.25	47.90	49.82	46.95	52.20	52.52	60.93	73.36	42.42 42.75
A Replacement of notic valve 55.27 NA NA 15.20 4.65	<u> </u>	₹ ₹ ; Z Z ;	▼ ₹ Z Z	Z Z	₹ ₹	Y :	Y Z	(4 Z Z	Ą Z	ΥZ	Y ?	₹ < Z Z	Z Z	ΥZ	¥:	Y S	(∢ 2 Z	۲	Y :	₹ < Z Z	ζ	Ą Z	A A	Ψ.	Z Z	Z Z	N A	Y S	۷ ۵ ۲ ۲	Z Z	Y :	Z Z	Z Z	Ϋ́	Ψ.	Z Z	(∢ Z Z	ΥZ	Y :	▼ < Z Z	ζ	 Z	Y Y	Y :	Y S	▼ < Z Z	 { Z Z	Z V	Y S	 {
Persistent and cardic valve 25.27 NA NA 16.20 24.44 24.45 24	4 4 4 2 2 2 2	Y Y Z	▼	₹ Z	₹ ₹ Z Z	Y :	▼	ζ 4 Ζ Ζ	Y Z	A A	Υ ·	Ψ < Z Z	Z Z	ΑN	Y S	▼	ζ ∢ Ζ Ζ	Υ	Ž:	Ψ < Z Z	ζ 4 Ζ Ζ	Z Z	A A	Υ ·	Z Z	Z Z	¥ X	Υ S	ζ 4 Ζ Ζ	Z Z	Y :	Υ S	¥ 2 Z	A A	Υ :	Z Z		A N	Y Z	Υ Υ	ζ 4 Ζ Ζ		Z V	Y :	Y S	Ψ < Z Z	 {	N A	Y ?	 4
A Replace of control of active with the contro	6.51 4.56 4.13	4.56 6.09	3.93	4.06	6.07	5.08	3.44 9.86	3.00 4 14	4.38	4.06	1.03		3.21	4.92	2.41	3.88	3.86	1.90	2.99	7.7.	0, 0, 1,00 1,00 1,00 1,00 1,00 1,00 1,00	4.65	4.05	0.04	4.40	4.66	4.87	4.76	- 68 - 0	0.73	1.04	1.37	2.12	0.88	4.55	4.69 7.01	5.42	4.37	5.19	5.51	0.63 4 41	. 8.	4.40	4.73	4.55	4.36	4.31	5.64	6.44	3.22
A Regist of antic valve 25.27 NA	20.44	13.53	13.38	13.41	18.60	17.66	11.22	13.17	12.87	14.06	10.20	9.26	11.19	15.66	11.92	12.55	11.37	8.27	10.63	9.95	12.76	14.80	13.18	0.10	15.45	16.88	17.12	17.38	0.0	1.56	2.29	3.03	4.47	1.88	15.85	16.97	17.54	12.90	15.58	18.60	12 49	12.66	13.30	13.93	13.00	13.69	12.98	16.09	20.19	11.58
A Replacement of acritic valve 55.27 NA Revision; public valve 55.27 NA Revision; public valve 55.27 NA Revision; public valve 55.27 NA Revision of mintal valve 55.27 NA Revision of mintal valve 55.27 NA Revision of mintal valve 55.27 NA Repair of mintal valve 55.27 NA Repair of mintal valve 55.27 NA Replacement of mintal valve 52.27 NA Revision of formonary valve 52.27 NA A CABG, valve fine 52.27 NA A CABG, arterly-vein, fino 52.27 NA A CABG, arterly	19.33	13.63	8.85	14.50	16.33	18.75	10.98	12.30	12.60	15.30	8.74	7.7.7	12.10	16.54	11.78	11.04	1.08	8.25	9.32	10.61	10.0	15.51	11.78	0.10	12.81	14.72	15.13	15.38	0.00	1.48	2.18	2.89	4.29	1.79	14.00	14.74	15.30	12.64	15.46	16.52	45 CL	13.30	12.17	13.41	11.20	12.37	12.49	16.37	18.36	10.73
A Repair of aortic valve 55.27	444 222	₹ ₹ ;	4	Z Z	▼	A :	Y Z	ζ 4	Z Z	A A	Y ?	∢ < Z Z	Z Z	ΥZ	A S	Y Y	₹ ₹ 2 Z	A A	Y :	∢ < Z Z	ζ 4	Z Z	A A	Y ?	Z Z	Z Z	N A	Y Z	ζ	Z Z	A :	Z Z	Z Z	N A	Y :	Z Z	₹ ₹ 2 Z	A N	Y Z	Υ <u>Υ</u>	ζ 4 Ζ Ζ	Z Z	N A	A :	Z Z	∢	 { Z Z	A A	 V 2	 4
Repair of aortic valve A Repair of aortic valve A Revision, subalvalualar lissue A Revision of mitral valve A Repair of mitral valve A Revision of peat richariber A Repair heart vessel fistual A Coronary artery graft A Coronary artery graft A Coronary artery graft A CABG, vein, innore A CABG, vein, innore A CABG, vein, innore A CABG, vein, won A CABG, vein, four A CABG, artery-vein, four A CABG, artery-vein four A CABG, vein, four A CABG, artery-vein four A CABG, vein, four A CABG, artery-vein four	<u> </u>	∢ ∢ ; Z Z :	ς ς Z Z	Y Z	4 4 2 2	Y S	Y Z	ξ	Z Z	N A	Y S	Y	Z	N A	Y S	Υ S	Z	A A	Z :	Y	ξ	Z Z	N A	Y S	4 Δ Ζ Ζ	Z Z	N A	Y S	ξ	Z Z	Y :	Υ	₹ ₹ 2 Z	N A	¥:	4 Δ Ζ Ζ	Z	N A	Y :	Y S	ζ <u> </u>	- X	Z Y	Y :	Y S	Ψ <u>Υ</u>	 ζ	Z Y	Y ?	 4
<u> </u>	55.27 39.27 29.70	29.13	25.64 29.58	38.37	41.28	49.81	27.97	30.93	33.58	32.79	21.24	22.79	25.85	44.81	26.37	27.34	27.79	19.39	21.65	22.22	38.33	37.78	31.33	0.31	33.45	38.73	39.69	40.50	2 57	4.84	7.11	9.39	13.93	5.85	37.38	38.81	40.79	32.65	41.12	42.46	30 11	29.14	31.33	31.68	31.20	35.47	35.72	38.92	48.56	28.47
<u> </u>	ic valve	9	Ve			al valve	valve	Die Control of the Co	Ve	valve	ry valve	ry valve	ry valve	nary valve	amber	amber	istula	istula	ection		a	ocation		vest					ingle	NO NO	nree	our	more	ass/reop	Φ		r more	ion	age	ntricle	Itelectorily		iorta	nduit	ant	Θ.	an an	<u> </u>	e	derect
<u> </u>	Replacement of aorti Repair of aortic valve Revision, subvalvula	Revise ventricle mus Repair of aortic valve	Revision of mitral value	Repair of mitral valve	Repair of mitral valve	Replacement of mitra	Revision of tricuspid	Valvuloplasty, tricust	Replace tricuspid val	Revision of tricuspid	Revision of pulmona	Valvotomy, pulmonal	Revision of pulmona	Replacement, pulmo	Revision of heart cha	Revision of heart cha	Repair heart vessel f	Repair heart vessel f	Coronary artery corre	Coronary artery graft	Benair artery w/time	Repair artery, translo	Repair art, intramura	Endoscopic vein har	CABG, vein, single.	CABG, vein, three	CABG, vein, four	CABG, vein, five	CABG artery-vein s	CABG, artery-vein, to	CABG, artery-vein, the	CABG, artery-vein, fo	Caba, artery-velli, ii Caba, art-vein, six or	Coronary artery, byp	CABG, arterial, singl	CABG, arterial, two	Caba, arterial, four o	Removal of heart les	Repair of heart dams	Restore/remodel, ver	Closure of valve	Closure of valve	Anastomosis/artery-a	Repair anomaly w/cc	Repair by enlargeme	Repair double ventric	Repair, modified font	Repair single ventric	Repair single ventric	Hepair neart septum Revision of heart vei
																																																		∢ ∢
						-			_				_		<u>.</u>									-																_									-	
						33430	•	•		33468 .	33470	•		33475 .	33476	33478	33500	33501	33502	33503	33505		33507 .	33508	33510	33512	33513 .	33514	•		•	33521			•	•			33545	33548	•			•	•	•	33615 .	33617 .	33619	33641

Addendum B.—Relative Value Units (RVUS) and Related Information Used in Determining Medicare Payments For 2007—Continued

ADL	ADDENDUM	ا م	RELATIVE VALUE UNITS (RVUS) AND	MELAIEU	INTORMA	RELATED INFORMATION USED IN DETERMINING MEDICARE	Ü IN DE	EMMINING	a IMEDICA	HE LAYN	PAYMENIS FOR		Zoo/—Continued	
CPT¹/ HCPCS²	Mod	Status	Description	Physician Work RVUs	Fully Implemented Non-Facility	Year 2007 Transi- tional Non-Fa- cility PE RVUs	Fully Implemented Facility PE RVUs	Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Prac- tice RVUs	Fully Implemented Non-Facility Total	Year 2007 Transi- tional Non-Fa- cility Total	Fully Im- plement- ed Facil- ity Total	Year 2007 Transi- tional Fa- cility Total	Global
33647		∢.	Repair heart septum defects	29.33	A Z	¥:	12.34	13.41	3.31	Y Z	A Z	44.98	46.05	060
33660		∢ <	Repair of heart defects	31.73	∀	▼	11.49	12.98	4.48	Z Z	∀	47.70	49.19	060
33670		۲ ۵	Repair of heart chambers	36.56	(4 2 Z	ζ 4	12.75	12.95	3.33 4.64	(4 2 Z	(4 2 Z	53.48	54 15	060
		< <	Repair heart septum defect	32.10	Ϋ́	A Z	13.28	14.33	4.44	ΥZ	Ϋ́	49.82	50.87	060
33684		⋖	Repair heart septum defect	34.27	Ϋ́	Y Y	19.40	15.07	3.38	Ϋ́	Ϋ́	57.05	52.72	060
33688		⋖ <	Repair heart septum defect	34.65	₹ Z	ΨZ Z	9.50	10.23	4.72	Y S	Y S	48.87	49.60	060
33692		∢ ⊲	Remiorce pulmonary artery	31.10	₹ 4 Z Z	₹ 4 Z Z	0.00 0.00	9.78	4 57	Z Z	₹ 4 Z Z	30.75	31.90	060
33694			Repair of heart defects	35.47	{	. ∢ Z Z	10.16	13.21	5.26	. ∠ . Z	{	50.89	53.94	060
33697		∢.	Repair of heart defects	37.47	Y :	Y :	21.66	16.57	4.08	¥:	Y :	63.21	58.12	060
33702			Repair of heart defects	27.07	₹ S	₹ Ş	11.48	12.29	3.67	Υ S	ď s	42.22	43.03	060
33720			Repair of heart defects	30.24	₹ ₹ ₹	₹ 4 Z Z	11.69	12.39	4. 6. 7. 8. 8.8.	Z Z	₹ ₹ ₹	46.35	48.U5 42.92	060
33722			Repair of heart defect	29.03	. ∠ . ∠	ξ ζ Ζ	8.75	12.58	1.30	Z Z	. ∠ . ∠	39.06	42.89	060
33730			Repair heart-vein defect(s)	35.97	Ϋ́	A N	13.35	13.93	5.01	ΥZ	Ϋ́	54.33	54.91	060
33732			Repair heart-vein defect	28.76	Υ Z	Υ :	14.75	13.72	3.67	Υ Z	Ϋ́	47.18	46.15	060
			Revision of heart chamber	22.00	∀	¥	9.50	9.09	1.9.1	∀	∀ ≤ 2	33.41	33.00	060
33737		(∢	Revision of heart chamber	22.30	(4 2 Z	(4 2 Z	2.62	10.10	3.05	(4 2 Z	(4 2 Z	33.16	35.64	060
33750		∶∢	Major vessel shunt	22.02	A Z	A N	11.30	10.48	1.16	A Z	A Z	34.48	33.66	060
33755		4	Major vessel shunt	22.40	Ϋ́	A A	7.87	8.57	3.25	Ϋ́	Ϋ́	33.52	34.22	060
33762		⋖ ·	Major vessel shunt	22.40	₹ Z	₹ Z	7.21	9.45	3.13	₹ Z	₹ Z	32.74	34.95	060
33/64		∢ <	Major vessel shunt & graft	22.40	∀	▼	92.5	99.00	3.00	∀ < Z Z	¥ S	34.69	35.39	060
33767		۷ ۲	Major vessel shunt	25.10	(4 2 Z	ζ 4	9.36	11.16	3.63	(4 2 Z	(4 2 Z	38.38	40.07	060
			Cavopulmonary shunting	8.00	Ž	Z Z	2.22	2.55	1.19	Z Z	Ž	11.41	11.74	ZZZ
33770			Repair great vessels defect	39.00	₹ Z	ΥZ:	10.67	13.68	5.72	Z :	₹ Z	55.39	58.40	060
33771			Repair great vessels detect	40.56 31.48	A N	Z Z	10.65	11.95	5.66	A N	A N	56.87	58.17	060
33775			Repair great vessels defect	32.79	Z Z		10.21	13.80	98.4	((<u> </u>	47.98	51.57	060
			Repair great vessels defect	34.45	Ϋ́Z	Ϋ́Z	13.39	15.20	5.07	NA	₹ Z	52.91	54.72	060
33777			Repair great vessels defect	33.87	₹ Z	₹ Z	10.02	14.21	5.47	₹ Z	₹ Z	49.36	53.55	060
			Repair great vessels defect	42.58	₹ S	Ψ Z Z	15.26	16.48	6.18	Z Z	₹ S	64.02	65.24	060
			Repair great vessels defect	43.13	(d	₹ 4 2 2	11.40	14.40	2.9	₹	(d	50.02	64.76	060
33781			Repair great vessels defect	43.14	Ą Z	A N	14.18	13.54	5.95	Ą Z	Ą Z	63.27	62.63	060
33786			Repair arterial trunk	41.70	Ϋ́	AN AN	11.53	15.42	5.69	Ϋ́	Ϋ́	58.95	62.81	060
33788			Revision of pulmonary artery	27.22	Ψ.	ΨZ Z	9.69	11.39	4.02	Υ S	Ψ.	40.93	42.63	060
33800			Repair vessel defect	18.20	₹	₹	75.7	. 9. 8	2.45	₹	₹	27.06	76.72 20.00	060
33803			Repair vessel defect	20.14	Z Z	Z Z	7.95	9.31	3.19	Z Z	Z Z	31.28	32.64	060
			Repair septal defect	21.19	Ϋ́	Ϋ́Z	9.00	10.43	3.12	Ϋ́Z	Ϋ́	33.31	34.74	060
33814			Repair septal defect	26.37	Ϋ́	A A	10.48	12.10	3.84	Ϋ́	Ϋ́	40.69	42.31	060
33820			Revise major vessel	16.59	₹ S	Ψ S	8.39	8.37	2.34	Y S	₹ S	27.32	27.30	060
33824		۲ ۵	Bevise major vessel	90.06	(d	₹	0.00	7.0	2.67	₹	(d	31 56	20.49 32.58	060
33840		(∢	Remove aorta constriction	21.17	(∢ Z Z	 {	8.99	9.97	2.15	Z Z	∑ Z	32.31	33.29	060
33845		< <	Remove aorta constriction	22.73	Ϋ́	Ϋ́Z	9.64	10.92	3.21	Ϋ́Z	Ϋ́	35.58	36.86	060
33851		∢ ·	Remove aorta constriction	21.81	Y Z	₹ Z	9.17	10.30	3.17	Y :	Ϋ́Z	34.15	35.28	060
33852		۷.	Repair septal defect	24.24	ΨZ:	Ψ.	06.6	11.00	2.15	Ϋ́ Z	ΨZ:	36.29	37.39	060
33853		∢ <	According portions and the	32.31	∀	Ψ < Z	13.03	14.37	4.47	∀ < Z Z	4 < Z	49.81	51.15	060
33861		(∢	Ascending aortic graft	43.88	(16.12	17.31	6.35	Z Z	Z Z	66.35	67.54	060
33863		<	Ascending aortic graft	48.52	Ϋ́	Ϋ́Z	17.69	18.44	6.57	Ϋ́Z	Ą	72.78	73.53	060
33870		⋖	Transverse aortic arch graft	45.87	ΑN	AN	16.67	17.95	09.9	- V V	ΑN	69.14	70.42	060

060	060	777 060	000	060	060	060	060	060	222	060	060	×	060	ž	000	ZZZ	000	000	000	000	060	×}	XX 6	060	X	060	\ \ \	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	ZZZ	000	777	060	2ZZ 060
54.38 80.61 49.93	31.69	11.49	23.01	44.66	35.97	43.17	40.53	38.12	8	49.38	67.72	0.00	98.01	0.00	27.07	15.23	7.18	0.95	19.91	14.46	24.48	30.40	33.80	37.17	67.67	98.52	0.00	26.63	17.34	17.35	39.92 25.55	27.71	39.85	20.86	28.03	17.40	27.13	43.33	29.93	27.85	32.61	35.41	36.42 35.36	33.62	6.02	10.03	6.94 28.04	19.87	5.88 52.55
53.68 82.50 47.77	30.06	11.07	22.26	44.59	36.28	42.85	39.22	28 58 58 58	8.43	46.04	65.24	0.00	93.96	0.00	27.59	14.70	7.63	0.98	10.10	14.89	24.41	30.66	32.4	36.25	67.26	98.41	00.00	25.99	16.66	16.71	38.77	26.59	39.08	20.16	29.85	16.74	25.98	42.20 20.31	30.46	27.30	31.36	34.31	34.95	31.89	5.82	9.65	13.71	19.19	5.72 50.40
	Z	g g Z Z	Y Z	¥ ₹	Ϋ́	Υ :	▼ \$ \$	₹ 4 Z Z	Y Z	A N	A A	0.00	A C	00.0	₹ ₹ 2 Z	Ϋ́	¥ :	Υ S	4 4 2 2	ζ Z	A A	¥ ž	₹ 4	¥ Ž	Z A	AN S	0.00 NA	Z Z	Ϋ́	Y Z	₹	Z Z	ΨZ:	¥ ž	¥ ₹	Ž	¥ :	¥ Z	ζ 4 2 Z	Z Z	AN.	¥:	Z Z	 {	Z V	¥ S	Δ Δ Z Z	N A	A A
4 4 4 4 Z Z Z Z	ζ ∢ :	4 4 2 2	Z Z	Z Z	N A	Y Z	Α < Ζ 2	4 Δ Ζ Ζ	\ \ \ \ \ \ \	A Z	A A	0.00	A C	0.00	Z Z	ΥZ	¥:	Υ S	Z Z	Z Z	A	Y Z	Ψ Δ Ζ Ζ	Z Z	A A	A S	0.00 NA	Z Z	NA	Y S	4 4 2 2	Z Z	Y Y	Υ <u>Υ</u>	Z Z	A A	¥:	Z Z	ζ 4 Ζ Ζ	Z Z	A S	A S	 V Z V	 { Z Z	Z Y	¥ ?	Z Z	Z Z	 ∢ ∢ Z Z
5.92 2.74	2.32	0.86	2.17	3.69	4.	3.66	3.69	4.37 00 8	28.0	4.60	6.20	0.00	9.03	0.00	2.66	0.88	0.35	0.07	- 0.82 2,75	1.26	1.73	3.06	3.23 0.83 0.83 0.83 0.83 0.83 0.83 0.83 0.8	3.30	6.95	8.56	0.00	2.20	1.41	1.40	3.55	2.35	3.09	1.55	2.05	1.41	2.34	3.62	25.32	1.73	2.45	2.32	2.00	2.00	0.59	1.18	1.50	1.28	0.44
13.86	6.8	2.43	4.92	11.41	9.73	11.24	11.74	2.5.1	6	13.55	16.86	0.00	27.42	0.00	5.08	3.44	1.99	0.24	2.35 0.00	3.45	7.86	6.37	10.64 10.64	5 1 5 4	14.79	25.20	0.00	7.57	5.12	5.14	10.02	7.69	10.41	90.9	5.91	5.20	8.11	11.91	8.67	8.43	8.74	9.42	9.72 o 40	9.07	1.31	2.11	3.04	5.91	1.32
13.16 18.83 10.59	7.01	2.01 6.25	4.17	1.34 2.45	10.04	10.92	10.43	85.11 84.11	2	10.21	14.38	0.00	73.37	0.00	5.60	2.91	2.44	0.27	2.5 4 0	3.88	7.79	6.63	28.7	10.52	14.38	25.09	0.00	6.93	4.44	4.50	8.87	6.57	9.64	5.36	7.73	4.54	96.9	10.78 70.7	9.19	7.88	7.49	8.32	8.25 8.18	7.34	1.1	1.73	12.1	5.23	1.16
4 4 4 4 Z Z Z Z	(4)	g g Z Z	Y S	¥ ₹	A A	Y :	Υ	4 4 2 2	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Z Z	A A	0.00	A C	0.00	ζ « Z Z	Ϋ́	¥:	Υ S	A A	Z Z	A	¥ ž	¥ 4 Z Z	¥ 2 Z	A A	AN S	0.00 V N	Z Z	N A	Υ S	₹ 4 Z Z	Z Z	A I	¥ ž	Z Z	A A	¥:	A Z	ζ	¥ X	A S	Y :	 V Z	 {	N A	¥ ?	A A	N A	A A Z Z
4 4 4 4 Z Z Z Z	Z Z :	▼	Y S	¥ ₹ Z Z	A A	₹ Z	▼	₹ 4 Z Z		A V	A A	0.00	A C	0.00	₹ ₹ Z Z	Ϋ́	¥ :	Υ Υ	A A	Υ Z	AN	Y S	₹ 4 Z Z	Z Z	A A	AN S	0.00 V N	Z Z	N A	A S	∀	Z Z	A I	Y Z	¥ ₹ Z Z	A A	¥ :	Z Z	ζ 4 Ζ Ζ	A A	A N	A S	 V Z	 {	N	Y S	A A	N A	 &
35.64 57.75 34.44	20.95	8.20 17.95	15.92	29.56	24.80	28.27	25.10	32.34 24.05	5.49	31.23	44.66	00.00	61.56	0.00	19.33	10.91	4.84	0.64	11 89	9.75	14.89	20.97	19.99	22.43	45.93	64.76	0.00	16.86	10.81	10.81	26.35 18.40	17.67	26.35	13.25	20.94	10.79	16.68	27.80	18.99	17.69	21.42	23.67	24.70	22.55	4.12	6.74	9.79	12.68	4.12 35.04
graft	Insert endovasc prosth, taa	aa, add-onelaved	dovas taa	remboli	· emboli	sselless	Irtery	irresia	shunt	w/o cpb	al w/cpb	t/lnng	art/lung	1	assist	assist	ice	st device	SIST	Φ Φ	balloon	device	device	device	I device	eal device	ocedure	<u>o</u> t	lot	ery clot	101	ry clot)t	nt		ot .	al vein	ava	valve		//sm tube	//2-p part	//3-p part	Wong tube	ice addon	th, femorl	ratt add-onth iliac	rosth, init	Endovasc exten prosth, addll
Thoracic aortic graft Thoracoabdominal graft Endovasc taa repr incl s	Insert endovasc pro	Endovasc prosth, te	Artery transpose/en	Remove lung arterv	Remove lung artery	Surgery of great ve	Repair pulmonary a	Transect pulmonary	Remove pulmonary	Rpr pul art unifocal	Repr pul art, unifoci	Prepare donor hear	I ransplantation, her	Transplantation of b	External circulation	External circulation	Insert ia percut dev	Remove aortic assi	Aortic circulation as	Insert balloon devic	Remove intra-aortic	Implant ventricular	Impiant ventricular (Remove ventricular	Insert intracorporea	Remove intracorpor	Cardiac surgery pro	Removal of artery of	Removal of artery c	Removal of arm art	Removal of arreny of	Removal of leg arte	Removal of vein clo	Repair valve, femor	Heconstruct vena c	Cross-over vein gra	Leg vein fusion	Endovas aaa repr v	Endovas iliac a dev	Xpose for endopros	Femoral endovas g Xpose for endopros	Endovasc extend p	Endovasc exten pro						
4444	(∢·	∢ ∢	⋖ <	< <	< <	∢.	∢ <	۲ ۵	< ∢	< <	∢	O (r (ه د	C <	< <	∢.	∢ <	∢ ⊲	< ∢	∢	∢ <	∢ ⊲	< <	< <	∢(೦ ⊲	< <	⋖	∢ <	∢ ⊲	< <	⋖ .	∢ <	< <	< <	∢.	∢ <	< ∢	< <	∢	۷٠	∢ ⊲	۲ ۷	∶∢	∢ •	∢ ∢	∶∢	۷ ۷
			-			-	-	· 			-	-	-	_		_	-				-					-					_		-				-	_		_	· 	-				-			<u> </u>
33875 33877 33880	33883	33884 33886		33910	33915	•	•	33920	33924		•	33933	33935	•			33967	•	33970		33974	•	33977		33979	33980	33999		34101		34151		34401	•	34471		34501	34502				•	34803		34808	•	34813 34820	34825	34826 34830

Addendum B.—Relative Value Units (RVUS) and Related Information Used in Determining Medicare Payments For 2007—Continued

ADI	ADDENDUM	ا מ	RELATIVE VALUE UNITS (RVUS) AND	MELAIEU	INTORMA	RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR	UN DE	EKMINING	i MEDICA	HE LAYIN	ENIS TO		Zoo/—Continued	5
CPT¹/ HCPCS²	Mod	Status	Description	Physician Work RVUs	Fully Implemented Non-Facility	Year 2007 Transi- tional Non-Fa- cility PE RVUs	Fully Im- plement- ed Facil- ity PE RVUs	Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Prac- tice RVUs	Fully Implemented Non-Facility Total	Year 2007 Transi- tional Non-Fa- cility Total	Fully Im- plement- ed Facil- ity Total	Year 2007 Transi- tional Fa- cility Total	Global
34831		∢.	Open aortoiliac prosth repr	37.79	A Z	¥ :	12.15	11.84	4.88	Y Z	A Z	54.82	54.51	060
34832			Voce for endomosth illac		∀	Υ S	11.68	13.89	4.84	A S	4 4 Z Z	54.31	56.52	060
34834			Xpose endoprosth brachial		(4 2 Z	Z Z	25.5	2 0.5	0.76	(4 2 Z	(4 2 Z	7.72	8 15	
34900			Endovasc iliac repr w/graft		Ϋ́	A Z	6.34	7.27	1.99	ΥZ	Ϋ́	25.06	25.99	060
35001			Repair defect of artery		Ϋ́	A N	7.64	9.07	2.80	Ϋ́	Ϋ́	31.07	32.50	060
35002			Repair artery rupture, neck		₹ Z	Ψ S	7.82	9.22	2.99	Y S	₹ Z	32.86	34.26	060
35011			Repair defect of artery		₹	₹ 4 Z Z	6.43	7 59	0.70	₹	₹	29.01	28.54	060
35013			Repair artery rupture, arm		Z Z	ξ Z	7.96	9.24	3.09	Z Z	Z Z	34.09	35.37	060
		⋖	Repair defect of artery		Y Y	Y Y	8.70	9.23	2.86	Y Y	Y Y	33.60	34.13	060
35022			Repair artery rupture, chest		₹ S	▼	9.50	9.76	3.16	Υ S	ď s	38.23	38.49	060
35081			Repair defect of artery		(4 4 2 2	11 10	11.37	44.2	Z Z	(48 41	48 68	060
: :			Repair artery rupture, aorta		Ą Z	A N	13.19	14.77	5.45	Ą Z	A Z	60.48	62.06	060
35091			Repair defect of artery		Ϋ́	Y Y	10.46	12.79	5.12	Ϋ́Z	Ϋ́	50.93	53.26	060
35092			Repair artery rupture, aorta		Y S	Ψ.	15.09	17.00	6.38	Y S	Y S	72.22	74.13	060
			Repair artery rupture groin		₹ ₹ ₹	₹ 4 Z Z	13.31	12.18	4.47 7.47	Z Z	₹ ₹ ₹	52.46 62.48	52.96 64.38	060
35111			Repair defect of arterv		Z Z		8.62	10.00	3.46	Z Z		38.19	39.57	060
			Repair artery rupture, spleen		Ϋ́	Ą Z	10.53	11.60	4.07	Ϋ́	Ϋ́	46.98	48.05	060
35121			Repair defect of artery		Ϋ́	A A	10.51	11.90	4.29	Ϋ́	Ϋ́	46.15	47.54	060
35122			Repair artery rupture, belly		ΨZ:	Ψ.	12.17	13.39	4.74	ΨZ:	ΨZ:	54.61	55.83	060
35131			Bensir artery rinting grain		¥	¥	8.92	11.86	3.79	₹	¥ \$ 2	38.94	40.31	060
35141			Repair defect of arterv		(ζ ₹ Ζ Ζ	7.15	8.47	2.83	((30.83	32.15	060
35142			Repair artery rupture, thigh		Ϋ́	Ą Z	8.46	68.6	3.35	A	₹ Z	36.78	38.21	060
35151			Repair defect of artery		₹ Z	ΨZ:	7.96	9.48	3.23	₹ Z	₹ Z	34.74	36.26	060
35152			Repair artery rupture, knee		∀	▼	9.15	10.82	3.60	Z Z	∀	40.22	41.89	060
35182			Repair blood vessel lesion		(4 2 Z	ζ 4	11.82	12.55	4 35	(4 2 Z	ζ Δ	47.69	48 42	060
35184			Repair blood vessel lesion		Ϋ́Z	Ą Z	96.9	7.96	2.52	A A	Ϋ́	28.15	29.15	060
35188			Repair blood vessel lesion		Y Y	₹ Z	6.23	7.28	2.15	Υ V	Ϋ́	23.36	24.41	060
35189			Repair blood vessel lesion		Υ S	Ψ S	10.15	11.50	4.00	Υ S	¥ ž	43.94	45.29	060
			Repair blood vessel lesion		(d	₹ 4 2 2	9.04	7.61	0 33	₹	(d	25.40 25.56	26.73	060
35206			Repair blood vessel lesion		{	 {	5.45	6.27	1.86		. ∠ Z	21.00	21.85	060
			Repair blood vessel lesion		Ϋ́Z	ΑN	09.9	7.16	1.48	ΥZ	Ϋ́Z	18.87	19.43	060
35211			Repair blood vessel lesion		₹ Z	Ϋ́ Z	10.11	10.49	3.19	Ž:	Ϋ́ Z	37.75	38.13	060
•			Repair blood vessel lesion		∀	▼	13.90	10.20	2.64	∀ < Z Z	¥ S	52.97	49.27	060
35226			Repair blood vessel lesion		(4 2 Z	ζ ζ Ζ Ζ	5.93	7.05	2.01	Z Z	(4 2 Z	23.10	24.24	060
			Repair blood vessel lesion		Ą Z	Ą Z	7.70	9.25	2.88	N N	Ą Z	31.62	33.17	060
35236			Repair blood vessel lesion		Ϋ́	A A	6.50	7.54	2.42	Ϋ́	Ϋ́	26.82	27.86	060
•			Repair blood vessel lesion		₹ S	Ψ S	9.97	10.83	3.52	Y S	Υ S	38.94	39.80	060
35246			Repair blood vessel lesion		Υ S	Α « Ζ 2	39.11	11.55	3.85	Ψ « Z 2	¥ S	43.91	43.51	060
35256			Repair blood vessel lesion		Z Z	4 4 2 2	9.83 655	7.93	4. c	Z Z	Z Z	28.74 28.21	29 49	060
35261			Repair blood vessel lesion		Z	Z Z	7.26	7.82	2.60	Z Z	Z Z	28.70	29.26	060
			Repair blood vessel lesion		Ϋ́Z	ΑN	5.72	6.68	2.09	ΥZ	Ϋ́Z	23.52	24.48	060
35271		⋖	Repair blood vessel lesion	24.45	Ϋ́	Y Y	69.6	10.31	3.15	Υ V	₹ Z	37.29	37.91	060
35276		⋖・	Repair blood vessel lesion	25.67	Y S	Ψ.	99.6	10.82	3.48	Ϋ́ Z	Y :	38.81	39.97	060
3528		∢ ⊲	Repair blood vessel lesion	12.00	₹	₹ 4 Z Z	9.81	2.1.7	3.90 3.40	₹	₹	43.54 25.84	45.06 27.00	060
35301		< ∢	Rechanneling of artery	19.49	Z	Z Z	06.9	8.05	2.67	Z Z	¥ Z	29.06	30.21	060
35311		< <	Rechanneling of artery	28.48	Ϋ́	Ą Z	69.6	11.23	3.41	Ϋ́	Ϋ́	41.58	43.12	060

																																						_	_	_			_
060	060	060	060	060	ZZZ	ZZZ	000	000	000	000	800	000	000	000	000	800	000	000	000	000	88	000	000	000 ZZZ	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060
25.75 42.05 40.09	37.02	45.40	48.57 23.91	28.69	4.66	4.45	10.32	11.03	14.07	12.84	12.69	14.86	10.24	10.84	13.62	16.36	11.51	12.28	15.29	14.23	11.80	10.37	15.66	14.62 9.31	30.67	32.39	38.09	35.94	33.83	37.79	33.45	36.47	34.31	32.49 48.98	57.92	44.86	50.53	40.50	34.53	37.63 42.48	39.17	35.11	39.49
24.71 40.41 38.38	35.81	43.94	47.08 22.83	27.41	4.50	4.18	96.6	8.73 10.68	13.65	12.36	12.78	15.42	10.29	10.92	13.50	16.30	11.23	12.03	14.77	13.83	12.31	10.70	16.24	14.81 9.06	29.79	30.98	37.87	34.16	32.31	37.17	34.20	35.21	32.63	30.85	56.03	43.56	48.84 30.86	39.16	33.44	36.74	38.58	34.02	38.06
	Z Z	Z Z	Δ Z Z Z	¥ ž	Z Z	▼	¥.	A A	¥ Z	¥ ž	91.48	102.7	67.83	89.03	64.49	NA N	Ϋ́	¥ ¥	Z Z	¥ ž	Z Z	Y Z	Z Z	Ψ Ψ Z Z	Y S	Z Z	Y Z	ZZ	Y S	Z Z	Z Z	Z Z	Y S	∀	ZZ	Y :	Y Z	Z Z	Y :	A A	ZZZ	Y Z	 . Z
	Z Z	₹ ₹	σ q Z Z	Y S	Z Z	Z Z	Y Z	Z Z	Y Z	Z Z	71.42	77.69	55.82	69.16	59.36	NA NA	Z Z	Α Α Ζ Ζ	Z Z	Y S	Z Z	Α Δ Ζ Ζ	Z Z	Ψ	Y Z	Z Z	Y Z	ZZ	Z Z	Z Z	Y S	ξ Z Z	Y S	Z Z	Z Z	Y :	Z Z	 {	Y ?	 & & & &	Z Z	Z Z	. Z
3.82	3.34	4.14	4.32 2.13	2.62	0.46	0.43	0.94	10.87	1.26	1.21	0.69	0.67	0.58	0.57	0.62	1.28	1.13	0.89	1.27	1.35	0.74	0.43	0.59	0.69 0.93	2.80	2.84	2.77	2.1	2.90	2.77	2.33	3.02	2.11	2. 4. 6. 1	5.16	3.84	4.61	3.69	2.97	3.29	3.09	2.99	3.51
7.04 10.68 10.29	9.19	11.21	12.09 6.59	7.61	1.01	1.02	2.48	2.19	3.33	3.01	3.38	4.14	2.76	2.92	3.52	4.02	2.78	2.43	3.60	3.40	3.46	3.30	4.65	4.45 1.94	8.17	8.95	9.37	9.58	8.85	9.02	7.05	9.41	9.19	8.83 13.93	13.84	11.29	12.38	10.41	90.6	10.07	9.52	9.18	10.05
6.00 9.04 8.58	7.98	9.75	10.60	6.33	0.85	3.22	2.12	1.83 30	2.91	2.53	3.47	4.70	2.83	3.00	3.40	3.96	2.50	2.73	3.08	3.00	3.97	3.63	5.23	4 64 1.69	7.29	7.54	9.15	7.80	7.33	8.45	7.80	8.15	7.51	7.19	11.95	9.99	10.69	9.07	7.97	9.18 06.0	8.93	8.09	8.62
	Z Z	₹ ₹	ΖΖ ΖΖ	Z Z	Z Z	Ζ Z	Z :	Y Z	Z Z	Y S	82.17	91.94	60.35	81.11	54.39	NAN	Y S	4 4 2 2	Z Z	Y S	Z Z	4 4 Z Z	Z Z	 ∢	Z Z	Z Z	Y Z	ZZ	Y S	Z Z	Y S	Z Z	Y :	Ζ Z	Z Z	Y :	Y Y	 {	Y S	 V V	Z Z	Y Y	 : Z
	Z Z	ζ ζ Ζ	 ∢ ∢ Z Z	Y S	Z Z	Z Z	Z Z	4 4 Z Z	Z Z	₹ S	62.11	66.97	48.34 47.23	61.24	49.26	Y V	Z Z	4 4 2 2	Y Z	Z Z	Z Z	Z Z	Z Z	Ψ Z Z	Z Z	Z Z	Y Z	ZZ	Y S	Z Z	Z Z	Z Z	₹ Z	Z Z	ζ ∀ Ζ Ζ	Y :	Y Z	Z Z	Y S	 V V	Z Z	Y Z	
16.47 27.55 26.03	24.49	30.05	32.16 15.19	18.46	3.19	3.00	06.9	6.03	9.48	8.62	8.62	10.05	06.9	7.35	9.48	11.06	7.60	8 0.0 4 0.0	10.42	9.48	7.60	6.64	10.42	9.48 6.44	19.70	20.60	25.95	24.25	22.08	25.95	24.07	23.94	23.01	21.55	38.92	29.73	33.54	26.40	22.50	24.27	26.56	22.94	25.93
					no-pp		Φ	Φ 0		Φ 9	υ Φ	Φ	Φ Φ	Φ	Φ.	haye					snoe	eous	snoe	eouss																			
of arteny of arteny of arteny	of arten	of artery	arter) arter)	ng of artery	Reoperation, carotid add-on	AngioscopyBonair arterial blockade	Repair arterial blockage	arterial blockage	arterial blockage	Repair arterial blockage	ous blockag rial blockag	rial blockag	Repair arterial blockage	rial blockag	Repair arterial blockage	Atherectomy, open	ıy, open	iy, open	y, open ly, open		Atherectomy, percutaneous	Atherectomy, percutaneous	Atherectomy, percutaneous	Atherectomy, percutaneous Harvest vein for bypass			graft	graft	graft	graft	graft	graft	graft	graft	graft	graft	graft	graft	graft	iss graft	ıss graft	iss graft	iss graft
Rechanneling Rechanneling Rechanneling	unnel	anne	Rechanneling Rechanneling	Rechanneling of	peratio	ioscop)	air arte	oair arte	Repair arte	oair arte	air veri air arte	air arte	air arte	air arte	air arte	erector	Atherectomy, open	Atherectomy, open Atherectomy, open	Atherectomy, open	Atherectomy, open	therector	Atherectomy,	Atherecton	Atherecton Harvest ve	Artery bypass graft	Artery bypass (Artery bypass	Artery bypass	Artery bypass			Artery bypass Artery bypass		Artery bypass			Artery bypass		Artery bypass	Artery bypass		Artery bypass	
	Rechanneling	Rechanneling	Rech	Rech	Reo	Ang	Reg	ž č	B.	Be d	Rep	Rep	Rep	Rep	Rep	¥	¥	₹ ₹	< <	⋖ <	₹ <									_				⋖	A	۷.	۹ ۵	۷ ح	⋖ ·	ة ة —	Α .		_
444																									< <	(∢																	: ⋖
444	< <					∢ ◊				∢ <				< <					< ∢	∢ <		∢ ⊲				ζ ζ	∢ <		∢ <		∢ <			∢ ⊲			∢ ⊲		∢ •	⋖			(4
	4	< <	∢ ∢	∢ <		∢ ◊	A	∢ ∢	< <	⋖ <	< <		∢ ∢	⋖	œ <	< <	⋖・	∢ ∢	< <	4 <	< <	∢ ⊲	< <	« «			4 4	< <	4 <	(∢	4 <	< <	۷,	∢ ላ	< <		4 4	(∢	∢ •	⋖	< ∢		(4

Addendum B.—Relative Value Units (RVUS) and Related Information Used in Determining Medicare Payments For 2007—Continued

ADI	ADDENDUM	ا ش	RELATIVE VALUE UNITS (RVUS) AND	RELATED	RELATED INFORMATION US	I ION OSE	ED IN DEI	EKMINING	ERMINING MEDICARE		PAYMENIS FOR	7002		
CPT¹/ HCPCS²	Mod	Status	Description	Physician Work RVUs	Fully Implemented Non-Facility	Year 2007 Transi- tional Non-Fa- cility PE RVUs	Fully Im- plement- ed Facil- ity PE RVUs	Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Prac- tice RVUs	Fully Implemented Non-Facility Total	Year 2007 Transi- tional Non-Fa- cility Total	Fully Im- plement- ed Facil- ity Total	Year 2007 Transi- tional Fa- cility Total	Global
35565		۷,	Artery bypass graft	24.94	Y S	Z Z	8.51	9.73	3.29	A S	Y S	36.74	37.96	060
35571		۷ ۵	Artery bypass graft Artery bypass graft	32.16 25.33	Z Z	Z Z	0.20 8 45	10.75	3.82	A A	Z Z	37.20	38 99	060
35572		< ⋖	Harvest femoropopliteal vein	6.81	Z Z	Z Z	.88	2.15	0.99	Z Z	Z Z	9.68	9.95	ZZZ
35583		⋖ -	Vein bypass graft	27.56	N N	Y :	9.01	9.87	3.16	Y N	Y S	39.73	40.59	060
35585		∢ •	Vein bypass graft	32.16	Υ S	Υ S	10.15	11.70	4.01	Y S	Υ S	46.32	47.87	060
35587		∢ ⊲	Vein bypass graft	26.02	A N	Z Z	8.69 1.54	10.76	3.51	Z Z	Z Z	38.22	40.29	080
35601		< ∢	Artery bypass graft	18.31	Z Z	Z Z	6.63	8.12	2.49	Z Z	Z Z	27.43	28.92	060
35606		⋖		22.32	N N	Y Y	7.68	8.68	5.69	Y Y	N N	32.69	33.69	060
:		∢ <	Artery bypass graft	16.64	Y S	Z Z	6.40	7.51	2.08	Y S	Z Z	25.12	26.23	060
:		< ⊲	Artery bypass graft	20.70	Z Z	Z Z	4.7	% % % %	2 6	4 4 2 2	Z Z	30.86	32.08	060
35623		< ∢	Bypass graft, not vein		Z Z	Z Z	8.65	10.03	3.45	Z Z	Z	37.83	39.21	060
35626			Artery bypass graft		Ϋ́	Y Z	10.25	11.54	4.07	A N	Y Y	43.34	44.63	060
35631			Artery bypass graft		Z Z	Z Z	1.04	13.13	4.95	Y S	Y S	51.83	53.92	060
35641			Artery bypass graft		₹	4 4 2 2	9.0 4.00	10.60	9. 6. 5. 5.3	4 Δ 2 Ζ	₹	39.09	47.35	060
35642			Artery bypass graft		Z Z	Υ Z	7.70	8.4	2.27	Z	Υ Υ	28.76	29.50	060
35645			Artery bypass graft		Ϋ́	AN	7.32	8.03	2.49	A N	A N	28.09	28.80	060
35646			Artery bypass graft		Υ :	Υ :	10.78	12.52	4.43	Y Z	Y :	47.99	49.73	060
•			Artery bypass graft		₹	₹ 5	97.6	7 0 7	3.98	₹ ₹	¥	43.33	44.82	080
35651		(∢	Artery bypass graft	25.90	Z Z	Z Z	8.8	10.25	3.35	Z Z	Z Z	38.09	39.50	060
35654		∢	Artery bypass graft	26.11	Ϋ́	AN	8.59	10.14	3.52	AN	AN	38.22	39.77	060
35656			Artery bypass graft	20.35	¥:	Y :	7.05	8.21	2.79	Z :	Z :	30.19	31.35	060
35661			Artery bypass graft	20.16	∀ \$ 2	Υ Z	7.30	8.52	2.71	Y S	Υ S	30.17	31.39	060
35665			Artery bypass graft	22.16	Z Z	Z Z	7.65	66.8	9. S	Z Z	Z Z	32.81	34.15	060
35666			Artery bypass graft	23.47	NA	NA	8.78	10.18	3.15	NA	NA	35.40	36.80	060
35671			4	20.58	Y S	Y S	7.98	9.05	2.77	Y S	Y S	31.33	32.37	080
35682			Composite bypass graft	7 19	Z Z	4 Δ 2 Ζ	1 78	0.50	1 0.73	Z Z	Z Z	10.00	10.45	777
35683			Composite bypass graft	8.49	Z Z	Z Z	2.12	2.65	1.28	ZZ	ZZ	11.81	12.34	777
35685		⋖	Bypass graft patency/patch	4.04	NA	N	1.01	1.27	0.58	NA	NA	5.63	5.89	ZZZ
35686		∢ •	Bypass graft/av fist patency	3.34	Υ :	Υ ?	0.85	1.06	0.47	Y S	Y ?	4.66	4.87	ZZZ
35691		∢ ⊲	Arterial transposition	18.26	A N	Z Z	. 6. 6. 6. 6. 6.	7.88	2.58	Z Z	A N	71.72	28.72	060
35694		(∢	Arterial transposition	19.13	Z Z	ZZ	6.59	8.10	2.69	Z Z	ZZ	28.41	29.92	060
35695		⋖	Arterial transposition	19.91	NA	N	6.64	8.07	2.73	NA	NA	29.28	30.71	060
•		∢ <	Reimplant artery each	3.00	Y S	Z Z	0.77	0.96	0.41	Y S	Y S	4.18	4.37	722
35701		< <	Exploration carotid artery	20.0	Z Z	Z Z	0.90	4.93	4 1 2	4 4 2 2	Z Z	14.45	15.12	777
		< <	Exploration, femoral artery	7.62	Z Z	Z Z	3.76	4.26	1.03	Y Y	Y Y	12.41	12.91	060
35741		⋖	Exploration popliteal artery	8.57	N A	A V	3.98	4.49	1.12	A N	N	13.67	14.18	060
35761		∢ •	Exploration of artery/vein	5.78	Υ :	Υ :	3.49	3.88	0.75	Y :	Y :	10.02	10.41	060
35800		∢ <	Explore neck vessels	7.94 90.08	A N	Y Z	3.96	4.48	0.95	Y Z	Z Z	12.85	13.37	060
35840		< <	Explore abdominal vessels	10.81		ζ Χ Ζ	4.89	5.18	1.34	Z Z	Υ Z	17.04	17.33	060
35860		⋖	Explore limb vessels	6.67	NA	N A	3.49	3.90	0.78	NA	NA	10.94	11.35	060
35870		∢ .	Repair vessel graft defect	24.32	∢ :	Y :	8.25	9.38	3.00	Y :	Y :	35.57	36.70	060
35875		< <	Removal of clot in graft	10.60	Z Z	Υ S	4.43	4.99	1.41	Υ S	Υ S	16.44	17.00	060
35879		∢ ⊲	Removal of clot in graft	17.70	Z Z	4 Δ 2 Ζ	9.6	7.17	2.39	Z Z	Z Z	25.23	26.20	060
35881		< <	Revise graft w/vein	19.16	Z	Z Z	6.72	8.18	2.55	A Z	Y V	28.43	29.89	060
35901		⋖	Excision, graft, neck	8.18	ΥN	A N	4.32	2.06	1.15	NA	AN	13.65	14.39	060

0 0 0 0 X X X X X X X X X X X X X X X X	****	*****	\$\$\$\$\$\$	18888 \ XXX	*****	X 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	X X X X X X X X X X X X X X X X X X X
16.47 50.34 55.45 0.24 3.06 1.33 3.41 4.45 4.93	3.53 4.24 4.85 2.78	2.83 2.77 7.24 6.61	6.76 6.76 7.51 8.95	0.00 0.54 0.00 0.00 0.54 0.54	0.25 0.25 0.04 0.04 0.04 0.04 0.05 0.05 0.05 0.0	2.92 2.92 2.98 2.98 4.64 4.67 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.0	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
15.40 6.33 6.33 7.33 7.33 7.33 8.38 1.34 1.37 1.37 1.37 1.37 1.37 1.37	3.73 4.24 4.66 2.73	2.87 2.74 3.54 6.77	0.09 7.07 7.07 9.10 7.4	6.51 0.00 0.52 0.52 0.52	7 4 6 5 6 5 6 5 6 5 6 5 6 5 6 5 6 5 6 5 6	2.07 2.07 2.05 2.05 3.07 3.07 3.07 3.07 3.07 3.07 3.07 3.07	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
N N N N N N N N N N N N N N N N N N N	23.63 23.09 26.02 15.16	14.39 14.12 15.86 19.08 31.74	54.47 59.88 36.32 35.06 55.34	A A N 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0.0 4.4.2 N N N N N N N N N N N N N N N N N N N	54.86 54.86 10.98 11.19 11.19 11.19	NAN NAN NAN NAN NAN NAN NAN NAN NAN NAN
NA NA NA 0.65 4.36 9.54 13.86 23.11 24.20	22.13 22.37 21.95 14.58	12.72 12.48 14.66 17.02 31.04	53.02 53.02 4.86 34.07 52.53	N N N N N N N N N N N N N N N N N N N	0.00 V V V V V V V V V V V V V V V V V V V	NA 3.67 43.94 43.99 9.60 40.88 10.11 NA NA	N N N N N N N N N N N N N N N N N N N
1.30 4.43 4.91 0.01 0.05 0.20 0.27	0.25 0.19 0.26 0.26	0.16 0.11 0.26 0.27	0.38 0.47 0.38	0.00 0.03 0.03 0.03	0.00 0.00 0.00 0.00 0.10 0.11	0.79 0.19 0.37 0.37 0.18 0.20 0.10	0.08 0.08 0.08 0.08 0.08 0.03 0.11 0.11 0.57 0.57
5.79 12.58 13.46 0.05 0.93 0.78 1.04	0.76 1.03 1.13 0.63	0.65	2.20 1.35 1.86 2.19	2.74 2.74 2.74 0.00 0.10	0.06 0.05 0.22 0.76 0.73 0.73	1. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.	0.69 0.71 0.67 0.67 0.93 0.93 0.76 0.76 0.76 0.76 0.78 2.84 2.84
4.72 10.76 11.35 0.06 0.82 0.37 0.75 0.97	0.96 1.03 0.94 0.58	0.70	- 2 0 2 - 2 0 9 6 9 9 5 6 9 6 9 6 6 9 6 6 9 6 6 9 6 6 9 6 6 9 6	2 4 8 8 9 8 9 8 9 9 9 9 9 9 9 9 9 9 9 9 9	0.08 0.05 0.02 0.03 0.78 0.78	0.70 0.66 0.80 0.89 0.89 2.10 1.25 0.31	0.58 0.05 0.05 0.05 0.06 0.06 0.06 0.06 0.06
NA N	20.86 19.88 22.30 11.88	12.22 12.02 13.08 15.82 26.80	20.07 53.15 31.34 29.41 48.58	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 V V 0 0 V V 0 0 0 V V 0 0 0 V V 0 0 0 V V 0 0 V V 0 0 V V 0 0 V V 0 0 V 0 V 0 0 V 0 V 0 0 V 0 V 0 0 V 0 V 0 0 V 0	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	NA NA 15.36 61.05 75.51 75.51 75.51 19.60 19.63 27.56 27.81 22.98
N N N N N N N N N N N N N N N N N N N	19.36 19.16 18.23 11.30	10.55 10.36 11.88 13.76 26.10	20.1-1 46.29 3.78 29.09 27.75 45.77	4 A A O O O O O	0	36.90 36.90 6.00 33.79 6.55 6.55 7 A N A N A N	NA NA NA 10.54 45.31 49.90 35.02 0.33 4.16 2.91 14.96 15.00 21.22 22.48 23.24 23.24 23.24 23.24 23.24
9.38 33.33 37.08 0.18 0.95 2.43 3.14	2.52 3.02 3.51 3.02 2.01	2.02 2.02 2.02 2.02 7.02 7.02	7.5.0 1.0.1 1.0.1 7.5.2 6.29	2.6.6.2.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	6.58 6.72 6.72 6.72 8.38 8.38 6.98 6.98	1.74 1.74 1.74 1.74 1.74 1.74 1.67 1.67 1.67 1.67 1.67 1.67 1.67 1.67
Excision, graft, extremity Excision, graft, thorax Excision, graft, abdomen Place needle in vein Pseudoaneurysm injection trt Injection ext venography Place catheter in vein Place catheter in vein Place catheter in vein			Place catheter in artery		Bl draw < 3 yrs other vein Non-routine bl draw > 3 yrs Nein access cutdown < 1 yr Vein access cutdown > 1 yr Blood transitusion service B push transituse, 2 yr or < Bl exchange/transituse, nb Bl exchange/transituse non-nb	Transfusion service, fetal Injection therapy of vein Injection therapy of vein Endovenous rf, 1st vein Endovenous rf, vein add-on Endovenous laser, 1st vein Endovenous laser vein addon Insertion of catheter, vein Insertion of catheter, vein Insertion of catheter, vein Insertion of catheter, vein	Apheresis wbc Apheresis rbc Apheresis platelets Apheresis platelets Apheresis, adsorp/reinfuse Apheresis, selective Photopheresis Declot vascular device Insert non-tunnel cv cath Insert tunneled cv cath
thorax abdomen went read abdomen minjection trt minjection trt mography in vein	artery artery artery artery o artery o artery	o arterý o aorta sorta artery	race catriete III ariety Place catheter in artery	Insection of infusion pump Revision of infusion pump Removal of infusion pump Vessel injection procedure BI draw < 3 yrs fem/jugular	BI draw < 3 yrs other Vein Non-routine bl draw > 3 yrs Vein access cutdown < 1 yr Wein access cutdown > 1 yr Blood transfusion service Bl push transfuse, 2 yr or < Bl exchange/transfuse, nb Bl exchange/transfuse non-nb	Transfusion service, fetal Injection therapy of vein Injection therapy of veins Endovenous rf. 1st vein Endovenous laser, 1st vein Endovenous laser vein addon Insertion of catheter, vein Insertion of catheter, vein Insertion of catheter, vein	s s s s s s s s s s s s s s s s s s s
Excision, graft, ext Excision, graft, tho Excision, graft, ab Place needle in ve Pseudoaneurysm Injection ext venog place catheter in v Place catheter in v Place catheter in v	catheter in a catheter in a catheter in a catheter in sish access tish access	ish access to vein shur ish access to catheter in cath	catheter in cathet	on of infusion of injection of inject	Bl draw < 3 yrs other vein Non-routine bl draw > 3 y Vein access cutdown < 1 Vein access cutdown > 1 Blood transfusion service Bl push transfuse, 2 yr or Bl exchange/fransfuse, no Bl exchange/fransfuse no	usion servic on therapy o on therapy o enous rf, 1s enous laser enous laser enous laser on of cathet	asis wbc asis rbc asis rbc asis rbc asis platelett asis platelett asis, adsorpasis, selectri orberesis vascular de non-turnel contunneled contuneled contun
Excisir Excisir Excisir Place Pseud Injectir Place Place	Place Place Place Establi Establi	Establ Artery Establ. Place		Inserti Revisi Remov Vessel BI drav	Bi drav Non-rc Vein a Vein a Blood - Blood - Bl excl	Transf Injectic Injectic Injectic Endov Endov Endov Insertic Insertic	Aphen Aphen Aphen Aphen Aphen Aphen Insert Insert Insert Insert Insert Insert Insert Insert Insert Insert Insert Insert Insert
4444444	⋖ ⋖⋖⋖	4444		(444044	<<<<<<<	⋖ ⋖⋖⋖⋖⋖⋖⋖	444444444444
35903 35905 35907 36000 36002 36005 36010 36011 36012 36012 36012 36012						36460 36471 36471 36475 36475 36476 36478 36479 36481 36500	
00000000000		0 0 0 0 0 0	, ., ., ., ., ., ., ., .		., ., ., ., ., ., ., ., ., ., .,		

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

ADL	ADDENDOM D	ı	MELATIVE VALUE UNITS (NVOS) AND	חבראובט	INTOTAL	DELATED INTOKWALION USED IN DETERMINING INEDICARE PAYMENTS	UN UE		MINITOLICA A	1 1 1 1 1 1 1 1 1 1	ENIS TOR	/007	Collinaed	5
CPT¹/ HCPCS²	Mod	Status	Description	Physician Work RVUs	Fully Implemented Non-Facility	Year 2007 Transi- tional Non-Fa- cility PE RVUs	Fully Im- plement- ed Facil- ity PE RVUs	Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Practice RVUs	Fully Implemented Non-Facility Total	Year 2007 Transi- tional Non-Fa- cility Total	Fully Im- plement- ed Facil- ity Total	Year 2007 Transi- tional Fa- cility Total	Global
36566		۷ ۵	Insert tunneled cv cath	6.49	114.71	47.80	2.67	3.00	0.57	121.77	54.86	9.73	10.06	010
		Α.	Insert picc cath	1.82	4.46		0.61	0.58	0.19	6.47	8.63	2.62	2.59	000
36570		∢ ∢	Insert picvad cath	5.31	23.19		2.34 42.42	2.63	0.57	30.90	36.56	8 8 8	8.51	010
36575		< <	Repair tunneled cv cath	0.67	3.33		0.23	0.25	0.20	4.20	4.74	1.10	1.12	000
36576		∢ <	Repair tunneled cv cath	3.19	5.88		1.55	1.77	0.19	9.26	10.06	4.93	5.15	010
36580		< <	Replace cvad cath	1.31	3.99		0.41	0.41	0.19	5.49	7.70	1.91	1.91	200
36581		∢ <	Replace tunneled cv cath	3.43	15.64		99.1	1.86	0.19	19.26	22.15	5.28	5.48	010
36583		∢ ∢	Replace tunneled cv cath	5.24	21.00		2.23	2.72	0.0	26.17	30.09	7.67	8 8. 0 1.0	010
		Α.	Replace picc cath	1.20	3.97		0.57	0.56	0.19	5.36	7.61	1.96	1.95	000
36585		∢	Replace picvad cath	4.79	22.75		2.30	2.62	0.19	27.73	31.53	7.28	7.60	010
36590		< <	Removal tunneled cv cath	3.30	3.64		1.59	1.69	0.44	7.38	7.18	5.33	5.43	010
36595		۷,	Mech remov tunneled cv cath	3.59	10.85		1.31	1.42	0.21	14.65	19.45	5.11	5.22	000
36596		∢	Mech remov tunneled cv cath	1.21	2.59		0.42	0.48	0.05	3.39	9.22	2 5	1.28	000
36598		(⊢	Ini w/fluor, eval cv device	0.74	2.25		0.26	2.05	0.02	3.04	3.33	1.05	2.84	800
		∢.	Withdrawal of arterial blood	0.32	0.50		0.08	0.09	0.02	0.84	0.83	0.42	0.43	XX
36620		∢ <		1.15	∀		0.17	0.22	0.07	Y Z	∀	1.39	1.44	000
36640		τ ∢	Insertion catheter, artery	2.10	ZZ		0.91	1.01	0.21	Z Z	Z Z	3.22	3.32	800
36660		⋖	Insertion catheter, artery	1.40	ΑN		0.20	0.38	0.14	A A	A A	1.74	1.92	000
36680		∢ <	Insert needle, bone cavity	1.20	Y S		0.33	0.45	0.11	Z Z	¥ ž	1.64	1.76	000
36810		< ⊲	Insertion of cannula	3.96	₹			4.1	0.73	4 4 2 2	ζ	5.7.	24.4	
		< <	Insertion of cannula	2.62	Z Z		40.	1.14	0.35	Z A	A A	4.01	4.11	000
36818		∢ <	Av fuse, uppr arm, cephalic	11.77	Z Z		4.88 26.00	5.74	68.	Y Z	¥ ž	18.54	19.40	060
36879		∢ ∢	Av fuse, uppr arm, basilic	14.35	Z Z		0. 7. 0. 2.	6.09	C 6	4 4 2 2	A A	92.12	22.39	060
36821		∶∢	Av fusion direct any site	9.10	Z Z		40.4	4.50	1.23	Z Z	¥ X	14.37	14.83	060
36822		۷.	Insertion of cannula(s)	5.47	N S		3.82	4.24	0.79	Z Z	₹:	10.08	10.50	060
36823		∢ ላ	Insertion of cannula(s)	9 95	Z Z		8.91 4.34	9.26	7 3. 88 3. 5.	4 4 2 2	A A	34.53 15.64	34.88	060
36830		< <	Artery-vein nonautograft	11.98	Z Z		4.25	4.99	1.66	Z Z	Y Y	17.89	18.63	060
36831		∢ •	Open thrombect av fistula	7.99	Z S		3.28	3.78	1.09	Y S	¥ ž	12.36	12.86	060
36833		∢ ∢	Av fistula revision	11.93	Z Z		4.25	16.4	4. 6.	4 4 2 Z	¥	17.83	18.54	060
		ď	Repair A-V aneurysm	11.07	NA		4.35	4.68	1.37	Z A	¥ ∀	16.79	17.12	060
36835		∢	Artery to vein shunt	7.38	A N		3.90	4.22 8.22	0.98	Y Z	Ψ Z	12.26	12.58	060
36860		< <	External cannula declotting	2.03	3.35		0.62	0.67	0.1	5.47	4.29	2.74	2.79	000
36861		∢.	Cannula declotting	2.52	NA		1.25	1.43	0.27	NA.	A N	4.04	4.22	000
36870		∢ <	Percut thrombect av fistula	5.15	41.10		2.67	3.03	0.29	46.54	55.49	8.11	8.47	060
37145		τ ∢	Revision of circulation	26.06	ZZ		9.04	10.42	3.25	Z Z	Z Z	38.41	39.73	060
37160		⋖	Revision of circulation	23.06	A A N		8.16	8.98	2.81	NA	Y Y	34.03	34.85	060
37180		∢ <	Revision of circulation	26.06	Z Z		00.00	9.97	3.34	Y S	¥ S	38.40	39.37	060
37182		۷ ح	Insert hepatic shunt (tips)	16.97	Z Z		5.73	5.98	1.00	Z Z	Z Z	23.70	23.95	000
37183		Α.	Remove hepatic shunt (tips)	7.99	N A		2.80	2.96	0.47	Y Y	¥ Z	11.26	11.42	000
37184		∢ <	Prim art mech thrombectomy	8.66	49.86		3.00	3.26	0.55	59.07	75.44	12.21	12.47	900
37186		۲ ح	Sec art m-thrombect add-on	4.92	34.21		2.53	1.63	0.32	39.45	50.84	6.77	6.87	777

														_															_	_	_	_
000X0000000000000000000000000000000000	000 Z 000 000 Z 000	ZZZ 000	080	77.5	66 × 6	060	060	010	060	060	060	060	060	060	060	060	060	060	} } }	060	ZZZ 060	060	000	000	3×	×	 2 X 5 X	XXX	010		060	090
11.60 8.37 0.00 6.32 7.79 9.22 7.32	25.46 12.66 5.90 12.42	3.16	28.64	2.33 5.33 5.53	0.00	19.88	14.53	5.29	12.43 29.21	35.50 10.13	17.94	33.46	6.96 11.08	13.16	17.21	15.05	7.12	35.18 13.47	0.00	28.20	6.97	26.50	3.70	2.21	1.63	2.07	3.36	3.36	4.47	11.56	14.42	17.47
11.35 8.17 0.00 6.31 7.57 7.26	25.38 12.77 6.02 11.89	3.15	28.59	2.31 2.31 2.31	0.00 0.00 0.00	18.51	14.76	5.20	29.10	34.56 9.97	13.60	32.77	6.70 10.68	12.70	16.62	14.17	6.86 6.96	37.33	00.0	28.83	6.69 31.43	26.21	3.78	2.1	1.57	2.01	8.0z 3.28	3.28	4.24	10.79	13.64	17.26
73.35 63.19 0.00 NA NA NA 37.55	4 4 4 4 Z Z Z Z	Y Z Z	4 4 5 Z Z 2	 &	00.0	(4 ¢	₹ ₹ ₹ 2 Z Z	7.80	₹ ₹ Z Z	Ψ Ψ Z Z	Y Y	Z Z	Υ Υ Σ Σ	4 4 2 2	4 4 2 2	Z Z :	9.50	A A	0.00	¥ ¥ Z Z	Y Y Z Z	A C	0.00 V	₹ S	4.59	5.09	Z Z	A A	6.62	 &		NA 7.94
57.25 48.59 0.00 0.00 NA NA NA 35.65	4 4 4 4 2 2 2 2	Y Y	∢ ∢ ∢ Z Z Z	 {	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	(4 5	₹ ₹ ₹ Z Z Z	7.60	4 4 2 Z	Α	Z Z	Z Z	4 4 Z Z	∢ ∢ Z Z	Z Z	ζ ζ :	9.33	Z Z	0.00	ξ ζ Z Z	Ψ	Z S	0.0 A	Y S	3.80	4.23	 {		6.12	 4	 ∢ ∢ Z Z	8.01
0.51 0.00 0.27 0.33 0.43	1.48 0.60 0.31	0.59	1.09	0.75	 90.0 40.00 50.00	2 4. 6	1.23	0.36	2.32	2.97	0.91	2.48	0.53	0.86	44.0	0.48	0.53	2.25	00.0	2.9	0.63	2.24	0.00	0.07	0.02	0.07	0.48 0.11	0.11	0.25	0.88	0.74	1.37
3.06 2.29 0.00 1.50 2.47 3.12	5.87 3.79 1.47 2.98	1.30	9.35 8.79	0.54	0.00 0.00 0.00	6.17	4.64 4.64	1.93	8.05	8.86 3.56	5.59	8.82	3.93	4.26 5.29	5.14	5.03	2.76	9.80	00.0	6.73	1.55 6.88	7.29	0.00	0.64	0.50	0.63	1.0.1	1.01	1.98	3.70	5.42	5.68
2.81 0.00 0.00 1.49 2.25 3.40	5.79 3.90 1.59 2.45	1.05	10.12 8.74	0.52	0.00 0.00 0.00	. 4 r	4.87	1.84	3.98 7.94	3.40	5.24	8.13	3.53	3.80	4.55	4.15	2.50	11.95	0.00	7.36	1.27	2.00	9.6	0.54	4. 4.	0.57	0.93	0.93	1.75	3.42	4.64	5.47
64.81 57.11 0.00 NA NA NA 32.24	4 4 4 4 Z Z Z Z	Z Z	4 4 4 Z Z Z		0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	(4 \$ 2 2	₹ ₹ ₹ ₹	44.4	∢ ∢ ; Z Z :		Z Z	Z Z	4 4 Z Z	4 4 Z Z	₹ 4 2	Z Z :	5.13	Z Z	0.00	Z Z		Z S	0.0 A	Y S	3.46	3.65	 {	 V V	4.13	 4	4 4 Z Z	NA 3.71
48.71 42.51 0.00 NA NA NA 30.34	4 4 4 4 Z Z Z Z	Y Y	ΖΖΖ ΖΖΖ		0.0	Z Z Z	₹ ₹ ₹ ₹	4.24	Y Y	 ∢ ∢ Z Z	4 4 Z Z	Z :	₹ Z Z	∢ ∢ Z Z	4 2 2		NA 4.96	Z Z	0.00	₹ ₹ 2 Z	▼	A S	0.00 V	∀	2.67	2.79	Y Y Z Z	 V V	3.63	 &		NA 3.78
8.03 5.71 0.00 4.55 4.99 5.67	18.11 8.27 4.12 8.27	4.12	18.81	7.1.60	0.00	12.30	8.66 4.16	3.00	18.84	23.67	11.44	22.16	3.72 7.01	8.04	10.63	9.54	3.83 3.83 3.83	23.13	00.0	19.43	4.79	16.97	2.64	1.50	 80.	1.37	4.78 2.24	2.24	2.24	6.49	8.26	10.42
omy add-on stroke infuse infuse	Idl	dall	sde	ld-on	adure			edure	artery t artery	Λ >	major vein	major vein	t leg vein	u u	00				Te			,		sll			lant	lant	noi	ions		sepo
Venous mech thrombectomy Venous m-thrombectomy add-on Thrombolytic therapy, stroke Transcatheter blopsy Transcatheter therapy infuse Transcatheter retrieval Transcatheter retrieval	Transcatheter occlusion Transcath iv stent/perc addl Transcath iv stent/perc addl Transcath iv stent/perc addl	Transcath iv stent/open addl	cath stent, cca w/ep cath stent, cca w/o	IV us first vessel add-on	Endoscopy ligate pen venis	Ligation of neck artery	Ligation of neck artery	Temporal artery procedure	Ligation of neck artery	Ligation of abdomen artery	on of major vein	Revision of major vein	Revise leg vein	Ligate/strip long leg vein	Ligation, leg veins, open	Phleb veins—extrem 20+	Revision of leg vein	Revascularization, penis	Vascular surgery procedure	nemoval or spieen, total Removal of spleen, partial	Removal of spleen, total Repair of ruptured spleen	Laparoscopy, splenectomy	Laparoscope proc, spieeri Injection for spleen x-ray	Harvest allogenic stem cells	narvest auto sterif celis	marrow biopsy	Bone marrow collection	Bone marrow/stem transplant	Drainage, lymph node lesion	Drainage, lymph node lesion Incision of lymph channels	Thoracic duct procedure Thoracic duct procedure	
Venot Venot Thror Trans Trans Trans	Trans Trans Trans	Trans	Trans	su vi	Vascu	Ligatic	Ligatic	Temp	Ligatic	Ligatic Ligatic	Revision of Bevision of	Revisi	Revisi Ligate	Ligate	Ligatic	Phleb	Revisi Ligate	Revas	Vascu	Remo	Remo	Lapar	Injecti	Harve	Bone	Bone	Bone	Bone	Drain	Draina Incisio	Thora Thora	Thora Biops)
440444	< < < <	44	űΖ<	∢ ∢ <	₹ O 4	< <	∢ ∢ <	< <	< <	∢ ∢	∢ ላ	< ∢ ·	∢ ∢	∢ ∢	< <	< ∢ ·	∢ ∢	∢ ∢	(O <	∢ ∢	∢ ∢	∢ (> ∢	œ a	۲ ∢	∢ [בת	ш 4	∶∢.	∢ ∢	∢ ∢	< <
	37204 37205 37206 37207			37250 37251 37500			37606 37606	37609		37617 37618	37620			37722 37735			37780 37785	37788		38100 38101	38102 38115		38200	38205				38241	38300	38305 38308	38380 38381	38382 38500

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

bal	0000 0000 0000 0000 0000 0000 0000 0000 0000
Global	
Year 2007 Transitional Factorial Total	8 4 4 5 1 1 1 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2
Fully Implemented Facility Total	1
Year Year 2007 Transi- tional lily Non-Fa-	2.5. 2.2. 2.5. 2.5. 2.5. 2.5. 2.5. 2.5.
Ily Im- iment- Non- acility	8.27 8.60 8.00 8.00 8.00 8.00 8.00 8.00 8.00 8.00 8.00 8.00 8.00
Mal-Prace ed	0.00001.0001.1.1.1.1.0001.1.4.1.1.00000001.1.4.1.1.1.1
Im- Year Year 2007 ant- Transi- Noil- tional Fa- til	0.8.8.8.4.4.8.8.8.6.0.0.0.9.4.4.0.8.8.9.4.4.0.8.8.8.4.4.8.8.8.8.4.4.8.8.8.8.8.4.4.8
Fully Im- plement- ed Facil- ity PE RVUs	0.016.8.4.8.4.7.7.7.8.8.8.8.0.0.0.9.9.9.0.0.0.0.4.0.0.0.0.0.0.0.0.0
Д 	2.5.0 6.5.4 A A A A A A A A A A A A A A A A A A A
Physician plement- Transi- Work ed Non- RVUs PE RVUs eith PE RVUs RVUs RVUs RVUs RVUs	5.28 A A A B A B A B A B A B A B A B A B A
Physician Work RVUs	1.1. 1.2. 1.2. 1.2. 1.2. 1.2. 1.2. 1.2.
Description	Needle biopsy, lymph nodes Biopsy/removal, lymph nodes Biopsy/removal, lymph nodes Biopsy/removal, lymph nodes Biopsy/removal, lymph nodes Explore deep node(s), neck Removal, neck/armpit lesion Removal, abdomen lymph nodes Removal abdomen lymph nodes Removal of lymph nodes, neck Removal of lymph nodes Remova armpit lymph nodes Remove armpit lymph nodes Remove armpit lymph nodes Remove abdominal lymph nodes Remove diaphtia cyrea Remove abdominal lymph nodes Remove diaphtiag not chest Chest procedure Exploration of chest Exploration of chest Chest procedure Repair of diaphragm hernia Repair of diaphra
. Statu	
Mod 8	
CPT¹/	38505 38505 38505 38520 38520 38530 38530 38542 38552 38564 38572 38572 38724 38724 38724 38726 38726 38726 38726 38726 38726 38726 38726 38726 38726 38726 38726 38726 38726 38726 38726 38730 38740 38740 38740 38740 38740 38750 39750 39750 39750 39750 39750 39750 39750 39750 39750 39750 39750

	, , , , , , , , , , , , , , , , , , ,			
00000000000000000000000000000000000000	010 000 000 000 000 000 000 000 000 000	090 000 000 000 000 000 000 000	090 010 010 010 010 090 090 090	090 090 090 090 000 000 000 000 000 000
23.93 23.93 23.24 25.93 27.47 0.00 3.10 5.53 3.18 5.76 0.85	2.50 2.50 2.50 7.65 6.77 6.77 6.73 16.66 16.66 16.74 16.74	29.32 33.33 0.00 0.00 2.80 6.35 6.35 7.51 2.67	2.88 2.82 2.82 2.82 2.82 2.82 2.82 6.21 6.35 16.35 5.43 2.43 2.43 2.43 2.43 2.43 2.43 2.43 2	2.25 56.29 69.49 69.49 69.49 69.23 7.53 7.54 7.54 6.52 6.52 6.52 6.53 6.54 6.54 6.55 6.55 6.55 6.55
23.97 29.73 29.73 29.73 26.38 26.38 0.00 3.18 5.39 5.57 5.57	2.03 2.03 2.04 2.04 2.04 2.04 2.04 2.04 2.04 2.04	27.21 30.58 0.00 0.00 0.00 0.00 0.00 0.00 0.00	2.68 2.68 2.68 2.17 2.17 6.15 6.15 6.15 6.23 3.48 2.48 2.48 2.48	30.99 51.45 52.31 66.30 66.30 66.20 86.15 66.15 60.20 60.20 60.20 60.20 60.20 60.20 60.20 60.20 60.20 60.20 60.20 60.30
A N N N N N N N N N N N N N N N N N N N	5.59 6.51 8.93 8.93 8.93 6.98 6.98 5.77 7.59 19.88 20.02 25.85	33.98 37.61 0.00 37.61 3.78 4.94 8.51 8.60 8.64 9.23 4.56 10.01	10.39 12.00 3.98 3.92 3.30 7.64 7.64 8.43 NA	A N N N N N N N N N N N N N N N N N N N
13.88 N N N N N N N N N N N N N N N N N N N	4.57 4.57 4.10 4.10 4.10 4.10 6.06 6.06 8.09 2.00 1.07 6.07 1.07 6.08	33.24 36.18 0.00 0.00 3.91 5.61 8.88 8.74 9.19 9.19 9.19 10.65	0.00 1.02 1.03 1.03 1.03 1.03 1.03 1.03 1.03 1.03	A A A A A A A A A A A A A A A A A A A
0.06 0.05 1.65 1.23 1.23 1.93 0.00 0.00 0.13 0.01 0.03 0.03 0.03	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	2.90 0.00 0.00 0.00 0.00 0.00 0.00 0.00	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	0.93 0.02 0.02 0.02 0.03 0.03 0.03 0.03 0.0
8.6.0 1.2 8.6 9.6 9.6 9.6 9.6 9.6 9.6 9.6 9.6 9.6 9	0.1. 0.6. 0.6. 0.6. 0.6. 0.6. 0.6. 0.6.	10.86 12.30 1.38 1.72 1.72 1.72 1.74 1.54 1.64 1.64 1.64 1.64 1.64 1.64 1.64 1.6	25.4.4.1.1.1.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2	25.38 25.34 25.34 25.34 26.35 26.10 26.10 27.70
4.6 6.0 1.13 1.13 1.13 1.13 1.13 1.13 1.13 1.	, , , , , , , , , , , , , , , , , , ,	8.75 9.55 9.55 1.29 1.71 2.73 1.73 1.37 4.02	4 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5	44. 49.55 20.38 20.38 20.38 20.38 20.38 20.38 20.00 20.0
84 A A A A A A A A A A A A A A A A A A A	7 6 6 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6	6.5.5 6.00 6.00 6.00 6.00 6.00 6.00 6.00	8 6 6 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	X X X X X X X X X X X X X X X X X X X
7 6 2 2 2 2 2 0 0 8 4 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	28.8.4.6.6.2.6.2.6.2.6.6.2.6.6.6.6.6.6.6.6.6	4,74 6,15 7,15 1,15 1,15 1,15 1,15 1,15 1,15 1	6.6.6.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2	A A A A A A A A A A A A A A A A A A A
5. £1 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6	2.5.66 2.5.66 2.5.66 2.5.66 2.5.66 2.5.66 2.5.66 2.5.66 2.5.66 2.5.66 2.5.66 2.5.66	6.00 6.00		29.43 28.63 29.44 39.46 39.46 39.46 20.27 20.27 20.00
Repair lip Repair cleft lip/nasal Lip surgery procedure Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Removal, foreign body, mouth Removal, foreign body, mouth Incision of lip fold	Biopsy of mouth lesion Excision of mouth lesion Excise/repair mouth lesion Excise/repair mouth lesion Excise oral mucosa for graft Excise oral mucosa for graft Excise lip or cheek fold Treatment of mouth lesion Repair mouth laceration Repair mouth laceration Reconstruction of mouth Reconstruction of mouth	Reconstruction of mouth Reconstruction of mouth Mouth surgery procedure Drainage of mouth lesion	Drainage of mouth lesion Drainage of mouth lesion Biopsy of tongue Biopsy of tongue Biopsy of floor of mouth Excision of tongue lesion Excision of tongue fold Excision of tongue fold Excision of tongue lesion Partial removal of tongue	Partial removal of tongue Tongue and neck surgery Tongue, mouth, jaw surgery Tongue, mouth, jaw surgery Tongue, mouth, neck surgery Tongue, jaw, & neck surgery Tongue jaw, & neck surgery Tongue laceration Repair tongue laceration Repair tongue laceration Fixation of tongue Tongue to lip surgery Tongue to lip surgery Tongue and mouth surgery Drainage of gum lesion Removal foreign body, gum Removal foreign body, jawbone
Repair lip Repair cleft lip Lip surgery pro Drainage of m Drainage of m Removal, forei Removal, forei Lipsion of lip I	biopsy of mouth lesion Excision of mouth lesion Excise/repair mouth lesion Excise/repair mouth lesion Excise or and mucosa for Excise or and mucosa for Excise lip or cheek fold Treatment of mouth laceration Repair mouth laceration Repair mouth laceration of mouth Reconstruction of mouth Recons	Reconstruction of mouth Reconstruction of mouth Mouth surgery procedure Drainage of mouth lesion Incision of tongue fold Drainage of mouth lesion	Drainage of mout Drainage of mout Biopsy of tongue Biopsy of tongue Biopsy of floor of Excision of tongue Excision of tongue Excision of tongue Excision of tongue Excision of tongue Excision of tongue Excision of tongue	Partial remove Tongue and n Removal of to Tongue remo Tongue, mout Tongue, jaw, idepair tongue, Repair tongue Repair tongue Reconstruction Tongue to lip is Reconstruction Tongue and m Drainage of greenval foreignes
444444U44444	444444444 4	[[]		⋖ ⋖⋖⋖⋖⋖⋖⋖⋖
	40808 40810 40812 40814 40818 40819 40830 40831 40842			41136 41145 41145 41145 41150 41153 41155 41251 41262 41500 41500 41500 41500 41500 41500 41500 41500 41500 41500 41500 41500 41500 41500 41500

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

	0010 0010 0010 0010 0010 0010 0010 001
Global	
Year 2007 Transitional Facility Total	4 7 7 4 7 7 4 7 7 4 8 3 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
Fully Implemented Facility Total	4 / 7 / 7 / 7 / 8 / 8 / 8 / 8 / 8 / 8 / 8
Year Year 2007 Transi- tional Non-Fa- cility Total	07.99 07
Fully Implement- ed Non- Facility Total	7.01 7.01 7.05
Mal-Practice RVUs	0.000000000000000000000000000000000000
Year 2007 Transitional Facility PE RVUs	8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
Physician plement- from definity in per RVUs PERVUS	7.7.7.7.7.7.7.7.7.7.7.7.7.7.7.7.7.7.7.
Year 2007 Transitional Non-Fa-cility PE RVUs	4.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2
Fully Implemented Non-Facility PERVUS	4.6.8.7.6.4.6.7.4.6. 4.6.8.8.4.4.8.8.8.4.4.8.8.8.4.4.8.8.8.8.
Physician Work RVUs	2.6. 1. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.
MELATIVE VALUE UNITS (HVUS) AND I	Excision of gum lesion Repair gum Repair tooth socket Drainage mouth roof lesion Biopsy roof of mouth roof Excision lesion, gualate Repair palate Repair palate Reconstruct cleft palate Reconstru
.	
ADDENDUM B	
ADDE CPT¹/ HCPCS²	41822 41823 41823 41826 41826 41826 41827 41828 41829 42100 42100 42100 42100 42100 42100 42100 42100 42100 42100 42100 42100 42100 42100 42100 42100 42200 420

						_												_		_													_					_
0000000	030 √ √ √ √ √	010	010	010	010	010	060	060	060	060	060	060	060	060	060	060	060	010	060	060	010	060	060	060	<u>}</u>	060	060	060	060	060	060	060	060	060	060	080	060	000
22.33 16.29 1.73 9.16	525 0.00 40.00	10.30	3.59	2.98	3.55 4.30	3.28	14.02	7.56	6.64	6.52 5.24	5.66	6.26	23.63	56.39 56.39	4.73	33.95	44.16	9.16	20.27	19.01	4.39	13.44	10.12	13.49	0.00	13.71	34.75 16.34	26.98	66.97 83.08	71.81	67.20	65.43	70.85	66.29	83.81	20.64	33.00	3.36
21.21 15.19 1.71 8.56 1.45	6. 4 0 6 0.00 0.00	9.59 19.69	3.18	2.71	3.93 3.93	3.22 6.94	13.49	6.99 7.31	6.08	6.06 96.4	5.34	5.84	23.61	53.25	4.50	33.68	44.29	8.44	19.02	18.03	10.17	12.52	9.60	12.53	0.00	12.69	34.28 15.48	26.52	65.77 87.80	70.15	69.36	64.03	73.56	65.12	88.98	19.42	33.63	3.42
AN AN 4.29 1.179 7.03.0	7.07 0.00	11.44 NA	3.70	4.98	5.55	4.25	Y S	g g Z Z	¥ S	¥ ¥	Z S	¥ Ž	Y S	X X Z Z	Y S	Z Z	¥ ₹	Z Z	Y Z	Z Z	A N	Ž	Y Y	Z Z	0.00 AN	A :	Y Y Z Z	A :	▼	¥ :	Ψ Z Z Z	(4 :	A A	Z Z	Y Z	ζ Ψ Ž Z	NA V	7.10
3.56 11.70 2.04	7.47 0.00	11.03 NA	3.77	4.67	5.45	4.09	Y S	Y Y Z Z	Y S	Ψ Z Z Z	¥ S	Z Z	¥ S	¥ ₹ Z Z	₹ Z	Z Z	Y Z	Z Z	Y Z	Z Z	A A	Z Z	 ∢	Z Z	0.00 AN	¥.	Y Y	Y Z	▼	¥ Z	V Z	 { Z Z :	 &		 & Z Z	ζ Υ Σ Ζ	NA 202	7.80
0.93 0.07 0.07 0.07	0.00	0.91	0.11	0.00	0. 0 5 1 0	0.16	0.61	0.31	0.25	0.27	0.22	0.26	0.71	1.98	0.18	1.05	1.28	0.50	0.72	0.80	0.19	0.58	0.39	0.62	0.00	0.70	2.58 0.93	2.31	5.22 4.07	5.79	4.42 20.50	5.17	4.10 90	5.40	4.15	1.16	2.33	0.15
9.82 7.43 0.69 0.69	2.49 0.00 655	3.55	1.34	46.	1.87 1.81	3.31	6.23	3.10 3.30	2.98	2.47	2.73	2.82	10.98	22.14	2.33	14.06	17.21 21.78	3.42	11.46	10.35	1.87	5.61	4.01	2.38	0.00	5.15	10.54 5.93	7.73	17.86	18.81	15.83	16.80	14.68	17.00	15.83	7.15	8.30	1.12
8.70 6.33 0.39 3.32 0.61	2.20 0.00 1.51	2.84 6.56	1.17	1.37	- t 4. 4.	3.40	5.70	2.53 2.68	2.42	2.42	2.41	2.40	10.96	19:00	2.10	13.79	17.34	2.70	10.21	9.37	1.59	4.69	3.49	4.42	0.00	4.13	10.07	7.27	20.50	17.15	17.99	15.40	17.39	15.83	21.00	5.93	8.93	1.18
2.97 6.55 6.55 7.13	0.00 0.00	4.69 AN	2.20	3.64	3.06	2.28	V	∀	₹ Z	∢ ∢ Z Z	₹ ₹	Z Z	₹ S	ζ <u>ζ</u> Ζ	₹ S	Z Z	Δ Δ	₹ ₹	Z Z	₹ ₹	Ζ Z	Z Z	▼ 4 Z Z	Z Z	0.00 AN	₹ Z	4 4 Z Z	¥.	≼	₹ 2	Z Z	۷ : ۲ : ۲ :		. ∠ . ∠	 ▼ 2	ζ ζ Ζ	N S	4.86
AN 2.22 4 4 5.24 5 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	0.00 0.00	4.28 NA	3.83	3.33	2.96	2.12	- X X	Y Y Z Z	Y Z	Y Y	Y S	Z Z	Y S	ζ ς Z Z	Y S	Z Z	Y Z	Z Z Z Z	Y Z	Z Z	Α Δ Ζ Ζ	Z Z	Y Y	Z Z	0.00 A N	Y :	Y Y	A S	Ψ 4 2 Z	Y Z	V Z	 (&	Z Z	Y Z	ζ Z	NA 5,53	5.56
11.58 8.20 1.25 4.81 0.77	2.53 0.00 6.00	6.31	1.39	1.24	2.30	3.25	7.18	4.15 4.28	3.41	2.57	2.71	3.18	11.94	32.27	2.22	18.84	25.67	5.24	8.09 25	7.86	2.33	7.25	5.72	7.49	0.00	7.86												
Parotid duct diversion Parotid duct diversion Injection for salivary x-ray Closure of salivary fistula Dilation of salivary duct	lation of salivary duct gation of salivary duct lilivary surgery procedure	ainage of throat abscess	ppsy of throat	opsy of upper nose/throat	opsy of upper nose/throat	emove pharynx foreign body	cision of neck cyst	move tonsils and adenoids	moval of tonsils	moval of tonsils	moval of adenoids	moval of adenoids	tensive surgery of throat	tensive surgery of throat	cision of tonsil tags	Partial removal of pharynx	Revision of pharyngeal walls	Repair throat wound	oat .	Surgical opening of throat	Control throat bleeding	Control throat bleeding	Control nose/throat bleeding	ontrol nose/throat bleeding	Throat surgery procedure	roat muscle surgery	sision of esophagus	Excision of esophagus lesion	moval of esophagusemoval of esophagus	moval of esophagus	emoval of esophagus	Ittial removal of esophagus	Irtial removal of esophagus	Irtial removal of esophagus	irtial removal of esophagus	Removal of esophagus	emoval of esophagus pouch	Esoph scope w/submucous inj
																																						Esc
44444																						4																
42509 42510 42550 42600	42665 42699 42699	42726 42725	42800	42804	42806 42808	42809		42820 42821	42825	42826 42830	42831	42836	42842	42845	42860	42890	42892	42900	42950	42955	42960	42962	42970	42972	42999	43030	43045 43100	43101	43107		43113	43117	43118	43122	43123	43130	43135	3201

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	
Year 2007 Transi-tional Fa-cility Total	20.00.00000000000000000000000000000000
Fully Implemented Facility Total	86.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Year Year 2007 Port Transi- tional ity Non-Fa-	2. 4.0 4.5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
LAYMI Ily Im- sment- acility Fotal	
Mal-Prace ection RVUs F1	0.000000000000000000000000000000000000
Vear Year 2007 Transi- It	0.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1
Fully Implemented Facility PERVUS	0. 1. 2. 1. 1. 1. 1. 1. 1. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.
Year 2007 Transitional Non-Fa-cility PE RVUs	R
Fully Implemented Non-Facility PE RVUS	
Physician Perment Transi-Work ed Non-Fares Pervice Control of the Pe	
MELATIVE VALUE UNITS (MVUS) AND I	Esophagus endoscopy, biopsy Esophagus endoscopy, ligation Esophagus endoscopy/ligation Esophagus endoscopy/ligation Esophagus endoscopy/ligation Esophagus endoscopy, esam Esoph endoscopy, dilation Esoph endoscopy, dilation Esoph endoscopy, esam Esoph endoscopy, esam Esoph endoscopy, was to by general endoscopy, diagnosis Uppr gi endoscopy, was to by general endoscopy, with tube Uppr gi endoscopy with tube Uppr gi endos
.	
ADDENDUM B	
ADD CPT ¹ / HCPCS ²	43202 43202 43204 43205 43215 43216 43217 43226 43226 43231 43231 4324 4324 4324 4324 4324 43

										_																																	_						_	_		_
060 060	060	060	060	060	060	060	060	060	060	060	060	060	86	000	000	000	060	\ \ \	060	000	060	060	000	060	060	060	060	060	060	060	060	90	77 6	060	060	060	060	060	36 ×	010	000	000	000	060	060	060	060	060	060	080	060	060
34.23 33.68 34.24	33.09 35.53	34.24	29.00	33.99	60.09	66.79	37.87	38.82	25.54	43.94	25.29	37.94	2.24	3.96	4.66	5.64	0.00	0.00	79.77	32.32	93.50	17,69	2.75	20.51	24.28	30.11	49.43	55.49	36.33	47.65	45.72	50.32	20.99	29.31	43.31	46.67	16.20	19.30	0.59	7.16	1.09	1.63	2.80	27.65	31.62	31.02	23.94	23.02	24.89	33.75 25.05	16.90	14.02
33.97 33.39 34.30	32.89 35.38	34.34	28.71	33.85 27.86	60.59	08.99	41.10	38.83	25.46	44.13	24.88	38.25	69.6	4.22	4.91	5.80	0.00	00.0	19.39	32.23 27.63	03.50	17.42	2.85	20.64	24.26	30.15	48.96	55.94 56.84	35.94	49.36	46.92	51.74	2.86	29.04	42.62	46.11	16.13	18.91	3./8	6.9	1.07	1.58	2.78	27.54	31.34	31.35	23.68	23.03	24.97	32.56	17.18	14.51
4 4 4 Z Z Z	Z Z	Z Z	(Z Z	Z Z	Y :	Y S	₹ ₹	ζ <u> </u>	Z	۷ Z	¥ ç	4.7	16.32	10.02	A A	0.00	00:0	Υ <u>Υ</u>	(< 2 Z	(4 2 Z	∠	Z	٧Z	ΥZ	∢ Z	Υ ·	₹ 4 2 2	ζ <u> </u>	ΥZ	N	Ψ.	¥ \$	(4 2 Z	ΥZ	A V	∢ Z	∢	¥ 0	8 8 8	ΥZ	6.02	3.26	Y :	Υ <u>Υ</u>	(4 Z Z	Z Z	A A	Z S	 Y	Z Z	N A
<u> </u>	∢ ∢ Z Z	₹ S	ζ ∢ ;	Α Δ Ζ Ζ	Z Z	Y :	¥ ż	4 4 2 2	ζ	Y Y	Y Y	A L	7 9.13	15.76	10.23	A A	0.00	0.00	Υ Υ	ζ 4 2 2	(4 Z Z	Z Z	Z Z	ΑN	A N	Y Z	Υ ·	4 4 2 2	ζ	Z Z	A	Υ ·	▼ Z Z	ζ	Z Z	A V	Y Z	Υ Υ	A C	8 Z	Z Z	14.28	3.12	Y :	▼	ζ Δ Ζ Ζ	Z Z	Α	 ₹ :	 4	Z Z	N A
2.75 2.59 2.84	2.62 2.93	2.45	1.42	2.46 0.5	4.96	4.49	1.95	3.04 4.02	2 7	3.52	1.43	3.05		0.20	0.24	0.31	0.00	0.00	1.45	4 00.0	1 48	1.36	0.14	1.58	1.93	2.35	3.95	9.4.7 8.03	4. c	2.98	3.05	3.32	0.27	2.23	3.15	3.53	1.33	1.55	0.0	0.43	0.02	60.0	0.13	2.18	2.54 6.54	2 - 3Z	8. 8.	1.81	1.93	2.03	1.25	1.03
8.68 9.31	8.47 9.73	8.99	8.35	9.74	15.26	16.88	10.51	9.48	7.61	11.80	7.27	10.07	0.0	1.19	1.36	1.54	0.00	0.00	5.05	0.27	9.99	5.16	0.70	5.33	6.13	7.57	11.63	12.12	0.6	9.72	9.72	10.55	0.66	7.45	10.98	11.83	4.74	5.62	42.24	2.13	0.26	0.44	99.0	7.68	8.50	9.52 50.52	6.48	5.90	6.20	.α .α 	26.94 26.94	4.68
8.42 8.39 9.37	8.27 9.58	9.09	8.06	9.60	15.81	16.89	13.74	94.0	7.53	11.99	98.9	10.38	102	1.45	1.61	1.70	0.00	0.00	5.27	<u>0</u> 0	68.0	4,89	0.80	5.46	6.11	7.61	11.16	12.5/	8,68	11.43	10.92	11.97	0.53	7.72	10.29	11.27	4.67	5.23	4.43 00	1.96	0.24	0.39	0.64	7.57	8 8 22 23 20 20 20	0.00 0.00	6.22	5.91	6.28	8.19 7.96	5.22	5.17
<u> </u>	∢ ∢ Z Z	₹ S	(Α Δ Ζ Ζ	Z Z	Y :	¥ ż	4 4 2 2	Z Z	Z Z	Y Y	NA V	6.0 1.0 1.0	13.55	6.72	A A	0.00	0.00	Α < Z	ζ 4 2 2	(4 Z Z	Z Z	Z Z	Υ	A N	Y Z	Υ ·	4 4 2 2	ζ	Z Z	A	Υ ·	▼ Z Z	ζ	Z Z	A V	Y Z	Υ Υ	A C	8 Z	Z Z	4.83	1.12	Y :	₹ <u>₹</u>	ζ Δ Ζ Ζ	Z Z	Α	Z :	- Z Z Z Z	Z Z	N A
 & & & & & &	Y Y	Y Z	Z Z	¥ ₹	Z Z	Y :	Y S	₹ < Z Z	ζ <u> </u>	N A	Ϋ́	NA	00.9	12.99	6.93	ΨZ V	0.00	0.00	▼ < Z Z	(< Z	(4 2 Z	Z Z	Z Z	Ϋ́	Ą Z	₹ Z	Υ :	₹	ζ	ΥZ	N A	Ψ.	Ψ <u>Σ</u> Σ	(4 2 Z	Z Z	ΥZ	₹ Z	▼	4 C	9 Z	Z Z	13.09	0.98	Ψ.	Y S	(Z Z	Ν		 &	(4 2 Z	NA A
22.80 22.41 22.09	22.00	22.80	19.23	21.79	39.82	45.42	25.41	26.30	16.22	28.62	16.59	24.85	5. 5.	2.57	3.06	3.79	0.00	0.00	12.67	25.41	14.95	11.17	1.91	13.60	16.22	20.19	33.85	39.34	24.32	34.95	32.95	36.45	2.06	19.67	29.18	31.31	10.13	12.13	% 6 6 7	4.60	0.81	1.10	2.01	17.79	20.58	20.20	15.62	15.31	16.76	22.32	10.71	8.31
Revise esophagus & stomach Revise esophagus & stomach Revise esophagus & stomach		ntestine	ophagus	ophagus	iir	iir	sins	ror veins	puno	onno	pening	pening				sophagus	ilcrovasc	procedure	stomach	macil	stomach	uscle			Excision of stomach lesion	lesion			partial	, partial	Removal of stomach, partial	, partial	i, partial	repair	oux-en-v	si smil i	nerve	nerve	storny	- Page	tent	/ tube	my tube	ust band	ast band	gast band	band/port	lorus	Fusion of stomach and bowel	nd bowel	de	nbe
Revise esophagus & Revise esophagus & Revise esophagus &	Repair of esophagus Repair of esophagus	Fuse esophagus & ii	Surgical opening, es	Surgical opening, es	Gastrointestinal repa	Gastrointestinal repa	Ligate esophagus ve	Esopnagus surgery	Repair esophagus w	Repair esophagus w	Repair esophagus o	Repair esophagus o	Dilate ecophagus	Dilate esophagus	Dilate esophagus	Pressure treatment	Free jejunum flap, m	Esophagus surgery	Surgical opening of	Surgical repair of etc	Surgical opening of	Incision of pyloric m	Biopsy of stomach	Biopsy of stomach	Excision of stomach	Excision of stomach	Removal of stomach	Removal of stomach	Hemoval of stomach	Vagotomy & pylorus	Lap gastric bypass/r	Lap gastr bypass inc	Laparoscopy, vagus	Laparoscopy, vagus	Laparoscopy, gastro	Place gastrostomy to	Nasal/orogastric w/s	Change gastrostomy	Reposition gastrosto	Lap, place gastr adji	Lap, revise adjust ga	Lap, remove adjust of	Lap remov adi qast l	Reconstruction of py	Fusion of stomach a	Fusion of stomach a	Place gastrostomy to	Place gastrostomy to				
444																																																				
																		:								:											:					:							-	i		
43324 43325 43326	43330 43331	43340	43350	43351	43360	43361	43400	43401 43405	43410	43415	43420	43425	43453	43456	43458	43460	43496	43499	43500	45501	43510	43520	43600	43605	43610	43611	43620	13621	43631	43632	43633	43634	43635	43641	43644	43645	43651	43652	43659	43750	43752	43760	43761	43770	43771	43773	43774	43800	43810	43820	43830	43831

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

IIS FOR ZOU/—Continued	Year 2007 Transi- plement- 2007 tional ed Facil- tional Fa- Non-Fa- ity Total cility Total	NA 28.34 26.11 NA 32.95 31.08 NA 32.95 31.08 NA 4.29 31.08 NA 4.29 31.08 NA 4.29 40.37 NA 4.29 40.39 NA 22.46 6.45 6.99 NA 22.46 6.45 6.43 NA 22.46 6.45 6.45 NA 22.46 6.45 6.45 NA 22.46 6.45 6.45 NA 22.46 6.45 6.45 NA 3.37 NA 22.46 6.45 6.45 NA 4.10 0.00 NA 3.37 NA 4.29 4.24 NA 4.10 0.00 NA 4.329 6.00 NA 4.329 6.00 NA 4.329 6.47 NA 55.32 6.07 NA 55.33 6.07 NA 55.32 6.07 NA 55.32 6.07 NA 55.33 6.07 NA 65.33 6.07
MEDICARE PAYMENIS	Mal-Prac- plement- ed Non- tice RVUs Facility N Total cil	1.22.23.4 & & & & & & & & & & & & & & & & & & &
DETERMINING IM	Year 2007 Transi- tional Fa- cility PE RVUs	7. 82 6 82 8 83 9 83 8 9 9 8 8 9 9 9 8 8 9 9 9 9 8 9 9 9 9
SED IN	Year 2007 Fully Im- Trans: plement- tional ed Facility PE RVUs RVUs	44444444444444444444444444444444444444
RELATED INFORMATION U	Fully Im- Physician plement- Work ed Non- RVUs Facility PE RVUs	22.22 23.02 23.02 22.02 23.02 22.03
HELATIVE VALUE UNITS (HVUS) AND F	Description	Place gastrostomy tube Repair of stomach lesion V-band gastroplasty Gastroplasty wo v-band Gastroplasty wo v-band Gastroplasty wo v-band Gastroplasty duodenal switch Gastric bypass incl small i Revision gastroplasty Revise stomach-bowel fusion Revise stomach-bowel fusion Revise stomach-bowel fusion Revise stomach-bowel fisula Repair stomach-bowel fisula Remove gastric port, open Stomach surgery procedure Freeing of bowel adhesion Incision of small intestine Decompress small bowel Reduce bowel obstruction Correct malrotation of bowel Bowel to bowel lesion(s) Excise intestine lallograft Removal of small intestine Removal of small intestine Removal of colon Partial removal of colon Removal of colon/ileostomy Removal of colon/ileostomy Removal of colon/ileostomy Removal of colon/ileostomy Removal of colon Lap, enterolysis Lap, enterolysis
I.	Status	4<2<4<4<4<4<4<4<4<4<4<4<4<4<4<4<4<4<4<4
ADDENDUM B	Mod	
ADDI	CPT1/ HCPCS ²	43832 43842 43843 43844 43845 43846 43846 43870 43856 43856 43865 43866 43866 43866 43866 43866 43866 43866 43866 43866 43866 44005 44005 44005 44005 44100 44112 4412 4412 4412 4412 4412 44

									_		_																													_		_	_			_	_	
060 ZZZ 060	060	060	060	060	ZZZ	R }	060	060	060	060	060	060	060	060	000	000	000	000	000	000	88	800	000	000	000	800	000	000	88	000	000	9 6	88	000	000	8 8	060	060	060	2000	060	060	060	060	060	060	060	DAN ZZZ
34.83 6.42 39.04 54.42	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	50.56	44.93	51.64	5.08	0.00	20.73	26.06	24.92	34.51	29.60	23.38	25.87	28.97	3.98	4.39	5.62	5.01	6.61	6.74	/2. / 8. 7. 8	5.26	7.80	8.21	10.54	1.00	2.06	4.51	3.76	4.28	4.74	5.70	5.70	7.16	0.60	0.68	33.44	38.11	26.50	26.76	21.20	25.29	40.65	35.32	34.61	39.56	26.32	4.46
34.45 6.15 38.33	43.62	49.82	44.48 54.85	51.33	4.83	0.00	20.84	25.89	25.17	35.11	29.63	24.05	25.94	29.13	4.28	4.71 68	00.9	5.32	7.09	7.24	6.09 7.09	5.49	8.11	8.69	11.16	- F	2.18	4.78	3 86	4.42	4.96	5.92 8.82	5.86	7.29	6.85	0.67	34.44	39.48	26.27	26.45 26.74	21.37	25.23	40.06	36.00	35.64	39.49	26.47	25.40 4.25
4 4 4 5 Z Z Z Z	(₹ ₹ Z Z	₹ Z	(∢ 2 Z	∀	0.00	¥:	▼ ×	 ζ Ζ Ζ Ζ	Y Y	¥:	∀ ≥	¥	N A	Υ :	Z Z	(4 Z Z	Α	Y :	Y S	₹ 4 2 2	Z Z	N A	¥:	∀ ≥	¥ Z	N A	Α ¦	5.71 8.99	8.42	10.13	13.47	10.93	12.40	12.78	X X	¥	¥ Z	₹ S	 ζ Ζ Ζ	Z Z	Y Y	Z Z	¥ ≥	Z Z	Y :	Z Z	 ₹ ₹ Z
4 4 4 4 Z Z Z Z	(₹ ₹ 2 Z	Z Z	₹ Z	Y Z	0.00	Y :	Α S	 {	Z Z	Y S	Υ	ζ	N N	Α:	Z Z	(4 Z Z	Υ	Y S	Υ Υ	¥ 4 Z Z	Z Z	A N	¥:	Υ	ζ	N N	Y S	9.97	9.19	10.47	7.2.1 2.1.2.1	11.53	13.14	13.27	Z Z	Z Z	Y Y	Y S	 { Z Z	Z Z	N A	 Y	Z Z	Z Z	Y S	Z Z	 {
2.84 0.57 3.10	3.45	3.87	3.41	3.77	0.44	0.00	1.60	1.98 0.0	1.74	2.37	2.25	1.54	1.96	2.12	0.19	0.21	0.27	0.24	0.32	0.33	0.37	0.27	0.42	0.40	0.52	0.08	0.12	0.21	رد . د د د	0.26	0.27	0.32	0.34	0.42	0.38	0.03	2.11	2.41	2.1	- 0.0	1.51	1.85	3.26	2.7.	2.13	2.80	- 66.1	0.37
8.79 1.4.1 0.71	11.09	12.89	11.72	13.58	1.14	0.00	5.52	6.63	6.63	8.74	7.66	8.80	6.91	7.44	1.20	1.31	1.02	1.46	1.89	1.90	Z	05:1	2.13	2.29	2.90	0.60	0.67	1.36	0.79	1.20	45.1	1.56	25.	1.91	8.5	0.16	6.73	7.73	6.37	6.69 6.69	2.38	6.28	9.61	8.47	8.69	9.53	6.49	0:00 0:00
8.41 1.14 9.00 00.00	10.60	12.15	11.27	13.27	0.89	00.0	5.63	6.46	5.88 	9.34	7.69	9.47	86.9	7.60	1.50		20.5	1.77	2.37	2.40	2.5 2.5 2.5	1.73	2.44	2.77	3.52	0.75	0.79	1.63	98.0	. . .	1.56	2.78	1.71	2.04	2.05	0.15	7.73	9.10	6.14	os: 4	5.55	6.22	9.05	8.13 0.13	9.72	9.46	6.64	0.78
4 4 4 4 2 2 2 2	Z Z Z	X Z	Y Z	ZZ	Y Z	00.0	Ϋ́ Z	Ψ × Z	 {	Ϋ́	 ∠ :	Y Z	(Ϋ́	Υ :	₹	(ΑN	₹ Z	₹ S	₹ 4 2 2	Z Z	N A	Y :	Y Z	₹ ₹	Ϋ́	Y ;	3.74	5.34	6.73	7.33 77	6.78	7.15	7.98	₹ ₹ 2 Z	Y Y	Ϋ́	∀	 ζ Ζ Ζ Ζ	Z Z	Y Y	 V 2	∀	Z Z	Y :	 V 2	 {
▼	(X X	Y Z	Z Z	Y Z	00.0	Y :	Y	 {	A N	Z :	Y S	(Ϋ́	Ψ.	Z Z	(ΥZ	∢ Z	▼	₹ 4 2 2	Z Z	ΥZ	Y :	Y S	ζ <u> </u>	Z Z	Ψ.	4.90 7.5	6.13	7.07	%6.7 %0.0	7.38	7.89	8.47	ζ <u> </u>	Y Y	ΥZ	Υ <u>Υ</u>	 { Z Z	Z Z	Y Y	 V 2	Z Z	Z Z	Y :	 V 2	 {
23.20 26.23 4.44	29.57	33.80	29.80	34.29	3.50	0.00	13.61	17.45	16.55	23.40	19.69	13.04	17.00	19.41	2.59	2.87	3.73	3.31	4.40	4.51	4.79	3.49	5.25	5.52	7.12	5.1	1.27	2.94	- c - 28.5 - c t	2.82	3.13	3.82	. 8. 18.	4.83	4.42	0.49	24.60	27.97	18.02	18.04 -	14.31	17.16	27.78	24.08	23.79	27.23	17.84	3.10
Lap. enterectomy	/ w/stoma	octostomy	ocolectomy	colectomy	fl add-on	intestine		omy	mv mv	, r		opsies	mv Smv)my	scopy	scopy/biopsy	300DV	scopy	scopy	scopy	scopy/stent	SCODY	scopy	scopy/biopsy	scopy	e w/stellt	scopy		el pouch	D	piopsy ysdoid	reign body	Vpectomy	n removal	are	al tube	tine	tine	tine	SION	ing	ling	iing	ristula	der fistula	der fistula	ntestine	prostnesis
Lap, enterectomy. Lap resect s/intesti Laparo partial cole	Lap coeccomy par Lap part colectomy	L colectomy/colopr	Laparo total procto	Laparo total procto	Lap, mobil splenic	Laparoscope proc,	Open bowel to skii	lleostomy/jejunosto	Revision of ileostor	Devise bowel pouc	Colostomy	Colostomy with bic	Revision of colosto	Revision of colostc	Small bowel endos	Small howel endos	Small bowel endos	lleoscopy w/stent	Endoscopy of bow	Colonoscopy, communication	Colonoscopy with	Colonoscopy for fo	Colonoscopy & por	Colonoscopy, lesic	Colonoscopy w/sn:	Intro. gastrointestin	Suture, small intes	Suture, small intes	Suture, large intes	Intestinal stricturon	Repair bowel open	Repair bowel open	Repair bowel oper	Repair bowel-skin	Repair bowel-bladd	Repair bowel-blade	Surgical revision, i	Suspena bower w										
⋖ ⋖ ⋖ ⋖																																																∢ ∢
0000	00		2.5	12		38	00		7 4		20		45	46			64		99		70	73	92	77	7.8	80	82		85 86 86 87	88		90	92	93	94	00	02	80		ر ب س	20	52		04.0	09			0.0
44202 44203 44204 4204	44206	44204	44210	44212	44213	44238	44300	44310	44314	44316	44320	44322	44345	44346	44360	44361	44364	44365	44366	44369	44370	44373	44376	44377	44378	44380	44382	44383	44385	44388	44389	44390	44392	44393	44394	44500	44602	44603	44604	44603	44620	44625	44626	44640	44660	44661	44680	44700

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
Year 2007 Transitional Facility Total	0.000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Fully Implemented Facility Total	0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.
Year Year 2007 Transi- tional lity Non-Fa-	0.00 N N N 0.00 62 62 62 64 64 64 64 64 64 64 64 64 64 64 64 64
Fully Implement- ed Non- Facility Total	0.0 N N N N N N N N N N N N N N N N N N
Physician plement- Transi- ed Facility PE RVUs RVUs PE RVUs RVUs RVUs PE RVUs RVUs RVUs RVUs RVUs RVUs RVUs RVUs	0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.000000
Year 2007 Transitional Facility PE RVUs	0.01 0.01 0.02 0.03 0.04 0.05
Fully Implemented Facility PE RVUs	00.01 00
Year 2007 Transitional Non-Fa- cility PE RVUs	0. N
Fully Implemented Non-Facility PE RVUS	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Physician Work RVUs	0.0.0.7.0.0.1.5.1.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0
MELATIVE VALUE UNITS (HVUS) AND I	Prepare donor intestine— Prepare donor intestine/venous Prep donor intestine/venous Prep donor intestine/artery Unlisted procedure intestine Excision of bowel pouch Excision of mesentery lesion Drain app abscess, open Drain app abscess, percut Appendectomy Appendectomy add-on Appendectomy Laparoscopy, appendectomy Laparoscopy, appendectomy Laparoscopy proc, app Drainage of rectal abscess Biopsy of rectum Removal of rectum Removal of rectum Partial removal of rectum Removal of rectum Partial removal of rectum Removal of rectum Removal of rectum Partial removal of rectum Removal of rectum Removal of rectum Partial removal of rectum Removal of rectum Removal of rectum Removal of rectum Partial removal of rectum Removal of rectum Removal of rectum Partial removal of rectum Removal of rectum Partial removal of rectum Removal of rectum Removal of rectum Partial removal of rectum Removal of rectum Removal of rectum Partial removal of rectum Removal of rectum Removal of rectum Partial removal of rectum Removal of rectum Removal of rectum Partial removal of rectum Removal of rectum Removal of rectum Partial removal of rectum Removal of rectum Removal of rectum Partial removal of rectum Partial removal of rectal profascosopy wilate Proctosigmoidoscopy witent Diagnostic sigmoidoscopy witent Diagnostic sigmoidoscopy wilate Proctosigmoidoscopy
.	044044404444444444444444444444444444444
ADDENDUM B	
AUDE CPT¹/ HCPCS²	44715 44715 44720 44800 44800 44800 44900

00000000000000000000000000000000000000	060 060 060 060 060
6. 4 5 9 6. 6 6 9 6 9 8 8 9 6 7 6 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	4.17 8.32 9.38 10.36 12.14 12.54
E. R. C. E. L. G. G. E. G. C.	7.47 7.77 8.54 10.01 11.43 13.25
C. C	0.00 11.40 A A N A A N A A N A A N A A N A A N A A N A A N A A A N A
8 L 0 4 4 4 4 8 8 2 0 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	
86.25 6.6.6.6.2.2.2.4.4.7.6.4.7.7.7.7.7.7.7.7.7.7.7.7.7.7.7	905
0.000000000000000000000000000000000000	0.30 0.48 0.58 0.64 0.68 0.76 0.79 0.79
70.00	
	- ผิญ ติ ต ต ต ต
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2.86 3.12 3.80 3.80 4.01 4.06 4.32 6.83
0.00	8.55 6.00 7.00 7.00 7.00 7.00 7.00 7.00 7.00
$\begin{array}{c} 2.62 - 2.42 - 2.62 - 2.42 - 2.62 - 2.$	7.5.7 4.13 5.64 6.22 6.61 7.57 7.57
Sigmoidoscopy w/tumr remove Sigmoidoscopy w/ablate tumr Sig w/balloon dilation Sigmoidoscopy w/ablate tumr Sigmoidoscopy w/us guide bx Sigmoidoscopy w/us guide bx Sigmoidoscopy w/us guide bx Sigmoidoscopy w/us guide bx Sigmoidoscopy w/stent Sigmoidoscopy w/stent Colonoscopy, submucous inj Colonoscopy w/stent Colonoscopy w/endoscope Lap. remova lof rectum Lap. remova lof rectum Lap. remova lof rectum Lap. remova lof rectum Treatment of rectal prolapse Correct rectal prolapse Repair rectum/remove sigmoid Repair rectal prolapse Dilation of rectal prolapse Dilation of rectal absocess Incision of rectal absocess Incision of rectal absocess Incision of anal sphinicter Incision of anal spetum Incision of anal spetum Incision of anal sphinicter Removal of anal reput Removal of anal reput Removal of anal tag. Ligation of hemorrhoid(s)	Hemoval of anal tags Hemorrhoidectomy Hemorrhoidectomy Hemove hemorrhoids & fissure Hemovrhoidectomy Hemorrhoids & fissure
e i i i i i i i i i i i i i i i i i i i	a la
Sigmoidoscopy w/tumr remove Sigmoidoscopy w/ablate tumr. Sigmoidoscopy w/ablate tumr. Sigmoidoscopy w/lutrasound. Sigmoidoscopy w/lutrasound. Sigmoidoscopy w/lutrasound. Sigmoidoscopy w/stent. Sigmoidoscopy w/stent. Colonoscopy w/b removal Colonoscopy w/b removal Colonoscopy w/b removal Colonoscopy w/b removal Colonoscopy w/stent. Colonoscopy	Removal of ana tags
Sigmoidoscopy w/turn reel Sigmoidoscopy w/abate to Sigmoidoscopy w/abate Sigmoidoscopy w/us guidoscopy w/us guidoscopy w/us guidoscopy w/us guidoscopy w/us guidoscopy w/us guidoscopy w/abate to Colonoscopy and bleocope Lesion removal colonoscopy w/abate strictute rectal prolapse Colonoscopy w/abate strictute rectal prolapse Repair of rectal prolapse Repair of rectal prolapse Repair of rectal prolapse Repair of rectal prolapse Repair istula w/colostomy Repair istula w/colost	tags my my hoids
copy v disk v copy v co	of anal dector dector emorri dector emorri
Sigmoidoscopy w/lun Sigmoidoscopy wwab Sigmoidoscopy with Sigmoidoscopy with Sigmoidoscopy with Sigmoidoscopy with Colonoscopy	oval o orrhoi ovrhoi ove hi ov
Sigmoidoscopy w/tumr remove Sigmoidoscopy w/ablate tumr Sig w/balloon dilation Sigmoidoscopy w/us guide bx Sigmoidoscopy w/stent Sigmoidoscopy w/stent Sigmoidoscopy w/stent Diagnostic colonoscopy Diagnostic colonoscopy Diagnostic colonoscopy Colonoscopy with removal Colonoscopy with removal Colonoscopy with removal Colonoscopy without Lesion removal colonoscopy Lesion removal colonoscopy Colonoscopy without Colonoscopy without Colonoscopy without Colonoscopy without Colonoscopy without Lap, removal of rectum Repair of rectal prolapse Correct rectal prolapse Correct rectal prolapse Correct rectal prolapse Dilation of rectal prolapse Dilation of rectal prolapse Dilation of rectal narrowing Repair fistula w/colostomy Reduction of rectal narrowing Repair fistula w/colostomy Reduction of rectal abscess Incision of anal septum Incision of anal septum Incision of anal septum Incision of anal septum Incision of anal fissure Removal of anal frasure Removal of anal reptitum Incision of anal abscess Incision of anal abscess Incision of anal septum Incision	The Tree Tree Tree Tree Tree Tree Tree T
	444444
283	
	46230 46250 46257 46258 46260 46261
4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	
Year 2007 Transi- tional Fa- cility Total	8 9 9 0 9 9 4 4 4 4 5 9 9 9 9 9 9 9 9 9 9 9 9 9
Fully Im- plement- ed Facil- ity Total	9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9
Year 2007 Transi- tional Non-Fa- cility Total	4 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Fully Implemented Non-Facility	1.25 A 2.25 A 2.25 B 4 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
Mal-Prac- tice RVUs	0.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Year 2007 Transi- tional Fa- cility PE RVUs	23.8.8.6.00000000000000000000000000000000
Fully Implemented Facility PERVUs	E 4 4 8 4 0 1 1 2 0 0 0 0 0 0 4 4 1 1 7 4 8 9 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Year 2007 Transi- tional Non-Fa- cility PE RVUs	8.8.7.4.4.8.7.7.4.0.8.8.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9
Fully Implemented Non-Facility	8 6 8 6 8 6 7 7 8 6 7 7 7 7 8 7 8 7 8 7
Physician Work RVUs	4.8.8.8.8.8.8.8.9.4.6.1.0.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9
Description	Removal of anal fistula Removal of anal fistula Removal of anal fistula Repair anal fistula Repair anal fistula Repair anal fistula Repair anal fistula Anoscopy and dilation Anoscopy, remove lesion Anoscopy, remove lesion Anoscopy, remove lesions Repair of anal stricture Repair of anal stricture Repair of anal stricture Repair of loacal anomaly Repair of loacal anomaly Repair of loacal anomaly Repair of cloacal anomaly Repair of anal sphincter Repair of anal spincter Repair of anal sion(s) Destruction of anal lesion(s) Destruction of hemorrhoids Cryotherapy of rectal lesion Treatment of anal fissure Ligation of hemorrhoids Anus surgery procedure Anus surgery procedure
Status	
Mod	
CPT¹/ HCPCS²	46270 46285 46286 46286 46286 46286 46500 46600 46600 46600 46611 46611 46611 46611 46611 46611 46611 46612 46612 46613 46613 46614 46614 46614 46614 46710 46710 46710 46710 46710 46710 46710 46710 46710 46710 46710 46710 46710 46710 46710 46710 46710 46711 47711

																																															_		_
7ZZ 060 000	060	060	060	060	060	060	060	3 ×	060	060	× }	060	060	060	060	060	060	} {	060	010	<u>}</u>	060	060	060	060	060	000	060	060	010	090	100	000	000		000	000	060	060	060	<u></u>	060	060	060	060	060	060	060	060
2.76 29.39 5.11	27.73 20.37	58.30	78.24	123.71	104.87	86.49	113.31	00:0	0.00	0.0	8.75	27.27	33.76	46.05	76.38	31.72	31.36	0.00	36.42	20.97	0.00	52.62	33.22	34.03	20.59	13.86	2.72	13.19	16.32	8.60	9.87	. 8 . 8 . 6	8.77	13.30	11.83	7.10	7.66	18.10	18.81	19.51	0.00	23.53	24.28	31.1/	34.14	14.97	25.76	38.60	49.67
29.35	28.06 20.64	57.62	76.57	121.22	102.46	86.20	102.01	0.00	0.00	0.00	8.37	27.64	33.83	46.00	75.19	30.91	31.37	0.00	35.92	2 8	0.00	52.48	33.17	33.45	21.20	13.45	2.72 •	12.69	16.01	8.38	9.53	8.77	8.76	13.13	1.30	6.79	7.40	18.35	18.69	19.31	0.00	24.05	24.26	50. E	33.97	14.72	25.71	38.43	49.14
4 4 4 2 2 2	4 4 Z Z	Z Z	₹ ₹ ?	A A	ZZ	Z S	A A	0.00	0.00	0.00	Z Z	ζ	Ą	N N	Z Z	₹ ₹ 2 Z	N	0.00	₹ < Z Z	Z Z	0.00	ΥZ	Z Z	Z Z	Z Z	Y :	Y S	ζ	N A	20.92	39.30 NA	¥ Ž	ž	¥:	Z Z	Z Z	¥:	Y S	Z Z	ž Ž	0.00	Y :	∀ \$ 2 2	A A	Z Z	N A	Z Z	Z Z	- V
	ς ς Z Z	₹ S	(4)	Z Z	Z Z	Y S	Α Z	0.00	0.00	0.00	¥ ž	₹ ₹	Ϋ́	A A	¥ ž	ζ ζ Ζ	A A	0.00	Υ <u>Υ</u>	ξ	0.00	A A	Z Z	Z Z	Z Z	¥.	¥ ž	₹ ₹ 2 Z	A A	20.79	37.06 NA	Z Z	A A	¥ ż	Z Z	Z Z	¥.	Y S	Z Z	¥	0.00	Y :	Α \$ Ζ 2	4 4 2 2	Z Z	N A	 Z 2	₹ ₹ 2 Z	N A
0.25	1.83	4.65	6.45	6.94 9.93	8.41	5.17	7 1.7	0.0	0.00	0.00	0.83	1.98	2.58	3.37	5.85	2.55	2.60	0.00	98.6	96.0	0.00	3.07	2.62	10.0 10.0	1.42	0.43	0.12	0.04	0.62	0.33	0.37	0.42	0.37	0.96	0.45	0.65	0.66	1.46	2.5 8.88		0.00	1.79	1.94	2.48	2.73	0.65	2.06	3.07 40.62	3.92
0.61	7.59 6.12	14.91	18.94	30.29	26.21	22.18	26.59	00:0	0.00	0.00	1.92	7.34	8.88	11.56	18.12	90.0	8.15	0.00	9.0	5.97	00.0	13.38	8.74	8 .7 8	6.11	5.43	0.64	2.85	4.98	2.73	3.60	2.36	5.06	3.29	2.47 7.78	1.57	1.83	5.07	ა ი ლ	5.30	00.0	6.30	6.48	7 .89	8.46	4.80	7.38	9.85	12.22
0.49 8.34 1.18	7.92	14.23	17.27	28.28	23.80	21.89	25.67 27.72	0.00	0.00	0.0	7. 7. 7. 8.	7.71	8.95	11.51	16.93	7.75	8.16	0.00	69.8	89. 73. 89. 89.	0.00	13.24	8.69	0/.6	6.72	5.02	0.64	4.35	4.67	2.51	3.26	2.32	2.05	3.12	2.50	1.26	1.57	5.32	5.13	5.10	00.0	6.82	6.46	7.78	8.29	4.55	7.33	89.6	11.69
4 4 4 Z Z Z	∢	∀	Z Z :	4 4 Z Z	Z Z	Y S	4 4 2 2	0.00	0.00	0.00	Y S	(Ϋ́Z	Y S	Y S	(Υ	0.00	₹ < Z Z	ζ	0.00	Ą Z	Z Z	4 4 2 2	Z Z	Y :	Y S	ζ <u> </u>	Ϋ́	15.05	33.03 NA	Z Z	Y Y	Y S	4 4 2 2	Z Z	Y :	Y S	∀	ζ ∢ Ζ Ζ	0.00	Y :	Z Z	4 4 2 2	Z Z	A A	 Z 2	₹ ₹ Z Z	- V
4 4 4 Z Z Z	4 4 Z Z	Υ Ζ Ζ	(Z Z	Z Z	¥ ż	Z Z	0.00	0.00	0.00	Z Z	Z Z	Ϋ́	Y Y	▼ Z 2	(4 Z Z	Α	0.00	Α < 2 2	ξ	0.00	A N	Y Z	Z Z	Z Z	¥:	▼ Z 2	ξ	Z Y	14.92	30.79 NA	Z Z	A	¥:	4 4 2 2	A N	Y:	¥ ż	Z Z	Z Z	0.00	Y :	Υ Υ	4 4 2 2	Z Z	A	 Y	4 4 2 2	_ V
1.90 19.21 3.69	18.31	38.74	52.85	57.00 83.15	70.25	59.14	71.17	0.0	0.00	0.00	0.00	17.95	22.30	31.12	52.41	20.61	20.61	00.0	24.37	15 17	0.00	36.17	21.86	22.72	13.06	8.00	1.96	7.88	10.72	5.54	2.90	6.03	6.34	9.05		4.88	5.17	11.57	11.98	12.56	0.00	15.44	15.86	20.80	22.95	9.52	16.32	25.71	33.53
d-on sion			<u> </u>			iver	iver	0	ment	plit						or rf	g	e, liver		cryo	ď.			p.				- 		ter	a	skin	skin	skin	skin	io	Asd	ectomy	y/graph	ostomy	ry							nor	mor
Needle biopsy, liver add-on Open drainage, liver lesion Percut drain, liver lesion	Inject/aspirate liver cyst	Partial removal of liver	Partial removal of liver	Partial removal of liver Transplantation of liver	Transplantation of liver	Partial removal, donor liver	Partial removal, donor liver	Prep donor liver, whole	Prep donor liver, 3-segment	Prep donor liver, lobe s	Prep donor liver/venous	Frep doilor liver/arterial	Repair liver wound	Repair liver wound	Repair liver wound	Laparo ablate liver tum	Laparo ablate liver cryosurg	Laparoscope procedure, liver	Open ablate liver tumor if	Open ablate liver rullor cryo	Liver surgery procedure	Incision of liver duct	Incision of bile duct	Incision of bile duct	Incision of gallbladder	Incision of gallbladder	Injection for liver x-rays	Injection for liver x-rays Insert catheter, bile duc	Insert bile duct drain	Change bile duct cathe	Revise/reinsert bile tube	Biliary endoscopy thru	Biliary endoscopy thru skin	Biliary endoscopy thru	Billary endoscopy thru	Laparoscopy w/cholangio	Laparo w/cholangio/biopsy	Laparoscopic cholecyst	Laparo cholecystectomy/graph	Laparo cholecysteeroniy/expli	Laparoscope proc, bilia	Removal of gallbladder	Removal of gallbladder	Removal of galibladder Removal of galibladder	Removal of gallbladder	Remove bile duct stone	Exploration of bile ducts	Excision of bile duct tumor	Excision of bile duct tumor
444	4 4	∢ <	(∢∙	∢ Œ	: œ	< •	< ⊲	(()	O	υ.	< <	(∢	. ≺	⋖ .	< <	(∢	<	υ.	< <	. ⊲		⋖	< <							∢.							⋖ ·	⋖・	< <	(∢	· · ·	∢.	< <	۲ ۵	. ∢	⋖	< <	< <	_
																			_		_								_																				_
						:	:											:	:																								:				-		
47001 47010 47011	47015 47100	47120	47125	47130	47136	47140	47141	47143	47144	47145	47146	47300	47350	47360	47361	47370	47371	47379	47380	47382	47399	47400	47420	47460	47480	47490	47500	47510	47511	47525	47530	47552	47553	47554	47556	47560	47561	47562	47563	47570	47579	47600	47605	47610	47620	47630	47700	47711	47712

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

	000000000000000000000000000000000000
Global	08000000000000000000000000000000000000
Year 2007 Transi-tional Facility Total	28 27 27 28 28 28 28 28 28 28 28 28 28 28 28 28
Fully Implemented Facility Total	2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2
Year Year 2007 Transi- tional lity Non-Fa-	2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2
LAYMI Ily Im- iment- Non- acility	2, 4, 8, 8, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7,
Mal-Prace edition RVUs Fi	9999447566694669999999999999999999999999
The leffMining Year 2007 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	8 8 7 7 8 8 9 1 1 2 1 1 4 9 8 8 8 9 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Fully Implemented Facility PERING	8 8 8 8 8 8 8 8 6 5 7 4 8 8 8 8 8 8 9 5 7 5 7 5 8 8 8 9 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
Year 2007 2007 Transitional Non-Fa- cility PE RVUs	00 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
Fully Implemented Non-Facility PE RVUS	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Physician Perment Tran Work Eaclity Non-RVUs Facility RVUs PERVUs RVUs RVUs RVUs RVUs RVUs RVUs RVUs	2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2
Description	Excision of bile duct cyst Fusion of bile duct cyst Fusion of bile duct cyst Fusion of bile duct cyst Fuse gallbladder & bowel Fuse bile ducts and bowel Fuse bile duct injury Fuse bancreas, open Fuse pancreas open Fuse pancreas besion Fuse pancreas and bowel Fuse pancreatectomy Fuse pancreas and bowel Fuse pancreas cyst and bowel F
.	
ADDENDOM D	
ADD CPT ¹ / HCPCS ²	47715 47715 47716 47721

000000000000000000000000000000000000000	00000000000000000000000000000000000000	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	060 060 060 060 060 060 060	777 777 777 777 777 777 777 777 777 77
2.1.12 2.40 2.4.36 2.5.70 2.4.06 19.40 8.60 8.60	0.084 0.096 0.096 0.096 0.097 0.097 0.097 0.097 0.097	23.10 23.10 23.10 23.10 23.10 23.10 24.15 25.10	200 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	12.19 1.40 1.140 1.264 1.264 1.264 1.275 1.283 1.275 1.633 1.643 1.643 1.643 1.643 1.643 1.643 1.643 1.643 1.643 1.643 1.643 1.643 1.644 1.643 1.644 1
2.1.2 2.2.3 2.3.35 23.95 77.74 23.82 14.88 19.46 19.46 16.63	9.31 16.01 2.00 2.00 2.59 9.73 9.73 9.71 1.08	1.66 1.66 1.66 1.66 1.66 1.66 1.66 1.66	23.00 23.00 23.00 23.00 23.00 23.00 23.00 23.00 23.00 23.00 23.00 23.00	25.57 2.67 2.67 2.67 2.68 2.68 2.68 2.68 3.68 3.68 3.68 3.68 3.68 3.68 3.68 3
6. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4.	Z Z O 4 Z Z O 6 Z Z O 7 Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	Z	
4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4	X X O 4 X X X X 4 8 X X X X X X X X X X X X X	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	X	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z O O Z Z Z O O
0.09 1.62 0.10 1.24 1.87 1.88 1.08 1.43 0.65	0.71 0.00 0.00 0.01 0.02 0.03 0.03 1.54	1.28 0.07 0.00 1.02 1.40 1.07 1.07 1.03 1.22 1.23	2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1	6.0.9 6.
0.43 0.57 0.57 13.88 13.73 14.28 15.62 15.62 16.63 17.	2.91 6.00 6.00 7.11 7.11 7.12 7.00 7.00 7.00 7.00 7.00 7.00 7.00 7.0	4 4 6 6 6 6 6 7 7 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5	3.35 3.35 3.35 3.35 3.35 3.35 3.35 3.35
0.55 4.66 6.66 6.66 6.66 6.66 6.66 6.66 6	2.86 0.00 0.00 0.57 3.16 2.64 0.28 5.32	6.5 6.5 6.5 6.5 6.5 6.5 6.5 6.5 6.5 6.5	4.0.4.4.4.4.4.4.4.4.4.4.6.6.6.6.6.6.6.6.	3.3.3.3 3.3.3.4 3.3.5.4 3.3.5.4 3.3.6.4 5.5.2 5.5.2 5.5.2 5.5.2 5.5.3 5.
2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2	Z Z O C Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	(2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2	Z Z O 2 Z Z O 2 Z Z Z Z Z E Z Z Z Z Z Z E Z Z Z Z Z Z Z	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	(
1.26 1.27 1.79 1.79 1.75 1.75 1.75 1.75 1.75 1.75 1.75 1.75	5.94 10.09 0.00 1.7.7 2.22 5.83 6.24 1.46 1.20 1.20	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	2.5.2 2.5.8 2.5.8 2.5.2 3.5.2 3.5.2 3.5.3	7.7.7 7.7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
Removal of abdominal fluid Remove abdomen foreign body Biopsy, abdominal mass Removal of abdominal lesion Removal abdom lesion, complex Excise searcal spine tumor Multiple surgery, abdomen Excision of umbilicus Removal of omentum Diag laparo separate proc Laparoscopy, biopsy	Laparoscopy, aspiration Laparo drain lymphocele Laparo proc, abdm/per/oment Air injection into abdomen Air injection into abdomen Instrabdom cath for chemotx Insert abdom drain, temp Insert abdom drain, perm Remove perm cannula/catheter Exchange drainage catheter Exchange drainage catheter Assess cyst, contrast inject Assess cyst, condrast inject	Revise abdomen-venous shunt Ligation, abdominal shunt Ligation of shunt Removal of shunt Rpr hern preemie reduc Rpr ing hernia baby, feduc Rpr ing hernia baby, blocked Rpr ing hernia baby, locked Rpr ing hernia, init, reduce Rpr ing hernia, init plocked Rpr ing hernia, init blocked	Perepair ing hernia, reduce Repair ing hernia, blocked Repair ing hernia, sliding Repair lumbar hernia Reprisem hernia, init reduce Rerepair fem hernia, reduce Rerepair fem hernia, locked Rerepair hern init, reduc Rerepair hern init, block Rerepair ventral hern init, block Rerepair ventral hern, reduce Rerepair ventral hern, reduce Rerepair wimesh Rerepair wimesh Represpir wimesh Represpir wimesh Represpire wimesh	Ppr epigastric hem, blocked Rpr umbil hem, reduc < 5 yr Rpr umbil hem, reduc > 5 yr Rpr umbil hem, block > 5 yr Rpr umbil hem, block > 5 yr Rpr umbil hem, block > 5 yr Repair spigelian hemia Repair umbilical lesion Repair of addoorninal wall Omental flap, extra-abdom Omental flap, microvasc
Remo Biops Biops Remo Remo Excise Multip Excise Remo Diag I.	Lapar Lapar Lapar Lapar Lapar Air inj Inst is Insert Insert Remo Excha Asses	Revis Ligatic Ligatic Ligatic Reprin Revin	Repair Repair Repair Repair Repair Repair Report Repair Report Re	Rpr u Repai
		 	 	
49081 . 49085 . 49180 . 49200 . 49215 . 49220 . 49250 . 49250 . 49255 . 49255 . 49320 . 49320	49322 . 49323 . 49329 . 49400 . 49419 . 49421 . 49422 . 49422 . 49424 . 49425 . 49425 . 49425 49425	49426 49427 49429 49429 49491 49496 49496 49500 49501 49502	495521 495521 49550 49553 49553 49557 49560 49565 49566 49568	49572 49580 49582 49585 49587 49600 49600 49611 49611 49611 49611 49650 49600 49600 49600 49600 49600 49600 49600 49600 49600 49600 49600 49600 49600

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Physical Part Physical Par	PoW	Status	:	Physician Work	Fully Im-			Year 2007	Mal-Prac-	Fully Implement	Year 2007 Transi-		Year 2007 Transi	
A Septiment of Active year of Control of Septiment Control of Se		~~~~	Description	RVUs	ed Non- Facility PE RVUs			tional Fa- cility PE RVUs	IIce nvos	ed Non- Facility Total	tional Non-Fa- cility Total		tional Fa-	Global
A Regional of Vietnyy area (1977) NA NA 1160 555 556 558			Abdomen surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	\ \
March Marc			Exploration of kidney	12.07	Y S	¥.	06.9	5.63	0.93	Y S	Y S	19.90	18.63	060
A principal of legistry must be considered as the construction of legistry must be constructed as th			Renal abscess, open drain	17.80	NA NA	NA PA	8.63	7.96	1.34	A S	A Z	27.77	27.10	060
A Figuration of kidney gione			Drainage of kidney	16.40	AN AN	S N	90.8	7.33	1.03	4.03 AN	AN AN	26.34	24.76	060
A Findency of Michaely Genome		_	Exploration of kidney	16.61	A Z	ΥZ	8.55	7.08	1.24	Z Z	Z	26.40	24.93	060
A finistian of kidney groves 2.5 in NA		_	Removal of kidney stone	20.74	AN	Y V	11.10	8.64	1.36	ΥZ	Ϋ́Z	33.20	30.74	060
A previous of blotchy gains A pr		_	Incision of kidney	22.11	Y Z	Y Z	11.69	7.48	1.59	₹ Z	Υ V	35.39	31.18	060
A Benevial of delayey gates A Benevial delayey		_	Incision of kidney	21.64	Α :	Y :	11.49	9.03	1.44	ΨZ:	ΨZ:	34.57	32.11	060
A Browned of blottery statements A Browned of blottery A Browned of blottery statements A Browned of blottery A Browned of		_	Removal of kidney stone	26.84	Υ S	Υ S	13.79	10.87	1.80	▼	ď s	42.43	39.51	060
Precise force force of the control		_	Removal of kidney stone	15.50	₹	4 4 2 2	40.8	0.80	- t	₹	¥	25.24	23.46	080
A Exponent of kidney grain and citation of			Bevise kidney blood vessels	17.07	ζ	₹	7.52	9.64	- c	(< Z	ζ <u> </u>	96.67	04.45 06.07	000
A Figure and driedwy stem			Exploration of kidney	17.00	ζ Δ Ζ Ζ	ζ 4 Ζ Ζ	ب د ه	70.7	2.00	(d	ζ	27.04	25.37	060
A Britained of kidney storing B B B B B B B B B B B B B B B B B B		_	Explore and drain kidney	17.61	ζ ζ Ζ	 ₹ Z	9.82	7.68	1.43	((<u> </u>	28.89	26.72	060
A Biopsy of kidney 2.83		_	Removal of kidney stone	18.61	Ϋ́Z	Z	10.12	7.90	1.22	AN	Ϋ́	29.95	27.73	060
A Biopsy of kidney 22.55	_	_	Exploration of kidney	20.38	A N	A N	10.81	8.53	1.33	ΥZ	Ϋ́	32.52	30.24	060
A Blonge (Midrey Caper. Corpus A Particle State Stat	_	_	Biopsy of kidney	2.63	AN	Y Y	1.13	1.25	0.16	Y V	A'N	3.92	4.04	000
A Bernoval kidney open, compilex B4 7		_	Biopsy of kidney	12.15	A A	Y Y	5.62	5.16	1.30	ΥN	A'N	19.07	18.61	060
A		_	Remove kidney, open	18.47	ΥZ	A A	9.64	7.83	1.35	A A	A A	29.46	27.65	060
A Removal of kidney gen, and calcal		_	Removal kidney open, complex	21.67	A A	A A	11.14	8.89	1.50	Ϋ́	A A	34.31	32.06	060
A		_	Removal kidney open, radical	23.63	₹ Z	Υ V	11.81	9.38	1.55	A A	AN AN	36.99	34.56	060
Perpendial of kidney Legistration of kidne		_	Removal of kidney & ureter	23.84	₹ Z	₹ Z	12.20	9.67	1.59	ΨZ Z	Υ V	37.63	35.10	060
A Permoval of kidney Jesion			Removal of kidney & ureter	26.66	Υ :	Y :	14.10	11.21	1.76	Ϋ́Z :	ΨZ:	42.52	39.63	060
Proposition of sidney lesson		_	Partial removal of kidney	23.93	Y S	Υ S	12.78	9.95	1.55	Z Z	Y S	38.26	35.43	060
Perpendication of kidney person 15.94			Cryoablate renal mass open	21.98	₹ ₹	Ψ < Z Z	10.01	9.62	95.1	₹ < Z Z	₹ 2	88.48 04.08	32.39	060
Ferrover kidney, living donor 2218			Removal of kidney lesion	15.94	ζ Δ Ζ Ζ	ζ Δ Ζ Ζ	9.33 19	08.9	1.13	(d	(d	25.72	24.72	060
C Prep cadaver fanal all aggraft 0.00 <t< td=""><td></td><td></td><td>Remove kidney. living donor</td><td>22.18</td><td>¥ Z</td><td>₹ 2</td><td>12.52</td><td>11.12</td><td>2.35</td><td>Z Z</td><td>Z Z</td><td>37.05</td><td>35.65</td><td>060</td></t<>			Remove kidney. living donor	22.18	¥ Z	₹ 2	12.52	11.12	2.35	Z Z	Z Z	37.05	35.65	060
C Prep rend graft/renous 0.00 </td <td></td> <td></td> <td>Prep cadaver renal allograft</td> <td>0.00</td> <td>0.00</td> <td>0.00</td> <td>0.00</td> <td>00:0</td> <td>0.00</td> <td>0.00</td> <td>0.00</td> <td>00:00</td> <td>00:00</td> <td>×</td>			Prep cadaver renal allograft	0.00	0.00	0.00	0.00	00:0	0.00	0.00	0.00	00:00	00:00	×
A Preprenal graft/vernus A Preprenal graft/vernus A Preprenal graft/vernus A Preprenal graft/vernus 3.56 NA NA 0.99 1.13 0.26 NA NA 5.99 5.88			Prep donor renal graft	0.00	0.00	0.00	0.00	00.0	0.00	0.00	0.00	00.0	00.0	×
A Preprenal graft/arterial 3.50 NA NA 0.98 1.13 0.26 NA NA 4.74 4.89		_	Prep renal graft/venous	4.00	AN	A A	1.10	1.29	0.29	A Z	AN	5.39	5.58	×
Prepreted graft/ureteral 3.34		_	Prep renal graft/arterial	3.50	A A	A A	0.98	1.13	0.26	ΥN	A A	4.74	4.89	××
A Permoval of kidney 13.79 NA NA 7.70 6.79 1.66 NA NA 8.223 A A Transplantation of kidney 45.50 NA NA 18.65 1.67 NA NA 6.042 A A Transplantation of kidney 29.48 NA NA 18.65 1.67 NA NA 60.42 A Remove transplanted kidney 29.48 NA NA 1.67 NA NA 8.95 27.96 6.84.7 A Remove ureter stent, percut 5.50 26.41 33.69 1.86 1.86 0.34 32.25 39.53 7.70 7.70 A Remove reter stent, percut 5.50 26.77 31.61 1.69 1.71 0.31 26.08 38.95 7.70 7.70 7.70 A Remove renal tube willoro 1.10 6.75 11.24 0.36 0.07 7.92 1.84 7.70 7.70 A Inser		_	Prep renal graft/ureteral	3.34	Y Y	Y Y	0.97	1.09	0.25	Ϋ́	A A	4.56	4.68	××
A Transplantation of kidney 40.27 NA NA 18.95 16.34 3.81 NA NA 69.62 A A Transplantation of kidney 45.50 NA NA 18.65 16.44 NA A 69.62 27.96 66.47 A Remoplantation of kidney 29.48 NA NA 18.65 68.47 A A Remoplantation of kidney NA 18.60 NA NA 9.35 7.70 7.70 27.96 27.96 27.96 27.90 27.70 7.70		_	- 1	13.79	Y Y	₹ Z	7.70	6.79	1.65	₹ Z	Ϋ́	23.14	22.23	060
A Premope transplantation of kidney 45.50 NA NA 19.63 18.55 4.42 NA NA 29.68 4.77 NA NA 29.68 4.77 NA NA 29.68 4.77 NA NA 29.62 27.96 A A Premplantation of kidney 29.48 NA NA 18.60 18.71 18.97 18.43 17.70 17.7				40.27	ΨZ:	Y :	18.95	16.34	3.81	ΨZ:	ΑZ:	63.03	60.42	060
A Remove transplanted funderly different stand transplanted funderly may a character passage to kidney draw a character passage to kidney funderly may a character passage to kidney funderl			Transplantation of kidney	45.50	ΨZ:	Y :	19.63	18.55	4.42	Α.	ΨZ:	69.55	68.47	060
A Hemparaterior of kidney 23.48 NA 16.43 13.12 2.50 NA 48.41 49.10 A Remove ureter stent, percut 5.00 20.77 31.61 1.86 0.34 20.85 38.53 7.70 7.70 A Remove ureter stent, percut 5.00 20.77 31.61 1.86 0.67 0.12 14.87 18.97 7.70 7.70 A Change extint ureter stent, percut 2.00 12.75 16.85 0.66 0.67 0.12 14.87 18.97 2.73 7.00 7.00 A Remove renal tube willuoro 1.10 6.75 11.24 0.36 0.67 0.12 7.02 12.41 1.54 0.75 0.77 3.61 3.61 3.61 3.69 2.70 7.70 7.70 7.00 7.00 7.00 7.00 7.00 7.00 7.00 7.00 7.00 7.00 7.00 7.00 7.00 7.00 7.00 7.00 7.00 7.00	_	_	Remove transplanted kidney	18.60	Y ?	Y S	9.35	7.69	1.67	Z Z	Y S	29.62	27.96	060
A		_	Reimplantation of Kluney	29.48	A V	Y C	10.43	3.5	2.50	A C	A C	148.41	45.10	080
Change activity curver settly consistent consistent settly consistent consistent settly consistent consistent settly consistent consistent consistent consistent consistent settly consistent consiste			Domovo urotor start porcut	9.30	20.41	23.03	00.1	6 5		32.23	26.03	0/./	0/./	88
Principle of kidney lesion 1.10 6.75 11.24 0.36 0.37 0.017 7.92 12.41 1.53 1.54 1.55 1.24 1.55 1.24 1.55 1.24 1.55 1.24 1.55 1.24 1.55 1.24 1.55 1.24 1.55 1.24 1.55 1.24 1.55 1.24 1.55 1.24 1.55 1.24 1.55 1.24 1.55 1.24 1.55 1.24 1.35 1.34 1.35 1.34 1.35 1.34 1.35 1.34 1.35 1.34 1.35 1.34 1.35 1.34 1.35 1.34 1.35 1.34 1.35 1.34 1.35 1.34 1.35 1.34 1.35 1.34 1.35 1.34 1.35 1.34 1.35 1.35 1.34 1.35 1.35 1.34 1.35 1.35 1.35 1.34 1.35 1.3			Change ext/int urater stept	90.0	12.75		60 99	0.67	5.0	14.87	18 97	0.7	20.7	
Definition of kidney lorsing per signature 1.96			Bemove renal tube w/fluoro	1 10	6.75	11 24	98.0	0.0	0.07	70.5	12.21	1.73	27.7	
Institute and tub			Drainage of kidney lesion	196	A Z	Į Z	90.0	490	0 0	1 A	Y Z	27.2	2.72	000
Name		_	Instll rx agnt into rnal tub	1.96	1.51	1.56	0.79	0.67	0.14	3.61	3.66	2.89	2.77	000
Insert uretefal tube NA NA 1.66 1.75 0.25 NA NA 0.60 0.15	_	_	Insert kidney drain	3.37	Ϋ́	Ϋ́	1.40	1.49	0.20	AN	AN	4.97	5.06	000
A Injection for kidney x-ray 0.76 1.88 2.48 0.56 0.64 0.05 2.69 3.29 1.37 1.45 A Create passage to kidney 2.09 NA 1.02 1.07 0.13 NA NA 5.06 5.08 A A Create passage to kidney 2.09 NA 1.02 1.07 0.13 NA 3.24 3.29 A A Create passage to kidney pressure 2.09 NA 1.02 1.07 0.13 NA 3.24 3.29 A A Change kidney tube 21.06 NA NA 1.112 8.68 1.38 NA NA 33.56 A Revision of kidney/ureter 25.61 NA NA 13.16 NA NA 10.06 1.78 NA NA 33.56 A Revision of kidney/ureter 25.61 NA NA 13.16 NA NA 10.06 1.78 NA NA 29.56 37.45 A		_	Insert ureteral tube	4.15	AN	A N	1.66	1.75	0.25	ΥZ	Ϋ́	90.9	6.15	000
A Create passage to kidney 3.37 NA 1.48 1.50 0.21 NA NA 5.08		_	Injection for kidney x-ray	0.76	1.88	2.48	0.56	0.64	0.02	5.69	3.29	1.37	1.45	000
A Measure kidney pressure 2.09 NA 1.02 1.07 0.13 NA 3.24 3.29 1.46 11.99 15.23 0.52 0.09 13.54 16.78 2.07 2.07 1.46 11.99 15.23 0.52 0.09 13.54 16.78 2.07 2.07 1.20 NA NA 11.12 8.68 1.38 NA NA 33.56 31.12 1.20 NA NA 11.12 8.68 1.78 NA 40.55 37.45 1.20 NA NA 10.99 8.61 2.01 NA 40.55 37.45 1.20 NA NA 9.40 7.92 1.49 NA 36.96 38.08 1.20 NA NA 10.39 9.49 1.83 NA 36.96 38.08		_	Create passage to kidney	3.37	Y :	₹ Z	1.48	1.50	0.21	Y Z	¥.	5.06	2.08	000
A Change kdney tube 1.46 11.99 15.23 0.52 0.09 13.54 16.78 2.07 2.07 A Revision of kidney/ureter 21.06 NA NA 11.12 8.68 1.38 NA NA 33.56 31.12 A Revision of kidney/ureter 25.61 NA NA 13.16 10.06 1.78 NA 40.55 37.45 A Repair of kidney/ureter 21.01 NA NA 9.29 8.61 2.01 NA 40.55 37.45 A Close kidney-skin fistula 18.67 NA NA 9.40 7.92 1.49 NA 29.56 28.08 A Robose kinishula 24.14 NA NA 10.39 9.49 1.83 NA 36.96 35.46		_	Measure kidney pressure	2.09	Y Z	Y !	1.02	1.07	0.13	YZ :	AN.	3.24	3.29	000
A Revision of kidney/ureter 21.06 NA NA 11.12 8.68 1.38 NA 33.56 31.12 A Revision of kidney wound 25.61 NA NA 9.29 8.61 2.01 NA NA 32.31 31.63 A Close kidney-skin fistula 24.14 NA NA 9.40 7.92 1.49 NA 36.96 35.46 A Repair renal-abdomen fistula 24.14 NA NA 10.99 9.49 1.83 NA NA 36.96 35.46		_	Change kidney tube	1.46	11.99	15.23	0.52	0.52	0.00	13.54	16.78	2.07	2.07	000
A Repair feather-abdomen fishla		_	Revision of kidney/ureter	21.06	Υ ·	Y S	11.12	89.8	1.38	Z Z	¥ :	33.56	31.12	060
A Prepair of Nucley Would	_		Revision of kidney/ureter	25.61	Y S	Ψ « Z Z	33.16	10.06	1.78	Ψ < Z Z	₹ \$ Z 2	40.55	37.45	060
A Repair renal-abdomen fistula			Repair of Klaney wound	21.01	¥ < Z	Υ < Ζ 2	9 . y	1 0.0	. K	₹ < Z Z	¥	32.31	20.15	080
			Glose Kidney-skill listula	10.07	ζ Δ Ζ Ζ	(4 2 Z	9.40	0.92		(d	(d	36.96	25.00 35.46	060

March A busine below would with the control of																																									_	
A busine tables and mass 12 2	060 060 060	060	060	} } }	88	88	800	060	88	000	800	000	050	060	060	060	060	060	80	000	200	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	060
March Marc	37.47 31.19 24.91 31.42 40.09	34.08 36.56	40.46	0.00	8.64	9.48	10.96	16.22	14.96	15.77	15.71	16.93	10.12	25.27	25.11	24.31	23.90	30.87	1.32	2.41	1.95	25.20	31.27	29.97	13.43	29.88	30.84	31 11	29.47	29.77	32.49	24.53	33.82	35.18	44.58	32.88	33.45	25.38 20.55	23.67	29.80	26.66	38.12
A Page	36.25 33.04 26.66 33.75 43.10	36.32 38.94 34.59	41.64	0.00	8.92	10.00	1.54	17.05	15.78	16.55	16.61	17.84	9.99	26.72	26.06	26.29	25.42	33.06	1.45	2.33	1.95	26.21	31.21	31.21	14.56	30.85	32.23	33.16	31.39	29.42	34.66	26.67	35.75	37.71	47.56	35.51	36.10	27.21	25.15	31.55	22.22	40.23
A harmonic former in the following the fol	4 4 4 4 4 2 2 2 2 2	4 4 4 Z Z Z	Z Z	0.00	10.75	11.86	13.38	₹ Z	Z Z	₹ Z	₹ ₹ Z Z	A S	138.2	Ϋ́	₹ S	Z Z	Y :	A A	5.57	4.72	2.95	¥:	4 4 Z Z	¥ Z	₹ S	Z Z	¥ :	Z Z	Z Z	¥ ž	Z Z	Y S	₹ ₹ Z Z	A A	₹ Z	₹	¥ :	Z Z	Z Z	₹ Z	 {	A A
A background related	4 4 4 4 4 Z Z Z Z Z	Α Ζ Ζ Ζ Ζ Ζ	4 4 2 2	0.00	10.82	12.09	13.92	V Z	X X Z Z	Y S	¥ Z Z Z	N N	84.23	Z Z	▼	ZZ	¥ :	Z Z	4.93	3.69	2.66	¥:	Y Y	N A	▼	 Z Z	¥ :	Z Z	Z Z	Y S	₹ Z Z	Y S	A A	Z Z	Υ S	Y Y Z Z	¥ :	Z Z	Z Z	Y S	T Z	Z Z
A Repair carbon delayer 25.25 NA NA 18.25	1.96 1.36 1.39 1.39	1.58	2.76	0.00	0.39	0.45	0.54	0.73	0.85	0.77	0.39	0.83	0.65	1.13	1.45	1.07	1.09	- 1 38 38 38	0.05	0.1	0.07	1.27	2.13	1.52	0.61	9. 6.	1.38	1.55	1.51	1.61	1.45	1.19	2.3 1.54	1.89	2.07	1.47	1.57	1.29	1.01	1.28	1.36	2.16
A Revision of not reserved with the company of	9.45 8.94 7.06 8.91 11.19	9.27	11.50	0.00	2.27	2.51	2.84	4.59 8.48	3.78	4.00	3.96	4.26	2.94	7.15	7.05	6.99	6.78	7.95 8.68	0.51	0.79	0.72	7.45	8.71 7.86	8.46	4.65	8.06	8.45	8.21 8.57	8.22	8.65	9.05	7.18	9.22	9.47	12.11	9.30	9.77	7 9 6 52 69 9	7.06	8.54	7.47	10.39
Peter Pete	8.23 10.79 8.81 11.24	11.51 12.35	12.68	0.00	2.55	3.03	3.42	5.42	4.60	4.78	6.06 4.86	5.17	2.81	8.60	8.00	8.97	8.30	10.15	0.64	0.71	0.32	8.46	8.65 8.02	9.70	5.78	9.03	9.84	9.84	10.14	8.30	11.19	9.32	1.63	12.00	15.09	11.93	12.42	9.05	8.54	10.29	8.78	12.50
A Hevision of norseshoe kidney 26.08	4 4 4 4 Z Z Z Z Z	4 4 4 2 2 2	Z Z	0.00	4.38	4.89	5.26	A Z	Z Z	Y S	Z Z	A S	13.61	Z	Y Z	ζ <u> </u>	Y S	e e	4.76	3.10	1.72	Y :	Z Z	Y Y	Y Z	Z Z	Y :	ĕ ¤	Z Z	Z Z	Z Z	Y S	4 4 2 2	Z	Y S	Z Z	¥ :	Ψ Ψ Z Z	Z Z	Y S	 {	4 4 Z Z
A Revision of horseshoe kidney A Laparo ablate renal asses A Laparo bather enal asses A Laparo bather enal asses Laparo bather enal asses Laparo partial nephrectomy A Laparo radical nephrectomy A Kidney endoscopy & loipsy at Reatment A Kidney endoscopy & loipsy at Reatment A Kidney endoscopy & treatment A Kidney endoscopy at treatment A Kidney endoscopy & treatment A Kidney endoscopy & treatment A Kidney endoscopy & treatment A Kidney endoscopy at treatment A Removal of ureter stone A Removal of ureter in bladder A Revise or ureter A Removal of ureter & kidney A Removal of ureter	4 4 4 4 Z Z Z Z Z	4 4 4 2 2 2	Z Z	0.00	4.45	5.12	5.80	Z Z	Z Z	Y S	Z Z	N N	77.05	Z	Y Z	Z Z	Y S	e e	4.12	2.07	1.43	Y :	Z Z	Y Y	Y Z	Z Z	Y :	Ψ	Z Z	Z Z	Z Z	Y S	4 4 2 2	Z	Y S	Z Z	¥ :	Y Y	Z Z	Y S	 {	4 4 Z Z
<	26.06 20.89 16.72 21.12 27.10	23.23 24.89 21.63	26.20	00:0	5.98	6.52	7.58	10.90	10.33	11.00	13.96	11.84	9.58 6.75	16.99	16.61	16.25	16.03	18.61	0.76	1.51	1.16	16.48	20.43	19.99	8.17	19.86	21.01	19.86	19.74	19.51	22.02	16.16	27.23	23.82	30.40	22.13 22.11	22.11	16.87	15.60	19.98	17.83	25.57
<	en fistula	olastyrectomy	or kidney	enal		biopsy	treatment	or resect		biopsy	treatment	treatment	ey stonetumor		ort	tone	tone		-ray	sure	Je/sterit -ray	,				idnev	idneý		bladder	bladder	pladder	wel	owel	dder	dder	owel	ymv	skin	istula	l fistula	lithotomy	ladder Jadder
<	Repair renal-abdomo Revision of horsesh Laparo ablate renal Laparo ablate renal Laparo partial nephr	Laparoscopy, pyelor Laparo radical nephr	Laparo removel don	Laparoscope proc, r	Kidney endoscopy .	Kidney endoscopy 8	Kidney endoscopy 8	Renal scope w/tumo	Kidney endoscopy .	Kidney endoscopy 8	Kidney endoscopy Kidney endoscopy 8	Kidney endoscopy 8	Perc rf ablate renal	Exploration of ureter	Insert ureteral support	Removal of ureter st	Removal of ureter st	Removal of ureter	Injection for ureter x	Measure ureter pres	Injection for ureter tut	Revision of ureter	Release of ureter	Release/revise urete	Revise ureter	Fusion of ureter & ki	Fusion of ureter & k	Eusion of ureters	Reimplant ureter in I	Reimplant ureter in I	Reimplant ureter in I	Implant ureter in bov	Urine shunt to intest	Construct bowel blace	Construct bowel blace	Replace ureter by bo	Appendico-vesicosto	Iransplant ureter to Benair of ureter	Closure ureter/skin f	Closure ureter/bowe	Helease or ureter	Laparo new ureter/b
																																∢ <	∢ ∢									
												<u>.</u>															-					<u> </u>	-		-							
							50561			50574	6/203 50576	50580			•	50620							50715 . 50722				50750					50800			50825	50840				50930	50940 50945	50947

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	\$\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Year 2007 Transitional Facility Total	0.08 8 8 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0
Fully Implemented Facility Total	0.00 0.00
Year Year 2007 Transi- tional lity Non-Fa-	0.01 t t 1 t 1 t 1 t 1 t 1 t 1 t 1 t 1 t 1
Fully Implemented Non-Facility Total	0.11.21.1 0.11.22.1 0.11.23.1 0.11.23.1 0.11.23.1 0.11.23.1 0.11.23.1 0.11.23.1 0.11.23.1 0.11.23.1 0.12.23.1 0.13.2
Physician plement Transi- work ed Non- Facility PE RVUs PERVUs PERVUs RVUs RVUs RVUs RVUs RVUs RVUs RVUs	0.000000000000000000000000000000000000
Year 2007 Transi- tional Facility PE RVUs	0.42424242424242424242424242424242424242
Fully Im- plement- ed Facil- ity PE RVUs	0.0.9
Year 2007 2007 Transi- tional Non-Fa- cility PE	0.4.4.6.4.4.0.4.4.0.4.4.0.4.4.4.0.4.4.4.4
Fully Implemented Non-Facility PE RVUs	0.4.8.8.8.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9
Physician Work RVUs	0.0.0.0 0.0.0 0.0.0
Description	Laparoscope proc, ureter Endoscopy of ureter Endoscopy of ureter Endoscopy of ureter Endoscopy & biopsy Ureter endoscopy & treatment Removal of bladder lesion Removal of bladder & nodes Removal of bladder x-ray Removal of bladder x-ray Urigation of bladder x-ray Urigation of bladder cath Remove bladder/revise tract Remove bladder/revise tract Remove bladder cath complex Change of bladder tube Endoscopic injection/implant Treatment of bladder cath Change of bladder tube Endoscopic injection/implant Change of bladder tube Endoscopic injection/impland Simple cystometrogram Complex cystometrogram Complex cystometrogram Complex cystometrogram Complex cystometrogram Complex cystometrogram Complex cystometrogram Urine flow measurement
. Statu	U00
Mod 8	28 TC
CPT ¹ /HCPCS ²	50949 500953 500953 500953 500954 500970 500

00000000000000000000000000000000000000	000000
88	5.50 5.33 6.71 7.77 7.98
8 6 6 2 2 1 1 2 6 6 6 2 2 2 2 2 2 2 2 2 2	5.89 7.20 8.33 8.09
0.0.9.1.0.1.0.1.0.1.0.1.0.1.0.1.0.1.0.1.	7.98 7.97 NA NA NA
0.0021-0.0002-0.	8.13 8.26 NA NA NA
0.000000000000000000000000000000000000	0.26 0.26 0.32 0.38 0.46
$\begin{array}{c} 0.00000000000000000000000000000000000$	1.51
$\begin{array}{c} 0.001.00 \\ 0.00$	1.90 1.87 2.30 2.65 2.13
0.000.00.00.00.00.00.00.00.00.00.00.00.	3.99 1.4 N N N N N N N N N N N N N N N N N N N
0.001.00.00.00.00.00.00.00.00.00.00.00.0	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
$\begin{array}{c} 0.01110 \\ 0.0110 \\ 0.01110 \\ 0.01110 \\ 0.01110 \\ 0.01110 \\ 0.01110 \\ 0.01110 \\ $	3.73 3.60 4.58 5.30
Urine flow measurement Urine flow measurement Urine flow measurement Electro-uroflowmetry, first Electro-uroflowmetry, first Electro-uroflowmetry, first Electro-uroflowmetry, first Electro-uroflowmetry, first Urethra pressure profile Anal/urinary muscle study Anal/urinary muscle study Anal/urinary muscle study Anal/urinary muscle study Urinary reflex study Urin	yy and treatment
Urine flow measurement	treatment . I treatment .
Urine flow measurement Urine flow measurement Urine flow measurement Electro-uroflowmetry, first Electro-uroflowmetry, first Electro-uroflowmetry, first Electro-uroflowmetry, first Electro-uroflowmetry, first Urethra pressure profile Urethra pressure profile Urethra pressure profile Urine pressure profile Anal/urinary muscle study Anal/urinary muscle study Anal/urinary muscle study Anal/urinary muscle study Urinary reflex study Anal/urinary muscle study Repair bladder/urethra Repair of bladder wound Repair of bladder wound Repair of bladder very Ustoscopy and treatment Oystoscopy an	Oystoscopy and treatment Cystoscopy and treatment Cystoscopy and treatment Cystoscopy and treatment Cystoscopy and treatment Cystoscopy and treatment Cystoscopy and treatment
\$	
92 93 28 28 28 28 38 38 38 3	
51736 51736 51741 51741 51741 51741 51741 51741 51742 51772 51772 51785	52283 52285 52290 52300 52301
	22222

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

	Tourist Register, von 71, 1101 1027 Tuesday, Tragast 22, 20007 Trapassa Tario	
Global		010
Year 2007 Transi- tional Fa- cility Total	7. 4 7. 7 8 8 8 8 8 7 7 7 4 7 7 8 8 8 8 8 8 8 8	4.93
Fully Im- ii- plement- ii ed Facil- a- ity Total	8 4 8 6 0 5 5 7 4 7 7 9 6 0 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	5.38
Year 2007 Transi- tional Non-Fa- cility Total	A 5.5.5. A 5.5.	6.14
Fully Implemented Non-Facility	A 5 2 2 4 2 5 2 5 2 5 2 5 5 5 5 5 5 5 5 5	6.34
Mal-Prac- tice RVUs	0.38 0.20 0.20 0.34	0.24
Year 2007 Transi- tional Fa- cility PE RVUs	21-12-22-22-2-1-1-1-2-2-2-2-2-2-2-2-2-2	1.57
Fully Implemented Facility PE	21-22:44-23:23:4-44:25:25:25:44-45:25:25:45:45:45:45:45:45:45:45:45:45:45:45:45	2.02
Year 2007 Transi- tional Non-Fa- cility PE RVUs	4 8 8 9 8 4 8 7 8 8 8 4 8 7 8 8 8 8 8 8 8 8 8 8	2.78
Fully Implemented Non-Facility	4.8.7.	2.98
Physician Work RVUs	2. 2. 2. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3.	
Description	Oystoscopy and treatment Oystoscopy, stone memoval Oystoscopy, and treatment Oystoscopy, and treatment Oystoscopy and treatment Oystoureter stricture tx Oysto w/up stricture tx Oystouretero stricture tx Oystouretero withous stricture Oystouretero wich stricture Oystouretero Oystouret	Treatment of urethra lesion
Status	444444444444444444444444444444444444444	
Mod		
CPT1/ HCPCS ²	52305 52317 52317 52317 52317 52317 52327 52327 52341 52341 52342 52342 52343 52344 52341 52341 52342 52342 52342 52342 52342 52342 52342 52342 52342 52342 52342 52342 52342 52342 52342 52343 52343 52344 52343 52344 52342 52342 52360 52360 5260 5260 5260 5260 5260 5260 5260 52	53265 53270

Name of the control								_		=	=									_	=																		_	=	_	=		=
A	010 090 090	060	060	060	060	060	060	060	060	060	060	060	060	060	000	000	86	800	000	300	060	060	}	010	010	010	010	010	010	000	010	060	060	060	060	060	060	010	010	010 010	010	010	060	000
Presentation of the control and part Presentation of	7.23 21.47 23.52 26.38	30.11 22.29	25.51	23.10	20.30	23.67	17.23	34.61	16.28	12.17	20.23	2.99	17.08	21.50	1.77	1.46		1.99	- 5	- 1- 30. 80.	15.05	16.28	0.00	2.72	8.41	2.43	2.21 5.52	2.29	3.27	2.95	5.81	21.55	25.33	11.05	21.76	32.09	40.99 2.64	3.83	3.85	5.23	5.68	4.97	14.39	3.65
Perfect or with a signal Perfect or with a s	7.63 23.13 25.51 28.47	32.86 22.46	27.13	33.46 25.60	22.60	25.00	18.65	37.22	17.76	13.28	21.18	13.80	18.30	22.98	1.87	1.58	- 89. 57.	2.13	1.22	 - 6.	16.55	18.06	0.00	3.14	8.91	2.67	2.53	2.69	3.70	3.34	6.21	23.33	27.30	12.23	23.58	34.51	94.10 54.54	4.22	4.12	5.72	6.35	5.58 2.45	15.47	3.96
Process current, single 1	4 4 4 4 2 2 2 2 2	₹ ₹ ;	₹ ₹ ;	∢ ∢ Z Z	Y S	ζ	Z Z	 . ∠ . ∠	 & 2 2	 {	Z Z	4 4 Ζ Ζ	Y Z	Y S	2.45	2.35	2 PA	3.46	2.08	N S	93.58	89.60	00.0	4.51	NAN	3.08	3.14	3.64	5.16	4.93	7.96	₹ ₹ Z	A N	11.95 NA	Z Z	Z :	NA 2.87	A N	6.70	NA 7	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	AN 0	S Z	6.31
A Review under sage 1	4 4 4 4 Z Z Z Z Z	V Υ Σ	₹ ₹ ;	Y Y	₹ S	X Z	▼ S	Z Z	Z Z	Σ Z	 ∠ 2	A A	Z Z	¥ ≥	2.46	2.43	3 45	3.28	2.09	NA NA	60.29	35.22	0.00	4.37	ţ.V	3.37	3.27	3.94	5.17	5.30	7.77	¥ Z Z	AN C	13.07 NA	Y Y	¥ :	4.53	N A	6.36	NA 7	Z	NA	¥ X	5.94
Repair of useful defect 452 NA NA 623 Repair of useful defect 154 Repair of useful defect 154 Repair of useful assign 154 Repair of us	0.32 0.98 1.10	0.96	1.15	0.96	0.82	0.99	0.72	1.50	0.68	0.50	0.90	0.62	0.74	1.05	0.0	0.07	0.09	0.10	0.05	0.00 0.00	0.67	0.70	0.0	0.11	0.38	0.08	0.08	0.09	0.13	0.0	0.25	0.96	1.1	0.43	0.95	1.52	1.87	0.19	0.19	0.23	0.21	0.18 0.08	0.56	0.17
A	2.39 6.57 6.97 7.75	6.35 6.34	7.43	8.8 8.8 18.9	6.20	7.53	5.68	9.91	5.22	4.06	6.52	4 4 5 25 6 25	5.57	6.41	0.47	0.41	0.44	0.54	0.35	0.32	4.44	3.24	0.00	1.07	2.72	±.5	10.91	0.96	1.21	0.95	2.07	6.35	7.45	3.85 2.01	6.43	86.8	02.11	1.33	1.18	1.73	2.22	2.04 - 06	5.04	1.06
A Repair of urethra defect 158	2.79 8.23 8.96 9.84	6.51	8.73	9.31	8.50	8.86	7.10	12.52	6.70	5.17	7.47	5.06 5.45	6.78	7.89	0.57	0.53	0.52	0.68	0.46	0.42	5.94	6.74	0.00	1.49	3.22	1.35	1.23	1.36	1.64	46.	2.47	8.13	9.42	5.03 6.81	8.25	11.40	14.31	1.72	1.45	2.22	2.89	2.65	6.12	1.37
A Repair of urethra defect 4.52	4444 2222	▼	∢ ∢ ; Z Z :	▼	Y S	ζ	Y Z	Z Z	 V 2	 {	Z Z	4 4 2 2	Z Z	Υ S	1.15	1.30	1 0 A	2.01	1.32	ည် O A	82.97	78.28	0.00	2.86	2 Z	1.76	1.67	2.31	3.10	2.93	4.22	Z Z	A I	4.75 NA	Z Z	Y :	3 PA	N A	4.03	NA 4 49	2 Y	NA 1	S A	3.72
Repair of urethra defect Revise urethra, stage 2 Revise urethra, stage 1 Revise urethra, stage 1 Reconstruction of urethra Reconstruction of urethra Reconstruct urethra, stage 2 Reconstruct urethra, stage 2 Reconstruct urethra stage 2 Remove/revise met a sing Remove/revise met a sing Remove uro sphincter Remove/reput stage 2 Reput no rethra stage 2 Reput no rethra nipur Repair of urethra nipur Repair of urethra nipur Repair of urethra stricture Reput no rethra stricture Remove pents & nodes Remove p	4 4 4 4 Z Z Z Z Z	Z Z Z	Y Y	A A	Y S	X X	Υ Z	 [V 2	 {		Α Δ Ζ Ζ	Z Z	₹ S	1.16	1.38	1 7 A	1.83	1.33	 - AN	49.68	46.82	0.00	2.72	AN AN	2.05	1.97	2.61	3.11	3.30	4.03	₹ ₹ Ζ Ζ	A I	5.87 NA	Z Z	¥ :	NA 2.56	A A	3.69	A 02	Z Z	NA 0.03	N A A	3.35
44444444444444444444444444444444444444	4.52 13.92 15.45 17.47	20.49 14.99	16.89	20.97 15.33	13.28	15.15	10.83	23.20	10.38	7.61	12.81	80 80 57 57	10.78	14.04	1.21	0.98	- F	1.35	0.71	0.76	9.94	10.62	0.00	1.54	5.3	1.24	22. 22	1.24	1.93	1.90	3.49	14.24	16.77	6.77	14.38	21.59	1.81	2.31	2.48	3.27	3.25	2.75	8.79	2.45
44444444444444444444444444444444444444		e 1	N 0	Jer		ter	70	omp			ed										notx	20	. 0) s	S)	(8)	()															
444444444444444444444444444444444444	ir of urethra defect e urethra, stage 1 e urethra, stage 2 nstruction of urethra	nstruction of urethra nstruct urethra, stag	nstruct urethra, stag nstruction of urethra	nstruct urethra/bladd sling procedure	ve/revise male sling	uro/ves nck sphinc	ve uro sphincter	verseplace as sprind	ir uro sphincter	ion of urethra	rlys, transvag w/sco	ir of urethra injury . ir of urethra injury	ir of urethra injury	ir of urethra injury	urethra stricture	urethra stricture	urethra stricture	urethra stricture	on of urethra	on or uretnra on of urethra	atic microwave therr	atic of thermotx	gy surgery procedur	g of prepuce	penis lesion	uction, penis lesion(uction, penis lesion(urgery penis lesion	surg, penis lesion(s	ion of penis lesion(s	y of penis	y of penis	penis lesion, graft	penis lesion, graft	ment ot penis lesion	val of penis	ve penis & nodes.	ve penis & nodes . mcision	mcision	mcision	mcision	ir of circumcision	lotomy of penis	ment of penis lesion	ment of penis lesion
	Repa Revis Revis Reco	Heco Reco	Reco	Male	Remc	Insert	Remc	Remo	Repa	Revis	Ureth	Repa	Repa	Repa	Dilate	Dilate	Dilate	Dilate	Dilati	Dilatic	Prost	Prost	Urolo	Slittin	Drain	Destr	Cryos	Laser	Destr	Biops	Biops	Treat	Treat	lreat Partia	Remo	Rem	Nem C	Oiron	Oircu	Circu I vsis	Repa	Frent	Treati	Treat
	4444	∢∢.	∢∢.	∢ ∢	⋖ <	< <	⋖ <	(∢	∢ <	٤ ح	⋖・	∢ ∢	< ∢	⋖ <	۷ ح	∢.	∢ ⊲	< <	⋖ <	∢ ∢	. ⋖	∢ ላ	(0	∢ <	۷ ح	∢.	∢ ∢	<	∢ ⊲	< <	⋖ <	۲ ح	۷,	∢ ⊲	< <	۷.	۷ ۵	< <	∢ <	∢ ⊲	(∢	∢ 4	< <	⋖
																																												-
	3275 3400 3405 3410	53415		53431 53440	53442		53446	53448			53500	53505		53515	53600			53621	53660			53852			54015	54050			54060			54111	54112						54160	54161	54163	54164	54205	54220

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

ADL	AUDENDOM B	l <u> </u>	HELATIVE VACOE CIVIS (110 CS) AND	ובראובה)	; ;	; 	IN CHAIR ON OCEU IN DELEGIMINA INCUINITALI			/007 -		3
CPT¹/ HCPCS²	Mod	Status	Description	Physician Work RVUs	Fully Implemented Non-Facility	Year 2007 Transi- tional Non-Fa- cility PE RVUs	Fully Im- plement- ed Facil- ity PE RVUs	Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Practice RVUs	Fully Implemented Non-Facility Total	Year 2007 Transi- tional Non-Fa- cility Total	Fully Im- plement- ed Facil- ity Total	Year 2007 Transi- tional Fa- cility Total	Global
54230		∢ <	Prepare penis study	1.34	1.41	1.16	0.91	0.70	0.09	2.84	2.59	2.34	2.13	000
54235		< <	Dynamic cavernosomeny Penile injection	1.19	1.40	1.07	06:0	0.66	0.08	2.67	2.34	2.17	1.93	800
54240		۷ <	Penis study	.3	1.55	1.16	1.55	1.16	0.17	3.03	2.64	3.03	2.64	000
54240	1C	< <	Penis study Penis study	0.00	1.05	0.71	1.05	0.71	0.0	1.11	0.77	1.11	0.77	000
54250		۷ ۹	Penis study	2.22	1.25	1.00	1.25	0.1	0.18	3.65	3.40	3.65	3.40	000
54250		< <	Penis study	0.00	0.90	0.73	0.37	0.73	0.05	0.39	0.26	0.39	0.26	800
54300		∢ •	Revision of penis	11.02	Y S	Y Z	6.80	5.87	0.76	Y S	Y S	18.58	17.65	060
54308		∢ ∢	Reconstruction of urethra	13.10	Z Z	¥ ¥	7.58	6.36	0.88	K K	Y Y	20.86	20.69	060
54312		. ∢	Reconstruction of urethra	14.30	N N	N A	8.58	7.38	1.24	A A	Z Z	24.12	22.92	060
54316		∢ ⊲	Reconstruction of urethra	17.84	A Z	A Z	10.07	8.47	1.21	A Z	A Z	29.12	27.52	060
54322		< ∢	Reconstruction of urethra	13.80	Z Z	Υ Z	7.94	6.82	0.92	Z Z	Z Z	22.66	21.54	060
54324		۷,	Reconstruction of urethra	17.34	A S	Y Z	9.83	8.42	1.1	¥ :	Y S	28.31	26.90	060
•		∢ ⊲	Reconstruction of urethra	16.81	A N	A Z	9.65	8.24	1.11	A Z	A N	27.57	26.16	060
54332		< <	Revise penis/urethra	18.16	(∢ Z Z	Z Z	10.20	8.34	1.21	Z Z	ZZ	29.57	27.71	060
		∢.	Revise penis/urethra	21.37	Y S	A :	11.88	10.68	2.20	¥.	Y :	35.45	34.25	060
54340		∢ <	Secondary urethral surgery	9.53	∀	Υ <u>Υ</u>	6.43	5.38 2.38	0.63	Υ S	Y S	16.58	15.54	060
54348		< <	Secondary urethral surgery	18.11	Z Z	X X	6.40	7.86	1.23	Z Z	₹Ź	25.74	27.20	060
54352		4	Reconstruct urethra/penis	25.88	Ϋ́	A N	13.72	11.81	2.24	A A	NA	41.84	39.93	060
54360		⋖ <	Penis plastic surgery	12.60	Y S	Y S	7.54	6.40	0.84	Y S	Y S	20.98	19.84	060
54385		۲ ∢	Repair penis	16.31	(4 4 2 2	0.03	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0.93	Z Z	Z Z	25.54	25.45	060
54390		. ∢	Repair penis and bladder	22.52	Z Z	N A	7.49	8.92	1.54	A A	Z Z	31.55	32.98	060
54400		⋖・	Insert semi-rigid prosthesis	9.04	₹ Z	Υ S	5.80	4.71	0.64	¥ ż	Y S	15.48	14.39	060
54401		∢ ∢	Insert self-contd prostnesis	10.20	Z Z	A Z	8 8	6.30	0.73	A A	A A	19.25	5. 7. 2. 2. 2. 2.	060
54406		< ∢	Remove muti-comp penis pros	12.70	Z Z	Z Z	7.70	5.98	0.86	Z Z	Z Z	21.26	19.54	060
54408		۷.	Repair multi-comp penis pros	13.67	Y :	AN:	8.31	6.37	0.90	A :	¥:	22.88	20.94	060
54410		∢ <	Remove/replace penis prosth	16.42	∀	Υ <u>Υ</u>	9.45	7.32	1.10	Υ S	Y S	26.97	24.84	060
54415		< <	Remove self-contd penis pros	8.69	Z Z	Z Z	90.9	4.66	0.58	Z Z	Z Z	15.33	13.93	060
54416		4	Remv/repl penis contain pros	11.79	A	NA	7.96	6.01	0.77	A A	NA	20.52	18.57	060
54417		∢ <	Remv/replc penis pros, compl	15.88	Z Z	Y Z	9.22	6.93	1.00	¥ ž	Y Z	26.10	23.81	060
54430		< <	Revision of penis	10.88	Z Z	X X	66.9	5.57	0.72	Z Z	Z Z	18.58	17.17	060
54435		4	Revision of penis	6.67	N A	NA	4.98	3.95	0.43	A A	NA	12.08	11.05	060
54440		υ <	Repair of penis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	060
54500		< <	Preputal stretching	131	NA NA	0.85 A A	0.80	0.62	0.00	2.00 NA	S A	2.21	2.03	000
54505		< <	Biopsy of testis	3.45	Ą Z	Υ V	2.41	2.04	0.27	Ą Z	A N	6.13	5.76	010
54512		۷.	Excise lesion testis	9.19	Y S	A S	5.72	4.52	0.67	¥.	Y S	15.58	14.38	060
54520		∢ <	Removal of testis	5.22	∀	Υ <u>Υ</u>	3.76	3.03	0.50	¥ ž	¥ S	9.48	8.75	060
54530		< <	Removal of testis	9.26	(. ∢ Ζ Ζ	6.13	4.71	0.66	Z Z	Z Z	16.05	14.63	060
54535		<	Extensive testis surgery	13.01	Ϋ́	Ϋ́	7.59	6.05	0.95	ΥZ	A N	21.55	20.01	060
54550		۷.	Exploration for testis	8.27	Y :	AN:	5.38	4.20	0.59	A :	¥:	14.24	13.06	060
54560		∢ ⊲	Exploration for testis	7 50	Z Z	Z Z	6.32 4 4	2. c.	0.90	A Z	Z Z	19.14	18.26	060
54620		. ∢	Suspension of testis	5.14	N N	N A	3.28	2.64	0.37	A A	Ž	8.79	8.15	010
54640		⋖	Suspension of testis	7.53	N V	A V	2.50	4.17	0.62	N V	A A	13.65	12.32	060

090 090 090 090 090 090 090 090 090	060 060	060 060 060	090 010 090 090	060000000000000000000000000000000000000	090 090 090 090	060 060 060	000000000000000000000000000000000000000	060000000000000000000000000000000000000	000 000 000 000 000 000 000 000 000 00
19.31 10.85 17.83 20.88 20.08 2.75 2.75 3.49	9.31 9.66 8.60 7.0.97	20.58 27.96 2.26 8.94	13.37 9.89 10.09 9.25	9.45 18.31 7.43 5.95 5.14	13.53 6.76 10.01 10.67 9.39	13.02 11.24 0.00 13.67 19.16	9.23 3.51 7.32 15.50 29.26 35.49	23.43 25.43 36.14 38.74 38.74 44.39 20.49	29.90 36.12 47.14 3.91 0.00 2.76 2.53 4.85
21.06 10.48 11.83 22.80 18.78 18.78 0.00 6.10	10.35 10.76 9.40 12.18	16.47 20.21 27.31 2.46 9.76	14.70 10.94 4.67 10.27	10.48 19.79 8.19 6.54 8.38	14.62 7.51 10.89 11.13 10.26	13.42 12.21 0.00 12.44 14.16 20.70	9.93 4.03 7.77 13.42 16.95 31.57 38.17	25.38 25.38 27.48 38.81 47.38 22.04	32.16 38.92 50.48 4.18 33.01 0.00 2.77 4.72
	4 4 4 4 4 Z Z Z Z Z	3.55 N A A S N A S	X X 6.2 X X 2 X X X X X X X X X X X X X X X X	16.11 AN AN 14.08	1.39 A A A A A A A	440444 220222	6 X X X X X X X X X X X X X X X X X X X	[AN N A S S S S S S S S S S S S S S S S S
	4 4 4 4 4 Z Z Z Z Z	8 X X X & X X X X X X X X X X X X X X X	A A V A A A	13.08 1.28 1.28	0.0 0.0 0.65 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	4 4 0 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	6 5 4 5 5 5 5 5 5 4 4 6 6 6 6 6	(5.21 8.00 8.79 8.07 8.07
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	0.40 0.41 0.45 0.45	0.63 1.82 0.11 0.43	0.60 0.46 0.43 0.39	0.37 0.33 0.25 0.25	0.64 0.29 0.55 0.45 0.45	0.94 0.00 0.00 0.62 0.064	7.0.0.0.0.0.1.1.0.0.0.0.1.1.0.0.0.0.0.0.	2.5.2.1.1.1.0.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2	2.4.1. 2.1.63. 3.1.0.0.00.000.0000000000000000000000
6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6	3.28 3.38 3.74	4.81 5.66 7.29 0.72	3.42 3.42 3.47 3.28	2.45 2.84 2.46 2.41 3.39	4.41 3.38 3.29 3.29 3.76	3.92 3.61 0.00 3.73 7.73	2. 0 2. 4 4 9 6 4 4 9 9 6 4 4 9 9 6 4 4 9 9 6 4 9 9 9 9	2.5.5. 2.3.5. 2.3.5. 3.0.5. 3.	8.58 10.17 12.81 1.17 0.00 0.00 0.98 1.65
27.7 4 4 4 7 7 7 8 7 7 8 9 7 9 9 9 9 9 9 9 9 9 9 9	4 4 8 8 4 6 8 4 8 8 4 8 8 8 4 8 8 8 8 8	5.29 6.64 0.92 3.98	47.24 4.52 5.13 6.30	3.38 3.38 3.00 1.63	5.50 8.24 8.26 9.44 8.45 8.45 8.45 8.45 8.45 8.45 8.45 8	4 4 9 5 8 8 5 8 8 5 8 8 9 9 9 9 9 9 9 9 9 9	0.5. + 2. 4. 6. 6. 4. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6.	6.50 8.73 12.82 13.67 14.90 7.90 7.90	48.01 26.25 44.1. 1.0.00 1.50 1.50 1.50 1.50 1.50 1.50
	4 4 4 4 4 2 2 2 2 2	2.0.2 A A A L A	8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	11.30 A A A A A A A A A A A A A A A A A A A	0 7	4 4 0 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	4 5 0 2 2 2 2 2 4 8 4 4 4 4 4	(AN N 7.1. AN AN 7.1.29 AN AN A
	4 4 4 4 4 2 2 2 2 2	A N N S. A N A S. A A S S S S S S S S S S S S S S S S S S	3.52 A A S	8 Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	V 0 4 4 4 4 2 0 2 2 2 2 0 2 2 2 2 2	4 4 0 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	8	(A A A A A A A A A A A A A A A A A A A
25.00 25.00	5.63 5.19 6.81	13.99 18.85 1.43 5.35	8.36 6.01 6.19 6.19	7.30 11.57 11.57 3.29 3.29	8.48 6.08 6.52 7.05	8.16 7.06 0.00 6.87 8.58	65.5 4 6.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5	22.52 15.58 17.01 24.38 26.24 30.46 15.55	24.32 22.32 22.17 20.19 0.00 1.39 2.84
Orchiopexy (Fowler-Stephens) Revision of testis Repair testis into the stis (Reportation of testis (Residual States) Laparoscopy, orchiedomy Laparoscopy, orchiedomy Laparoscope proc. testis Drainage of scrotum Bloosy of epididymis									
v v v v v v v v v v v v v v v v v v v	mis esion esion	ls	Removal of hydroceles Repair of hydrocele Drainage of scrotum abscess Explore scrotum Removal of scrotum lesion	Removal of scroum Revision of scrotum Incision of sperm duct Removal of sperm duct x-ray Prepare, sperm duct x-ray	Repair of sperm duct	Revise hernia & sperm veins Laparo ligate spermatic vein Laparo proc, spermatic cord Incise sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch	Hemove sperm pouch lesion Blopsy of prostate Blopsy of prostate Drainage of prostate abscess Drainage of prostate abscess Removal of prostate augery Extensive prostate surgery	Extensive prostate surgery Removal of prostate Removal of prostate Extensive prostate surgery Extensive prostate surgery Extensive prostate surgery Percut/needle insert, pros Surgical exposure, prostate	Extensive prostate surgery Extensive prostate surgery Laparo radical prostatectomy Electroejaculation Cryoablate prostate Genital surgery procedure Genital surgery procedure Drainage of gland abscess Surgery for vulva lesion
Orchiopexy (Fowler-Stephens) Revision of testis Repair testis injury Relocation of testis(es) Laparoscopy, orchiocomy Laparoscopy, orchiopexy Laparoscope proc, testis Laparoscope proc, testis Drainage of scrotum	on of epididy epididymis le epididymis le of epididym	of epididym f spermatic c f spermatic c of hydroceli of hydroceli	of hydrocele in hydrocele of scrotum is conturn of scrotum of scrotum of scrotum is of scrotum is the scrotum i	Hemoval of scrotum Revision of scrotum Revision of scrotum Incision of sperm duct Removal of sperm duct Prepare, sperm duct x-	Repair of sperm duct. Ligation of sperm duct Removal of hydrocele Removal of sperm corr Revise spermatic cord Revise spermatic cord Revise spermatic cord	ernia & sper gate sperma roc, spermal erm duct po erm duct po sperm duct	Hemove sperm pouch lesic Biopsy of prostate	Extensive prostate surgery Removal of prostate Removal of prostate Removal of prostate Extensive prostate surgery Extensive prostate surgery Extensive prostate surgery Percut/needle insert, pros	Extensive prostate surgery
Orchiopexy Revision of Repair testi Relocation Laparoscop Laparoscop Laparoscop Drainage of Bioosy of ed	Explorati Remove Remove Removal	Hemoval Fusion o Fusion of Drainage Removal	Removal Repair of Drainage Explore s Removal	Revision Revision Incision C Removal Prepare,	Repair or Ligation or Removal Removal Revise species s	Revise h Laparo li Laparo p Incise sp Incise sp Remove	Hemove Biopsy o Biopsy o Drainage Drainage Removal Extensive	Extensive programmer of Removal of Removal of Removal of Extensive programmer of Extensive programmer of Removal of Remov	Extensive Extensive Laparo ra Electroeja Cryoabla Genital selectroeja Drainage Drainage Surgery f
⋖ ⋖⋖⋖⋖	<<<<<	4444	⋖ ⋖⋖⋖⋖	.	⋖ ⋖⋖⋖⋖	440444	বিবৰবৰবৰ	(বেবববববব ব	ববববব ০ববব
54650 54660 54670 54690 54692 54699 54700			55041 55060 55100 55110				55580 55700 55705 55720 55721 55801		55862 55865 5586 55870 55873 55899 56405
\$ \$\tilde{V}\$ \$\ti	່ດ້ວ່ດວ່	ນີ້ ນີ້ ນໍ້ ນໍ້ ນໍ້	2 2 2 2 2	2 2 2 2 2 2	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	7 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Year 2007 Transi- tional Fa- cility Total	88 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9
Fully Im- plement- ed Facil- ity Total	8.5.00 1.5.00
Year 2007 Transi- tional Non-Fa- cility Total	8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
Fully Implemented Non-Facility Total	8 8 8 8 7 7 7 8 8 8 8 8 8 8 8 8 8 8 8 8
Mal-Prac- tice RVUs	0.000 0.0000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.0000 0.0000 0.0000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.000000
Year 2007 Transi- tional Fa- cility PE RVUs	4 4 4 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
Fully Im- plement- ed Facil- ity PE RVUs	6.55
Year 2007 Transi- tional Non-Fa- cility PE RVUs	2.2.2.00.00 2.2.2.2.00 2.2.2.2.00 2.2.2.2.00 2.2.2.2.00 2.2.2.2.00 2.2.2.2.00 2.2.2.2.00 2.2.2.2.00 2.2.2.2.00 2.2.000 2
Fully Implemented Non-Facility	1. 1. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
Physician Work RVUs	
Description	Lysis of labial lesion(s) Destroy, vulva lesions, sim Destroy vulva lesions, sim Biopsy of vulva/perineum Biopsy of vulva/perineum Biopsy of vulva/perineum Partial removal of vulva Extensive vulva surgery Remove vagina desions, comple Bepair of vagina Exambiopsy of vulva w/scope Exploration of vagina Bepair of vagina Bepair of vagina Beptory vag lesions, comple Bestroy vag lesions, comple Benove vagina tissue, part Remove vagina tissue, comple Remove vagina infection Remove vagina infection Remove vagina infection Remove vagina infection Remove vagina lesion Treat vagina infection Treat vagina lesion Repair of urethral lesion Repair of vagina Repair of urethral lesion Repair of vagina
Status	444444444444444444444444444444444444444
Mod	
CPT¹/ HCPCS²	56441 56601 56605 56605 56605 56606 56606 56603 56603 56603 56603 56603 56603 56603 56603 56603 56700 56700 57000 57000 57100

9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	000000000000000000000000000000000000000
25. 25. 25. 25. 25. 25. 25. 25. 25. 25.	25.27 25.27 33.58 35.23 35.03 46.64 64.54 64.54 64.67 22.63 26.58 28.28 28.28
23.55 24.55 25	25.78 26.50 27.78 27.78 27.78 27.38 27.38 27.38 27.38 27.38
2 X X X X X X X X X X X X X X X X X X X	
Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	(
$\begin{array}{c} 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 $	2.2 4 4 4 2 2 4 4 4 4 4 4 4 4 4 4 4 4 4
7.4.7.7.6.6.6.4.4.4.6.7.7.4.4.4.6.8.4.4.6.7.7.4.6.7.4.	8.59 7.26 9.43 7.18 9.53 12.57 17.19 6.48 8.04 6.79
7.4 7.6 6.7 6.4 7.6 7.4 7.7 7.6 7.7 7.7 7.7 7.7 7.7 7.7 7.7 7.7	7.7.6 6.53 6.53 6.33 6.33 7.02 7.02 6.53 6.53 6.53 6.53 6.53 6.53 6.53
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN	[
Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	
6. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	20.20 17.17 17.17 16.46 22.29 30.70 30.73 13.38 13.38 17.77 17.77 17.77
Suspension of vagina Colpopexy, extraperitioneal Colpopexy, intraperitioneal Repair paravaginal defect Revise/remove sling repair Repair bladder defect Repair bladder defect Repair bladder defect Repair bladder defect Construct vagina with graft Change vaginal graft Change vaginal graft Change vaginal graft Change vaginal lesion Repair rectum-vagina lesion Repair urethrovaginal lesion Repair urethrovaginal lesion Repair urethrovaginal lesion Repair urethrovaginal lesion Repair vagina Fistula repair, descope Repair vagina Fistula repair, descope Repair vagina Pelvic examination Repair vagina w/scope Exam/biopsy of vag w/scope Baycsopy, surg, colpopexy Exam of cervix w/scope Baycsopy, surg, colpopexy Exam of cervix w/scope Baycsor cervix w/scope Baycsor cervix w/scope, leep Conz of cervix w/scope, leep Conz of cervix w/scope, leep Bordocev curettage w/scope Bordocev curettage w/scope Endocev curettage Cauterization of cervix Conization of cervix Removal of residual cervix Removal of residual cervix Removal of residual cervix Remove cervix/repair vagina Remove cervix/repair vagina Remove cervix/repair vagina Remove cervix/repair pelvis Remove cervix/repair pelvis Remove cervix/repair vagina	
ritioneal introneal introneal introneal introneal defect cot gigna introneal introneal introneal introneal introneal introneal introneal system introduced	n complex y y omy ontents n y omy n ong n ong n epair ele repair
Suspension of vagina	ctomy vag in ctomy abdounce of comy abdounce of ctomy abdounce of ctomy in the ctom
Suspen Colpop Repair Repair Repair Constr. Constr. Constr. Constr. Constr. Constr. Constr. Change Repair Remove Re	Myoune Myoune Tokal hy Total hy Partial I Extensi Extensi Extensi Extensi Vaginal Vag hys Vag hys Vag hys
8884788847888658888888888888888888888888	0,1,3,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57280 57283 57284 57284 57284 57289 57289 57290 57290 573000 57300	58146 58146 58146 58152 58180 5820 58210 58240 58260 58263 58263 58263

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2007—Continued

Global	X 250 000 000 000 000 000 000 000 000 000
Year 2007 Transi- tional Fa- cility Total	83 83 83 83 83 83 83 84 7 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Fully Implemented Facility Total	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Year 2007 Transi- tional Non-Fa- cility Total	A A A A A A A A A A A A A A A A A A A
Fully Implemented Non-Facility Total	A N N N N N N N N N N N N N N N N N N N
Mal-Prac- tice RVUs	2.2.29 2.2.29 2.2.29 2.2.29 2.2.30 2.30
Year 2007 Transi- tional Fa- cility PE RVUs	7 7 7 8 8 9 9 7 7 9 9 8 9 9 9 9 9 9 9 9
Fully Im- plement- ed Facil- ity PE RVUs	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Year 2007 Transi- tional Non-Fa- cility PE RVUs	AAN NA
Fully Implemented Non-Facility	A A A A A A A A A A A A A A A A A A A
Physician Work RVUs	58 88 82 82 82 82 82 82 82 82 82 82 82 82
Description	Hysterectomy/revise vagina Hysterectomy/revise vagina Hysterectomy/revise vagina Extensive hysterectomy Vag hyst complex Vag hyst two & repair, compl Vag hyst winch to, complex Vag hyst wince too complex Artificial insemination Hysteroscopy, temove adhexa Laparoscopy, temove adhexa Laparoscopy, temove adhexa Laparoscopy, temove adhexa Laparoscopy, tubal ablock Laparoscopy, tubal acutery Laparoscopy, tubal cautery Laparoscopy, tubal ca
Status	
Mod	
CPT ¹ / HCPCS ²	58275 58286 58285 58286 58290 58291 58291 58291 58291 58300 58321 58322 58322 58345 58345 58346 58346 58346 58346 58346 58346 58346 58346 58356

0000000000000000000000000000000000000	WIND WIND WIND WIND WIND WIND WIND WIND
23.22 23.25 20.05 20	21.61 24.74 2.88 2.58 9.07 15.97 3.50 53.23
2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.	20.45 20.45 20.45 20.45 20.45 20.45 3.29 24.25 24.25 24.25
2. 2. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4.	1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
X X 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	20.62 20.63 20.63 20.63 20.63 20.63 20.63
$\begin{array}{c} \cdot \cdot \cdot \cdot \circ $	3.3.5.4 3.3.5.1 3.3.5.1 3.0.5.0 3.0.5.0 5.0.5.0 5.0.5.0 5.0.5.0 6.0.5.0
6 6 6 7 8 8 8 8 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1	15.08 4.92 5.97 0.59 0.59 0.81 1.81 3.16 0.87 16.95
8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	2.97 0.65 0.65 0.65 0.65 0.66 0.66 16.03
AN 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	A N N N A S S S S S S S S S S S S S S S
8	A N N A A A A A A A A A A A A A A A A A
13. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4.	26.53 13.48 15.26 1.71 1.61 10.84 2.13 30.05
(s) ((s) ((s) ((s) ((s) ((s) (s) (s) (s)	
Remove tubal obstruction Create new tubal opening Drainage of ovarian cyst(s) Drainage of ovarian cyst(s) Drainage of ovarian cyst(s) Drain ovary abscess, pend Transposition, ovary(s) Biopsy of ovary(s) Partial removal of ovary(s) Removal of ovary(s) Resect ovarian malignancy Transfer of embryo Transfer of embryo Transfer of embryo Transfer of embryo Genital surgery procedure Amniocentesis, therapeutic Fetal contract stress test Fetal contract stress test Fetal contract stress test Fetal contract stress test Fetal non-stress test Fetal non-stress test Fetal monitor/interpret only Transabdom amnioinfus w/us Fetal monitor/interpret only Treat ectopic pregnancy Treat ectopic pregnan	Obstetrical care Obstetrical care Obstetrical care Obstetrical care Antepartum manipulation Antepartum care only Antepartum care only Care after delivery Cesarean delivery Cesarean delivery
Remove tubal obstruction Create new tubal opening Drainage of ovarian cyst(s). Drain ovary abscess, open Drain ovary abscess, percut Transposition, ovary(s) Biopsy of ovary(s) Removal of ovary(s) Removal of ovary(s) Resect ovarian malignancy. Resect ovarian malignancy. Resect ovarian malignancy. Tan trad dissect for debulk. Tan trad dissect for debulk characteristic of embryo. Exploration of abdomen Retrieval of ocyte Can transfer of embryo Can transfer of embryo Aminocentesis, therapeutic Aminocentesis, Aminocentesis, Aminocentesis, Aminoc	Obstetrical care Antepartum manipuli Antepartum care onli Care after delivery Cesarean delivery Cesarean delivery
Remove tubal or Create new tubal or Create new tubal Drainage of ove Drain ovary abs Drain pelvic abs Transposition, or Biopsy of ovarian Hersect ovarian Resect ovarian Pransfer of emplesse, omentector Exploration of a Retrieval of occ Transfer of emplesses, omentector of Exploration of a Retrieval of occ Transfer of emplesses, Fetal contract s Fetal non-stress Fetal non-treas Fetal non-stress Fetal non-treas Fetal non-stress Fetal non-treas Fetal non-trea	Obstetrical care Obstetrical care Obstetrical care Obstetrical care Antepartum mar Deliver placenta Antepartum care Antepartum care Care after delive Cesarean delive
020000000000000000000000000000000000000	
58776 58877 58880 58880 58882 58882 58882 58882 58890 58990 58997 58997 58997 58990 589000 589000 589000 589000 589000 589000 589000 589000 5	59400 59400 59410 59411 59414 59425 59426 59426 59426 59430 59510

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	MMMM MMMMM MMMMM MMMMM MMMMM MMMMM MMMMM
Year 2007 Transi- tional Fa- cility Total	26.51 27.52 28.53 28
Fully Implemented Facility Total	821 84 24 24 24 24 24 24 24 24 24 24 24 24 24
Year 2007 Transi- tional Non-Fa- cility Total	A Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
Fully Implemented Non-Facility	0.000 A A A A A A A A A A A A A A A A A
Mal-Prac- tice RVUs	4.1. 2.2. 2.2. 2.2. 2.2. 2.2. 2.3. 2.3. 2
Year 2007 Transi- tional Fa- cility PE RVUs	4 8 8 8 5 5 6 6 6 7 7 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8
Fully Im- plement- ed Facil- ity PE RVUs	2 2 2 4 4 6 6 6 6 8 8 6 8 8 8 8 8 8 8 8 8 8 8
Year 2007 Transi- tional Non-Fa- cility PE RVUs	A A A A A A A A A A A A A A A A A A A
Fully Implemented Non-Facility	X X X X X X X X X X X X X X X X X X X
Physician Work RVUs	88 8 2 2 2 2 6 6 6 6 6 6 6 6 6 6 6 6 6 6
Description	Cesarean delivery Neac delivery Neac delivery Noac delivery Noac delivery Noac delivery Noac delivery Noac delivery Noac delivery Attempted vaca delivery Abortion Ab
Status	
Mod	
CPT¹/ HCPCS²	59515 59610 59612 59612 59614 59614 59614 59614 59614 59614 59616 59616 59620 59841 59840 60200 60210 60100 60210 60220

000000000000000000000000000000000000000	000000000000000000000000000000000000000	060 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	060 060 060 060 060 060	060 060 060 060 060 060 060 060 060 060
2.73 3.25 3.25 3.44 3.44 2.11 10.87 8.64 2.15 17.75 33.17	24.30 30.86 31.40 10.06 11.36 23.73 23.73 41.66 49.78	4 4 9 28 4 9 28 4 9 28 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	3.1.45 3.5.99 3.5.99 5.1.42 4.7.21 5.2.17 5.2.17 4.7.03 4.7.03 4.7.03 4.7.03 5.8.61 5.8.66	54.67 65.37 47.00 47.00 70.16 70.16 97.14 97.14 81.84 82.54 88.42 74.84 74.84 74.84 74.84 74.84 74.84 74.84 74.84 74.84 74.84 74.84 76.01
2. 2. 2. 3. 3. 4. 4. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	24.87 31.82 31.82 31.44 12.44 12.43 23.79 49.60 51.71	4.9.79 4.8.20 5.2.17 5.9.39 5.9.88 5.9.88 4.6.73 4.6.73	3.0.3 3.0.3	54.96 64.54 64.54 66.68 67.24 67.24 67.55 68.36 69.68 69.69 69
4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4		4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4		4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	2. 2. 4. 4. 2. 2. 2. 2. 4. 4. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.	6.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6.	7.7.4 6.88 7.7.7.7.7 7.7.7.7 7.7.7.7 7.88 8.00 1.7.9 8.00 9.00 9.21	7.33 6.52 6.52 6.33 6.33 7.46 7.46 7.76 7.76 7.76 7.76 7.76 7.76
20.1.1.4.0.1.2.4.1.1.0.2.4.1.1.0.2.4.1.1.0.2.4.1.1.0.1.0.1.1.0.1.1.0.1.1.0.1.1.0.1.1.0.1.1.0.1.1.0.1.1.0.1.1.0.1.1.0.1.0.1.1.0.1.1.0.1.1.0.1.1.0.1.1.0.1.1.0.1.1.0.1.1.0.1.1.0.1.1.0.1.0.1.1.0.1.0.1.1.0.1	7.38 9.89 9.84 9.84 7.77 7.74 15.25 15.25	46.00 6.00	10.25 16.64 16.36 15.36 15.39 16.09 13.67 13.67 10.76 10.26	20.93 14.46 14.46 14.46 10.01 10.02 10.03
2.2.1.1.2.3.1.2.3.1.2.3.1.2.3.1.2.3.1.3.3.0.0.3.3.3.3.3.3.3.3.3.3.3.3.3.3	2.48 9.48 9.88 2.18 2.44 7.49 12.61 15.07	2.4.4.2.9.2.2.4.4.2.9.2.9.2.9.4.1.1.2.9.2.9.2.9.4.1.1.2.9.2.9.2.9.2.9.2.9.2.9.2.9.2.9.2.9	1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9	17.08 14.53 14.53 14.53 14.53 16.56 25.64 25.64 25.64 25.64 15.78 15.78 16.26 18.18 10.26 11.76 11.76 11.76 11.76 11.76
4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4		4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	4	
4444444444444		4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
6.5.1. 6.5.1. 6.5.1. 6.6.0. 6.0.0. 6.0.0. 6.0.0. 6.0.0. 6.0.0.	75.48 17.34 17.34 17.38 11.38 12.38 23.27 28.46	27.88 29.772 20.328 30.328 34.00 28.46 28.46 29.46	2.7.91 2.7.93 2.7.93 2.7.93 2.7.93 2.7.93 2.7.93 2.7.93 2.7.93 2.7.93 2.7.93 2.7.93	26.95 26.95 26.95 26.95 26.95 39.61 39.61 46.78
				Removal of brain lesion Removal of brain abscess Removal of brain abscess Removal of brain elsion Removal of brain lesion
y fluid y fluid fluid nal luid nod redure trion y y y y y y y y y y y y y	age cold cold cold cold cold cold cold cold	ge	object ression refs junction object y y y wound y y y y y y y y l bone	esion coss coss coss coss coss coss coss co
cranial cavity brain cavity brain cavity brain cavity into brain cap brain canal floral canal floral canal for implanta for drainage for puncture for drainage unil for biopsy unil for drainage in the capacity canal c	ull for arains ull & remove ull for darins ull implant (in-fluid devi ull & explore ull & explore ull for explore Ill for darainag	ull for draina, all for draina	infifremove oral decomp oral decomp oral decomp oral decomp oral for surger ull for surger oral for surger of skull lesif surger of skull lesif surger infected skull surger surger infected skull surger surger of skull lesif surger surger of skull lesif surger s	of brain lesi brain lining I of brain abs of brain lesi brain lesi brain lining I of brain lesi of brain lesi
Remove Remove Remove Injection Brain car Twist dril Drill skull Burr holel Pierce sk	Pierce sk Pierce sk Pierce sk Pierce sk Pierce sk Open sku	Open skr Open skr	Explore C Subtemp Incise SK Incise S	Removal Removal Implt bra Removal
				444444444444444
	61151 61154 61216 61215 61253 61305			61510 61512 61514 61517 61518 61520 61521 61522 61522 61523 61533 61533 61533 61533 61533 61533 61533 61533 61533

Addendum B.—Relative Value Units (RVUS) and Related Information Used in Determining Medicare Payments For 2007—Continued

					\ V o					_			
Mod	Status	Description	Physician Work RVUs	Fully Implemented Non-Facility	Tear 2007 Transi- tional Non-Fa- cility PE RVUs	Fully Im- plement- ed Facil- ity PE RVUs	Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Practice RVUs	Fully Implemented Non-Facility Total	Year 2007 Transi- tional Non-Fa- cility Total	Fully Implemented Facility Total	Year 2007 Transi- tional Fa- cility Total	Global
	∢ <	Removal of brain tissue	39.31	A S	A S	18.80	16.18	6.92	Y S	A Z	65.03	62.41	060
		Removal of brain tissue		Z Z	Z Z	15.91	16.91	8.30	Z Z	Z Z	55.45	56.45	060
		Incision of brain tissue		AN	A N	16.10	16.18	6.58	A A	N	53.44	53.52	060
		Removal of brain tissue		Y :	Y :	16.23	17.42	8.01	Υ :	¥:	57.22	58.41	060
		Removal of brain tissue		Υ S	Υ S	16.35	16.37	7.54	Υ S	¥ ž	55.02	55.04	060
		Remove & treat brain lesion		4	4	14.39	13.96	5.95	₹	₹ ₹	47.56	47.13	060
		Excision of pituitary cland		(4 2 Z	ζ	16.62	17 27	7.65	(d	X Z	57.53	58 17	060
		Removal of pituitary gland		. ∠ Z	Z Z	11.37	12.43	3.42	Z Z	Z Z	38.02	39.08	060
		Release of skull seams		A N	A N	5.70	6.62	0.98	Ϋ́	Z	22.06	22.98	060
		Release of skull seams		ΥN	A N	6.71	8.51	1.06	Ϋ́	AN	27.99	29.78	060
		Incise skull/sutures		A V	A N	12.76	11.71	4.64	A N	ΥZ	41.36	40.31	060
		Incise skull/sutures		A N	A N	13.73	13.65	5.78	A A	A N	42.61	42.53	060
		Excision of skull/sutures		A V	A N	8.24	12.70	1.36	A A	ΥZ	35.89	40.35	060
		Excision of skull/sutures		A V	A N	18.83	19.19	8.48	A A	ΥZ	61.05	61.41	060
		Excision of skull tumor		ΑN	AN	14.31	15.01	5.15	AN	Ϋ́	47.77	48.47	060
		Excision of skull tumor		Ϋ́	AN	16.25	17.77	8.75	A N	Ϋ́	59.53	61.05	060
		Removal of brain tissue		Ϋ́	A N	16.65	17.49	6.92	Ϋ́	Ϋ́	55.83	26.67	060
		Incision of brain tissue		Y X	A N	16.84	19.71	6.52	AN	Z	60.12	65.39	060
		Bemove foreign body brain		A Z	Ą	14 16	13 97	2 86	AN	A Z	46.35	46.16	060
		Indice chill for brain wound		Z Z	Ž Z	15.01	7.5	22	ΔZ	ζ Z	50.02	50.10	
		Skull base/brainstem surgeny		ζ Δ	Z Z	1. 7. 1. 7. 7.	ο α Ε	7	(ζ	57.03	90.5	060
		Skull base/brainstem surgery		ζ Φ	Z Z	20.00 88.00	32.53	2. 7.	2 2	ζ	27.70	9 6	060
		Orani Dase/Dialitisterii sulgely		2 2	2 2	20.00	36.32	0.00	2 2	2 2	1.00	93.1	000
		Craniolacial approach, skull		¥ \$ 2	¥ \$	20.09	24.30	ئ ئ	Υ Υ	ζ <u>ς</u>	200.0	01.98	060
		Craniotacial approach, skull		¥ ;	₹ :	24.86	23.80	19.51	Ψ.	Y :	67.55	66.49	080
		Craniofacial approach, skull		Y V	A V	30.37	28.07	7.19	Y Y	Y Z	72.39	40.02	060
		Craniofacial approach, skull		A N	Ϋ́	25.79	25.28	9.18	A A	Ϋ́	73.34	72.83	060
		Orbitocranial approach/skull		AN	Ϋ́Z	25.56	24.78	8.16	AN	ΥN	71.29	70.51	060
		Orbitocranial approach/skull		AN	Ϋ́Z	24.83	26.08	7.01	AN	Ϋ́ Z	74.24	75.49	060
		Besect nasonharvnx skull		Ą	ĄZ	23.97	22 93	4 36	ΔN	AN	55.53	54 49	060
		Infratometral approach/skull		Z Z	ŽŽ	25.52	27.36	9 6	2 2	ZZ	20.52	25.07	
		Infatomoral paragoph/phill		2 2	2 2	20.70	25.72	2.0	2 2	2 2	12:07	0.00	
:		Illirateriporal approacri/skull		¥ :	¥ :	22.73	70.07	0.0	ξ :	۲ :	70.10	20.02	080
		Orbitocranial approach/skull		ΨZ	Y Z	27.58	26.77	10.04	AN	A A	80.56	79.75	060
		Transtemporal approach/skull		Ϋ́	Ϋ́Z	19.29	21.59	3.97	AN	Ϋ́	56.75	29.02	060
		Transcochlear approach/skull		Ϋ́	Ϋ́	18.52	22.96	3.39	ΑN	Ϋ́	61.16	65.60	060
		Transcondylar approach/skill		ΔN	ΔN	22.86	20 96	ά	ΔN	ΔN	72 34	72 44	060
		Transportational practication of the community of the com		Ž	Ž	5.50	50.10	9 9	2	Ž	20.10	90.70	
		I alispetiosal apploacilismii		2 2	2 2	70.0	22.03	0 0	ζ <u>ς</u>	2 2	102.04	9.6	000
		Resecvexcise cranial lesion		۲ :	¥ :	18.31	19.6	3.78	¥ :	¥ :	20.182	52.95	080
		Hesect/excise cranial lesion		ΨZ	Y Y	22.32	20.95	6.61	AN	A A	59.93	98.96	060
		Resect/excise cranial lesion		Ϋ́Z	Ϋ́Z	17.57	20.86	2.85	A V	ΨZ	52.74	26.03	060
		Resect/excise cranial lesion		Ϋ́Z	Ϋ́Z	24.31	24.94	8.94	AN	Ϋ́	75.13	75.76	060
		Resect/excise cranial lesion		₹Z	Ž	20.51	22.96	6.88	AN	Ϋ́	68.15	70.60	060
		Besect/excise cranial lesion		ΔN	AN	26.51	26.56	10 72	AN	AN	82 62	82 67	060
		Transport artors, ginne		Ź	Ź	20.00	7 2 2	1 1 1 1	Ź	Ź	10.01	10.0	777
		Tiensect arterly, sillus		2 2	2 2	2 7	5.0	1 1.	2 2	2 2	0.0	9.6	177
		Iransect artery, sinus		42	¥Z	5	2.62	99./	Y.	42	48.48	48.84	777
		Transect artery, sinus		ΨZ	AN	2.80	3.57	1.88	AN	Ψ N	12.09	12.86	777
		Transect artery, sinus		Ϋ́Z	Ϋ́Z	8.15	12.02	4.30	AN	Ϋ́	40.29	44.16	222
		Remove aneurysm. sinus		Ϋ́Z	Ϋ́Z	27.54	26.58	8.42	ΑN	Δ Z	80.84	79.88	060
		Becent/expise legion skull		ΔZ	ΔZ	10.35	24 20	177	ΔN	ΔN	20 67	62 17	000
		nesection lesion, skull		2 2	2 2	19.00	00.12	7.7	ζ <u>ς</u>	2 2	50.00	7 7 00	000
		Hesect/excise lesion, skull		ΨZ Z	Y Y	26.45	28.10	8.24	AN	A A	81.23	82.88	060
		Repair dura		Ϋ́Z	Ϋ́Z	10.11	10.36	3.71	AN	Ϋ́	32.34	32.59	060
		Benair dura		Ą	Ą	10.97	11 92	3 94	ΔN	AN	36.86	37.81	060
		Endowood to manage wood one		2 2	2 2	0.97	20.1	10.0	2 2	2 2	30.00	5.5	000
		Endovasc tempory vessel occi		¥ \$	ξ <u>ς</u>	04.5	0.0	0 1	¥ \$	ξ <u>2</u>	04.40	9. 60	000
:		I ranscath occlusion, chs		۲ <u>۲</u>	AN AN	0.80	0.8/	- SS.	Z Z	ΨZ	28.8	78.34	200
:		Tropogoth coolinging non con									.		

No. of the control																																						_	_	_	_	_	_
Note	060 060 060	060	060	060	060	060	060	060	060	060	060	060	060	060	060	ZZZ	060	030	77060	ZZZ	060	060	060	010	060	060	060	060	060	060	060	060	060	060	060	ZZZ	ZZZ	060	060	060	060	060	010
National State Nati	35.03 38.35 57.56 110.11	117.53	54.57 94.56	104.19 109.64	90.28	33.27	65.60	49.23	66.93	36.84	35.10	34.10	38.25	20.65	32.20	6.69 23.58	38.90	37.86	12.04	17.07	29.49	13.30	14.71	10.16	20.79	38.13	40.73	45.54 25.24	47.92	45.10	26.26	28.79	25.60	35.16	30.23	3.32	5.20	38.31	30.41	49.50	39.59	22.05	9.34
Note the properties of the p	30.54 33.46 57.12 106.43	72.17	53.94 92.49	104.82	87.45	33.55	64.37	49.01	66.01	28.39 36.21	35.37	34.55	36.46	22.06	31.95	6.19	38.25	38.39	54.92	16.28	28.69	13.97	16.30	10.10	22.06	38.28	40.02	42.09 44.03	47.41	43.06	26.47	28.98	26.16	34.64	29.79 35.43	3.24	4.89	38.33	30.87	49.48	39.38	22.49	10.37
Note that the control of shall be control of	4444 2222	V Υ Σ	A A	ς ς Z Z	Y Z	X X	Y Z	X Z	Y :	¥	Y Z	Y Z	Z Z	Y Z	Ϋ́	Y Z	ZZ	Y Z	4 4 2 2	₹ Z	Α Δ Ζ Ζ	Z Z	Y Z	X X	Ϋ́	4 4 2 Z	A :	4 4 2 2	Z V	∀	¥ Z Z	A S	¥ Z Z Z	Y :	A A	Z Z	Y S	 &	Z Y	Z Z	ξ ζ Z Z	A Z	Z Z
No. Intercential angloids No.	4 4 4 4 2 2 2 2 2	∢ ∢ ; Z Z ;	4 4 Z Z	 ∢ ∢ Z Z	₹ ₹	Z Z	₹ Ş	ζ	¥:	∀ ₹ ₹	Y Y	∀	ξ ζ Ζ	∀	A A	ΥZ Z	Z Z	₹ Z	₹ ₹ Z Z	A A	₹ Z	Z Z	∀		Y S	₹ ₹ Z Z	₹ Z	4 4 Ζ Ζ	Z Y	Υ Ζ Ζ	Z Z	₹ S	₹ ₹ Z Z	¥.	Α Z	Z Z	Y S	 4			 {	 ∀	 {
N Intercent angoes Name	2.20 7.93 15.85	16.66	13.39	12.81	12.98	4.05	8.84	4.51	9.39	2.78	4.71	4.55	3.54	2.87	4.45	0.79	4.94	5.41	5.41	5.41	3.86	1.66	1.59	- 1 8 ES	1.06	5.12	4.83	5.49 6.09	4.52	2.99	3.46	3.75	3.36	4.49	3.61	0.48	0.77	5.17	4.00	5.36	3.00 4.97	2.79	0.92
No. Intracental angiopsty, wiston 22 20 0 NA NA NA Intracental angiopsty, wiston 22 22 14 43 NA NA Intracental angiopsty wiston 22 22 NA NA NA Intracental angiopsty wiston 22 22 NA NA NA Intracental angiopsty wiston 23 24 NA NA NA Intracental angiopsty wiston 23 24 NA NA NA Intracental angiopsty 25 24 NA NA NA NA NA NA NA NA	10.99 11.91 17.29 30.99	33.61	16.51 26.78	28.22 27.75	26.86	10.56	18.84	13.57	19.49	9.51	10.70	10.97	11.66	6.38 50	10.04	1.87	11.84	11.95	17.69	3.75	9.43	4.80	5.83	3.65	5.94	11.76	12.55	13.30	15.20	17.80	8.39	9.11	7.17 8.23	10.72	9.48	0.84	1.43	12.10	10.07	14.95	12.21	7.23	2.78
Name	6.50 7.02 16.85 27.31	30.29	15.88 24.71	28.85 30.92	24.03	10.84	17.61	13.35	18.57	8.13	10.97	11.42	9.87	7.79	9.79	1.37	11.19	12.48	16.69	2.96	8.63 8.83	5.47	7.42	3.59	7.21	11.91	11.84	13.97	14.69	15.76	8.60	9.30	8.79	10.20	9.04	0.76	1.12	12.12	10.53	14.93	12:00	7.67	3.81
N Intracranial viscoles along the process of a proces		4 4 ; Z Z ;	Ψ Ψ Z Z	▼	₹ ₹	 ₹ Z	₹ S	 Σ Ζ	¥:	∀	₹ Z	₹ ¤	Z Z	₹ ¤	Y Y	▼	Z	Y S	▼	N A	ΨZ Z	Z Z	₹ S	¥ ZZ	¥ ž	₹ ₹ 2 Z	¥.	Ψ Ψ Z Z	Z Z	Y S	¥ Z Z	₹ S	₹ ₹ Z Z	Y :	ΨZZ	Z Z	₹ Z	 4	 Z		 {	▼	 (
Intracranial angiopisty vistent		▼	A A Z Z	 ∢ ∢ Z Z	₹ Z	Z Z	₹ Z	Y Y Z Z	¥:	▼	₹ Z	¥ ¤	Z Z	¥ ¤	Y Y	▼ 2 Z 2	 	Y S	▼	A N	¥ ¤	Z Z	₹ Z	¥ Z Z	¥ S	₹ ₹ 2 Z	¥.	4 4 Ζ Ζ	Z Z	Y S	¥ Z Z	₹ Z	ξ ς Z Z	¥:	ΨZZ	Z Z	₹ Z	 &	\ \ Z		 {	 ∢	 {
ZZ444444444444444444444444444444444444	22.03 24.24 32.34 63.27	41.43 67.26	31.14 54.39	63.16 69.39	50.44	18.66	37.92	31.15	38.05	17.48	19.69	18.58	23.05	11.46	17.71	4.03	22.12	20.50	32.82	7.91	16.20	6.84	7.29	5.18	13.79	21.25	23.35	24.63	28.20	24.31	14.41	15.93	14.01	19.95	17.14	2.00	3.00	27.04 	16.34	29.19	22.41 	12.03	5.64
ZZ444444444444444444444444444444444444																																											
ZZ444444444444444444444444444444444444	tent ary	ary ary	ary ary	mpk	nple		3d	30 m		>>						nputer		7	idal	addll		ctrode	rray	seiver		,			· +-	u								edoos	emoval	scope	scope	nunt	
ZZ444444444444444444444444444444444444	angioplasty igioplsty w/s vessel surge vessel surge	vessel surge vessel surge	vessel surge vessel surge	ysm repr, co ysm repr, co	ysm repr, sii	artery	lation to he	uation to he	kull arteries	brain surger brain surger	brain biopsy	/ w/ct/mr gui	for treatmen	inal nerve .	tion beam	ry using con	roelectrodes	roelectrode	roelectrae, a roelectrode	roelectrde, a	roelectrodes	ove neuroele	eurostim 1 a	ove neurored	racture	racture of head injur	, fluid leaka	of skull defec	of skull defec	cavity lesion	repail cull defect	cull defect	uli piate/flap uli piate/flap	cull & brain .	cull with graf	ap to fix sku	scopy add-or	n w/scope . Iloid cyst w/s	scopy w/fb re	ain tumor w/s	ult turrior w/s ain cavity sh	ain cavity st	allı cavııy sı gate cathete
ZZ444444444444444444444444444444444444	Intracranial Intracran ar Intracranial Intracranial	Intracranial Intracranial	Intracrania Intracranial	Brain aneur Brain aneur	Brain aneur	Clamp neck	Revise circu	Revise circu	Fusion of sl	Incise skull/ Incise skull/	Incise skull/	Brain biops	Incise skull	Treat trigen	Focus radia	Brain surge	Implant neu	Implant neu	Implant neu Implant neu	Implant neu	Implant neu	Revise/rem	Insrt/redo n	Revise/rem	Treat skull 1	Treatment of	Repair brain	Reduction of	Reduction	Repair skull	Repair of shall	Repair of sh	Replace ski	Repair of sh	Repair of st	Retr bone f	Neuroendos	Dissect brain Remove co	Neuroendo	Remove bra	Establish br	Establish br	Replace/irri
61635 61686 61687 61688 61699 61699 61700 61700 61700 61770 61770 61789 61770 61789 61770 61789 61770 61789 61770 61789 61770 61789 61770 61789 61770 61789 61770 61789 61770 61789 61770 61789 61770 61789 61770 61789 61770 61770 61789 61770 61789 61770																																i											
	61630 61635 61680 61682	61684	61690 61692	61697 61698	61700	61703	61705	61710	61711	61720	61750	61751	61770	61790	61793	61795	61860	61863	61867	61868	61870	61880	61885	61888	62000	62010	62100	62115	62117	62120	62140	62141	62143	62145	62146	62148	62160	62161 62162	62163	62164	62180	62190	62194

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

2 Z Z Z 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
82 83 82 82 82 82 82 82 82 82 82 82 82 82 82
\$ 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
A N N N N N N N N N N N N N N N N N N N
A N N N N N N N N N N N N N N N N N N N
4.6. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8.
0.00 8 8 4 4 8 8 8 1 1 2 1 2 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
0.00 0.00
A A A A A A A A A A A A A A A A A A A
N N N N N N N N N N N N N N N N N N N
6.000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Establish brain cavity shunt Brain cavity shunt wiscope Establish brain cavity shunt Replace/frivide catheter Replace/frivide catheter Replace/frivide brain shunt Csf shunt reprogram Csf spinal cord lesion Treat spine wcdth. ct/t. Inject s
100
62200 62220 62221 62222 62225 62225 62225 62226 62226 62226 62226 62227 62281 62381 63381

080 080 080 080 080 080 080 080 080 080	080 080 080 080 080 080 080 080 080 080	080 080 080 080 080 080 080		060000000000000000000000000000000000000	060 060 060 060 060 060
- 116 - 116 - 129 - 129	25 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	2,28 8,89 8,83 2,76 2,76 2,76 2,76 2,76 2,76 2,76 3,76 3,76 4,76 5,76 5,76 5,76 5,76 5,76 5,76 5,76 5	5.7 5.7 5.7 5.7 5.7 5.7 5.7 5.7 5.7 5.7	24 25 99 12 90 12	7.3.3.5.5.8 2.2.2.7.3.3.5.5.8 1.6.69
0.83 c. 7.5 4.4 4.5 c. 7.5 8.8 8.6 7.5 c.	2 Kg	7, C 4, 83, 83, C, 86, 45, 54, 55, 55, 56, 56, 56, 56, 56, 56, 56, 56	8, 6, 7, 7, 8, 8, 8, 8, 8, 7, 4, 4, 4, 4, 8, 7, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8,	5, 5, 5, 4, 4, 4, 5, 5, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8,	39.65 38.79 38.79 53.58 49.98 47.35 66.73 66.73 70.07 8.202 8.202 8.202 8.202 8.203
30.50 27.80 5.23 35.35 41.69 41.04 8.44 8.44 8.44 8.44 8.44	35.14 6.53 37.88 37.88 37.88 6.53 4.54 4.57 4.95 4.95 4.95	67.8 6.78 6.78 6.74 7.29 7.29 39.53 35.44 35.24	35.14 36.14 37.17 37.17 37.14	73.78 76.20 76.20 76.24 76.24 76.20	39.39 38.56 52.77 52.77 52.77 66.07 66.07 68.74 69.68 7.61 7.61 7.61 7.61 89.68
4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4		1	1	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
		4	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	
3.55 3.23 3.23 4.66 4.66 5.27 1.22 5.69	0.94 0.96 0.96 0.96 0.66 0.05 0.05 0.05	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	6. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	9.01 10.64 1	5.01 4.55 7.27 7.17 7.17 6.26 9.28 9.29 9.39 9.39 9.39 9.39 9.39 9.39 9.39
10.11 9.77 1.56 11.10 12.95 12.27 12.27 12.27 14.47	2	2.04 2.04 3.35 3.36 3.36 3.37 3.32 3.32 3.32 3.32 3.32 3.32 3.32	200 200 200 200 200 200 200 200 200 200	20.21 22.03 22.03 22.03 22.03 13.20 11.11 10.48 14.59 14.59 14.59 14.59 13.69	12.43 16.23 16.23 16.23 16.28 17.4 19.7 20.18 20.45 1.94 1.10
9.88 9.87 1.25 1.71 1.71 1.74 1.97 1.34 1.34	11.12	10.83 1.16 1.17 1.18 1.78 1.78 1.31 1.31 1.31	2.25 7.25 10.16 10.78 8.65 8.65 13.88 13.88 13.43 9.01	21.09 21.36 21.36 21.41 13.27 10.84 15.34 15.34 13.84 13.84 13.84 13.73	20.05 20.05
< < < < < < < < < < < < < < < < < < <	X	4	1	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	
4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4		1		4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	
17.07 15.16 3.26 21.82 25.32 23.37 21.68 5.25 26.04	2. 6. 4. 9. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8.	25.4.5 26.6.8 26.4.6.8 26.4.6.8 26.6.8 26.6.8 26.6.8 26.6.8 36.8 36.8 36.8 36.8 36.8 36.8 36.8	2.5.35 1.6.37 1.8.71 1.9.2 25.09 23.90 23.90 23.90 23.90 23.90 23.90 23.90	6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6	22.22 21.94 22.94 27.94 27.94 26.55 26.55 26.65 26.65 27.84 26.65 27.84 26.65 27.84 26.65 27.84
Removal of spinal lamina Removal of spinal lamina Remove spinal lamina add-on Cervical laminoplasty C-laminoplasty wgraft/plate Decompress spinal cord add-on Decompress spinal cord add-on	k surgery k surgery sery, thorax gery, thorax gery, thorax sery sery sery add-on tebral body add-on	rebrial body area body add-on treat body add-on trebral body area body add-on trebral body area body add-on trebral body add-on treat body add-on treat body add-on area body add-on area body add-on cord ideaments.	ord ligaments circl ligaments lumn/nerves lumn/nerves lumn/nerves lumn & cord	Revise spinal cord vessels Revise spinal cord vessels Revise spinal cord vessels Revise intraspinal lesion Excise intraspinal lesion Biopsylexicise spinal tumor	spinal tumor
Removal of spinal lamina Removal of spinal lamina Remove spinal lamina ad Cervical laminoplasty C-laminoplasty w/graft/pla Decompress spinal cord . Decompress spinal cord . Decompress spinal cord . Decompress spina	Neck spine dis Neck spine dis Spine disk surg Spine disk surg Removal of ver Removal of vertet Removal of vertet	hemoval of ver Remove vertet Remove ortet Removal of ver Removal of ver Remove vertet Incise spinal of Drainage of sp Drainage of sp Revise sonal of se	Tevise spinal of the spinal of	Revise spinal C Revise spinal C Revise spinal C Revise intraspil Excise intraspil	Biopsylexises spinal tumor Repair of faminectomy defe Removal of vertebral body Removal of vertebral body
				44444444444	
					
63046 63047 63050 63050 63051 63055 63056 63064 63064		63087 63088 63090 63101 63102 63172 63173			

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

State Property P		_			_									
Figure 1997	Nod	Status	Description	Physician Work RVUs	Fully Implemented Non-Facility PE RVUs	Year 2007 Transi- tional Non-Fa- cility PE RVUs		Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Practice RVUs	Fully Implemented Non-Facility Total	Year 2007 Transi- tional Non-Fa- cility Total		Year 2007 Transi- tional Fa- cility Total	Global
Preprint of vertical body Preprint Pre		∢,	₹ ′	30.94	Y Z	Y S	14.83	15.59	5.53	Y S	Y S	51.30	52.06	060
A		∢ ⊲	₽ ₽	33.37	A N	Z Z	14.68	16.35	6.68	A N	A A	52.73	24.40 92.40	060
A Removal of venterab body			Removal of vertebral body		ΥZ	Υ Z	17.60	17.93	5.71	Z	₹ Z	59.34	59.67	060
A Remove verticals book add or control of \$4.50 NA NA 1768 1702 446 NA NA 184 158 158 NA NA 1768 1702 446 NA NA 184 158 158 NA NA 1768 1702 446 NA NA 184 158 158 NA NA 184 158 NA			Removal of vertebral body		Y Y	A N	15.77	17.29	8.33	NA	Y Y	59.43	96.09	060
A Periodic of Spiral Britation C 2.57 LAS RAY 4.85 2.83 RAY RAY 1.89 8.24 RAY RAY RAY RAY 8.24 8.24 8.24 RAY RAY 8.24 8.24 8.24 8.24 8.24 8.24 8.24 8.24 8.24 8.24 8.24 8.24 8.24 8.24			Removal of vertebral body		Υ ·	Υ S	17.66	17.02	4.46	Υ S	¥ ?	56.87	56.23	030
Figure belong of grand good 775 78 78 78 78 78 78 7			Remove vertebral body add-on		₹ < Z Z	¥ ×	.93	243	62.1	₹ < Z Z	¥	8.46	8.30	777
Property of the property of			Stimulation of spinal cond		4 C C L	18 21	10.4	0.20	2.52	23.78	17 8 0	1 1 1	11.66	080
Properties of the processor of the pro			Bemove lesion of spinal cord		AZ Z	- 4Z	- 1. 90.	8 44	28.0	0 Z	9 N	26.00	28 46	060
A Reveselventrove normelectrodes 6138 NA NA 784 77:3 2.47 NA NA 10.57 10.54 NA NA 10.57 10.54 NA NA 10.57 10.54 NA NA 10.57 10.54 NA NA 10.57 10.55 NA NA 10.57 NA NA 10.57 NA NA 10.55 NA NA 10.57 NA NA 10.55 NA NA NA NA 10.55 NA		< <	Implant neuroelectrodes	7.53	ΥZ	A N	2.98	3.12	0.53	Z Z	Y V	11.04	11.18	060
A Performance of Separation Separation of Separation of Separation Separation of Separation Separation of Separation of Separation Separation of Separation Separation of Separation Separat		⋖	Implant neuroelectrodes	11.38	AN	ΥZ	7.84	7.13	2.43	Ϋ́	٧Z	21.65	20.94	060
A Revisite opinio generator 678 NA NA 357 404 1.65 NA NA 1058 10.58 A Revisite rough of grain alternation 19.20 NA NA 10.58 11.01 3.52 NA NA NA 10.58 10.58 A Revisite of spinio alternation 19.20 NA NA 10.58 11.01 3.52 NA NA NA 36.50 30.58 30.58 A Repaid of spinio alternation 19.20 NA NA 10.58 11.01 3.52 NA NA NA 36.50 30.58 30.58 A Repaid of spinio alternation 19.20 NA NA 10.58 11.01 3.52 NA NA NA 36.50 30.58 30.58 A Repaid of spinio alternation 19.20 NA NA 10.58 11.01 3.52 NA NA NA 36.50 30.58 30.58 A Revision of spinio alternation 19.20 NA NA 10.58 NA NA NA 10.58 NA NA 10.58 NA		4	Revise/remove neuroelectrode	6.83	ΑN	A N	3.36	3.55	0.78	Ϋ́	¥ V	10.97	11.16	060
A Repate of spiral perhalton TO MA NA 356 0.88 NA NA 305			Insrt/redo spine n generator		Y Y	A A	3.74	4.04	1.05	Ϋ́	A A	12.62	12.92	060
A Repair of spiral brintation 17.26 NA NA 10.17 3.12 NA A 9.78 10.17 3.12 NA 3.65 30.56			Revise/remove neuroreceiver		A A	ΨZ	3.60	3.56	0.89	A A	Y Y	10.55	10.51	060
A Repair of spinal hermatero 22.15 NA NA 12.05 11.05 NA NA 12.05 NA NA 12.05 11.05 NA NA 12.05 11.05 NA NA 12.05 11.05 NA NA 12.05 NA NA 12.05 11.05 NA NA 12.05 NA NA NA 12.05 NA NA NA 12.05 11.05 NA NA NA 12.05 NA NA NA NA 12.05 NA NA NA 12.05 NA NA NA NA 12.05 NA			Repair of spinal herniation		Y Y	₹ Z	9.78	10.17	3.52	₹ Z	∢ Z	30.56	30.95	060
A Repair of spiral bernation 22.15 NA 15.26 12.83 4.57 NA 4.63 39.23 39.22 39.23 </td <td></td> <td></td> <td>Repair of spinal herniation</td> <td></td> <td>Y :</td> <td>Y :</td> <td>10.93</td> <td>11.01</td> <td>4.12</td> <td>₹ Z</td> <td>Y :</td> <td>34.25</td> <td>34.33</td> <td>060</td>			Repair of spinal herniation		Y :	Y :	10.93	11.01	4.12	₹ Z	Y :	34.25	34.33	060
Pages spiral bernation 22.07			Repair of spinal herniation		Y :	Y :	12.60	12.83	4.57	Y :	YZ:	39.32	39.52	060
A Repair spinal fluid leakage 1247			Repair of spinal herniation		Y :	Y Z	15.07	13.95	6.23	Y Z	Y Z	46.37	45.25	060
A figher spiral filted idealede			Repair spinal fluid leakage		A A	ΨZ	7.90	7.75	2.51	ΨZ	₹ Z	22.88	22.73	060
A digital spinal shurt with spinal spin			Repair spinal fluid leakage		Y :	Y :	90.6	9.31	3.09	ΥZ:	Y :	27.62	27.87	060
A Install sportal shurt			Graft repair of spine defect		ΑZ:	Ψ Z	9.26	90.6	3.40	Ψ.	ΨZ:	27.88	27.71	060
A Removal of spinal shurtt			Install spinal shunt		ΑZ:	Y :	8.25	7.57	2.93	Ψ.	ΨZ:	23.63	22.95	060
Provided spinal struct		∢ •	Install spinal shunt	86.8	Υ « Ζ :	Υ « Ζ :	4.85	8/./8	1.66	Z Z	Z Z	15.49	15.42	060
A N block (n), inclinate). 1,12 1,41 1,72 0.45 0.45 0.09 2.89 2.91 1.87 1.87 0.45 0.09 2.89 2.91 1.87 1.82 1.82 1.83 1.62 1.83 1.62 1.83 1.82 1.83 1.82 1.83 1.85 1.83 1.82 1.83 1.82 1.83 1.85 1.83 1.85 1.83 1.85 1.83 1.85		∢ •	Revision of spinal shunt	1 03	Z Z	Ψ « Z 2	6.06	5.45	68.	Z Z	Κ « Ζ 2	16.78	16.17	060
A N block nij, dredinal 1.17 1.47 1.47 0.45 0.04 2.93 2.95 1.62 A N block nij, dredin 1.32 1.47 0.45 0.54 0.00 2.89 2.91 1.87 1.82 A N block nij, premer 1.43 1.82 2.35 0.52 0.48 0.09 2.89 2.91 1.87 1.82 A N block nij, premer bewas 1.40 1.30 0.55 0.48 0.09 2.84 3.86 2.04 2.00			Removal of spinal shunt	22.	Ψ,	Y Y	4.75	4.02	1.53	A C	A N	13.50	72.77	060
A N block fill, bright cooplaid 1.25 1.45 1.55 0.55 0.09 2.67 2.79 1.87 A N block fill, breated pleasus 1.45 1.55 0.70 0.81 0.10 2.96 2.07 1.92 A N block fill, breated pleasus 1.44 1.55 0.70 0.81 0.10 2.96 2.07 2.04 1.97 A N block fill, prented pleasus 1.48 1.50 2.48 0.08 2.57 3.19 1.96 1.97 A N block fill, prented pleasus 1.48 1.50 2.44 0.63 0.09 2.58 2.04 2.07 1.97			N block inj, trigeminal	1.11	1.41	1.77	0.45	0.44	0.07	2.59	2.95	1.63	1.62	000
A N block fill, godbjedt 1.32 1.17 1.39 0.51 0.01 2.36 2.77 1.37 1.37 1.37 1.37 1.37 0.04 0.03 3.34 3.86 2.04 2.00 0.09 3.34 3.86 2.04 2.00 0.00 3.34 3.86 2.04 2.00 0.00 3.34 3.86 2.04 2.00 0.00 3.34 3.86 2.04 2.00 0.00 3.34 3.86 2.04 2.00 0.00 3.34 3.86 2.04 2.00 0.00 3.34 3.86 2.04 2.00 0.00 3.34 3.86 2.04 2.00 1.97 </td <td></td> <td></td> <td>N block Inj, facial</td> <td>5.5</td> <td>1.46</td> <td>79.</td> <td>0.53</td> <td>0.58</td> <td>0.09</td> <td>2.80</td> <td>18.2 18.5</td> <td>8. 7</td> <td>26.</td> <td>000</td>			N block Inj, facial	5.5	1.46	79.	0.53	0.58	0.09	2.80	18.2 18.5	8. 7	26.	000
A N block (ii), spiral accessor 1,41 1,55 0.70 0.81 0.10 2.93 3.06 2.21 2.32 A N block (ii), spiral accessor 1,48 1,50 0.55 0.46 0.09 3.34 3.06 2.21 2.32 A N block (ii), spiral accessor 1,14 1,30 1,71 0.49 0.09 3.34 3.06 2.21 2.02 A N block (ii), spiral accessor 1,44 1,50 2.48 0.09 3.07 4.05 1.97 1.07 A N block (ii), spiral accessor 1,44 1,50 2.48 0.34 3.06 2.21 3.06 2.00 3.07 4.05 1.99			N block inj, occipital	1.32	1.17	1.39	0.51	0.47	0.08	2.57	2.79	1.91	1.87	000
A N block mi, printendecessor 1.43 1.82 2.33 0.05 0.48 0.09 3.34 3.89 2.04 2.00 A N block mi, gentral plexus 1.40 1.30 1.71 0.47 0.49 0.08 3.78 1.97 1.97 A N block mi, cervical plexus 1.40 1.30 1.71 0.44 0.08 2.78 3.19 1.97 1.97 A N block mi, cervical plexus 3.88 N.A N.A 0.57 0.74 0.31 N.A 4.70 1.97 1.90 2.01 1.90 2.01 1.97 1.97 1.94 0.08 3.74 1.97 1.97 1.94 0.09 2.74 1.91 1.90 2.01 1.97 1.97 1.94 0.09 2.77 1.91 1.97 1.97 1.94 0.09 2.77 1.77 1.97 1.97 1.97 1.90 2.01 1.90 2.01 1.90 2.01 1.90 2.01 1.90 <t< td=""><td></td><td></td><td>N block Inj, vagus</td><td></td><td>1.45</td><td>1.55</td><td>0.70</td><td>0.81</td><td>0.10</td><td>2.96</td><td>3.06</td><td>L2.2</td><td>2.32</td><td>000</td></t<>			N block Inj, vagus		1.45	1.55	0.70	0.81	0.10	2.96	3.06	L2.2	2.32	000
A N block mi, sprala accessor 1.18 2.09 2.50 0.45 0.08 3.31 3.76 1.81 1.72 A N block mi, sprala accessor 1.48 1.50 2.48 0.34 0.49 0.08 3.31 3.76 1.81 1.72 A N block mi, brachial plexus 1.48 1.50 2.48 0.34 0.49 0.09 3.07 4.05 1.91 2.00 A N block mi, prachial plexus 1.44 1.51 2.66 0.06 0.01 3.07 4.05 1.91 2.00 A N block mi, praceost wild 1.48 1.50 2.44 0.52 0.46 0.07 3.93 1.91 2.00 A N block mi, incrost, mit 1.18 2.40 0.55 0.54 0.65 0.16 3.07 4.00 2.17 1.00 A N block mi, incrost, mit 1.11 1.44 1.57 0.56 0.65 0.16 0.73 3.45 2.44 2.24			N block Inj, phrenic		7.82 1.82	2.33	0.52	0.48	0.09	3.34	3.85	2.04	00.7	000
A N block (in), cardical plexus 1.40 1.50 1.71 0.44 0.04 2.76 3.19 1.39 1.99 A N block (in), cardical plexus 1.44 1.50 2.44 0.57 0.74 0.03 2.76 1.39 1.99 2.01 A N block (in), cardical plexus 1.44 1.51 2.46 0.07 3.29 3.83 1.91 1.90 2.01 A N block (in), infercost, and infercost			N block Inj. spinal accessor		2.02	7.50	0.55	0.46	0.08	3.37	3.76	20. 0	7.72	000
A N block ont influes, b plex. 1.48 1.50 2.48 0.34 0.04 0.01 3.07 4.05 1.91 2.00 A N block inj, axillary. b plex. 1.44 1.51 2.65 0.35 0.44 0.01 3.06 4.20 1.91 2.00 A N block inj, axillary. 1.32 1.90 2.44 0.85 0.46 0.01 3.06 4.20 1.91 2.00 A N block inj, intercost, mlt. 1.68 3.55 5.45 0.55 0.11 3.06 4.20 1.91 1.98 2.93 4.90 2.01 1.86 4.20 2.71 1.86 2.34 2.31 1.90 2.01 1.90 2.01 1.90 2.01 1.90 2.01 1.90 2.01 1.90 2.01 1.90 2.01 1.90 2.01 1.90 2.01 1.90 2.01 1.90 2.01 1.90 2.01 1.90 2.01 1.90 2.01 1.90 <td< td=""><td></td><td></td><td>N block Inj, cervical plexus</td><td></td><td>08.1</td><td>L/.L</td><td>0.47</td><td>0.49</td><td>0.08</td><td>2.78</td><td>3.19</td><td>CS: 7</td><td>1.97</td><td>000</td></td<>			N block Inj, cervical plexus		08.1	L/.L	0.47	0.49	0.08	2.78	3.19	CS: 7	1.97	000
A N block (in); autilates, b plex. 3.85 NA 0.57 0.74 0.31 NA 4.73 4.90 A N block (in); suprascapular 1.32 1.44 1.51 2.65 0.46 0.11 3.06 4.90 1.91 1.80 2.44 0.55 0.46 0.11 3.06 4.90 1.91 1.80 2.44 0.55 0.46 0.07 3.29 3.83 1.91 1.89 2.94 0.01 3.86 4.77 1.89 2.94 0.01 3.86 4.77 1.89 2.94 0.01 3.86 4.77 1.89 2.94 0.05 0.06 0.01 3.85 0.01 3.86 4.77 1.89 2.44 0.55 0.05 0.05 0.05 0.05 0.01 3.97 4.05 2.44 2.31 4.00 2.17 2.27 2.24 2.23 2.44 2.32 2.34 2.42 2.34 2.44 2.34 2.44 2.34 2.44 2.43 2.41<			N block inj, brachial plexus		1.50	2.48	0.34	0.43	0.00	3.07	4.05	1.91	2.00	000
A N block rin, swillay 1.51 2.65 0.35 0.46 0.11 3.06 4.20 1.90 2.01 A N block rin, superscapular 1.38 1.90 2.44 0.52 0.01 3.29 3.83 1.91 1.85 A N block rin, intercost, mit intercost, m			N block cont infuse, b plex		Ψ.	Y Y	0.57	0.74	0.31	Y Y	Y N	4.73	4.90	010
A N block in; suprascapular 1.32 1.90 2.44 0.52 0.46 0.07 3.29 3.83 1.91 1.85 A N block in; intercost, snd 1.18 2.40 3.51 0.44 0.05 0.08 3.66 4.77 1.70 1.69 A N block in; intercost, snd 1.75 1.34 1.57 0.56 0.65 0.13 3.22 2.31 1.75 1.69 2.44 2.49 0.78 0.66 0.10 3.97 4.05 2.34 2.72 2.31 0.10 3.97 4.05 2.44 2.42 2.73 0.66 0.10 3.97 4.00 2.17 2.27 2.31 0.10 3.25 4.00 2.17 2.27 2.31 0.66 0.10 3.25 4.00 2.17 2.27 4.00 2.17 2.27 4.00 2.17 2.27 4.00 2.17 2.27 4.00 2.17 2.27 4.00 2.17 2.27 4.00 2.10			N block inj, axillary		1.51	2.65	0.35	0.46	0.11	3.06	4.20	1.90	2.01	000
A N block inj. intercost, sng 1.18 2.40 3.51 0.44 0.43 0.08 3.66 4.77 1.70 1.69 A N block inj. intercost, mit intercost, mit block inj. incling/hydrodal 1.76 1.34 1.57 0.56 0.13 3.22 2.34 2.42 2.34 2.42 2.43 2.45 0.55 0.13 3.24 2.42 2.43 2.45 0.56 0.13 3.24 2.42 2.43 2.42 2.43 2.42 2.43 2.42 2.43 2.42 2.45 0.56 0.16 0.10 3.97 4.05 2.43 2.47 2.43 2.43 0.56 0.16 0.10 3.97 4.00 2.17 2.24 2.43 0.16 0.10 3.97 4.00 2.17 2.43 2.43 2.43 2.43 2.43 2.41 2.42 0.56 0.56 0.50 0.70 0.10 2.17 2.24 2.43 2.43 2.43 2.43 2.43 2.43 2.43 <td></td> <td></td> <td>N block inj, suprascapular</td> <td></td> <td>1.90</td> <td>2.44</td> <td>0.52</td> <td>0.46</td> <td>0.02</td> <td>3.29</td> <td>3.83</td> <td>1.91</td> <td>1.85</td> <td>000</td>			N block inj, suprascapular		1.90	2.44	0.52	0.46	0.02	3.29	3.83	1.91	1.85	000
A N block inj, intergraby, mile megroshy mile 3.55 5.45 0.53 0.724 2.32 2.34 7.24 2.31 A N block inj, intergraby, mile megroshy mile 1.75 1.34 1.57 0.56 0.65 0.13 3.22 3.45 2.44 2.43 A N block inj, inchedrala. 1.46 2.49 0.78 0.56 0.66 0.16 3.61 4.00 2.17 2.27 A N block inj, inchedral scatter, sng 1.48 1.67 2.42 0.56 0.66 0.16 3.61 4.00 2.17 2.27 A N block inj, inchedral scatter, sng 1.48 1.67 2.42 0.59 0.50 0.78 0.71 0.71 <			N block inj, intercost, sng		2.40	3.51	0.44	0.43	0.08	3.66	4.77	1.70	1.69	000
A N block in, illio-ing/hypogi 1.75 1.34 1.57 0.56 0.55 0.13 3.22 3.45 2.44 2.43 A N block in, pudendal 1.46 2.241 2.49 0.78 0.66 0.01 3.97 4.05 2.34 2.17 A N block in, pudendal 1.45 2.24 0.05 0.66 0.16 3.25 4.00 2.17 2.27 A N block in, paracerror and certain 3.61 NA NA 0.59 0.50 0.20 NA A.40 2.17 2.27 A N block in, fem, sofatic, cont inf 3.61 NA NA 0.59 0.20 NA NA 4.40 2.17 2.27 A N block in, fem, sofatic, cont inf 3.24 NA NA 0.47 0.73 0.18 0.09 NA NA 4.40 4.71 2.71 2.81 4.71 2.72 4.71 2.71 2.82 4.71 2.71 2.82 4.71			N block inj, intercost, mlt	1.68	3.55	5.45	0.53	0.52	0.11	5.34	7.24	2.32	2.31	000
A N block inj, pudendal 146 2.41 2.49 0.78 0.61 0.10 3.97 4.05 2.37 A N block inj, pudendal 1.45 2.00 2.39 0.56 0.16 3.61 4.00 2.17 2.27 A N block inj, paracervical 1.45 2.00 2.42 0.56 0.60 0.16 3.61 4.00 2.17 2.27 A N block inj, fem, single 3.61 NA NA 0.21 0.38 0.09 NA NA 4.01 4.27 A N block inj fem, single 1.50 NA NA 0.21 0.38 0.09 NA A.01 4.01			N block inj, ilio-ing/hypogi	1.75	1.34	1.57	0.56	0.55	0.13	3.22	3.45	2.44	2.43	000
A N block inj, paracervical 1.45 2.00 2.39 0.56 0.66 0.16 3.61 4.00 2.27 A N block inj, solatic, cont inf 3.61 NA NA 0.59 0.50 0.09 NA NA 4.01 2.07 A N block inj, fem, single 1.50 NA NA 0.21 0.38 0.09 NA NA 4.01 4.71 A N block inj, fem, single 1.50 NA NA 0.21 0.38 0.09 NA NA 1.97 A N block inj fem, single 1.50 NA NA 0.47 0.73 0.18 NA 4.01 4.71 4.71 A N block inj fem, cont inf 1.50 NA NA 0.49 0.84 0.15 NA A.01 4.27 A N block inj fem, cont inf 1.50 1.23 0.69 0.89 0.11 0.11 2.67 2.67 2.67 A N block inj fem, con			N block inj, pudendal	1.46	2.41	2.49	0.78	0.61	0.10	3.97	4.05	2.34	2.17	000
A N block inj, sciatic, sngt, sngt, sngt, sngt, sngt, sngt, sold in paravertebral of the men epidural of the men epidural ded-on sold in paravertebral of the men epidural ded-on sold in the men epidural ded on sold in			N block inj, paracervical	1.45	2.00	2.39	0.56	99.0	0.16	3.61	4.00	2.17	2.27	000
A N blik inj, sciatic, cont inf 3.61 NA 0.59 0.20 NA A.40 4.71 A N block inj fem, single 1.50 NA NA 0.21 0.38 0.09 NA 1.97 A N block inj fem, single 1.50 NA NA 0.47 0.73 0.18 NA 1.97 A N block inj, lempar plexus 3.36 NA NA 0.49 0.84 0.13 2.69 2.65 1.90 1.89 A N block, other peripheral 1.27 1.29 1.25 0.50 0.49 0.13 2.69 2.65 1.90 1.89 A Inj paravertebral of add-on 1.29 1.25 0.50 0.49 0.04 0.08 2.60 2.67 2.67 2.67 A Inj paravertebral of add-on 1.21 1.87 0.23 0.70 0.71 2.77 2.92 1.72 A Inj paravertebral of add-on 0.88 1.12 0.82 <td< td=""><td></td><td></td><td>N block inj, sciatic, sng</td><td>1.48</td><td>1.67</td><td>2.42</td><td>0.52</td><td>0.51</td><td>0.10</td><td>3.25</td><td>4.00</td><td>2.10</td><td>5.09</td><td>000</td></td<>			N block inj, sciatic, sng	1.48	1.67	2.42	0.52	0.51	0.10	3.25	4.00	2.10	5.09	000
A N block inj fem, single 1.50 NA 0.21 0.38 0.09 NA NA 1.97 A N block inj fem, cont inf 3.36 NA NA 0.47 0.73 0.18 NA 4.01 4.27 A N block inj, lumbar plexus 3.24 NA NA 0.49 0.84 0.15 NA 3.88 4.23 A N block, other peripheral 1.29 1.25 0.50 0.49 0.71 0.71 0.11 5.83 8.35 2.67 2.67 A Inj paravertebral c/t add-on 1.29 1.23 2.06 0.34 0.34 0.08 2.60 3.43 1.71 1.71 A Inj paravertebral c/t add-on 0.98 1.12 1.85 2.06 0.34 0.08 2.60 3.43 1.71 1.71 A Inj paravertebral c/t add-on 0.98 1.12 0.82 0.07 2.21 2.92 1.28 1.74 3.19 A			N blk inj, sciatic, cont inf	3.61	A A	A A	0.59	06.0	0.20	A A	ΥN	4.40	4.71	010
A N block inj fem, cont inf 3.36 NA NA 0.47 0.73 0.18 NA 4.01 4.27 A N block inj, lumbar plexus 3.24 NA NA 0.49 0.84 0.15 NA A.01 4.27 A N block, other peripheral 1.27 1.29 1.25 0.50 0.49 0.13 2.69 2.65 1.90 1.89 A Inj paravertebral c/t add-on 1.29 1.25 0.50 0.74 0.71 0.71 0.71 0.71 2.65 1.71 1.71 1.71 A Inj paravertebral c/t add-on 0.98 1.12 0.87 0.24 0.07 2.17 2.92 1.28 1.29 A Inj paravertebral L/s add-on 0.98 1.12 0.87 0.07 2.17 2.92 1.28 1.29 A Inj foramen epidural c/t 2.20 3.81 6.57 0.82 0.76 0.81 4.15 2.02 2.09 A			N block inj fem, single	1.50	A A	A V	0.21	0.38	0.09	A A	Y V	1.80	1.97	000
A N block inj, lumbar plexus 3.24 NA 0.49 0.84 0.15 NA NA 3.88 4.23 A N block, other peripheral 1.27 1.29 1.25 0.50 0.49 0.13 2.69 2.65 1.90 1.89 A Inj paravertebral of tadd-on 1.29 1.25 0.06 0.04 0.08 2.60 3.43 1.71 1.71 A Inj paravertebral Is add-on 0.98 1.12 1.87 0.23 0.07 2.17 2.92 1.28 1.29 A Inj paravertebral Is add-on 0.98 1.12 1.87 0.23 0.04 0.07 2.17 2.92 1.28 1.29 A Inj foramen epidural c/t 2.20 3.81 6.57 0.82 0.87 0.10 3.14 4.15 2.02 A Inj foramen epidural add-on 1.50 2.51 0.38 0.45 0.11 5.86 8.89 2.77 2.92 A Inj			N block inj fem, cont inf	3.36	AN	ΥN	0.47	0.73	0.18	Ϋ́	Ϋ́Z	4.01	4.27	010
A N block, direr peripheral 1.27 1.29 1.25 0.50 0.49 0.13 2.69 2.65 1.90 1.89 A Inj paravertebral of and-on paravertebral of and and-on paravertebral of and and-on paravertebral of and-on paravertebr			N block inj. lumbar plexus	3.24	Ϋ́	Ϋ́	0.49	0.84	0.15	Ϋ́	Ϋ́Z	3.88	4.23	010
A Inj paravertebral of transvertebral of transvertebral of transvertebral of transvertebral of transvertebral of transvertebral uses. 1.85 3.87 6.39 0.71 0.71 0.11 5.83 8.35 2.67 2.67 2.67 A Inj paravertebral uservertebral use			N block, other peripheral	1.27	1.29	1.25	0.50	0.49	0.13	2.69	2.65	1.90	1.89	000
A Inj paravertebral of add-on 1.29 1.23 2.06 0.34 0.34 0.08 2.60 3.43 1.71			Ini paravertebral c/t		3.87	6.39	0.71	0.71	0.11	5.83	8.35	2.67	2.67	000
A Inj paravertebral I/s add-on			Ini paravertebral c/t add-on		1.23	2.06	0.34	0.34	0.08	2.60	3.43	1.71	1.71	777
A Inj foramen epidural dod-on 2.20 3.81 6.57 0.28 0.45 0.01 5.14 3.19 A Inj foramen epidural dod-on 2.51 0.85 6.88 0.75 0.71 5.06 8.89 3.14 3.19 A Inj foramen epidural dod-on 3.85 6.88 0.75 0.75 0.71 5.08 0.87 0.10 3.14 4.15 2.02 2.09 A Inj foramen epidural dod-on 3.85 6.88 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75		< ⊲	Ini naravertehral I/s		3.72	60.9	0.60	0.62	01.0	20.00	7.60		- 6	0
Market M		(⊲	Inj paravertebral I/s add-on		27.5	20.0	00.0	20.0	2000	2.50	00.7	- 1 2	2 - 5	222
A Inj foramen epidural add-on		(<	Inj paraverenal i/s add-on		7 - 0	70.0	0.63	0.24	0.00	7 0	2.32	07.1	62	77
A Inj foramen epidual alk		∢ <	Inj foramen epidural c/t			0.57	0.82	0.87	0.0	0 c	8.89	ა 4 წ	ი ი	000
A Init forwards and interest plantage is a second of the s		(<	Inj formon opidural 1/0		00	- 00	0.30	5.0	5 5	о 1		20.0	20.0	77
		< <	Inj loralmen epidual //s		0.00	0.00	0.70	0.0	- 6	0.00	00.0	7.77	7.02	9 6

		-				
000000000000000000000000000000000000000	010 010 010 090 090	000000000000000000000000000000000000000	010 010 010 010 010 010	222 010 010 000 010 010 090	060 060 060 060 060	080 080 080 080 080 080 080 080 080 080
2.14 1.87 1.78 1.97 2.32 0.24	3.69 3.87 10.61 3.16 15.00 7.45	20.5 20.8 20.8 20.9 20.9 10.0 10.0 10.0 10.0 10.0 10.0 10.0 1	25.21 3.22 3.24 3.27 3.61 5.33 5.33 7.33	2.6.6 1.50 1.50 1.30 1.30 1.30 1.30 1.30	24.8 24.8 25.8 25.8 25.8 25.8 26.9 27.0 27.0 27.0 27.0 27.0 27.0 27.0 27.0	24.7 26.0 27.0
01 50 50 50 50 50 50 50 50 50 50 50 50 50	8 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	19888888	5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	8 8 5 6 4 8 8 8 8	201128871288	<u> </u>
4 - 4 - 4 - 4 0 6	8. 8. 1. 8. 7. 8. 8.	2 × 2 4 · 0 4 · 0 · 0	<u> </u>	4 0	8 <u> </u>	4. 4. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
2.67 2.4.4.4.6.7 2.1.3.6.7.6.7.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9	5.43 5.18 35.11 NA NA	NA NA 12.17 11.34	7.7.3 4.33 4.61 5.12 7.70 10.03 3.68	5.22 5.97 6.80 1.61 1.86 NA	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	4
2.57 3.08 3.21 4.01 4.33 0.39 6.39	5.03 5.07 27.60 4.36 NA	8 0 0 0 4 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0	3.68 3.92 3.92 7.28 6.48 7.28	8.98 6.03 1.54 6.81 8.98	0.22 A A A A A & & A A A A A A A A A A A A	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
07718018	00-0-4	+ (0 10 C D D D + (0 m = = 0 0 m (0 0	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	- (0 10 01 00 00 10 V 00 00 1	+ m m m o l m m m (o l m m + m + (o m (
00000000	0000-0-	- 0 - 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2-000000	700000000000000000000000000000000000000		0.089 0.089 0.099 0.099 0.099 0.099 0.099 0.099 0.099
0.68 0.82 0.54 0.05 0.05 1.73	1.23 1.23 3.05 1.27 5.29 2.50	2.33 2.33 1.99 2.33 2.33 2.33	2 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	75.0 0.27 1.53 0.34 1.35 1.36	3.28 4.42 5.72 7.72 8.00 7.73 8.00 7.73 8.00 8.00 8.00 8.00 8.00 8.00 8.00 8.0	2,4 - 0, 4 - 0, 4 - 4, 4 - 0,
0.73 0.48 0.67 0.67 0.60 0.06 0.06	3.87 3.87 3.87 5.44 5.00 7.87	2.24 2.24 2.24 2.20 2.20 2.20	355 355 1.36 1.31 1.27 1.27 1.27	78 0.25 1.88 1.09 1.09 1.32 7.23	6.54.4.6.6.4.4.6.6.6.6.6.6.6.6.6.6.6.6.6	$\begin{array}{c} 2.7 \\ -1.4 \\ -1.$
2.96 3.07 2.47 4.51 4.00 2.75	2.97 2.60 2.60 3.08 NA NA	N N N N N N N N N N N N N N N N N N N	2.0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	3.99 3.99 3.75 0.90 0.90 NA	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	
1.11 1.89 1.92 1.70 2.62 2.50 2.50	20.04 20.04 20.04 2.47 NA	N 8 7.9 8 7.9 8 7.9 8 7.9 8 7.9 8 7.9 8 7.9		4.44 88.82 1.84.83 1.84.83 1.84.83 1.84.83 1.84.83 1.84.83	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	4
1.36 1.22 1.22 1.35 1.58 2.31	2.27 2.36 7.05 1.76 8.11 4.34	2.44 1.13 1.73 3.44 9.44	2.20 2.20 2.20 2.20 3.00 8.00 8.00 8.00	2.1.6 2.2.6 2.3.00 2.3.00 2.62 3.78 6.02	6.56 6.17 7.32 10.37 10.37 6.88 6.98 6.98 7.78 7.78	7.4.6.4.6.6.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0
		1111111				
N block, spenopalatine gangl N block, carotid sinus s/p N block, stellate ganglion N block ini, hypogas plxs N block, lumbar/thoracic N block ini, celiac pelus Apply neurostimulator Implant neuroelectrodes	Implant neuroelectrodes	Implant neuroelectrodes Implant neuroelectrodes Revise/remove neuroelectrode Inst/redo perph n generator Revise/remove neuroreceiver Revise/remove neuroreceiver	Injection treatment of nerve Destroy nerve, face muscle Destroy nerve, reck muscle Destroy nerve, extrem musc Distroy nerve, extrem musc Destr paravertebri nerve l/s Destr paravertebri n add-on Destr paravertebri n add-on	Destr paravertebra nerve c/r Destr paravertebral nadd-on Injection treatment of nerve Injection treatment of nerve Chemodenerv eccrine glands Chemodenerv eccrine glands Injection treatment of nerve Injection treatment of nerve Revise finger/toe nerve	Revise hand/foot nerve Revise arm/leg nerve Revision of sciatic nerve Revision of arm nerve(s) Revise low back nerve(s) Revise und rerve at elbow Revise ulnar nerve at wist Carpal tunnel surgery Relieve pressure on nerve(s)	releases root/loe nerve inclaid of brown erve incision of brown nerve incision of cheek nerve incision of chin nerve incision of chin nerve incision of chin nerve incision of tongue nerve incision of tongue nerve incise diaphragm nerve incision of vagus nerve incision of vagus nerve incision of vagus nerve incision of pelvis nerve incise hip/thigh nerve
	Implant neuroelectrodes	9 _		0.0		Internal nerve nerve internal nerve revision incision of brow nerve incision of cheek nerve incision of chin nerve incision of figw nerve incision of facial nerve incise nerve, back of head incise diaphragm nerve incision of vagus nerve incision of vagus nerve incision of vagus nerve incision of pelvis nerve incision of pelvis nerve incise hip/thigh nerve incise hi
e gangles/ps/ps/ps/pslxss.slxsl	8 8 8 8 8	es es electroc lerator eceivel nerve	nerve nuscle nuscle n musc nerve ve l/s .	ve c/t add-on nerve nerve glands nerve nerve	e	ve e e e e e e e e e e e e e e e e e e
palatine s gangl oogas p r/thorac ac pelu	Implant neuroelectrodes	lectrod lectrod neuroe neuror neuror lent of	injection treatment of nerve Destroy nerve, face muscle Destroy nerve, neck muscle Destroy nerve, extrem musc Destroy nerve, extrem musc Destroy nerve, extrem musc Destr paravertebri nerve I/s Destr paravertebri nerve I/s	son ner sbral n lent of lent of eccrine lent of lent of	ot nervenerve atic nervenervenervenervenervenervenervenerv	Internate reoution nerve informal nerve revision incision of brow nerve incision of chin nerve Incision of chin nerve Incision of tawn nerve Incision of tawn nerve incision of tawn nerve incision of vagus nerve incision of pelvis nerve incision of pelvis nerve incise hip/thigh nerve Sever cranial nerve
speno carotic stellat inj, hyp lumba inj, celi	neuroe neuroe neuroe neuroe neuroe	neuroe neuroe emove o perpl emove treatm	treatm nerve, nerve, nerve, treatm traverte	Iravente Iravente Ireatm Ireatm enerv enerv treatm treatm treatm inger/tc	nand/fo arm/leg of sciric ow bac of cra linar ne ulnar ne unnel s	Toovice of browned by the property of the prop
block, block, block block block, block pply ne	nplant nplant nplant nplant nplant	nplant nplant nplant evise/r evise/r evise/r	jection estroy estroy estroy ijection estr pa	estr pa estr pa estr pa jjection hemod hemod jjection jjection	evise hevise a evise a evision evision evision evision evision evision evise u evise u evise u evise u evise u euise u elieve	Internal nerve revision internal nerve revision incision of brow nerve incision of cheek nerve incision of chin nerve incision of form nerve incision of facial nerve incision of vagus nerve incision of vagus nerve incision of vagus nerve incision of vagus nerve incision of pelvis nerve incision of pelvis nerve incision of pelvis nerve incision of pelvis nerve incision of succession of succession of pelvis nerve incision
222245		= = = T = T = T = T	= = 0 0 0 = 0 0 0	 		
-						
64505 64508 64510 64517 64520 64530 64553	64555 64560 64561 64565 64573 64575	64580 64581 64585 64585 64590 64595 64600	64610 64612 64613 64614 64614 64620 64623	64627 64627 64630 64640 64650 64653 64681 64681	64704 64708 64712 64713 64714 64714 64716 64718 64722	64720 64737 64738 64738 64738 64740 64740 64765 64766 64763 64763

Addendum B.—Relative Value Units (RVUS) and Related Information Used in Determining Medicare Payments For 2007—Continued

ADL	ADDENDUM	ا מ	RELATIVE VALUE UNITS (RVUS) AND	MELA I ED	INFORMALION O	n	ED IN DEI		a MEDICARE	HE PAYMENIS	EN IS TOR	7002	-confinned	5
CPT¹/ HCPCS²	Mod	Status	Description	Physician Work RVUs	Fully Implemented Non-Facility	Year 2007 Transi- tional Non-Fa- cility PE RVUs	Fully Im- plement- ed Facil- ity PE RVUs	Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Practice RVUs	Fully Implemented Non-Facility Total	Year 2007 Transi- tional Non-Fa- cility Total	Fully Im- plement- ed Facil- ity Total	Year 2007 Transi- tional Fa- cility Total	Global
64774		∢ •	Remove skin nerve lesion	5.66	A S	A S	3.97	3.87	0.74	Y Z	Y Z	10.37	10.27	060
64778		∢ ⊲	Nicit nerve surgery add-on	2.49	₹ ₹ ₹	₹ 4 Z Z	3.73	3.69	0.76	₹ ₹	₹ ₹ ₹	9.98	9.99	080
64782		< ∢	Remove limb nerve lesion	6.72	{	ζ ζ Z Z	2 - 4	3.86	0.86	Z Z	(∢ Z Z	11.69	11.44	060
64783		V	Limb nerve surgery add-on	3.71	Ϋ́Z	A N	1.41	1.73	0.51	NA	Ϋ́Z	5.63	5.95	ZZZ
64784		⋖・	Remove nerve lesion	10.44	₹ Z	Ϋ́ Z	6.20	6.49	1.38	Υ Z	₹ Z	18.01	18.30	060
64786		∢ ⊲	Remove sciatic nerve lesion	16.07	A N	Z Z	8.97	9.62	2.60	A N	A N	27.64	28.29	080
64788		< <	Remove skin nerve lesion	5.10	(4 2 Z	ζ	3.87	3.56	0.38	Z Z	(4 2 Z	9.70	0.00	060
64790		. ∢	Removal of nerve lesion	11.92	Z Z	Z A	6.81	7.10	2.10	A A	Z Z	20.83	21.12	060
64792		< <	Removal of nerve lesion	15.65	Ž	Y S	8.40	8.72	2.48	Z Z	Z Z	26.53	26.85	060
64/95		∢ ⊲		10.5	∀	₹ 4 Z Z	44. 4 00 4	1.53	0.52	Z Z	4 4 2 2	15.70	5.06	000
64804			Remove sympathetic nerves	15.73	Z Z	Z Z	6.10	6.90	2.14	Z Z	Z Z	23.97	24.77	060
			Remove sympathetic nerves	14.57	Ϋ́	A N	09.9	2.97	1.50	NA	Ϋ́Z	22.67	22.04	060
64818			Remove sympathetic nerves	11.20	Y S	Z Z	4.36	5.05	1.33	A S	Y S	16.89	17.58	060
64821			Remove sympathetic nerves	0.00	(4 4 2 Z	7.04 6.64	7.10	1.49 1.74	Z Z	(16.99	17.52	060
			Remove sympathetic nerves	9.11	Z Z	Υ Υ	6.45	7.04	1.30	Z Z	Z Z	16.86	17.45	060
64823		⋖	Remove sympathetic nerves	10.72	Ϋ́	A A	7.11	7.88	1.57	Ϋ́	Ϋ́	19.40	20.17	060
64831		⋖ <	Repair of digit nerve	10.18	Y S	Y S	6.67	6.97	1.41	Y S	₹ Z	18.26	18.56	090
6483Z		4 ⊲	Repair of hand or foot nerve	10.67	₹ ₹	₹	7.30 7.70	6.79	0.85	₹	¥	8.80 18.78	9.29	777
64835		< ∢	Repair of hand or foot nerve	11.55	Z Z	ξ Z	7.32	7.60	1.73	Z Z	Z Z	20.60	20.88	060
64836		⋖	Repair of hand or foot nerve	11.55	Ϋ́	A N	7.04	7.51	1.67	ΥZ	Ϋ́Z	20.26	20.73	060
64837		⋖ •	Repair nerve add-on	6.25	₹ Z	Υ S	2.67	3.09	0.97	Y S	₹ Z	9.89	10.31	ZZZ
64840		< <	Repair of leg nerve	13.81	4 × 2	₹ ₹	5.07	0.40	1.37	∀	4	20.25	22.64	080
64857		< <	Repair arm/leg nerve	15.64	Z Z	Z Z	8.93	9.46	2.21	Z Z	Z Z	26.78	27.31	060
		4	Repair sciatic nerve	17.64	A A	N	10.15	10.62	3.33	N A	Y Y	31.12	31.58	060
64859		⋖ •	Nerve surgery	4.25	₹ Z	₹ Ş	1.88	2.1	0.67	Y S	₹ S	6.80	7.03	ZZZ
64861		∢ ⊲	Repair of low hack nerves	20.08	₹ 4 Z Z	4 4 Z Z	0.0 40.0 83	10.66	4.08	Z Z	۷ م ۷ ۲	8.4.80 00.05	35.85	060
64864		< <	Repair of facial nerve	13.27	{	 ₹ Ζ	7.03	8.33	1.26		Z Z	21.56	22.86	060
64865		4	Repair of facial nerve	15.91	Ϋ́	A N	9.89	12.61	1.50	NA	Ϋ́Z	27.30	30.02	060
64866		⋖・	Fusion of facial/other nerve	16.65	ΨZ:	Υ :	12.27	12.94	2.04	Υ :	Ψ.	30.96	31.63	060
64868		∢ ⊲	Fusion of facial/other nerve	14.76	₹ ₹ ₹	₹ 4 Z Z	9.07	0.84 7.84	.43	Z Z	₹ 4 2 2	25.25	27.03	060
64872		< <	Subsequent repair of nerve	1.99	Ą Z	Υ V	0.81	1.01	0.29	N N	Ą Z	3.09	3.29	ZZZ
64874		۷.	Repair & revise nerve add-on	2.98	₹ Z	₹ Z	1.21	1.45	0.42	Y :	₹ Z	4.61	4.85	ZZZ
64876		∢ <	Repair nerve/shorten bone	3.37	∀	₹ \$ Z 2	0.78	1.50	0.47	Y S	∀	4.62	5.34	777
64886		< <	Nerve graft, head or neck	20.72	(ζ ζ	89.6	12.58	2.08	Z Z	(32.48	35.38	060
		<	graft, hand or foot .	16.06	Ϋ́	A Z	9.05	9.76	2.29	Ϋ́	Ϋ́	27.40	28.11	060
64891		۷.	graft,	17.17	Y :	Y S	9.87	8.15	1.63	Y S	Y S	28.67	26.95	060
64892		< <	arm or leg	15.56	Z Z	Υ S	8.95	88.8	2.47	Z Z	ď ž	26.98	26.91	060
64895 64895		∢ ∢	Nerve graft, arm or leg	20.09	Z Z	Z Z	10.07	9.8	2.01	Z Z	4 4 2 2	32.87	32.52	060
64896		< <	graft,	21.75	Ą Z	Υ Z	11.89	11.21	3.16	N N	Ą Z	36.80	36.12	060
64897		Α.	graft,	19.20	Y Z	₹ Z	10.43	10.63	2.54	Y :	Y :	32.17	32.37	060
64898		∢ <	Nerve graft, arm or leg	20.76	∀	▼	11.28	11.66	2.77	Z Z	∀	34.81	35.19	060
64902		(∢	Nerve graft add-on	11.81	(4 2 Z	ζ	3.02 4.25	55.53	55.	(4 2 Z	Z Z	17.61	18.89	722
64905		< <	pedicle trans	14.93	Ϋ́Z	Υ Z	6.84	8.08	2.00	Y Y	Ϋ́Z	23.77	25.01	060
64907		⋖ '	Nerve pedicle transfer	19.85	Υ V	Y Z	6.41	10.99	3.16	Υ Z	Y Y	29.45	34.00	060
64888		٥	Nervous system surgery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
64999		ပ	Nervous system surgery	0.0	_	_	0.00	0.00 0.00	0.00 0.00 0.00	0.00 0.00 0.00 0.00	0.00 0.00 0.00 0.00 0.00	0.00 0.00 0.00 0.00 0.00 0.00	0.00 0.00 0.00 0.00 0.00 0.00 0.00	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Color																										_
A Service of the final control of the control of	060 060 060 060 060	060 060 060	060	0000	060 060	010	060	000	000	060	888	060	060	060	060	060	060	000	060	060	010	060	060	000	090	010
A Review eye with right A Review eye wit	15.39 17.55 18.32 20.14 29.27 34.71 35.89 6.81	17.34 17.66 19.09 14.16	20.35 15.64 1.04	1.04	15.86 22.26 25.01	3.34 7.92 8.74	15.34	24.04 11.25 11.28	13.58	10.97	1.66	7.31	25.60	28.95	33.07 9.23	12.77	31.32	3.15	10.58	17.78	7.03	11.30	14.53	22.68	15.17	2.57
Perfect of the property of t	14.31 16.52 17.30 19.09 27.70 32.40 33.90 6.49	16.41 16.65 18.13	19.13 14.73 1.07	1.05	16.05 21.79 24.47	3.21 7.90 8.63	15.18	23.00 11.18 14.18	13.51 2.44	8.01 4.80 4.81	1.63	7.11	25.07	28.22	32.24 9.16	12.40	30.02 25.95	3.07	10.67	16.90	6.74	10.71	14.18	21.85	14.53	2.49
Protects on the implication of the content imp	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	Z Z Z Z	NA NA 1.37	1.67	4 4 4 Z Z Z	6.88 12.04 NA	12.68 NA	17.25 NA	15.64	15.83	1.93	7.42	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	4 4 Z Z	NA 10.52	4 4 Z Z	4 4 Z Z	3.71	NA 15.58	A A	8.16	2 Z Z	₹ ₹ 2 2 2 2	 {	A N A 4	4.12
Pervise eye, with righter	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	 	N N S S S S S S S S S S S S S S S S S S	1.62	4 4 4 Z Z Z	5.87 11.13 NA	12.77 NA	15.61 NA	15.14	11.40	1.85	7.19	₹ ₹ 2 Z	Z Z Z Z	10.11	▼	Z Z Z Z	3.45	14.18	Z Z	7.62	Y Z	({	Z N 4	3.67
Parelle one with implement	0.32 0.34 0.35 0.37 0.42 0.81 1.30 0.19	0.35 0.40 0.31	0.50	0.00	0.37 0.57 0.62	0.09	0.26	0.27	0.30	0.25	0.00	0.16	0.61	0.74	0.87	0.28	4 4	0.09	0.24	0.40	0.10	0.28	0.00	0.50	0.37	0.06
A Revise ete price and with implant C 88	7.99 8.28 9.18 10.11 13.15 15.36 15.88 3.50	8.85 8.98 9.55 7.60	10.07 8.18 0.30	0.39 0.28 0.39	6.80 9.50 10.44	1.35 3.29	3.95 6.18	9, 4, 4, 80, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6,	6.10	4.35	0.70	. 6. 6. 4. 88. 6. 4. 88. 6.	11.02	11.73	12.92	5.83	13.24	1.15	4.73	8.76	3.00	5.43	89.9	- 86.0 - 86.0	6.62 1.41	1.26
A	6.91 7.00 8.15 9.06 11.58 13.05 13.69 8.11 8.18	7.92 7.97 8.59 6.47	8.85 7.27 0.33	0.29	6.99 6.03 6.90	1.22 3.27 3.43	3.99	6.70 6.53 55.55	6.03	4.07	0.90	3.68 5.75	10.49	11.00	12.09	5.46 9.18	11.94	1.07	4.82	7.88	2.71	1 4 n	6.33	9.15	5.98	1.18
A Revise eye with impart 208	Z Z Z Z Z Z Z Z S S S S	4 4 4 4 2 2 2 2	0.63 A A	0.79	4 4 4 Z Z Z	4.89 7.41 AN	6.34 NA	10.60 A N	8.16	9.73	0.97	3.99	4 4 2 Z	Z Z Z Z	NA 5.40	∢ ∢ Z Z	Z Z	1.71	9.54	A A	4.13	A Z	({	 Z Z Z Z Z C	2.81
Revise eye with implant heaves eye with implant heaves eye with implant heaves eye five with implant heaves eye/ervise socket heaves eye/ervise socket heaves coular implant heaves ocular inexplant heaves of eye ocular inexplant heaves ocular inexplant of eye adhesions heaves of eye ocular inexplant inexplant of eye adhesions heaves of eye ocular inexplant inexplant inexplant of eye adhesions heaves of eye ocular inexplant	Z Z Z Z Z Z Z Z Z 8.00	4 4 4 4 2 2 2 2	N N N 0.59	0.74 0.60 0.81	4 4 4 Z Z Z	3.88 6.50 AA	6.43 NA	8.96 A N	7.66	7.03 8.41	0.89	3.76 4.58	Z Z	▼	4.99	▼	∢ ∢ Z Z	1.45	A 41.8	4 4 4 4	3.59	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	({	Z N 6	2.36
444444444444444444444444444444444444	7.08 8.08 8.08 8.56 9.61 15.31 19.05 3.12	8.32 9.14 6.25	9.78 7.15 0.71	0.84 0.71 0.93	8.69 12.19 13.95	- 4 4 - 44 - 86	8.78	6.38 82.98 82.98	7.18	5.85	0.92	3.27	13.97	16.48	19.28	6.66	17.64	1.91	5.61	8.62	3.84	5.59	7.53	12.16	8.18 5.09	1.25
444444444444444444444444444444444444444	ant ant (et		ınt om eye	om eye	om eye om eye om eye			pun				sion			ant	n nt	ntnt			ure	Sdi	ons ons	ons successions		eye	
444444444444444444444444444444444444444	se eye	rt ocular implant rt ocular implant ch ocular implant se ocular implant	sert ocular implant loval of ocular impla love foreign body frc	love foreign body fro love foreign body fro love foreign body fro	love toreign body fro love foreign body fro love foreign body fro	air of eye wound air of eye wound		air of eye wound air of eye wound air of eve socket wo	loval of eye lesion sy of cornea	ioval of eye lesion loval of eye lesion	ieal smear tte/treat cornea	the/rieat cornea tment of corneal lession of cornea	leal transplant	eal transplant	se cornea with impla ection of astigmatisr	ection of astigmatisr ar reconst. transplaı	ar reconst, transplar ar reconst, transplar	nage of eyenage of eye	nage of eyenage of eve	eve inner eye pressu	ar surgery of eye	e inner eye adhesio	e inner eye adhesio	iove eye lesion	love litiplatit of eye love blood clot from tion treatment of ev	tion treatment of ey
																										_
		65130 65135 65140 65150										65450 65450 65600		65750 65755			65781 65782		65810 65815		65855	5865		65900	65930 66030	06099

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Year 2007 Transi- tional Fa- cility Total	\$2 \text{2.6} 2.
Fully Implemented Facility Total	5 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Year 2007 Transi- tional Non-Fa- cility Total	1271 AANAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
Fully Implemented Non-Facility Total	8.6 8.4 A A A A A A A A A A A A A A A A A A A
Mal-Prac- tice RVUs	0.000 0.000
Year 2007 Transi- tional Fa- cility PE RVUs	7. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
Fully Im- plement- ed Facil- ity PE RVUs	2.000000
Year 2007 Transi- tional Non-Fa- cility PE RVUs	21. N N N N N N N N N N N N N N N N N N N
Fully Implemented Non-Facility	7. N N N N N N N N N N N N N N N N N N N
Physician Work RVUs	2000 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Description	Remove eye lesion Glaucoma surgery Incision of eye Incision of eye Incision of iris Removal of iris Revision of iris Removal of lens material Removal of lens prosthesis Cataract surgery, complex Cataract surgery procedure Extraction of lens Extraction of lens Extraction of lens Extraction of lens Cataract surgery, complex Cataract surgery procedure Extraction of eye fluid Release of eye fluid Replace eye fluid Rep
Status	444444444444444444444444444444444444444
Mod	
CPT1/ HCPCS ²	66130 66150 66150 66160 66170 66180 662185 66225 66225 66620 66700 67000

0.000000000000000000000000000000000000	099 099 099 099 099 099 099 099 099 099	010 010 000 000
28.87 33.30 15.38 15.38 17.71 20.89 11.05 11.05 11.30 12.55 13.25 15.57	2 5 5 5 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	3.20 3.93 8.36 1.30
28.04 32.38 4.15.27 36.86 36.87 36.87 36.86 36.86 36.86 11.18 11.25 11.25 15.40 15.40	4 5 5 6 6 6 7 5 6 7 6 7 6 7 6 7 6 7 6 7 6	3.09 3.79 8.31 2.20
20.35 NAA NAA NAA NAA NAA NAA NAA NAA NAA NA	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	3.87 4.78 NA 5.01
NAN 15.64 NAN NAN NAN NAN NAN NAN NAN NAN NAN NA	24 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	3.70 4.58 NA 5.41
0.37 0.37 0.37 0.37 0.25 0.25 0.25 0.25 0.25 0.26 0.27	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	0.09 0.11 0.06 0.06
10.00 10.00	8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	1.23 1.60 3.75 0.68 0.55
11.08 6.38 6.38 6.38 10.74 11.27 11.27 5.07 5.45 8.25 8.25 8.25 8.25 8.25 8.25 8.25 8.2	5.65 1.148 1.1	1.12 1.46 3.70 0.66 0.52
N N N N N N N N N N N N N N N N N N N	6.65 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	1.90 2.45 NA 3.47 0.56
N N N N N N N N N N N N N N N N N N N	1.3.9.9.0.0.0 A A A A A A A A A A A A A A A A A	1.73 2.25 NA 3.87 0.45
	9 9 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	1.88 2.22 4.42 1.48 0.71
Laser treatment of retina Laser treatment of retina Repair detached retina Rerepair detached retina Rerepae eye implant material Remove eye implant material Remove eye implant material Treatment of retina Treatment of retina lesion Treatment of retinal lesion	Treatment of retinal lesion Treatment of retinal lesion Treatment of choroid lesion Ocular photodynamic ther add-on Coular photodynamic ther add-on Treatment of retinal lesion Relinforce/graft eye wall Eye surgery procedure Revise eye muscle Revise eye muscles Revise eye muscles add-on Eye surgery follow-up add-on Eye surgery follow-up add-on Revise eye muscles add-on Revise eye muscle add-on Revise eye muscle add-on Revise eye muscle socket Eye surgery procedure Eye surgery procedure Eye surgery procedure Explore/freat eye socket Inject/freat eye soc	Remove eyelid lesions
Laser treatment of retina Laser treatment of retina Repair detached retina Rerepair detached retina Rerepair detached retina Release encircling mater Remove eye implant mat Remove eye implant mat Remove eye implant mat Treatment of retina Treatment of retina lesio Treatment of retina lesio	Treatment of retinal lesion Treatment of retinal lesion Treatment of retinal lesion Cullar photodynamic ther a Coullar photodynamic ther a Treatment of retinal lesion ocular photodynamic ther a Treatment of retinal lesion and the photodynamic there is a present of the photodynamic there is a surgery procedure	Remove eyelid lesior Remove eyelid lesior Remove eyelid lesior Biopsy of eyelid Revise eyelashes
	444E4444044444444444444444444444444444	
67039 67040 67040 67040 67101 667105 67108 67108 67110 667112 667112 667112 667112 667121 667141 667141 667141 67710 677121 677141 67710 677141 67710 677141 67710		67801 67805 67808 67810 67820

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

)	ם ווסקווים			ובראובה	TELEVIED IN CHIMALION COED IN DELETIONING MEDIOPITE I ALMENIO I OLI	2	בו ה	,)))		-)	7007		,
CPT¹/ HCPCS²	Mod	Status	Description	Physician Work RVUs	Fully Implemented Non-Facility	Year 2007 Transi- tional Non-Fa- cility PE RVUs	Fully Im- plement- ed Facil- ity PE RVUs	Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Prac- tice RVUs	Fully Implemented Non-Facility Total	Year 2007 Transi- tional Non-Fa- cility Total	Fully Implemented Facility Total	Year 2007 Transi- tional Fa- cility Total	Global
67825		4	Revise eyelashes	1.38	1.44	1.66	1.30	1.38	0.07	2.89	3.11	2.75	2.83	010
		∢,		1.70	4.10	5.17	1.36	1.47	0.08	5.88	6.95	3.14	3.25	010
67835		∢ ⊲	Revise eyelashes	5.55	A P	A L	8 F. 4	LC: 4	0.78	NA 15	NA 7 25	10.01	3 75	090
67850		< <	Treat evelid lesion	1.69	3.26	3.34	5. 1. 5. 4.3	1.46	0.07	5.05	5.10	3.19	3.22	010
		⋖	Closure of eyelid by suture	1.35	2.45	3.09	0.86	0.92	0.07	3.87	4.51	2.28	2.34	000
67880		∢ <	Revision of eyelid	4.42	5.58	6.35	3.67	3.77	0.19	10.19	10.96	8.28	8.38	060
67900		< <	Repair brow defect	0.0	0.50	8.68	4.02	5.12	0.23	14.53	15.69	11.73	12.13	060
67901		< <	Repair eyelid defect	7.39	9.25	6.36	5.46	5.45	0.54	17.18	14.29	13.39	13.35	060
67902		∢ <	Repair eyelid defect	9.60	NA	NA 0	6.58	5.74	0.60	NA	NA 17	16.78	15.94	060
67904		∢ ∢	Repair eyelid defect	0.30	0.02	0.00	4. rc	5.23	0.47	16.63	17.50	13.70	13.47	060
67906		< <	Repair eyelid defect	6.78	N N	Z Z	4.63	4.93	0.46	N A A	N N	11.87	12.17	060
80629		∢	Repair eyelid defect	5.12	5.71	6.40	4.25	2.07	0.28	11.11	11.80	9.65	10.47	060
67909		∢ <	Revise eyelid defect	5.39	6.39	7.62	4. r	4.79	0.31	12.09	13.32	10.01	10.49	060
67912		(⊲	Correction evelid w/implant	0.7	13 18	17 49	2.C 4.74	90. 70	0.0	19 63	23.94	11 19	11 78	060
67914		< ∢	Repair evelid defect	3.67	4.88	5.98	2.76	2.98	0.19	8.74	9.84	6.62	6.84	060
67915		⋖	Repair eyelid defect	3.18	4.54	5.62	2.57	2.74	0.16	7.88	8.96	5.91	80.9	060
67916		∢ <	Repair eyelid defect	5.30	6.53	7.67	4.26	4.64	0.28	12.11	13.25	9.84	10.22	060
67921		∢ ⊲	Repair eyelid defect	0.0	0.9	8.07	40.4 40.4	4.00 4.00 4.00	0.30	3.28	444	0.9	1.3	060
67922		< ∢	Repair evelid defect	3.06	4.44	5.54	2.51	2.69	0.15	7.65	8.75	5.72	5.90	060
67923		⋖		28.9	6.63	7.75	4.46	4.84	0.30	12.80	13.92	10.63	11.01	060
67924		∢•	Repair eyelid defect	5.78	7.11	8.47	4.19	4.56	0.30	13.19	14.55	10.27	10.64	060
67930		∢ <	Repair eyelid wound	3.60	4.50	5.41	- c 8: 6	2.09	0.19	8.29	9.20	5.64	5.88	010
67938		< <	Remove evelid foreign body	1.33	3.95	5.05	1.27	1.26	0.09	5.34	6.41	2.66	2.65	010
67950		< <	Revision of eyelid	5.81	6.80	8.17	4.47	5.03	0.36	12.97	14.34	10.64	11.20	060
67961		⋖ ·		5.68	7.00	8.26	4.43	4.88	0.33	13.01	14.27	10.44	10.89	060
67966		∢ <	Revision of eyelid	8.75	8.29 NA	8.92 NA	5.93	5.65	0.37	17.41 NA	18.04 NA	15.05	14.77	060
67973		(∢	Reconstruction of evelid	12.85	(4 2 Z	(4 2 Z	8 02	00.8	0.75	Z Z	Z Z	21.62	22.59	060
		< <	Reconstruction of eyelid	12.82	A A	¥ X	8.04	8.93	0.75	Y Y	Z Z	21.61	22.50	060
67975		∢ (Reconstruction of eyelid	9.12	ΥZ	₹ Z	9.16	6.75	0.50	NA	N N	15.78	16.37	060
67999		ပ <	Revision of eyelid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	\
68040		(∢	Treatment of evelid lesions	0.85	0.62	69.0	0.37	0.42	0.00	1.51	1.58	1.26	13.1	000
68100		⋖	Biopsy of eyelid lining	1.35	2.41	3.04	0.88	0.93	0.07	3.83	4.46	2.30	2.35	000
68110		∢ •		1.77	3.15	3.86	1.52	1.62	0.00	5.01	5.72	3.38	3.48	010
68115		∢ ⊲	Remove eyelid lining lesion	2.36	44.4	5.58 8.24	1.74	78.1	ZL 0	12.00	8.06	4 o	4.35 5.40	010
68135		< ∢	Remove evelid lining lesion	1.84	1.63	1.77	15.1	1.62	0.09	3.56	3.70	3.52	3.55	010
68200		4	Treat eyelid by injection	0.49	0.47	0.52	0.30	0.32	0.05	0.98	1.03	0.81	0.83	000
68320		⋖ .	Revise/graft eyelid lining	6.36	9.42	10.82	5.47	5.51	0.27	16.05	17.45	12.10	12.14	060
68325		∢ <	Revise/graft eyelid lining	8.35	¥ ž	¥ ź	6.16	6.45	0.44	¥ ž	Y S	14.95	15.24	060
68328			Revise/graft eyelid lining		(4 2 Z	ζ 4 2 Z	9.0	7 13	0.33	(4 2 Z	X	16.37	16.84	060
68330			Revise eyelid lining		7.64	8.97	4.59	4.69	0.24	13.45	14.78	10.40	10.50	060
68335			Revise/graft eyelid lining		ΥZ	ΥZ	6.13	6.32	0.36	ΥZ	AN	14.67	14.86	060
68340			Separate eyelid adhesions		7.07	8.42	3.99	4.07	0.21	12.07	13.42	8.99	9.07	060
68362			Revise eyelid lining		0.60 NA	00. V	70.9	6.35	0.03	- V	20.2 NA	9.20	15.04	060
68371			Harvest eye tissue, alograft		A A	¥ X	4.18	4.59	0.44	A A	Z Z	9.51	9.95	010
668399		ပ	Eyelid lining surgery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-

000000000000000000000000000000000000000	090	000000000000000000000000000000000000000	010 010 010 010 010 010 010 010 010 010	010 010 000 090 090	000000000000000000000000000000000000000	000 000 000 000 000 000 000 000 000 00	010 000 000 000 000 000 000	090 090 090 090 090 090
3.44 2.25 22.25 23.12 6.93 16.11 6.55 6.35	21.57 26.68 13.83 3.91 17.81	2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2	6.10 6.10 1.50 0.00 2.90	4.02 3.59 1.23 1.66 8.14	21.65 6.08 27.32 43.29 1.39 0.87	27.38 27.38 39.22 0.00 1.56 5.02	2.99 3.92 1.59 3.24 1.59 13.02 13.02 18.49	24.56 30.62 31.42 42.41 70.11 3.20 26.27 66.89
2.39 2.387 2.30 2.196 6.94 6.94 6.28 6.28	21.06 26.06 13.65 3.79 17.24	58.6.2.4.2.4.2.4.4.4.4.4.4.4.4.4.4.4.4.4.4	2 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	3.73 3.36 1.22 1.57 7.96 9.51	20.91 25.18 39.89 1.40 2.82	2.5.1 2.2.5.2 2.5.81 36.46 0.00 1.51 4.24	2.85 3.56 1.54 3.09 3.87 16.48 17.97	23.38 28.83 29.48 64.28 3.00 24.29 37.75
7.31 8.23 8.23 2.87 NA NA NA NA NA	Z Z Z 0.0 Z Z Z 0.0 Z Z Z Z Z	Z C C C C C C C C C C C C C C C C C C C	2.90.0 1.68 1.68 1.4.4	5.16 2.55 3.29 10.66	8.8 8.8 8.0 8.0 8.0 8.0 8.0 8.0 8.0 8.0	2.6.2. 2.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.	2.4 2.6 2.7.4 2.6.4 2.6.4 3.6.4 4.6.4 6.6.4 6.6.4 6.6.4 6.6.4 6.6.4 6.6.4 6.6.4 6.6.4 6.6.4 6.6.	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
6.21 7.11 7.27 NA NA NA NA NA NA NA NA NA NA NA NA NA	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	3.30 3.30 3.30 3.30 8.48 8.48	9.94 2.87 1.56 0.00	5.02 5.44 2.64 3.39 11.23 NA	2.24 A S S A S S S S S S S S S S S S S S S	3.50 0.00 0.22 0.00	4.4 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7	X X X X X 4 4 4 4 4 6 6 X X X 4 4 4 4 4 6 4 4
0.08 0.11 0.05 0.05 0.23 0.23 0.22 0.18	0.52 0.80 0.32 0.10 0.44 0.53	0.000000000000000000000000000000000000	0.00 0.00 0.00 0.00 0.00 0.00	0.17 0.03 0.07 0.30 0.38	0.65 0.21 1.22 1.92 0.00 0.10	0.00 0.72 0.85 0.00 0.00 0.05	0.11 0.07 0.13 0.19 0.61 0.45	1.00 1.05 1.09 1.54 2.92 0.10 0.10 2.91 2.91
	0 4 0 10 V a	0-0-0-0	300732	4004	450-0		£4 \ 6 £ 6 £ 6 £ 6 £ 6 £ 6 £ 6 £ 6 £ 6 £ 6	0 0 ω 0 0 0 - 4 ω
1.67 1.94 1.26 1.26 1.27 1.93 2.52	9.2 1.11 5.9 7.7 7.6		2.2.2. 5.0.00 5.0.00		6. 8. 4. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6.		2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0	11.2 16.6 16.8 30.0 30.0 1.9 14.4 19.6 19.6 19.6
1.22 1.46 1.21 9.11 2.11 6.68 6.68	8.71 10.52 5.74 1.63 7.10	7.45 7.64 1.50 5.88 7.45	2.17 2.49 1.32 0.00 1.24	1.45 1.76 0.38 0.65 4.23 5.09	12:30 3:10 10:55 15:01 0:57 0:57	0.61 1.73 14.19 18.16 0.00 0.61 0.56	1.41 1.68 0.62 1.44 1.72 8.31 6.96 7.80	10.02 14.81 14.89 17.97 24.19 1.70 13.06 16.55
5.54 1.88 1.88 1.88 NA NA NA NA NA NA NA NA NA NA NA NA NA	A A A E A A	NA NA 1.92 1.94 1.94	NA NA 1.59 1.59 1.00 1.00 1.00	2.88 3.95 1.73 NA	N N N N N N N N N N N N N N N N N N N	3.80 NA NA 1.30 1.30	N N N N N N N N N N N N N N N N N N N	 &
			, , , , , , ,	.,	2, 14 0 1			· ·
4.4 4.70 1.28 NA NA NA NA NA NA NA NA NA	Z Z Z Z E Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	2.66 4.88 1.82 1.82 1.82	0.72 0.72 0.00 0.00	2.74 3.84 1.80 2.47 7.50 NA	6.53 2.03 2.03 2.03 2.03 2.03 2.03 2.03 2.0	9.3.6 9.6.0 0.00 0.00 0.00 0.00 0.00	3.05 3.05 3.05 8.05 8.05 8.05 8.05 8.05 8.05	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
1.69 1.69 1.69 1.69 1.69 1.69 1.69 1.69	.83 .74 .59 .06 06	287.78 10.04 10.04	5 6 6 5 5 6 5 5	1	96. 14.62 15.02 16.02 16.03			
+ 40 ti 4 8 4 0	<u>+</u> 4 × 000	,, o, e e a o c	140-00-	W = 00 0 4	K44040406	2-0540004	0100	44698-558
			\$ \$\frac{1}{2}\$	ion nal rtial				euo
Incise/drain tear gland	Remove tear gland lesion	Create tear duct drain Close tear duct opening Close tear duct opening Close tear system fistula Close tear duct opening	Probe nasolacimal duct Probe nasolacimal duct Probe nasolacimal duct Explore/irrigate tear ducts Injection for tear sac x-ray Tear duct system surgery Drain external ear lesion	Drain external ear lesion	Remove ear canal lesion(s) Remove ear canal lesion(s) Extensive ear canal surgery Clear outer ear canal Clear outer ear canal Clear outer ear canal	Ulean out mastoid cavity Clean out mastoid cavity Revise external ear Rebuild outer ear canal Rebuild outer ear canal Outer ear surgery procedure Inflate middle ear canal Cattheferize middle ear canal Cattheferize middle ear canal	Incision of eardrum Incision of eardrum Remove ventilating tube Create eardrum opening Cycate eardrum opening Exploration of middle ear Eardrum revision Mastoidectomy	Mastoidectomy Remove mastoid structures Extensive mastoid surgery Extensive mastoid surgery Remove part of temporal bone Remove ear lesion
Incise/drain tear gland Incise/drain tear sac Incise tear duct opening Removal of tear gland Partial removal, tear gland Biopsy of tear gland Removal of tear sac Blopsy of tear sac	Remove tear gland lesion Remove tear gland lesion Repair tear ducts Revise tear duct opening Create tear sac drain Create tear duct drain	Greate tear duct drain Create tear duct drain Glose tear duct opening Close tear system fistula Close tear system fistula Dilate tear duct opening	Probe nasolacrimal duct Probe nasolacrimal duct Probe nasolacrimal duct Explore/irrigate tear ducts Injection for tear sac x-ray Tear duct system surgery Drain external ear lesion .	Drain external ear lesion Drain outer ear canal lesion Biopsy of external ear Biopsy of external ear canal Remove external ear, partial Removal of external ear	Remove ear canal lesion(s) Remove ear canal lesion(s) Extensive ear canal surgery Clear outer ear canal Clear outer ear canal Remove impacted ear wax	d cavity d cavity at canal proce proce canal canal	m m juliant de la composition della compo	Mastoidectomy Remove mastoid structures Extensive mastoid surgery Extensive mastoid surgery Remove part of temporal b Remove ear lesion
Incise/drain tear gland Incise/drain tear sac Incise tear duct openin Removal of tear gland Partial removal, tear gl Biopsy of tear gland Removal of tear sac Blopsy of tear asc Blopsy of tear deduct collearance of tear duct Clearance of tear duct	ear glar ear glar ir ducts ar duct ir sac c	ir duct o duct o duct o syster o duct o duct o syster o duct o duct o duct o duct o	olacrim olacrim igate te or tear system	rnal ea ir ear c externs externs xternal	Remove ear canal les Remove ear canal les Extensive ear canal su Extensive ear/neck su Clear outer ear canal Clear outer ear canal	Clean out mastoid caving Clean out mastoid caving Bevise external ear	Incision of eardrum Incision of eardrum Remove ventilating Create eardrum ope Create eardrum ope Exploration of middl Eardrum revision	Mastoidectomy Remove mastoid st Extensive mastoid st Extensive mastoid st Extensive part of ten Remove ear lesion Remove ear lesion Remove ear lesion Remove ear lesion
se/drai se/drai se tear moval c tial ren psy of moval c psy of arance	move te nove te sair tea vise tea tea tea tea tea tea tea tea tea te	sate tea se tear se tear se tear se tear ate tear	be nas be nas be nas slore/irr ction fo ar duct	uin exterin oute psy of psy of psy of nove e novel control	move e ensive e ensive e ensive ar oute ar oute	an out an out an out an out an out ise extracted or onlid or our ate mid ate mid ate mid ate mid ate mid iheteriz	Incision of eard Incision of eard Remove ventila Create eardrum Create eardrum Exploration of r Eardrum revisio Mastoidectomy	Mastoidectomy Remove mastc Extensive mast Extensive mast Remove part o Remove ear le Remove ear le Remove ear le
nc lnc lnc lnc lnc lnc lnc lnc lnc lnc l	B.B. B. S.	Create Close Close Close Dilate	F. C. F. F. C. F.	Bio		Cat in the	Inc Cre Cre Exr Ear	Marian Ma
<u> </u>	44444		(444404	44444	<<<<<<<	<< < < < < < < < < < < < < < < < < < <	~ ~ ~ ~ ~ ~ ~ ~	<u> </u>
68400 68420 68440 68500 68505 68510 68520 68520	68540 68550 68700 68705 68720	68750 68760 68761 68770 68801	68811 68815 68840 68850 68899 69000	69005 69020 69100 69105 69120	69145 69145 69150 69155 69200 69205 69210	69220 69222 69300 69310 69320 69399 69400	69420 69421 69424 69433 69436 69440 69450	69502 69505 69511 69530 69530 69540 69550 69552

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Fully im- plement- plement- fiv PE 2007 plement-plement- plement- plement- plement-plement- plement-plement- plement-plement- plement-plement- plement-plement- plement-plement- plement-plement- plement-plement- plement-plement-plemen	חחא			HELATIVE VALUE CIVIS (11VOS) AND	והואו	ס אוסו ואואים חאוו חם ואום ה	2	קרם וויי הרים ווייים ביים ביים ביים ביים ביים ביים		מ ועובטוטאווא	-		1007		
Massied suppry vertical 1352	~ %	Mod	Status	Description	Physician Work RVUs	Fully Implemented Non-Facility PE RVUs	Year 2007 Transi- tional Non-Fa- cility PE RVUs		Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Practice RVUs		Year 2007 Transi- tional Non-Fa- cility Total		Year 2007 Transi- tional Fa- cility Total	Global
Marchel auglory revision 1, 100			⋖・	surgery revision	13.22	Y:	4 2 2	10.84	12.21	1.07	Y Z	4 2 2	25.13	26.50	060
Masted agraph version 14.00 NA NA 1157 1154 NA NA 156 NA NA NA 156 NA NA NA 156 NA NA NA 156 NA NA NA NA NA NA NA N				Mastoid surgery revision		A Z	Ψ Δ Z Z	15.03	12.81	01.1	Ψ Z Z Z	A A	30.22	32.67	060
A https://doi.org/10.1006/10				Mastoid surgery revision		Υ Z	Y Z	11.67	13.19	1.14	Z Y	A A	26.81	28.33	060
A Registration of activities C A A A S A A A A S A A A A A S A A A A	-			Mastoid surgery revision		ΑZ,	Y Z	17.50	20.09	1.50	Ϋ́	Y Y	37.46	40.05	060
A Revisit and/order structures 2 88 NA NA 1418 10 00 0.000 1/4 10 0 0.000 1/4 10 0 0.000 1/4 10 0 0.000 1/4 10 0 0.000 1/4 10 0 0.000 1/4 10 0 0.000 1/4	-			Repair of eardrum		4.47	5.28	2.30	3.03	0.36	9.25	10.06	7.08	7.81	010
A fibrile deform structures 2 m	-			Repair eardrum etructures		40.01 4 N	0.83 VIA	5.29	10.04	0.48	16.40 AN	1.2./	1.65 1.65	21.68	060
A Figure cardum structures 12.00				Rebuild eardrum structures		ζ ζ Ζ	ζ 4 2 Z	12.08	13.12	1.03	Z Z	ζ 4 Ζ Ζ	25.84	26.88	060
A Regular autrum stuctures 15.00 NA NA 16.00 16.00 NA NA 16.00 NA NA 16.00 16.00 NA NA 16.00				Rebuild eardrum structures		Υ Z	Z Z	11.91	12.77	0.98	Υ Z	ξ Z	24.97	25.83	060
A Rebuild aequrum stuctures 15.20	-			Repair eardrum structures		A N	A V	14.83	16.26	1.08	AN A	A A	29.22	30.65	060
A Review mixture ear a masted 15.69 NA NA 11.37 11.22 NA NA 25.89 A A Review mixture ear a masted 15.69 NA NA 11.37 11.24 NA NA 25.93 A A Review mixture ear a masted 15.86 NA NA 11.24 NA NA 25.93 A A Review mixture ear a masted 11.84 NA NA 11.27 NA	-			Rebuild eardrum structures		Y Z	Y Z	16.60	18.63	1.23	Y Y	Y Y	33.03	35.06	060
A Revise middle ear for missed 1.28 is NA NA 14.15 1.27 1.27 1.28 NA NA 14.15 1.27 1.27 1.27 NA NA 22.27 1.27 N	-			Rebuild eardrum structures		Y :	Ψ.	16.58	18.56	1.22	Ψ.	Y :	32.89	34.87	060
A Revise middle ear foreward 17.00 NA NA 17.01 17.	-			Revise middle ear & mastoid		Υ S	Υ S	11.31	12.41	1.03	Υ S	Υ S	25.03	26.13	060
Page 1975 Page 297	-			Revise middle ear & mastold		Ψ <u>Υ</u> 2	¥ \$	0.4.0	15.72	92.1	Ψ <u>Υ</u>	Υ S	32.22	33.89	060
Packer middle are from seriod 16.4 m				Revise middle ear & masteid		₹ ₹	Υ	17.81	19.32	1.24	¥ < Z	¥ 4 Z Z	79.4-	30.92	060
A Felerase middle ear brone 18.14 NA NA 17.45 19.58 NA NA 19.05				Bevise middle ear & masteid		ξ Δ Ζ Ζ	ζ Δ Ζ Ζ	17.03	19.57	1.57	₹	ζ Δ Ζ Ζ	37.80	37.08	060
A Review middle ear brone 155				Bevise middle ear & mastoid		(4 2 Z	Z Z	17 42	19.67	1 46	Z Z	Z Z	37.02	39.53	060
A Proces middle ear brone 11.88 NA 12.5 NA 11.89 NA 12.92 NA NA 22.91 NA NA 22.91 NA NA 22.91 NA NA 12.92 NA NA NA 20.92 NA NA NA 20.92 NA				Release middle ear bone		₹ Z	Z Z	8.64	9.59	0.78	Z Z	¥ Z	19.07	20.02	060
A Protes emiddle ear bone 15.72 NA 12.7 14.07 13.7 NA 12.7 NA 12.7 NA 12.7 NA 12.7 NA NA 12.7 NA NA 12.9 NA NA 13.9 NA NA				Revise middle ear bone		Ϋ́	A N	9.52	10.77	0.96	AN	¥ Z	22.36	23.61	060
A Revise middle ear structures 9.74 NA 11.29 9.73 NA NA 19.45 A Repair middle ear structures 9.75 NA NA 11.25 NA NA 19.45 NA NA NA 19.45 NA NA NA NA NA NA NA N	-			Revise middle ear bone		₹ Z	A A	12.17	14.07	1.27	A A	A A	29.16	31.06	060
A Repair middle ear structures 9.74 NA NA 8 82 9.71 NA 19.35 A A Repair middle ear structures 9.75 NA NA 10.15 NA NA 10.15<				Revise middle ear bone		ΥZ	A A	11.29	13.14	1.25	A A	A A	27.96	29.81	060
Pepelir mode ear structures 9.55	i			Repair middle ear structures		٧ Z	A A	8.92	9.71	0.79	A A	Ϋ́	19.45	20.24	060
A Hemove middle ear mere 1155 NA NA 765 814 0.61 NA NA 1.55 NA NA	-			Repair middle ear structures		Y :	Y :	8.83	69.6	0.79	A :	¥:	19.37	20.23	060
A Ference and	-			Remove mastoid air cells		Ϋ́Z Z	Y :	10.15	11.32	0.93	Α :	Υ :	22.63	23.80	060
Particle	-			Remove middle ear nerve		Υ S	Ψ < Z Z	9.63	10.47	0.81	Υ S	Ψ < Z Z	19.95	20.79	060
The properties of the proper	-			Domovo/ropair booring aid		₹ < Z Z	Υ < 2 2	7.00	8.84 10.44	0.07	¥ < Z	¥	10.34	21.73	060
Temple bre implirit wistimulat				Implant temple hope w/stimul		Z Z	ζ φ 2 Ζ	10.56	10.45	5. 5.	Z Z	(4 Z Z	25.92	27.50	060
Temple bone implant revision 15.21				Temple bne implnt w/stimulat		ζ ζ Ζ	ζ 4 2 Z	11.94	14.26	1.48	Z Z	Z Z	32.32	34.46	060
A Please's temple bone implant 118 97 NA 20 26 16 54 3.21 NA 42.44 A Pleases stalal neve 17.48 NA 12.75 14.08 1.16 NA NA 42.44 A Pleases stalal neve 16.34 NA 11.77 12.85 1.27 NA NA 48.10 A Pleases stalal neve 16.34 NA 11.77 12.85 1.27 NA NA 48.10 A Please stalal neve 16.84 NA NA 11.77 12.85 1.27 NA NA 28.56 A Please stalal neve 16.84 NA NA 11.77 12.85 1.77 NA 17.99 A Please stalal stal alone ner 10.00 0.				Temple bone implant revision		Z Z	Z Z	11.31	13.68	06:0	Υ Z	Z Z	27.42	29.79	060
A Belease facial neve 14.48 NA NA 12.75 14.08 1.16 NA 28.39 A Belease facial neve 27.36 NA NA 16.30 19.17 2.44 NA A 69.16 A Bepair facial neve 16.12 NA NA 11.87 1.44 NA 28.56 A Repair facial neve 16.84 NA NA 11.87 1.42 NA A 69.17 A Repair facial neve 16.84 NA NA NA 11.87 1.42 NA NA 28.56 A Incise inner ear 10.32 NA NA NA 8.75 NA NA 1.05 NA NA 22.82 A Incise inner ear window 10.24 NA NA 9.37 10.62 NA NA 22.82 A Remove inner ear window 10.24 NA NA 11.68 NA NA 10.08 NA NA 22.64 A Remove inner ear window 10.24 NA NA				Revise temple bone implant		ΥZ	₹ Z	20.26	16.54	3.21	Υ Z	A Z	42.44	38.72	060
A Prepare facial nerve 27.36 NA 16.3 NA 16.3 NA 16.4 NA 46.10 A Prepare facial nerve 16.12 NA NA 11.17 12.85 1.27 NA NA 28.56 C Middle ear surgery procedure 0.00 <				Release facial nerve		Ϋ́	A N	12.75	14.08	1.16	AN	A N	28.39	29.72	060
A Repair facial nerve 16.12 NA NA 11.17 12.85 1.27 NA NA 28.56 C Middle ear surgery procedure 0.00	-			Release facial nerve		A A	A N	16.30	19.17	2.44	A A	A A	46.10	48.97	060
A Repair facial nerve 16.84 NA 11.87 14.20 1.14 NA 29.85 A Incise inner ear 0.00 0.0	-			Repair facial nerve		ΥZ	A A	11.17	12.85	1.27	AN	A A	28.56	30.24	060
C Middle ear surgery procedure 0.00	-			Repair facial nerve		٧Z	A A	11.87	14.20	1.14	A A	A A	29.85	32.18	060
A Incise inner ear B 55 NA NA 8.75 9.28 0.69 NA NA 24.39 A Explore inner ear 1.32 NA NA 9.80 1.12 NA NA 24.39 A Explore inner ear 1.245 NA NA 9.80 1.13 NA NA 22.82 A Explore inner ear 10.24 NA NA 9.80 1.13 NA NA 22.82 A Explore inner ear window 10.24 NA NA 9.80 1.13 NA NA 22.82 A Revise inner ear window 10.24 NA NA 11.67 1.08 0.79 NA NA 22.06 A Revise inner ear window 11.08 NA NA 11.67 1.08 0.79 NA NA 22.06 A Remove inner ear ear near ear ear ear ear ear ear ear ear ear	-			Middle ear surgery procedure		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	<u></u>
Main	-			Incise inner ear		Y :	Y :	8.75	9.28	0.69	Y :	Y Z	17.99	18.52	060
A Explore inner ear Explore inner ear 12.45 NA 9.80 11.36 1.12 NA 25.41 A Explore inner ear window 10.24 NA NA 9.37 10.62 1.00 NA NA 22.67 A Revise inner ear window 10.24 NA NA 11.67 12.80 0.79 NA NA 22.70 A Revise inner ear window 11.08 NA NA 11.67 12.80 0.79 NA NA 22.70 A Remove inner ear window 11.08 NA NA 11.67 NA NA 22.70 A Remove inner ear window 11.08 NA NA NA 11.69 NA NA 22.70 A Remove inner ear window 11.08 NA NA NA 11.69 NA NA 12.80 0.79 NA NA 22.73 A Incise inner ear window 11.54 NA NA 11.40 NA NA 12.90 NA NA 12.90	-			Incise inner ear		▼ :	Y :	10.54	11.88	1.06	Z :	Z :	24.92	26.26	060
A Explore inflict earl 12.45 NA NA 9.83 10.02 NA NA 22.02 A Revise inner ear window 10.24 NA NA 11.67 12.80 NA NA 22.05 A Remove inner ear window 10.24 NA NA 11.67 12.80 NA NA 22.05 A Remove inner ear window 11.08 NA NA 11.63 0.09 NA NA 22.05 A Remove inner ear and window 13.73 NA NA 11.39 1.07 NA NA 22.06 A Implant cochlear device 22.57 NA NA 11.39 1.07 NA NA 22.06 C Inner ear nerve 22.57 NA NA 11.39 1.07 NA NA 30.71 C Incise inner ear nerve 22.38 NA NA 15.41 18.89 2.74 NA 44.78 Belease finci en reve	1			Explore Inner ear		₹ ₹	¥ S	9.80	11.36	2 6	Y S	Υ Υ	14.02	26.97	060
Persistent of the following carried by the carried books inner ear and contrast x-ray of brain ear ary of the carried books inner ear garden for carried brain for carried brain for carried brain for carried for carried brain for carried for carried for carried brain for carried for carri	-			Explore limer ear		₹ ≤ 2	¥ < 2	9.5/	10.02	9.6	¥ < 2	Υ < 2 2	24.02	24.07	060
Name of the contract with th				Dovies inner ear will dow		(<u> </u>	ζ < Ζ Ζ	9.03	10.07	0.30	ζ <u> </u>	ζ < 2 Z	21.03	22.03	060
Name of the contract of the	-			Remove inner ear		(d	(d). C	11.03	06.0	(d	2 2	22.70	23.03	060
Incise inner ear nerve 22.57				Remove inner ear 8. mactoid		(d	ζ	00.0	11.33	2.90	(d	ζ Δ Ζ Ζ	24.59	26.19	060
Microsurgery add-on 17.54 NA NA 11.81 14.02 1.36 NA NA 30.77				Incise inner ear nerve		(4 2 Z	Z Z	13.38	15.69	69	Z Z	Z Z	37.64	39.95	060
C Inner ear surgery procedure 0.00 0				Implant cochlear device		\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Z Z	11.81	14.02	38.	Z Z	Z Z	30.71	32.92	060
Macrosurgery add-on A Microsurgery add-on 27.38 bit with the contrast x-ray of brain NA bit with the contrast x-ray of brain 15.12 bit with the contrast x-ray of brain 17.30 bit with the contrast x-ray of brain 22.28 bit with the contrast x-ray of brain NA bit with the contrast x-ray of brain NA bit with the contrast x-ray of brain NA bit with the contrast x-ray of brain 17.30 bit with the contrast x-ray of br				Inner ear surgery procedure		0.00	0.00	00.0	0.00	00:00	00:0	0.00	00.00	0.00	<u>}</u>
A Release facial nerve	-			Incise inner ear nerve		Ϋ́	ΑN	15.12	17.96	2.28	AN	A A	44.78	47.62	060
A Release inner ear canal 29.14 NA NA 15.41 18.89 2.17 NA NA 46.72 A Remove inner ear lesion 32.13 NA NA 17.78 21.90 2.41 NA NA 52.32 C Temporal bone surgery 0.00 <td< td=""><td>:</td><td></td><td></td><td>Release facial nerve</td><td></td><td>Ϋ́</td><td>AN</td><td>17.30</td><td>20.36</td><td>2.48</td><td>AN</td><td>AN</td><td>48.92</td><td>51.98</td><td>060</td></td<>	:			Release facial nerve		Ϋ́	AN	17.30	20.36	2.48	AN	AN	48.92	51.98	060
A Remove inner ear lesion 32.13 NA NA 17.78 21.90 2.41 NA NA 52.32 C Temporal bone surgery 0.00 <t< td=""><td></td><td></td><td></td><td>Release inner ear canal</td><td></td><td>Ϋ́</td><td>A V</td><td>15.41</td><td>18.89</td><td>2.17</td><td>AN</td><td>AN</td><td>46.72</td><td>50.20</td><td>060</td></t<>				Release inner ear canal		Ϋ́	A V	15.41	18.89	2.17	AN	AN	46.72	50.20	060
C Temporal bone surgery 0.00 <td>-</td> <td></td> <td></td> <td>Remove inner ear lesion</td> <td></td> <td>AN</td> <td>Y V</td> <td>17.78</td> <td>21.90</td> <td>2.41</td> <td>A N</td> <td>AN</td> <td>52.32</td> <td>56.44</td> <td>060</td>	-			Remove inner ear lesion		AN	Y V	17.78	21.90	2.41	A N	AN	52.32	56.44	060
R Microsurgery add-on	-			Temporal bone surgery		0.00	00.00	00.00	0.00	0.00	0.00	0.00	0.00	0.00	λ
A Contrast x-ray of brain	-		œ .	Microsurgery add-on	3.46	Y Y	Y Z	1.29	1.67	0.89	Y Y	Y Y	5.64	6.02	222
			Α	Contrast x-ray of brain	1.19	2.77	4.23	- A	- VA	0.27	4.23	2.69	- N	- NA	×××

	₹ŠŠ
2. 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	2 Z Z S Z Z
2. 7. 6. 7.	S S S
1.66 3.36 3.36 3.36 0.024 0.025 0.036 0.037 0.037 0.037 0.037 0.038 0.038 0.038 0.039 0.047 0.047 0.039 0.039 0.047 0.039 0.03	- 58. - 86. - 78.
-4) O O
1.65 1.65 1.65 1.65 1.65 1.65 1.65 1.65	0.96
$\begin{smallmatrix} 0&0&0&0&0&0&0&0&0&0&0&0&0&0&0&0&0&0&0&$	200
	 8 4 4
	>
2.5 A	2 Z Z 2 Z Z
$\begin{array}{c} 0.0.0 \\$	0.81
2.240 2.285 2.240	.90. 9.91 —————————————————————————————————
000000000000000000000000000000000000000	,00
$\begin{smallmatrix} 1 & 0 & 0 & 1 & 1 & 1 & 1 & 1 & 1 & 1 &$	0.00
	
ain	
ay of brain af of action as body and astoids and astoid and astoids and astoid	teeth teeth
b b b b b b b b b b b b b b b b b b b	ੂੰ ਰੂ ਰ
ast x-ray of b ast x-ray of ast x-ray of j aw exam of j aw exam of j aw exam of mas exam of faci exam of faci exam of faci exam of faci exam of since exam of settle exam of teet exam	ruii moutn x-ray Full mouth x-ray X-ray exam of ja
Contrast Con	Full mo
444444444444444444444444444444444444444	< < <
26	TC ::
70010 700110 700115 700015 700010 70100 70100 70100 701110 701120 701130	70320 70320 70328

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2007—Continued

Global	
Year 2007 Transitional Facility Total	2.0 A A B S A A A B A A A A A A A A A A A A
Fully Im- plement- ed Facil- ity Total	22 A A S S A A S A
Year 2007 Transi- tional ity Non-Fa-	0.025 0.033 0.033 0.052 0.052 0.052 0.053
_ ≧¤Z g g	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Mal-Practice RVUs	0.000000000000000000000000000000000000
Fully Im- Plement- ed Facil- ity PE Cility PE Cility PE Cility PE RVUs	0. X X 0. X 0
Fully Implement ed Facility PE RVUs	0.8
O ᅩᅩᆢᆱᅝ몺	0.000000000000000000000000000000000000
Fully Implemented Non-Facility PE RVUs	0.00 1 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2
Physician plement Trans Work ed Non- RVUs Facility North PERVUs RVUs RVUs RVUs RVUs RVUs RVUs RVUs	0.000000000000000000000000000000000000
Description	X-ray exam of jaw joint X-ray head for orthodontia X-ray exam of neck X-ray exam of salivary gland X-ray exam o
. Statı	444444444444444444444444444444444444444
Wod 8	85 85 85 85 85 85 85 85 85 85 85 85 85 8
CPT1/ HCPCS ²	70328 70330 70330 70330 70332 70332 70332 70332 70335 70336 70355 70355 70350 70450

A 5 5 4 5 5 4 5 5 5 5 5 5 5 5 5 5 5 5 5	A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L A N N L L L A N N L L A N L L L A N L L L A N L L L A N L L L A N L
A Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	A A A A B A A A A A A A A A A A A A A A
8.6.6.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.	23.38 4.1.5.64 4.1.2.5.64 4.1.2.5.64 2.3.36
0.00 0.00	24.50 1.4.93 1.6.29 1.6
0.000000000000000000000000000000000000	0.000000000000000000000000000000000000
2 4 5 7 4 6 5 4 5 5 4 5 5 5 5 5 5 5 5 5 5 5 5 5	O O O O O O O O O O O O O O O O O O O
Z 4 Z N 6 Z 2 4 Z 2 4 Z 2 4 Z 2 Z 2 Z 2 Z 2 Z 2 Z	A A 8 8 A A 8 8 A A 8 A A A A A A A A A
6.0.0 6.0 6.0 6.0 6.0 6.0 6.0 6.0 6.0 6.	2.2.79 12.73 12.73 12.73 12.73 12.73 13.83 14.46 14.46 14.46 15.50 16.50 17.46 17.46 18.47 19.60 1
8.00 C C C C C C C C C C C C C C C C C C	23.91 16.09 16.09 16.03 16.03 16.03 17.03 18.03 18.03 19
6.50 6.50 6.50 6.50 6.50 6.50 6.50 6.50	0.00 0.00
Ct maxillofacial w/dye Ct maxillofacial w/dye Ct maxillofacial w/dye Ct maxillofacial w/d & w/dye Ct maxillofacial w/o & w/dye Ct maxillofacial w/o & w/dye Ct maxillofacial w/o & w/dye Ct soft tissue neck w/o dye Ct soft tissue neck w/dye Ct st tsue nck w/o & w/dye Ct st tsue nck w/o & w/dye Ct angiography, head Ct angiography, head Ct angiography, neck Mri orbit/face/neck w/dye Mri angiography head w/dye Mr angiography head w/dye Mr angiography head w/o&w/dye	Mr angiograph head w/o&w/dye Mr angiography neck w/o dye Mr angiography neck w/o dye Mr angiography neck w/o dye Mr angiography neck w/dye Mr angiography neck w/o&w/dye Mr angiograph neck w/o&w/dye Mr brain w/o dye Mri brain w/o dye Mri brain w/o & w/dye Mri brain w/o dye
444444444444444444444444444444444444444	<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
26 26 26 27 26 26 26 26 26 26 26 26 26 26 26 27 26 26 26 27 26 27 27 27 27 27 27 27 27 27 27 27 27 27	
0487 0487 0488 0498 0498 0499 0499 0496 0496 0496 0496 0496 0496 0496 0496 0496 0496 0497 0497 0498 0498 0498 0498 0498 0498 0643 0644 0646	74446 744448884747474747474747474747474747474
70487 704887 704887 70488 70488 70498 70499 70499 70498 70498 70498 70498 70498 70498 70498 70540 7054	70546 70547 70547 70548 70548 70549 70549 70559 70551 70552 70552 70553

Addendum B.—Relative Value Units (RVUS) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	
Year 2007 Transi- G tional Fa- cility Total	A 22 A 2 2 A 2 A 2 A 2 A 2 A 2 A 2 A 2
	A 2 2 4 4 5 5 5 4 5 5 5 5 5 5 5 5 5 5 5 5
Fully Implement ed Facility Total	
Year 2007 Transi- tional Non-Fa- cility Total	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Fully Implemented Non-Facility Total	0.64 0.29 0.39 0.39 0.39 0.30 0.30 0.30 0.30 0.3
Mal-Prac- tice RVUs	0.000000000000000000000000000000000000
Year 2007 Transi- tional Fa- cility PE RVUs	00 Z Z O Z Z
Fully Implemented Facility PE	A 20 5 4 5 0 5 4 5 6 5 5 5 6 5 5 5 6 5 5 5 6 5 5 5 6 5 5 5 6 5 5 6 5 5 6 5 5 6 5 5 6 5 6 5 5 6 6 5 6 5 6 6 5 6 6 5 6 6 5 6 6 5 6 6 5 6 6 5 6 6 5 6 6 5 6
Year 2007 Transi- tional Non-Fa- cility PE RVUs	0.05 0.05
Fully Implemented Non-Facility	0.00 0.00
Physician Work RVUs	0.000 8 8 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Description	Chest x-ray and fluoroscopy Chest x-ray Chest
Status	
Mod	18 12 28 12
CPT1/ HCPCS ²	71010 71010 71010 71010 71010 71020 71020 71020 71020 71020 71020 71030 71100 71111 71111 71111

																																										_		
***	{	××	X	××	×	žž	×	× š	žž	××	X	××	×	× >	ξ× ×	X	××	ξ× ×	X	××	X	× š	××	X	× }	₹×	×	××	ξ× ×	×	žž	×	××	ξ× ×	X	××	{×	×	× >	ξ× ×	× >	ξ× ×	× }	{× ×
A A 7.5	Z Z 8	Z Z	2.64	 ≰ ₹	2.00	¥ ₹	2.38	¥ S	3 N	Z Z	Ϋ́	05.5 AN	¥ Z	0.62	₹	0.21	Y Y	0.30	¥:	0 A A	Z Z	ΣS	0.50 AN	Ž	0.31	¥	0.30	Z Z	0.30	¥ 2	N 0	Ž	A S	S Z	¥	0.38 NA	 ₹ ₹	0.30	¥ S	0.42	 ₹ 2	0.50	¥ S	08.0
AN 1.68	5 € 8	Z Z	83	4 4 2 2	0.5	 ≰	.37	¥ S	<u>₹</u> ∓		ξi	رة A	¥	9.5	ξş	57	¥ S	<u>ر</u> ج	¥:	₹ 4	! §	ξŞ	94. N	≨	ج ج ج	<u>₹</u>	8	¥ ₹	ج ج ج	¥ S	4 S	¥	¥ %	8 X	¥	66. A	Y Y	8	¥	5 4	¥ £	50 4	¥ S	₹ E.
-	-		7		7		7		cr.)	•	N		0		0		0		C	•	•	>		0		0		0		0		c	>		0		0		0		0		0
6.27 9.27 1.70	11.41	9.53	2.64	12.46	2.00	7.38	2.38	15.00	3 10	24.88	15.22	2.50	1.77	0.62	0.65	0.21	0.44	0.30	0.67	0.42	0.97	1.73	0.50	0.87	0.31	0.00	0.30	1.07	0:30	0.77	0.30	96.0	00.0	0.70	1.15	0.38	1.03	0.30	0.73	0.42	1.00	0.50	1.32	0.30
6.41 9.67 1.68	12.05	10.17	2.63	11.53	2.00	20.49	2.37	18.1	3.45	22.84	18.03	15.53	1.98	0.60	0.64	0.21	0.44	0.30	0.74	0.45 0.45	1.03	1.83	0.49	1.02	0.3	0.0	0.30	0.61	0.30	0.75	0.30	0.94	0.97	0.66	1.34	0.39	1.08	0.30	0.78	0.42	1.10	0.50	1.51	0.31
	22.52	9 4	200	 51 39	96.	£ 8		22.52	 2 C	2 88	25	20 G		2 %	 	5.5	2) R	3.5	4 ;			<u>ه</u> و	N 6	. e		7 75	5	4 % —	3 5	22		9	5 5	- 4	22	<u> </u>	4 元 ——		4 b		90	 8	9.0	
0.31 0.42 0.05	000	òò	000	ö ö	ö	òö	0.0	0.0	o c	öö	0.0		0.0	ö ö	öö	0.0	o c	öö	0.0		öö	0.0		ö	0.0	o o	0.	ö c	öö	0.0	o o	ö	ö c	öö	0.	ö ö	3 0	0.0	ö ö	; ö	0.0		0.0	
A N 6 5	₹ ₹ £	¥ Z	0.63	<u> </u>	0.48	≰	0.57	ž ž	7 V V	ž Ž	Ϋ́	19.0 V	₹	0.15	ξŞ	0.05	₹ \$ 2 2	0.07	≨:	Z C	2 <u>4</u>	¥ S	N 8	ž	0.08	₹ ₹	0.07	Δ Z Z	0.07	¥ S	0.0 V	ž	Z 2	ž	¥	0.09 V	ξŽ	0.07	<u> </u>	0.10	¥ ž	0.12 	¥ ž	0.07
																														-														
0.39 A A 8	₹ ¥ 4	ZZZ	0.62	₹ ₹ Z	0.48	¥ ₹	0.56	₹	0 75 75	<u>8</u> ₹	Ϋ́	0.62 NA Z	Ϋ́	0.13	₹₹	0.05	₹ \$ 2 2	0.07	₹:	A C	<u>8</u> ₹	₹	L.O A	Ž	0.08	₹₹	0.02	Z Z	0.07	Ϋ́	0.07	Ϋ́	A C	ΣŽ	Ϋ́	0.10	₹₹	0.07	₹ ≥	0.10	¥ ž	0.12	ŽΞ	0.08
9555	- 	· <u> </u>	ာက္က၊	2	1 00	- <u>-</u>		φ <u>5</u>	4 4 —	- 0	4	- 4	4	رم د) I-	ις O	Ņ Ç	- C	·Ω			<u>ල</u> ල	N 1~	- 21	<u> </u>	4 0		က္ တ	- C	10		0	ლ <u>Ի</u>	- 9	Ŋ	<u>ඉ</u> ද	ა რ —		 0 Z	 	4 c	 p q	9.9	- E
5.96 7.61 0.41	9. 6 7. 6. 6	9.0	0.0	12.0	0.4	12.4	0.5	14.4	24.C	24.2	12.7	0.5	1.5	- 0	0.4	0.0	0.0	0.0	9.0		0.0	7	5 -	0.6	0.0	0.0	0.0	0.0	0.0	0.7		0.6	0.0	0.0	9.0	0.0	. 0	0.0	9	- 5 - 5	0.6	- 6	4. 0	0.0
6.10 8.01 0.39	0.15	9.71	0.62	1.14	0.48	6.27 8.16	92.0	7.59	18.2	2.16	5.55	0.62 24 24	1.45	0.13	0.46	0.05	0.42	0.07	0.70	7.07	0.97	1.39	1.72	0.77	0.08	0.03	0.07	0.57	0.07	0.70	0.95	0.88	0.70	0.62	1.01	0.10	0.32 0.81	0.07	0.74	0.10	1.04	0.12	1.45	0.08
	÷ -	- -	,		•			- -	N -	~	-		•																															
0.00	9.4.8	0.00	1.92	0.00	1.46	1.73	1.73	0.00	2 2	0.00	<u>6</u> . <u>6</u>	8.0	0.45	0.45	0.15	0.15	0.00	0.22	0.00	0.0 2.0 2.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5	0.0	0.36	0.00	0.22	0.22	0.00	0.22	0.0	0.22	0.00	0.22	0.00	0.22	0.0	0.28	0.28	0.22	0.22	0.00	0.31	0.00	0.36	0.0	0.22
	: :	::	: :	: :	:	: :		-	:	: :	:	: :	: :		: :		:	: :	-:	-	: :	-	: :	: :		: :	-	:	: :	:	: :	: :	:	: :	:	:	: :		-	<u> </u>				. .
						0																																						
	0.0										w/o dye	w/o dye	6				9	pine ::	pine	pine pine	pine ::	pine	pine pine		pine	or trumk spime of thoracic spine	c spine	thoracic spine	thoracic spine	of thoracic spine	thoracic spine thoracic spine	thoracic spine	pine	pine ::	pine	spine	spine	spine	spine	spine ::	spine	spine spine	spine	spirre :: spire ::
dye e e	thorax w/uye thorax w/o & w/dye		angiography, chest	angiography, chest i chest w/o dye	dye	~			& w/dye	& w/dye	st w or w/o	angio chest w or w/o	spine	spine .	spine	spine	spine			neck spine	neck spine		neck spine		trunk spine	thoracic spine	thoracic					thoraci	trunk spine	trunk spine	trunk spine	trunk	lower	lower	lower	lower	lower	lower	lower	lower
thorax w/o dye thorax w/dye thorax w/dye	thorax w/o &	thorax w/o &	ograph	angiography, ch chest w/o dye	chest w/o	chest w/o dy chest w/dve	chest w/dye	chest w/dye	chest w/o		angio chest	or ches	exam of	exam of			exam of			exam of		exam of	exam of			exam of		exam of			exam of exam of		exam of	₹ 5	ъ.	exam of	exam of		exam of			exam or exam of		exam of
Ct thorax Ct thorax Ct thorax				Ct angi Mri che		Mri che Mri che	Mri che	Mri che	Mri che	Mri che	Mri ang	Mri ang Mri ang	X-ray e	X-ray e	X-ray e	X-ray e X-ray e	X-ray e	X-ray e	X-ray e X-ray e	X-ray e	X-ray e	X-ray e X-rav e	X-ray e	X-ray e X-ray e	X-ray e	X-ray e	X-ray e X-rav e	X-ray e	X-ray e X-ray e	X-ray e	X-ray e	X-ray e	۸-اتم X-ray e	X-ray e	X-ray e	X-ray e	X-ray e	Х-гау е Х-гау е	X-ray e	۸-ray e X-ray e				
4 4 4 4			< ∢ ·	∢ ∢	∢ <	∢ ∢	∢ :	∢ <	-		:	: c	< <				∢ <		:	∢ ∢ ∷	< <	•			-	∢ ∢	∢ ·	-		∢ <			∢ ⊲	< ⋖		⋖ <	₹	< -	⋖ <	< <	⋖ <	₹ ₹	∢ <	< <
TC 26	<u> </u>		26	ည	26	<u>:</u> ၁	26	 2	26	122		 9 Z L)	26	2	26	: ၁ —	26	10 10	26	12		0 C	2	26	: د	26	: ပ	26	10 12	26		26	1 C		26 T	: د	26	: ပ	26	TC ::	26	10 ::	26
														:																														
71250 71260 71260	71270	71270	71275	71275 71550	71550	71551	71551	71551	71552	71552	71555	71555	72010	72010	72020	72020	72020	72040	72040	72050	72050	72052	72052	72069	72069	72070	72070	72070	72072	72072	72074	72074	72080	72080	72090	72090	72100	72100	72100	72110	72110	72114	72114	72120
1-1-1-1																																												

Addendum B.—Relative Value Units (RVUS) and Related Information Used in Determining Medicare Payments For 2007—Continued

		_
Global	\$	{X
Year 2007 Transi- tional Fa- cility Total	A A 6 6 4 A 6 6 4 A 6 4 A	Y Y Y
Fully Im- plement- ed Facil- ity Total	A S 8 A S 8	 { \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
Year 2007 Transi- tional Non-Fa- cility Total	0.00 0.00	15.93
Fully Implemented Non-Facility Total	0.17	17.33
Mal-Prac- tice RVUs	0.000000000000000000000000000000000000	0.74
Year 2007 Transi- tional Fa- cility PE RVUs	A A 8 A A A A A A A A A A A A A A A A A	
Fully Im- plement- ed Facil- ity PE RVUs	A A C C A A C C A A C C A A C C A A C C A A C C A A C C A A C C A A C C A A C C A A C C A A C C A A C C A A C C A A C C A A C C A A C C C A C C C C A C	 Ç ₹
Year 2007 Transi- tional Non-Fa- cility PE RVUs	0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	13.39
Fully Implemented Non-Facility PE RVUs	0.4.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0	14.79
Physician Work RVUs	0.00 0.00	1.80
Description	X-ray exam of lower spine C neck spine w/o dye C chest spine w/o dye C c chest spine w/o dye C c c c c c c c c c c c c c c c c c c c	Mr angio spine w/o& w/dye
Status	<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<	ίZ
Mod	5 85 <t< td=""><td>2</td></t<>	2
CPT¹/ HCPCS²	72122 72122 72122 72122 72123 72123 72123 72123 72123 72123 72123 72133 72133 72134 7214 721	72159

25 A A A A A A A A A A A A A A A A A A A	A A 1.1 A A 18 A A 0.0 A A 1.1 A A 1.2 A A A 2.2 A A A 2.2 A A 4.1 A A 2.2 A A 4.1 A A 4.1 A A 4.1 A A 4.1 A
25 A A B B A B B A B B A B B A B B B A B B B A B B B A B B B A B B B A B	A A L L A A L B A A B B A A L L A A A B B A A L L A A A B B A A L L A A A B B A A B B A A B B A B A
252 0.74 0.75 0.75 0.75 0.73 0.73 0.73 0.73 0.73 0.73 0.73 0.73	3.97 4.96 1.12 3.83 7.60 7.79 3.17 1.00 1.57 7.74 1.157 7.74 1.157 7.74 1.157 7.74 1.157 7.74 1.157 7.74 1.157 7.74 1.157 7.74 1.157 7.74 7.74 7.74 7.74 7.74 7.74 7.74 7.
2.32 0.00 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.23 0.29	2.22 3.59 1.13 2.64 5.64 5.64 1.82 3.85 1.72 1.72 1.12 1.12 1.12 1.13 0.75 0.75 0.75
0.000000000000000000000000000000000000	0.022 0.022 0.033 0.033 0.040 0.040 0.040 0.033 0.033 0.040 0.040 0.040 0.033
0. N.	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
4	0
0.000000000000000000000000000000000000	2.5.5.0 2.5.5.0 2.5.5.0 2.5.5.0 2.5.5.0 2.5.5.0 2.5.5.0 2.5.5.0 2.5.5.0 2.5.5.0 2.5.5.0 2.5.5.0 2.5.5.0 2.5.5.0 2.5.5.0 2.5.5.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2
$\begin{smallmatrix} 0.4 & 0.0 & 0.0 & 0.1 & 0.0 & 0.$	2.50 2.20 2.20 2.20 2.20 2.20 2.20 2.20
8.000000000000000000000000000000000000	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Mr angio spine w/o&w/dye Mr angio spine w/o&w/dye X-ray exam of pelvis Ct angiograph pelv w/o&w/dye Ct angiograph pelv w/o&w/dye Ct angiograph pelv w/o&w/dye Ct pelvis w/o dye Ct pelvis w/o dye Ct pelvis w/o dye Ct pelvis w/o & w/dye Mri pelvis w/o & w	ay, thorax spine ay, lower spine ay, lower spine ay, spi
Mr angio spine w/o&w/dy Mr angio spine w/o&w/dy X-ray exam of pelvis Ct angiograph pelv w/o& Ct angiograph pelv w/o& Ct angiograph pelv w/o& Ct pelvis w/o dye Ct pelvis w/o dye Ct pelvis w/o & w/dye Mri pelvis w/o dye Mri pelvis w/o & w/dye Mri pelvi	Contrast x-ray, Contrast x-ray, Contrast x-ray, Contrast x-ray, Contrast x-ray, Contrast x-ray, Epidurography Epidurography Epidurography X-ray of spine o X-ray of spine o X-ray of lower s X-ray exam of o X-ray exam of o X-ray exam of o X-ray exam of o
ZZ	<i>⋖⋖⋖⋖⋖⋖⋖⋖⋖⋖</i> ⋖⋖⋖⋖
25 25 25 25 25 25 25 25 25 25 25 25 25 2	
72159 72170 72170 72170 72190 72190 72190 72191 72192 72193 72194 72195 72196 72196 72197 72197 72198 72200 7200 720	72265 72265 72265 72270 72270 72270 72275 72275 72275 72275 72285 72285 72285 72285 72285 72285 72285 72285 72285 72295 72295 72295 73000 73000

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2007—Continued

Global	
Year 2007 Transi- tional Fa- cility Total	2.2 A A 2.2 A
Fully Im- plement- ed Facil- ity Total	2442445445445445445445445445445445445445
Im- 2007 on- tional lity Non-Fa-	0.02 0.03
- ≧ĔZġō	0.22 0.03 0.02 0.03 0.03 0.03 0.03 0.03
Mal-Practice RVUs	20000000000000000000000000000000000000
Physician perment Transi- Mork ed Non- Facility PE RVUs PERVUs cility PE RVUs RVUs RVUs RVUs RVUs RVUs RVUs RVUs	0.5 A 2.5 A 5.5 A
Fully Implementation of Facility PE RVUs	0. X X 0. X 0. X 0. X 0
Year 2007 2007 Transi- tional Non-Fa- cility PE RVUs	0.000000000000000000000000000000000000
Fully Implemented Non-Facility PE RVUS	0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.
Physician Work RVUs	$\begin{array}{c} 0.00000000000000000000000000000000000$
Description	X-ray exam of shoulder blade X-ray exam of shoulder blade X-ray exam of shoulder X-ray exam of humerus X-ray exam of elbow X-ray exam of forearm X-ray exam of wrist X-ray exam of hand X-ray exam of han
. Statu	444444444444444444444444444444444444444
Wod 8	25 25 25 25 25 25 25 25 25 25 25 25 25 2
CPT ¹ /HCPCS ²	73010 73010 73020 73020 73020 73020 73020 73020 73030 73030 73040 73040 73050

×××	× ×																																												
.,,,,,	\$ \$	× ×	{ } }	žž	× }	žž	×	×	{×	××	× >	××××××××××××××××××××××××××××××××××××××	××	× }	ξ× ×	X	×	{×	×	X	××	{× ×	X	××	ξ× ×	×3	žž	×	××	××××××××××××××××××××××××××××××××××××××	×	××	×	××	XX	×	×	×	₹×	××	× }	XX	×	××	××
1.67 N A S	2.48	Z Z	1.85	¥ ¥	2.23	4 4 2 2	2.96	Ψ <u>ξ</u>	1.86	Ϋ́	Y S	25.2 A	Ϋ́	2.96 NA	¥ Ž	2.43	Ψ <u>Σ</u>	0.24	Ž	Y S	0.29 NA	₹	0.36	Z Z	0.75	Ž Ž	0.40	Ž	A &	N A	N S	0./8 NA	Ž	0.24 NA	ž ž	0.24	¥:	A G	0.23 A	Ϋ́	0.30	4 4 2 2	0.24	A A	0.74 NA
A 9 8 5	2.49	₹ Z	- 88. - 58. - 58.	₹ ₹	2.22	¥	2.95	<u> </u>	1.87	¥	¥ &	Z X	¥	2.96 NA	₹	2.23	<u> </u>	0.24	Σ	Ϋ́	0.29 NA	₹	0.35	¥ ≱	0.74	¥ ž	0.39	Ž	A S	N A	Ϋ́	0.76 NA	Ž	0.23 NA	₹ ₹	0.24	¥:	A G	S.S.	¥	0.31	¥ ¥	0.24	₹ ₹	0.75 NA
10.21	13.66	11.17	1.85	16.57	2.23	27.13	2.96	24.17	1.86	12.16	16.32	14.09	26.79	2.96	14.87	2.43	12.44	0.72	0.48	0.94	0.29	1.08	0.36	0.72 2.85	0.75	2.10	0.40	Z	0.93	0.65	2.72	1.08	0.83	0.24	0.29	0.24	0.54	0.89	0.63	1.01	0.30	0.70	0.24	3.40	0.74
12.40	13.13	10.64	1.86	17.84	2.22	22.46	2.95	19.51	1.87	13.88	16.87	14.63	21.13	2.96	17.19	2.23	14.96	0.09	0.45	1.04	0.29	1.10	0.35	0.75	0.74	1.74	0,39	N A	1.05	0.77	1.86	1.10	0.76	0.23	0.79	0.24	0.55	0.96	0.71	1.14	0.31	0.85	0.24	3 1 1	0.75
0.05	0.47	0.39	90.0	0.39	0.07	0.97	0.10	0.84	0.0	0.39	0.54	0.47	0.94	0.10	0.69	0.10	0.59	0.00	0.02	0.05	0.0	0.02	0.01	0.0 4 4 7	0.03	0.12	0.03	0.05	0.02	0.0	0.15	0.03	0.05	0.0	9.00	0.01	0.02	0.02	0.0	0.05	0.0	9.0	0.01	0.02	0.03
0.40 A 0.40	0.59	¥ Z	0.4.7	₹ ₹	0.54	¥ ¥	0.71	₹ <u>₹</u>	0.45	Ą Ą	A Z	t ∢	¥	0.71	 { Z	09:0	₹	90.0	₹ Z	Y Y	0.07 NA	₹ ₹	0.09	¥ Ż	0.18	¥ ž	0.10	¥	A C	§ ₹	¥ S	0 AN	Ž	0.06 NA	₹ ₹	90.0	¥:	A O	9. ₹	Ą	0.07	⊈	90.0	A A	0.17 VAN
A S S S S S S S S S S S S S S S S S S S	09:0	Z Z	0.45	₹ ₹	0.53	Z Z	0.70	¥ \$	0.46	N A	A R		X A	0.71	₹	0.40	¥ \$	900	Ž	¥.	0.07 NA	₹	0.08	Y Z	0.17	Z Z	0 O	Ž	¥ 6	ξŽ	¥,	0.14 AN	Ž	0.05 NA	ž Ž	90.0	Ž:	A S	8 Z	N A	0.08	¥ ¥	90.0	₹ ₹	0.18 VA
8.55 0.40 8.15	0.59	10.78	0.44.0	14.41	0.54	24.04	0.71	23.33	0.45	11.77	14.16	13.62	23.70	0.71	12.45	0.60	11.85	0.06	0.46	0.68	0.07	0.77	0.09	0.68	0.18	1.98	0.10	Z	0.68	0.61	1.98	1.0	0.61	0.06	0.58	90.0	0.52	0.66	0.00	0.74	0.07	0.00	90.0	0.52	0.17
10.74	10.85	10.25	0.45	15.68	0.53	19.37	0.70	18.67	0.46	13.49	14.71	14.16	18.04	0.71	14.77	0.40	14.37	0.09	0.43	0.78	0.07	0.79	0.08	0.71	0.17	1.62	0.09	A A	0.80	0.73	1.12	0.14	0.54	0.05	0.49	90.0	0.53	0.73	0.00	0.87	0.08	0.79	90.0	0.59	0.18
22.00	8. 6.	0.00	56.0	1.62	1.62	2.15	2.15	0.00	 	0.00	1.62	0.00	2.15	2.15	1.73	1.73	0.00	0.17	0.00	0.21	0.21	0.26	0.26	0.00	0.54	0.0	0.29	0.00	0.20	0.00	0.59	60.0	0.17	0.17	0.00	0.17	0.00	0.18	0.0	0.22	0.22	0.00	0.17	0.00	0.54
w/o&w/dye w/o&w/dye w/o&w/dye	ı w/o&w/dye ı w/o&w/dye	ייייייייייייייייייייייייייייייייייייי	extremity w/o dye	Mri upper extremity W/o dye	y w/dye	y w/aye w/o&w/dve	w/o&w/dye	extremity w/o&w/dye	upr extrem w/o dve	extrem w/o dye	upr extrem w/dye	extrem w/dve	extr w/o&w/dye	extr w/o&w/dye	Mr angio upr extr w/o&w/dve	w/o&w/dye	w/o&w/dye				X-ray exam of hip		exam of hips	Gie	Q.E.	dir			vis & hips	vis & hips	iliac joint	iliac joint	h l	X-ray exam of thigh	e. 1 or 2	e, 1 or 2	knee, 1 or 2	knee, 3	ດ ຕໍ່			4 or more	ses	X-ray exam of knees	knee joint knee joint
Ct uppr extremity w/o&w/dye Ct uppr extremity w/o&w/dye Ct uppr extremity w/o&w/dye		Ct angio upr extrm w/o&w/dye	Mri upper extremit	Mri upper extremity w/o dy	Mri upper extremity w/dye	Mri upper extremity w/o&w/	uppr		joint upr	joint upr	joint upr	oin	joint upr	Mri joint upr extr w/o&w/dye	Mr angio upr extr	Mr angio upr extr w/o&w/dye	Mr angio upr extr	X-ray exam of hip	X-ray exam of hips	X-ray exam of hips	X-ray exam of hips	Contrast x-ray of hip	Contrast x-ray of hip	X-ray exam of hip	X-ray exam of hip	X-ray exam of pely	X-ray exam of pelv	X-ray exam, sacro	X-ray exam, sacro	X-ray exam of thig	X-ray exam of thig	X-ray exam of the	X-ray exam of knee,	exam of	exam of	exam of exam of	exam, kı		X-ray exam, knee, 4 X-ray exam of knees	exam	X-ray exam of knees	Contrast x-ray of k			
< < < ·	∢ ∢	∢ <	< < <	∢ ∢	< <	∢ ∢	< <	∢ <	(∢	⋖	∢ <	(∢	⋖	∢ <	ζZ	z	z «	< ∢	. ∢	∢.	∢ ⊲	(∢	∢.	∢ <	(∢												∢•	∢ <	< <	⋖	∢ <	< <	∶∢	∢	< <
26 TC	26	TC	26	: :	26	<u>:</u> د	26	ار 	26		90	22 22 22		26)	26	 	26			26)	26	ار الد	26	TC	26		96	12		 Q.E.		26	<u>:</u> د	26	<u>۔۔۔۔</u>		 2 2 2		26	: ເ	26	ارد الد	26 TC
	.,	· 	.4 [.41					_				., .									:	<u> </u>	.,					-						.,	-	-					.,		.41-
73202 . 73202 . 73202 .	73206 . 73206 .	73206 .	73218		73219 .	73220		73220 .	73221		73222	73222	73223	73223 .	73225 .	73225 .	73225 .	73500	73500	73510 .	73510 .	73520 .	73520 .	73520 . 73525	73525	73525 .	73530	73530	73540 .	73540	73542	73542	73550	73550 .	73560	73560	73560	73562 .	73562	73564 .	73564 .	73565	73565 .	73565 . 73580	73580 .

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2007—Continued

Global	
Year 2007 Transi- tional Fa- cility Total	A 4 4 8 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
Fully Im- plement- ed Facil- ity Total	A S S A A S A
Im- Year 2007 on- tional lity Non-Fa-	0.00 0.02 0.02 0.02 0.02 0.02 0.03
- ≥ĕZZgö	0.02 0.03 0.03 0.05
Physician plement Transi of Non-Fa- RVUs PE RVUs RVUs RVUs RVUs RVUs RVUs RVUs RVUs	0.000000000000000000000000000000000000
Year 2007 Transi- tional Fa- cility PE RVUs	4 6 4 4 6 6 4 4 6 6 4 4 6 6 4 6 6 4 6
Fully Im- plement- ed Facil- ity PE RVUs	A 2 4 5 5 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Year 2007 2007 Transi- tional Non-Fa- cility PE RVUs	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Fully Implemented Non-Facility PE RVUS	0.000000000000000000000000000000000000
Physician Work RVUs	0.000000000000000000000000000000000000
Description	X-ray exam of lower leg X-ray exam of ankle Contrast x-ray of ankle Contrast x-ray of ankle X-ray exam of foot X-ray exam of loe(s) X-ray exam of loot X-ray exa
Statu	444444444444444444444444444444444444444
Wod 88	85 85 85 85 85 85 85 85 85 85 85 85 85 8
CPT ¹ /HCPCS ²	73590 73590 73590 73592 73592 73592 73592 73600 73610 73610 73610 73610 73610 73610 73610 73610 73610 7360 7360 7360 7360 7360 7370 7

***************************************	***********
2	N N N N N N N N N N N N N N N N N N N
A A 2 A A 2	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
23. 12. 25. 25. 25. 25. 25. 25. 25. 25. 25. 2	2.22 0.00 0.00 0.00 0.05 0.05 1.69 1.73 1.25 1.25 1.25 0.95
2.50 2.50 2.50 2.50 2.50 2.50 2.50 2.50	2.55 1.072 1.072 1.083 3.00 0.00 0.09 2.15 2.25 2.25 2.25 2.35 0.94 0.94 0.95 0.9
8	0.000 0.000
N N N N N N N N N N N N N N N N N N N	
N N N N N N N N N N N N N N N N N N N	22
90000000000000000000000000000000000000	2.5.4 2.
1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	2.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.	
Mri joint lwr extr w/o&w/dye Mr ang lwr ext w or w/o dye Mr ang lwr ext w or w/o dye Mr ang lwr ext w or w/o dye A-ray exam of abdomen X-ray exam series, abdomen X-ray exam of abdomen Min abdomen w/o & w/dye Min angio, abdom w orwio dye Min angio,	Cinevid x-ray, throat/esoph Cinevid x-ray, throat/esoph Cinevid x-ray, throat/esoph Cinevid x-ray, throat/esoph Remove esophagus obstruction Remove esophagus obstruction Remove esophagus obstruction Remove esophagus obstruction X-ray exam, upper gi tract Contrest x-ray uppr gi tract Contrest x-ray uppr gi tract
< < < < < < < < < < < < < < < < < < <	
5 5	26 26 27 26 26 26 27 27 27 27 27 27 27 27 27 27 27 27 27
73723 73725 73725 73725 74000 74000 74010 74010 74020 74020 74020 74022 74022 74150 74170 74181 74181 74181 74182 74183 74183 74183 74183 74184 74184 74184 74184 74184 74185 74186 74180 74190 74190 74210	74230 74230 74230 74235 74235 74235 74240 74241 74241 74241 74241 74245 74245 74245

Addendum B.—Relative Value Units (RVUS) and Related Information Used in Determining Medicare Payments For 2007—Continued

1	XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	< ×
Global		€₿
Year John Polement Transi- tional Fa- cility Total cility Total	A	₹ ₹
	A 2 4 4 5 4 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4	ξŽ
y Im- 2007 ment- Transi- tolity Non- tonal cility Non-Fa- otal	7.7	
	74.00.00.000000000000000000000000000000	ζ Υ
Mal-Practice RVUs	00000000000000000000000000000000000000	0.16
Physician plement- Transi- plement- Work ed Non- front RVUs PE	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	<u>.</u>
Fully Im- plement- ed Facil- ity PE RVUs	A S S S S S S S S S S S S S S S S S S S	ΣŽ
Year 2007 Transi- tional Non-Fa- cility PE RVUs	7 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	 { Z Z
Fully Implemented Non-Facility	7.2.0.9.4.9.4.9.0.0.0.0.0.0.0.0.0.0.0.0.0.0	 ζ Ζ Ζ Ζ
Physician Work RVUs	0.0.0000000000000000000000000000000000	
tatus Description	Contrst x-ray uppr gi tract X-ray exam of small bowel Contrast x-ray exam of colon Contrast x-ray gallbladder Contrast x-ray, gallbladder Contrast x-ray of bile ducts/pancreas X-ray bile ducts/pancreas Contrast x-ray of bile ducts Contrast x-ray of	A-tay unerpand endoscopyX-rav duide for GI tube
Wod /So	57 82 <td< td=""><td>)</td></td<>)
CPT1/ HCPCS ²	74246 74247 74249 74249 74249 74249 74250 74250 74251 74260 74260 74260 74260 74260 74260 74260 74280 74290 74290 74290 74290 74290 74290 74290 74290 74290 74290 74290 74290 74290 74290 74290 74290 74290 74300 74300 74300 74300 74320	74340

***************************************	************
5.5. A A 4.5 A A 6.5 A 6	0.00 0.00 0.00 0.00 0.00 0.00
+ 4 5 + 9 4 + 4 4 9 4 4 - 4 + 5 9 9 5 - 9 5 9 4 9 4 9 4 9 4 9 1 4 9 4 9 4 9 4 9 4 9	T (0 0 10 0 10 0 m 0 m 0 m 0 m 0 m 0 m 0 m
0 41.8 4 N 0.0 S 1	0.000000000000000000000000000000000000
0 8 - 1 9 - 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.	0.0000000000000000000000000000000000000
N N S S S S S S S S S S S S S S S S S S	N N N N N N N N N N N N N N N N N N N
	0 0 0 000
L. A. S.	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
0.0	0.00 0.00
0.000 0.000	7.18 (2.29 (
	0-404000-0-000
00000000000000000000000000000000000000	
X-ray guide for Gl tube X-ray guide, stomach tube X-ray guide, stomach tube X-ray guide, stomach tube X-ray guide, stomach tube X-ray guide, intestinal tube X-ray guide, intestinal tube X-ray guide, intestinal tube X-ray guide, intestinal tube X-ray guide, Gl dilation X-ray guide, Gl dilation X-ray, bile duct dilation X-ray, bile duct dilation X-ray, bile duct dilation X-ray, bile duct dilation X-ray, uninary tract Contrast x-ray, uninary tract Contras	
## ## ## ## ## ## ## ## ## ## ## ## ##	ert on .
r GI tubu to mach to m	cath ins cath ins cath ins cath ins cath ins cath ins it dilatic i
guide fo guide fo guide, si guide, si guide, si guide, ir guide, ir guide, ir guide, G guide,	control, control, control, control, guide, Gguide, Ggu
X-ray guide for Gl tube X-ray guide, stomach tub X-ray guide, stomach tub X-ray guide, stomach tub X-ray guide, intestinal tub X-ray guide, intestinal tub X-ray guide, Gl dilation X-ray guide, Gl dilation X-ray, bile duct dilation X-ray, unimary trac Contrat x-ray, unimary trac Cont	X-ray
85 :85 :85 :85 :85 :85 :85 :85 :85 :85 :	2
	74480 74485 74485 74485 74485 74710 74710 74740 74742 74742 74742

ō	Global	*****	****
—Continued	Year 2007 Transi- tional Fa- cility Total	2.24 A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B B A B B B A B B B A B B B A B B B A B	1.83 NA NA NA NA NA NA NA
2007	Fully Im- plement- ed Facil- ity Total	8.0 8.4 8.4 8.4 8.4 8.4 8.4 8.4 8.4 8.4 8.4	2.37 A A N N A N A N A N A N A N A N A N A N
PAYMENTS FOR	Year 2007 Transi- tional Non-Fa- cility Total	0.86 NA NA 15.88 13.67 17.62 17.62 17.62 17.62 17.62 17.63 17	1.83 10.95 13.40 2.30 11.10 12.77 1.82 10.95
	Fully Implemented Non-Facility	2.56 2.56 2.56 2.56 2.56 2.56 2.56 2.56	1.85 6.99 6.99 2.37 4.63 1.86 4.06
3 MEDICA	Mal-Prac- tice RVUs	0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03	0.07 0.65 0.72 0.07 0.65 0.06
DETERMINING MEDICARE	Year 2007 Transi- tional Fa- cility PE RVUs	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	0.45 N N N N N N N N N N N N N N N N N N N
<u>z</u>	Fully Im- plement- ed Facil- ity PE RVUs	0.0 A A A A A A A A A A A A A A A A A A	0.4 A A A A A A A A A A A A A A A A A A A
TION USE	Year 2007 Transi- tional Non-Fa- cility PE RVUs	NA NA NA NA NA NA NA NA NA NA	0.45 10.30 11.02 0.57 10.45 10.75 0.45
INFORMATION USED	Fully Implemented Non-Facility	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.47 3.40 4.61 0.64 3.98 3.90 0.49
RELATED	Physician Work RVUs	0.000 0.000	1.31 0.00 1.66 0.00 1.31 1.31
RELATIVE VALUE UNITS (RVUS) AND	Description	X-ray exam of perineum X-ray exam of perineum Heart mri for morph w/o dye Heart mri for morph w/o dye Heart mri for morph w/o dye Heart mri for morph w/dye Cardiac MRI/function Mrethy x-rays, head & neck Artery x-rays, head &	Artery x-rays, neck Artery x-rays, spine Artery x-rays, spine Artery x-rays, spine
B.—R	Status		
ADDENDUM I	Mod	26 26 27 26 26 27 27 27 27 27 27 27 27 27 27 27 27 27	26 TC 26 TC TC
ADDE	CPT1/ HCPCS ²		

X 0.0 X 1.0 X 2.0	
A S S S S S S S S S S S S S S S S S S S	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
0 0 0 000 0	0
3.98 3.98	A N N N N N N N N N N N N N N N N N N N
C C C C C C C C C C C C C C C C C C C	2
	2 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
0.000	
Z C C C C C C C C C C C C C C C C C C C	N N N N N N N N N N N N N N N N N N N
A C A A A A A A A A A A A A A A A A A A	0
0, m	- 4 4 (0 4 4 M 4 + 10 M 4 M 4 + + + O
20.00 20	2 X X 2 2 X 4 1 0 1 X 2 X 2 X 4 1 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
0.022 0.025 0.	758
400000404000004000000000000000000000000	
22.28 26.27 27.28 27.20 27	0.00 0.81 0.00 0.00 0.00 0.00 0.47 0.47 0.00 0.00
Artery x-rays, spine Artery x-rays, spine Artery x-rays, amvleg Artery x-rays, amvleg Artery x-rays, amvleg Artery x-rays, amvlegs Artery x-rays, ams/legs Artery x-rays, kidney Artery x-rays, adromal gland Artery x-rays, ung Artery x-rays, ung Artery x-rays, lung Artery x-rays	
land land land land land land land land	88 88 88 88 88 88 88 88 88 88 88 88 88
ine	ay, am ay, trum ay, ay, and ay, ay, and ay, ay, and ay,
ayys, spi ayys, spi ayys, arrays, kid ayys, kid ayys, kid ayys, kid ayys, kid ayys, kid ayys, arbays, kid ayys, arrays, arrays, arrays, arrays, arrays, lun ays, lun ays	ssel x-1 ssel x-1 sse
eny x-rr eny x-	mph ve mvascu nvascu nvascu in x-ray in x-r
- CLCCCSSTATATATATATATATATATATATATATATATATAT	
444444444444444444444444444444444444444	
29 129 129 129 129 129 129 129 129 129 1	
75705 75705 75706 75710 75710 75710 75710 75711 75716 75716 75724 75724 75724 75724 75724 75724 75724 75724 75731 75731 75731 75731 75731 75731 75731 75731 75731 75731 75731 75731 75731 75741 75741 75741 75741 75742 75740 75740 75740 75740 75740 75740 75740 75740 75740 75770	
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%	ススススススススススススススススス

Addendum B.—Relative Value Units (RVUS) and Related Information Used in Determining Medicare Payments For 2007—Continued

Column C	Mater Status Proposition Property of the control of	ADL		o	HELATIVE VALUE ONITS (HVOS) AND	חבראובת	JIMP CLINIT	heraled intohinalion Osed in Del		ייוויוואורח	ENIMINING IMEDICARE L'ATMENTS L'OR		5 - 0 C	7007		
10	150	 CS ₂	Mod	Status	Description	Physician Work RVUs	Fully Implemented Non-Facility	Year 2007 Transi- tional Non-Fa- cility PE RVUs		Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Prac- tice RVUs	Fully Implemented Non-Facility Total	Year 2007 Transi- tional Non-Fa- cility Total	Fully Im- plement- ed Facil- ity Total	Year 2007 Transi- tional Fa- cility Total	Global
The control of the	The control of the		90	∢ <	arms/legs	1.06	3.18	2.16	AN G	AN O	0.13	4.37	3.35	NA A	AN L	**
10	No. No.		TC	(∢	ggs	00.0	2.83	1.82	S Z	S Z	0.08	2.91	1.90	¥ Y	Y A	ξ× ×
The control of the	TOP A Value receiv their 10.0 2.85 10.0 MA NA 0.05 4.25 10.7 NA NA NA 0.05 1.55 1.55 NA NA 0.05 1.55 1.55 1.55 NA NA 0.05 1.55			⋖ <	Vein x-ray, trunk	4	2.93	10.46	A S	NA	0.72	4.79	12.32	N N	NA P	× }
26	26		 22 24	τ <	Vein X-ray, trunk	0.00	2.57	10.09	8. S	S.S.	0.07	3.22	10.74	è Z	8 N	{×
The control of the	Color			⋖ -	Vein x-ray, chest	1.14	2.98	10.47	¥	NA	0.70	4.82	12.31	NA	N	X
17.0 A View rang kidney 114 114 114 115	1.5 1.5		26	∢ <	Vein x-ray, chest	4.1	0.36	0.37	0.36	0.37	0.05	1.55	1.56	1.55	1.56	× >
25	25		2	< <		1.14	3.05	10.49	₹Ž	ZZ	0.71	4.90	12.34	ΣZ	ξŞ	ξ× ×
17	1.5 A Very Kingley Very King		26	∢ •	Vein x-ray, kidney	1.14	0.36	0.37	0.36	0.37	0.06	1.56	1.57	1.56	1.57	X
26	10			∢ ⊲	kidney kidneys	0.00	3.71	10.12	Z Z	A Z	0.65	3.34	10.77	A N	A Z	××
The control of a voice stay, activated grand The control of a voice	17.0 A Venn Forsy adherest gland=		26	< <	kidneys	1.49	0.48	0.49	0.48	0.49	0.09	2.06	2.07	2.06	2.07	₹×
Name A Value Array, advantal glands	26		10 	٨	kidneys	0.00	3.23	10.26	Ž	Z	0.65	3.88	10.91	NA	A	X
The control of the	The color of the			⋖ •	Vein x-ray, adrenal gland	4.1	3.29	10.56	Z S	A S	0.72	5.15	12.42	A S	Ψ.	× š
1.5 A Vein x-ray, adented gends 1.46 1.64	1.00		92 L	∢ ⊲	gland	4 C C	0.45	0.40	0.45 NA	0.40 NA	0.07	3.49	1.61	99.L	1.6.1	××
26 A Vein recty, actival iglands 149 0.48 0.48 0.49	10))	< <	Vein x-ray, adrenal glands	1.49	3.68	10.73	₹₹	Z Z	0.72	5.89	12.94	ΣŽ	ξŽ	×××
10	17 17 18 19 19 19 19 19 19 19		26	⋖ -	Vein x-ray, adrenal glands	1.49	0.49	0.48	0.49	0.48	0.07	2.05	2.04	2.05	2.04	X
1.14 0.25 0.45	26 A Vehi Arry, neck 111 250 0.42 0.42 0.64 166		 		=	0.00	3.19	10.25	Y S	Y S	0.65	3.84	10.90	Y S	₹ Ş	× }
TC A Vein x-ay, reack 100 2.96 10.19 NA NA 0.05 5.77 12.94 NA NA 2.6 A Vein x-ay, skull 114 3.29 10.19 NA NA 0.05 5.77 12.94 NA NA 2.6 A Vein x-ay, skull 114 3.29 10.16 NA NA 0.05 5.94 10.18 NA NA 0.05 3.49 10.19 NA NA<	TC A Vietn scap, skull 114 329 1059 NA NA 0.65 357 1204 NA NA 26 A Vietn scap, skull 114 329 1059 0.39 0.59 0.59 1059 NA		26		Vein x-ray, neck	1 4	0.50	0.45	0.50	0.42	0.03	1.68	1.60	1.68	1.60	{×
26 A Voin x-ray, skull 1.14 0.35 1.05 NA NA<	6 A Vehin x-ray, skull 1.14 3.23 1.055 NA NA NA NA NA TC A Vehin x-ray, skull 1.14 3.23 1.055 NA NA 0.07 1.58 1.88 1.88 NA NA TC A Vehin x-ray, skull 1.14 0.02 2.84 1.015 NA NA 0.05 5.84 1.081 NA NA TC A Vehin x-ray, skull 1.14 0.02 2.89 0.03 0.04 1.08 NA <		10		Vein x-ray, neck	0.00	2.96	10.19	¥ Y	NA	0.65	3.61	10.84	N A	A	××
26 A Vern Krapy, skull 1.14 2.34 0.35	20 A voin x-ray, studi 114 0.34 0.034				Vein x-ray, skull	1.14	3.23	10.55	NA S	A S	0.70	5.07	12.39	Y S	Ϋ́,	X
1.14	26 A Ven K-ray, skall 1.14 3.97 10.71 NA 0.78 5.84 12.64 NA NA 26 A Ven K-ray, skall 1.14 0.29 1.63 NA 0.78 0.74 1.70 1.66 1.70 1.66 26 A Ven K-ray, skall 0.00 2.99 1.63 NA 0.86 0.96		26 TC		Vein x-ray, skull	1.14	0.39	0.39	0.39	0.39	0.05	1.58	1.58	1.58	1.58	××
26 A Vein x-ray, skull 114 0.42 0.38 0.42 0.08 0.14 1.70 166 1.70 166 1.70 166 1.70 166 1.70 166 1.70 166 1.70 166 1.70 166 1.70 166 1.70 166 1.70 166 1.70 166 1.70 166 1.70 166 0.70 2.93 1.62 0.23 0.23 0.23 0.23 0.24 0.74 </td <td>26 A Vein x-say, skull 114 0.42 0.38 0.42 0.13 0.14 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 170 166 170 166 170 166 170 170 166 170 170 166 170 170 166 170 170 170 170 170 166 170</td> <td></td> <td>)</td> <td></td> <td>Vein x-ray, shall</td> <td>1.14</td> <td>3.91</td> <td>10.71</td> <td>Z Z</td> <td>Z Z</td> <td>0.79</td> <td>5.84</td> <td>12.64</td> <td>ΣŽ</td> <td>¥ Z</td> <td>XX</td>	26 A Vein x-say, skull 114 0.42 0.38 0.42 0.13 0.14 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 166 170 170 166 170 166 170 166 170 170 166 170 170 166 170 170 166 170 170 170 170 170 166 170)		Vein x-ray, shall	1.14	3.91	10.71	Z Z	Z Z	0.79	5.84	12.64	ΣŽ	¥ Z	XX
TC A Vein x-ray, skull NA	TC A Vein x-ray, syeld 0.00 3.48 10.32 NA NA 0.65 4.13 10.97 NA NA 26 A Vein x-ray, sye socket 0.70 2.99 1.65 0.23 0.03 3.78 0.96		26	<		1.14	0.42	0.38	0.42	0.38	0.14	1.70	1.66	1.70	1.66	×
26 A Venin xaray, eye socket 0.70 2.39 0.23 0.23 0.23 0.23 0.24 0.70 0.29 0.70 0.71 0.71 0.71 0.71 0.71 0.71 0.71 0.71 0.71 <td>26 A Voin x-ray, eye socket 0.70 2.99 1.63 NA <t< td=""><td></td><td></td><td>⋖・</td><td>Vein x-ray, skull</td><td>0.00</td><td>3.48</td><td>10.32</td><td>Y :</td><td>¥:</td><td>0.65</td><td>4.13</td><td>10.97</td><td>¥:</td><td>¥ :</td><td>X</td></t<></td>	26 A Voin x-ray, eye socket 0.70 2.99 1.63 NA NA <t< td=""><td></td><td></td><td>⋖・</td><td>Vein x-ray, skull</td><td>0.00</td><td>3.48</td><td>10.32</td><td>Y :</td><td>¥:</td><td>0.65</td><td>4.13</td><td>10.97</td><td>¥:</td><td>¥ :</td><td>X</td></t<>			⋖・	Vein x-ray, skull	0.00	3.48	10.32	Y :	¥:	0.65	4.13	10.97	¥:	¥ :	X
TC A Vein x-ray, lose C 2.76 1.40 0.00 2.76 1.40 0.00 2.76 1.40 0.00 2.76 1.40 0.00 2.76 1.40 0.00 2.76 1.40 0.00 2.76 1.40 0.00 2.76 1.40 0.00 2.76 1.40 0.00 1.40 0.00 1.40 0.00 1.40 0.00 1.40 0.00 1.40 0.00 1.27 1.80 NA	The color of the		96	∢ ⊲	Vein x-ray, eye socket	0.70	2.99	1.63	N C	N C	0.09	3.78	2.42	N O	A O	××
26 A Vein x-ray, liver 1.44 3.17 10.66 NA NA 0.71 5.32 1.275 NA NA TC A Vein x-ray, liver 0.00 2.70 10.13 NA 0.06 1.97 1.97 1.97 1.97 TC A Vein x-ray, liver 0.00 2.70 10.14 0.35 10.64 NA 0.06 2.79 1.97	26 A Vein x-ray, liver 1.44 3.17 1.060 NA NA 0.65 1.27 1.97 1.97 1.97 NA		2 2 2 2	< <	Vein x-ray, eye socket	0.00	2.76	1.40	NA V	NA	0.00	2.82	1.46	N A	A N	ž
26 A Vein x-ray, liver 1.44 0.47 0.47 0.64 1.97 1.97 1.97 1.97 TC A Vein x-ray, liver 1.44 0.51 0.04 2.70 10.13 NA 0.06 2.91 1.97 NA NA 26 A Vein x-ray, liver 0.00 2.84 10.16 NA 0.06 2.01 1.98 2.01 1.98 26 A Vein x-ray, liver 0.00 2.84 10.16 NA 0.07 4.91 1.38 2.01 1.98 26 A Vein x-ray, liver 0.00 2.84 10.16 NA NA 0.06 2.91 1.08 NA <	26 A Vein x-ray, liver 144 0.47 0.47 0.47 0.47 0.47 0.48 0.47 0.48 0.47 0.48 0.51 0.68 3.35 1.07 NA			⋖	Vein x-ray, liver	1.44	3.17	10.60	N A	NA	0.71	5.35	12.75	NA	A A	XX
26 A Vein x-ray, liver 0.00 2.70 10.13 NA 0.05 2.01 1.278 NA	1CC A Vein X-ray, Iver 0.00 2.70 10.13 NA 0.74 0.85 3.35 10.78 NA		26	< <	iver	4. 6	0.47	0.47	0.47	0.47	0.06	1.97	1.97	1.97	1.97	× š
26 A Verify (red) C 5 1 C 48 O.51 C 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	26 A Vein x-ray, liver 1.44 0.51 0.48 0.65 2.01 1.38 2.01 1.38 TC A Vein x-ray, liver 1.14 0.00 284 10.16 NA NA 0.65 3.49 10.81 NA NA 26 A Vein x-ray, liver 1.14 3.07 10.50 NA NA 0.05 1.57 1.56 1.57 1.56 1.57 1.56 1.56 1.56 1.57 1.56 1.57			∢ ⊲	i ver	0.00	2.70	10.13	Z Z	A N	0.65	3.35 7.75	12.79	Z Z	₹	ž
TC A Vein x-ray, liver 0.00 2.84 10.16 NA NA 0.65 3.49 10.81 NA NA 26 A Vein x-ray, liver 1.14 0.37 10.50 NA 0.65 3.35 10.78 NA NA 26 A Vein x-ray, liver 0.00 2.70 10.13 NA 0.65 3.35 10.78 NA NA 26 A Vein x-ray, liver 0.00 2.70 10.13 NA NA 0.65 3.35 10.78 NA NA 26 A Vein x-ray, liver 1.14 0.37 0.37 0.05 1.56 1.56 1.56 1.56 1.56 1.56 1.56 1.56 1.56 1.56 1.56 1.57 NA NA NA NA NA NA 0.05 0.74 0.74 0.74 NA N	TC A Vein x-ray, liver 0.00 2.84 10.16 NA NA 0.65 3.49 10.81 NA NA 26 A Vein x-ray, liver 1.14 3.07 10.15 NA 0.05 1.57 1.56 1.57 1.56 26 A Vein x-ray, liver 0.00 2.70 10.13 NA 0.65 3.35 10.78 NA NA 26 A Vein x-ray, liver 0.00 2.70 10.13 NA 0.65 3.35 10.77 NA		26		š š	4	0.51	0.48	0.51	0.48	0.00	2.01	1.98	2.01	1.98	××××××××××××××××××××××××××××××××××××××
26 A Vein x-ray, liver 1.14 3.37 10.50 NA 0.70 4.91 12.34 NA NA 26 A Vein x-ray, liver 1.14 0.38 0.37 0.05 1.57 1.56 1.57 NA NA	26 A Vein x-ray, liver 1.14 3.07 10.50 NA 0.70 4.91 12.34 NA NA 26 A Vein x-ray, liver 0.00 2.70 10.13 0.37 0.05 1.57 1.56 1.57 1.56		<u>۲</u>		iver	0.00	2.84	10.16	Y Y	NA	0.65	3.49	10.81	N A	ĄZ	×
26 A Vein x-ray, liver 1.14 0.38 0.37 0.05 1.57 1.56 1.57 1.56	26 A Vein x-ray, liver 1.14 0.38 0.37 0.05 1.57 1.56			⋖	Vein x-ray, liver	1.14	3.07	10.50	Y Y	Y V	0.70	4.91	12.34	Ą Ż	₹ Z	××
1C A Veil x-ray, liver NA NA NA 0.05 3.35 10.78 NA NA 26 A Vein x-ray, liver 1.14 3.37 0.037 0.037 0.037 0.037 0.037 0.037 0.037 0.037 0.037 0.037 0.037 0.065 1.56<	1C A Verif X-ray, INer NA 0.05 3.35 10.78 NA NA 26 A Vein x-ray, INer 1.14 3.05 10.49 NA 0.05 1.56 1.57		26	< <		1.14	0.38	0.37	0.38	0.37	0.05	1.57	1.56	1.57	1.56	X }
26 A Veil x-day, liver 1.14 0.37 0.34 0.77 NA	26 A Verin x-ray, liver 1.14 0.37 0.07 0.34 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.34		: :	∢ <	, se	0.00	2.70	10.13	Y S	¥ \$	0.65	3.35	10.78	¥ S	₹ Ş	××
LC A Ventus sampling by catheter C.54 2.87 10.12 NA NA 0.65 3.33 10.77 NA NA Z6 A Ventus sampling by catheter 0.54 2.87 10.30 NA NA 0.67 4.08 11.51 NA NA Z6 A Venous sampling by catheter 0.54 0.18 0.18 0.02 0.74 <td>CC A Venior x-ray, liver CO COS COS</td> <td></td> <td>96</td> <td>(⊲</td> <td>, d</td> <td></td> <td>0.03</td> <td>0.49</td> <td>7 2 0</td> <td>7 2 0</td> <td>0.70</td> <td>90.4 90.4</td> <td>7.55</td> <td>- - - - -</td> <td>- -</td> <td>< ×</td>	CC A Venior x-ray, liver CO COS		96	(⊲	, d		0.03	0.49	7 2 0	7 2 0	0.70	90.4 90.4	7.55	- - - - -	- -	< ×
26 A venous sampling by catheter 0.54 2.87 10.30 NA NA 0.67 4.08 11.51 NA NA 26 A venous sampling by catheter 0.54 0.18 0.18 0.02 0.74 </td <td>26 A Venous sampling by catheter 0.54 2.87 10.30 NA NA 0.67 4.08 11.51 NA NA 26 A Venous sampling by catheter 0.54 0.18 0.18 0.02 0.74</td> <td></td> <td></td> <td>(<</td> <td>Vein X-ray, IIVer</td> <td>00.0</td> <td>2.68</td> <td>10.12</td> <td>S Z</td> <td>S A</td> <td>0.65</td> <td>3.33</td> <td>10.77</td> <td>S. A</td> <td>9 Z</td> <td>XX</td>	26 A Venous sampling by catheter 0.54 2.87 10.30 NA NA 0.67 4.08 11.51 NA NA 26 A Venous sampling by catheter 0.54 0.18 0.18 0.02 0.74			(<	Vein X-ray, IIVer	00.0	2.68	10.12	S Z	S A	0.65	3.33	10.77	S. A	9 Z	XX
26 A Venous sampling by catheter 0.54 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.09 0.74 0.7	26 A Venous sampling by catheter 0.54 0.18 0.18 0.18 0.18 0.01 0.02 0.74 0.7			< <	Venous sampling by catheter	0.54	2.87	10.30	Z	¥ Z	0.67	4.08	11.51	¥ Z	¥ Z	××
TC A Venous sampling by catheter 0.00 2.69 10.12 NA NA 0.65 3.34 10.77 NA NA 26 Na NA <td>TC A Venous sampling by catheter 0.00 2.69 10.12 NA NA 0.65 3.34 10.77 NA NA TC Ma X-rays, transcath therapy 1.31 0.42 0.43 0.42 0.43 0.06 1.81 1.82 1.81 1.82 TC Ma NA NA NA NA NA NA NA TC Ma NA NA NA NA NA NA NA TC Ma NA NA NA NA NA NA NA TC Ma NA NA</td> <td></td> <td>26</td> <td>⋖</td> <td>Venous sampling by catheter</td> <td>0.54</td> <td>0.18</td> <td>0.18</td> <td>0.18</td> <td>0.18</td> <td>0.05</td> <td>0.74</td> <td>0.74</td> <td>0.74</td> <td>0.74</td> <td>××</td>	TC A Venous sampling by catheter 0.00 2.69 10.12 NA NA 0.65 3.34 10.77 NA NA TC Ma X-rays, transcath therapy 1.31 0.42 0.43 0.42 0.43 0.06 1.81 1.82 1.81 1.82 TC Ma NA NA NA NA NA NA NA TC Ma NA NA NA NA NA NA NA TC Ma NA NA NA NA NA NA NA TC Ma NA NA		26	⋖	Venous sampling by catheter	0.54	0.18	0.18	0.18	0.18	0.05	0.74	0.74	0.74	0.74	××
26 A X-rays, transcarth therapy 1.31 NA NA <t< td=""><td>26 A X-rays, transcarth therapy 1.31 0.42 0.43 0.43 0.08 1.81 1.82 1.81 1.82 26 A X-rays, transcarth therapy 0.00 NA <t< td=""><td></td><td> </td><td></td><td>Venous sampling by catheter</td><td>0.00</td><td>2.69</td><td>10.12</td><td>Y :</td><td>Ϋ́ Z</td><td>0.65</td><td>3.34</td><td>10.77</td><td>¥ :</td><td>¥ :</td><td>X</td></t<></td></t<>	26 A X-rays, transcarth therapy 1.31 0.42 0.43 0.43 0.08 1.81 1.82 1.81 1.82 26 A X-rays, transcarth therapy 0.00 NA NA <t< td=""><td></td><td> </td><td></td><td>Venous sampling by catheter</td><td>0.00</td><td>2.69</td><td>10.12</td><td>Y :</td><td>Ϋ́ Z</td><td>0.65</td><td>3.34</td><td>10.77</td><td>¥ :</td><td>¥ :</td><td>X</td></t<>		 		Venous sampling by catheter	0.00	2.69	10.12	Y :	Ϋ́ Z	0.65	3.34	10.77	¥ :	¥ :	X
ZO A A-rays, transcath therapy 1.31 O.42 O.43 O.44 O.45 O.45<	Zo A A-rays, transcatt therapy 1.31 0.54 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.65<	-			X-rays, transcath therapy	E. 5	A S	Z Z	Z S	A C	1.35	Y Z	A C	Y Y	Z Z	×
X-rays, transcath therapy 1.31 NA NA NA 1.15 NA	26 A X-rays, transcath therapy 1.31 0.51 0.47 0.51 0.47 0.51 0.47 0.51 0.47 0.651 0.47 0.651 0.47 0.651 0.47 0.651 0.47 0.651 0.652 0.651 <th< td=""><td></td><td></td><td></td><td>X-rays, transcatt therapy</td><td>رن د د</td><td>0.42 A N</td><td>0.43 AN</td><td>0.4Z</td><td>24.0 VA</td><td>1.27</td><td>- 0: I</td><td>20. Z</td><td>o. N</td><td>20.1 AN</td><td>XX</td></th<>				X-rays, transcatt therapy	رن د د	0.42 A N	0.43 AN	0.4Z	24.0 VA	1.27	- 0: I	20. Z	o. N	20.1 AN	XX
26 A X-rays, transcath therapy 1.31 0.51 0.47 0.051 0.47 0.051 0.47 0.051 0.87 1.87 1.83 TC A X-rays, transcath therapy 0.00 NA NA NA NA NA NA NA NA A Follow-up angiography 1.65 NA	26 A X-rays, transcath therapy amgiography 1.31 0.51 0.47 0.67 0.05 1.87 1.83 1.87 1.83 TC A X-rays, transcath therapy amgiography 0.00 NA NA NA NA NA NA NA NA NA 26 A Follow-up angiography 1.65 0.60 0.66 0.60 0.56 0.00 0.56 0.07 2.32 2.32 2.32)		X-rays, transcath therapy	1.31	Z Z	A Z	Z Z	Z	1.15	Z Z	Ą Z	Z Z	Z Z	××
TC A X-rays, transcath therapy	TC A X-rays, transcath therapy 0.00 NA NA NA 1.10 NA NA NA				X-rays, transcath therapy	1.31	0.51	0.47	0.51	0.47	0.05	1.87	1.83	1.87	1.83	XX
2 Follow-up angiography ————————————————————————————————————			10 		X-rays, transcath therapy	0.00	A N	Υ Υ	Z	Y Y	1.10	A A	₹ Z	₹ Z	₹ Z	×
					Follow-up angiography	59.	AN C	Z C	Z S	A C	0.13	A C	A S	Y S	A S	X }

						_	_		_																						_	_	_	_		_		_
****	ž ž ž ž	* * * *	{	X	žž	222	722	× }	{X	××	X	××	×	××	×	××	X	××	X	žž	× }	{×	× }	₹×	××	XX	XX	ZZZ	XX	X	×××	727	ZZZ	X	××	X	××	××
A N O O O O O	0.6 A N S	0.0 4.0 X	0.76	ZZ	0.58 NA	0.00	00.0	0.00	0.00	0.00	0.00	3,15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.07	0.00	1.16	¥ ž	5.81	¥ Z	0.76	NA 7	0.51	62.7 AN	1.86	NA 7	0.52	7.30 NA	1.15	¥ Z	0.74	Z Z	1.97
A) A A I	2 2 4 5 5 5	0.75	Z Z (0.59 NA	0.00	00.00	0.00	0.00	0.00	0.00	90.0	0.00	0.00	0.00	00:0	0.00	0.00 5.32	0.00	0.00	0.00	1.19	Y S	5.80	Y Z	0.77	8 S	0.52	2.69 N	1.94	.3 NA	0.54	2.72 NA	1.15	Z Z	0.73	₹ ₹ Z Z	1.97
NA 0.068 NA 0.068	2.82 2.73	2.19	0.76	ZZ	0.58 NA	0.00	00:0	0.00	0.00	0.00	0.00	3.15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.16	NA S	5.81	9.23	0.76	13.47	0.51	7.29	1.86	13.55	0.52	7.30 NA	1.15	NA R	0.74	13.41 NA	1.97
0.68 0.68 0.68 0.68	79.0 7.87 7.88 7.88	2.35	0.75	Z Z	0.59 NA	0.00	0.00	0.00	0.00	0.00	0.00	3.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.19	NA	5.80	3.75	0.77	3.20	0.52	6.41	1.94	3.25	0.54	2.72 NA	1.15	NA 86	0.73	3.94 NA	1.97
0.00	0.02	0.00	0.00 40.00	0.28	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	00.0	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.77	0.73	0.55	0.03	0.83	0.03	0.43	0.06	0.83	0.05	0.43	0.0	0.60	0.02	0.35	0.06
N N N N N N N N N N N N N N N N N N N	0 V N N V	2 A Z	0.18	Z Z	0.14 NA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	00.0	00.0	0.00	0.00	0.00	0.00	0.29	¥ ž	1.39	¥ Ž	0.19	NA 98	0.12	98.9 VA	0.49	A N	0.14	6.87 NA	0.28	¥ Ž	0.18	¥ Z	0.47
AN O. 16 AN A. 6	0 V V V	2 Z Z	0.17	Z Z	0.15 NA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.32	A S	1.38 8.1	A Z	0.20	NA 38	0.13	2:26 NA	0.57	AN 4	0.16	2.29 NA	0.28	Y Z	0.17	¥ Z	0.47
0.10 NA 1.20 N	0.16 1.99 1.49	1.36	0.18	Z Z	0.1 4 N	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.29	NA NA	1.39	8.68	0.19	12.64	0.12	13.20	0.49	12.72	0.14	6.87 NA	0.28	NA 12.76	0.18	12.58 NA	0.47
NA N	0.16 4.04 1.64	1.52	0.17	Z Z	0.15 NA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.32	NA S	1.38	3.20	0.20	3.34	0.13	2.26 4.21	0.57	3.64	0.16	2.29 NA	0.28	NA 201	0.17	E N	0.47
0.00	0.00	0.00	0.00 4.00 4.00 4.00 6.00	0.40	0.40	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	00.0	0.00	00.0	0.00	0.00	0.00	3.50	0.00	0.82	0.00	4 2 4 4 2 4	0.00	0.54	0.00	0.36	0.00	1.3	0.00 0.36	0.36	0.00	0.83	0.00	0.54	0.0 4.1	1.44
Follow-up angiography	emove cva device obstruct emove cva device obstruct emove cva lumen obstruct	emove ova lumen obstructemove ova lumen obstruct	ray placement, vein litter	ray pacement, ven met	itravascular ustravascular us	itravascular us add-on	irrayascular us adu-ori Itrayascular us add-on	ndovasc repair abdom aorta	ndovasc repair abuoni abutandovasc repair abdom abuta	bdom aneurysm endovas rpr	bdom aneurysm endovas rpr	ac aneurysm endovas rprac aneurysm endovas rpr	ac aneurysm endovas rpr	ray, endovasc thor ao repr	ray, place prox ext thor aoray. place prox ext thor ao	ray, place prox ext thor ao	ray, place dist ext thor aoray, place dist ext thor ao	ray, place dist ext thor ao	ranscath iv stem rs&iranscath iv stem rs&i	ranscath iv stent rs&i	etrieval, broken catheter etrieval, broken catheter	etrieval, broken catheter	epair arterial blockageepair arterial blockage	epair arterial blockageepair artery blockage each	epair artery blockage, each	epair artery blockage, eachepair arterial blockage	epair arterial blockage	epair arterial blockage	epail aftery blockage, each	epair artery blockage, each	ascular biopsy	ascular biopsy	epair venous blockage	epair venous blockageontrast xray exam bile duct	ontrast xray exam bile duct			
40404.																																						Δ - -
			26		76				 1C	26		26	i	26		26		26		26	-						 ပ		<u>်</u>		ပ္							35
																					Ì																	-
75898 75900 75900 75900 75901	75901 75901 75902	75902	75940 75940	75945	75945 75945	75946	75946 75946	75952	75952	75953 75953	75953	75954 75954	75954	75956 75956	75956	75957	75957	75958 75958	75958	75959	75959	75960	75960	75961	75961	75962	75962 75964	75964	75964 75966	75966	75966	75968	75968	75970	75970	75978	75980	75980

Addendum B.—Relative Value Units (RVUS) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	
Year 2007 Transitional Facility Total	A N N N N N N N N N N N N N N N N N N N
Fully Implemented Facility Total	A N N N N N N N N N N N N N N N N N N N
y Im- Year 2007 Ment- Transi- Nion- tional cility Non-Fa- otal cility Total	AN N N N N N N N N N N N N N N N N N N
	NAN
Mal-Practice RVUs	90000000000000000000000000000000000000
Physician Pervice Rous Facility Results Rous PERVUS RUS PERVUS RUS PERVUS RUS PERVUS RUS RVUS RVUS RVUS RVUS RVUS RVUS R	A N S S A S A S S A S S A S S A S S A S S A S S A S S A S S A S S A S S A S A S S A S S A S A S S A S A S S A S
Fully Implemented Facility PE RVUs	A N N S N N N S N N S N N S N N S N N S N N S N N S N N S N N S N N S N N S N N N S N N S N N S N N S N N S N N S N N S N N S N N S N N S N N N S N N S N N S N N S N N S N N S N N S N N S N N S N N S N N
Year 2007 Transitional Non-Fa-cility PE-RVUs	ANN 0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0
Fully Implemented Non-Facility PE RVUS	A N N N N N N N N N N N N N N N N N N N
Physician Work RVUs	0.00 0.00
tatus Description	Contrast xray exam bile duct Xray control catheter change Atherectomy, x-ray exam Atherectomy exterbroplasty, fluor Bercut vertebroplasty, ct A-rays for bone age A-rays for bone age A-rays for bone exaluation X-rays, bone evaluation X-rays, bone evaluation X-rays, bone evaluation
	404044444440400400400404444444444444444
Mod 8	5 85 <t< td=""></t<>
CPT ¹ /	75980 75982 75982 75982 75983 75984 75989 75989 75993 75995 75995 75995 75996

***************************************	************
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2
A 2 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	1.18 1.18 1.18 1.18 1.23 1.23 1.23 1.23 1.34 1.35 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.4
7.75 7.75	2.70 2.25 2.25 2.129 2.23 2.678 2.678 2.23 2.23 8.27 8.27 1.97
0.00 0.00	2.22 2.22 2.22 2.22 2.23 2.242 2.242 2.23 2.23
0.000000000000000000000000000000000000	0.04 0.07 0.00 0.00 0.03 0.03 0.09 0.09 0.09 0.09
	N N N N N N N N N N N N N N N N N N N
A 4 8 8 7 1 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	A N N N N N N N N N N N N N N N N N N N
1.22 1.07 1.07 1.07 1.07 1.07 1.07 1.07 1.07	0.28 0.28 1.45 1.45 1.12 1.12 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.53
1.4.3 1.6.2 1.6.2 1.6.3	22.11 1.84 1.84 1.20 2.20 2.203 2.203 2.203 2.203 2.203 1.50 1.34 0.53 0.63 0.63 0.63 0.63 0.63 0.63 0.63 0.6
4.45 6.00	0.87 0.00 0.70 0.70 0.00 1.63 1.63 1.59 0.00 0.00 0.56 0.56
al a	is i
survey survey survey survey survey survey survey survey evaluation evaluation evaluation evaluation single view single v	both breast, both breast, both breast, screening as screening. Screening ge, breast age, breast age, breast age, both bre ge, both bre ge, both bre ast blopsy breast breast blopsy blop
X-rays, bone survey X-rays, bone evaluation Ct bone density, axial Ct bone density, peripheral Ct bone density, axial Ct bone density, peripheral Ct bone density, peripheral Ct bone density, axial Ct	fammogram fammog
26 26 26 27 27 26 26 26 26 26 27 27 27 27 27 27 27 27 27 27 27 27 27	26 26 26 26 26 26 26 26 26 26 26 27 27 27 27 27 27 27 27 27 27 27 27 27
76061 76061 76062 76065 76065 76065 76065 76065 76070 76070 76070 76070 76070 76070 76070 76070 76070 76080	76091 76091 76092 76092 76093 76093 76094 76094 76095 76095 76096 76096

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	
Year 2007 Transi- tional Fa- cility Total	A S S A S A S S A S S A S A S S A S A S S A S A S S A
Fully Im- plement- ed Facil- ity Total	A S S A A S A
Year 2007 Transi- tional Non-Fa- cility Total	0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.00
Fully Implemented Non-Facility Total	0.000 4 0.00 0.00 0.00 0.00 0.00 0.00 0
Mal-Prac- tice RVUs	0.000 0.000
Year 2007 Transi- tional Fa- cility PE RVUs	A 2 2 4 4 4 4 4 4 4 6 4 4 4 6 4 4 4 6 4 4 4 6 4 4 4 6 4 4 4 4 4 6 4 4 4 4 4 6 4 4 4 4 4 6 4 4 4 4 4 6 4 4 4 4 4 4 6 4 4 4 4 4 4 6 4
Fully Implemented Facility PERVUS	A S A S A S A S A S A S A S A S A S A S
Year 2007 Transi- tional Non-Fa- cility PE RVUs	00.00000000000000000000000000000000000
Fully Implemented Non-Facility PERILLY	0.000 0.000
Physician Work RVUs	0.000 0.0000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.
Description	X-ray exam, breast specimen X-ray exam, breast specimen X-ray exam, breast specimen X-ray exam of body section x-ray Complex body section x-ray Complex body section x-ray Complex body section x-rays Conplex body body body bone marrow Conplex body body brocedure Conplex body brocedure Conplex body section concedure C
Status	444444444444444444444444444444444444444
Mod	85 85 85 85 85 85 85 85 85 85 85 85 85 8
CPT1/ HCPCS ²	76098 76098 76100 76100 76101 76101 76101 76101 76102 76102 76120

00000000000000000000000000000000000000	2
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	5 N S O S O S O S O S O S O S O S O S O S
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	2.53 0.76 0.82 0.76 1.17 0.75 1.13 1.13 1.01 1.01 1.01 1.01 1.01 1.01
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	2.60 2.60 3.35 3.35 3.35 3.35 3.35 3.35 3.34 3.34
00000000000000000000000000000000000000	20000000000000000000000000000000000000
00000000000000000000000000000000000000	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
0.00 0.00	1.13 1.13 1.13 1.13 1.13 1.13 1.13 1.13
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	2.008 2.008 2.008 2.009
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	0.57 0.57 0.57 0.56 0.56 0.56 0.57 0.57 0.58 0.69 0.74
procedure procedure procedure procedure procedure procedure procedure procedure procedure diographic procedure process process process process process procedure process proce	d neck an neck an neck an neck an mplete mplete mplete mylete mylete wall, comp wall, comp wall, lim splant
e e e e e e e e e e e e e e e e e e e	of eye of eye of eye of eye head ann head ann head ann head ann head ann head ye heat, b-sc hest, b-sc heat, b-sc heat, b-sc heat, b-sc heat, b-sc heat, b-sc hest, b-sc heat, b-sc heat
Ct procedur Ct procedur Ct procedur Ct procedur Ct procedur Ct procedur Mri procedur Mri procedur Mri procedur Mri procedur Badiograph Radiograph Radiograph Radiograph Radiograph Radiograph Radiograph Radiograph Cophth us, b Ophth us, b Ophth us, q Ophth us, d Ophth us, d Ophth us, b Ophth us, b Cophth	Echo exam of eye Echo exam of eye Echo exam of eye Echo exam of eye Us exam of head and neck Us exam of head and neck Us exam of head and neck Us exam, chest, b-scan Us exam, chest, b-scan Us exam, breast(s) Us exam, abdom, complete Us exam, abdom, complete Us exam, abdom, complete Us exam abdo back wall, comp Us exam abdo back wall, comp Us exam abdo back wall, im Us exam kidney transplant Us exam kidney transplant Us exam kidney transplant Us exam, spinal canal
85 85 85 85 85 85 85 85 85 85 85 85 85 8	26 26 26 26 26 26 26 26 26 26 26 26 26 2
76497 76497 76498 76499 76499 76499 76499 76506 76506 76506 76512 76512 76513	76529 76529 76529 76529 76536 76536 76604 76604 76645 76645 76700 76700 76700 76700 76700 76700 76700 76700 76700 76700 76700 76700 76770

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2007—Continued

Global	
Year 2007 Transitional Facility Total	2.1.1. A 1.3.5. S.
Fully Implemented Facility Total	84
Year 2007 Transi- tional Non-Fa- cility Total	224 1.15 1.10 1.09 1.09 1.09 1.09 1.09 1.09 1.09
Fully Implemented Non-Facility Total	1.96 1.196 1.197 1.197 1.198 1
Mal-Practice RVUs	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Physician plement to all Non-Fa- Facility Non-Fa- PRVME IN DELEKMINING MEDICARE PAYMENTS FOR Year 2007 plement Transi- plement to all Non-Fa- ity PE RVUs PERVUS PERVUS PERVUS RVUS RVUS RVUS RVUS RVUS RVUS RVUS	25 4 4 5 6 6 6 7 4 7 6 6 7 4 7 6 7 7 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8
Fully Implemented Facility PERVUS	25.7.2.4.2.5.4.2.5.4.5.4.5.4.5.4.5.4.5.4.5.4
Year Year 2007 Transitional Non-Fa-cility PE RVUs	1.25 1.25
Fully Implemented Non-Facility	0.097 0.
Physician Work RVUs	0.00 0.00
HELATIVE VALUE UNITS (HVUS) AND Description	Ob us < 14 wks, addil fetus Ob us < 14 wks, addil fetus Ob us < 14 wks, addil fetus Ob us > 14 wks, addil fetus Ob us > 14 wks, addi fetus Ob us detailed, sng fetus Ob us detailed, sng fetus Ob us, detailed, sng fetus Ob us, detailed, and fetus Ob us, detailed, and fetus Ob us, detailed, and fetus Ob us, detailed, addi fetus Ob us, follow-up, per fetus Ob us, follow-up, follow-up, follow-up, foll
. Statu	444444444444444444444444444444444444444
ADDENDUM B	\$2 \$2 \$2 \$2 \$2 \$2 \$2 \$2 \$2 \$2 \$2 \$2 \$2 \$
ADDI CPT ¹ / HCPCS ²	76802 76802 76802 76805 76805 76805 76810 76810 76811 76811 76811 76812 76812 76813 76820

									_																												_	_	_	_	_	_	_	_	
×××	××	××	XX	X	××	X	×}	XX	×	×>	XX	X	××	₹ X	X	××	××	××	× š	<u> </u>	777	ZZZ	××	X	×}	{×	×	××	₹×	×	××	××××××××××××××××××××××××××××××××××××××	X }	XX	X	X	×××	{X	X	X	×××	{X	XX	ž×	XX
NA NA 0.53	A A	0.88 AN	NA	S Z	AN 6	Ž Š	¥ 5	 S ≥	Ž		¥ ¥	0.85	∀ 2	0.96	¥:	A C	Ş.₹	¥	2.78	0 A A	0.43	0.52	N P P P	N A	N N N	<u>è</u> ₹	₹ Z	0.92 NA	₹	0.92	¥ ₹	0.53	¥ ž	0.53	N A	Ϋ́	0.79 NA	 {	1.86	¥:	O NA		¥,	 ย N พ	NA 0.08
0.54 NA PA PA	₹ Ž Ž Ž	0.88 AA	₹ S	Z Z	N C	Z Z	A S	8 Z	Z Z	0.99 VN	₹ ₹ Z	0.83	Υ Δ Ζ	.03	¥:	Z Z	₹	N A	2.79	Z Z	0.42	0.62	A 6	Ž	N A	2 Z	Z Y	0.93 VA	¥ Z	0.91	Y Z	0.51	Ϋ́	0.51	Z Y	ξĮ	0.77 NA	Σ Z	1.90	¥:	O NA	S S	¥;	L X 4 X	AN VO
1.89 2.46 0.53	1.94	0.88	3.37	2.41	9.40	2.45	2.71	1.90	2.99	1.01	2.52	0.85	1.68	0.96	1.68	N 0	S Z	9.19	2.78	0.40	0.43	0.52	2 9.5	Z Z	NA V	<u>§</u> 8	4.28	0.92	N AN	0.92	NA Be	0.53	1.33	0.53	1.33	2.10	0.79	6.51	1.86	4.64	1.90 0.55	1.36	Y ?	ار الا X الا X	0.08
2.69 2.99 5.4	3.60	0.88	4.26	3.26	5.19 2.15	3.03	3.89	3.09	4.08	0.99	3.03	0.83	2.20	1.03	1.86	A Z	Z Z	8.51	2.79	27.6	0.42	0.62	0 PA	N A	NA P	. S	5.63	0.93	N Y	0.91	N O	0.51	0.44	0.51	0.44	1.84	1.07	2.89	1.90	0.99	2.62 0.53	2.09	Y,	L. N 4 K	0.22
0.10	0.06	0.03	0.14	0.10	0.25	0.16	0.1	0.08	0.13	0.03	0.0	0.03	0.08	0.02	0.10	21.0	0.10	0.47	0.13	4 C. C.	0.03	0.10	0.60	0.29	0.15	0.0	0.13	0.03	0.05	0.03	0.08	0.02	0.10	0.02	0.10	0.10	0.03	0.37	0.08	0.29	0.0 0.0 0.0	0.06	0.14	0.04	0.06
AN CL	A A	0.21 NA	N N	NA A	N O	N A	A S	2 Z	₹ Z	0.24	¥ ¥	0.20	¥ ₹	0.27	¥:	A C	N AN	A A	0.66	N 0	0.10	0.42	A S	N A	A S	0.46 AN	¥ Z	0.22	¥	0.22	Y Z	0.13	¥ ž	0.13	Z Z	A S	0.18 NA	 {	0.44	¥:	O NA	2 Z	A S	0.28 NA	NA 0.02
X X 7 5	₹ Z Z Z	0.21 NA	NA V	N S	N S	N A	Y S	<u>0</u> ₹	N A	0.22	¥ ¥	0.18	e d Z Z	0.34	¥:	NA R	S Z	Ϋ́	0.67	0 PA	60.0	0.52	N 0	N A	A S	₹ Z	Ϋ́	0.23 NA	Z Z	0.21	Y Z	0.11	Ϋ́	0.1 1.0	Z Y	¥ S	0.16 NA	 Σ ≥	0.48	¥:	A F	Z S	A S	0.29 AA	NA 10.0
2.00	1.88	0.21	2.54	2.31	2.80	2.29	2.01	1.82	2.12	0.24	1.79	0.20	1.60	0.27	1.58	AN C	NAN	6.73	0.66	0.00	0.10	0.42	N 0	Z Z	A S	0.45 Q A	3.48	0.22	NAN	0.22	N P	0.13	1.23	0.13	1.23	1.42	0.18	24.8 08.4	0.44	4.35	1.42 0.13	1.30	A S	0.28 NA	0.66
2.59	2.38	0.21	3.43	3.16	3.39	2.87	3.19	3.01	3.21	0.22	2.30	0.18	2.12	0.34	1.76	NA SP	S Z	6.05	0.67	5.38 0.61	0.0	0.52	N O	N A	Z S	4. A	4.83	0.23	P A	0.21	A S	0.13	0.34	0.43	0.34	1.16	0.16	- -	0.48	0.70	2.14 0.11	2.03	A C	0.29 NA	0.11
0.00	0.00	0.00	0.69	0.00	1.55	0.00	0.59	0.00	0.74	0.74	0.00	0.62	0.00	0.67	0.00	0.67	0.0	1.99	1.99	0.00	0:30	0.00	00.0	0.0	4.34	4.00 4.00	0.67	0.67	0.67	0.67	0.00	0.38	0.0	86.0 88.0	0.00	0.58	85.0 0.0	- 25. - 34. 	45.	0.00	0.40 0.40	0.0	0.81	- 0.0 0.00	0.05
exam, exam, exam,	exam, pel exam, scr	Us exam, scrotum	transrect	transrect	Echograp trans r, pros studyEchograp trans r, pros study	tra	exam, ext	Us exam, extremity	exam infa	Us exam infant hips, dynamic	exam infa exam infa	exam infa	Us exam intant hips, static	Echo guide, cardiocentesis	guide, o	Echo guide for heart blopsy	guide fo	guide fo	guide fo	Echo guide for artery repair	guide, vas guide, vas	guide, vas	Us guide, tissue ablation	Us guide, tissue ablation	9 4	Echo guide for transfusion	guide fo	guide fo		guide, 1	Echo guide, villus sampling	guide fo	guide fo	Echo guide, ova aspiration	guide, o	guidanc	Echo guidance radiotherapy	guidanc	guidanc	Echo guidance radiotherapy	Ultrasound exam follow-up	Ultrasound exam follow-up	endoscopi	Gl endoscopic ultrasound	bone den
444	∢ ∢	∢ ∢	∶∢∢	< <	∢ ₫	< ∢	⋖ <	(∢	∶∢	∢ <	(∢	∢.	∢ ⊲	(∢	∢ .	∢ ⊲	(∢	⋖	⋖ <	∢ ⊲	< <	∢ •	∢ ⊲	< ∢	∢ <	(∢	∶∢	∢ <	(∢	⋖ ·	∢ ⊲	(∢	∢ <	< <	< <	⋖・	∢ ◊	۲∢	< ∢	∢.	∢	(∢	< •	∢ ∢	: ∢ ∢
TC	<u></u>	26		100	26	12	90	 10 10 10		26	2	26	ည	26	TC	96	122		26	<u>:</u> د	26	TC	26					26	2	26))	26	TC	26			26	<u>:</u> د	26	TC	26	TC 22		26	26
6 5 7	0	0 0	0.00	2 2	e e		0	00	5	5			9 0		o	N 0	1 0	9	9		7	7	0 0	0				0.0	5	5	2	9	9	0 80		0	0 0	22.0	2	5	0 0	00	5	ייט	7
76856 76857 76857	76857 76870	76870	76872	76872	76873	76873	76880	76880	76885	76885	76886	76886	76886	76930	76930	76932	76932	76936	76936	76937	76937	76937	76940	76940	76941	76941	76942	76942	76945	76945	76945	76946	76946	76948	76948	76950	76950	76965	76965	76965	76970	7697	76975	76975	76977

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	
Year 2007 Transi- tional Fa- cility Total	AA7.400000144 A000000 A400000 A400000 A400000 A400000 A400000 A400000 A40000 A40000 A4000
Fully Im- plement- ed Facil- ity Total	A A B A A C C C C C C C C C C C C C C C
Year 2007 Transi- tional Non-Fa- cility Total	0.000 0.000
Fully Implemented Non-Facility Total	NAN 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Mal-Prac- tice RVUs	0.000000000000000000000000000000000000
Year 2007 Transi- tional Fa- cility PE RVUs	A N S S S S S S S S S S S S S S S S S S
Fully Implemented Facility PERVUS	A A S C C C C C C C C C C C C C C C C C
Year 2007 Transi- tional Non-Fa- cility PE RVUs	00 00 00 00 00 00 00 00 00 00 00 00 00
Fully Implemented Non-Facility PERVUS	00 00 00 00 00 00 00 00 00 00 00 00 00
Physician Work RVUs	00.00000000000000000000000000000000000
Description	Us bone density measure Ultrasound guide intraoper Ultrasound guide intraoper Ultrasound guide intraoper Echo examination procedure Echo examination procedure Echo examination procedure Echo examination procedure Radiation therapy field Set radiation therapy field Teletx isodose plan intermed Teletx isodose plan intermed Teletx isodose calc simp Brachytx isodose calc simp Brachytx isodose calc interm Brachytx isodose plan complex Prachytx isodose calc interm Brachytx isodose plan complex Special radiation dosimetry Special radiati
Status	444000444444444444444444444444444444444
Mod	5 85 85 85 85 85 85 85 85 85 85 85 85 85
CPT¹/ HCPCS²	76977 76986 76986 76986 76999 77269 77280 77280 77280 77280 77290 77290 77290 77300 77300 77300 77301 77301 77301 77301 77302 77302 77302 77303 77303 77303 77303 77303 77304 77305 77306 77306 77306 77307 77307 77308

Padiation treatment 26						_	_	_																												_	_	_	
70	××××	××	XX3	{	××;	×× ××	××	(X)	žž	×3	žž	××	X	××	{×	X}	₹×	X}	žž	××	X	žž	××	X	××	X	××	X	žž	× }	₹×	× }	žž	X	××	×	×××	060	060
T.C. A Registion beaument edition 12 12 12 13 14 15 15	0.7.0 A N N 4.1.	Z Z	9.E A S	Z Z	0.00	0.0 V A	A S	Z Z	¥ ¥	₹ Z	¥ ¥	¥ ₹	Ž	¥ ₹	₹	A S	4 A	¥ ž	4.55	2.58	Z Z	28.2 A N	0.00	00.0	00.0	0.00	0.00 A	2.10	₹ ₹	2.88	¥ ¥	2.13	<u>₹</u> ₹	2.83	Y Y	2.25	AN 4.	6.67	8.22
10	0.72 NA NA	<u>4</u> 4	26. A 5	Z Z	0000	0.5 S A	 & & Z Z	Z Z	₹ ₹ 2 2	Ž	₹ ₹ Ž Ž	Z Z	Ž	Y Z	ξŞ	A C	NA AN	Ž Ž	4.56	2.58	3 5 6	N.Y.	0.00	0.00	00.0	0.00	0.0 V	1.99	₹ <u>₹</u>	2.78	¥ ₹	2.07	₹ ₹	2.75	4 4 2 2	2.17	9.41 	6.50	9.72 5.04
To A Particulo Resiment adds 125 1	0.74 1.42 2.73	1.59	3.18	3.38	0.00	0.00	2.48	2.49	3.04	2.98	3.13 1.13	3.57	3.79	3.79	16.90	3.61	3.07	4.36	3.78 4.55	2.58	12.10	2.85 9.25	0.00	0.00	0.00	0.00	0.00	2.10	4.69 10.24	2.88	8.61	2.13	12.09	2.83	9.25	2.25	4.74 8.44	6.67	8.22
17	0.72	0.34	2.44	2.51	0.00	0.00	4.26	4.30	4.29 5.51	5.30	5.80	6.91	7.79	7.78	13.15	2.46	1.94	11.92	4.56	2.58	4.55	1.78	0.00	0.00	0.00	0.00	0.00	1.99	9.13	2.78	18.34	2.07	16.28	2.75	24.17	2.17	9.34	6.50	9.72 5.04
To A Regidation reserved id 19 19 19 19 19 19 19 1	0.03	0.11	0.06	0.0	0000	0.00	0 C	 : E ;	0.11	0.12	0.0 7.51	0.13	0.13	0.13	0.0	0.12	0.02	0.13	0.13	0.09	0.70	0.59	0.0	0.0	00.0	0.00	0.00	0.08	0.38	0.16	0.24	0.08	0.33	0.11	0.22	0.20	0.16	0.25	0.33
10	0.17 NA NA	Z Z	0.39 NA	ZZ	0000	0.00 NA	A S	Z Z	A A	¥ S	¥ Z	Z Z	₹ Z	A A	¥ Ž Ž	A S	2 N	¥ S	1.07	0.68	N S	0.65 NA	0.00	0.00	00.0	0.00	0.00 AN	0.46	A A	0.63	¥ ¥	0.49	¥ ¥	0.63	Y Y	0.49	3.22	1.52	4.09 - 1.08
10	0.15 NA NA	Z Z	0.34 NA	¥	0000	0.0 NA	 &	ZZ	<u>₹</u> ₹	¥ ž	₹ ₹ 2 Z	¥ Z	Ž	₹ Z	¥	¥ ;	- ₹	¥ S	1.08	0.68	¥ [0.5/ NA	0.00	0.00	00.0	0.00	0.00 AN	0.35	¥ ¥	0.53	¥ Z Z	0.43	≰	0.55	A A	0.41	AN 4.19	1.35	5.59 1.05
100	1.35	3.39	3.01	3.20	0000	0.00	2.37	238	2.37	2.86	2.99	3.44	3.66	3.66	16.77	3.10	2.97	4.23	1.07	0.68	9.31	0.65 8.66	0.00	0.00	00.00	0.00	0.00	0.46	7.77	0.63	6.81	0.49	6.32	0.63	9.03	0.49	4.58 3.22	1.52	4.09 1.08
10	0.15	0.23	2.27	2.33	0000	0.00	4.15	91.7	4.18 5.39	5.18	5.68	6.78	7.66	7.65	13.02	1.95	1.84	11.79	1.08	0.68	1.76	1.19	0.00	0.00	00.0	0.00	0.00	0.35	16.90	0.53	16.54	0.43	24.51	0.55	23.95	0.41	9.18	1.35	5.59
2	0.54	0.00	0.00	0.00	0000	0.00	00.0	00.0	00.0	0.00	00.0	0.00	0.00	0.00	0.0	0.39	00.0	0.00	3.31	1.81	2.09	00.0	0.00	0.00	00.0	0.00	0.00	1.56	0.00	2.09	1.56	1.56	0.00	2.09	0.00	1.56	0.00	06.4	3.80
2	treatment aid(s)treatment aid(s)treatment aid(s)	treatment aid(s)	treatment aid(s)	physics consult	radiation dosimetry	radiation dosimetry	treatment delivery	treatment delivery	reatment delivery		rreatment delivery	r treatment delivery	treatment delivery	I treatment delivery	y port min(s)	opic x-ray guidance	opic x-ray guidance opic x-ray guidance	beam tx, simple	beam tx, complex	therapy management	adiation treatment	adiation treatmentadiation treatment	therapy management	therapy management	nt, simple w/o compnt simple w/comp	mt, intermediate	eatment, complexrmia treatment	rmia treatment	rmia treatmentrmia treatment	rmia treatment	rmia treatment	rmia treatment	rmia treatmentrmia treatment	rmia treatment	rmia treatment	rmia treatment	rmia treatmentdioactive materials	dioactive materials	dioactive materials cav radiat simple
25 52 53 52 55 52 55 55 55 55 55 55 55 55 55 55	Radiation Radiation Radiation Radiation	Radiation	Radiation Radiation	Radiation	External	External Radiation	Radiation Radiation	Radiation	Radiation Radiation	Radiation	Radiation	Radiation	Radiation	Radiation	Radiation	Stereosco	Stereosco	Neutron I	Radiation	Radiation	Special re	Special range	Radiation	Radiation	Proton tri	Proton trr	Proton tre	Hyperthe	Hyperthe Hyperthe	Hyperthe	Hyperthe	Hyperthe	Hyperthe	Hyperthe	Hyperthe	Hyperthe	Hyperthe Infuse rac	Infuse rav	Apply inti
#P	<u> </u>	∶ ∢∢	<u> </u>	(<	<u> </u>	ე ∢	∢	(∢•	∢ ∢	⋖ •	< <	∢ ላ	< <	∢ ⊲	< <	⋖ <	. ≺	⋖ <	4 ⋖	∢ ላ	< <	∢ ∢	00	0	ပပ	0	O E	<u> </u>	r œ	<u>ac</u> a	c œ	<u>ac</u> a	<u> </u>	<u> </u>	<u> </u>	: œ		. ⋖ <	<u>.</u> < <
	26 TC	10			26	<u>۔</u> د										90					-		26	 22 21 22				26		26	_ ا		<u>۔</u> د	26		26	ည		
					77399		77402	77404		•	77411	77412	77414 .	77416	77418	77421	77421	77422				77470	•	77499 .	77520		77525	77600	77605	77605	77610	•	77615	77615			77620	77750	77761 . 77761 .

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2007—Continued

Global	888888888888888888888888888888888888888
Year 2007 Transi- tional Fa- cility Total	2. 1. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4.
Fully Im- plement- ed Facil- ity Total	4 5 7 7 8 5 1 8 5 1 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Im- Year 2007 Pent- Transi- tional lity Non-Fa- all cility Total	8.1.1 1.686 1.
Fully Implemented Non-Facility Total	4.67 4.68 4.69
Mal-Practice RVUs	4 4 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Year 2007 Transi- tional Fa- cility PE RVUs	2.7.7.2.7.2.7.2.7.2.7.2.7.2.7.2.7.2.7.2
Fully Im- plement- ed Facil- ity PE RVUs	4 % 1 - 1 % % 2 % % 1 - 2 % 8 % 8 % 8 % 9
Year 2007 Transitional Non-Fa- cility PE RVUs	2000 2000
Physician plement Transi ed Fauly Im- 2007 Fully Peracre ed Non- tional ed Facility PE Facility PE RVUs RVUs RVUs RVUs RVUs RVUs RVUs RVUs	4.6. 6. 8. 8. 9. 6. 6. 4. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6.
Physician Work RVUs	0.00 0.00
Description	Apply intreav radiat simple Apply intreav radiat interm Apply intreav vadiat compl Apply intreav vadiat compl Apply intersit radiat simpl Apply intersit radiat simpl Apply intersit radiat simpl Apply intersit radiat simpl Apply intersit radiat compl Apply intersit radiat compl Apply intersit radiat compl Apply intersit radiat compl High intersity brachytherapy High intensity brachytherapy High
 	
Mod Str	2
CPT1/ HCPCS ²	777761 77762 777762 777763 777763 777763 777776 777776 777778 777778 77778 77778 77778 77778 77778 77778 77778 77778 77778 77779 777

The control of the																																					_	_	_	_	
To A Through off the fine wings To To A Through off the fine wings To To A Through off the fine wings To To To To To To To T	××××	(XX)	XXX	(X)		XX	××	X	žž	X	žž	× }	žž	X	××	X	×3	{×	×	××	{X	×;	{×	× }	{X	×	XX	XX	××	×	××	XXX	× }	žž	X	××	××××××××××××××××××××××××××××××××××××××	××	{X	××	 {
To A Proposed reading with flow 0.00 6.25 6.25 0.25	AN 0.9	Ας E	ξ Υ ^c	- X &	0.82	N A	L. 4 S —	Z S	N A	0.00	00.0	N S	0 K	¥.	1.03 NA	¥ Z	1.10	 ₹	0.27	¥ Ż	0.31	¥ ž	0.32	¥ ž	4.0	¥ S	0.63	¥:	N N	¥.	A 0	S Z	A S	9. 8 8. 8	¥ N	0.56 NA	Z Z	1.55	Y Z	0.84 AA	NA 1.66
The control of the	A N O O P A N O O	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	4 4 E	. A .	0.80	Z A	1.12 NA A	Z S	9.¥	0.00	0.00	A Z	4 X	Ϋ́	10.1 P	ž Ž	1.10	¥	0.26	A A	0.30	¥ S	0.37	¥ S	0.43	¥ 2	0.61	¥:	A 48	Z S	N C	ξŽ	Σg	8.8 8.8	¥	0.54 NA	Ç Y	1.51	ξ Z Z Z	0.83 NA	N N 1.
To A Thyroid relaping with flow 0.07 0.64	3.04 4.30 0.93	1.13	7.47	6.28	0.82	5.24	4.14	8.24	1.02 7.22	0.00	0.00	3.41	2.65	4.88	3.85	5.88	1.10	1.57	0.27	1.30	0.31	2.59	0.32	1.91	0.44	2.85	0.63	4.22	3.96	3.12	0.89	00.9	4.67	3.83	3.73	0.56	8.31	1.55	7.52	0.84	7.01
Column C	6.27 0.91	9.66	9.15 1.17	7.98	0.80	4.40	1.12	2.73	1.73	0.00	00.0	4.86	4.12	6.38	1.01	7.35	1.10	2.42	0.26	2.16	0.30	2.23	0.31	2.13	0.43	2.24	0.61	2.35	4.33	3.49	9.51	8.64	3.72	2.83	5.77	0.54	0.52	1.51	9.0-4 -44-	0.83	0.14
10																																									
TO A Tryood imaging with flow CO CO CO CO CO CO CO C																																									
TC A Thyroid metagring with flow 0.00 0.00 441 2.91 1.00	Z Z Z Z	2 8 2	228	i ≯ ₹	0.5	<u> </u>	0.25 Z Z	Ž	Ž	0.0	0.0	Ž	<u>"</u>	Ž	0.22	Ž	0.27	⋛ ⋛	0.0	ŽŽ	0.0	Ž 2	800	ŽŽ	0	Ž 2	0.10	Ž	2 0	į Ž ;	Ž %	2	Ž	N Z	Ž	0.12 V	żŻ	0.38	<u></u>	0.20	; <u>S</u> 9.
TC A Thyroid maging with flow 0.00 441	0 NA	0.26 0.26	Z Z C	N S	0.18	- N	0.26 NA	¥ S	NA NA	0.00	0.00	N N	È Z	N S	0.23 NA	Z Z	0.27	₹ ₹	0.06	Z Z	0.07	Ϋ́	0.07	Ϋ́	0.10	Ϋ́	0.14 0.14	¥:	N O	Y Y	A C	NA NA	Z Z	0 Z	NA	0.12 NA	Ž	0.34	ΣŽ	0.19 NA	NA 0.37
15	2.91 3.46 0.23	0.28	6.28	5.99	0.20	4.27	0.28	7.18	0.25 6.93	0.00	0.00	2.72	2.53	3.93	0.25	4.83	0.27	1.31	0.07	1.24	0.08	2.45	0.08	1.80	0.11	2.71	0.16	3.98	3.18	2.98	5.97	5.75	3.82	3.62	3.18	0.14	6.84	0.38	6.51	0.20	5.53
16	4.4.6.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.	8.63 0.26	7.96	7.69	0.18	3.43	0.26	11.67	11.44	0.00	0.00	4.17	4.00	5.43	0.23	6.30	0.27	2.16	90.0	2.10	0.07	2.09	0.03	2.02	0.10	2.10	0.14	2.11	3.55	3.35	8.59	8.39	2.87	2.68	5.22	0.12	9.05	0.34	3.43	0.19	8.66 0.37
2	0.00	0.82	0.00	0.00	000	0.82	0.82	0.74	0.00	0.00	0.00	0.55	0.00	0.75	0.75	0.80	0.80	0.00	0.19	0.0	0.22	0.00	0.23	0.00	0.32	0.00	0.45	0.00	0.61	0.00	0.64	0.0	0.61	0.0	0.40	0.40	1.09	1.09	0.61	0.61	1.20
1 1 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-</td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td>-</td> <td></td>										-														-				-													
2										0	m m																														
1 1 <td>with flow ging</td> <td>jing/studies</td> <td>ging/studies ging, body . ging, body .</td> <td>jing, body . Ke</td> <td>2 & &</td> <td>ke sar imaging</td> <td>ear imaging</td> <td>maging</td> <td>maging maging</td> <td>ır procedur</td> <td>ir procedur ir procedur</td> <td>aging, Itd</td> <td>aging, ita aaina, Ita</td> <td>aging, mult</td> <td>aging, mult</td> <td>aging, body</td> <td>aging, body</td> <td>aging, boay single</td> <td>single</td> <td>single</td> <td>multiple</td> <td>multiple</td> <td>ngle ingle</td> <td>ingle</td> <td>nultiple</td> <td>nultiple</td> <td></td> <td></td> <td>study</td> <td>study</td> <td>kinetics</td> <td>kinetics</td> <td>ration</td> <td>ration</td> <td></td> <td></td> <td>kinetics</td> <td>kinetics</td> <td>KINEUCS</td> <td></td> <td>naging</td>	with flow ging	jing/studies	ging/studies ging, body . ging, body .	jing, body . Ke	2 & &	ke sar imaging	ear imaging	maging	maging maging	ır procedur	ir procedur ir procedur	aging, Itd	aging, ita aaina, Ita	aging, mult	aging, mult	aging, body	aging, body	aging, boay single	single	single	multiple	multiple	ngle ingle	ingle	nultiple	nultiple			study	study	kinetics	kinetics	ration	ration			kinetics	kinetics	KINEUCS		naging
1 1 <td>d imaging of met imaged met image</td> <td>d met imag</td> <td>d met imag</td> <td>d met imag</td> <td>d met upta</td> <td>u iiiet upta iyroid nucle</td> <td>iyroid nucle</td> <td>al nuclear i</td> <td>al nuclear I al nuclear i</td> <td>rine nuclea</td> <td>rine nuclea rine nuclea</td> <td>marrow im</td> <td>marrow ima marrow ima</td> <td>marrow im</td> <td>marrow ima marrow ima</td> <td>marrow im</td> <td>marrow im</td> <td>marrow mis a volume.</td> <td>a volume,</td> <td>a volume,</td> <td>a volume, a</td> <td>a volume,</td> <td>ell mass, si ell mass, si</td> <td>ell mass, si</td> <td>ell mass, n</td> <td>ell mass, m</td> <td>volume</td> <td>volume</td> <td>ell survival</td> <td>ell survival</td> <td>ell survival</td> <td>ell survival</td> <td>ell sequest</td> <td>ell sequest ell sequest</td> <td>imaging .</td> <td>imaging .</td> <td>t survival,</td> <td>et survival,</td> <td>st survivai, et survival</td> <td>et survival</td> <td>system in system in system in</td>	d imaging of met imaged met image	d met imag	d met imag	d met imag	d met upta	u iiiet upta iyroid nucle	iyroid nucle	al nuclear i	al nuclear I al nuclear i	rine nuclea	rine nuclea rine nuclea	marrow im	marrow ima marrow ima	marrow im	marrow ima marrow ima	marrow im	marrow im	marrow mis a volume.	a volume,	a volume,	a volume, a	a volume,	ell mass, si ell mass, si	ell mass, si	ell mass, n	ell mass, m	volume	volume	ell survival	ell survival	ell survival	ell survival	ell sequest	ell sequest ell sequest	imaging .	imaging .	t survival,	et survival,	st survivai, et survival	et survival	system in system in system in
26 26 26 26 26 26 26 26 26 26 26 26 26 2	Thyroi Thyroi	Thyroi	Thyroi	Thyroi	Thyroi	Parath	Paratr Parath	Adren	Adren	Endoc	Endoc	Bone	Bone	Bone	Bone	Bone	Bone	Plasm	Plasm	Plasm	Plasm	Plasm	Redo	Red C	Red or	Red C	Blood	Blood	Ned o	Red Co	Red C	Red co	Red C	Red of	Spleer	Spleer	Platek	Platek	Platele	Platele	Lymph Lymph
2 82 82 82 82 82 82 82 82 82 82 82 82 82	444	<<<	₹	< ∢ ⊲	< <	(∢	∢ ∢	∶∢∢	∢ ∢	00	ى د	< <	< <	⋖.	∢ ⊲	< ∢	∢ <	< <	< <	∢ ⊲	(∢	∢ <	< <	∢ <	< <	⋖ <	∢ ∢	∢.	∢ ∢	∶∢ ⋅	∢ ⊲	< ∢	⋖ <	< <	< <	∢ ⊲	(∢	∢ <	۲∢	∢ <	(∢∢
			ا ا ا	21 22	26 TC	<u>:</u> :) (1C		 2 1 2 1)	26		26	TC	26	TC		TC	26	TC	26	TC			26	10 10		- C		26	2	26	2	26	
	78011 78015 78015		78018 78018	78018	78020	78070	78070 78070 .	78075	78075 .	78099	, 8087 78099	78102	78102 78102 .	78103	78103	78104	78104	78110 78110	78110	78110	78111	78111	78120	78120	78121	78121	78122 78122	78122	78130	78130	78135	78135	78140	78140 78140	78185	78185	78190	78190	78191 .	78191	

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

<u>8</u>	
Global	
Year 2007 Transi- tional Fa-	A 60 60 60 8 4 6 6 6 8 4 8 6 8 8 8 8 8 8 8 8 8 8 8
Fully Im- plement- ed Facil- ity Total	A 6 6 6 6 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
Year Year 2007 Inn- 2007 Innsi- Itinal Innsi- Itina	5.35 0.00
lly Im- ment- I Non- acility Total	8.51 0.0000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0
Year 2007 Transi- Mal-Prac- ple tional Fa- tice RVUs Facility PE RVUs	0.000000000000000000000000000000000000
Year 2007 Transi- tional Fa- cility PE RVUs	A N N N N N N N N N N N N N N N N N N N
Fully Im- plement- ed Facil- ity PE RVUs	A N S S A A A S A A S A A A S A A S A A A S A A A S A A A S A A A A A S A
Year 2007 Transi- tional Won-Fa- cility PE RVUs	5.13 5.13
Fully Im- plement- Facility Facility PE RVUs Facility RMI	8 0 0 0 0 4 0 4 4 0 4 4 0 4 4 0 4 6 0 0 0 0
Physician Work RVUs	0.000000000000000000000000000000000000
Description	Lymph system imaging Blood/lymph nuclear exam Liver imaging Liver imaging Liver imaging with flow Liver imaging (3D) Liver image (3d) with flow Liver and spleen image/flow Liver & spleen image/flow Liver & spleen imaging Liver & spleen imaging Liver & spleen imaging Liver and spleen image/flow Liver and spleen imaging Liver and spleen imaging Liver & spleen imaging Liver & spleen imaging Liver & spleen imaging Liver & spleen imaging Liver function study Hepatobiliary imaging Salivary gland function exam Wit B-12 absorption exam Wit B-12 absorption exam Wit B-12 absorption exam, int fac Vit B-12 absorption exam, int fac Vit B-12 absorption exam, int fac Vit B-12 absorption exam, int fac
	400044444444444444444444444444444444444
Mod Stat	25 25 25 25 25 25 25 25 25 25 25 25 25 2
CPT¹/ HCPCS²	78195 78199 78199 78201 78202 78205 78205 78205 78205 78205 78205 78215 78215 78216 78230 78230 78230 78230 78230 78231

F6 A A 6 6 6 6 6 6 6 A A 4 4 A A 6 6 6 6
7. 7 A N 1. 3 A A 2. 3 A A 3. 3 A 3
8. N N N N N N N N N N N N N N N N N N N
7.2.3.3 7.3.3.6 7.3
0.00 0.00
0.000000000000000000000000000000000000
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
0.000 0.00
0.000 0.000
$\begin{array}{c} 0.1.8 \\ 0.0.9 \\ 0.0.0 \\$
0.000 0.000
Vit B-12 absorp, combined Acute Gl blood loss imaging Gl protein loss exam Meckells divert exam Gl nuclear procedure Gl nuclear exam Musculoskeletal nuclear exam Non-imaging heart function Vascular flow imaging Vascular flow imaging Venous thrombosis images, bilat Ven thrombosis images, bilat Ven thrombosis images, bilat Heart muscle imaging (PET) Heart muscle blood, single
12 absorp, combined
Vit B-12 absorp, combined Acute GI blood loss imaging GI protein loss exam GI protein loss exam GI protein loss exam GI protein loss exam Meckells divert exam Leveen/shunt patency exam GI nuclear procedure Bone imaging, whole body Bone imaging, sphase Bone imaging, whole body Bone imaging, whole body Bone imaging, whole body Bone imaging, whole body Bone imaging, sphase Bone imaging, s
<<<<<0<0<0<0<0<<<<<<<<<<<<<<<<<<<<<<<<
25 25 25 25 25 25 25 25 25 25 25 25 25 2

Addendum B.—Relative Value Units (RVUS) and Related Information Used in Determining Medicare Payments For 2007—Continued

	TOO
Global	*************************************
Year 2007 Transi- total Fa- cility Total	A 1. 2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
Fully Implement	A 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
y Im- 2007 Year 2007 Won- tional collity Non-Fa- otal cility Total	8 12 1 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	7.1.1.2.2.2.1.1.2.2.2.2.2.2.2.2.2.2.2.2.
Mal-Practice RVUs	4 4 5 6 6 6 7 4 7 6 8 8 7 7 7 8 8 8 8 8 8 8 8 8 8 8 8 8
Physician Pervice Rolls Facility Pervice Roll	A 4 5 7 5 8 5 8 5 8 5 8 5 8 5 8 5 8 5 8 5 8
Fully Implemented Facility PE RVUs	A 4 A Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
Year 2007 2007 Transitional Non-Fa- cility PE RVUs	7.00.00 7.0
Fully Implemented Non-Facility PE RVUS	8.00.000000000000000000000000000000000
Physician Work RVUs	1.099 1.
tatus Description	Heart image (3d), single Heart image (3d), single Heart image (3d), multiple Heart image (3d), multiple Heart infarct image Heart infarct image Heart infarct image (ef) Heart infarct image (3D) Heart infarct image (2D) Heart infarct image (2D) Heart wall motion add-on Heart wall motion add-on Heart wall motion add-on Heart first pass, single Heart first pass, single Heart first pass, multiple Heart first pass, multiple Heart image (pet), single Heart image (pet), single Heart image (pet), multiple Heart image, spect Heart image, spect Heart image, spect Heart first pass add-on Lung perfusion imaging Lung y/Q image single breath Lung y/Q image imgle breath Lung y/Q image imgle breath Lung y/Q imageing
ن ا ن	444444444444444444444444444444444444444
Mod S ²	26 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
CPT1/ HCPCS ²	78464 78464 78464 78465 78465 78466 78466 78466 78466 78466 78466 78469 78472 78472 78473 78473 78473 78473 78473 78473 78473 78473 78473 78481 78481 78481 78481 78481 78481 78481 78481 78481 78481 78481 78481 78481 78481 78482 78481 78482 78483 78483 78484 78484 78484 78484 78494 78496

A A 5.5 A 5.5 A A 5.5	N 0.85
A A A A A A A A A A A A A A A A A A A	N 83
$\begin{array}{c} 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 $	6.67 0.85
$ \begin{array}{c} 8 \\ 4 \\ 0 \\ 4 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0$	9.50
$ \begin{array}{c} \circ \circ$	0.27
A S . S . S . S . S . S . S . S . S . S	NA 15:0
A S C S S C S C S C S C S C S C S C S C	0 NA
$ \begin{array}{c} 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 $	5.79
$ \begin{array}{c} @ \ 4 \ 0 \ 4 \ 0 \ 0 \ 0 \ 0 \ 0 \ 4 \ 0 \ 4 \ 0 \ 0$	8.62 0.19
$\begin{array}{c} 0.000000011100000000000000000000000000$	
Lung V/Q imaging — Aerosol lung image, single — Aerosol lung image, single — Aerosol lung image, single — Aerosol lung image, multiple — Perfusion lung image — Perfusion lung imaging	eakage imaging
Aeroscoscoscoscoscoscoscoscoscoscoscoscosco	CSF K
44444444444444444444444444444444444444	: : :
2	- : 0
	.00
78586 78586 78586 78587 78587 78581 78581 78591 78591 78593	78650 78650 78650

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	
Year 2007 Transi- tional Fa- cility Total	AA \$\frac{6}{2} \text{A A \$\frac{6}{2} \text{A \$\frac{6}{2} A \$\fr
Fully Im- plement- ed Facil- ity Total	AA C A O O O O A A A A A A A A A A A A A
Year 2007 Transi- tional Non-Fa- cility Total	20.000 20.0000 20.000 20.000 20.000 20.000 20.000 20.000 20.000 20.00
Fully Implemented Non-Facility Total	8 4 6 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Mal-Prac- tice RVUs	0.000000000000000000000000000000000000
Year 2007 Transi- tional Fa- cility PE RVUs	######################################
Fully Implemented Facility PERVUS	A
Year 2007 Transi- tional Non-Fa- cility PE RVUs	$\begin{smallmatrix} 6,6,6,6\\ 6,6,6,6\\ 6,6,6,6\\ 6,6,6,6,6\\ 6,6,6,6,$
Fully Implemented Non-Facility PERVUS	8 4 4 0 4 0 0 0 0 4 0 4 2 0 0 0 0 0 0 4 0 4
Physician Work RVUs	0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.
Description	CSF leakage imaging Nuclear exam of tear flow Nervous system nuclear exam Niclney imaging, static Kidney imaging with flow Kidney imaging with flow Kidney imaging with flow Kidney flow/function image Kidney flow/function study Kidney function study Kidney function study Kidney function study Ureteral reflux study Uretera
Status	<<<<0000<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
Mod	5 85 <t< td=""></t<>
CPT¹/ HCPCS²	78650 78660 78660 78669 78700 78700 78701 78701 78701 78701 78701 78704 78704 78704 78709 78709 78709 78709 78709 78709 78709 78716 78716 78716 78716 78716 78716 78716 78716 78716 78716 78726 78730 78730 78730 78730 78730 78730 78730 78740 78740 78740 78740 78740 78730

~~~~		·	~ ~	~ ~	· ~ `	~ ~	~ \	<i>-</i> ~	~ ~		~ ~	. ~ .	~ ~		~ ~	· ~	~ ~	· ~	~ \	· ~	~ \	· ~	~ \	<i>-</i> ~	~ `	~ ~	. ~	~ \	/ \	~ .	~ ~	· ~	~ \	<i>-</i> ~	~ `	~ ~	~`	/ <b>~</b> ~
****		<b>₹</b> \$\$	88	22	<b>3</b>	\$\$	\$\$	€	22	2	<b>\$</b> \$	\$	<b>\$</b> \$	8	<b>\$</b> \$	<b>\$</b> \$	22	<b>\$</b> \$	\$\$	€	\$\$	<b>\$</b> \$	\$	€\$	8	\$\$	<b>X</b>	\$\$	€	2	<b>\$</b> \$	<b>\$</b> \$	<b>\$</b> }	€	8	\$\$	\$	<b>₹</b> \$\$
1.51 A N A L A N A L	4. A 8	5	A 6.	Z Z	1.5	8 8 8 8	2.17	0.0	2.69	0.00	2.78	0.00	3.05	0.00	3.37	0.00	3.45	S Z	0.08 NA	Z Z	0.15	0.00	0.00	9 Z	2.46	≰	2.71	¥ S	2.75	¥.	0.00	0.0	Z S	0 Y	Ϋ́	2.76 NA	0.00	00.0
												_																				_						
71.1 A N A S A S A S A S A S A S A S A S A S	24.1 A A A	06.0 8.00	A 1.	A Z	1.47	0.0 0.0	2.13	9.0	2.65	0.00	2.73	0.00	2.96	0.0	3.32	0.0	3.38	S Z	0.07	ZZ	0.13	0.0	0.0	. Z	2.41	α α Z Z	2.72	Ž Ž	2.67	Ž,	0.00	0.0	A S	S.S.	Z S	2.68 Z.68	0.0	0.00 0.00
6.42 6.42 10.44 1.51 8.93	.24	1.01	3.38	7.19	15.	00.0	17	00.0	69.	00.0	00	00.0	3.05	00.0	3.37	00.0	3.45	22.	90.0	.14	15	00.	00.0	00.7 88.4	2.46	142	17.	2.46	2.75	.51	000	00.0	7.07	3.88	5.16	40	00.0	00.00
+ 0 5 + 0 5	7 - 54 /	, - 0,	ω -	1, 5	2 - 0		., .	, ,	., .	, 0	., .		٠, د	, 0	., .		(,)		0 +	- (4		10		J 4	.,	. 4 4.	, (4	., .	., (4		<i>-</i> ((	. 0	1~ 0	, (,)	u) (			, 0 0
1.17 8.20 16.51 1.48 15.02	1.45	0.99	9.60	8.43	1.47	0.00	2.13	0.00	2.65	0.00	2.73	0.00	2.99	0.00	3.32	0.00	3.39	0.51	0.07	1.13	0.13	0.00	0.00	3.80	2.41	1.39 82,4	2.72	1.55	2.67	1.74	0.00	0.00	5.32	2.29	3.98	2.68 1.30	0.00	0.00
	-			-	- ,	-																																
0.040	0.04	0.03	0.39	0.35	9.00	0.00	0.0	80.0	0.1	0.00	0.0	0.00	0.0	0.00	0.0	0.0	0.0	0.07	0.01	0.14	0.01	0.0	0.0	0.00	0.08	0.0 4.0 7.0	0.08	0.14	0.09	0.14	0.00	0.0	0.24	0.15	0.22	0.08	0.00	0.00
0.29 N N N N N N N N N N N N N N N N N N N	0.36 NA	0.25 A	NA 0.29	Z Z	0.38	0.0 A	0.52	0.0	0.65	0.00	0.67	0.00	0.74	0.00	0.82	0.0	0.0 2.8 0.0	8. <b>₹</b>	0.02 NA	₹Ž	0.0 V	0.00	0.0	8. ₹	0.58	₹ Z	0.67	₹ź	0.67	Ϋ́	0.00	0.00	¥ §	5 8 8	¥8	0.69 N	0.00	0.00
-											-																											
0.27 NA NA N	0.34 A A	0.23 A	NA 0.27	ΥZ	0.34	0.0 8 0.0	0.48	0.0	0.61	0.0	0.62	0.00	0.08	0.00	0.7	0.0	0.78	S.₹	0.0 N	ΣŹ	0.02	0.0	0.0	8 <b>≥</b>	0.53	Z Z	0.68	₹ź	0.59	Α	0.00	0.00	A S	8 Z	Ϋ́	0.0 F9.0 V	0.00	0.00
																																					_	
0.29 6.12 8.95 0.37 8.58	0.36	0.25	7.13	6.84	0.38	0.00	0.52	0.0	0.65	0.00	0.67	0.00	0.74	0.00	0.82	0.00	0.84	1.10	0.02	2.22	0.04	0.00	0.00	2.86	0.58	2 2 2	0.67	2.32	0.67	2.37	0.00	0.00	4.58	3.74	2.95	0.69	0.00	0.00
	m c																				01.0		-		~ .							_						
0.27 7.90 15.02 0.34 14.67	26.0	9.29	8.35	8.08	0.37	0.00	0.48	0.0	0.61	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.78	0.36	0.0	0.80	0.0	0.0	0.0	1.78	0.53	2.5	0.68	4.6	0.59	1.60	0.00	0.0	2.83	2.15	1.77	1.16	0.00	0.00
	- C 0			0.0		20	4 0		m C						<del></del>		0.0	2.10	10.0		0.0			20									10.11					
0.00	-00	0.0	0.0	0.6	6	5 6	<del>ر</del> بې چ	000	6.0	0.0	0 0 0 0	0.0	N C	0.0	9 C	0.0	2 2	0.0	0.0	0.0	0 0	0.0	0.0	2 8.	9. 6	5 <del>-</del>	6.6	0.5		0.0	0	0.0	2.2	0.0	9. 9	- 0 6. 0	0.0	0.00
	: : :	: : :		-:	: :	: :	-	: :	-	: :	:	: :	:	: :	:	: :	:	: :	:	: :	:	: :	:	: :	-	:	: :	-	: :	-		: :	:	: :	-	: :	:	
																									rx, oral admin		rx, iv admin			Nuclear rx, intracav admin	Nucir rx, interstit colloid							
																			medicine data proc	200				diagnostic exam rx, oral admin							interstit colloidinterstit colloid							
e body e body	i i ii Ggg,	inaging, ita area imaging, Ita area imagina. Ita area	body . body .			ess ted		igh ::	: dgir	 b	(pet) full body	ed	Lumor image pet/ct, limited Tumor image pet/ct_limited	high	high High	 ody 	: ody ody	 	9 8	3 :										u								rx, intra-arterial rx, intra-arterial medicine therapy
imaging, whole body imaging, whole body imaging (3D)	ole bo	imaging, lid area imaging, Itd area imaging. Itd area	imaging, whole body imaging, whole body	imaging, whole body	localization/abscess	localization/abscess maging (pet), limited	÷,÷	/,	(pet)/skul-thigh	full bo	₽ ⊒ ⊒ ⊒	t, limit	, <u>m</u>	skul-t	skul-t	t full b	image pet/ct full body	medicine data proc	lata pr	proc	proc	diagnostic exam	diagnostic exam	exam min	min .	: :: ::		n	, admi	/ admi	Diolo	olloid .	lear tx	ear tx	ticular	rx, intra-articular rx. intra-articular	rx, intra-arterial	rx, intra-arterial rx, intra-arterial medicine therapy
ng, wholing (3D)	ng, k Pigi w	ging, ging, aina,	ging, v	ging, v	ization	lizatior ng (pe	ng (pe	) (bet)	(pet)	(pet)	(pet)	pet/c	pet/c	pet/ct	pet/ct	percr	e pet/c	icine c	icine	med data proc	med data proc	nostic	nostic	nostic ral adi	ral ad	raladi Zadmi	/ admi	rx, iv admin	niaca) traca)	ıtraca∖	rstit od	rstit oc	ic nucl	ic nuc	ıtra-ar	ntra-ar ntra-ar	ıtra-ar	rx, intra-arterial rx, intra-arterial medicine therap
imagii magii magii	imagi imagi	ss ima ss ima ss ima	ss ima	ss ima	r loca	ır local imagi	imagi	image	image	image	mage	image	image	image	mage	image	image	ır med	ir med	ir med				r diag	ır rx, o	0 .= X X = =		 	ביד קאָ קאָ	ır ıx, ir	x, inte	x, inte	opoiet	opolet	יי. ייי	ב צׄצׂ		
Tumor imaging, whole body Tumor imaging, whole body Tumor imaging (3D) Tumor imaging (3D) Tumor imaging (3D)	Tumor imaging, whole body Tumor imaging, whole body Absocs imaging H assa	Abscess Abscess	Abscess Abscess	Abscess imaging, whole bod	Nuclear	Nuclear localization/abscess Tumor imaging (pet), limited	Tumor imaging (pet), limited	Tumor imagnig (pet), ininted Tumor image (pet)/skul-thigh	Tumor image (pet)/skul-thighTimor image (pet)/skul-thigh	Tumor image (pet) full body	Tumor image (pet) full body Tumor image (pet) full body	Tumor image pet/ct, limited	Lumor image pet/ct, limited Tumor image pet/ct_limited	Tumorimage pet/ct skul-thigh	Tumor	Tumor image pet/ct full body	Tumor image pet/ct full body	Nuclear	Nuclear	Nuclear	Nuclear	Nuclear	Nuclear	Nuclear	Nuclear	Nuclear	Nuclear	Nuclear	Nuclear IX, Intracay admin Nuclear IX, intracay admin	Nuclea	Nucir IX,	Nuclr rx, interstit colloid	Hematopoietic nuclear tx	nematopoletic nuclear tx Hematopoletic nuclear tx	Nuclear rx, intra-articular	Nuclear rx, ıntra-articular Nuclear rx, intra-articular	Nuclear	Nuclear Nuclear Nuclear
	· ·																																					
<u> </u>	< < <	< <	∢∢	∢ ◊	< <	∢ ()	∢ (	υO	∢ C	0	∢ C	0	∢ C	O.	<b>∢</b> C	0	∢ C	о Ш	ω α	<u> </u>	ω α	0	0	> د	∢.	∢ ∢	< <	∢ <	< <	∢ (	೦ ∢	0	∢ <	< <	∢•	< <	<u>ن</u> د	(00
26 TC 26 TC	26 TC	26	26		26	<u>်</u>	26	2	26		26 TC		26 TC		26	2	26	2	26	2	26	) )	26	<u>:</u> د	26	<u>:</u>	26	TC	26	TC	26		90	TC		TC	ç	10
78802 78803 78803 78803 78803	78804 78804 78805	78805 78805 78805	: :	:		/880/ 78811		78812	•	78813	2 2 3 3 3	8814		78815	78815		78816	78890	:	: :	8891	66687	78999			79005	9101	10167		79200	79300		79403	9403 :: 3403	79440	79440 79440	9445	9445 9445 9999
7 8 8 8 8 8 8 8 8 8	28 8 8	2 8 8	78	2 A	287	20 00	78	78	78	78	% / / / /	78	χ α	78	ω α /	78	7 8	78	78	78	78	78	78	79	79	5 6	79	79	7 6	79	79	79	79	0 0	79	5 G	79	9 6 6

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Year Year 2007 Transi- tional Fa- cility Total	0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 00000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0000 00000 00000 00000 0000 0000 0000 0000 0000 0000 00000 0	
	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00	
Year Year 2007 Transi- plement- tronal ed Facil- Non-Fa- ity Total		
Fully Im- Plement- Plement- Plement- Tra ed Non- Facility Non Total cility	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00	1.67 0.67
Physician plement- tonal for Non-Facility PE RVUs Facility PE RVUs PERVUs PERVU	000000000000000000000000000000000000000	20.0 4 00.0
Year 2007 Transi- tional Fa- cility PE RVUs	00000000000000000000000000000000000000	NA 0,20
Fully Implemented Facility PERVIS	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	0.15
Year 2007 Transitional Non-Fa-cility PE RVUs	000000000000000000000000000000000000000	0.99
Fully Implemented Non-Facility PERVUS	00000000000000000000000000000000000000	
Physician Work RVUs	0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000	0.50
HELATIVE VALUE UNITS (HVUS) AND  Description	nedicine there hedicine there hedicine there hedicine there hology consultation and provided the hedicine there has a manufacture of the hedicine the hedicine sear interpretation and the hedicine sear interpretation and the hedicine sear interpretation as any whole it helood bank is and antibody, and antibody, and antibody, and antibody sint antibody. Sear and antibody sint antibody, and antibody sint antibody sint antibody, sint antibody sint antibody, fluids and proposition of the sear in the sear concentrate con	Cytopath smear, other source
#	004444444444444444444444444444444444444	۷ ۷
ADDENDUM B	85 888888 8 8 8 88888888 8 25 85 85 85 85 85 85 85 85 85 85 85 85 85	26
ADD CPT1/ HCPCS ²	79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999 79999	88161

***************************************	**********
A 1. 2	N A A C C C C C C C C C C C C C C C C C
0.000000000000000000000000000000000000	0.57 0.57 0.70 0.70 0.35 0.30 0.90 0.90 0.90
1.87 1.08 1.08 1.08 1.08 1.08 1.08 1.08 1.08	2.44 2.44 1.84 3.95 0.75 3.20 3.79 2.46 1.37 1.35 1.35 1.35
0.99 0.99 0.99 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00	1.85 3.46 0.57 0.57 0.70 0.70 0.70 0.70 1.74 4.13 4.84 4.84 4.84 4.84 1.38 1.38 1.38 1.38 1.38 1.38 1.38 1.38
0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
A 9 9 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	NA N
A L A A B A A A A B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A A B B A B A B B A B A B B A B A B B A B A B B A B A B B A B A B B A B A B B A B A B B A B A B B A B A B B A B A B B A B A B B A B A B B A B A B B A B A B B A B B A B B A B B A B B A B B A B B A B B A B B B A B B A B B A B B A B B A B B A B B A B B A B B A B B A B B A B B A B B B A B B B A B B B A B B B A B B B A B B B B A B B B B B B B B B B B B B B B B B B B B	N A N O O O O O O O O O O O O O O O O O
0.00 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.04 0.04 0.05 0.00 0.00 0.00 0.00 0.00	1.86 1.99 0.17 1.83 3.38 3.38 3.38 0.20 0.78 1.89 0.55 1.39 0.55 1.39 0.66 1.14
1.18 0.01 0.01 0.03 0.03 0.03 0.03 0.03 0.03	1.83 3.01 0.03 3.29 3.29 0.15 0.74 0.74 1.77 1.77 1.27 0.69 0.69
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00	
Cytopath smear, other source Cytopath smear, other source Cytopath swear, other source Cytopath swear, other source Cytopathology eval of fna Cytopathology swear Flowcytometry/read, 2-8 Flowcytometry/read, 2-8 Flowcytometry/read, 2-8 Flowcytometry/read, 2-8 Flowcytometry/read, 16 & > Cytopathology procedure Cytopathology proce	Histochemical stain Chemical histochemistry Chemical histochemistry Chemical histochemistry Enzyme histochemistry Enzyme histochemistry Enzyme histochemistry Enzyme histochemistry Microslide consultation Microslide consultation Microslide consultation Microslide consultation Comprehensive review of data Path consult introp Path consult introp Path consult intraop, 1 bloc
444444444444440004044444444444444444444	
26 26 27 26 26 26 26 26 27 26 27 26 27 26 27 27 27 27 27 27 27 27 27 27 27 27 27	26 26 26 26 70 26 26 26
88162 88172 88173 88173 88173 88173 88173 88186 88188 88189 88199 88300 88300 88304 88304 88307 88307 88307 88309 88309 88301 88309 88309 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 88301 8001 80	88318 88318 88318 88319 88319 88321 88323 88323 88323 88323 88323 88323 88323 88323 88323

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	
Year 2007 Transi- tional Fa- cility Total	A A A A A A A A A A A A A A A A A A A
Fully Im- plement- ed Facil- ity Total	A N O S A S A S A S A S A S A S A S A S A S
Im- 2007 ent- Transi- on- tional lity Non-Fa-	0.70 0.85 0.70 0.85 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70
Fully Implemented Non-Facility  Total	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Mal-Practice RVUs	44000000000000000000000000000000000000
Physician plement Transi- plement Transi- plement tional Facility Non-Fa- cility PE RVUs PE RVUs PE RVUs RVUs RVUs RVUs RVUs PE RVUs RVUs RVUs Transi- plement tional Facility PE RVUs RVUs RVUs RVUs Total Facility PE RVUs RVUs RVUs Total Facility PE RVUs RVUs RVUs Total Facility PE RVUs RVUs RVUs RVUs RVUs RVUs RVUs RVUs	A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S S A N S
Fully Im- plement- ed Facil- ity PE RVUs	A N O O O O O O O O O O O O O O O O O O
Year 2007 Transi- tional Non-Fa- cility PE RVUs	0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0
Fully Implemented Non-Facility PE RVUs	0.000.000.000.000.000.000.000.000.000.
Physician Work RVUs	0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00
Description	Path consult intraop, addll Path consult intraop, addll Path consult intraop, addll Path consult intraop, addll Intraop cyto path consult, 1 Intraop cyto path consult, 2 Intraop cyto path co
Statu	
Wod 8	25 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62 12 62
CPT ¹ / HCPCS ²	88331 88332 88333 88333 88333 88333 88333 88334 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346 88346

Marchelle protection   10																													_	_			_	_	_	
To   C   Eval introduction grows, 11-60   C   C   C   C   C   C   C   C   C	*****	~~~	×××	{XX	XX	{	žž	××	× >	X	žž	ZZZ	XXX	XX	3×	ZZZ XXX	ZZZ	XXX	ZZ	XX	×;	X	××	XX	××	X	žž	X	ž×	X	××	X	××	(X)	××	××
To   C   Manufacture probes   1-50   Manufacture probes	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	2.65 A 565 A 565	0000	1.71	0.94	0.67	1.19	0.37	1.23	Ž Ž	0.0 V	0.27	0.27	N C	0.24	0.21 NA	¥ Z	Y Y	¥ ž	₹ <b>₹</b>	¥ S	¥ ¥ Z Z	0.00	3.98	1.58	2.43	3.65	3.84	1.73	2.57	3.78	3.98	1.70	2.55	3.79	3.94
The Color of the	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	2.28 N A	0000	1.66	1.22	0.86	1.50	0.54	1.28	Z Z	0. S	0.20	0.25	Z S	0.22	0.19 AN	₹ Z	₹ ₹	₹ Z	₹ ₹ 2 Z	₹ S	₹ ₹ ₹ 2	0.00	3.73	1.45	2.22	3.33	3.53	1.59	2.34	3.46	3.66	1.59	2.35	3.47	3.69
T.C.   C   Feat molecular problem; 11-50   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00	0.00 0.00 0.00 10.62	10.98 2.65 8.33	00.0	5.03	4.22	3.51	4.47	3.30	4.36	0.12	0.00	0.29	0.35	0.53	0.36	0.26	0.51	2.00	1.07	0.53	0.50	0.70	0.00	4.36	1.74	2.55	3.79	3.98	1.87	2.76	3.98	4.16	 V V			
TC	0.00 0.00 0.00 0.00 16.37 1.80	16.69 14.43	00.0	5.08	9.50	7.42	9.70	7.35	6.42	0.10	0.00	0.28	0.35	0.63	0.34	0.24	0.45	1.90	0.92	0.54	0.49	0.65	0.00	4.59	1.78	2.41	3.52	3.87	1.87	2.64	3.00	4.11	 V Z		 &	 &
10	0.00	0.00 0.08 0.08	0000	0.00	0.03	20.0	0.0	0.0	0.03	0.05	0.0	0.01	0.0	0.01	0.0	0.01	0.0	0.07	0.0	0.0	0.02	9.0	0.00	0.07	0.03	0.0	0.09	0.07	0.0 40.0	0.04	0.05	0.07	0.03	0.04	0.05	0.08
CC	0.00 0.00 0.00 0.00 0.00 0.55 0.55	0.0 8 0.0 8 0.0 8 0.0 8 0.0	0000	0.25	0.31	0.20	0.36	0.15	0.35	Z Z	0.0 V	0.11	0.09	¥ F	90:0	0.05 NA	Z Z	A A	Y Z	¥ ¥	¥ S	¥ ¥	0.00	0.90	0.34	0.53	0.56	0.82	0.37	0.56	0.60	0.85	0.42 0.43	0.62	09:0	0.87
TC	0.00 0.00 0.00 0.00 0.00 0.02 4 4 5 7	0.0 8.00 8.00 8.00 8.00 8.00 8.00 8.00	0000	0.20	0.59	0.39	0.67	0.32	0.40	Z Z	0.0 V	0.04	0.03	A S	0.0	0.03 NA	Z Z	A A	Y Z	¥ ¥	A S	¥ ¥	0.00	0.65	0.21	0.32	0.35	0.51	0.23	0.33	0.37	0.53	0.31 0.35	0.42	0.46	0.62
TC	0.00	8.94 0.69 8.25	00:0	3.57	3.59	3.04	3.64	3.28	3.48	0.10	0.00	0.13	0.17	0.35	0.13	0.10	0.38	1.72	0.84	0.35	0.31	0.56	0.00	1.28	0.50	0.65	0.70	0.96	0.51	0.75	0.78	1.03	 V V		 &	Z Z Z Z
TC	0.00 0.00 0.00 0.00 2.7.5 4.7.5	14.65 0.30 14.35	00.0	3.62	8.87	6.95	8.87	7.13	5.54	0.08	0.00	0.12	0.10	0.45	0.16	0.08	0.32	1.62	0.69	0.45	0.30	0.51	0.00	1.5.1	0.59	0.51	0.70	0.85	0.51	0.63	0.82	0.98	 V Z		 &	 V V
1	0.00	26.0 88.1 00.0	0000	1.40	0.60	0.45	0.79	0.21	0.85	0.00	0.00	0.15	0.15	0.17	0.13	0.15	0.09	0.21	0.19	0.17	0.17	0.10	0.00	3.01	1.21	1.86	2.02	2.95	1.32	1.97	2.13	3.06	1.25	- 68.1	2.05	1.36
10	ss, 11–50 ss, 11–50 ss, 11–50 51–250 51–250	251–500 251–500 251–500	rocedure	ermia	ntents	itents	rents	ntents	ntents	- L	Jure	inj, < 8 y	n, < 8 yrs addl < 8 y	7	asal	nasal addl	add-on	f, init	iv inf	sc/im	S S S S S S S S S S S S S S S S S S S	v pusm v	proc	N	min w/e&m		min	e&m	80 min v/e&m	00 min	iin w/e&m	/e&m	nina&m	nin	nin w/e&mnin w/e&m	nin w/e&m
2	Microdissection Eval molecular probe Eval molecular probe Eval molecular probe Eval molecular probes, Eval molecul probes, Eval molecul probes,	molecul molecul molecul	Surgical pathology programmer surgic	Chot for mal hyperthe	Sample intestinal cor	Sample stomach con	Sample stomach con	Sample stomach con	Sample stomach con	Collect sweat for test	Pathology lab procec   Immune admin 1 ini.	Immune admin addi	Immune admin o'n, a	Immunization admin	Immune admin oral/r	Immune admin oral/r	Hydrate iv infusion, a	Ther/proph/diag iv int	Tx/proph/dg addl sec	Ther/diag concurrent Ther/proph/diag inj, s	Ther/proph/diag inj, is	Ther/proph/diag inj, r	Ther/prop/diag inj/inf	Intac psy dx interviev	Psytx, office, 20–30 I Psytx, off, 20–30 mir	Psytx, off, 45–50 mir	Psytx, off, 45–50 mir   Psytx, office, 75–80	Psytx, off, 75–80, w/e	Intac psytx, off, zu-3 Intac psytx, 20-30, w	Intac psytx, off, 45–5	Intac psytx, 45–50 m	Intac psytx, 75–80 w	Psytx, hosp, 20–30 r   Psvtx hosp 20–30 r	Psytx, hosp, 45–50 r	Psytx, hosp, 45–50 r   Psytx, hosp, 75–80 r	Psytx, hosp, 75–80 r
<u>P   &amp; P   &amp;</u>	000044	(444	000	) <b>4</b> 4	∶∢ ◊	(∢∢	∢ ∢	∢ ∢	∶∢<	(∢(	ე ∢	< □	rœ	∢ <	ς Œ	Œ 4	(∢	∢ ∢	∶∢∢	∢ ∢	∢ <	∢∢	Ο ⊲	(∢	⋖ ⋖	∶∢ •	∢ ∢	⋖・	∢ ∢	∶∢.	∢ ∢	∶∢.	∢	(∢.	∢ ∢	∢ ∢
		)																																		
														-							-												· !			
								89136 39140						90471		•		: :			6773						30807 30808 :	•		90812	•		90816 30817	90818	90819 30821	90822 30823

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
Year 2007 Transi- tional Fa- cility Total	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Fully Implemented Facility Total	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Year 2007 Transi- tional Non-Fa- cility Total	NAN
Fully Implemented Non-Facility	NAA
Mal-Prac- tice RVUs	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Year 2007 Transi- tional Fa- cility PE RVUs	4 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Fully Implemented Facility PERVUS	0.03 0.04 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
Year 2007 Transi- tional Non-Fa- cility PE RVUs	NA N
Fully Implemented Non-Facility	ANN NA
Physician Work RVUs	2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Description	Intac psytx, hsp 20–30 w/e&m Intac psytx, hosp, 45–50 min Intac psytx, hosp, 75–80 wie&m Intac psytx, hosp, 75–80 wie&m Intac psytx, hosp, 75–80 wie&m Intac psytx, hsp 75–80 wie&m Psychoanalysis Family psytx wipatient Family psytx wipatient Multiple family group psytx Medication management Narcosynthesis Electroconvulsive therapy Intac group psytx wipatient Narcosynthesis Electroconvulsive therapy Psychophysiological therapy Hyprotherapy Psychophysiological therapy Psychoph
Status	<pre></pre>
Mod	25 25 26 25 25 25 25 25 25 25 25 25 25 25 25 25
CPT1/ HCPCS ²	90824 90828 90828 90828 90829 90829 90845 90847 90886 90897 90897 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997 90997

888888888888888888888888888888888888888
2.5.6.4.4.5.5.5.4.4.6.6.8.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6
2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2
2.2.5.4 2.2.5.4 2.2.5.4 2.2.5.4 2.2.5.4 2.2.5.7 2.2.5.7 2.2.5.7 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8 2.3.8
2.5.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2
000000000000000000000000000000000000000
24.0.4.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0
44.4.0.6.1.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0
10.93
11.33 11.33 11.33 11.33 11.33 11.33 11.33 11.33 11.33 11.33 11.33 11.33 11.33 11.33 11.34 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35 11.35
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Acid perfusion of esophagus Gastroesophageal reflux test Gastroesoph reflx st wielectrod G-esoph reflx st wielectrod G-esoph imped function test Esoph imped function test Esoph imped funct test > 1h Esoph imped funct test > 1h Esoph balloon distension tst Gastric analysis test Gastric analysis test Gastric analysis test Gastric analysis test Gastric intubation for smear Gastric intubation for smear Gastric intubation for smear Gastric saline load test Gastric leactogastrography witest Electrogastrography w
sion of esoph phageal refluu effix tst w/elec effix tst w/elec eed function the eed function the eed function the eed function to eed funct test con distensio loon distens
Acid perfu Gastroesc Gastroesc Gastroesc Gastroesc Gastroesc Gastroesc G-esoph implement of Gastric and Gastric and Gastric and Gastric implement of Gastric implement of Gastric implement of Gastric implement of Gastric and Gastric implement of Gastroent of Gast
<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
5       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82       82
91034 : : : : : : : : : : : : : : : : : : :

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	
Year 2007 Transi- tional Fa- cility Total	A 60 A 7 5 4 5 5 4 5 5 6 6 6 7 5 5 6 6 6 7 5 5 6 6 6 7 5 6 6 6 7 5 6 6 6 7 5 6 6 6 7 5 6 6 6 7 5 6 6 6 7 5 6 6 6 7 5 6 6 6 7 5 6 6 6 7 5 6 6 6 7 5 6 6 6 7 5 6 6 6 7 5 6 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5 6 7 5
Fully Im- plement- ed Facil- ity Total	A 0. A 2. S 2. S 2. S 2. S 3. S 3. S 3. S 3. S
Physician plement Transi- work ed Non- tional Facility PE RVUs RVUs PE RVUs RVUs RVUs RVUs RVUs RVUs RVUs RVUs	1.10 1.10 1.10 1.10 1.10 1.10 1.10 1.10
Fully Implemented Non-Facility Total	1.83 1.23 1.23 1.23 1.23 1.33 1.33 1.33 1.3
Mal-Prac- tice RVUs	0.0000000000000000000000000000000000000
Year 2007 Transi- tional Fa- cility PE RVUs	A H H H H H H H H H H H H H H H H H H H
Fully Implemented Facility PERVUS	A 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
Year 2007 Transi- tional Non-Fa- cility PE RVUs	1.26 1.29 1.29 1.20 1.20 1.20 1.20 1.20 1.20 1.20 1.20
Fully Implemented Non-Facility	1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Physician Work RVUs	4 4 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
ls Description	Visual field examination(s) Serial tonometry exam(s) Opthalmic dx imaging Opthalmic biometry Claucoma provocative tests Special eye exam with photos Eye
aft	
Mod	25 25 25 25 25 25 25 25 25 25 25 25 25 2
CPT ¹ / HCPCS ² Mod St	92082 92082 92083 92083 92083 92083 92130 92130 92135 92136 92136 92240 92240 92240 92250 92250 92250 92250 92250 92250 92250 92250 92250 92250 92265 92265 92285 92286 92286 92286 92286 92287 92286 92286 92286 92286 92286 92286 92286 92286 92286 92286 92287 92286 92286 92286 92286 92286 92286 92286 92286 92286 92286 92286 92287 92288

							_	_	_	_										_	_															_	_	_	_	_				_	_
***	<b>*</b> * * *	×××	XX	žž	××	X	××	{ X	XX	2 X	×	×}	<u> </u>	××	X	××	××××××××××××××××××××××××××××××××××××××	××	× š	ž×	X	×}	××	X	××	žž	×	××	{×	X	77.	₹×	X	××	₹×	XX	×	×××	{X	X	× }	ž×	X	ž×	××
0.61	N S	0.64	0.51	0.69 AA	A N	0.46	 \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	0.00	0.00	2.59	1.25	0.75	1.61	0.74	0.64	27.0	Z Z	0.59	¥ S	0 A A	 	Z Z	0.16 AN	Y Y	0.38	¥ ¥	0.34	Z Z	0.42	Y Y	0.15 NA	0.75	¥:	Y Y	¥ Ž	¥:	 Y 2	 V V	 Z Z	¥:	 Y 2	 {	¥ ?	 {	N A
0.59	Z Z S	0.59	0.47	0.64 NA	A Z	0.41	A S	0.00	0.00	0.33	1.13	0.68	1.48	0.72	0.56	LO: 0	S Z	0.54	¥ ž	0 4 4	Z S	A S	0.14 4.0	¥ Z	0.35	₹ <b>₹</b>	0.31	Y Z	0.39	N A	0.17 NA	0.67	¥:	¥ ž	¥ Ž	A :	¥ ž	A Z	 Σ Ζ	Y :	Y S	¥ Z	¥ 2	ξ Z Z	N A
1.81	1.47	1.15	0.03	6.82	3.37	0.85	0.55	0.00	0.00	NA 0.70	3.65	1.67	4.08	1.66	1.63	1.39	1.50	0.59	0.91	1.54	1.06	0.71	0.16	1.23	0.38	1.12	0.34	0.78	0.42	1.86	0.15	0.75	2.02	0.51	0.42	0.62	1.33	0.80	0.46	0.53	0.41	0.36 0.36	0.39	0.43	0.43
1.81	0.80	0.95	0.95	21.1	0.46	0.73	0.26	0.00	0.00	NA 0.74	4.17	1.73	3.79	1.50	1.59	1.69 2.25	1.60	0.54	1.06	0.100	1.22	0.78	0.14 0.64	1.35	0.35	1.29	0.31	0.98	0.39	1.83	0.17	0.67	1.70	0.60	0.42	0.58	1.39	0.85	0.57	0.56	0.31	0.30	0.20	0.44	0.53
0.02	0.0	0.0	0.01	0.02	0.01	0.05	0.02	0.00	0.00	0.05 0.05	0.03	0.05	0.03	0.05	0.01	0.03	9.0	0.02	0.02	0.03 0.03	0.05	0.05	0.0	0.03	0.0	0.03	0.01	0.05	0.0	0.05	0.06	0.02	0.13	0.0	0.0	0.06	0.12	0.0 0.0 0.0 -	0.0	0.05	0.04	0.0 0.04	0.04	0.0 40.0	0.04
0.15	4 4 °	0.16	0.13	- A	A Z	0.12	Z 6	0.00	0.00	1.03 0.08	0.36	0.21	0.74	0.17	0.20	0.35	2 Z	0.17	¥ S	N 0	? Z	A S	0.0 V	Ϋ́	0.1	¥ ¥	0.10	₹ Z	0.12	¥	0.09 NA	0.23	¥:	¥ S	₹	¥:	¥ S	 &	ς δ Σ	Ž	Z Z	 1	Y S	₹ ₹ 2 Z	N A
0.13	<u> </u>	0.11	0.00	N A F. N	A Z	0.07	¥ S	0.00	0.00	0.77	0.24	0.14	0.00	0.15	0.12	0.23	2 ₹	0.12	¥ ž	V C	? <u>₹</u>	¥ S	0.03 AA	¥.	0.08	¥	0.07	¥ ≱	0.0	¥.	0.11	0.15	¥:	₹ S	₹	¥:	¥ ž	Δ Z	Z Z	¥:	 ₹	 ₹ ₹	¥ ?	₹ ₹ 2 ₹	¥
0.98	. 4.1 1.4.0	0.67	0.65	0.70	3.36	0.51	0.53	0.00	0.00	NA 0.51	2.76	1.13	3.21	1.09	1.19	1.67	1.06	0.17	0.89	0.18	1.04	0.59	0.05	0.94	0.11	0.86	0.10	0.76	0.12	1.84	0.09	0.23	1.89	0.47	0.38	0.56	1.21	0.74 0.48	0.42	0.48	0.37	0.32	0.35	0.28	0.39
1.35	0.76	0.47	0.57	0.60	0.45	0.39	0.24	0.00	0.00	NA 0.55	3.28	1.19	2.92	0.93	1.15	L 6.9 1 8 8	1.16	0.12	40.	0.10	1.20	0.66	0.03	1.06	0.08	1.03	0.07	0.96	0.00	1.81	0.11	0.15	1.57	0.56	0.38	0.52	1.27	0.79	0.53	0.51	0.27	0.50	0.16	0.40	0.49
0.45	0.00	0.47	0.37	0.50	0.00	0.32	0.00	0.00	0.00	0.18	0.86	0.52	0.20	0.55	0.43	0.75	0.40	0.40	0.0	0.33	0.00	0.10	0 0	0.26	0.26	0.23	0.23	0.00	0.29	0.00	0.00	0.50	0.00	0.00	0.00	0.00	0.00	00.00	0.00	0.00	0.00	00.0	0.00	00.0	0.00
Prescription of contact lens Prescription of contact lens Prescription of contact lens	Modification of contact lens	Fitting of spectacles Fitting of spectacles	Special spectacles fitting	Special spectacles fitting	Special spectacles fitting	Pepair & adjust spectacles	Repair & adjust spectacles	Eye service or procedure	Eye service or procedure	Ear and throat examination	Speech/hearing evaluation	Speech/hearing therapy	Speeding trerapy	Nasal function studies	Facial nerve function test	Carlyngeal function studies	Spontaneous nystadmus test	Spontaneous nystagmus test	Spontaneous nystagmus test	Positional nystagmus test	Positional nystagmus test	Caloric vestibular test	Caloric Vestibular test	Optokinetic nystagmus test	Optokinetic nystagmus test	Optokinetic riystagrilus test	Oscillating tracking test	Oscillating tracking test	Sinusoidal rotational test	Sinusoidal rotational test	Supplemental electrical test	Posturography	Posturography	Pure tone audiometry, air	Speech threshold audiometry	Speech audiometry, complete	Comprehensive hearing test	Bekesy audiometry, diagnosis	Tone decay hearing test	Sisi hearing test	Stenger test, pure tone	lympanometry	Acoustic reflex decay test	Filtered speech hearing test	Lombard test
444						z	ш (	υO	ω,	∢ ∢	∶∢	∢ <	< <	⋖	∢ •	∢ ⊲	( ∢	⋖	∢ <	∢ ⊲	. ∢	∢ <	∢ ∢	∶∢	∢ <	∢ ∢	<	∢	( ∢	⋖ .	∢ ⊲	(∢	∢.	∢ <	( ∢										⋖
								26										26	TC	26	1C		 1 20 1 20		26	ַ	26	٦٥ 	26	TC		26													
10.00 \$ 1					•					OI ==						•		:				•			•	+ 10					-														
92315 92316 92317	92325	92341	92352	92353	92355	92370	92371	92499 92499	92499	92502 92504	92506	92507	92500	92512	92516	92520	92541	92541	92541	92542	92542	92543	92543	92544	92544	92544	92545	92545	92546	92546	92547 92548	92548	92548	92552	92555	92556	92557	92561	92563	92564	92565	92567	92569	925/1	92573

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

)al	
Global	
Year 2007 Transitional Facility Total	A N N N N N N N N N N N N N N N N N N N
Fully Implemented Facility Total	A N N N N N N N N N N N N N N N N N N N
MAYMENTS FOR	0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
TAYMIN IN I	1.00.001.001.0001.0001.0001.0001.0001.
Mal-Practice RVUs	0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.
Year 2007 Transi- tional Fa- cility PE RVUs	A A A A A A A A A A A A A A A A A A A
Fully Implemented Facility PERVUS	A A A A A A A A A A A A A A A A A A A
Year 2007 Transitional Non-Fa-cility PE RVUs	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Fully Implement of Non-Facility PE RVUs	1.00 0.02 0.05 0.05 0.05 0.05 0.05 0.05 0
Physician plement Transi ed Racil tional Facility PE RVUs PERVUs PERVUs PERVUs PERVUs PERVUs PERVUs RVUs RVUs RVUs RVUs RVUs RVUs RVUs	0.000000000000000000000000000000000000
MELATIVE VALUE UNITS (MVUS) AND TO THE CONTROL OF T	Sensorineural acuity test Synthetic sentence test Stenger test, speech Visual audiometry (vra) Conditioning play audiometry Select picture audiometry Select picture audiometry Select picture audiometry Electrocochleography Auditor evoke potent, compre Evoked auditory test Evo
.	
ADDENDUM B	26 22 26 22 36 22 36 22 36 22 36 22 36 22 36 36 36 36 36 36 36 36 36 36 36 36 36
ADDE CPT¹/ HCPCS²	92575 92576 92577 92576 92578 92588 92588 92587 92587 92587 92587 92587 92601 92602 92601 92601 92602 92602 92603 92603 92604 92603 92604 92604 92604 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607 92607

878788888888787	********
	<
25.6.5.4.6.8.8.8.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9	AN S.: AN AN A
42 4 8 8 4 8 8 4 8 8 4 8 8 4 8 8 4 8 8 4 8 8 4 8 8 8 4 8 8 8 4 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	N N N N N N N N N N N N N N N N N N N
444446004460044760044600644806	2 8 8 8 9 5 7 8 8 8 8 9 8 9 8 9 8 9 9 9 9 9 9 9 9 9
ANNNA COOOO ANN COO COO COO COO COO COO COO COO COO C	70.000 00 00 00 00 00 00 00 00 00 00 00 0
N N N N N N N N N N N N N N N N N N N	3.00 4.96 1.41 3.55 3.33 0.82 0.12 3.29 6.83 NA
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.	0.13 0.26 0.03 0.15 0.02 0.13 0.03 0.09 0.06 0.06
20	Z Z G, Z Z G, Z C, Z G, Z C, Z C, Z C, Z
8.8.2.9 6.2.2.9 6.2.2.9 6.2.2.9 7.5.9.8 A S. 0.0.0 7.5.9 A S. 0.0.0 8.2.0.0 A S. 0.0.0 A	N N N N N N N N N N N N N N N N N N N
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	7.1.7 4.10 7.10 7.10 7.10 7.10 7.10 7.10 7.10 7
44444400444400hn-nnnnn044m004n0m0anm04nn-0-n-04000nr/m-1	<u> </u>
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN	2 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
4.4.0.4.2.2.2.2.8.8.8.0.0.0.0.0.0.0.0.0.0.0.0.0	
Insert intracoronary stent Insert intracoronary stent Coronary artery dilation Coronary artery dilation Revision of aortic valve Revision of mitral valve Revision of heart chamber Coronary atherectomy add-on Pul art balloon repr, percut Ful art balloon repr, percut Coronary atherectomy add-on Ful art balloon repr, percut Ful art percut percut Ful art	
t t t t t t t t t t t t t t t t t t t	
any stem  Ililation  Ililation  I valve  onary v  chamb  c	or art art art ageal ageal ageal
accorone artery of artery	sthorac n of he n of he n of he n of he sesoph sesoph sesoph sesoph
Insert intracoronary stent Coronary artery dilation Coronary artery dilation Revision of aortic valve Revision of aortic valve Revision of mitral valve Revision of mitral valve Revision of heart chambe Coronary atherectomy and Pul art balloon repr, perce Electrocardiogram, completed and art balloon repr, perce Electrocardiogram, tracing Electrocardiogram report Transmission of ecg Report actives tes Cardiovascular stress tes Cardiovascular stress tes Cardiovascular stress tes Cardiovascular stress test. Cardiova	ho tran ho exar ho exar ho exar ho exar ho tran ho tran ho tran ho tran
$ar{\epsilon}$ $$	
444444004444444444444444444444444444444	4444444444
28 28 28 29 29 29 29 29 29 29 29 29 29 29 29 29	26 26 26 26 26 26 26 26 26 26 26 26 26 2
	93304 93307 93307 93308 93308 93308 93312 93312
3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

1	* * * * * * * * * * * * * * * * * * *
Global	XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
Year 2007 Transitional Facility Total	NA NA S.
ZUU/— Fully Im- plement- ed Facil- ity Total	84 N O O O O O O O O O O O O O O O O O O
Year Year 2007 Transi- tional Non-Fa- cility Total	1.73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
FE PAYMI Fully Im- plement- ed Non- Facility Total	1.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Mal-Practice RVUs	0.000000000000000000000000000000000000
Year 2007 Transitional Fa- cility PE RVUs	NA N
Fully Implementation PE	00.00000000000000000000000000000000000
Year 2007 Transitional Non-Fa- cility PE RVUs	0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Physician plement tional ed Faully Im- RVUS PERVUS PERVUS PERVUS PERVUS REVUS	0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Physician Work RVUs	1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25
MELATIVE VALUE UNITS (HVUS) AND Description	Echo transesophageal Echo transforacitation Echo transforacitation Echo transforacitation Echo transforacitation E
.   State	440404040404444444444444444404004004004
ADDENDUM B	82 82 82 82 82 82 82 82 82 82 82 82 82 8
ADD CPT ¹ / HCPCS ²	93314 93315 93315 93315 93315 93317 93317 93320 93320 93321 93321 93320 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93321 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 93322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 9322 932

80000000000000000000000000000000000000	000 000 000 000 000 000 000 000 000 00
4.000.000.000.000.000.000.000.000.000.0	4 X X X X X X X X X X X X X X X X X X X
7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7. 7	AN A
4. N N N N N N N N N N N N N N N N N N N	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
7.7	
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000	2.13 N A A C C C C C C C C C C C C C C C C C
25.00.00.00.00.00.00.00.00.00.00.00.00.00	2.68 A N A A S A S A S A S A S A S A S A S A
2.5. A A L L A A A A A A A A A A A A A A A	N A N S 1.3 A N A N A N A N A N A N A N A N A N A
2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5	2.68 N A A A A A A A A A A A A A A A A A A A
7. 4. 4. 4. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6.	
Rt. It heart catheterization Rt. heart cath congenital Rt. heart cath, congenital Rt. heart flow reserve measure Rundle of His recording Rundle of His recording Rundle of His recording Rundle ventricular recording Right ventricular recording Right ventricular recording	Map tachycardia, acd-on Map tachycardia, add-on Map tachycardia, add-on Intra-atrial pacing Intra-atrial pacing Intra-atrial pacing Intra-entricular pacing Intraventricular pacing Intraventricular pacing Esophageal recording
Ri, it heart catheterization	ap tachycardia, ap tachycardia, ap tachycardia, ap tachycardia, ap tachycardia, and tachycardia ap tachycardia ap tachycardia pacing tra-atrial pacing traventricular pactraventricular pactrave
\$0. \$0. \$0. \$0. \$0. \$0. \$0. \$0. \$0. \$0.	<del> </del>
20	26 26 26 26 26 26 26 26 26 26 26 26 26 2
838888888888888888888888888888888888888	
93529 93529 93530 93531 93531 93531 93532 93532 93532 93533 93533 93533 93533 93533 93533 93544 93544 93544 93544 93544 93555 93555 93555 93556 93556 93557 93567 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577 93577	93609 93609 93609 93609 93610 93612 93612 93612 93615 93616 93616 93616

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

=	
Global	000000000000000000000000000000000000000
Year 2007 Transi- tional Fa- cility Total	8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
Fully Implemented Facility Total	8.87 A A A A A A A A A A A A A A A A A A A
Year 2007 Transi- tional Non-Fa- cility Total	8.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Facility  Facility  Total	AN A
Mal-Practice RVUs	2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.5.0 2.
Physician PERVUS Facility PE RVUS  PERVUS  PER	A W A A S S S S S S S S S S S S S S S S
Fully Implemented Facility PE RVUs	NA N
Year 2007 Transi- tional Non-Fa- cility PE RVUs	NA N
Fully Implemented Non-Facility PERVUS	N N N N N N N N N N N N N N N N N N N
Physician Work RVUs	4 4 8 8 8 4 9 9 9 9 9 9 9 9 9 9 9 9 9 9
Description	Heart rhythm pacing Electrophysiology evaluation Stimulation, pacing heart Stimulation, pacing heart Stimulation, pacing heart device Electrophysiology evaluation Int table evaluation Intracardiac ecg (ice) Intracard
itatı .	444440400400400404440404444444444444444
Mod S ²	25 55 55 55 55 55 55 55 55 55 55 55 55 5
CPT1/ HCPCS ²	93618 93618 93618 93619 93620 93620 93620 93620 93621 93622 93622 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93624 93640 93641 93641 93641 93641 93642 93641 93642 93641 93642 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93644 93774 93774 93774 93774 93774

***************************************	****************	****
£	A 6 5 4 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6	N N N N N N N N N N N N N N N N N N N
4 A N N N N N N N N N N N N N N N N N N	A A A A A A A A A A A A A A A A A A A	1.59 A A A A A A A A A A A A A A A A A A A
6.000000000000000000000000000000000000	22.1. 20.0.00000000000000000000000000000000	5.30 7.22 1.65 5.57 7.04
4.000000000000000000000000000000000000	2.31 2.65 2.66 2.66 2.66 2.66 2.66 2.66 2.66	6.52 8.60 1.59 7.01 8.27
0.000000000000000000000000000000000000	0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000	0.39 0.45 0.39 0.45
0.0 N N N N N N N N N N N N N N N N N N	A A A A A A A A A A A A A A A A A A A	O O O O O O O O O O O O O O O O O O O
0. X X 0.	A N N N N N N N N N N N N N N N N N N N	O O A A A A A A A A A A A A A A A A A A
0.539 0.688 0.088 0.098 0.039 0.039 0.039 0.039 0.039 0.039 0.040 0.040 0.040	0.44 0.44 0.44 0.65 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00	5.62 5.62 0.44 5.18
0.09 0.03 0.03 0.03 0.03 0.03 0.03 0.03	0.56 0.05 0.04 0.00 0.00 0.00 0.00 0.00 0.00	6.13 7.00 0.38 6.62 6.67
0.00 0.00 0.03 0.03 0.03 0.03 0.04 0.05 0.05 0.05 0.05 0.05 0.05 0.05	1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00	0.00
Analyze pacemaker system Analyze pacemaker system Telephone analy, pacemaker Telephone analy, pacemaker Telephone analy, pacemaker Telephone analy, pacemaker Analyze pacemaker system Telephonic analy, pacemaker analy	Analyze ht pace device dual Set-up cardiovert-defibril Set-up cardiovert-defibril Set-up cardiovert-defibril Set-up cardiover-defibril Set-up card	
maker system aly, pacemaker aly, pacemaker aly, pacemaker aly, pacemaker maker system aly, pacemaker aly, pacemaker aly, pacemaker aly, pacemaker aly, pacemaker aly, pacemaker gradient studiess gradient studiess gradient studies sog ce device sngl ce dev	Analyze ht pace device dual An	tivity study etect w/o inj etect w/o inj etect w/o inj etect w/inj
Analyze pace Analyze pace Telephone ar Telephone ar Telephone ar Analyze pace Analyze pace Analyze pace Analyze pace Analyze pace Analyze pace Telephonic ar Telephonic ar Telephonic ar Temperature Temperature Temperature Analyze ht pa Analyze ht pa Analyze th pa Analyze th pa Analyze th pa Analyze th pa	Analyze th pace device danalyze the pace device daserup cardiovert-defibrill.  Set-up cardiovert-defibrill.  Set-up cardiovert-defibrill.  Set-up cardiovert-defibrill.  Measure venous pressure Measure venous pressure Ambulatory BP monitoring Ambulatory BP recording Ambulatory BP recording Cardiac rehab/monitor.  Cardiac rehab/monitor.  Cardiac rehab/monitor.  Cardiac rehab/monitor.  Cardiac rehab/monitor.  Cardiavascular procedure Cardiovascular procedure Cardiovascular procedure Cardiovascular study Extracranial study Extracranial study Intracranial study Intracra	Tcd, vasorear Tcd, emboli of Tcd, emboli of Tcd, emboli of Tcd, emboli of
	<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<	
		7C 26 10 10 10 10 10 10 10 10 10 10 10 10 10
		93890 93892 93892 93893
い い o o o o o o o o o o o o o o o o o o	0) U)	<b>00000</b>

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	
Year 2007 Transi- tional Fa- cility Total	66 4 4 6 6 4 4 4 6 6 4 4 4 6 6 4 4 6 6 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
2007— Fully Im- plement- ed Facil- ity Total	6.5 A A S. S. A S. S. A S. S. A S. S. A S. S. S. A S. S. S. S. A S.
PAYMENTS FOR Year Ment-Transi- Itonal	$\begin{array}{c} -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\ -6.66 \\$
	1.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
MEDICA Mai-Practice RVUs	0.000000000000000000000000000000000000
Year 2007 Transi- tional Fa- cility PE RVUs	44 A A B B A A C A A B B A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A
Fully Implemented Facility PERVUS	88 A S S A S A S A S A S A S A S A S A S
Physician plement Transi ed Nork Facility Non-Fe Facility Non-Fe RVUs PE RVUs PE RVUs	4 0 0 2 0 2 4 0 4 7 0 0 0 4 0 0 4 0 0 0 0 0 0 0 0 0
Fully Implemented Facility	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
RELATED Physician Work RVUs	1.000000000000000000000000000000000000
—HELATIVE VALUE UNITS (HVUS) AND	Tcd, emboli detect winj Extremity study Lower extremity study Upper extremity st
B.—KE	
ADDENDUM S2 Mod	25 62 62 62 62 62 62 62 62 62 62 62 62 62
ADDI CPT1/ HCPCS ²	93893 93893 938922 933922 933923 933924 933924 933924 933926 933926 933926 933931 933976 933976 933976 933976 933976 933976 933976 933976 933976 933976 933976 933976 933976 933976 933976 933977 933976 933976 933976 933976 933976 933976 933976 933976 933976 933976 933976 933976 933976 933976 933976 933976 933976 9339776 933976 933976 933976 933976 933976 933976 933976 933976 9339776 933976 933976 933976 933976 933976 933976 933976

No. 1995   State   S					
March   Peter condicion of version   March	**********	*****	*********	*********	
Note of the particular of violating principles   Note of the particular of violating principles   Note of the particular of violating principles   Note o	25.7 17.0 17.1 17.1 17.0 10.8 10.8 10.8 10.8 10.8 10.8 10.8 10	0.15 0.35 0.35 0.15 0.15 0.15	0.35 NA NA N	A A A A S S A A A A A A A A A A A A A A	0.54 NA NA N
National Color	4.7.0 0.7.0 0.7.0 0.7.0 AN AN AN AN AN AN AN AN AN AN AN AN AN	0.15 NA NA N	0.00 NA A S S S S S S S S S S S S S S S S S	A A A A S S A A 5 S A A A S A A A A A A	0.53 N A N N A N N N N N N N N N N N N N N N
Page	1.35 0.64 0.71 1.51 0.41 1.60 0.80 0.79 0.79 0.79 0.79	0.60 0.15 0.45 1.03 0.35 0.75 0.15	0.81 0.63 0.05 0.70 0.70 0.35 0.05 0.05 0.05	0.65 0.98 0.57 1.38 0.55 0.53 0.63 1.42 0.73	1.49 1.49 1.49 1.90 1.49 1.49 1.49 1.49 1.49 1.60 1.60 1.60 1.60
Paint recorded storometry   0.02	148 0.77 0.71 1.70 0.40 1.74 0.78 0.95 0.95 0.48	0.65 0.15 0.50 1.16 0.34 0.70 0.70 0.16	0.95 0.17 0.35 0.35 0.35 0.98 0.98	0.60 0.60 0.53 0.53 0.53 0.54 1.56 1.56	1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Columb	0.000000000000000000000000000000000000	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	000000000000000000000000000000000000000	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
Color   A Protection of Section   Color   Co	0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z	Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z Z O Z Z Z O Z Z Z	
A	0.0	0 2 5 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	0 2 2 8 8 2 5 6 5 8 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z O Z Z	0.000 A A B A A B A A A B A A A B A A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A A B A B A A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B
A Patient recorded spirometry   0.52	0.63 0.63 0.17 0.09 0.09 0.17 0.69 0.69 0.69	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	0.63 0.09 0.09 0.09 0.00 0.00 0.00 0.00 0.0	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	2. 1. 1. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.
A Patient recorded spirometry   A Evaluation of wheezing   Evaluation   Evaluat	0.0 0.76 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	0.053 0.003 0.084 0.007 0.007 0.053	0.00 0.03 0.09 0.09 0.09 0.09 0.09 0.09	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	
10	0.55 0.05 0.31 0.00 0.00 0.00 0.00 0.00 0.00	0.00 0.00 0.00 0.00 0.00 0.00 0.00	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
10	Patient recorded spirometry Patient recorded spirometry Review patient spirometry Evaluation of wheezing Vital capacity test Vital capacity test Vital capacity test	Lung function test (MBC/MVV) Lung function test (MBC/MVV) Lung function test (MBC/MVV) Residual lung capacity Residual lung capacity Residual lung capacity Residual lung capacity Expired gas collection Expired gas collection	Thoracic gas volume Thoracic gas volume Thoracic gas volume Lung nitrogen washout curve Lung nitrogen washout curve Lung nitrogen washout curve Measure airflow resistance Measure airflow resistance Measure airflow resistance Breath airway closing volume Breath airway closing volume	Breath airway closing volume Respiratory flow volume loop Respiratory flow volume loop Respiratory flow volume loop CO2 breathing response curve CO2 breathing response curve Hypoxia response curve Hast w/report Hast w/report	Hast wloxygen titrate Hast wloxygen titrate Hast wloxygen titrate Hast wloxygen titrate Pulmonary stress test/simple Pulmonary stress test/simple Pulm stress test/complex Pulm stress test/complex Pulm stress test/complex Airway inhalation treatment Aerosol inhalation treatment Initial ventilator mgmt Continued ventilator mgmt Continued ventilator, cnp Evaluate pt use of inhaler Chest wall manipulation Chest wall manipulation Exaladed air analysis, o2 Exhaled air analysis, o2 Exhaled air analysis, o2
	26 7C 7C 7C 7C 7C		26 75 75 75 76 76	26 TC	25 62 12 26 12 12 12 12 12 12 12 12 12 12 12 12 12

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

1	100000000000000000000000000000000000000
Global	
Year 2007 Transitional Facility Total	A V S S S S S S S S S S S S S S S S S S
Fully Im- plement- ed Facil- ity Total	0.2.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0
Physician plement- from the Annie and Nork ed Non-Fa- in Per RVUs  PERVUS  PER	2.50 2.23 2.23 2.23 2.23 2.23 2.23 2.23 2.2
Fully Implemented Non-Facility  Total	1.45 1.16 1.17 1.18 1.19 1.19 1.19 1.19 1.19 1.19 1.19
Mal-Practice RVUs	20000000000000000000000000000000000000
Year 2007 Transi- tional Fa- cility PE RVUs	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Fully Implemented Facility PE RVUs	4 0 4 5 0 5 4 6 5 4 5 5 4 5 5 5 5 5 5 5 5 5 5 5 5
Year 2007 2007 Transi- tional Non-Fa- cility PE RVUs	20.01.1.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.
Fully Implemented Non-Facility PE RVUS	1.0.1.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0
Physician Work RVUs	0.000000000000000000000000000000000000
Description	Exhaled air analysis, o2/co2 Exhaled air analysis, o2/co2 Exhaled air analysis, o2/co2 Exhaled air analysis Monoxide diffusing capacity Monoxide diffusing capacity Membrane diffusion capacity Measure blood oxygen level Meas
iatı	
Wod Wod 8	85 85 85 85 85 85 85 85 85 85 85 85 85 8
CPT'/ HCPCS ²	94681 94681 94681 94690 94690 94720 94720 94720 94725 94725 94750 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770 94770

		_
***************	**********	***************************************
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2. Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	X 4.4.0.000000 1. X 4.4.0.000000 1. X 4.4.0.000000 1. X 4.4.0.00000 1. X 4.4.0.000000 1. X 4.4.0.00000 1. X 4.4.0.000000 1. X 4.4.0.00000 1. X 4.4.0.000000 1. X 4.4.0.00000 1. X 4.4.0.000000 1. X 4.4.0.00000 1. X 4.4.0.000000 1. X 4.4.0.00000 1. X 4.4.0.00000 1. X 4.4.0.00000 1. X 4.4.0.00000 1. X 4.4.0.000000 1. X 4.4.0.0000000 1. X 4.4.0.000000000000000000000000000000
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	4 4 4 8 8 4 4 4 4 4 4 4 4 8 8 8 8 8 8 8	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
7.07 2.59 2.59 3.55 3.22 2.27 2.27 2.27 2.27 2.27 2.27 2.38 2.38 2.39 6.23.96 5.39 6.23.96 5.75 5.75 5.75 5.75 5.75 5.75 5.75 5.7	3.1.56 2.2.36 2.2.36 2.3.36 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56 3.3.56	27.45 5.03 5.03 6.65 1.04 1.12 1.13 1.13 1.13 1.13 1.13 1.14 1.14 1.14
9.58 2.24 2.22 2.22 2.23 3.83 3.47 15.45 15.45 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 18.05 1	25.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.5.7 8.7	23.67 4.80 0.68 0.06 0.96 1.18 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.44 0.44 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45
0.093 0.093 0.093 0.098 0.098 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050 0.050	0.000000000000000000000000000000000000	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
0.0 N N N N N N N N N N N N N N N N N N	0.000	N N N N N N N N N N N N N N N N N N N
A 7.0 N A 2.0	0.31 NA N S S A N N S S A N S S S A N S S S A N S S S A N S S S S	N N N N N N N N N N N N N N N N N N N
7.7.7.7.7.7.7.7.9.9.0.0.0.0.0.0.0.0.0.0.	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	27.43 3.22 0.34 0.34 0.55 0.60 0.60 0.60 0.64 0.64 0.64 0.64 0.64
2.7.7 6.76 6.76 6.76 6.76 6.76 1.65 1.65 1.65 1.65 1.65 1.65 1.65 1.6	6.31 6.64 6.64 6.64 6.14 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15 6.15	23.65 2.99 0.33 0.34 0.55 0.55 0.55 1.16 0.51 1.16 1.36 1.36 0.63 1.34 1.34 1.34 1.34 1.34 1.34 1.34 1.3
1.88 1.00 1.00 1.00 1.00 1.00 1.00 1.00	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	0.00 0.28 0.29 0.47 0.06 0.06 0.09 0.00 0.00 0.00 0.00 0.00
Multiple sleep latency test  Multiple sleep latency test  Multiple sleep latency test  Sleep study, unattended Sleep study, unattended Sleep study, attended Polysomnography, 4 or more Polysomnography, 4 or more Polysomnography w/cpap Polysomnography w/cpap Polysomnography w/cpap Polysomnography w/cpap	Eeg, 41–60 minutes Eeg, 41–60 minutes Eeg, over 1 hour Eeg, over 1 hour Eeg, over 1 hour Eeg, awake and drowsy Eeg, awake and drowsy Eeg, awake and asleep Eeg, awake and asleep Eeg, awake and asleep Eeg, awake and asleep Eeg, coma or sleep only Eeg, coma or sleep only Eeg, coma or sleep only Eeg, cerebral death only Eeg, all night recording Eeg, all night recording Surgery electrocorticogram Surgery electrocorticogram	Surgery electrocorticogram Insert electrodes for EEG Limb muscle testing, manual Hand muscle testing, manual Body muscle testing, manual Body muscle testing, manual Body muscle testing, manual Range of motion measurements Range test, 2 limbs Range test, 3 limbs Range test, 3 limbs Range test, 4 limbs Range test, 4 limbs Range test, 4 limbs Range test, 1 larynx
444444444444444	<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<	<i>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</i>
25 25 25 25 25 25 25 25 25 25 25 25 25 2	25 52 52 52 52 52 52 52 52 52 52 52 52 5	55 25 85 55 55 55 55 55 55 55 55 55 55 55 55
27.7.7.9.8.8.8.9.2.7.7.9.8.8.8.9.2.7.7.7.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9	2 3 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	0.8 - 2.8 4 - 2.9 - 0.8 - 0.2 - 1.2 8 8 8 4 4 4 8 8 8 8
95805 95805 95806 95806 95806 95806 95807 95807 95808 95810 95811 95811 95811	95812 95813 95813 95813 95814 95816 95816 95829 95829 95824 95827 95827 95829 95827 95827 95827	95829 95830 95831 95833 95833 95854 95865 95860 95860 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 95864 96864 96864 96864 96864 96864 96864 96864 96864 96864 96864 96864

Addendum B.—Relative Value Units (RVUS) and Related Information Used in Determining Medicare Payments For 2007—Continued

		_
Global	\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$	XX
Year 2007 Transi- tional Fa- cility Total	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	NA
Fully Im- plement- ed Facil- ity Total	Z X N N N N N N N N N N N N N N N N N N	N N
Year 2007 Transi- tional Non-Fa- cility Total	44444444444444444444444444444444444444	1.48
Fully Implemented Non-Facility Total	7.00.10	2.99
Mal-Prac- tice RVUs	00000000000000000000000000000000000000	0.00
Year 2007 Transi- tional Fa- cility PE RVUs	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	NA
Fully Implemented Facility PERVUS	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	NA
Year 2007 Transi- tional Non-Fa- cility PE RVUs	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	1.42
Fully Implemented Non-Facility	0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.040 0.	2.93
Physician Work RVUs	2.000000000000000000000000000000000000	0.00
Description	Muscle test, hemidiaphragm Muscle test cran nerv unilat Muscle test cran nerv unilat Muscle test cran nerv unilat Muscle test cran nerve bilat Muscle test cran nerve bilat Muscle test, thor paraspinal Muscle test, thor paraspinal Muscle test, nonparaspinal Muscle test, none fiber Muscle test, one fiber Muscle test, etcsting Somatosensoy testing Somatosensoy testing Somatosensoy testing	Somatosensory testing
Status	444444444444444444444444444444444444444	< <
Mod	85     85     85     85     85     85     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     82     <	TC
CPT1/ HCPCS ²	95866 95867 95867 95867 95867 95868 95869 95870 95870 95872 95873 95874 95873 95874 95872 95873 95874 95872 95873 95873 95874 95873 95875 95875 95875 95876 95876 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877 95877	95927

***************************************
A 2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
A 22 A 2 2 A 2 4 6 8 8 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A 2 5 A
$\begin{array}{c} 4.4.9167678 \\ 4.4.916767 \\ 4.4.916767 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167 \\ 4.4.9167$
6 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
0.000000000000000000000000000000000000
A 90 A A 90 A 4 A A 90 A A 90 A 90 A 90
A A A A A A C C A A C C C C C C C C C C
3.00
8.8.3.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.
6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C motor evoked, uppr limbs C motor evoked, uppr limbs C motor evoked, wer limbs C motor evoked potential test Visual evoked potential test H-reflex test H-
A A A A A A A A A A A A A A A A A A A
26 27 26 27 26 27 26 27 26 27 26 27 26 27 26 27 27 26 27 27 27 27 27 27 27 27 27 27 27 27 27
95928 95928 95928 95928 95929 95929 95930 95930 95931 95931 95931 95931 95931 95931 95931 95931 95931 95931 95931 95931 95931 95951 95951 95951 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952 95952

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

ADD	ADDENDOM B	l	DELATIVE VALUE UNITS (NVOS) AND	JELAIEU	YMLOTNI TWL	RELATED INFORMATION USED IN DETERMINING INEDICARE P	D IN DE		NITUCA FOIDAM	7 T A 1 IV	AYMENIS TOR	- / 007 F	Conillined	
CPT¹/ HCPCS²	Mod	Status	Description	Physician Work RVUs	Fully Implemented Non-Facility	Year 2007 Transi- tional Non-Fa- cility PE RVUs	Fully Im- plement- ed Facil- ity PE RVUs	Year 2007 Transi- tional Fa- cility PE RVUs	Mal-Prac- tice RVUs	Fully Implemented Non-Facility Total	Year 2007 Transi- tional Non-Fa- cility Total	Fully Implemented Facility Total	Year 2007 Transi- tional Fa- cility Total	Global
		∢ ⊲	Analyz neurostim brain addonSnin/brain pump refil & main	1.64	0.73	0.84	0.47 NA	0.64 NA	0.08	2.45	2.56	2.19 NA	2.36 NA	ZZZX
95991		۷.	Spin/brain pump refil & main	0.77	1.67	1.54	¥ Z	Ž	0.00	2.50	2.37	Z Z	¥ Z	X
95999		O <	Neurological procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	× }
96001		( ∢	Motion test w/ft press meas	2.15	Z Z	 ₹ Z	0.53	0.63	0.0	Z Z	Z Z	2.78	2.88	XX XX
		∢•	Dynamic surface emg	0.41	Y :	₹ Z	0.11	0.14	0.02	¥ :	₹:	0.54	0.57	X
96003		∢ ∢	Dynamic fine wire emg	0.37	NA 0.54	N 0	4L.0	0.13	0.02	NA 2 79	80 S	0.53	3.09	××
96101		∶∢.	Psycho testing by psych/phys	1.86	0.34	0.57	0.33	0.56	0.05	2.25	2.48	2.24	2.47	X
96102		∢ ⊲	Psycho testing by technician	0.50	1.20	0.80	60.0	0.15	0.0	1.71	1.31	0.60	0.66	××
96105		< <	Assessment of aphasia	0.00	2.06	1.84	S Z	Z Z	0.18	2.24	2.02	N A	N S	XX
		⋖ <	Developmental test, lim	0.00	0.18	0.18	N S	¥ S	0.18	0.36	0.36	A S	N S	× }
96111		∢ ∢	Developmental test, extend	1.60	0.66	0.95	0.53	0.92	. c	3.44	2.73	3.31 2.46	3.70 2.63	××
96118		< <	Neuropsych tst by psych/phys	1.86	0.81	1.25	0.32	0.55	0.18	2.85	3.29	2.36	2.59	X
96119		⋖ <	Neuropsych testing by tech	0.55	1.53	1.15	0.00	0.17	0.18	2.26	1.88	0.82	06.0	×
96120		∢ ∢	Neuropsych tst admin w/comp	0.50	9.0	0.16	60.0	0.0	0.02	0.61	0.50	0.02	0.68	XX XX
96151		< ⋖	Assess htth/behave, subseq	0.48	0.09	0.16	0.09	0.15	0.01	0.58	0.65	0.58	0.64	X
96152		⋖・	Intervene hlth/behave, indiv	0.46	0.09	0.15	0.08	0.14	0.01	0.56	0.62	0.55	0.61	X
96153		∢ ⊲	Intervene hith/behave, group	0.10	0.02	0.04 71	0.02	0.03	0.0	0.13	0.15	0.13	0.0	××
96155		z	Interv hlth/behav fam no pt	0.4	0.10	0.16	0.10	0.15	0.02	0.56	0.62	0.56	0.61	×××
96401		⋖	Chemo, anti-neopl, sq/im	0.21	1.87	1.35	Ϋ́	¥ N	0.01	2.09	1.57	N A	A A	××
96402		⋖ •	Chemo hormon antineopl sq/im	0.19	0.72	0.94	A S	A S	0.01	0.92	1.14	¥!	NA SIS	XX
96405		∢ ∢	Chemo intralesional, up to /	0.52	8.6 9.4 9.0 9.0	3.07	0.22	92.0	0.03	40.4	3.25	1 10	1.79	86
96409		< ⋖	Chemo, iv push, sngl drug	0.24	2.78	2.89	Į Š	N N	0.00	3.08	3.19	¥ Y	Į Ą	×××
96411		∢ •	Chemo, iv push, addl drug	0.20	1.50	1.58	¥ :	¥ ż	90.0	1.76	1.84	Ϋ́	¥:	ZZZ
96413		∢ ∢	Chemo, IV Infusion, 1 nr	0.28	3.63	0.74	A A	A A	0.08	3.99 0.90	1.00	Y Z	A N	XXX
		< <	Chemo prolong infuse w/pump	0.21	4.08	4.47	Ž	Ž	0:08	4.37	4.76	Z Z	A Z	l××
96417		⋖・	Chemo iv infus each addl seq	0.21	1.72	1.89	¥:	¥:	0.07	2.00	2.17	¥:	¥ :	ZZZ
96420		∢ ⊲	Chemo ia inflision in to 1 hr	0.17	3.70	7.67	¥ Z	A A	80.0	3.95	2.92	Z Z	Y Y	××
96423		< ∢	Chemo ia infuse each addl hr	0.17	1.93	1.89	Ž	Ž	0.02	2.12	2.08	Z Z	¥ Ž	ZZZ
96425		⋖ <	Chemotherapy, infusion method	0.17	4.54	4.49	¥ S	N N	0.08	4.79	4.74	A S	N S	×
96440		∢ ∢	Chemotheraby, Intracavitary	2.37	5.45	7.39	0.9	1.12	0.17	8.10	9.73	3.58 4.08	3.46	000
		< <	Chemotherapy, into CNS	1.53	5.02	6.47	0.83	1.18	0.09	6.64	8.09	2.45	2.80	000
96521		∢ <	Refil/maint, portable pump	0.21	3.14	3.61	¥ ž	¥ ž	0.00	3.41	3.88	Y S	₹ Ş	×
96523		< ⊢	Irriq drug delivery device	0.0	0.64	0.68	¥ ¥	₹₹	0.0	0.69	0.73	¥ Z	¥ ¥	XX
96542			Chemotherapy injection		3.55	4.08	0.32	0.58	0.07	4.37	4.90	1.14	1.40	××
96549			Chemotherapy, unspecified	0.0	0.00	0.00	0.00 V	0.00 V	0.0	0.00	0.00	0.00	0.00	××
96570			Photodynamic tx, 30 min		0.41	0.38	0.41	0.38	0.0	1.62	1.59	1.62	1.59	ZZZ
			Photodynamic tx, addl 15 min		0.20	0.19	0.20	0.19	0.03	0.78	0.77	0.78	0.77	ZZZ
00696			Ultraviolet light therapy		0.55	0.47	A C	N C	0.02	0.57	0.49	N S	N C	××
96910			Photochemotherapy with UV-B		1.95	1.23	N S	N S	0.0	1.99	1.27	NA A	S A	XX
96912			Photochemotherapy with UV-A		2.51	1.57	¥.	Y :	0.05	2.56	1.62	Y:	¥:	X
96913			Photochemotherapy, UV-A or B		3.55	2.15	N 0	NA 0.56	0.10	3.65	3.94	A F	A 2	×
		:		:	;	i	;	;	;	;	;	:	)	)

888888888888888888888888888888888888888	******	*********		
0 0 2 7 N N N N N N N N N N N N N N N N N N	2 2 2 2 2 2 2 2 2 0 2 2 2 2 2 2 2 2 2 2	Z Z Z O Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	NA A NA A SO CO	0.00 0.00 0.03 0.03 0.03 0.03 0.00 0.00
- 0.0 Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	4 4 4 4 4 4 4 0 4 4 4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	4 4 0 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	0.00 N A A A A A C C C C C C C C C C C C C C	0.00 0.00 0.00 0.00 0.00 0.00 0.00
4.00 0.00 1.198 0.11 1.26 0.13 0.038 0.038 0.039	4 £ £ 7 £ 8 £ 8 £ 8 £ 8 £ 8 £ 8 £ 8 £ 8 £	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	7.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.6.6 6.	6.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0		0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.	000000000000000000000000000000000000000	5000000000000		8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		Z Z Z O Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	N N N N N N N N N N N N N N N N N N N	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
2.80 0.00 0.03 0.44 0.85 0.64 0.06 0.19 0.19 0.20	0.07 0.08 0.17 0.17 0.10 0.10 0.29 0.29 0.29	0.45 0.26 0.26 0.26 0.34 0.21 0.25 0.25	0.78 0.36 0.37 0.33 0.33 0.30 0.00 0.00 0.38 0.38	0.23 0.27 0.27 0.27 0.29 0.29 0.00 0.00
3.39 4.46 0.00 0.068 0.77 0.77 0.07 0.19 0.25 0.34	0.00 0.00 0.20 0.20 0.46 0.10 0.00 0.33 0.33	0.23 0.23 0.23 0.23 0.23 0.23 0.23 0.23	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	0.00 0.00 0.00 0.00 0.00 0.00 0.00
1.17 0.00 0.00 0.00 0.06 0.06 0.06 0.18 0.18 0.18	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	0.00 0.00 0.00 0.027 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.0	0.55 0.60 0.60 0.60 0.65 0.65 0.65 0.65	0.55 0.55 0.45 0.45 0.87 1.19 0.40 0.00 0.00
Laser tx, skin 250–500 sq cm Laser tx, skin > 500 sq cm Dermatological procedure Pt evaluation Ot evaluation Ot re-evaluation Hot or cold packs therapy Mechanical traction therapy Vasopneumatic device therapy Vasopneumatic device therapy Whirlpool therapy Whirlpool therapy	microwave	Addato: Interapy exercises:  Gait training therapy Massage therapy Physical medicine procedure Manual therapy Manual therapy Therapeutic activities Cognitive skills development Sensory integration Self care mngment training Community/work reintegration Wheelchalir mngment training	care/20 cm or care/20 cm or care > 20 cm und tx, < 50 cm und tx, > 50 cm und tx, > 50 cm undlogy assess land training ning c/prosth use c/prosth use idine procedure indiv, subseq indiv, subseq on, group	Acupunct w/o stimul addi 15m Acupunct w/stimul 15 min Acupunct w/stimul addi 15m Osteopathic manipulation Osteopathic manipulation Osteopathic manipulation Osteopathic manipulation Osteopathic manipulation Osteopathic manipulation Chiropractic manipulation Chiropractic manipulation Chiropractic manipulation Chiropractic manipulation Chiropractic sanipulation Chiropractic sanipulation Chiropractic sanipulation Chiropractic sanipulation Chiropractic manipulation Chiropractic manipulation Chiropractic sanipulation Chiropractic sanipula
Laser tx, skin Laser tx, skin Dermatologics Pt evaluation Pt re-evaluation Ot re-evaluation Ot re-evaluation Ot re-evaluation Vascopneumat Vascopneumat Paraffin bath Whiripool thee	Diathermy eg Infrared thera Ultraviolet the Electrical stim Electric curren Contrast bath Ultrasound the Hydrotherapy Physical thera Therapeutic e	Aduatic fineral data training the Massage then Physical medid Manual therap therap Therapeutic a Cognitive skill Sensory integ Self care mng Community/w Wheelchair m	Active wound Active wound Neg press wo Neg press wo Neg press wo Physical perfic Assistive tech Orthotic mgm Prosthetic trai Prysical medi Physical medi Medical nutrition, Med nutrition, Medical nutrition,	Acupunct w/s Acupunct w/s Acupunct w/s Osteopathic n Osteopathic n Osteo
				22244444442000
			<del> </del>	
			97597 97598 97598 97605 97760 97750 97761 97762 97762 97762 97799 97803	
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2007—Continued

Global	
Year 2007 Transi- tional Fa- cility Total	00000 VANANA NA N
Fully Im- plement- ed Facil- ity Total	00000 NAN NAN NAN NAN NAN NAN NAN NAN NAN NAN
Year 2007 Transi- tional Non-Fa- cility Total	0.000 8.1 - 8.0 9.1 - 1.0 8.0 8.0 8.0 8.0 8.0 8.0 8.0 8.0 8.0 8
Fully Im- plement- ed Non- Facility Total	0.000 8.0 8.1 1.1 9.0 1.1 1.1 9.8 8.0 0.00 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1
Mal-Prac- tice RVUs	0.00.00.00.00.00.00.00.00.00.00.00.00.0
Year 2007 Transi- tional Fa- cility PE RVUs	00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 000000
Fully Im- plement- ed Facil- ity PE RVUs	00.000 000 000 000 000 000 000 000 000
Year 2007 Transi- tional Non-Fa- cility PE RVUs	0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Fully Im- plement- ed Non- Facility PE RVUs	0.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Physician Work RVUs	0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Description	Mod cs diff phys < 5 yrs Mod cs diff phys 5 yrs + Mod cs diff phys add-on Induction of vomiting Hyperbaric oxygan therapy Regional hypothermia Phlebotomy Special sewice/procreport Office/outpatient visit, new Office/outpatient visit, new Office/outpatient visit, est Observation care Observation care Observation care Observation same date Observations same date Observinces vancatitation Office consultation Office
Status	000444440444444444444444444444444444444
Mod	
CPT1/ HCPCS ²	99148 99149 99149 99149 99170 99170 99170 99185 99185 99186 99201 99202 99201 99211 99221 99222 99224 99224 99224 99224 99224 99228 99248 99248 99248 99288 99288 99288 99288

						_					_							,			_		_					1										
****	×××	žžž	××	××	X	××	××	X	××	X	žž	X	××	X	××	X	222	777	ZZZ	žž	X	žž	X	ž ž	X	ž ž	X	žž	X	××	X	××	XX	×}	ž×	X	ž×	žž
24.73 10.66 3.78 3.49 3.36	1.73 2.29 2.83	2.09 2.09 2.09	2.62	2.13	. ₹ :	<u>*</u> \$	₹ Z	Ž	₹ ₹	Ž	 ≰	₹:	▼ 4 Z Z	¥:	₹ Z Z	Z	2.47	2.37	2.39	3.06	1.53	1.52	2.39	 	1.88	2 2 2	2.60	2.84 1.41	1.65	 8. 8.	1.88	2.12	0.66	46.0	2.01 2.68	0.21	0.35	1.70
23.96 10.07 3.58 3.41 3.27	1.70 2.24 2.75	0.90 1.47 2.06	2.58	2.07	Ž.	₹ ₹ Z Z	Z Z	Ϋ́	Υ Υ Σ Σ	¥:	<u> </u>	¥:	ς ς Z Z	¥:	A A	Z Z	2.35	2.29	2.29	2.20	1.41	1.40	2.19	1.52	1.73	1.95 1.95	2.39	1.30	1.52	1.52	1.73	1.95	09:0	1.23	1.84 2.45	0.19	0.32 1.49	1.62
4 4 4 4 4 2 2 2 2 2	1.73 2.29 2.83	2.09 2.09 2.09	2.62	2.13	1.54	3.24	4.27 5.28	1.19	1.88	4.25	1.51 2.23	3.25	5.28	1.19	1.88 0.00	4.27	2.59	VS.S	¥,	3.15	1.81	1.80	2.72	2.62 2.83	2.78	3.02	3.55	3.86 2.04	2.29	2.26	2.52	3.07	1.05	1.77	3.17	0.35	NA NA	2.28 NA
	1.70 2.24 2.75	1.47 2.06	2.58	2.07	1.49	3.10	4.08	1.16	1.80	4.06	1.43	3.06	5.02	1.16	1.81	4.07	2.50	NA AN	Z Z	2.56	1.70	1.69	2.55	2.25	2.45	2.67	3.11	3.42 1.93	2.15	2.15	2.36	2.58	0.85	1.48	2.08	0.38	U.51	2.35 NA
0.32 0.17 0.16 0.15	0.05	0.00 0.00 0.00	0.08	0.06	0.05	0.07	0.13	0.04	90.0	0.13	0.05	0.10	0.13	0.04	90.0	0.13	0.08	0.07	0.08	0.05	0.05	0.0	0.06	0.05	0.05	90.0	0.07	0.07	0.05	0.05	0.05	90.0	0.0	0.02	0.04 	0.01	0.05 0.05	0.07
5.11 2.35 0.86 0.83	0.48 0.61 0.73	0.45	0.77	0.57	Z Z	<u>4</u> 4	<b>4</b> 4 2 2	¥ Z	A A	¥:	<u> </u>	¥:	e e	¥:	A A	Ž Ž	0.62	0.59	0.60	1.26	0.38	0.38	09.0	0.41	0.47	0.53	0.65	0.71	0.41	0.41	0.47	0.53	0.17	0.34	1.c.0 0.68	0.05	0.09	0.37
4.34 1.76 0.66 0.75	0.45 0.56 0.65	0.43	0.73	0.51	₹ Z	₹ ₹ Z Z	A A	¥ Z	∢ ₹ Z Z	¥:	g g	₹:	4 4 2 2	₹ Z	A A	ž Ž	0.50	0.57	0.50	0.20	0.26	0.40	0.40	0.32	0.32	0.36	0.44	0.48	0.28	0.28	0.32	0.36	0.11	0.23	0.34	0.03	0.06	0.29
4 4 4 4 4 2 2 2 2 2	0.48 0.61 0.73	0.45 0.61	0.77	0.57	0.48	0.65	1.11	0.39	0.56	1.09	0.45	0.88	1.11	0.39	0.56	1.1.	0.74	NA S	A S	1.35	0.66	0.66	0.93	1.38	1.37	1.43 6.43	1.60	1.73	1.05	1.02		9.1	0.56	0.77	1.17	0.19	0.25 NA	0.95 NA
4 4 4 4 4 2 2 2 2 2	0.45 0.56 0.65	0.43	0.73	0.51	0.43	0.56	0.92	0.36	0.48	0.90	0.37	0.69	1.08	0.36	0.49	0.91	0.65	NA NA	A I	0.76	0.55	0.76	0.76	1.01	1.04	90.1	1.16	1.29	0.91	0.91	0.95	0.99	0.36	0.48	0.59	0.22	0.25 NA	1.02 NA
18.46 7.99 2.75 2.50 2.40	1.20 1.61 2.01	0.1. 1.00 1.00	1.77	1.50	10.1	1.52 2.27	3.03	0.76	1.26	3.03	1.01	2.27	3.03	0.76	1.26	3.03	1.7	1.71	1.71	1.73	1.10	1.10	1.73	1.36	1.36	1.53	1.88	1.02	1.19	1.19	1.36	1.53	0.48	0.98	1.46	0.15	0.25	1.26 0.62
																	-				-		-		-										-			
				o.t																																		al
Neonate crit care, initial	are, init are, init are, init	, subsed , subsed	, subseq	narge daý	isit new pat	isit new pat isit new pat	Domicil/r-home visit new pat	isit est pat .	Domicil/r-home visit est pat	isit est pat .	Home visit, new patient	patient	patient	atient	atient	atient	e, office	e, omce e, inpatient	e, inpatient	Home health care supervision	pervision	pervision supervision	Nursing fac care supervision	Prev visit, new, infant Prev visit, new, age 1-4	age 5–11	age 12–17 age 18–39	age 40-64	35 & over fant	je 1–4	ge 5–11	Prev visit, est, age 18–39	Prev visit, est, age 40–64	seling, indiv	seling, indiv	seling, inalv selina, indiv	seling, group	Preventive counseling, group	Newborn care, not in hosp
Neonate crit care, initial Neonate critical care sub Ic for Ibw infant < 1500 g Ic, Ibw infant 1500–2500 Ic, infant pbw 2501–5000	ing facility c ing facility c ing facility c	ing fac care ing fac care ing fac care	ing fac care ing fac discl	ing fac discl	cil/r-home v	icil/r-home v icil/r-home v	icil/r-home	icil/r-home v	icil/r-home v	cil/r-home v	e visit, new e visit, new	e visit, new	e visit, new	e visit, est p	e visit, est p	e visit, est p	nged servic	nged servicinged service	nged servic	e neaim car e health car	ice care su	ice care su ing fac care	ing fac care	visit, new, i	visit, new, a	visit, new, a	visit, new,	visit, new, ( visit. est. in	visit, est, a	visit, est, aç	visit, est, a	visit, est, a	entive count	entive couns	entive court	entive couns	entive coun:   care, norm	oorn care, n al newborn
Neor Neor Ic, b	Nurs Nurs	N N N S S S S S S S S S S S S S S S S S	Nurs	Nurs	Dom	Dom Dom	Dom	Dom	Dom	Dom	E É OH H	HoH :	E É	Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho H	E E	E OP	Prok	Proc	Prok	E OF	Hosp	Nursi	Nurs	Prev Prev	Prev	Prev Prev	Prev	Prev Prev	Prev	Prev Prev	Prev	Prev	Prev	Prev	Prev.	Prev	Prev   Initia	New
4444	< < < ·	4 4 4	۷ ۷	۷ ۵	< ∢ ⋅	∢ ∢	∢ ላ	< <	∢ ∢	< √	∢ ∢	∢.	۷ ۷	< ⋅	۷ ۵	< <	∢ <	< <	∢ (	n _	ω.		<u>m</u> :	zz	z	zz	z	zz	z	zz	: z :	zz	z	ZZ	zz	: z :	z «	۷ ۷
		60866 60866			99324		99327	99334			99341 99342		99344	99347			99354	9322		99374	99377	99378		99381	99383			99387		99393		99396		99402	99403 99404		99412 99431	99432 99433

Addendum B.—Relative Value Units (RVUs) and Related Information Used in Determining Medicare Payments For 2007—Continued

Global	
Year 2007 Transi- tional Fa- cility Total	2.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fully Im- plement- ed Facil- ity Total	0.0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
Year 2007 Transi- tional Non-Fa- cility Total	NAA N N N N N N N N N N N N N N N N N N
Fully Implemented Non-Facility Total	AAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAA NAAAA NAAAA NAAA NAAAA NAAAA NAAAA NAAA NAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAAA NAAAA NAAAA NAAAA NAAAA NAAAA NAAAAA NAAAAA NAAAA NAAAAAA NAAAAA NAAAA NAAAAAA NAAAAA NAAAAA NAAAAAA NAAAAA NA
Mal-Prac- tice RVUs	00000000000000000000000000000000000000
Year 2007 Transi- tional Fa- cility PE RVUs	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Fully Implemented Facility PE	7 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Year 2007 Transi- tional Non-Fa- cility PE RVUs	AAA 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.
Fully Implemented Non-Facility	A A N O O O O O O O O O O O O O O O O O
Physician Work RVUs	1. 1. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.
Description	Newborn discharge day hosp Attendance, birth Unlisted e&m service Unlisted e&m service CA screen;pelvic/breast exam Prostate ca screening; dre Coloroctal scm; hi risk ind Color catal scm; hi risk ind Colon CA screen;barium enema Colon ca scm high risk direc Glaucoma scm high risk direc Glaucoma scm high risk ind Colon ca scm; barium enema Colon ca scm; barium en
Status	
Mod	26 26 26 26 26 26 26 26 26 26 26 26 26 2
CPT1/ HCPCS ²	99435 99436 99436 99436 99436 99436 99440 99499 601010 60102 60102 60106 60108 601017 60112 60122 60120 60121 60122 60120 60121 60122 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120 60120

											_														_																			=			_	_	_	_	=	
X	₹¥	222	X X	×	XX	×	×	×	X	ž >	{	{ X	X	×	×	×	×	X S	<u> </u>	<	<b>{</b> }	<	< >	X X	{X	X	×	×	000	060	060	XX XX	XXX	×	×	×	×	×	× }	<b>X</b>	ž >	X X	X	X	×	×	X	ž š	žž	ξ×	X	××
2.08	0.70	0.37	S Z	Ž:	AN 2	20.95	17.50	13.75	14.51	L2.01	5.55	10.54	832	7.97	6.59	5.21	16.97	11.84	22.01	0.40	0.00	0.33	0.40	0.53 AN	000	1.89	00.00	0.00	9.94	18.63	30.65		O.ZO NA	0.36	Ϋ́Z	0.67	Y Y	0.24	0.24	9.0 45.0	0.00 VA	2 08	A Z	0.49	0.65	Y Y	0.24	A S	0.52	0.00	0.00	0.00
0.80	0.32	0.40	N A	¥:	N N	18.68	15.77	11.64	13.66	11.07	41.08	9.74	7.38	7.53	60.9	4.64	13.65	10.39	8.80	40.0	20.0	50.0	0.30	12.0 AN	000	1.74	00.00	0.00	9.60	18.51	30.60	1.86	VS.O	0.34	¥ Z	0.55	¥ Z	0.25	0.22	0.32	0.62	2 0	A N	0.44	0.82	Ą Ą	0.23	= \ \ \ \ \ \	0.49 	0.00	0.00	0.00
1.25	0.76	Y S	0.31	0.31	8.39 A A	20.95	17.50	13.75	14.51	12.01	4.03	10.54	832	7.97	6:29	5.21	16.97	11.84	10.32	0.40	0.00	0.00	0.40	0.00	000	689	0.00	0.00	A A	₹ Z	A C	2.56	0.33	0.36	4.47	29.0	0.43	0.24	0.48	9.00	0.60	08.0	1.70	0.86	0.65	0.61	0.24	0.38	1.08 0.38	0.00	0.00	0.00
1.89	0.32	₹ S	0.34	0.34		18.68	15.77	11.64	13.66	11.07	4 4 08	9.74	7.38	7.53	60.9	4.64	13.65	10.39	8.80	40.0 40.0	20.0	00.00	0.00	- 0.0	00.0	1.74	00.00	00.0	ΥZ	₹ Z	Y ;	2.54	5.84	0.34	5.50	0.55	0.30	0.25	0.22	0.32	0.62	- 6	233	1.27	0.82	0.50	0.23	0.27	1.15 	0.00	0.00	0.00
0.02	0.0	0.0	0.0	0.01	0.18	0.42	0.36	0.28	0.34	0.29	0.22	0.23	0.17	0.17	0.14	0.11	0.36	0.29	0.23	5	0.0	5 5	9 5	9 5	000	60.0	00.00	0.00	0.48	1.46	2.06	0.10	0.00	0.02	0.23	0.03	0.05	0.01	0.01	9.0	5.5	- e	0.08	0.01	0.05	0.03	0.01	0.02	0.02	0.00		0
0.54	0.15	1.1	<u>₹</u>	¥:	NA 0.75	7.79	6.53	4.98	4.44		7.02	. t	2 63	2.71	2.21	1.71	0.09	3.44	9.76 00.00	0.00	0.22	- 6	2 0	0.0 V	00.0	0.90	0.00	0.00	2.48	5.25	8.74	0.47	0.0 AN	60.0	Y Z	0.47	Ϋ́	90.0	0.06	0.00	91.0	0 0	2 X	0.11	0.21	Y Y	90:0	A S	0.13	00.0	0.00	00.00
0.35	90:0	4 5	t e	¥:	0.59	5.52	4.80	2.87	3.59	7.67	3.13	5.6	1.69	2.27	1.71	1.14	2.68	1.99	1./3	- 0	9 6	0.03	0.0	0.00 AN	00.00	0.31	0.00	00.00	2.14	5.13	8.69	24.0	) N	0.07	¥ Z	0.35	Y Y	0.07	0.04	0.07	5 Z	0	Z Z	0.06	0.38	Y Y	0.05	A S	0.0	300	0.00	0.00
0.54	0.15	₹ S	0.12	0.12	8.21 NA	7.79	6.53	4.98	4.44	3.61	7.82	+ 6 - 4 - 1	2.63	2.71	2.21	1.71	6.00	3.44	3.19	0.00	0.22	- 6	0.0	0.00	00:0	0.46	00:0	0.00	A A	₹ Z	AN,	N 4	4 33	0.00	4.24	0.47	0.41	0.06	0.30	0.03	0.1 1 0 1	- 0.0	1.62	0.48	0.21	0.41	0.06	0.36	0.69	0.00	0.00	0.00
0.35	0.00	Z Z	0.15	0.15	0.99 VA	5.52	4.80	2.87	3.59	7.67	1.80	5.6	1.69	2.27	1.71	1.14	2.68	1.99	1./3		0.0	0.03	0.00	0.00	00.0	0.31	00:0	0.00	A A	Y :	ΑΥ,	01.1	5.34	0.07	5.27	0.35	0.28	0.07	0.04	0.07	0.13	0.19	2.23	0.89	0.38	0:30	0.05	0.25	0.76	0.00	0.00	00:00
0.61						12.74	10.61	8.49	9.73	8.1 	φ. 9.0 9.0 9.0	06.9	2.52	5.09	4.24	3.39	10.61	8.11	06.90	4.24	0.00	0.23	77.0	+ O	00.0	23.5	00.00	00.00	6.98	11.92	19.85	1.34	0.16	0.25	00.0	0.17	0.00	0.17	0.17	92.0	0.48		00.0	0.37	0.42	0.17	0.17	0.00	78.0	30.0	0.00	00.00
P	Group MNT 2 or more 30 mins				Recon, CTA for surg plan	Vrs	yrs	S	related svs 4+mo 2-11yr	ESRD relate svs 2–3 mo 2–11y	ESRD related svs 1 mon 2–11ly	0.1	^6	related svs 4+mo 20+yrs	ESRD related svs 2-3 mo 20+y	A	2	-11y	ESKD related svs nom mo12-19	- VO+	zyr		٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠٠	0							Laparotomy islet cell transp			SS	SS			0.1	1	01-	0		Ultrasound exam AAA screen		/ss/		Cardiokymography		Obtaining screen pap smear	ş	2	
nitial dxpacted wax md	or more 30 m	ardiac cath	tend for press	r than wound	or surg plan	svc 4+mo < 2	svc 2-3mo <2	svc 1 vst <2yı	svs 4+mo 2–1	vs 2-3 mo z-	SVS 1 mon 2-	svs 4+o svs 2-3mo/12	svs 1vis/12-1	svs 4+mo 20+	svs 2-3 mo 2	svs 1visit 20+	s home undr	vs home mo z	svs hom mot	svs nome mo	vs nome/dy <	ome/day/ z=1	ome/dy 20±vr	tx for illers	nmiinoglobulir	ation preelecti	ura com. first	g fractx 2-5	islet celltrans	slet cell trans	et cell transp	/e exam	aspirate abiop in hemo acces	d hemo acces	d hemo acces	prevent exam	r initial prev.	& report preve	quired tor PMI	o counseing 3	o counseling >	am AAA seree	am AAA scree	nonitoring	smear by phy	арһу	aphy	aphy	en pap smear	ay equipinein Radioelemen	able x-ray	x-ray multipl
PET imaging initial dxRemoval of impacted wax md	Group MNT 2	Renal angio, c	Elec stim unat	Elec stim othe	Arthro loose t	ESRD related	ESRD related svc 2–3mo <2yrs	ESRD related svc 1 vst <2yrs	ESRD related	ESHU relate s	ESHU related	ESRD related svs 4+ III0 1z=19	ESRD related	ESRD related svs 4+mo 20+yrs	ESRD related	ESRD related svs 1visit 20+y	ESD related svs home undr 2	ESRDrelatedsvs home mo 2–11y	ESRD related	ESDD volote and home and surface	ESED soleta bomo/doss/ 0 115%	ESDD roloto bomo/dv.10 10v.r	ESBD relate home/dv 20±vrs	Estromagntic tx for ulcars	Preadmin IV immunoglobulin	Hospice evaluation preelecti	Robot lin-radsurg com. first	Robt lin-radsurg fractx 2-5	Percutaneous islet celltrans	Laparoscopy islet cell trans	Laparotomy is	Initial preventive exam	Vessel manning hemo access	Vessel mapping hemo access	Vessel mapping hemo access	EKG for initial prevent exam	EKG tracing for initial prev	EKG interpret & report preve	MD service required for PMD	Smoke/tobacco counseing 3-10	Smoke/tobacco counseling >10	Ultrasound exam AAA screen	Ultrasound ex	Visit for drug monitoring	Screening pap	Cardiokymogr	Cardiokymogr	Cardiokymography	Obtaining screen pap smear	Set up port xray equipment	Transport portable x-ray	Transport port x-ray multipl
Zď						. ∢	<	< -	⋖・	∢ <	< <	٠	. ⊲	<	<	<	⋖・	< •	< <	( <	<b>.</b>	( <	[ ⊲	( ⊲	( C	× د	( ()	O	<	⋖ .	< •	< <	. ⊲	. ⋖	< <	<	<	⋖ .	< <	∢ <	< <	( ⊲	. ∢	. σ	4	<	۷.	۰ ۵	⋖ <	₹ C	 د د	O
				-			-	-	-	_			_	_	-	-	:		_	_	_			_	_			-	-	-	-						-	-							_	-		i				
26	: : 	:		-			:	-	-		-	-		_	:	:	:	:		-	_	:	:	_				-	-	:	:	-	:	26	Ĕ	:	-	-	:	-	:	26	12	. : 		-	26		:	-		
	G0271	G0275			G0288		G0309	•	G0311	•	G0313	G0315			G0318	G0319	G0320	G0321	G0322	•	•	•	G0350	•				G0340		G0342	G0343	G0344	G0365	G0365	G0365	G0366		G0368	G03/2		GU3/6			M0064	P3001	Q0035	Q0035	Q0035	Q0091 D0082	Q30092		
`	_		_	_ '		_	-	_				_	_	_	_	_	- '	- '	_			_		_	_	_	_	-	_	_	- '	•	_	_	_	_	_		- `			_	_	_	_	_	- '	- `		_	_	_

¹ CPT codes and descriptors only are copyright 2005 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. ² Copyright 2005 American Dental Association. All rights reserved.

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PERC RECOMMENDATIONS ON PE DIRECT COST INPUTS—Continued

CPT Codes	Short descriptor	CPT Codes	Short descriptor	CPT Codes	Short descriptor
00100	Anesth, salivary gland	00563	Anesth, heart surg w/arrest	00930	Anesth, testis suspension
00102	Anesth, repair of cleft lip	00566	Anesth, cabg w/o pump	00932	Anesth, amputation of penis
00103	Anesth, blepharoplasty	00580	Anesth, heart/lung transpint	00934	Anesth, penis, nodes removal
00104	Anesth, electroshock	00600	Anesth, spine, cord surgery	00936	Anesth, penis, nodes removal
00120	Anesth, ear surgery	00604	Anesth, sitting procedure	00938	Anesth, insert penis device
00124	Anesth, ear exam	00620	Anesth, spine, cord surgery	00940	Anesth, vaginal procedures
00126	Anesth, tympanotomy	00622	Anesth, removal of nerves	00942	Anesth, surg on vag/urethral
00140	Anesth, procedures on eye	00630	Anesth, spine, cord surgery	00944	Anesth, vaginal hysterectomy
00142	Anesth, lens surgery	00632	Anesth, removal of nerves	00948	Anesth, repair of cervix
00144	Anesth, corneal transplant	00634	Anesth for chemonucleolysis	00950	Anesth, vaginal endoscopy
00145	Anesth, vitreoretinal surg	00635	Anesth, lumbar puncture	00952	Anesth, hysteroscope/graph
00147	Anesth, iridectomy	00640	Anesth, spine manipulation	01112	Anesth, bone aspirate/bx
00147	Anesth, eye exam	00670	Anesth, spine, cord surgery	01112	Anesth, pelvis surgery
00160		00700		01130	
00162	Anesth, nose/sinus surgery Anesth, nose/sinus surgery	00700	Anesth, abdominal wall surg	01140	Anesth, body cast procedure
00164			Anesth, for liver biopsy		Anesth, amputation at pelvis
	Anesth, biopsy of nose	00730	Anesth, abdominal wall surg	01150 01160	Anesth, pelvic tumor surgery
00170	Anesth, procedure on mouth	00740	Anesth, upper gi visualize		Anesth, pelvis procedure
00172	Anesth, cleft palate repair	00750	Anesth, repair of hernia	01170	Anesth, pelvis surgery
00174	Anesth, pharyngeal surgery	00752	Anesth, repair of hernia	01173	Anesth, fx repair, pelvis
00176	Anesth, pharyngeal surgery	00754	Anesth, repair of hernia	01180	Anesth, pelvis nerve removal
00190	Anesth, face/skull bone surg	00756	Anesth, repair of hernia	01190	Anesth, pelvis nerve removal
00192	Anesth, facial bone surgery	00770	Anesth, blood vessel repair	01200	Anesth, hip joint procedure
00210	Anesth, open head surgery	00790	Anesth, surg upper abdomen	01202	Anesth, arthroscopy of hip
00212	Anesth, skull drainage	00792	Anesth, hemorr/excise liver	01210	Anesth, hip joint surgery
00214	Anesth, skull drainage	00794	Anesth, pancreas removal	01212	Anesth, hip disarticulation
00215	Anesth, skull repair/fract	00796	Anesth, for liver transplant	01214	Anesth, hip arthroplasty
00216	Anesth, head vessel surgery	00797	Anesth, surgery for obesity	01215	Anesth, revise hip repair
00218	Anesth, special head surgery	00800	Anesth, abdominal wall surg	01220	Anesth, procedure on femur
00220	Anesth, intrcrn nerve	00802	Anesth, fat layer removal	01230	Anesth, surgery of femur
00222	Anesth, head nerve surgery	00810	Anesth, low intestine scope	01232	Anesth, amputation of femur
00300	Anesth, head/neck/ptrunk	00820	Anesth, abdominal wall surg	01234	Anesth, radical femur surg
00320	Anesth, neck organ, 1 & over	00830	Anesth, repair of hernia	01250	Anesth, upper leg surgery
00322	Anesth, biopsy of thyroid	00832	Anesth, repair of hernia	01260	Anesth, upper leg veins surg
00326	Anesth, larynx/trach, < 1 yr	00834	Anesth, hernia repair < 1 yr	01270	Anesth, thigh arteries surg
00350	Anesth, neck vessel surgery	00836	Anesth hernia repair preemie	01272	Anesth, femoral artery surg
00352	Anesth, neck vessel surgery	00840	Anesth, surg lower abdomen	01274	Anesth, femoral embolectomy
00400	Anesth, skin, ext/per/atrunk	00842	Anesth, amniocentesis	01320	Anesth, knee area surgery
00402	Anesth, surgery of breast	00844	Anesth, pelvis surgery	01340	Anesth, knee area procedure
00404	Anesth, surgery of breast	00846	Anesth, hysterectomy	01360	Anesth, knee area surgery
00406	Anesth, surgery of breast	00848	Anesth, pelvic organ surg	01380	Anesth, knee joint procedure
00410	Anesth, correct heart rhythm	00851	Anesth, tubal ligation	01382	Anesth, dx knee arthroscopy
00450	Anesth, surgery of shoulder	00860		01390	Anesth, knee area procedure
00452	Anesth, surgery of shoulder	00862		01392	Anesth, knee area surgery
00454	Anesth, collar bone biopsy	00864		01400	Anesth, knee joint surgery
00470	Anesth, removal of rib	00865		01402	Anesth, knee arthroplasty
00472	Anesth, chest wall repair	00866	Anesth, removal of adrenal	01404	Anesth, amputation at knee
00474	Anesth, surgery of rib(s)	00868	Anesth, kidney transplant	01420	Anesth, knee joint casting
00500 00520	Anesth, esophageal surgery Anesth, chest procedure	00870 00872	Anesth, bladder stone surg Anesth kidney stone destruct	01430 01432	Anesth, knee veins surgery
	Anesth, chest lining biopsy				Anesth, knee vessel surg
00522		00873 00880	Anesth kidney stone destruct	01440	Anesth, knee arteries surg
00524	Anesth, chest drainage	00882	Anesth, abdomen vessel surg	01442	Anesth, knee artery surg
00528	Anesth, chest partition view		Anesth, major vein ligation	01444	Anesth, knee artery repair
00529	Anesth, chest partition view	00902	Anesth, anorectal surgery	01462	Anesth, lower leg procedure
00530	Anesth, pacemaker insertion	00904	Anesth, perineal surgery	01464	Anesth, ankle/ft arthroscopy
00532	Anesth, vascular access	00906	Anesth, removal of vulva	01470 01472	Anesth, lower leg surgery
00534	Anesth, cardioverter/defib	00908	Anesth, removal of prostate	-	Anesth, achilles tendon surg
00537	Anesth, cardiac electrophys	00910	Anesth, bladder surgery	01474	Anesth, lower leg surgery
00539	Anesth, trach-bronch reconst	00912	Anesth, bladder tumor surg	01480	Anesth, lower leg bone surg
00540	Anesth, chest surgery	00914	Anesth, removal of prostate	01482	Anesth, radical leg surgery
00541	Anesth, one lung ventilation	00916	Anesth, bleeding control	01484	Anesth, lower leg revision
00542	Anesth, release of lung	00918	Anesth, stone removal	01486	Anesth, ankle replacement
00546	Anesth, lung, chest wall surg	00920	Anesth, genitalia surgery	01490	Anesth, lower leg casting
00548	Anesth, trachea, bronchi surg	00921	Anesth, vasectomy	01500	Anesth, leg arteries surg
00550	Anesth, sternal debridement	00922	Anesth, sperm duct surgery	01502	Anesth, lwr leg embolectomy
00560	Anesth, heart surg w/o pump	00924	Anesth, testis exploration	01520	Anesth, lower leg vein surg
00561	Anesth, heart surg < age 1	00926	Anesth, removal of testis	01522	Anesth, lower leg vein surg
00562	Anesth, heart surg w/pump	00928	Anesth, removal of testis	01610	Anesth, surgery of shoulder

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PERC RECOMMENDATIONS ON PE DIRECT COST INPUTS—Continued

CPT	Short descriptor	CPT	Short descriptor	CPT	Short descriptor
Codes	Short descriptor	Codes	Short descriptor	Codes	Short descriptor
0.1.000	<b>A</b>	0.1.000	A	05110	D
01620	Anesth, shoulder procedure	01992	Anesth, n block/inj, prone	25116	Remove wrist/forearm lesion
01622	Anes dx shoulder arthroscopy	01995	Regional anesthesia limb	25118	Excise wrist tendon sheath
01630	Anesth, surgery of shoulder	01996	Hosp manage cont drug admin	25119	Partial removal of ulna
01632	Anesth, surgery of shoulder	01999	Unlisted anesth procedure	25120	Removal of forearm lesion
01634	Anesth, shoulder joint amput	23500	Treat dialogation (froature	25125	Remove/graft forearm lesion
01636	Anesth, forequarter amput	23680	Treat dislocation/fracture	25126	Remove/graft forearm lesion
01638	Anesth, shoulder replacement	24130	Removal of head of radius	25130	Removal of wrist lesion
01650 01652	Anesth, shoulder artery surg	24134 24136	Removal of arm bone lesion	25135 25136	Remove & graft wrist lesion
01654	Anesth, shoulder vessel surg	24138	Remove radius bone lesion Remove elbow bone lesion	25145	Remove & graft wrist lesion Remove forearm bone lesion
01656	Anesth, shoulder vessel surg Anesth, arm-leg vessel surg	24140	Partial removal of arm bone	25150	Partial removal of ulna
01670	Anesth, shoulder vein surg	24145	Partial removal of radius	25151	Partial removal of radius
01680	Anesth, shoulder casting	24147	Partial removal of elbow	25170	Extensive forearm surgery
01682	Anesth, airplane cast	24495	Decompression of forearm	25210	Removal of wrist bone
01710	Anesth, elbow area surgery	24500	Treat humerus fracture	25215	Removal of wrist bones
01712	Anesth, uppr arm tendon surg	24500	Treat humerus fracture	25230	Partial removal of radius
01714	Anesth, uppr arm tendon surg	24505	Treat humerus fracture	25240	Partial removal of ulna
01716	Anesth, biceps tendon repair	24515	Treat humerus fracture	25248	Remove forearm foreign body
01730	Anesth, uppr arm procedure	24516	Treat humerus fracture	25260	Repair forearm tendon/muscle
01732	Anesth, dx elbow arthroscopy	24530	Treat humerus fracture	25263	Repair forearm tendon/muscle
01740	Anesth, upper arm surgery	24535	Treat humerus fracture	25265	Repair forearm tendon/muscle
01742	Anesth, humerus surgery	24538	Treat humerus fracture	25270	Repair forearm tendon/muscle
01744	Anesth, humerus repair	24545	Treat humerus fracture	25272	Repair forearm tendon/muscle
01756	Anesth, radical humerus surg	24546	Treat humerus fracture	25274	Repair forearm tendon/muscle
01758	Anesth, humeral lesion surg	24560	Treat humerus fracture	25280	Revise wrist/forearm tendon
01760	Anesth, elbow replacement	24565	Treat humerus fracture	25290	Incise wrist/forearm tendon
01770	Anesth, uppr arm artery surg	24566	Treat humerus fracture	25295	Release wrist/forearm tendon
01772	Anesth, uppr arm embolectomy	24575	Treat humerus fracture	25300	Fusion of tendons at wrist
01780	Anesth, upper arm vein surg	24576	Treat humerus fracture	25301	Fusion of tendons at wrist
01782	Anesth, uppr arm vein repair	24577	Treat humerus fracture	25310	Transplant forearm tendon
01810	Anesth, lower arm surgery	24579	Treat humerus fracture	25312	Transplant forearm tendon
01820	Anesth, lower arm procedure	24582	Treat humerus fracture	25315	Revise palsy hand tendon(s)
01829	Anesth, dx wrist arthroscopy	24586	Treat elbow fracture	25316	Revise palsy hand tendon(s)
01830	Anesth, lower arm surgery	24587	Treat elbow fracture	25320	Repair/revise wrist joint
01832	Anesth, wrist replacement	24600	Treat elbow dislocation	25335	Realignment of hand
01840	Anesth, lwr arm artery surg	24605	Treat elbow dislocation	25337	Reconstruct ulna/radioulnar
01842	Anesth, lwr arm embolectomy	24615	Treat elbow dislocation	25350	Revision of radius
01844	Anesth, vascular shunt surg	24620	Treat elbow fracture	25355	Revision of radius
01850	Anesth, lower arm vein surg	24635	Treat elbow fracture	25360	Revision of ulna
01852	Anesth, lwr arm vein repair	24640	Treat elbow dislocation	25365	Revise radius & ulna
01860	Anesth, lower arm casting	24650	Treat radius fracture	25370	Revise radius or ulna
01905	Anes, spine inject, x-ray/re	24655	Treat radius fracture	25375	Revise radius & ulna
01916	Anesth, dx arteriography	24665	Treat radius fracture	25390	Shorten radius or ulna
01920	Anesth, catheterize heart	24666	Treat radius fracture	25391	Lengthen radius or ulna
01922	Anesth, cat or mri scan	24670	Treat ulnar fracture	25392	Shorten radius & ulna
01924	Anes, ther interven rad, art	24675	Treat ulnar fracture	25393	Lengthen radius & ulna
01925	Anes, ther interven rad, car	24685	Treat ulnar fracture	25400	Repair radius or ulna
01926	Anes, tx interv rad hrt/cran	25000	Incision of tendon sheath	25405	Repair/graft radius or ulna
01930	Anes, ther interven rad, vei	25020	Decompress forearm 1 space	25415	Repair radius & ulna
01931	Anes, ther interven rad, tip	25023	Decompress forearm 1 space	25420	Repair/graft radius & ulna
01932	Anes, tx interv rad, th vein	25028	Drainage of forearm lesion	25425	Repair/graft radius or ulna
01933	Anesth hum less 4 persent	25031	Drainage of forearm bursa	25426	Repair/graft radius & ulna
01951	Anesth, burn, less 4 percent	25035	Treat forearm bone lesion	25440	Repair/graft wrist bone
01952 01953	Anesth, burn, 4–9 percent	25040 25066	Explore/treat wrist joint	25450 25455	Revision of wrist joint Revision of wrist joint
01958	Anesth, burn, each 9 percent Anesth, antepartum manipul	25075	Biopsy forearm soft tissues Removal forearm lesion subcu	25490	Reinforce radius
01960	Anesth, vaginal delivery	25076	Removal forearm lesion deep	25491	Reinforce ulna
01961	Anesth, cs delivery	25077	Remove tumor, forearm/wrist	25492	Reinforce radius and ulna
01962	Anesth, emer hysterectomy	25085	Incision of wrist capsule	25500	Treat fracture of radius
01963	Anesth, cs hysterectomy	25100	Biopsy of wrist joint	25505	Treat fracture of radius
01965	Anesth, inc/missed ab proc	25100	Explore/treat wrist joint	25515	Treat fracture of radius
01966	Anesth, induced ab procedure	25105	Remove wrist joint lining	25520	Treat fracture of radius
01967	Anesth/analg, vag delivery	25107	Remove wrist joint uning	25525	Treat fracture of radius
01968	Anes/analg cs deliver add-on	25110	Remove wrist tendon lesion	25526	Treat fracture of radius
01969	Anesth/analg cs hyst add-on	25111	Remove wrist tendon lesion	25530	Treat fracture of ulna
01990	Support for organ donor	25112	Reremove wrist tendon lesion	25535	Treat fracture of ulna
01991		25115		25545	

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PERC RECOMMENDATIONS ON PE DIRECT COST INPUTS—Continued

CPT Codes	Short descriptor	CPT Codes	Short descriptor	CPT Codes	Short descriptor
25560	Treat fracture radius & ulna	26445	Release hand/finger tendon	26706	Pin knuckle dislocation
25565	Treat fracture radius & ulna	26449	Release forearm/hand tendon	26715	Treat knuckle dislocation
25574	Treat fracture radius & ulna	26450	Incision of palm tendon	26720	Treat finger fracture, each
25575	Treat fracture radius/ulna	26455	Incision of finger tendon	26725	Treat finger fracture, each
25600	Treat fracture radius/ulna	26460	Incise hand/finger tendon	26727	Treat finger fracture, each
25605	Treat fracture radius/ulna	26471	Fusion of finger tendons	26735	Treat finger fracture, each
25611	Treat fracture radius/ulna	26474	Fusion of finger tendons	26740	Treat finger fracture, each
25620		26476		26742	Treat finger fracture, each
	Treat tracture radius/ulna		Tendon lengthening	26742	Treat finger fracture, each
25622	Treat wrist bone fracture	26477	Tendon shortening		Treat finger fracture, each
25624	Treat wrist bone fracture	26478	Lengthening of hand tendon	26750	Treat finger fracture, each
25628	Treat wrist bone fracture	26479	Shortening of hand tendon	26755	Treat finger fracture, each
25630	Treat wrist bone fracture	26480	Transplant hand tendon	26756	Pin finger fracture, each
25635	Treat wrist bone fracture	26483	Transplant/graft hand tendon	26765	Treat finger fracture, each
25645	Treat wrist bone fracture	26485	Transplant palm tendon	26770	Treat finger dislocation
25650	Treat wrist bone fracture	26489	Transplant/graft palm tendon	26775	Treat finger dislocation
25651	Pin ulnar styloid fracture	26490	Revise thumb tendon	26776	Pin finger dislocation
25652	Treat fracture ulnar styloid	26492	Tendon transfer with graft	26785	Treat finger dislocation
25660	Treat wrist dislocation	26494	Hand tendon/muscle transfer	26820	Thumb fusion with graft
25670	Treat wrist dislocation	26496	Revise thumb tendon	26841	Fusion of thumb
25671	Pin radioulnar dislocation	26497	Finger tendon transfer	26842	Thumb fusion with graft
25675	Treat wrist dislocation	26498	Finger tendon transfer	26843	Fusion of hand joint
25676	Treat wrist dislocation	26499	Revision of finger	26844	Fusion/graft of hand joint
25680	Treat wrist fracture	26500	Hand tendon reconstruction	26850	Fusion of knuckle
25685	Treat wrist fracture	26502	Hand tendon reconstruction	26852	Fusion of knuckle with graft
25690	Treat wrist dislocation	26504	Hand tendon reconstruction	26860	Fusion of finger joint
25695	Treat wrist dislocation	26508		26862	Fusion/graft of finger joint
			Release thumb contracture		
25800	Fusion of wrist joint	26510	Thumb tendon transfer	26910	Amputate metacarpal bone
25805	Fusion/graft of wrist joint	26516	Fusion of knuckle joint	26951	Amputation of finger/thumb
25810	Fusion/graft of wrist joint	26517	Fusion of knuckle joints	26952	Amputation of finger/thumb
25820	Fusion of hand bones	26518	Fusion of knuckle joints	27000	Incision of hip tendon
25825	Fuse hand bones with graft	26520	Release knuckle contracture	27001	Incision of hip tendon
25830	Fusion, radioulnar jnt/ulna	26525	Release finger contracture	27003	Incision of hip tendon
25900	Amputation of forearm	26536	Revise/implant finger joint	27005	Incision of hip tendon
25905	Amputation of forearm	26540	Repair hand joint	27006	Incision of hip tendons
25907	Amputation follow-up surgery	26541	Repair hand joint with graft	27025	Incision of hip/thigh fascia
25909	Amputation follow-up surgery	26542	Repair hand joint with graft	27030	Drainage of hip joint
25915	Amputation of forearm	26545	Reconstruct finger joint	27033	Exploration of hip joint
25920	Amputate hand at wrist	26548	Reconstruct finger joint	27035	Denervation of hip joint
25922	Amputate hand at wrist	26550	Construct thumb replacement	27041	Biopsy of soft tissues
25924	Amputation follow-up surgery	26555	Positional change of finger	27048	Remove hip/pelvis lesion
25927	Amputation of hand	26560	Repair of web finger	27049	Remove tumor, hip/pelvis
25929	Amputation follow-up surgery	26561	Repair of web finger	27050	Biopsy of sacroiliac joint
25931	Amputation follow-up surgery	26562	Repair of web finger	27052	Biopsy of hip joint
26350	Repair finger/hand tendon	26565	Correct metacarpal flaw	27054	Removal of hip joint lining
26352	Repair/graft hand tendon	26567	Correct finger deformity	27060	Removal of ischial bursa
26356	Repair finger/hand tendon	26568	Lengthen metacarpal/finger	27062	Remove femur lesion/bursa
26357	Repair finger/hand tendon	26580	Repair hand deformity	27065	Removal of hip bone lesion
26358	Repair/graft hand tendon	26590	Repair finger deformity	27066	Removal of hip bone lesion
26370	Repair finger/hand tendon	26591	Repair muscles of hand	27067	Remove/graft hip bone lesion
26372	Repair/graft hand tendon	26593	Release muscles of hand	27075	Extensive hip surgery
26373	Repair finger/hand tendon	26596	Excision constricting tissue	27076	Extensive hip surgery
26390	Revise hand/finger tendon	26600	Treat metacarpal fracture	27077	Extensive hip surgery
26392	Repair/graft hand tendon	26605	Treat metacarpal fracture	27078	Extensive hip surgery
26410	Repair hand tendon	26607	Treat metacarpal fracture	27079	Extensive hip surgery
26412	Repair/graft hand tendon	26608	Treat metacarpal fracture	27080	Removal of tail bone
26415	Excision, hand/finger tendon	26615	Treat metacarpal fracture	27087	Remove hip foreign body
26416	Graft hand or finger tendon	26641	Treat thumb dislocation	27202	Treat tail bone fracture
26418	Repair finger tendon	26645	Treat thumb fracture	27310	Exploration of knee joint
26420	Repair/graft finger tendon	26650	Treat thumb fracture	27315	Partial removal, thigh nerve
26426	Repair finger/hand tendon	26665	Treat thumb fracture	27320	Partial removal, thigh nerve
26428	Repair/graft finger tendon	26670	Treat hand dislocation	27324	Biopsy, thigh soft tissues
26432	Repair finger tendon	26675	Treat hand dislocation	27328	Removal of thigh lesion
26433		26676	Pin hand dislocation	27329	
	Repair finger tendon				Remove tumor, thigh/knee
26434	Repair/graft finger tendon	26685	Treat hand dislocation	27330	Biopsy, knee joint lining
26437	Realignment of tendons	26686	Treat hand dislocation	27331	Explore/treat knee joint
26440	Release palm/finger tendon	26700	Treat knuckle dislocation	27332	Removal of knee cartilage
26442	Release palm & finger tendon	26705	Treat knuckle dislocation	27333	Removal of knee cartilage

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PERC RECOMMENDATIONS ON PE DIRECT COST INPUTS—Continued

CPT	Chart descriptor	CPT	Chart descriptor	CPT	Chart dassrints
Codes	Short descriptor	Codes	Short descriptor	Codes	Short descriptor
27334	Remove knee joint lining	27646	Extensive lower leg surgery	27886	Amputation follow-up surgery
27335	Remove knee joint lining	27647	Extensive ankle/heel surgery	27888	Amputation of foot at ankle
27340	Removal of kneecap bursa	27650	Repair achilles tendon	27889	Amputation of foot at ankle
27345	Removal of knee cyst	27652	Repair/graft achilles tendon	27892	Decompression of leg
27350	Removal of kneecap	27654	Repair of achilles tendon	27893	Decompression of leg
27355	Remove femur lesion	27675	Repair lower leg tendons	27894	Decompression of leg
27356	Remove femur lesion/graft	27676	Repair lower leg tendons	28030	Removal of foot nerve
27357	Remove femur lesion/graft	27680	Release of lower leg tendon	28102	Remove/graft foot lesion
27365	Extensive leg surgery	27681	Release of lower leg tendons	28106	Remove/graft foot lesion
27380	Repair of kneecap tendon	27687	Revision of calf tendon	28130	Removal of ankle bone
27381	Repair/graft kneecap tendon	27690	Revise lower leg tendon	28309	Incision of metatarsals
27385	Repair of thigh muscle	27691	Revise lower leg tendon	28320	Repair of foot bones
27386	Repair/graft of thigh muscle	27695	Repair of ankle ligament	28400	Treatment of heel fracture
27455	Realignment of knee	27696	Repair of ankle ligaments	28405	Treatment of heel fracture
27500	Treatment of thigh fracture	27698	Repair of ankle ligament	28406	Treatment of heel fracture
27501	Treatment of thigh fracture	27705	Incision of tibia	28415	Treat heel fracture
27502	Treatment of thigh fracture	27707	Incision of fibula	28420	Treat/graft heel fracture
27506	Treatment of thigh fracture	27709	Incision of tibia & fibula	28430	Treatment of ankle fracture
27507	Treatment of thigh fracture	27712	Realignment of lower leg	28435	Treatment of ankle fracture
27508	Treatment of thigh fracture	27715	Revision of lower leg	28436	Treatment of ankle fracture
27509	Treatment of thigh fracture	27720	Repair of tibia	28445	Treat ankle fracture
27510	Treatment of thigh fracture	27722	Repair/graft of tibia	28450	Treat midfoot fracture, each
27511	Treatment of thigh fracture	27724	Repair/graft of tibia	28455	Treat midfoot fracture, each
27513	Treatment of thigh fracture	27725	Repair of lower leg	28456	Treat midfoot fracture
27514	Treatment of thigh fracture	27727	Repair of lower leg	28465	Treat midfoot fracture, each
27516	Treat thigh fx growth plate	27734	Repair lower leg epiphyses	28470	Treat metatarsal fracture
27517	Treat thigh fx growth plate	27745	Reinforce tibia	28475	Treat metatarsal fracture
27519	Treat thigh fx growth plate	27750	Treatment of tibia fracture	28476	Treat metatarsal fracture
27520	Treat kneecap fracture	27752	Treatment of tibia fracture	28485	Treat metatarsal fracture
27524	Treat kneecap fracture	27756	Treatment of tibia fracture	28490	Treat hig toe fracture
27530	Treat knee fracture	27758	Treatment of tibia fracture	28495	Treat big toe fracture
27532	Treat knee fracture	27759	Treatment of tibia fracture	28496	
27535	Treat knee fracture	27760			Treat big toe fracture
			Treatment of ankle fracture	28505	Treat big toe fracture
27536	Treat knee fracture	27762	Treatment of ankle fracture	28510	Treatment of toe fracture
27538	Treat knee fracture(s)	27766	Treatment of ankle fracture	28515	Treat to free ture
27540	Treat knee fracture	27780	Treatment of fibula fracture	28525	Treat toe fracture
27550	Treat knee dislocation	27781	Treatment of fibula fracture	28530	Treat sesamoid bone fracture
27552	Treat knee dislocation	27784	Treatment of fibula fracture	28531	Treat sesamoid bone fracture
27556	Treat knee dislocation	27786	Treatment of ankle fracture	28540	Treat foot dislocation
27557	Treat knee dislocation	27788	Treatment of ankle fracture	28545	Treat foot dislocation
27558	Treat knee dislocation	27792	Treatment of ankle fracture	28546	Treat foot dislocation
27560	Treat kneecap dislocation	27808	Treatment of ankle fracture	28555	Repair foot dislocation
27562	Treat kneecap dislocation	27810	Treatment of ankle fracture	28570	Treat foot dislocation
27566	Treat kneecap dislocation	27814	Treatment of ankle fracture	28575	Treat foot dislocation
27580	Fusion of knee	27816	Treatment of ankle fracture	28576	Treat foot dislocation
27590	Amputate leg at thigh	27818	Treatment of ankle fracture	28585	Repair foot dislocation
27591	Amputate leg at thigh	27822	Treatment of ankle fracture	28600	Treat foot dislocation
27592	Amputate leg at thigh	27823	Treatment of ankle fracture	28605	Treat foot dislocation
27594	Amputation follow-up surgery	27824	Treat lower leg fracture	28606	Treat foot dislocation
27596	Amputation follow-up surgery	27825	Treat lower leg fracture	28615	Repair foot dislocation
27598	Amputate lower leg at knee	27826	Treat lower leg fracture	28630	Treat toe dislocation
27600	Decompression of lower leg	27827	Treat lower leg fracture	28635	Treat toe dislocation
27601	Decompression of lower leg	27828	Treat lower leg fracture	28636	Treat toe dislocation
27602	Decompression of lower leg	27829	Treat lower leg joint	28645	Repair toe dislocation
27607	Treat lower leg bone lesion	27830	Treat lower leg dislocation	28660	Treat toe dislocation
27610	Explore/treat ankle joint	27831	Treat lower leg dislocation	28665	Treat toe dislocation
27612	Exploration of ankle joint	27832	Treat lower leg dislocation	28666	Treat toe dislocation
27615	Remove tumor, lower leg	27840	Treat ankle dislocation	28675	Repair of toe dislocation
27620	Explore/treat ankle joint	27842	Treat ankle dislocation	28705	Fusion of foot bones
27625	Remove ankle joint lining	27846	Treat ankle dislocation	28715	Fusion of foot bones
27626	Remove ankle joint lining	27848	Treat ankle dislocation	28725	Fusion of foot bones
27635	Remove lower leg bone lesion	27870	Fusion of ankle joint, open	28730	Fusion of foot bones
27637	Remove/graft leg bone lesion	27871	Fusion of tibiofibular joint	28735	Fusion of foot bones
27638	Remove/graft leg bone lesion	27880	Amputation of lower leg	28737	Revision of foot bones
27640	Partial removal of tibia	27881	Amputation of lower leg	29000	Application of body cast
27641	Partial removal of fibula	27882	Amputation of lower leg	29010	Application of body cast
27645		27884	Amputation follow-up surgery	29015	Application of body cast
			,		F F

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PERC RECOMMENDATIONS ON PE DIRECT COST INPUTS—Continued

CPT Codes	Short descriptor	CPT Codes	Short descriptor	CPT Codes	Short descriptor
29020	Application of body cast	32120	Re-exploration of chest	33788	Revision of pulmonary artery
29025	Application of body cast	32124	Explore chest free adhesions	33800	Aortic suspension
29035	Application of body cast	32140	Removal of lung lesion(s)	33802	Repair vessel defect
29040	Application of body cast	32141	Remove/treat lung lesions	33803	Repair vessel defect
29044	Application of body cast	32150	Removal of lung lesion(s)	33813	Repair septal defect
29046	Application of body cast	32151	Remove lung foreign body	33814	Repair septal defect
29049	Application of figure eight	32160	Open chest heart massage	33820	Revise major vessel
29055	Application of shoulder cast	32200	Drain, open, lung lesion	33822	Revise major vessel
				22040	
29058	Application of shoulder cast	33015	Incision of heart sac		Remove aorta constriction
29065	Application of long arm cast	33414	Repair of aortic valve	33845	Remove aorta constriction
29075	Application of forearm cast	33415	Revision, subvalvular tissue		Remove aorta constriction
29085	Apply hand/wrist cast	33417	Repair of aortic valve	33852	Repair septal defect
29086	Apply finger cast	33468	Revision of tricuspid valve	33853	Repair septal defect
29105	Apply long arm splint	33470	Revision of pulmonary valve	33917	Repair pulmonary artery
29125	Apply forearm splint	33471	Valvotomy, pulmonary valve	33920	Repair pulmonary atresia
29126	Apply forearm splint	33503	Coronary artery graft		Transect pulmonary artery
29130	Application of finger splint	33504	Coronary artery graft		Removal of artery clot
29131	Application of finger splint	33505	Repair artery w/tunnel		Removal of artery clot
29200	Strapping of chest	33506	Repair artery, translocation		Removal of artery clot
29220	Strapping of low back	33600	Closure of valve		Removal of arm artery clot
29240	Strapping of shoulder	33602	Closure of valve		Removal of artery clot
29260		33606		24201	Removal of leg artery clot
	Strapping of elbow or wrist		Anastomosis/artery-aorta	04404	Demoval of vair elet
29280	Strapping of hand or finger	33608	Repair anomaly w/conduit		Removal of vein clot
29305	Application of hip cast	33610	Repair by enlargement	34421	
29325	Application of hip casts	33611	Repair double ventricle	34451	Removal of vein clot
29345	Application of long leg cast	33612	Repair double ventricle	34471	Removal of vein clot
29355	Application of long leg cast	33615	Repair, modified fontan	34490	Removal of vein clot
29358	Apply long leg cast brace	33617	Repair single ventricle	34501	Repair valve, femoral vein
29365	Application of long leg cast	33619	Repair single ventricle	34502	Reconstruct vena cava
29405	Apply short leg cast	33645	Revision of heart veins		Transposition of vein valve
29425	Apply short leg cast	33647	Repair heart septum defects	34520	Cross-over vein graft
29435	Apply short leg cast	33660	Repair of heart defects	34530	Leg vein fusion
29440	Addition of walker to cast	33665	Repair of heart defects	35001	Repair defect of artery
29445	Apply rigid leg cast	33670	Repair of heart chambers	35002	Repair artery rupture, neck
29450	Application of leg cast	33681	Repair heart septum defect	35005	Repair defect of artery
29505	Application, long leg splint	33684	Repair heart septum defect	35011	Repair defect of artery
29515	Application lower leg splint	33688	Repair heart septum defect	35013	Repair artery rupture, arm
29520	Strapping of hip	33690	Reinforce pulmonary artery	35021	Repair defect of artery
29530	Strapping of knee	33692	Repair of heart defects	35022	Repair artery rupture, chest
29540	Strapping of ankle and/or ft	33694	Repair of heart defects	35045	Repair defect of arm artery
29550	Strapping of toes	33697	Repair of heart defects		Repair defect of artery
29580	Application of paste boot	33702	Repair of heart defects		Repair defect of artery
29590	Application of foot splint	33710	Repair of heart defects		Repair artery rupture, thigh
29700	Removal/revision of cast	33720	Repair of heart defect	35151	Repair defect of artery
29705	Removal/revision of cast	33722	Repair of heart defect		Repair artery rupture, knee
29710	Removal/revision of cast	33730	Repair heart-vein defect(s)	35180	
29715	Removal/revision of cast	33732	Repair heart-vein defect	35184	Repair blood vessel lesion
29720	Repair of body cast	33735	Revision of heart chamber	35188	Repair blood vessel lesion
29730	Windowing of cast	33736	Revision of heart chamber	35190	Repair blood vessel lesion
29740	Wedging of cast	33737	Revision of heart chamber	35201	Repair blood vessel lesion
29750	Wedging of clubfoot cast	33750	Major vessel shunt	35206	Repair blood vessel lesion
29800	Jaw arthroscopy/surgery	33755	Major vessel shunt	35207	Repair blood vessel lesion
29804	Jaw arthroscopy/surgery	33762	Major vessel shunt	35226	Repair blood vessel lesion
31760	Repair of windpipe	33764	Major vessel shunt & graft	35231	Repair blood vessel lesion
31766		33766		35236	
	Reconstruction of windpipe		Major vessel shunt	35246	Repair blood vessel lesion
31770	Repair/graft of bronchus	33767	Major vessel shunt		Repair blood vessel lesion
31775	Reconstruct bronchus	33770	Repair great vessels defect	35261	Repair blood vessel lesion
31780	Reconstruct windpipe	33771	Repair great vessels defect	35266	Repair blood vessel lesion
31781	Reconstruct windpipe	33774	Repair great vessels defect	35286	Repair blood vessel lesion
31785	Remove windpipe lesion	33775	Repair great vessels defect	35311	Rechanneling of artery
31786	Remove windpipe lesion	33776	Repair great vessels defect	35321	Rechanneling of artery
31805	Repair of windpipe injury	33777	Repair great vessels defect	35371	Rechanneling of artery
32035	Exploration of chest	33778	Repair great vessels defect	35372	Rechanneling of artery
32036	Exploration of chest	33779	Repair great vessels defect	35381	Rechanneling of artery
32095	Biopsy through chest wall	33780	Repair great vessels defect	35501	Artery bypass graft
32100	Exploration/biopsy of chest	33781	Repair great vessels defect	35506	Artery bypass graft
32110	Explore/repair chest	33786	Repair arterial trunk	35507	Artery bypass graft

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PERC RECOMMENDATIONS ON PE DIRECT COST INPUTS—Continued

CPT Codes	Short descriptor	CPT Codes	Short descriptor	CPT Codes	Short descriptor
35508	Artery bypass graft	43045	Incision of esophagus	44010	Incision of small bowel
35509	Artery bypass graft  Artery bypass graft	43100	Excision of esophagus lesion	44020	Explore small intestine
35511	Artery bypass graft	43101	Excision of esophagus lesion	44021	Decompress small bowel
35515	Artery bypass graft	43108	Removal of esophagus	44025	Incision of large bowel
35516	Artery bypass graft	43113	Removal of esophagus	44050	Reduce bowel obstruction
35518	Artery bypass graft	43116	Partial removal of esophagus	44055	Correct malrotation of bowel
35526	Artery bypass graft	43118	Partial removal of esophagus	44110	Excise intestine lesion(s)
35556	Artery bypass graft	43123	Partial removal of esophagus	44111	Excision of bowel lesion(s)
35558	Artery bypass graft	43124	Removal of esophagus	45190	Destruction, rectal tumor
35571	Artery bypass graft	43130	Removal of esophagus pouch	45500	Repair of rectum
35583	Vein bypass graft	43135	Removal of esophagus pouch	45505	Repair of rectum
35585	Vein bypass graft	43300	Repair of esophagus	45541	Correct rectal prolapse
35587	Vein bypass graft	43320	Fuse esophagus & stomach	45550	Repair rectum/remove sigmoid
35601	Artery bypass graft	43324	Revise esophagus & stomach	45560	Repair of rectocele
35606 35612	Artery bypass graft	43325 43326	Revise esophagus & stomach	45562 45563	Exploration/repair of rectum
35616	Artery bypass graft Artery bypass graft	43330	Revise esophagus & stomach Repair of esophagus	45800	Exploration/repair of rectum Repair rect/bladder fistula
35626	Artery bypass graft	43331	Repair of esophagus	45805	Repair fistula w/colostomy
35642	Artery bypass graft  Artery bypass graft	43340	Fuse esophagus & intestine	45820	Repair rectourethral fistula
35645	Artery bypass graft	43341	Fuse esophagus & intestine	45825	Repair fistula w/colostomy
35650	Artery bypass graft	43350	Surgical opening, esophagus	46045	Incision of rectal abscess
35656	Artery bypass graft	43351	Surgical opening, esophagus	46060	Incision of rectal abscess
35661	Artery bypass graft	43352	Surgical opening, esophagus	46070	Incision of anal septum
35666	Artery bypass graft	43360	Gastrointestinal repair	46257	Remove hemorrhoids & fissure
35671	Artery bypass graft	43361	Gastrointestinal repair	46258	Remove hemorrhoids & fistula
35691	Arterial transposition	43400	Ligate esophagus veins	46260	Hemorrhoidectomy
35693	Arterial transposition	43401	Esophagus surgery for veins	46261	Remove hemorrhoids & fissure
35694	Arterial transposition	43405	Ligate/staple esophagus	46262	Remove hemorrhoids & fistula
35695	Arterial transposition	43410	Repair esophagus wound	46280	Removal of anal fistula
35701	Exploration, carotid artery	43415	Repair esophagus wound	46288	Repair anal fistula
35721	Exploration, femoral artery	43420	Repair esophagus opening	46700	Repair of anal stricture
35741	Exploration popliteal artery	43425	Repair esophagus opening	46705	Repair of anal stricture
35761	Exploration of artery/vein	43500	Surgical opening of stomach	46715	Rep perf anoper fistu
35800	Explore neck vessels	43501	Surgical repair of stomach	46716	Rep perf anoper/vestib fistu
35860 35875	Explore limb vessels	43502 43520	Surgical repair of stomach	46730 46735	Construction of absent anus Construction of absent anus
35876	Removal of clot in graft Removal of clot in graft	43605	Incision of pyloric muscle Biopsy of stomach	46740	Construction of absent anus
35901	Excision, graft, neck	43610	Excision of stomach lesion	46742	Repair of imperforated anus
35903	Excision, graft, extremity	43611	Excision of stomach lesion	46744	Repair of cloacal anomaly
36260	Insertion of infusion pump	43620	Removal of stomach	46746	Repair of cloacal anomaly
36261	Revision of infusion pump	43621	Removal of stomach	46748	Repair of cloacal anomaly
36262	Removal of infusion pump	43622	Removal of stomach	46750	Repair of anal sphincter
36475	Endovenous rf, 1st vein	43631	Removal of stomach, partial	46751	Repair of anal sphincter
36476	Endovenous rf, vein add-on	43632	Removal of stomach, partial	46753	Reconstruction of anus
36478	Endovenous laser, 1st vein	43633	Removal of stomach, partial	46760	Repair of anal sphincter
36479	Endovenous laser vein addon	43634	Removal of stomach, partial	46761	Repair of anal sphincter
36566	Insert tunneled cv cath	43640	Vagotomy & pylorus repair	46762	Implant artificial sphincter
36835	Artery to vein shunt	43641	Vagotomy & pylorus repair	47010	Open drainage, liver lesion
37565	Ligation of neck vein	43800	Reconstruction of pylorus	47015	Inject/aspirate liver cyst
37600	Ligation of neck artery	43810	Fusion of stomach and bowel	47100 47120	Wedge biopsy of liver Partial removal of liver
37605 37606	Ligation of neck artery Ligation of neck artery	43820 43825	Fusion of stomach and bowel Fusion of stomach and bowel	47120	Extensive removal of liver
38740	Remove armpit lymph nodes	43830	Place gastrostomy tube	47125	Partial removal of liver
38745	Remove armpit lymph nodes	43831	Place gastrostomy tube	47130	Partial removal of liver
38760	Remove groin lymph nodes	43832	Place gastrostomy tube	47300	Surgery for liver lesion
38765	Remove groin lymph nodes	43840	Repair of stomach lesion	47350	Repair liver wound
38770	Remove pelvis lymph nodes	43842	V-band gastroplasty	47360	Repair liver wound
38780	Remove abdomen lymph nodes	43846	Gastric bypass for obesity	47400	Incision of liver duct
39501	Repair diaphragm laceration	43847	Gastric bypass incl small i	47420	Incision of bile duct
39502	Repair paraesophageal hernia	43848	Revision gastroplasty	47425	Incision of bile duct
39503	Repair of diaphragm hernia	43850	Revise stomach-bowel fusion	47460	Incise bile duct sphincter
39520	Repair of diaphragm hernia	43855	Revise stomach-bowel fusion	47480	Incision of gallbladder
39530	Repair of diaphragm hernia	43860	Revise stomach-bowel fusion	47490	Incision of gallbladder
39531	Repair of diaphragm hernia	43865	Revise stomach-bowel fusion	47600	Removal of gallbladder
39540	Repair of diaphragm hernia	43870	Repair stomach opening	47605	Removal of gallbladder
39541	Repair of diaphragm hernia	43880	Repair stomach-bowel fistula	47610	Removal of gallbladder
39545	Revision of diaphragm	44005	Freeing of bowel adhesion	47612	Removal of gallbladder

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PERC RECOMMENDATIONS ON PE DIRECT COST INPUTS—Continued

CPT Codes	Short descriptor	CPT Codes	Short descriptor	CPT Codes	Short descriptor
47620	Removal of gallbladder	51925	Hysterectomy/bladder repair	54560	Exploration for testis
47700		51940	Correction of bladder defect	54600	Reduce testis torsion
47701	Bile duct revision	51960	Revision of bladder & bowel	54640	Suspension of testis
47711		51980	Construct bladder opening	54650	Orchiopexy (fowler-stephens)
47712		52000	Cystoscopy	54660	Revision of testis
47715		52001	Cystoscopy, removal of clots	54670	Repair testis injury
47716		52005	Cystoscopy & ureter catheter	54680	Relocation of testis(es)
47720	Fuse gallbladder & bowel	52281		54820	Exploration of epididymis
47721		52283	Cystoscopy and treatment	54830	Remove epididymis lesion
47740		52285		54840	Remove epididymis lesion
47741		52332		54860	Removal of epididymis
47760	Fuse bile ducts and bowel	52647	Laser surgery of prostate	54861	Removal of epididymis
47765	Fuse liver ducts & bowel	52648	Laser surgery of prostate	54900	Fusion of spermatic ducts
47780	Fuse bile ducts and bowel	53010	Incision of urethra	54901	Fusion of spermatic ducts
47785	Fuse bile ducts and bowel	53080	Drainage of urinary leakage	55040	Removal of hydrocele
47800	Reconstruction of bile ducts	53085	Drainage of urinary leakage	55041	Removal of hydroceles
47801	Placement, bile duct support	53210	Removal of urethra	55060	Repair of hydrocele
47802	Fuse liver duct & intestine	53215	Removal of urethra	55500	Removal of hydrocele
47900	Suture bile duct injury	53220	Treatment of urethra lesion	55520	Removal of sperm cord lesion
48000		53230	Removal of urethra lesion	55530	Revise spermatic cord veins
48001	Placement of drain, pancreas	53235	Removal of urethra lesion	55535	Revise spermatic cord veins
48005	Resect/debride pancreas	53240		55540	Revise hernia & sperm veins
48020	Removal of pancreatic stone	53250	Removal of urethra gland	55600	Incise sperm duct pouch
48100	Biopsy of pancreas, open	53400	Revise urethra, stage 1	55605	Incise sperm duct pouch
48120		53405	Revise urethra, stage 2	55650	Remove sperm duct pouch
48140		53410	Reconstruction of urethra	55680	Remove sperm pouch lesion
48145	Partial removal of pancreas	53415	Reconstruction of urethra	55720	Drainage of prostate abscess
48146	Pancreatectomy	53420	Reconstruct urethra, stage 1	55725	Drainage of prostate abscess
48148	Removal of pancreatic duct	53425	Reconstruct urethra, stage 2	55801	Removal of prostate
48150		53430	Reconstruction of urethra	55810	Extensive prostate surgery
48152		53445	Insert uro/ves nck sphincter	55812	Extensive prostate surgery
48153	Pancreatectomy	53449	Repair uro sphincter	55815	Extensive prostate surgery
48154		53450	Revision of urethra	55821	Removal of prostate
48155		53460	Revision of urethra	55831	Removal of prostate
48180		53502	Repair of urethra injury	55840	Extensive prostate surgery
48500	Surgery of pancreatic cyst	53505	Repair of urethra injury	55842	Extensive prostate surgery
48510 48520		53510	Repair of urethra injury	55845 55860	Extensive prostate surgery
48540		53515	Repair of urethra injury		Surgical exposure, prostate
48545	Fuse pancreas cyst and bowel Pancreatorrhaphy	53520 54205	Repair of urethra defect Treatment of penis lesion	55862 55865	Extensive prostate surgery Extensive prostate surgery
48547	Duodenal exclusion	54300	Revision of penis	56620	Partial removal of vulva
49215	1	54304		56625	Complete removal of vulva
49900	Repair of abdominal wall	54308		56630	Extensive vulva surgery
51020	Incise & treat bladder	54312		56631	Extensive vulva surgery
51500	Removal of bladder cyst	54316		56632	Extensive vulva surgery
51530	Removal of bladder lesion	54318	Reconstruction of urethra	56633	Extensive vulva surgery
51535	Repair of ureter lesion	54322	Reconstruction of urethra	56634	Extensive vulva surgery
51550	Partial removal of bladder	54324	Reconstruction of urethra	56637	Extensive vulva surgery
51555	Partial removal of bladder	54326	Reconstruction of urethra	56640	Extensive vulva surgery
51565	Revise bladder & ureter(s)	54328	Revise penis/urethra	56805	Repair clitoris
51570	Removal of bladder	54332	Revise penis/urethra	57010	Drainage of pelvic abscess
51575	Removal of bladder & nodes	54336	Revise penis/urethra	57106	Remove vagina wall, partial
51580	Remove bladder/revise tract	54340	Secondary urethral surgery	57107	Remove vagina tissue, part
51585	Removal of bladder & nodes	54344	Secondary urethral surgery	57109	Vaginectomy partial w/nodes
51590	Remove bladder/revise tract	54348	Secondary urethral surgery	57110	Remove vagina wall, complete
51595	Remove bladder/revise tract	54352	Reconstruct urethra/penis	57111	Remove vagina tissue, compl
51596	Remove bladder/create pouch	54360	Penis plastic surgery	57112	Vaginectomy w/nodes, compl
51597	Removal of pelvic structures	54380	Repair penis	57120	Closure of vagina
51715	Endoscopic injection/implant	54385	Repair penis	57210	Repair vagina/perineum
51800	Revision of bladder/urethra	54390	Repair penis and bladder	57307	Fistula repair & colostomy
51820	Revision of urinary tract	54400	Insert semi-rigid prosthesis	57308	Fistula repair, transperine
51845	Repair bladder neck	54401	Insert self-contd prosthesis	57310	Repair urethrovaginal lesion
51860	Repair of bladder wound	54405	Insert multi-comp penis pros	57311	Repair urethrovaginal lesion
51865	Repair of bladder wound	54520	Removal of testis	57320	Repair bladder-vagina lesion
51880	Repair of bladder opening	54530	Removal of testis	57330	Repair bladder-vagina lesion
E4000	I Demograph to the state of the	E 4 E O E			
51900 51920	Repair bladder/vagina lesion Close bladder-uterus fistula	54535 54550	Extensive testis surgery Exploration for testis	57335 57530	Repair vagina Removal of cervix

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PERC RECOMMENDATIONS ON PE DIRECT COST INPUTS—Continued

CPT Codes  Short descriptor Co						
Forestable   Removal of trigroid   G1680   Intracrarial vessel surgery   F7545   Removal corrivors   G2624   Extensive thyroid surgery   G1682   Intracrarial vessel surgery   G7555   Removal of residual cervix   G2620   Repeat thyroid surgery   G1684   Intracrarial vessel surgery   G7555   Removal of residual cervix   G2620   Repeat thyroid surgery   G1684   Intracrarial vessel surgery   G7555   Remove cervive feath of the surgery   G1684   Intracrarial vessel surgery   G75700   Revision of cervix   G2621   Remove thyroid duct lesion   G1692   Intracrarial vessel surgery   G77700   Revision of cervix   G2621   Remove thyroid duct lesion   G1692   Intracrarial vessel surgery   G1684   Intracrarial vessel surgery   G1685   Intracrarial vessel s		Short descriptor		Short descriptor		Short descriptor
Forestable   Removal of trigroid   G1680   Intracrarial vessel surgery   F7545   Removal corrivors   G2624   Extensive thyroid surgery   G1682   Intracrarial vessel surgery   G7555   Removal of residual cervix   G2620   Repeat thyroid surgery   G1684   Intracrarial vessel surgery   G7555   Removal of residual cervix   G2620   Repeat thyroid surgery   G1684   Intracrarial vessel surgery   G7555   Remove cervive feath of the surgery   G1684   Intracrarial vessel surgery   G75700   Revision of cervix   G2621   Remove thyroid duct lesion   G1692   Intracrarial vessel surgery   G77700   Revision of cervix   G2621   Remove thyroid duct lesion   G1692   Intracrarial vessel surgery   G1684   Intracrarial vessel surgery   G1685   Intracrarial vessel s	57531	Removal of cervix radical	60240	Removal of thyroid	- <del></del>	Benair dura
57556.         Remova convivírepair pelvis         60224   Extensive thyroid surgery         61682   Intracranial vessel surgery           57550.         Remova convivírepair vagina         60270   Removal of thyroid         61688   Intracranial vessel surgery           57555.         Remove convivírepair vagina         60271   Removal of thyroid         61689   Intracranial vessel surgery           57555.         Remove convivírepair bovel         60271   Removal of thyroid of the side of the sid						
57550.         Removal or fresidual cervix         60260         Repeat thyroid surgery         61684         Intracranial vessel surgery           57555.         Remove cervix, repair bowel         60271         Removal of thyroid         61686         Intracranial vessel surgery           57700.         Revision of cervix         60280         Remove thyroid duct lesion         61692         Intracranial vessel surgery           57720.         Revision of cervix         60281         Remove thyroid duct lesion         61802         Intracranial vessel surgery           57720.         Revision of cervix         60281         Revision of cervix         60282         Removal of thymus gland         61703         Cerpic perate pe						
57556         Remove cervix, repair bowel         60271         Removal of thyroid         61680         Intracranial vessel surgery           57700         Revision of cervix         60280         Remove thyroid duct lesion         61702         Intracranial vessel surgery           58120         Dilation and curettage         60502         Explore parathyroids         61702         Increase value vessel surgery           58140         Myomectomy abdom method         60502         Repair of parathyroids         61703         Camp neck artery           58140         Suspension of uterus         60521         Removal of thymus gland         61708         Revise circulation to head           58520         Repair of ruptured uterus         60522         Removal of thymus gland         61711         Fusion of uterus           58550         Heaper of ruptured uterus         60524         Explore adrenal gland         61720         Incise skull/brain surgery           58552         Removal of thymus gland         61721         Fusion of uterus         60540         Explore adrenal gland         61720         Incise skull/brain surgery           58562         Heaper of ruptured uterus         60545         Explore adrenal gland         61720         Incise skull/brain surgery           58562         Hysteroscopy, kockise         6160	57550	Removal of residual cervix	60260			Intracranial vessel surgery
57700 Revision of cervix 57200 Revision of cervix 57200 Revision of cervix 57200 Dilation and curettage 58140 Myomectorny addom method 58140 Myomectorny wag method 58140 Revision of uterus 58140 Revisio	57555	Remove cervix/repair vagina	60270	Removal of thyroid	61686	Intracranial vessel surgery
57720 — Revision of cervix 58120 — Dilation and curettage 58140 — Myomectomy abdom method 58500 — Spice parathyroid glands 58410 — Suspension of uterus 58400 — Suspension of uterus 58400 — Suspension of uterus 58400 — Suspension of uterus 58520 — Repair of pubred uterus 58520 — Repair						
Self-10   Dilation and curettage   60500   Explore parathyroid glands   61702   Inner skull vessel surgery   56140   Myomectomy wag method   60502   Revesptore parathyroid glands   61703   Clare   56400   Suspension of uterus   60520   Removal of thymus gland   61708   Revise circulation to head   56500   Removal of thymus gland   61708   Revise circulation to head   56500   Removal of thymus gland   61708   Revise circulation to head   56500   Removal of thymus gland   61708   Revise circulation to head   61708   Revise circulation   61709   Revise circulation head   61709   Revise circulation   61709   Revise circulatio		1				
Seit   Myomectomy abdom method   60502   Re-explore parathryroids   61705   Revise circulation to head   58400   Suspension of uterus   60520   Removal of thymus gland   61706   Revise circulation to head   58520   Repair of ruptured uterus   60521   Removal of thymus gland   61701   Revise circulation to head   58520   Revision of uterus   60522   Removal of thymus gland   61701   Revise circulation to head   58520   Revision of uterus   60522   Removal of thymus gland   61701   Revise circulation to head   58520   Revision of uterus   60522   Removal of thymus gland   61701   Revise circulation to head   61705   Revise overland   61701   Revise circulation to head   61701   Revise circulation to head   61705   Revise overland   61701   Revise circulation to head   61701   Revise circulation to head   61705   Revise overland   61705						
58400 Suspension of uterus 60520 Removal of thyruns gland 61705 Revise circulation to head 58410 Suspension of uterus 60521 Removal of thyruns gland 61710 Revise circulation to head 58520 Repair of ruptured uterus 60522 Removal of thyruns gland 61711 Revise circulation to head 58520 Repair of ruptured uterus 60522 Removal of thyruns gland 61710 Revise circulation to head 58520 Repair of ruptured uterus 60524 Removal of thyruns gland 61710 Revise circulation to head 58556 Hysteroscopy, tops 60540 Explore adrenal gland 61720 Incise skull/brain surgery 18558 Hysteroscopy, tops 60600 Remove carolid body lesion 61750 Incise skull/brain surgery 18560 Remove carolid body lesion 61750 Brain biopsy without 18560 Remove carolid body lesion 61750 Brain biopsy without 18560 Remove carolid body lesion 61750 Brain biopsy without 18560 Remove carolid body lesion 61750 Brain biopsy without 18560 Remove carolid body lesion 61750 Brain biopsy without 18560 Remove carolid body lesion 61750 Brain biopsy without 18560 Remove carolid body lesion 61750 Brain biopsy without 18560 Remove carolid body lesion 61750 Brain biopsy without 18560 Remove carolid body lesion 61750 Brain biopsy without 18560 Remove carolid body lesion 61750 Brain biopsy without 18560 Remove carolid body lesion 61750 Brain biopsy without 18560 Revise fallopsin biopsy without 18560 Removal of skull lesion 61850 Implant neuroelectrodes 61450 Removal of skull lesion 61850 Revise fallopsin tube(s) 61500 Removal of skull lesion 61850 Revise fallopsin tube(s) 61500 Removal of skull lesion 61850 Revise fallopsin tube(s) 61500 Removal of brain lesion 62100 Treat skull fracture 185820 Drain ovary absoess, percut 61512 Removal of brain lesion 62116 Removal of brain les						,
58410 Suspension of uterus 60520 Removal of thymus gland 61708 Revise circulation to head 58520 Repair of ruptured uterus 60521 Removal of thymus gland 61711 Fusion of skull arteries 65840 Revision of uterus 60522 Removal of thymus gland 61711 Fusion of skull arteries 65840 Revision of uterus 60522 Removal of thymus gland 61711 Fusion of skull arteries 65840 Revision of uterus 60540 Explore adrenal gland 61735 Incise skull/brain surgery 158555 Hysteroscopy, topic policy 60600 Remove carotid body lesion 61750 Incise skull/brain surgery 158552 Hysteroscopy, the fusion of taliopian tube 61845 Incise skull (prese relief) 1750 Implant brain electrodes 161840 Incise skull (prese relief) 1750 Implant brain electrodes 161840 Incise skull (prese relief) 1750 Implant brain electrodes 161840 Incise skull (prese relief) 1750 Implant brain electrodes 161840 Incise skull (prese relief) 1750 Implant brain electrodes 161840 Incise skull (prese relief) 1750 Implant brain electrodes 161840 Incise skull (prese relief) 1750 Implant brain electrodes 161840 Incise skull (prese relief) 1750 Implant brain electrodes 161840 Incise skull (prese relief) 1750 Implant brain electrodes 161840 Incise skull (prese relief) 1750 Incise						
58410 Suspension of uterus 60521 Removal of thymus gland 61710 Flevise circulation to head 58520 Repair of ruptured uterus 60542 Explore adrenal gland 61720 Incise skull/brain surgery 185554 Revision of uterus 60540 Explore adrenal gland 61720 Incise skull/brain surgery 185555 Hysteroscopy, to, sep proc 60540 Explore adrenal gland 61720 Incise skull/brain surgery 185568 Hysteroscopy, remove th 60540 Remove carolid body lesion 61750 Incise skull/brain surgery 185690 Division of fallopian tube 61343 Incise skull (press relief) 61750 Implant brain electrodes 161750 Incise skull for surgery 61790 Implant brain electrodes 161750 Incise skull for surgery 61790 Implant brain electrodes 16150 Incise skull for surgery 61790 Treat trigeminal rever 61450 Incise skull for surgery 61790 Treat trigeminal rever 61450 Incise skull for surgery 61790 Treat trigeminal rever 61450 Incise skull for surgery 61790 Treat trigeminal rever 61450 Incise skull for surgery 61790 Treat trigeminal rever 61450 Incise skull for surgery 61790 Treat trigeminal rever 61450 Incise skull for surgery 61890 Implant neuroelectrodes 61460 Incise skull for surgery 61890 Implant neuroelectrodes 61891 Removal of fallopian tube 61460 Incise skull for surgery 61890 Implant neuroelectrodes 61891 Removal of prain surgery 61890 Implant neuroe				Explore parathyroid glands		
58520         Repair of ruptured uterus         60522         Removal of thymus gland         61711         Fusion of skull arteries           58554         Revision of uterus         60540         Explore adrenal gland         61720         Incise skull/brain surgery           58558         Hysteroscopy, biopsy         60600         Remove carolid body lesion         61750         Incise skull/brain surgery           58600         Division of falloplan tube         61343         Incise skull fore surgery         61760         Incise skull for surgery           58600         Division of falloplan tube         61344         Releive cranial pressure         61770         Incise skull for return funcies skull for surgery         61780         Implant brain electrodes           58600         Division of falloplan tube         61440         Incise skull for surgery         61791         Treat tigeminal nerve           58602         Laparoscopy, salpingostomy         61460         Incise skull for surgery         61791         Treat tigeminal nerve           58702         Removal of falloplan tube         61480         Incise skull for surgery         61870         Incise skull for surgery<						
58556 Hysteroscopy, ki, sep proc 60546 Explore adrenal gland 61720 Incise skull/brain surgery 68555 Hysteroscopy, ki, sep proc 60545 Explore adrenal gland 61726 Incise skull/brain surgery 68556 Hysteroscopy, remove the 60605 Remove carotid body lesion 61750 Incise skull/brain surgery 61750 Incise skull/brain surgery 61750 Incise skull forsit skull (press relief) 61760 Incise skull brain biopsy 61760 Incise skull forsit brain surgery 61760 Incise skull forsit brain state of 1760 Implant brain electrodes 61745 Incise skull for surgery 61790 Irreat trageminal nerve 758600 Incise skull for surgery 61790 Irreat trageminal read 75860 Implant brain electrodes 61745 Incise skull for surgery 61790 Irreat trageminal read 758672 Laparoscopy, tubal cautery 61456 Incise skull for surgery 61790 Irreat trageminal read 758672 Laparoscopy, subhriboplasty 61450 Incise skull for surgery 61790 Irreat trageminal read 75870 Removal of slioplain tube 61480 Incise skull for surgery 61800 Implant neuroelectrodes 758700 Removal of slioplain tube 61480 Incise skull for surgery 61870 Implant neuroelectrodes 758700 Removal of slioplain tube 61510 Removal of slioplain sling lesion 61512 Removal of slipplain sling lesion 62100 Removal of slipplain sling lesion 62100 Removal of slipplain sling lesion 62100 Removal of slipplain slipplain for slipplain for slipplain for slipplain for slipplain for slipplain for surgery 61870 Removal of slipplain slipplain for surgery 61870 Removal of slipplain for surgery 61870 Removal of slipplain for surgery 61870 Removal of slipplain slipplain for surgery 61						
S8555 Hysteroscopy, chiopsy 60600 Remove carotid body lesion 61750 Incise skull/brain biopsy skibsos Hysteroscopy, remove fb 60600 Remove carotid body lesion 61751 Brain biopsy witchm guide Incise skull (press relief) 61760 Division of fallopian tube 61344 Incise skull (press relief) 61760 Incise skull for surgery 61790 Incise skull for surgery 61790 Incise skull for surgery 61790 Incise skull for surgery 61791 Treat trigeminal nerve 61760 Laparoscopy, bubla cautery 61450 Incise skull for surgery 61791 Treat trigeminal reat 617672 Laparoscopy, sphiposabrow 61450 Incise skull for surgery 61791 Treat trigeminal reat 617672 Laparoscopy, sphiposabrow 61450 Incise skull for surgery 61860 Implant brain electrodes 61450 Incise skull for surgery 61860 Implant nervoelectrodes 61450 Incise skull for surgery 61870 Implant nervoelectrodes 61450 Incise 5450 Inc						
58558Hysteroscopy, Imperenve fb66060Remove carotid body lesion61750Incises skull/brain biopsy58600Division of fallopian tube61343Incise skull (press relief)61760Implant brain electrodes58605Division of fallopian tube61344Incise skull for surgery61770Implant brain electrodes58660Laparoscopy, scvise lesions61450Incise skull for surgery61790Treat trigeminal nerve58662Laparoscopy, Imbrioplasty61456Incise skull for surgery61790Treat trigeminal nerve58672Laparoscopy, Imbrioplasty61460Incise skull for surgery61860Implant neuroelectrodes58673Laparoscopy, Shimbrioplasty61470Incise skull for surgery61860Implant neuroelectrodes58700Removal of fallopian tube61480Incise skull for surgery61860Implant neuroelectrodes58720Removal of varyfube(s)61490Incise skull for surgery61875Implant neuroelectrodes58740Revise fallopian tube61500Removal of brain lesion61885Implant neuroelectrodes58752Revise cavarian tube(s)61510Removal of brain lesion61886Instrécto neurostin 1 array58760Remove tubal obstruction61512Removal of brain lesion62005Treat skull fracture58820Drain ovary abscess, open61516Removal of brain lesion62116Repair of skull defect58820Drain ovary abscess, open61521Removal of brain		1				
58560         Hysteroscopy, remove fb         66060         Flemove carotid body lesion         61751         Brain biopsy wictim guide           58600         Division of fallopian tube         61345         Incise skull (press relief)         61760         Incise skull for surgery         61770         Incise skull for surgery         61791         Incise skull for surgery         61790         Incise skull for surgery         61791         Treat trigeminal nerve           58670         Laparoscopy, bubal cautery         61458         Incise skull for surgery         61791         Treat trigeminal nerve           58672         Laparoscopy, spinipostomy         61460         Incise skull for surgery         61850         Implant neuroelectrodes           58672         Laparoscopy, spinipostomy         61480         Incise skull for surgery         61850         Implant neuroelectrodes           58720         Removal of fallopian tube (s)         61490         Incise skull for surgery         61870         Implant neuroelectrodes           58720         Removal of fallopian tube(s)         61500         Removal of skull lesion         61870         Implant neuroelectrodes           58750         Repair oviduct         Incise skull for surgery         61870         Incise skull for surgery         61870         Implant triar lesion           58770						
Division of fallopian tube   61343   Incise skull (press relief)   61760   Implant brain electrodes   168605   Division of fallopian tube   61345   Relieve cranial pressure   61770   Incise skull for terment   168606   Laparoscopy, kysis   61440   Incise skull for surgery   61790   Treat trigeminal nerve   168602   Laparoscopy, kycise lesions   61450   Incise skull for surgery   61791   Treat trigeminal nerve   168607   Laparoscopy, highingostomy   61450   Incise skull for surgery   61850   Implant neuroelectrodes   16872   Laparoscopy, salpingostomy   61470   Incise skull for surgery   61860   Implant neuroelectrodes   168700   Removal of ovary/tube(s)   61490   Incise skull for surgery   61870   Implant neuroelectrodes   168740   Removal of skull lesion   61880   Revise fallopian tube   61501   Remove infected skull bone   61880   Revise fallopian tube(s)   61501   Remove infected skull bone   61880   Revise revise not tube   61501   Remove infected skull bone   61885   Instruedo neurostim 1 array   16870   Remove tubal obstruction   61512   Remove brain lining lesion   62000   Treat skull fracture   168770   Create new tubal opening   61514   Removal of brain lesion   62000   Treat skull fracture   168820   Drain ovary abscess, open   61516   Removal of brain lesion   62110   Repair brain fluid leakage   168820   Drain ovary abscess, open   61518   Removal of brain lesion   62116   Reduction of skull defect   168822   Drain ovary abscess, open   61519   Removal of brain lesion   62116   Reduction of skull defect   168920   Partial removal of ovary(s)   61520   Removal of brain lesion   62114   Repair of skull defect   168920   Removal of ovarian cyst(s)   61524   Removal of brain lesion   62142   Remove skull plate/flap   168940   Removal of ovarian cyst(s)   61524   Removal of brain lesion   62142   Repair of skull defect   168940   Removal of ovarian cyst(s)   61530   Removal of brain lesion   62142   Repair of skull defect   168940   Removal of brain lesion   62145   Repair of skull defect   168960   Re				1		
58605 Laparoscopy, kosis elisions 61440 Incise skull for surgery 61790 Treat trigenimal nerve fis6660 Laparoscopy, excise lesions 61450 Incise skull for surgery 61791 Treat trigenimal nerve fis6662 Laparoscopy, kosise lesions 61450 Incise skull for surgery 61791 Treat trigenimal tract fis6670 Laparoscopy, fimbrioplasty 61460 Incise skull for surgery 61875 Focus radiation beam fis672 Laparoscopy, spainipogotomy 61470 Incise skull for surgery 61860 Implant neuroelectrodes Incise skull for surgery 61860 Implant neuroelectrodes 58700 Removal of fallopian tube 61480 Incise skull for surgery 61870 Implant neuroelectrodes 16720 Removal of sallopian tube 61480 Incise skull for surgery 61875 Implant neuroelectrodes 68740 Revise fallopian tube 61500 Removal of skull lesion 61880 Revise/remove neuroelectrodes 68750 Repair oviduct 61501 Remova infected skull bone 61885 Instrteed neurositin 1 array 58752 Revise ovarian tube(s) 61510 Removal of brain lesion 62000 Treat skull fracture 758760 Remove tubal obstruction 61512 Remove brain lining lesion 62000 Treat skull fracture 758770 Create new tubal opening 61514 Removal of brain lesion 62000 Treat skull fracture 758805 Drain ovary abscess, open 61518 Removal of brain lesion 62010 Repair brain fluid leakage 58820 Drain ovary abscess, open 61518 Removal of brain lesion 62110 Repair for influid leakage 58820 Drain ovary abscess, open 61518 Removal of brain lesion 62110 Repair of skull defect 68825 Transposition, ovary(s) 61520 Removal of brain lesion 62111 Reduction of skull defect 68825 Transposition, ovary(s) 61520 Removal of brain lesion 62114 Repair of skull defect 68920 Removal of ovary(s) 61521 Removal of brain lesion 62141 Repair of skull defect 68920 Removal of ovary(s) 61521 Removal of brain lesion 62141 Repair of skull defect 68920 Resect ovarian malignancy 61531 Implant brain electrodes 62141 Repair of skull defect 68920 Resect ovarian malignancy 61531 Removal of brain lesion 62146 Repair of skull with graft 69934 Removal of brain lesion 62147 Repair of skull with gra						
58660         Laparoscopy, kysis         61440         Incise skull for surgery         61790         Treat trigeminal nerve           58660         Laparoscopy, kycise lesions         61450         Incise skull for surgery         61793         Focus radiation beam           58672         Laparoscopy, Imbrioplasty         61460         Incise skull for surgery         61850         Implant neuroelectrodes           58673         Laparoscopy, Imbrioplasty         61470         Incise skull for surgery         61850         Implant neuroelectrodes           58700         Removal of dallogian tube         61480         Incise skull for surgery         61870         Implant neuroelectrodes           58740         Revise clalopian tube(s)         61500         Removal of skull lesion         61880         Implant neuroelectrodes           58750         Repair oviduct         61501         Remove intected skull bone         61885         Implant neuroelectrodes           58750         Repair oviduct         61510         Remove intected skull bone         61885         Implant neuroelectrodes           58750         Repair oviduct         61510         Remove intected skull bone         61885         Implant neuroelectrodes           58750         Remove tubal obstruction         61512         Remove intected skull bone         618		Division of fallopian tube				
58662         Laparoscopy, excise lesions         61450         Incise skull for brain wound         61793         Treat trigeminal tract           58672         Laparoscopy, fimbrioplasty         61460         Incise skull for surgery         61850         Implant neuroelectrodes           58673         Laparoscopy, spalingostomy         61460         Incise skull for surgery         61860         Implant neuroelectrodes           58700         Removal of fallopian tube         61480         Incise skull for surgery         61870         Implant neuroelectrodes           58740         Removal of ovary/tube(s)         61500         Removal of skull for surgery         61875         Implant neuroelectrodes           58750         Repair oviduct         61500         Removal of skull for surgery         61886         Insferdo neurostim 1 array           58750         Remove tubal obstruction         61510         Removal of brain lesion         62000         Treat skull fracture           58770         Remove tubal obstruction         61514         Removal of brain elsion         62000         Treat skull fracture           58770         Create new tubal opening         61514         Removal of brain elsion         62100         Repair oviduo           58805         Drain ovary abscess, open         61518         Removal of brain lesion<						
58677 Laparoscopy, flubal cautery 61458   Incise skull for brain wound 61793   Focus radiation beam 58672   Laparoscopy, salpingostomy 61470   Incise skull for surgery 61850   Implant neuroelectrodes 58700   Removal of fullopian tube 61480   Incise skull for surgery 61870   Implant neuroelectrodes 58720   Removal of vary/tube(s) 61490   Incise skull for surgery 61870   Implant neuroelectrodes 58750   Removal of vary/tube(s) 61490   Incise skull for surgery 61870   Implant neuroelectrodes 58750   Removal of vary/tube(s) 61501   Removal of skull lesion 61886   Implant neuroelectrodes 58750   Repair oviduct 61501   Removal of skull lesion 61886   Revise/remove neuroelectrode 58750   Repair oviduct 61501   Removal of brain lesion 62000   Treat skull fracture 58760   Remove tubal obstruction 61512   Removal of brain lesion 62000   Treat skull fracture 58770   Create new tubal opening 61514   Removal of brain lesion 62000   Treat skull fracture 58770   Drainage of ovarian cyst(s) 61516   Removal of brain lesion 62100   Repair brain fluid leakage 68220   Drain ovary abscess, open 61518   Removal of brain lesion 62100   Repair brain fluid leakage 68220   Drain ovary abscess, open 61518   Removal of brain lesion 62110   Reduction of skull defect 68252   Transposition, ovary(s) 61520   Removal of brain lesion 62116   Reduction of skull defect 68252   Removal of brain lesion 62116   Reduction of skull defect 68252   Removal of ovarian cyst(s) 61526   Removal of brain lesion 62140   Repair of skull defect 68252   Removal of ovarian cyst(s) 61526   Removal of brain lesion 62141   Repair of skull defect 68252   Removal of ovarian cyst(s) 61526   Removal of brain lesion 62141   Repair of skull defect 68252   Removal of ovary(s) 61526   Removal of brain lesion 62141   Repair of skull defect 68252   Removal of ovarian brain electrodes 62141   Repair of skull with graft 68960   Resect ovarian malignancy 61534   Removal of brain lesion 62145   Repair of skull with graft 68960   Resect ovarian malignancy 61534   Removal of brain l	58662	Laparoscopy, excise lesions	61450	Incise skull for surgery	61791	Treat trigeminal tract
Laparoscopy, salpingostomy   61470   Incise skull for surgery   61860   Implant neuroelectrodes	58670	Laparoscopy, tubal cautery	61458		61793	
S8700 Removal of fallopian tube (s) 61480 Incise skull for surgery 61870 Implant neuroelectrodes 58740 Removal of ovary/tube(s) 61490 Incise skull for surgery 61875 Implant neuroelectrodes 58740 Revise fallopian tube(s) 61500 Removal of skull lesion 61880 Revise/remove neuroelectrodes 58750 Repair oviduct 61501 Remove infected skull bone 61885 Instredo neurostim 1 array 58752 Revise ovarian tube(s) 61510 Remove infected skull bone 62000 Treat skull fracture 58776 Revise ovarian tube(s) 61510 Remove brain lining lesion 62000 Treat skull fracture 58770 Create new tubal opening 61514 Removal of brain lesion 62000 Treat skull fracture 58770 Drain ago of ovarian cyst(s) 61516 Removal of brain lesion 62100 Treat skull fracture 58822 Drain ovary abscess, open 61518 Removal of brain lesion 62100 Repair brain fluid leakage 58822 Drain ovary abscess, percut 61519 Removel of brain lesion 62115 Reduction of skull defect 58920 Parlial removal of ovary(s) 61520 Removal of brain lesion 62116 Reduction of skull defect 58920 Parlial removal of ovary(s) 61521 Removal of brain lesion 62117 Reduction of skull defect 58920 Removal of ovary(s) 61522 Removal of brain lesion 62141 Repair of skull defect 58920 Removal of ovary(s) 61526 Removal of brain lesion 62141 Repair of skull defect 58926 Removal of ovary(s) 61526 Removal of brain lesion 62141 Repair of skull defect 589526 Removal of ovary(s) 61526 Removal of brain lesion 62143 Replace skull plate/flap 58940 Resect ovarian malignancy 61531 Implant brain electrodes 62147 Repair of skull with graft 58951 Resect ovarian malignancy 61531 Implant brain electrodes 62147 Repair of skull with graft 58952 Resect ovarian malignancy 61533 Removal of brain lesion 62143 Replace skull plate/flap 58950 Resect ovarian malignancy 61534 Removal of brain lesion 62149 Establish brain cavity shunt 59120 Treat ectopic pregnancy 61541 Removal of brain lesion 62146 Repair of skull with graft 58952 Resect ovarian malignancy 61534 Removal of brain lesion 62190 Establish brain cavity shunt 59150 Treat ectop	58672	Laparoscopy, fimbrioplasty	61460		61850	Implant neuroelectrodes
58720Removal of ovarlyfube(s)61490Incise skull for surgery6187Implant neuroelectrodes58740Revise fallopian tube(s)61500Removal of skull lesion61880Revise/ermove neuroelectrode58750Repair oviduct61501Removal of brain lesion62000Treat skull fracture58760Remove tubal obstruction61512Removal of brain lesion62000Treat skull fracture58770Create new tubal opening61516Removal of brain abscess62010Treat skull fracture58770Drain ovary abscess, open61516Removal of brain lesion62100Repair brain fluid leakage58805Drain ovary abscess, open61518Removal of brain lesion62115Reduction of skull defect58822Drain ovary abscess, open61521Removal of brain lesion62116Reduction of skull defect58822Drain ovary abscess, open61521Removal of brain lesion62117Reduction of skull defect58900Biopsy of ovary(s)61521Removal of brain lesion62117Reduction of skull defect58920Partial removal of ovary(s)61524Removal of brain lesion62141Repair of skull defect58943Removal of ovary(s)61526Removal of brain lesion62142Remove skull plate/flap58950Resect ovarian malignancy61531Implant brain electrodes62147Repair of skull with graft58951Resect ovarian malignancy61534Removal of brain lesion62145			61470		61860	Implant neuroelectrodes
58740         Revise fallopian fube(s)         61500         Removal of skull lesion         61880         Revise/remove neuroelectrode           58752         Repair oviduct         61501         Remove infected skull bone         61885         Instr/redo neurostin 1 array           58752         Remove tubal obstruction         61512         Remove brain lining lesion         62000         Treat skull fracture           58760         Create new tubal opening         61514         Removal of brain abscess         62010         Treat skull fracture           58802         Drain and passess, open         61518         Removal of brain lesion         62100         Repair brain fluid leakage           58822         Drain ovary abscess, open         61518         Removal of brain lesion         62116         Reduction of skull defect           58825         Transposition, ovary(s)         61520         Removal of brain lesion         62140         Reduction of skull defect           58920         Partial removal of ovary(s)         61524         Removal of brain lesion         62141         Repair of skull defect           58925         Removal of ovary(s)         61526         Removal of brain lesion         62141         Repair of skull defect           58943         Remov				, ,		
Repair oviduct				,		
58752Revise ovariant tube(s)61510Remove brain lining lesion62000Treat skull fracture58770Create new tubal opening61514Remove brain lining lesion62005Treat skull fracture58770Create new tubal opening61514Removal of brain abscess62010Treat skull fracture58805Drain ovary abscess, open61516Removal of brain lesion62105Repair brain fluid leakage58822Drain ovary abscess, open61518Removal of brain lesion62116Reduction of skull defect58822Drain ovary abscess, open61519Removal of brain lesion62116Reduction of skull defect58825Transposition, ovary(s)61520Removal of brain lesion62117Reduction of skull defect58920Partial removal of ovary(s)61521Removal of brain lesion62140Repair of skull defect58920Partial removal of ovary(s)61524Removal of brain lesion62141Repair of skull defect58940Removal of ovary(s)61524Removal of brain lesion62142Remove skull plate/flap58943Removal of ovary(s)61530Removal of brain lesion62142Repove skull plate/flap58955Resect ovarian malignancy61531Implant brain electrodes62146Repair of skull with graft58960Exploration of abdomen61534Removal of brain lesion62190Establish brain cavity shunt59120Treat ectopic pregnancy61538Removal of brain lissue6220				1		
58760Remove tubal obstruction61514Removal ob brain lining lesion62005Treat skull fracture58770Create new tubal opening61514Removal of brain abscess62010Treatment of head injury58805Drain ovary abscess, open61516Removal of brain lesion62100Repair brain fluid leakage58822Drain ovary abscess, percut61519Remove brain lining lesion62115Reduction of skull defect58822Drain pay abscess, percut61521Remove brain lining lesion62116Reduction of skull defect58820Drain pay abscess, percut61521Removal of brain lesion62117Reduction of skull defect58900Biopsy of ovary(s)61522Removal of brain lesion62140Repair of skull defect58920Partial removal of ovary(s)61522Removal of brain lesion62141Repair of skull defect58925Removal of ovary(s)61526Removal of brain lesion62142Removal skull plate/flap58940Removal of ovary(s)61526Removal of brain lesion62143Repair of skull with graft58955Resect ovarian malignancy61531Implant brain electrodes62146Repair of skull with graft58952Resect ovarian malignancy61534Removal of brain lesion62147Repair of skull with graft58960Exploration of abdomen61534Removal of brain lesion62180Establish brain cavity shunt59120Treat ectopic pregnancy61538Removal of brain l				1		1
58770 Create new tubal opening 61514 Removal of brain abscess 62101 Treatment of head injury 58805 Draina ovary abscess, open 61518 Removal of brain lesion 62100 Repair brain fluid leakage 58820 Drain ovary abscess, open 61518 Removal of brain lesion 62115 Reduction of skull defect 58822 Transposition, ovary(s) 61520 Removal of brain lesion 62116 Reduction of skull defect 58900 Biopsy of ovary(s) 61520 Removal of brain lesion 62116 Reduction of skull defect 58900 Partial removal of ovary(s) 61521 Removal of brain lesion 62140 Repair of skull defect 58920 Partial removal of ovary(s) 61522 Removal of brain lesion 62140 Repair of skull defect 58925 Removal of ovarian cyst(s) 61524 Removal of brain lesion 62142 Repair of skull defect 58943 Removal of ovary(s) 61526 Removal of brain lesion 62142 Remove skull plate/flap 58943 Removal of ovary(s) 61530 Removal of brain lesion 62143 Repair of skull defect 58950 Resect ovarian malignancy 61531 Implant brain electrodes 62146 Repair of skull dwith graft 58951 Resect ovarian malignancy 61531 Implant brain electrodes 62146 Repair of skull dwith graft 58952 Resect ovarian malignancy 61534 Removal of brain lesion 62180 Establish brain cavity shunt 59100 Removal of brain lesion 62190 Establish brain cavity shunt 59100 Treat ectopic pregnancy 61536 Removal of brain lesion 62190 Establish brain cavity shunt 59121 Treat ectopic pregnancy 61541 Incision of brain lissue 62200 Establish brain cavity shunt 59130 Treat ectopic pregnancy 61541 Incision of brain lissue 62201 Establish brain cavity shunt 59135 Treat ectopic pregnancy 61546 Removal of brain lissue 62201 Establish brain cavity shunt 59135 Treat ectopic pregnancy 61546 Removal of brain lissue 62201 Establish brain cavity shunt 59135 Treat ectopic pregnancy 61546 Removal of brain lissue 62201 Replace/revise brain shunt 59136 Treat ectopic pregnancy 61546 Removal of brain lissue 62203 Replace/revise brain shunt 59136 Treat ectopic pregnancy 61546 Removal of priuitary gland 62258 Replace/revise brain cavity shunt 59135 Treat e		, ,				
58805         Drainage of ovarian cyst(s)         61516         Removal of brain lesion         62100         Repair brain fluid leakage           58822         Drain ovary abscess, open         61518         Removal of brain lesion         62116         Reduction of skull defect           58822         Drain ovary abscess, percut         61520         Removal of brain lesion         62116         Reduction of skull defect           58825         Transposition, ovary(s)         61521         Removal of brain lesion         62140         Repair of skull defect           58920         Partial removal of ovarian(s)         61524         Removal of brain lesion         62141         Repair of skull defect           58925         Removal of ovarian(sy)(s)         61524         Removal of brain lesion         62142         Removal of brain lesion           58943         Removal of ovary(s)         61530         Removal of brain lesion         62145         Repair of skull plate/flap           58950         Resect ovarian malignancy         61531         Implant brain electrodes         62146         Repair of skull with graft           58952         Resect ovarian malignancy         61534         Removal of brain lesion         62185         Repair of skull with graft           58952         Resect ovarian malignancy         61534         Re		1				
58820Drain o'vary abscess, open61518Removal of brain lesion62115Reduction of skull defect58822Drain ovary abscess, percut61519Remove brain lining lesion62117Reduction of skull defect58920Transposition, ovary(s)61520Removal of brain lesion62117Reduction of skull defect58920Partial removal of ovary(s)61521Removal of brain abscess62141Repair of skull defect58920Partial removal of ovary(s)61524Removal of brain abscess62141Repair of skull defect58940Removal of ovary(s)61526Removal of brain lesion62142Remove skull plate/flap58940Removal of ovary(s)61530Removal of brain lesion62143Repair of skull with graft58943Resect ovarian malignancy61531Implant brain electrodes62144Repair of skull with graft58951Resect ovarian malignancy61531Implant brain electrodes62147Repair of skull with graft58960Exploration of abdomen61535Removal of brain lesion62180Establish brain cavity shunt59100Treat ectopic pregnancy61536Removal of brain lesion62190Establish brain cavity shunt59121Treat ectopic pregnancy61538Removal of brain tissue62200Establish brain cavity shunt59130Treat ectopic pregnancy61542Removal of brain tissue62220Establish brain cavity shunt59131Treat ectopic pregnancy61542Removal o				1		
58822Drain ovary abscess, percut61519Remove brain lining lesion62116Reduction of skull defect58825Transposition, ovary(s)61520Removal of brain lesion62117Reduction of skull defect58920Biopsy of ovary(s)61521Removal of brain lesion62140Repair of skull defect58925Removal of ovarina of ovarina cyst(s)61522Removal of brain lesion62142Repair of skull defect58926Removal of ovary(s)61526Removal of brain lesion62143Repair of skull plate/flap58940Removal of ovary(s)61526Removal of brain lesion62143Repair of skull plate/flap58940Removal of ovary(s)61530Removal of brain lesion62143Repair of skull with graft58950Resect ovarian malignancy61531Implant brain electrodes62146Repair of skull with graft58951Resect ovarian malignancy61533Implant brain electrodes62147Repair of skull with graft58952Resect ovarian malignancy61535Removal of brain lesion62180Establish brain cavity shunt58950Resect ovarian malignancy61535Removal of brain lesion62190Establish brain cavity shunt58950Resect ovarian malignancy61536Removal of brain lesion62190Establish brain cavity shunt59960Exploration of abdomen61535Removal of brain lesion62190Establish brain cavity shunt599120Treat ectopic pregnancy61538Remova				1		, .
58825Transposition, ovary(s)61520Removal of brain lesion62117Reduction of skull defect58900Biopsy of ovary(s)61521Removal of brain absocess62141Repair of skull defect58925Removal of ovary(s)61524Removal of brain absocess62141Repair of skull defect58940Removal of ovary(s)61526Removal of brain lesion62142Remove skull plate/flap58940Removal of ovary(s)61530Removal of brain lesion62143Replace skull plate/flap58943Removal of ovary(s)61530Removal of brain lesion62145Repair of skull & brain58950Resect ovarian malignancy61531Implant brain electrodes62146Repair of skull with graft58951Resect ovarian malignancy61534Implant brain electrodes62147Repair of skull with graft58952Resect ovarian malignancy61534Removal of brain lesion62180Establish brain cavity shunt58960Exploration of abdomen61535Removal of brain lissue62190Establish brain cavity shunt59120Treat ectopic pregnancy61538Removal of brain tissue62200Establish brain cavity shunt59121Treat ectopic pregnancy61539Removal of brain tissue62201Brain cavity shunt59130Treat ectopic pregnancy61541Removal of brain tissue62220Establish brain cavity shunt59131Treat ectopic pregnancy61542Removal of brain tissue62223E						
58900Biopsy of ovary(s)61521Removal of brain lesion62140Repair of skull defect58920Partial removal of ovary(s)61522Removal of brain abscess62141Repair of skull defect58925Removal of ovary(s)61526Removal of brain lesion62142Removal brain defect58940Removal of ovary(s)61526Removal of brain lesion62143Replace skull plate/flap58940Removal of ovary(s)61530Removal of brain lesion62144Repair of skull & brain58950Resect ovarian malignancy61531Implant brain electrodes62146Repair of skull with graft58951Resect ovarian malignancy61533Implant brain electrodes62147Repair of skull with graft58952Resect ovarian malignancy61533Implant brain electrodes62180Establish brain cavity shunt58960Exploration of abdomen61535Removal of brain lesion62180Establish brain cavity shunt59100Remove uterus lesion61536Removal of brain lesion62190Establish brain cavity shunt59120Treat ectopic pregnancy61539Removal of brain tissue62200Establish brain cavity shunt59130Treat ectopic pregnancy61542Removal of brain tissue62220Establish brain cavity shunt59136Treat ectopic pregnancy61543Removal of brain tissue62223Establish brain cavity shunt59136Treat ectopic pregnancy61546Removal of brain tissue62						
58920Partial removal of ovary(s)61522Removal of brain abscess62141Repair of skull defect58925Removal of ovarian cyst(s)61524Removal of brain lesion62142Removal of brain lesion58940Removal of ovary(s)61526Removal of brain lesion62143Replace skull plate/flap58940Removal of ovary(s)61530Removal of brain lesion62145Repair of skull & brain58950Resect ovarian malignancy61531Implant brain electrodes62146Repair of skull with graft58951Resect ovarian malignancy61534Removal of brain lesion62180Establish brain cavity shunt58960Exploration of abdomen61535Removal of brain lesion62190Establish brain cavity shunt59100Remove uterus lesion61538Removal of brain lesion62192Establish brain cavity shunt59120Treat ectopic pregnancy61538Removal of brain lissue62200Establish brain cavity shunt59130Treat ectopic pregnancy61541Incision of brain tissue62220Establish brain cavity shunt59135Treat ectopic pregnancy61542Removal of brain tissue62220Establish brain cavity shunt59136Treat ectopic pregnancy61544Removal of brain tissue62223Establish brain cavity shunt59136Treat ectopic pregnancy61544Removal of brain tissue62223Establish brain cavity shunt59151Treat ectopic pregnancy61545Excision of br				1		
58925Removal of ovarian cyst(s)61524Removal of brain lesion62142Remove skull plate/flap58940Removal of ovary(s)61526Removal of brain lesion62143Replace skull plate/flap58943Removal of ovary(s)61530Removal of brain lesion62145Repair of skull & brain58950Resect ovarian malignancy61531Implant brain electrodes62146Repair of skull with graft58951Resect ovarian malignancy61533Implant brain electrodes62147Repair of skull with graft58952Resect ovarian malignancy61534Removal of brain lesion62180Establish brain cavity shunt58960Exploration of abdomen61535Removel of brain lesion62190Establish brain cavity shunt59100Remove uterus lesion61536Removal of brain lesion62192Establish brain cavity shunt59120Treat ectopic pregnancy61538Removal of brain tissue62200Establish brain cavity shunt59121Treat ectopic pregnancy61539Removal of brain tissue62201Brain cavity shunt w/scope59130Treat ectopic pregnancy61541Incision of brain tissue62220Establish brain cavity shunt59135Treat ectopic pregnancy61543Removal of brain tissue62225Establish brain cavity shunt59136Treat ectopic pregnancy61544Removal of brain tissue62225Replace/irrigate catheter59150Treat ectopic pregnancy61546Excision of brain						
58943Removal of ovary(s)61530Removal of brain lesion62145Repair of skull & brain58950Resect ovarian malignancy61531Implant brain electrodes62147Repair of skull with graft58951Resect ovarian malignancy61533Implant brain electrodes62147Repair of skull with graft58952Resect ovarian malignancy61534Removal of brain lesion62180Establish brain cavity shunt58960Exploration of abdomen61536Removal of brain lesion62192Establish brain cavity shunt59100Remove derus lesion61536Removal of brain lissue62200Establish brain cavity shunt59120Treat ectopic pregnancy61538Removal of brain tissue62200Establish brain cavity shunt59130Treat ectopic pregnancy61541Incision of brain tissue62201Brain cavity shunt59130Treat ectopic pregnancy61542Removal of brain tissue62220Establish brain cavity shunt59135Treat ectopic pregnancy61543Removal of brain tissue62223Establish brain cavity shunt59136Treat ectopic pregnancy61544Removal of brain tissue62223Establish brain cavity shunt59150Treat ectopic pregnancy61545Excision of brain timmor62256Replace/irrigate catheter59812Treat ectopic pregnancy61546Removal of pituitary gland62258Replace brain cavity shunt59915Treat ectopic pregnancy61546Removal of pit	58925	Removal of ovarian cyst(s)	61524			
58950Resect ovarian malignancy61531Implant brain electrodes62146Repair of skull with graft58951Resect ovarian malignancy61534Implant brain electrodes62147Repair of skull with graft58952Resect ovarian malignancy61534Removal of brain lesion62180Establish brain cavity shunt58960Exploration of abdomen61535Remove brain electrodes62190Establish brain cavity shunt59100Remove uterus lesion61536Removal of brain lesion62192Establish brain cavity shunt59120Treat ectopic pregnancy61538Removal of brain tissue62200Establish brain cavity shunt59121Treat ectopic pregnancy61539Removal of brain tissue62201Brain cavity shunt wiscope59130Treat ectopic pregnancy61541Incision of brain tissue62220Establish brain cavity shunt59135Treat ectopic pregnancy61543Removal of brain tissue62223Establish brain cavity shunt59136Treat ectopic pregnancy61544Removal of brain tissue62223Establish brain cavity shunt59150Treat ectopic pregnancy61544Removal of brain tumor62256Replace/revise brain shunt59812Treat ectopic pregnancy61548Removal of pituitary gland62257Replace brain cavity shunt59850Abortion61550Release of skull seams63170Incise spinal cord tract(s)59855Abortion61556Incise skull/sutures		Removal of ovary(s)	61526	Removal of brain lesion	62143	Replace skull plate/flap
58951Resect ovarian malignancy61533Implant brain electrodes62147Repair of skull with graft58952Resect ovarian malignancy61534Removal of brain lesion62180Establish brain cavity shunt58960Exploration of abdomen61535Remove brain electrodes62190Establish brain cavity shunt59100Remove uterus lesion61536Removal of brain lesion62192Establish brain cavity shunt59121Treat ectopic pregnancy61538Removal of brain tissue62200Establish brain cavity shunt59130Treat ectopic pregnancy61539Removal of brain tissue62201Brain cavity shunt w/scope59130Treat ectopic pregnancy61541Incision of brain tissue62220Establish brain cavity shunt59135Treat ectopic pregnancy61542Removal of brain tissue62223Establish brain cavity shunt59136Treat ectopic pregnancy61544Removal of brain tissue62225Replace/irrigate catheter59136Treat ectopic pregnancy61544Removal of brain tumor62225Replace/irrigate catheter59150Treat ectopic pregnancy61545Excision of brain tumor62256Remove brain cavity shunt59812Treat ectopic pregnancy61546Removal of pitultary gland62287Percutaneous diskectomy59850Abortion61550Release of skull seams63170Incise spinal cord tract(s)59851Abortion61556Incise skull/sutures63180<	58943			Removal of brain lesion	62145	Repair of skull & brain
58952Resect ovarian malignancy61534Removal of brain lesion62180Establish brain cavity shunt58960Exploration of abdomen61535Remove brain electrodes62190Establish brain cavity shunt59100Remove uterus lesion61536Removal of brain lesion62192Establish brain cavity shunt59120Treat ectopic pregnancy61538Removal of brain tissue62200Establish brain cavity shunt59121Treat ectopic pregnancy61539Removal of brain tissue62201Brain cavity shunt w/scope59130Treat ectopic pregnancy61541Incision of brain tissue62220Establish brain cavity shunt59135Treat ectopic pregnancy61542Removal of brain tissue62220Establish brain cavity shunt59136Treat ectopic pregnancy61543Removal of brain tissue62220Establish brain cavity shunt59150Treat ectopic pregnancy61544Removal of brain tissue62225Replace/irrigate catheter59151Treat ectopic pregnancy61545Excision of brain tumor62230Replace/irvise brain shunt59812Treat ectopic pregnancy61546Removal of pituitary gland62256Removal of pituitary gland59812Treat ectopic pregnancy61548Removal of pituitary gland62287Percutaneous diskectomy59850Abortion61550Release of skull seams63170Incise spinal cord tract(s)59851Abortion61556Incise skull/sutures63180<						
58960Exploration of abdomen61535Remove brain electrodes62190Establish brain cavity shunt59100Remove uterus lesion61536Removal of brain lesion62192Establish brain cavity shunt59120Treat ectopic pregnancy61538Removal of brain tissue62200Establish brain cavity shunt59121Treat ectopic pregnancy61539Removal of brain tissue62201Brain cavity shunt w/scope59130Treat ectopic pregnancy61541Incision of brain tissue62220Establish brain cavity shunt59135Treat ectopic pregnancy61542Removal of brain tissue62223Establish brain cavity shunt59136Treat ectopic pregnancy61543Removal of brain tissue62225Replace/irrigate catheter59136Treat ectopic pregnancy61544Remove & treat brain lesion62230Replace/irrigate catheter59150Treat ectopic pregnancy61545Excision of brain tumor62256Remove brain cavity shunt59151Treat ectopic pregnancy61546Removal of pituitary gland62258Replace/irevise brain shunt59851Treat ectopic pregnancy61546Removal of pituitary gland62258Replace brain cavity shunt59851Treat ectopic pregnancy61548Removal of pituitary gland62287Percutaneous diskectomy59851Abortion61550Release of skull seams63170Drainage of spinal cyst59852Abortion61556Incise skull/sutures63180						
59100Remove uterus lesion61536Removal of brain lesion62192Establish brain cavity shunt59120Treat ectopic pregnancy61538Removal of brain tissue62200Establish brain cavity shunt59121Treat ectopic pregnancy61539Removal of brain tissue62201Brain cavity shunt w/scope59130Treat ectopic pregnancy61541Incision of brain tissue62220Establish brain cavity shunt59135Treat ectopic pregnancy61542Removal of brain tissue62223Establish brain cavity shunt59136Treat ectopic pregnancy61544Removal of brain tissue62225Replace/irrigate catheter59136Treat ectopic pregnancy61544Removal of brain tumor62256Replace/irrigate catheter59150Treat ectopic pregnancy61545Excision of brain tumor62256Remove brain cavity shunt59151Treat ectopic pregnancy61546Removal of pituitary gland62258Replace/revise brain shunt598512Treatment of miscarriage61548Removal of pituitary gland62258Percutaneous diskectomy59852Abortion61550Release of skull seams63170Incise spinal cyst59855Abortion61557Incise skull/sutures63180Revise spinal cord ligaments59856Abortion61558Excision of skull/sutures63185Incise spinal column/nerves59870Evacuate mole of uterus61563Excision of skull tumor63190Incise spinal colum				1		
59120Treat ectopic pregnancy61538Removal of brain tissue62200Establish brain cavity shunt59121Treat ectopic pregnancy61539Removal of brain tissue62201Brain cavity shunt w/scope59130Treat ectopic pregnancy61541Incision of brain tissue62220Establish brain cavity shunt59135Treat ectopic pregnancy61542Removal of brain tissue62223Establish brain cavity shunt59135Treat ectopic pregnancy61543Removal of brain tissue62225Replace/irrigate catheter59136Treat ectopic pregnancy61544Remove & treat brain lesion62230Replace/irrigate catheter59150Treat ectopic pregnancy61545Excision of brain tumor62256Remove brain cavity shunt59812Treat ectopic pregnancy61546Removal of pituitary gland62258Replace/revise brain shunt59815Treat ectopic pregnancy61546Removal of pituitary gland62258Replace brain cavity shunt59850Abortion61550Release of skull seams63170Incise spinal cord tract(s)59851Abortion61556Incise skull/sutures63172Drainage of spinal cyst59852Abortion61556Incise skull/sutures63180Revise spinal cord ligaments59856Abortion61557Excision of skull tumor63182Revise spinal column/nerves59870Evacuate mole of uterus61563Excision of skull tumor63190Incise spinal column/nerve				1		
59121Treat ectopic pregnancy61539Removal of brain tissue62201Brain cavity shunt w/scope59130Treat ectopic pregnancy61541Incision of brain tissue62220Establish brain cavity shunt59130Treat ectopic pregnancy61542Removal of brain tissue62223Establish brain cavity shunt59135Treat ectopic pregnancy61543Removal of brain tissue62225Replace/irrigate catheter59136Treat ectopic pregnancy61544Remove & treat brain lesion62230Replace/irrigate catheter59150Treat ectopic pregnancy61545Excision of brain tumor62256Remove brain cavity shunt59151Treat ectopic pregnancy61546Removal of pituitary gland62258Replace brain cavity shunt59812Treatment of miscarriage61548Removal of pituitary gland62287Percutaneous diskectomy59850Abortion61550Release of skull seams63170Incise spinal cord tract(s)59851Abortion61556Incise skull/sutures63173Drainage of spinal cyst59855Abortion61556Incise skull/sutures63180Revise spinal cord ligaments59857Abortion61559Excision of skull/sutures63185Incise spinal column/nerves59870Evacuate mole of uterus61564Excision of skull tumor63190Incise spinal column/nerves60210Partial thyroid excision61571Incise skull for brain wound63195Incise spinal column						
59130Treat ectopic pregnancy61541Incision of brain tissue62220Establish brain cavity shunt59130Treat ectopic pregnancy61542Removal of brain tissue62223Establish brain cavity shunt59135Treat ectopic pregnancy61543Removal of brain tissue62225Replace/irrigate catheter59136Treat ectopic pregnancy61544Remove & treat brain lesion62230Replace/irrigate catheter59150Treat ectopic pregnancy61545Excision of brain tumor62256Remove brain cavity shunt59151Treat ectopic pregnancy61546Removal of pituitary gland62258Replace/revise brain shunt59812Treatment of miscarriage61548Removal of pituitary gland62287Percutaneous diskectomy59850Abortion61550Release of skull seams63170Incise spinal cord tract(s)59851Abortion61555Release of skull seams63172Drainage of spinal cyst59852Abortion61556Incise skull/sutures63180Revise spinal cord ligaments59856Abortion61557Incise skull/sutures63180Revise spinal cord ligaments59857Abortion61558Excision of skull tumor63190Incise spinal column/nerves59870Evacuate mole of uterus61563Excision of skull tumor63191Incise spinal column/nerves60210Partial thyroid excision61571Incise skull for brain wound63196Incise spinal column & cord				1		
Treat ectopic pregnancy 59130 Treat ectopic pregnancy 59135 Treat ectopic pregnancy 59136 Treat ectopic pregnancy 5914 Remove final treat brain lesion 62230 Remove brain tumor 62258 Replace Previate catheter 62258 Replace Prain cavity shunt 62258 Replace Prain cavity shunt 62258 Replace Prain cavity shunt 62258 Replace of skull seams 63170 Incise spinal cord ligaments 63170 Drainage of spinal cyst 63173 Drainage of spinal cyst 63180 Revise spinal cord ligaments 63180 Revise spinal cor				1		
Treat ectopic pregnancy 59136 Treat ectopic pregnancy 59136 Treat ectopic pregnancy 59150 Treat ectopic pregnancy 59151 Treat ectopic pregnancy 59812 Treatment of miscarriage 59850 Abortion 59851 Abortion 59852 Abortion 59855 Abortion 59856 Abortion 59857 Abortion 59857 Abortion 59857 Abortion 59857 Abortion 598587 Abortion 598587 Abortion 59859 Abortion 61559 Excision of brain tumor 61559 Excision of pituitary gland 62258 Remove brain cavity shunt 62258 Replace brain cavity shunt 62268 Replace brain cavity shunt 62629 Partial thyroid excision 61550 Remove foreign body, brain 6226 Replace brain cavity shunt 6226 Replace brain cavity shunt 6226 Replace brain cavity shunt 6226						
59136Treat ectopic pregnancy61544Remove & treat brain lesion62230Replace/revise brain shunt59150Treat ectopic pregnancy61545Excision of brain tumor62256Remove brain cavity shunt59151Treat ectopic pregnancy61546Removal of pituitary gland62258Replace brain cavity shunt59812Treatment of miscarriage61548Removal of pituitary gland62287Percutaneous diskectomy59850Abortion61550Release of skull seams63170Incise spinal cord tract(s)59851Abortion61552Release of skull seams63172Drainage of spinal cyst59852Abortion61556Incise skull/sutures63173Drainage of spinal cord ligaments59855Abortion61557Incise skull/sutures63180Revise spinal cord ligaments59856Abortion61558Excision of skull/sutures63182Revise spinal cord ligaments59870Evacuate mole of uterus61563Excision of skull tumor63190Incise spinal column/nerves60200Remove thyroid lesion61564Excision of skull tumor63191Incise spinal column/nerves60210Partial thyroid excision61571Remove foreign body, brain63196Incise spinal column & cord60212Partial thyroid excision61575Skull base/brainstem surgery63197Incise spinal column & cord				1		
59150Treat ectopic pregnancy61545Excision of brain tumor62256Remove brain cavity shunt59151Treat ectopic pregnancy61546Removal of pituitary gland62258Replace brain cavity shunt59812Treatment of miscarriage61548Removal of pituitary gland62287Percutaneous diskectomy59850Abortion61550Release of skull seams63170Incise spinal cord tract(s)59851Abortion61552Release of skull seams63172Drainage of spinal cyst59852Abortion61556Incise skull/sutures63173Drainage of spinal cyst59855Abortion61557Incise skull/sutures63180Revise spinal cord ligaments59856Abortion61558Excision of skull/sutures63182Revise spinal cord ligaments59877Abortion61559Excision of skull tumor63185Incise spinal column/nerves59870Evacuate mole of uterus61563Excision of skull tumor63190Incise spinal column/nerves60200Remove thyroid lesion61564Excision of skull tumor63191Incise spinal column/nerves60210Partial thyroid excision61571Remove foreign body, brain63195Incise spinal column & cord60212Partial thyroid excision61575Skull base/brainstem surgery63197Incise spinal column & cord				1		
59151Treat ectopic pregnancy61546Removal of pituitary gland62258Replace brain cavity shunt59812Treatment of miscarriage61548Removal of pituitary gland62287Percutaneous diskectomy59850Abortion61550Release of skull seams63170Incise spinal cord tract(s)59851Abortion61552Release of skull seams63172Drainage of spinal cyst59852Abortion61556Incise skull/sutures63173Drainage of spinal cyst59855Abortion61557Incise skull/sutures63180Revise spinal cord ligaments59856Abortion61558Excision of skull/sutures63182Revise spinal cord ligaments59877Abortion61559Excision of skull/sutures63185Incise spinal column/nerves59870Evacuate mole of uterus61563Excision of skull tumor63190Incise spinal column/nerves60200Remove thyroid lesion61564Excision of skull tumor63191Incise spinal column/nerves60210Partial thyroid excision61571Remove foreign body, brain63195Incise spinal column & cord60212Partial thyroid excision61575Skull base/brainstem surgery63197Incise spinal column & cord				1		
59812Treatment of miscarriage61548Removal of pituitary gland62287Percutaneous diskectomy59850Abortion61550Release of skull seams63170Incise spinal cord tract(s)59851Abortion61552Release of skull seams63172Drainage of spinal cyst59852Abortion61556Incise skull/sutures63173Drainage of spinal cyst59855Abortion61557Incise skull/sutures63180Revise spinal cord ligaments59856Abortion61558Excision of skull/sutures63182Revise spinal cord ligaments59857Abortion61559Excision of skull/sutures63185Incise spinal column/nerves59870Evacuate mole of uterus61563Excision of skull tumor63190Incise spinal column/nerves60200Remove thyroid lesion61564Excision of skull tumor63191Incise spinal column/nerves60210Partial thyroid excision61570Remove foreign body, brain63195Incise spinal column & cord60212Partial thyroid excision61571Incise skull for brain wound63196Incise spinal column & cord60220Partial removal of thyroid61575Skull base/brainstem surgery63197Incise spinal column & cord						,
59850Abortion61550Release of skull seams63170Incise spinal cord tract(s)59851Abortion61552Release of skull seams63172Drainage of spinal cyst59852Abortion61556Incise skull/sutures63173Drainage of spinal cyst59855Abortion61557Incise skull/sutures63180Revise spinal cord ligaments59856Abortion61558Excision of skull/sutures63182Revise spinal column/nerves59877Abortion61559Excision of skull/sutures63185Incise spinal column/nerves60200Remove thyroid lesion61563Excision of skull tumor63190Incise spinal column/nerves60210Partial thyroid excision61570Remove foreign body, brain63195Incise spinal column & cord60212Partial thyroid excision61571Incise skull for brain wound63196Incise spinal column & cord60220Partial removal of thyroid61575Skull base/brainstem surgery63197Incise spinal column & cord						
59851Abortion61552Release of skull seams63172Drainage of spinal cyst59852Abortion61556Incise skull/sutures63173Drainage of spinal cyst59855Abortion61557Incise skull/sutures63180Revise spinal cord ligaments59856Abortion61558Excision of skull/sutures63182Revise spinal column/nerves59870Abortion61559Excision of skull/sutures63185Incise spinal column/nerves60200Remove thyroid lesion61563Excision of skull tumor63190Incise spinal column/nerves60210Partial thyroid excision61570Remove foreign body, brain63195Incise spinal column & cord60212Partial thyroid excision61571Incise skull for brain wound63196Incise spinal column & cord60220Partial removal of thyroid61575Skull base/brainstem surgery63197Incise spinal column & cord	59850		61550		63170	
59852Abortion61556Incise skull/sutures63173Drainage of spinal cyst59855Abortion61557Incise skull/sutures63180Revise spinal cord ligaments59856Abortion61558Excision of skull/sutures63182Revise spinal cord ligaments59870Abortion61559Excision of skull/sutures63185Incise spinal column/nerves59870Evacuate mole of uterus61563Excision of skull tumor63190Incise spinal column/nerves60200Remove thyroid lesion61564Excision of skull tumor63191Incise spinal column/nerves60210Partial thyroid excision61570Remove foreign body, brain63195Incise spinal column & cord60212Partial thyroid excision61571Incise skull for brain wound63196Incise spinal column & cord60220Partial removal of thyroid61575Skull base/brainstem surgery63197Incise spinal column & cord				1		
59855Abortion61557Incise skull/sutures63180Revise spinal cord ligaments59856Abortion61558Excision of skull/sutures63182Revise spinal cord ligaments59870Abortion61559Excision of skull/sutures63185Incise spinal column/nerves59870Evacuate mole of uterus61563Excision of skull tumor63190Incise spinal column/nerves60200Remove thyroid lesion61564Excision of skull tumor63191Incise spinal column/nerves60210Partial thyroid excision61570Remove foreign body, brain63195Incise spinal column & cord60212Partial thyroid excision61571Incise skull for brain wound63196Incise spinal column & cord60220Partial removal of thyroid61575Skull base/brainstem surgery63197Incise spinal column & cord	59852	Abortion		Incise skull/sutures	63173	
59857 Abortion 61559 Excision of skull/sutures 63185 Incise spinal column/nerves 62200 Remove thyroid lesion 61564 Excision of skull tumor 63190 Incise spinal column/nerves 6220 Partial thyroid excision 61571 Remove foreign body, brain 6220 Partial removal of thyroid 61575 Skull base/brainstem surgery 63197 Incise spinal column/nerves 63191 Incise spinal column/nerves 63195 Incise spinal column/nerves 6319	59855	Abortion	61557	Incise skull/sutures	63180	
59870 Evacuate mole of uterus 61563 Excision of skull tumor 63190 Incise spinal column/nerves 60200 Remove thyroid lesion 61564 Excision of skull tumor 63191 Incise spinal column/nerves 60210 Partial thyroid excision 61570 Remove foreign body, brain 63195 Incise spinal column/nerves 63195 Incise spinal column/nerves 63195 Incise spinal column & cord 60212 Partial thyroid excision 61571 Skull base/brainstem surgery 63197 Incise spinal column & cord 63196 Incise spinal column & cord 63196 Incise spinal column/nerves 63190 Incise spinal column/nerves 63191 Incise spinal column/nerves 63191 Incise spinal column/nerves 63195 Incise spinal column & cord 63196 Incise spinal column/nerves 63191 Incise spinal column/nerves 63195 Incise spinal column/nerves 63195 Incise spinal column/nerves 63195 Incise spinal column & cord 63196 Incise spinal column & cord 63196		1		1		
60200 Remove thyroid lesion Partial thyroid excision Partial thyroid excision Partial thyroid excision Partial removal of thyroid Partial removal of		1		1		
60210 Partial thyroid excision Partial thyroid excision Partial thyroid excision Partial removal of thyroid Partial remova		1		1		
60212 Partial thyroid excision 61571 Incise skull for brain wound 60220 Partial removal of thyroid 61575 Skull base/brainstem surgery 63197 Incise spinal column & cord 63196 Incise spinal column & cord 63197 Incise spinal column & cord						
60220 Partial removal of thyroid 61575 Skull base/brainstem surgery 63197 Incise spinal column & cord						
00225   Fatual reflioval of thyroto   01010   nepair dura   03198   Incise spinal column & cord						
	0∪∠∠5	raniai removai oi myroid	אוטוס	nepair dura	03198	incise spinal column & cord

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PERC RECOMMENDATIONS ON PE DIRECT COST INPUTS—Continued

CPT Codes	Short descriptor	CPT Codes	Short descriptor	CPT Codes	Short descriptor
63199	Incise spinal column & cord	64736	Incision of chin nerve	65260	Remove foreign body from eye
63200	Release of spinal cord	64738	Incision of jaw nerve	65265	Remove foreign body from eye
63250	Revise spinal cord vessels	64742	Incision of facial nerve	65270	Repair of eye wound
63251	Revise spinal cord vessels	64744	Incise nerve, back of head	65272	Repair of eye wound
63252	Revise spinal cord vessels	64746	Incise diaphragm nerve	65273	Repair of eye wound
63265	Excise intraspinal lesion	64752	Incision of vagus nerve	65275	Repair of eye wound
63266					
	Excise intraspinal lesion	64755	Incision of stomach nerves	65280	Repair of eye wound
63267	Excise intraspinal lesion	64760	Incision of vagus nerve	65285	Repair of eye wound
63268	Excise intraspinal lesion	64761	Incision of pelvis nerve	65286	Repair of eye wound
63270	Excise intraspinal lesion	64763	Incise hip/thigh nerve	65290	Repair of eye socket wound
63271	Excise intraspinal lesion	64766	Incise hip/thigh nerve	65400	Removal of eye lesion
63272	Excise intraspinal lesion	64771	Sever cranial nerve	65410	Biopsy of cornea
63273	Excise intraspinal lesion	64772	Incision of spinal nerve	65420	Removal of eye lesion
63275	Biopsy/excise spinal tumor	64774	Remove skin nerve lesion	65426	Removal of eye lesion
63276	Biopsy/excise spinal tumor	64776	Remove digit nerve lesion	65430	Corneal smear
63277	Biopsy/excise spinal tumor	64782	Remove limb nerve lesion	65435	Curette/treat cornea
63278	Biopsy/excise spinal tumor	64784	Remove nerve lesion	65436	Curette/treat cornea
63280	Biopsy/excise spinal tumor	64786	Remove sciatic nerve lesion	65450	Treatment of corneal lesion
63281	Biopsy/excise spinal tumor	64788	Remove skin nerve lesion	65600	Revision of cornea
63282	Biopsy/excise spinal tumor	64790	Removal of nerve lesion	65710	Corneal transplant
63283	Biopsy/excise spinal tumor	64792	Removal of nerve lesion	65730	Corneal transplant
63285	Biopsy/excise spinal tumor	64802	Remove sympathetic nerves	65750	Corneal transplant
63286	Biopsy/excise spinal tumor	64804	Remove sympathetic nerves	65755	Corneal transplant
63287	Biopsy/excise spinal tumor	64809	Remove sympathetic nerves	65760	Revision of cornea
63290	Biopsy/excise spinal tumor	64818	Remove sympathetic nerves	65765	Revision of cornea
63300	Removal of vertebral body	64820	Remove sympathetic nerves	65767	Corneal tissue transplant
63301	Removal of vertebral body	64831	Repair of digit nerve	65770	Revise cornea with implant
63302	Removal of vertebral body	64834	Repair of hand or foot nerve	65771	Radial keratotomy
63303	Removal of vertebral body	64835	Repair of hand or foot nerve	65772	Correction of astigmatism
63304	Removal of vertebral body	64836	Repair of hand or foot nerve	65775	Correction of astigmatism
63305	Removal of vertebral body	64840	Repair of leg nerve	65780	Ocular reconst, transplant
63306	1			65781	
	Removal of vertebral body	64856	Repair/transpose nerve		Ocular reconst, transplant
63307	Removal of vertebral body	64857	Repair arm/leg nerve	65782	Ocular reconst, transplant
63650	Implant neuroelectrodes	64858	Repair sciatic nerve	65800	Drainage of eye
63655	Implant neuroelectrodes	64861	Repair of arm nerves	65805	Drainage of eye
63660	Revise/remove neuroelectrode	64862	Repair of low back nerves	65810	Drainage of eye
63685	Insrt/redo spine n generator	64870	Fusion of facial/other nerve	65815	Drainage of eye
63688	Revise/remove neuroreceiver	64890	Nerve graft, hand or foot	65820	Relieve inner eye pressure
63700	Repair of spinal herniation	64891	Nerve graft, hand or foot	65850	Incision of eye
63702	Repair of spinal herniation	64892	Nerve graft, arm or leg	65855	Laser surgery of eye
63704	Repair of spinal herniation	64893	Nerve graft, arm or leg	65860	Incise inner eye adhesions
63706	Repair of spinal herniation	64895	Nerve graft, hand or foot	65865	Incise inner eye adhesions
63707	Repair spinal fluid leakage	64896	Nerve graft, hand or foot	65870	Incise inner eye adhesions
63709	Repair spinal fluid leakage	64897	Nerve graft, arm or leg	65875	Incise inner eye adhesions
63710	Graft repair of spine defect	64898	Nerve graft, arm or leg	65880	Incise inner eye adhesions
63740	Install spinal shunt	64905	Nerve pedicle transfer	65900	Remove eye lesion
63741	Install spinal shunt	64907	Nerve pedicle transfer	65920	Remove implant of eye
63744	Revision of spinal shunt	65091	Revise eye	65930	Remove blood clot from eye
63746	Removal of spinal shunt	65093	Revise eye with implant	66020	Injection treatment of eye
64573	Implant neuroelectrodes	65101	Removal of eye	66030	Injection treatment of eye
64575	Implant neuroelectrodes	65103	Remove eye/insert implant	66130	Remove eye lesion
64577	Implant neuroelectrodes	65105	Remove eye/attach implant	66150	Glaucoma surgery
64580	Implant neuroelectrodes	65110	Removal of eye	66155	Glaucoma surgery
64612	Destroy nerve, face muscle	65112	Remove eye/revise socket	66160	Glaucoma surgery
64702	Revise finger/toe nerve	65114	Remove eye/revise socket	66165	Glaucoma surgery
64704	Revise hand/foot nerve	65125	Revise ocular implant	66170	l
64708		65130	·		Glaucoma surgery
	Revise arm/leg nerve		Insert ocular implant	66172	Incision of eye
64712	Revision of sciatic nerve	65135	Insert ocular implant	66180	Implant eye shunt
64713	Revision of arm nerve(s)	65140	Attach ocular implant	66185	Revise eye shunt
64714	Revise low back nerve(s)	65150	Revise ocular implant	66220	Repair eye lesion
64718	Revise ulnar nerve at elbow	65155	Reinsert ocular implant	66225	Repair/graft eye lesion
64719	Revise ulnar nerve at wrist	65175	Removal of ocular implant	66250	Follow-up surgery of eye
64721	Carpal tunnel surgery	65205	Remove foreign body from eye	66500	Incision of iris
64722	Relieve pressure on nerve(s)	65210	Remove foreign body from eye	66505	Incision of iris
64726	Release foot/toe nerve	65220	Remove foreign body from eye	66600	Remove iris and lesion
64732	Incision of brow nerve	65222	Remove foreign body from eye	66605	Removal of iris
64734	Incision of cheek nerve	65235	Remove foreign body from eye	66625	Removal of iris
			-		

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PERC RECOMMENDATIONS ON PE DIRECT COST INPUTS—Continued

CPT	Chart descriptor	CPT	Chart descriptor	CPT	Chart descriptor
Codes	Short descriptor	Codes	Short descriptor	Codes	Short descriptor
66630	Removal of iris	67318	Revise eye muscle(s)	67950	Revision of eyelid
66635	Removal of iris	67320	Revise eye muscle(s) add-on	67961	Revision of eyelid
66680	Repair iris & ciliary body	67331	Eye surgery follow-up add-on	67966	Revision of eyelid
66682 66700	Repair iris & ciliary body	67332 67334	Rerevise eye muscles add-on	67971 67973	Reconstruction of eyelid Reconstruction of eyelid
66710	Destruction, ciliary body Ciliary transsleral therapy	67335	Revise eye muscle w/suture Eye suture during surgery	67974	Reconstruction of eyelid
66711	Ciliary endoscopic ablation	67340	Revise eye muscle add-on	67975	Reconstruction of eyelid
66720	Destruction, ciliary body	67343	Release eye tissue	67999	Revision of eyelid
66740	Destruction, ciliary body	67345	Destroy nerve of eye muscle	68020	Incise/drain eyelid lining
66761	Revision of iris	67350	Biopsy eye muscle	68040	Treatment of eyelid lesions
66762	Revision of iris	67399	Eye muscle surgery procedure	68100	Biopsy of eyelid lining
66770	Removal of inner eye lesion	67400	Explore/biopsy eye socket	68110	Remove eyelid lining lesion
66820	Incision, secondary cataract	67405	Explore/drain eye socket	68115	Remove eyelid lining lesion
66821	After cataract laser surgery	67412	Explore/treat eye socket	68130	Remove eyelid lining lesion
66825	Reposition intraocular lens	67413	Explore/treat eye socket	68135	Remove eyelid lining lesion
66830	Removal of lens lesion	67414	Explr/decompress eye socket	68200	Treat eyelid by injection
66840	Removal of lens material	67415	Aspiration, orbital contents	68320	Revise/graft eyelid lining
66850	Removal of lens material	67420	Explore/treat eye socket	68325	Revise/graft eyelid lining
66852	Removal of lens material	67430	Explore/treat eye socket	68326	Revise/graft eyelid lining
66920	Extraction of lens	67440	Explore/drain eye socket	68328	Revise/graft eyelid lining
66930	Extraction of lens	67445	Explr/decompress eye socket	68330	Revise eyelid lining
66940	Extraction of lens	67450	Explore/biopsy eye socket	68335	Revise/graft eyelid lining
66982	Cataract surgery, complex	67500	Inject/treat eye socket	68340	Separate eyelid adhesions
66983	Cataract surg w/iol, 1 stage	67505	Inject/treat eye socket	68360	Revise eyelid lining
66984		67515	Inject/treat eye socket	68362	Revise eyelid lining
66985	Insert lens prosthesis	67550	Insert eye socket implant	68371	Harvest eye tissue, alograft
66986	Exchange lens prosthesis	67560	Revise eye socket implant	68399	Eyelid lining surgery
66990	Ophthalmic endoscope add-on	67570	Decompress optic nerve	68400	Incise/drain tear gland
66999	Eye surgery procedure	67599	Orbit surgery procedure	68420	Incise/drain tear sac
67005	Partial removal of eye fluid	67700	Drainage of eyelid abscess	68440	Incise tear duct opening
67010	Partial removal of eye fluid	67710	Incision of eyelid	68500	Removal of tear gland
67015	Release of eye fluid	67715	Incision of eyelid fold	68505	Partial removal, tear gland
67025	Replace eye fluid	67800	Remove eyelid lesion	68510	Biopsy of tear gland
67027	Implant eye drug system	67801	Remove eyelid lesions	68520	Removal of tear sac
67028	Injection eye drug	67805	Remove eyelid lesions	68525	Biopsy of tear sac
67030	Incise inner eye strands	67808	Remove eyelid lesion(s)	68530	Clearance of tear duct
67031		67810	Biopsy of eyelid	68540	Remove tear gland lesion
67036	Removal of inner eye fluid	67820	Revise eyelashes	68550	Remove tear gland lesion
67038	Strip retinal membrane	67825	Revise eyelashes	68700	Repair tear ducts
67039	Laser treatment of retina  Laser treatment of retina	67830	Revise eyelashes	68705	Revise tear duct opening
67040 67101		67835 67840	Revise eyelashes Remove eyelid lesion	68720 68745	Create tear sac drain Create tear duct drain
67105	Repair detached retina Repair detached retina	67850	Treat eyelid lesion	68750	Create tear duct drain
67107	Repair detached retina	67875	Closure of eyelid by suture	68760	Close tear duct opening
67107		67880	Revision of eyelid	68761	
67110		67882	Revision of eyelid	68770	Close tear duct opening  Close tear system fistula
67112	Rerepair detached retina	67900	Repair brow defect	68801	Dilate tear duct opening
67115	Release encircling material	67901	Repair eyelid defect	68810	Probe nasolacrimal duct
67120	Remove eye implant material	67902	Repair eyelid defect	68811	Probe nasolacrimal duct
67121	Remove eye implant material	67903	Repair eyelid defect	68815	Probe nasolacrimal duct
67141	Treatment of retina	67904	Repair eyelid defect	68840	Explore/irrigate tear ducts
67145	Treatment of retina	67906	Repair eyelid defect	68850	Injection for tear sac x-ray
67208	Treatment of retinal lesion	67908	Repair eyelid defect	68899	Tear duct system surgery
67210	Treatment of retinal lesion	67909	Revise eyelid defect	76075	Dxa bone density, axial
67218	Treatment of retinal lesion	67911	Revise eyelid defect	76510	Ophth us, b & quant a
67220	Treatment of choroid lesion	67912	Correction eyelid w/implant	76511	Ophth us, quant a only
67221	Ocular photodynamic ther	67914	Repair eyelid defect	76512	Ophth us, b w/non-quant a
67225	Eye photodynamic ther add-on	67915	Repair eyelid defect	76513	Echo exam of eye, water bath
67227	Treatment of retinal lesion	67916	Repair eyelid defect	76514	Echo exam of eye, thickness
67228	Treatment of retinal lesion	67917	Repair eyelid defect	76516	Echo exam of eye
67250	Reinforce eye wall	67921	Repair eyelid defect	76519	Echo exam of eye
67255	Reinforce/graft eye wall	67922	Repair eyelid defect	76529	Echo exam of eye
67299	Eye surgery procedure	67923	Repair eyelid defect	78350	Bone mineral, single photon
67311	Revise eye muscle	67924	Repair eyelid defect	78472	Gated heart, planar, single
67312	Revise two eye muscles	67930	Repair eyelid wound	78481	Heart first pass, single
67314	Revise eye muscle	67935	Repair eyelid wound	78483	Heart first pass, multiple
67316	Revise two eye muscles	67938	Remove eyelid foreign body	91010	Esophagus motility study

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PERC RECOMMENDATIONS ON PE DIRECT COST INPUTS—Continued

CPT Codes	Short descriptor	CPT Codes	Short descriptor	CPT Codes	Short descriptor
91034 91037 91038 92002 92004 92012 92015 92018 92019 92060 92065 92070 92081 92083	Refraction New eye exam & treatment Eye exam & treatment Special eye evaluation Special eye evaluation Orthoptic/pleoptic training	92100 92120 92130 92135 92136 92140 92225 92230 92235 92240 92250 92260 92260 92270 92275	Serial tonometry exam(s) Tonography & eye evaluation Water provocation tonography Opthalmic dx imaging Ophthalmic biometry Glaucoma provocative tests Special eye exam, initial Special eye exam, subsequent Eye exam with photos Eye exam with photos Icg angiography Eye exam with photos Ophthalmoscopy/dynamome try Eye muscle evaluation Electro-oculography Electroretinography Color vision examination	92284 92285 92286 92310 92311 92313 92314 92315 92316 92317 92325	Dark adaptation eye exam Eye photography Internal eye photography Internal eye photography Contact lens fitting Contact lens fitting Contact lens fitting Contact lens fitting Prescription of contact lens Replacement of contact lens

ADDENDUM D.—PROPOSED 2007 GEOGRAPHIC PRACTICE COST INDICES BY MEDICARE CARRIER AND LOCALITY

Carrier	Locality	Locality name	Work GPCI	PE GPCI	MP GPCI
00510	00	Alabama	0.982	0.847	0.740
00831	01	Alaska	1.017	1.105	1.013
00832	00	Arizona	0.987	0.994	1.052
00520	13	Arkansas	0.961	0.832	0.431
31140	03	Marin/Napa/Solano, CA	1.035	1.342	0.640
31140	05	San Francisco, CA	1.060	1.546	0.640
31140	06	San Mateo, CA	1.073	1.539	0.629
31140	07	Oakland/Berkley, CA	1.054	1.373	0.640
31140	09	Santa Clara, CA	1.083	1.543	0.595
31146	17	Ventura, CA	1.028	1.181	0.732
31146	18	Los Angeles, CA	1.041	1.158	0.939
31146	26	Anaheim/Santa Ana, CA	1.034	1.238	0.939
31140	99	Rest of California*	1.007	1.054	0.721
31146	99	Rest of California*	1.007	1.054	0.721
00824	01	Colorado	0.986	1.015	0.790
00591	00	Connecticut	1.038	1.172	0.886
00903	01	DC + MD/VA Suburbs	1.048	1.252	0.911
00902	01	Delaware	1.012	1.020	0.877
00590	03	Fort Lauderdale, FL	0.988	0.990	1.675
00590	04	Miami, FL	1.000	1.048	2.233
00590	99	Rest of Florida	0.973	0.936	1.251
00511	01	Atlanta, GA	1.010	1.091	0.950
00511	99	Rest of Georgia	0.979	0.874	0.950
00833	01	Hawaii/Guam	1.005	1.113	0.930
05130	00	Idaho	0.968	0.869	0.767
00952	12			0.869	1.722
00952	15	East St. Louis, IL	0.988	1.117	1.722
	_	Suburban Chicago, IL	1.018		
00952	16	Chicago, IL	1.025	1.128	1.837
00952	99	Rest of Illinois	0.974	0.874	1.174
00630	00	Indiana	0.985	0.908	0.429
00826	00	lowa	0.967	0.869	0.579
00650	00	Kansas*	0.968	0.880	0.709
00740	04	Kansas*	0.968	0.880	0.709
00660	00	Kentucky	0.970	0.855	0.859
00528	01	New Orleans, LA	0.986	0.947	1.178
00528	99	Rest of Louisiana	0.970	0.848	1.000
31142	03	Southern Maine	0.980	1.014	0.626
31142	99	Rest of Maine	0.962	0.887	0.626
00901	01	Baltimore/Surr. Cntys, MD	1.012	1.080	0.932
00901	99	Rest of Maryland	0.993	0.981	0.748
31143	01	Metropolitan Boston	1.030	1.331	0.810
31143	99	Rest of Massachusetts	1.007	1.015	0.810
00953	01	Detroit, MI	1.037	1.056	2.700
00953	99	Rest of Michigan	0.997	0.922	1.494
00954	00	Minnesota	0.991	1.006	0.404
					2

# ADDENDUM D.—PROPOSED 2007 GEOGRAPHIC PRACTICE COST INDICES BY MEDICARE CARRIER AND LOCALITY—Continued

Carrier	Locality	Locality name	Work GPCI	PE GPCI	MP GPCI
00512	00	Mississippi	0.960	0.841	0.711
00523	01	Metropolitan St. Louis, MO	0.992	0.956	0.926
00740	02	Metropolitan Kansas City, MO	0.989	0.977	0.931
00523	99	Rest of Missouri*	0.950	0.803	0.878
00740	99	Rest of Missouri*	0.950	0.803	0.878
00751	01	Montana	0.950	0.845	0.889
00655	00	Nebraska	0.959	0.876	0.447
00834	00	Nevada	1.003	1.045	1.050
31144	40	New Hampshire	0.981	1.029	0.927
00805	01	Northern NJ	1.058	1.222	0.958
00805	99	Rest of New Jersey	1.043	1.121	0.958
00521	05	New Mexico	0.972	0.888	0.880
00801	99	Rest of New York	0.997	0.919	0.666
00803	01	Manhattan, NY	1.065	1.300	1.000
00803	02	NYC Suburbs/Long I., NY	1.052	1.283	1.756
00803	03	Poughkpsie/N NYC Suburbs, NY	1.014	1.076	1.148
14330	04	Queens, NY	1.032	1.230	1.682
05535	00	North Carolina	0.971	0.922	0.630
00820	01	North Dakota	0.946	0.861	0.593
00883	00	Ohio	0.992	0.934	0.960
00522	00	Oklahoma	0.964	0.856	0.376
00835	01	Portland, OR	1.002	1.059	0.434
00835	99	Rest of Oregon	0.968	0.927	0.434
00865	01	Metropolitan Philadelphia, PA	1.016	1.106	1.364
00865	99	Rest of Pennsylvania	0.992	0.904	0.793
00973	20	Puerto Rico	0.906	0.699	0.755
00524	01	Rhode Island	1.045	0.991	0.895
00880	01	South Carolina	0.975	0.894	0.388
00820	02	South Dakota	0.943	0.877	0.359
05440	35	Tennessee	0.977	0.881	0.621
00900	09	Brazoria, TX	1.020	0.963	1.277
00900	11	Dallas, TX	1.009	1.064	1.044
00900	15	Galveston, TX	0.990	0.954	1.277
00900	18	Houston, TX	1.016	1.016	1.276
00900	20	Beaumont, TX	0.983	0.862	1.277
00900	28	Fort Worth, TX	0.997	0.802	1.044
00900	31	Austin, TX	0.991	1.048	0.970
00900	99	Rest of Texas	0.968	0.866	1.120
00900	09	Utah	0.900	0.888	0.651
31145	50		0.968	0.938	0.505
00973		Vermont			0.505
00973	50 00	Virgin Islands	0.967 0.981	1.015 0.942	0.987
00836	00	Virginia			0.569
00836	99	Seattle (King Cnty), WA	1.014 0.987	1.133	0.805
		Rest of Washington		0.980	
00884 00951	16 00	West Virginia	0.973 0.987	0.820 0.920	1.522 0.777
00951	21	Wisconsin	0.987	0.920	0.777
00023	21	Wyoming	0.930	0.000	0.920

# ADDENDUM E.—2007 PROPOSED GAFS

Carrier	Locality	Locality name	GAF
31140	09	Santa Clara, CA	1.265
31140	06	San Mateo, CA	1.259
31140	05	San Francisco, CA	1.256
00803	02	NYC Suburbs/Long I., NY	1.180
31140	07	Oakland/Berkley, ČA	1.177
00803	01	Manhattan, NY	1.165
31140	03	Marin/Napa/Solano, CA	1.154
31143	01	Metropolitan Boston	1.153
14330	04	Queens, NY	1.144
00903	01	DC + MD/VA Suburbs	1.132
00805	01	Northern NJ	1.126
31146	26	Anaheim/Santa Ana, CA	1.120
00953	01	Detroit, MI	1.110
00952	16	Chicago, IL	1.102
00591	00	Connecticut	1.091
31146	18	Los Angeles, CA	1.088
00952	15	Suburban Chicago, IL	1.085

# ADDENDUM E.—2007 PROPOSED GAFS—Continued

17 99 01 04 02 01	Ventura, CA	1.084 1.074 1.069
01 04 02	Metropolitan Philadelphia, PA	
04 02		1.069
02	A Alicandia (FI)	
	Miami, FL	1.069
01	Seattle (King Cnty), WA	1.058
	Alaska	1.055
 03	Poughkpsie/N NYC Suburbs, NY	1.046
 01	Hawaii/Guam	1.044
01	Atlanta, GA	1.043
 01	Baltimore/Surr. Cntys, MD	1.039
 11	Dallas, TX	1.035
 18	Houston, TX	1.026
00	Nevada	1.023
 99	Rest of California*	1.017
99		1.017
		1.016
		1.015
	·	1.015
		1.011
		1.005
		1.005
		1.003
		1.000
		0.996
		0.995
		0.993
		0.993
		0.989
-		0.985
		0.984
		0.982
		0.981
	•	0.978
		0.977
		0.976
		0.975
		0.974
		0.968
		0.965
		0.951
		0.950
		0.950
 00		0.948
	Utah	0.947
 99	Rest of Pennsylvania	0.946
 20	Beaumont, TX	0.942
 99	Rest of Illinois	0.938
 00	North Carolina	0.936
 99	Rest of Georgia	0.932
 05	New Mexico	0.932
 00	Indiana	0.930
 99	Rest of Oregon	0.929
 99	Rest of Texas	0.929
16	West Virginia	0.927
		0.921
		0.919
		0.919
		0.918
		0.917
		0.916
		0.915
		0.914
		0.910
		0.909
		0.905
		0.903
		0.902
	' !	0.898
		0.895
	Oklahoma	0.894
 02	South Dakota	0.891 0.884
	99 01 03 31 01 01 09 09 01 01 99 40 28 12 00 00 01 150 155 155 10 10 10 10 10 10 10 10 10 10 10 10 10	99   Rest of California'   Rinde Island

### ADDENDUM E.—2007 PROPOSED GAFS—Continued

Carrier	Locality	Locality name	GAF
00523	99 99 20	Rest of Missouri Rest of Missouri Puerto Rico	0.883 0.883 0.790

### ADDENDUM F.—PROPOSED CPT/ HCPCS IMAGING CODES DEFINED BY SECTION 5102(B) OF THE DRA

ADDENDUM F.—PROPOSED CPT/ HCPCS IMAGING CODES DEFINED BY SECTION 5102(B) OF THE DRA— Continued ADDENDUM F.—PROPOSED CPT/ HCPCS IMAGING CODES DEFINED BY SECTION 5102(B) OF THE DRA— Continued

HCPCS/		- Continued		Continued		
CPT	Short descriptor	LICDOC/		LICDOC/		
		HCPCS/ CPT	Short descriptor	HCPCS/ CPT	Short descriptor	
31620	Endobronchial us add-on	<u> </u>		<u> </u>	•	
37250	lv us first vessel add-on	70548	Mr angiography neck w/dye	72142	Mri neck spine w/dye	
37251	Iv us each add vessel add-on	70549	Mr angiograph neck w/o & w/dye	72146	Mri chest spine w/o dye	
51798	Us urine capacity measure	70551	Mri brain w/o dye	72147	Mri chest spine w/dye	
70010	Contrast x-ray of brain	70552	Mri brain w/dye	72148	Mri lumbar spine w/o dye	
70015	Contrast x-ray of brain	70553	Mri brain w/o & w/dye	72149	Mri lumbar spine w/dye	
70030	X-ray eye for foreign body	70557	Mri brain w/o dye	72156	Mri neck spine w/o & w/dye	
70100	X-ray exam of jaw	70558	Mri brain w/dye	72157	Mri chest spine w/o & w/dye	
70110	X-ray exam of jaw	70559	Mri brain w/o & w/dye	72158	Mri lumbar spine w/o & w/dye	
70120	X-ray exam of mastoids	71010	Chest x-ray	72159	Mr angio spine w/o & w/dye	
70130	X-ray exam of mastoids	71015	Chest x-ray	72170	X-ray exam of pelvis	
70134	X-ray exam of middle ear	71020	Chest x-ray	72190	X-ray exam of pelvis	
70140	X-ray exam of facial bones	71021	Chest x-ray	72191	Ct angiograph pelv w/o & w/dye	
70150	X-ray exam of facial bones	71022	Chest x-ray	72192	Ct pelvis w/o dye	
70160	X-ray exam of nasal bones	71023	Chest x-ray and fluoroscopy	72193	Ct pelvis w/dye	
70170	X-ray exam of tear duct	71030	Chest x-ray	72194	Ct pelvis w/dye	
70190	X-ray exam of eye sockets	71034	Chest x-ray and fluoroscopy	72195	Mri pelvis w/o dye	
70200	X-ray exam of eye sockets	71035	Chest x-ray	72196	Mri pelvis w/dye	
70210	X-ray exam of sinuses	71040	Contrast x-ray of bronchi	72197	Mri pelvis w/o & w/dye	
70220	X-ray exam of sinuses	71060	Contrast x-ray of bronchi	72198	Mr angio pelvis w/o & w/dye	
70240	X-ray exam, pituitary saddle	71090	X-ray & pacemaker insertion	72200	X-ray exam sacroiliac joints	
70250	X-ray exam of skull	71100	X-ray exam of ribs	72202	X-ray exam sacroiliac joints	
70260	,	71101	X-ray exam of ribs/chest	72220	X-ray exam of tailbone	
70300	X-ray exam of teeth	71110	X-ray exam of ribs	72240	Contrast x-ray of neck spine	
70310	X-ray exam of teeth	71111	X-ray exam of ribs/chest	72255	Contrast x-ray, thorax spine	
70320	Full mouth x-ray of teeth	71120	X-ray exam of breastbone	72265	Contrast x-ray, lower spine	
70328	X-ray exam of jaw joint	71130		72270	Contrast x-ray, spine	
70330	X-ray exam of jaw joints	71250	Ct thorax w/o dye	72275	Epidurography	
70332	X-ray exam of jaw joint	71260	Ct thorax w/dye	72285	X-ray c/t spine disk	
70336	Magnetic image, jaw joint	71270	Ct thorax w/o & w/dye	72295	X-ray of lower spine disk	
70350	X-ray head for orthodontia	71275	Ct angiography, chest	73000	X-ray exam of collar bone	
70355	Panoramic x-ray of jaws	71550	Mri chest w/o dye	73010	X-ray exam of shoulder blade	
70360	X-ray exam of neck	71551	Mri chest w/dye	73020	X-ray exam of shoulder	
70370	Throat x-ray & fluoroscopy	71552	Mri chest w/o & w/dye	73030	X-ray exam of shoulder	
70371	Speech evaluation, complex	71555	Mri angio chest w or w/o dye	73040	Contrast x-ray of shoulder	
70373	Contrast x-ray of larynx	72010	X-ray exam of spine	73050	X-ray exam of shoulders	
70380	X-ray exam of salivary gland	72020	X-ray exam of spine	73060	X-ray exam of humerus	
70390	X-ray exam of salivary duct	72040	X-ray exam of neck spine	73070	X-ray exam of elbow	
70450	Ct head/brain w/o dye	72050		73080	X-ray exam of elbow	
70460	Ct head/brain w/dye	72052		73085	Contrast x-ray of elbow	
70470	Ct head/brain w/o & w/dye	72069		73090	X-ray exam of forearm	
70480	Ct orbit/ear/fossa w/o dye	72070	X-ray exam of thoracic spine	73092	X-ray exam of arm, infant	
70481	Ct orbit/ear/fossa w/dye	72072	X-ray exam of thoracic spine	73100	X-ray exam of wrist	
70482	Ct orbit/ear/fossa w/o& w/dye	72074		73110	X-ray exam of wrist	
70486	Ct maxillofacial w/o dye	72080		73115	Contrast x-ray of wrist	
70487	Ct maxillofacial w/dye	72090	X-ray exam of trunk spine	73120	X-ray exam of hand	
70488	Ct maxillofacial w/o & w/dye	72100		73130		
70490	Ct soft tissue neck w/o dye	72110	X-ray exam of lower spine	73140	X-ray exam of finger(s)	
70491	Ct soft tissue neck w/dye	72114	X-ray exam of lower spine	73200	Ct upper extremity w/o dye	
70492	Ct sft tsue nck w/o & w/dye	72120	X-ray exam of lower spine	73201	Ct upper extremity w/dye	
70496	Ct angiography, head	72125	Ct neck spine w/o dye	73202	Ct uppr extremity w/o & w/dye	
70498	Ct angiography, neck	72126	Ct neck spine w/dye	73206	Ct angio upr extrm w/o & w/dye	
70540	Mri orbit/face/neck w/o dye	72127	Ct neck spine w/o & w/dye	73218	Mri upper extremity w/o dye	
70542	Mri orbit/face/neck w/dye	72128	Ct chest spine w/o dye	73219	Mri upper extremity w/dye	
70543	Mri orbt/fac/nck w/o & w/dye	72129	Ct chest spine w/dye	73220	Mri uppr extremity w/o & w/dye	
70544	Mr angiography head w/o dye	72130	Ct chest spine w/o & w/dye	73221	Mri joint upr extrem w/o dye	
70545	Mr angiography head w/dye	72131	Ct lumbar spine w/o dye	73222	Mri joint upr extrem w/dye	
70546	Mr angiograph head w/o & w/	72132		73223	Mri joint upr extr w/o & w/dye	
	dye	72133	Ct lumbar spine w/o & w/dye	73225	Mr angio upr extr w/o & w/dye	
70547	Mr angiography neck w/o dye	72141	Mri neck spine w/o dye	73500	X-ray exam of hip	
	· ·		•		•	

ADDENDUM F.—PROPOSED CPT/ HCPCS IMAGING CODES DEFINED BY SECTION 5102(B) OF THE DRA— Continued ADDENDUM F.—PROPOSED CPT/ HCPCS IMAGING CODES DEFINED BY SECTION 5102(B) OF THE DRA— Continued ADDENDUM F.—PROPOSED CPT/ HCPCS IMAGING CODES DEFINED BY SECTION 5102(B) OF THE DRA— Continued

HCPCS/ CPT	Short descriptor	HCPCS/ CPT	Short descriptor	HCPCS/ CPT	Short descriptor
73510	X-ray exam of hip	74327	X-ray bile stone removal	75820	Vein x-ray, arm/leg
73520	X-ray exam of hips	74328	X-ray bile duct endoscopy	75822	Vein x-ray, arms/legs
73525	Contrast x-ray of hip	74329	X-ray for pancreas endoscopy	75825	Vein x-ray, trunk
73530	X-ray exam of hip	74330	X-ray bile/panc endoscopy	75827	Vein x-ray, chest
73540		74340		75831	Vein x-ray, kidney
73542		74350	X-ray guide, stomach tube	75833	Vein x-ray, kidneys
73550	X-ray exam of thigh	74355	X-ray guide, intestinal tube	75840	Vein x-ray, adrenal gland
73560		74360	X-ray guide, GI dilation	75842	Vein x-ray, adrenal glands
73562		74363		75860	Vein x-ray, neck
73564		74400			Vein x-ray, skull
73565		74410		75872	Vein x-ray, skull
73580		74415		75880	Vein x-ray, eye socket
73590		74420	Contrst x-ray, urinary tract	75885	Vein x-ray, liver
73590		74425		75887	
73600		74423		75889	
				75009	Vein x-ray, liver
73610		74440	X-ray, male genital tract	75891	Vein x-ray, liver
73615	,	74445		75893	Venous sampling by catheter
73620		74450		75894	X-rays, transcath therapy
73630		74455		75896	
73650		74470	X-ray exam of kidney lesion	75898	
73660		74475		75900	Intravascular cath exchange
73700		74480		75901	
73701	, ,	74485		75902	Remove cva lumen obstruct
73702		74710	X-ray measurement of pelvis	75940	X-ray placement, vein filter
73706		74740	X-ray, female genital tract	75945	Intravascular us
73718	Mri lower extremity w/o dye	74742	X-ray, fallopian tube	75946	Intravascular us add-on
73719	Mri lower extremity w/dye	74775	X-ray exam of perineum	75952	Endovasc repair abdom aorta
73720	Mri lwr extremity w/o & w/dye	75552	Heart mri for morph w/o dye	75953	Abdom aneurysm endovas rpr
73721	Mri jnt of lwr extre w/o dye	75553	Heart mri for morph w/dye	75954	Iliac aneurysm endovas rpr
73722	Mri joint of lwr extr w/dye	75554	Cardiac MRI/function	75956	Xray, endovasc thor ao repr
73723	Mri joint lwr extr w/o & w/dye	75555	Cardiac MRI/limited study	75957	Xray, endovasc thor ao repr
73725	Mr ang lwr ext w or w/o dye	75556		75958	Xray, place prox ext thor ao
74000		75600		75959	Xray, place dist ext thor ao
74010		75605		75960	Transcath iv stent rs&i
74020		75625	Contrast x-ray exam of aorta	75961	Retrieval, broken catheter
74022		75630	X-ray aorta, leg arteries	75962	Repair arterial blockage
74150		75635	Ct angio abdominal arteries	75964	Repair artery blockage, each
74160		75650	Artery x-rays, head & neck	75966	Repair arterial blockage
74170	,	75658	Artery x-rays, arm	75968	Repair artery blockage, each
74175	,	75660	Artery x-rays, head & neck	75970	Vascular biopsy
74181		75662		75978	Repair venous blockage
74182		75665		75980	
74183	Mri abdomen w/o & w/dye	75671		75982	
74185		75676			Xray control catheter change
74190		75680		75989	
74210	l _ '	75685		75992	Atherectomy, x-ray exam
74220	Contrast x-ray, esophagus	75705	Artery x-rays, spine Artery x-rays, spine	75993	Atherectomy, x-ray exam
74230	Cine/vid x-ray, throat/esoph	75710	Artery x-rays, spine Artery x-rays, arm/leg	75993	Atherectomy, x-ray exam
74235	Remove esophagus obstruction	75716	Artery x-rays, arms/legs	75994 75995	Atherectomy, x-ray exam
74240	X-ray exam, upper gi tract	75722	Artery x-rays, kidney	75996	l
74241		75724		75998	Atherectomy, x-ray exam
	X-ray exam, upper gi tract		Artery x-rays, kidneys		Fluoroguide for vein device
74245	X-ray exam, upper gi tract	75726	Artery x-rays, abdomen	76000 76001	Fluoroscope examination
74246	Controt x-ray uppr gi tract	75731	Artery x-rays, adrenal gland		Fluoroscope exam, extensive
74247	Contrst x-ray uppr gi tract	75733	Artery x-rays, adrenals	76003	Needle localization by x-ray
74249	Contrst x-ray uppr gi tract	75736	Artery x-rays, pelvis	76005	Fluoroguide for spine inject
74250	X-ray exam of small bowel	75741	Artery x-rays, lung	76006	X-ray stress view
74251	X-ray exam of small bowel	75743	Artery x-rays, lungs	76010	X-ray, nose to rectum
74260	X-ray exam of small bowel	75746	Artery x-rays, lung	76012	Percut vertebroplasty fluor
74270	Contrast x-ray exam of colon	75756	Artery x-rays, chest	76013	Percut vertebroplasty, ct
74280	Contrast x-ray exam of colon	75774	Artery x-ray, each vessel	76020	X-rays for bone age
74283	Contrast x-ray exam of colon	75790	Visualize A-V shunt	76040	X-rays, bone evaluation
74290	Contrast x-ray, gallbladder	75801	Lymph vessel x-ray, arm/leg	76061	X-rays, bone survey
74291	Contrast x-rays, gallbladder	75803	Lymph vessel x-ray,arms/legs	76062	X-rays, bone survey
74300	X-ray bile ducts/pancreas	75805	Lymph vessel x-ray, trunk	76065	X-rays, bone evaluation
74301	X-rays at surgery add-on	75807	Lymph vessel x-ray, trunk	76066	Joint survey, single view
74305	X-ray bile ducts/pancreas	75809	Nonvascular shunt, x-ray	76070	Ct bone density, axial
74320	Contrast x-ray of bile ducts	75810	Vein x-ray, spleen/liver	76071	Ct bone density, peripheral

ADDENDUM F.—PROPOSED CPT/ HCPCS IMAGING CODES DEFINED BY SECTION 5102(B) OF THE DRA— Continued ADDENDUM F.—PROPOSED CPT/ HCPCS IMAGING CODES DEFINED BY SECTION 5102(B) OF THE DRA— Continued ADDENDUM F.—PROPOSED CPT/ HCPCS IMAGING CODES DEFINED BY SECTION 5102(B) OF THE DRA— Continued

HCPCS/ CPT	Short descriptor	HCPCS/ CPT	Short descriptor	HCPCS/ CPT	Short descriptor
76075 76076 76077	Dxa bone density, axial Dxa bone density/peripheral Dxa bone density/v-fracture	76827 76828 76830	Echo exam of fetal heart Echo exam of fetal heart Transvaginal us, non-ob	78300 78305 78306	Bone imaging, limited area Bone imaging, multiple areas Bone imaging, whole body
76078	Radiographic absorptiometry	76831	Echo exam, uterus	78315	Bone imaging, 3 phase
76080 76086	X-ray exam of fistula X-ray of mammary duct	76856 76857	Us exam, pelvic, complete Us exam, pelvic, limited	78320 78350	Bone imaging (3D) Bone mineral, single photon
76088	X-ray of mammary ducts	76870	Us exam, scrotum	78351	Bone mineral, dual photon
76093	Magnetic image, breast	76872	Us, transrectal	78428	Cardiac shunt imaging
76094	Magnetic image, both breasts	76873	Echograp trans r, pros study	78445	Vascular flow imaging
76095	Stereotactic breast biopsy	76880	Us exam, extremity	78456	Acute venous thrombus image
76096 76098	X-ray of needle wire, breast X-ray exam, breast specimen	76885 76886	Us exam infant hips, dynamic Us exam infant hips, static	78457 78458	Venous thrombosis imaging Ven thrombosis images, bilat
76100	X-ray exam of body section	76930	Echo guide, cardiocentesis	78459	Heart muscle imaging (PET)
76101	Complex body section x-ray	76932	Echo guide for heart biopsy	78460	Heart muscle blood, single
76102	Complex body section x-rays	76936	Echo guide for artery repair	78461	Heart muscle blood, multiple
76120	,	76937	Us guide, vascular access	78464	Heart image (3d), single
76125 76140	Cine/video x-rays add-on X-ray consultation	76940 76941	Us guide, tissue ablation	78465 78466	Heart image (3d), multiple
76150	X-ray exam, dry process	76941	Echo guide for transfusion Echo guide for biopsy	78468	Heart infarct image Heart infarct image (ef)
76350	Special x-ray contrast study	76945	Echo guide, villus sampling	78469	Heart infarct image (3D)
76355	Ct scan for localization	76946	Echo guide for amniocentesis	78472	Gated heart, planar, single
76360	Ct scan for needle biopsy	76948	Echo guide, ova aspiration	78473	Gated heart, multiple
76362	Ct guide for tissue ablation	76950	Echo guidance radiotherapy	78478	Heart wall motion add-on
76370 76376	Ct scan for therapy guide 3d render w/o postprocess	76965 76970	Echo guidance radiotherapy Ultrasound exam follow-up	78480 78481	Heart function add-on Heart first pass, single
76377	3d rendering w/postprocess	76975	GI endoscopic ultrasound	78483	Heart first pass, single Heart first pass, multiple
76380	CAT scan follow-up study	76977	Us bone density measure	78491	Heart image (pet), single
76390	Mr spectroscopy	76986	Ultrasound guide intraoper	78492	Heart image (pet), multiple
76393	Mr guidance for needle place	77417	Radiology port film(s)	78494	Heart image, spect
76394 76400	Mri for tissue ablation	77421	Stereoscopic x-ray guidance	78496 78580	Heart first pass add-on
76496	Magnetic image, bone marrow Fluoroscopic procedure	78006 78007	Thyroid imaging with uptake Thyroid image, mult uptakes	78584	Lung perfusion imaging Lung V/Q image single breath
76497	Ct procedure	78010	Thyroid imaging	78585	Lung V/Q imaging
76498	Mri procedure	78011	Thyroid imaging with flow	78586	Aerosol lung image, single
76506	Echo exam of head	78015	Thyroid met imaging	78587	Aerosol lung image, multiple
76510	Ophth us, b & quant a	78016	Thyroid met imaging/studies	78588	Perfusion lung image
76511 76512	Ophth us, quant a only Ophth us, b w/non-quant a	78018 78020	Thyroid met imaging, body Thyroid met uptake	78591 78593	Vent image, 1 breath, 1 proj Vent image, 1 proj, gas
76513		78070	Parathyroid nuclear imaging	78594	Vent image, mult proj, gas
76514		78075	Adrenal nuclear imaging	78596	Lung differential function
76516	Echo exam of eye	78102	Bone marrow imaging, Itd	78600	Brain imaging, Itd static
76519	,	78103	Bone marrow imaging, mult	78601	Brain imaging, ltd w/flow
76529 76536		78104 78135	Bone marrow imaging, body Red cell survival kinetics	78605 78606	Brain imaging, complete Brain imaging, compl w/flow
76604		78140	Red cell sequestration	78607	Brain imaging (3D)
76645	Us exam, breast(s)	78185	Spleen imaging	78608	Brain imaging (PET)
76700	Us exam, abdom, complete	78190	Platelet survival, kinetics	78609	
76705	Echo exam of abdomen	78195	Lymph system imaging	78610	Brain flow imaging only
76770 76775	Us exam abdo back wall, comp Us exam abdo back wall, lim	78201 78202	Liver imaging Liver imaging with flow	78615 78630	Cerebral vascular flow image Cerebrospinal fluid scan
76778	Us exam kidney transplant	78205	Liver imaging (3D)	78635	CSF ventriculography
76800	Us exam, spinal canal	78206	Liver image (3d) with flow	78645	CSF shunt evaluation
76801	Ob us < 14 wks, single fetus	78215	Liver and spleen imaging	78647	Cerebrospinal fluid scan
76802	Ob us < 14 wks, add'l fetus	78216	Liver & spleen image/flow	78650	CSF leakage imaging
76805 76810	Ob us >/= 14 wks, sngl fetus Ob us >/= 14 wks, addl fetus	78220 78223	Liver function study Hepatobiliary imaging	78660 78700	Nuclear exam of tear flow Kidney imaging, static
76811	Ob us, detailed, sngl fetus	78230	Salivary gland imaging	78701	Kidney imaging, static  Kidney imaging with flow
76812	Ob us, detailed, addl fetus	78231	Serial salivary imaging	78704	Imaging renogram
76815	Ob us, limited, fetus(s)	78232	Salivary gland function exam	78707	Kidney flow/function image
76816	Ob us, follow-up, per fetus	78258	Esophageal motility study	78708	Kidney flow/function image
76817 76818	Transvaginal us, obstetric	78261	Gastric mucosa imaging	78709 78710	Kidney flow/function image
76819	Fetal biophys profile w/nst Fetal biophys profil w/o nst	78262 78264	Gastroesophageal reflux exam Gastric emptying study	78715	Kidney imaging (3D) Renal vascular flow exam
76820	Umbilical artery echo	78278	Acute GI blood loss imaging	78730	Urinary bladder retention
76821	Middle cerebral artery echo	78282	GI protein loss exam	78740	Ureteral reflux study
76825		78290		78760	Testicular imaging
76826	Echo exam of fetal heart	/8291	Leveen/shunt patency exam	78761	Testicular imaging/flow

ADDENDUM F.—PROPOSED CPT/ HCPCS IMAGING CODES DEFINED BY SECTION 5102(B) OF THE DRA-Continued

ADDENDUM F.—PROPOSED CPT/ HCPCS IMAGING CODES DEFINED BY SECTION 5102(B) OF THE DRA-Continued

ADDENDUM F.—PROPOSED CPT/ HCPCS IMAGING CODES DEFINED BY SECTION 5102(B) OF THE DRA-Continued

HCPCS/ CPT	Short descriptor	HCPCS/ CPT	Short descriptor	HCPCS/ CPT	Short descriptor	
78800	Tumor imaging, limited area	93325	Doppler color flow add-on	93981	Penile vascular study	
78801	Tumor imaging, mult areas	93350	Echo transthoracic	93990	Doppler flow testing	
78802	Tumor imaging, whole body	93555	Imaging, cardiac cath	0028T	Dexa body composition study	
78803	Tumor imaging (3D)	93556	Imaging, cardiac cath	0042T	Ct perfusion w/contrast, cbf	
78804	Tumor imaging, whole body	93571	Heart flow reserve measure	0066T	Ct colonography;scree n	
78805	Abscess imaging, ltd area	93572	Heart flow reserve measure	0067T	Ct colonography;dx	
78806	Abscess imaging, whole body	93875	Extracranial study	T0800	Endovasc aort repr rad s&i	
78807	Nuclear localization/absce ss	93880	Extracranial study	0081T	Endovasc visc extnsn s&i	
78811	Tumor imaging (pet), limited	93882	Extracranial study	0144T	CT heart wo dye; qual calc	
78812	Tumor image (pet)/skul-thigh	93886	Intracranial study	0145T	CT heart w/wo dye funct	
78813	Tumor image (pet) full body	93888	Intracranial study	0146T	CCTA w/wo dye	
78814	Tumor image pet/ct, limited	93890	Tcd, vasoreactivity study	0147T	CCTA w/wo, quan calcium	
78815	Tumorimage pet/ct skul-thigh	93892	Tcd, emboli detect w/o inj	0148T	CCTA w/wo, strxr	
78816	Tumor image pet/ct full body	93893	Tcd, emboli detect w/inj	0149T		
78890	Nuclear medicine data proc	93922	Extremity study	0150T		
78891	Nuclear med data proc	93923	Extremity study	0151T	CT heart funct add-on	
93303	Echo transthoracic	93924	Extremity study	0152T	Computer chest add-on	
93304	Echo transthoracic	93925	Lower extremity study	G0120	Colon ca scrn; barium enema	
93307	Echo exam of heart	93926	Lower extremity study	G0122	Colon ca scrn; barium enema	
93308	Echo exam of heart	93930	Upper extremity study	G0130	Single energy x-ray study	
93312	Echo transesophageal	93931	Upper extremity study	G0219	PET img wholbod melano nonco	
93313	Echo transesophageal	93965	Extremity study	G0235		
93314	Echo transesophageal	93970	Extremity study	G0275	j	
93315	Echo transesophageal	93971	Extremity study	G0278		
93316	Echo transesophageal	93975	Vascular study	G0288	Recon, CTA for surg plan	
93317	Echo transesophageal	93976	Vascular study	G0365	Vessel mapping hemo access	
93318	Echo transesophageal intraop	93978	Vascular study			
93320	Doppler echo exam, heart	93979	Vascular study	[FR Doc. 06-	-6843 Filed 8–8–06; 4:15 pm]	
93321	Doppler echo exam, heart	93980	Penile vascular study	BILLING CODE 4120-03-P		